

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: C12N 1/21, A61K 38/16, A61K 38/17, C07K 14/00, C07K 14/435, C07K 16/00, C12N 5/10, C12N 15/11, C12N 15/12, C12N 15/63, G01N 33/50	A1	(11) International Publication Number: WO 00/06698 (43) International Publication Date: 10 February 2000 (10.02.2000)
---	----	---

(21) International Application Number: PCT/US99/17130

(22) International Filing Date: 29 July 1999 (29.07.1999)

Published

(30) Priority Data:

60/094,657	30 July 1998 (30.07.1998)	US
60/095,454	06 August 1998 (06.08.1998)	US
60/095,455	06 August 1998 (06.08.1998)	US
60/095,486	05 August 1998 (05.08.1998)	US
60/096,319	12 August 1998 (12.08.1998)	US

(60) Parent Application or Grant

HUMAN GENOME SCIENCES, INC. [/];
 (). KOMATSOULIS, George, A. [/]; (). ROSEN, Craig, A. [/];
 (). RUBEN, Steven, M. [/]; (). DUAN, Roxanne [/];
 (). MOORE, Paul, A. [/]; (). SHI, Yanggu [/]; (). LAFLEUR,
 David [/]; (). WEI, Ying-Fei [/]; (). NI, Jian [/];
 (). FLORENCE, Kimberly, A. [/]; (). YOUNG, Paul, E. [/];
 (). BREWER, Laurie, A. [/]; (). SOPPET, Daniel, R. [/];
 (). ENDRESS, Gregory, A. [/]; (). EBNER, Reinhard [/];
 (). OLSEN, Henrik, S. [/]; (). MUCENSKI, Michael [/];
 (). KOMATSOULIS, George, A. [/]; (). ROSEN, Craig, A. [/];
 (). RUBEN, Steven, M. [/]; (). DUAN, Roxanne [/];
 (). MOORE, Paul, A. [/]; (). SHI, Yanggu [/]; (). LAFLEUR,
 David [/]; (). WEI, Ying-Fei [/]; (). NI, Jian [/];
 (). FLORENCE, Kimberly, A. [/]; (). YOUNG, Paul, E. [/];
 (). BREWER, Laurie, A. [/]; (). SOPPET, Daniel, R. [/];
 (). ENDRESS, Gregory, A. [/]; (). EBNER, Reinhard [/];
 (). OLSEN, Henrik, S. [/]; (). MUCENSKI, Michael [/];
 (). HOOVER, Kenley, K. ; ().

(54) Title: 98 HUMAN SECRETED PROTEINS

(54) Titre: 98 PROTEINES HUMAINES SECRETEES

(57) Abstract

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

(57) Abrégé

La présente invention concerne de nouvelles protéines humaines sécrétées, ainsi que des acides nucléiques isolés contenant les régions codantes des gènes codant pour ces protéines. L'invention concerne également des vecteurs, des cellules hôtes, des anticorps, et des méthodes de recombinaison permettant de produire les protéines humaines sécrétées. L'invention concerne enfin des méthodes diagnostiques et thérapeutiques utilisées dans le traitement de troubles associés à ces nouvelles protéines humaines sécrétées.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 1/21, 5/10, 15/11, 15/12, 15/63, A61K 38/16, 38/17, C07K 14/00, 14/435, 16/00, G01N 33/50		A1	(11) International Publication Number: WO 00/06698 (43) International Publication Date: 10 February 2000 (10.02.00)													
(21) International Application Number: PCT/US99/17130 (22) International Filing Date: 29 July 1999 (29.07.99) (30) Priority Data: <table><tr><td>60/094,557</td><td>30 July 1998 (30.07.98)</td><td>US</td></tr><tr><td>60/095,486</td><td>5 August 1998 (05.08.98)</td><td>US</td></tr><tr><td>60/095,455</td><td>6 August 1998 (06.08.98)</td><td>US</td></tr><tr><td>60/095,454</td><td>6 August 1998 (06.08.98)</td><td>US</td></tr><tr><td>60/096,319</td><td>12 August 1998 (12.08.98)</td><td>US</td></tr></table> (71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): KOMATSOUKIS, George, A. [US/US]; 9518 Garwood Street, Silver Spring, MD 20901 (US). ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Road, Laytonville, MD 20882 (US). RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Ol- ney, MD 20832 (US). DUAN, Roxanne [US/US]; 5515 Northfield Road, Bethesda, MD 20817 (US). MOORE, Paul, A. [GB/US]; 19005 Leatherbark Drive, Germantown, MD 20874 (US). SHI, Yanggu [CN/US]; Apartment 102, 437 West Side Drive, Gaithersburg, MD 20878 (US). LAFLEUR, David [US/US]; 3142 Quesada Street, N.W., Washington, DC 20015 (US). WEI, Ying-Fei [CN/US]; 242 Gravatt Drive, Berkeley, CA 94705 (US). NI, Jian [CN/US]; 5502 Manorfield Road, Rockville, MD 20853 (US). FLORENCE, Kimberly, A. [US/US]; 12805 Atlantic Avenue, Rockville, MD 20851 (US). YOUNG, Paul, E. [US/US]; 122 Beckwith Street, Gaithersburg, MD 20878 (US). BREWER, Laurie, A. [US/US]; Apartment 115, 410 Van Dyke Street, St. Paul, MN 55119-4321 (US). SOPPET, Daniel, R. [US/US]; 15050 Stillfield Place, Centreville, VA 22020 (US). ENDRESS, Gregory, A. [US/US]; 9729 Clagett Farm Drive, Potomac, MD 20854 (US). EBNER, Reinhard [DE/US]; 9906 Shelburne Terrace #316, Gaithersburg, MD 20878 (US). OLSEN, Henrik, S. [DK/US]; 182 Kendrick Place #24, Gaithersburg, MD 20878 (US). MUCENSKI, Michael [US/US]; 3265 Mandale Drive, Cincinnati, OH 45239 (US). (74) Agents: HOOVER, Kenley, K. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, CG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published • With international search report. • With an indication in relation to deposited biological material furnished under Rule 13bis separately from the description.		60/094,557	30 July 1998 (30.07.98)	US	60/095,486	5 August 1998 (05.08.98)	US	60/095,455	6 August 1998 (06.08.98)	US	60/095,454	6 August 1998 (06.08.98)	US	60/096,319	12 August 1998 (12.08.98)	US
60/094,557	30 July 1998 (30.07.98)	US														
60/095,486	5 August 1998 (05.08.98)	US														
60/095,455	6 August 1998 (06.08.98)	US														
60/095,454	6 August 1998 (06.08.98)	US														
60/096,319	12 August 1998 (12.08.98)	US														
(54) Title: 98 HUMAN SECRETED PROTEINS																
(57) Abstract <p>The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.</p>																

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	RS	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	YN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Description

5

10

15

20

25

30

35

40

45

50

55

5

98 Human Secreted Proteins

Field of the Invention

10

This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and their production.

15

Background of the Invention

20

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

25

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

30

35

Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

40

45

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of

50

55

the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent medical disorders by using secreted proteins or the genes that encode them.

Summary of the Invention

The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting disorders related to the polypeptides, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying binding partners of the polypeptides.

Detailed Description

Definitions

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

5 In specific embodiments, the polynucleotides of the invention are less than
300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, or 7.5 kb in length. In a further
10 embodiment, polynucleotides of the invention comprise at least 15 contiguous
nucleotides of the coding sequence, but do not comprise all or a portion of any intron.
5 In another embodiment, the nucleic acid comprising the coding sequence does not
contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene in the
15 genome).

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid
sequence contained in SEQ ID NO:X or the cDNA contained within the clone
20 deposited with the ATCC. For example, the polynucleotide can contain the
nucleotide sequence of the full length cDNA sequence, including the 5' and 3'
untranslated sequences, the coding region, with or without the signal sequence, the
secreted protein coding region, as well as fragments, epitopes, domains, and variants
25 of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a
15 molecule having the translated amino acid sequence generated from the
polynucleotide as broadly defined.

30 In the present invention, the full length sequence identified as SEQ ID NO:X
was often generated by overlapping sequences contained in multiple clones (contig
analysis). A representative clone containing all or most of the sequence for SEQ ID
20 NO:X was deposited with the American Type Culture Collection ("ATCC"). As
shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the
35 ATCC Deposit Number. The ATCC is located at 10801 University Boulevard,
Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the
terms of the Budapest Treaty on the international recognition of the deposit of
40 25 microorganisms for purposes of patent procedure.

A "polynucleotide" of the present invention also includes those
polynucleotides capable of hybridizing, under stringent hybridization conditions, to
45 sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within
the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an
30 overnight incubation at 42° C in a solution comprising 50% formamide, 5x SSC (750
mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's
50

5 solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA,
10 followed by washing the filters in 0.1x SSC at about 65°C.

15 Also contemplated are nucleic acid molecules that hybridize to the
polynucleotides of the present invention at lower stringency hybridization conditions.
5 Changes in the stringency of hybridization and signal detection are primarily
accomplished through the manipulation of formamide concentration (lower
15 percentages of formamide result in lowered stringency); salt conditions, or
temperature. For example, lower stringency conditions include an overnight
incubation at 37°C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M
20 NaH_2PO_4 ; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 µg/ml salmon
sperm blocking DNA; followed by washes at 50°C with 1XSSPE, 0.1% SDS. In
addition, to achieve even lower stringency, washes performed following stringent
25 hybridization can be done at higher salt concentrations (e.g. 5X SSC).

30 Note that variations in the above conditions may be accomplished through the
inclusion and/or substitution of alternate blocking reagents used to suppress
background in hybridization experiments. Typical blocking reagents include
Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and
commercially available proprietary formulations. The inclusion of specific blocking
35 reagents may require modification of the hybridization conditions described above,
due to problems with compatibility.

40 Of course, a polynucleotide which hybridizes only to polyA+ sequences (such
as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a
complementary stretch of T (or U) residues, would not be included in the definition of
"polynucleotide," since such a polynucleotide would hybridize to any nucleic acid
45 molecule containing a poly (A) stretch or the complement thereof (e.g., practically
any double-stranded cDNA clone).

50 The polynucleotide of the present invention can be composed of any
polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or
DNA or modified RNA or DNA. For example, polynucleotides can be composed of
55 single- and double-stranded DNA, DNA that is a mixture of single- and double-
stranded regions, single- and double-stranded RNA, and RNA that is mixture of
single- and double-stranded regions, hybrid molecules comprising DNA and RNA

5

5

10

15

that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

20

25

30

35

40

45

50

55

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

(See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

Polynucleotides and Polypeptides of the Invention

FEATURES OF PROTEIN ENCODED BY GENE NO: 1

The translation product of this gene is a human glycoprotein-associated amino acid transporter (See, e.g., Genbank Accession No. embICAA10198.11 (AJ130718); all references available through this accession are hereby incorporated by reference herein). Amino acid transport across cellular membranes is mediated by multiple transporters with overlapping specificities. The transport system L, which mediates Na⁺-independent exchange of large neutral amino acids, consists of a novel amino acid permease-related protein (LAT1 or AmAT-L-1c) which for surface expression and function requires formation of disulfide-linked heterodimers with the glycosylated heavy chain of the h4F2/CD98 surface antigen. h4F2hc also associates with other mammalian light chains, e.g. γ-LAT1 from mouse and human which are

approximately 48% identical with LAT1 and thus belong to the same family of glycoprotein-associated amino acid transporters.

The novel heterodimers form exchangers which mediate the cellular efflux of cationic amino acids and the Na⁺-dependent uptake of large neutral amino acids.

These transport characteristics and kinetic and pharmacological fingerprints identify them as y⁺L-type transport systems. mRNA encoding y⁺LAT1 is detectable in most adult tissues and expressed at high levels in kidney cortex and intestine. This indicates that the y⁺LAT1-4F2hc heterodimer, besides participating in amino acid uptake/secretion in many cell types, is the basolateral amino acid exchanger involved in transepithelial reabsorption of cationic amino acids; hence, its defect might be the cause of the human genetic disease lysinuric protein intolerance.

The gene encoding the disclosed cDNA is believed to reside on chromosome 14. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 14.

Preferred polypeptides comprise the following amino acid sequence:

LALYSALFSYSGWDTLN (SEQ ID NO: 237), VTTEEIKNPERNLPL (SEQ ID NO: 238), IGISMPIVT (SEQ ID NO: 239), IYILTNVAYYTVL (SEQ ID NO: 240), SDAVAVTFADQ (SEQ ID NO: 241), VALSCFGGLNASI (SEQ ID NO: 242), SRLFFVGSREGHLPD (SEQ ID NO: 243), SFSYWFFVGLS (SEQ ID NO: 244), VGQLYLRWKEP (SEQ ID NO: 245), RPRPLKLSVFFPIVFC (SEQ ID NO: 246), DTINSLIGI (SEQ ID NO: 247), LLAAACICLLTFINCA YVKWGTLVQDIFTYAKVLALIAVI VAGIVRLGQGASTHFENSFEGSSFAVGDIALLALYSALFSYSGWDTLNYVTEEIKNPERNLPLSIGISMPIVTIYILTNVAYYTVLDMRDILASDAVAVTFADQIFGIF NWIIPLSVALSCFGGLNASIVAASRLFFVGSREGHLPDAICMIHVERFTPVPSSL FNGIMALIYLCVEDIFQLINYYSFSYWFFVGLSIVGQLYLRWKEPDRPRPLKLS VFFPIVFCLCTIFLVA VPLYSDTINSLIGIAIALSGLPFYFLIRVPEHKRPLYLRRI VGSATRYLQVLCMSVAAEMDLEDGGEMPKQRDPKSN (SEQ ID NO: 249) and/or ATALPPKIVGSATRYLQVLCMSVAAEMDLEDGGEMPKQRDPKSN (SEQ ID NO: 248). Polynucleotides encoding these polypeptides are also provided.

Contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of THP-1 monocyte cells to calcium. Thus, it is likely that the product of this gene is involved in a signal

transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of both THP-1 monocytes, in addition to other cell-lines or tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating monocytes.

This gene is expressed primarily in endothelial cells and brain, and, to a lesser extent, in a wide variety of human tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the neural or gastrointestinal systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the circulation system or central nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, gastrointestinal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 124 as residues: Glu-102 to Asn-110, Arg-256 to Leu-266, Pro-316 to Trp-328, Pro-331 to Arg-336, Met-350 to Gly-358. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain combined with its homology to a amino acid transporter and biological activity of increasing ion flux in monocytes indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease,

Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:11 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1550 of SEQ ID NO:11, b is an integer of 15 to 1564, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:11, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 2

The gene encoding the disclosed cDNA is believed to reside on the X chromosome. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for the X chromosome.

Preferred polypeptides of the invention comprise the following amino acid sequence:

AARGSGVRDPLEEA \dot{Y} CPFSDLQLHAGRTTALFKAVRQGHLSLQRLLLSFVCL
CPAPRGGAYRGRQASLSCGGLHPVRASRLCLPKQAWAMAGAPPPVSLPPCS
LISDCCASNQRDSVG (SEQ ID NO: 250). Polynucleotides encoding these
polypeptides are also provided.

This gene is expressed primarily in cord blood cells, and, to a lesser extent, in frontal lobe of the brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental, reproductive, hematopoietic or neural disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and central nervous systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, developmental, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 125 as residues: His-56 to Gln-65, Leu-80 to Ile-85. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in cord blood cells indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

5 The gene product may also be involved in lymphopoiesis, therefore, it can be
used in immune disorders such as infection, inflammation, allergy, immunodeficiency
10 etc. In addition, this gene product may have commercial utility in the expansion of
stem cells and committed progenitors of various blood lineages, and in the
5 differentiation and/or proliferation of various cell types. Alternatively,
polynucleotides and polypeptides corresponding to this gene are useful for the
15 diagnosis and treatment of cancer and other proliferative disorders. Expression within
embryonic tissue and other cellular sources marked by proliferating cells indicates
that this protein may play a role in the regulation of cellular division. Similarly,
20 embryonic development also involves decisions involving cell differentiation and/or
apoptosis in pattern formation. Thus, this protein may also be involved in apoptosis or
tissue differentiation and could again be useful in cancer therapy. Furthermore, the
protein may also be used to determine biological activity, to raise antibodies, as tissue
25 markers, to isolate cognate ligands or receptors, to identify agents that modulate their
interactions, in addition to its use as a nutritional supplement. Protein, as well as,
15 antibodies directed against the protein may show utility as a tumor marker and/or
immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
20 related to SEQ ID NO: 12 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
35 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
more polynucleotides comprising a nucleotide sequence described by the general
40 25 formula of a-b, where a is any integer between 1 to 1743 of SEQ ID NO: 12, b is an
integer of 15 to 1757, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO: 12, and where b is greater than or equal to a + 14.

45 FEATURES OF PROTEIN ENCODED BY GENE NO: 3

30 This gene is expressed primarily in human T cell lymphomas.

Therefore, polynucleotides and polypeptides of the invention are useful as
50 reagents for differential identification of the tissue(s) or cell type(s) present in a

5 biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, T cell lymphoma, immunodeficiencies, in addition to other immune
10 system disorders. Similarly, polypeptides and antibodies directed to these
polypeptides are useful in providing immunological probes for differential
5 identification of the tissue(s) or cell type(s). For a number of disorders of the above
tissues or cells, particularly of the immune system, expression of this gene at
15 significantly higher or lower levels is routinely detected in certain tissues or cell types
(e.g., immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph,
serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample
20 taken from an individual having such a disorder, relative to the standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid from an
individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic
25 epitopes shown in SEQ ID NO: 126 as residues: Met-1 to Phe-10. Polynucleotides
15 encoding said polypeptides are also provided.

The tissue distribution in human T cell lymphomas indicates polynucleotides
and polypeptides corresponding to this gene are useful for the diagnosis and treatment
30 of a variety of immune system disorders. Representative uses are described in the
"Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14,
20 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene
product indicates a role in regulating the proliferation; survival; differentiation; and/or
35 activation of hematopoietic cell lineages, including blood stem cells. This gene
product is involved in the regulation of cytokine production, antigen presentation, or
other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting
40 immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene
product is involved in immune functions. Therefore it is also used as an agent for
45 immunological disorders including arthritis, asthma, immunodeficiency diseases such
as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory
30 bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,
such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and
50 tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity

5 disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic
10 lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's
Disease, scleroderma and tissues. Moreover, the protein may represent a secreted
factor that influences the differentiation or behavior of other blood cells, or that
5 recruits hematopoietic cells to sites of injury. In addition, this gene product may have
commercial utility in the expansion of stem cells and committed progenitors of
15 various blood lineages, and in the differentiation and/or proliferation of various cell
types. Furthermore, the protein may also be used to determine biological activity,
raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify
20 agents that modulate their interactions, in addition to its use as a nutritional
supplement. Protein, as well as, antibodies directed against the protein may show
utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
25 available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO: 13 and may have been publicly available prior to conception of
30 the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
more polynucleotides comprising a nucleotide sequence described by the general
20 formula of a-b, where a is any integer between 1 to 1359 of SEQ ID NO:13, b is an
integer of 15 to 1373, where both a and b correspond to the positions of nucleotide
35 residues shown in SEQ ID NO:13, and where b is greater than or equal to a + 14.

40 FEATURES OF PROTEIN ENCODED BY GENE NO: 4

25 The protein product of this clone shares sequence homology with the C-
terminus of a human N-acetylglucosamine-phosphate mutase (See, e.g., Genbank
Accession No. gblAAC72409.11 (AF102265); all references available through this
45 accession are hereby incorporated by reference herein.) Hofmann, et al. (Eur. J.
Biochem. 221:741-747 (1994)) studied the N-acetylglucosamine-phosphate mutase of
30 *Saccharomyces cerevisiae* and showed it to be essential for viability. A *S. cerevisiae*
agm1 deletion mutant progressed through only approximately five cell cycles to form
50 a 'string' of undivided cells with an abnormal cell morphology resembling

glucosamine auxotrophic mutants. Expression of the AGM1 gene on a multi-copy plasmid led to a significantly increased N-acetylglucosamine-phosphate mutase activity. Unlike over-expression of the *S. cerevisiae* AGM1 gene in a phosphoglucomutase (pgm1 delta/pgm2 delta) double deletion mutant which could restore phosphoglucomutase activity, over-expression of the PGM2 gene encoding the major isoenzyme of phosphoglucomutase did not increase N-acetylglucosamine-phosphate-mutase activity and did not restore growth of agm1 deletion mutant cells. These observations indicate that the different hexosephosphate mutases of *S. cerevisiae* have partially overlapping substrate specificities but, nevertheless, distinct physiological functions. The human N-acetylglucosamine-phosphate-mutase is expected to share at least some biological activities with the Agm1 protein.

Preferred polypeptide fragments of the invention comprise the following amino acid sequences: LSKAFLDSPNRLLAVEMNTDHLRLTVPNGIGALKLRXM EHYFSQGLSVQLFNDGSKGKLNHLGADFVKSHQKPPQGMEIKSNERCCSFD GDADRIVYYYHDADGHFHLIDGDKIATLISSFLKELLVEIGESLNIGVVQTAYA NGSSTRYLEEVMKVPVYCTKTGVKHLHHKAQEFDIGVYFEANGHTALFST AVEMKIKQSAEQLEDKKRKAAMLENIIDLFNQAAGDAISDMLVIEAILALK GLTVQQWDALYTDLPNRQLKVQVADRRVISTTXAERQAVTPPGLQEAINDL VKKYKLSRAFVRPSGTEDVVRVYAEADSQESADHLAHEVSLAVFQLAGGIGE RPQPGF (SEQ ID NO: 251), LSKAFLDSPNRLLAVEMNTDHLRLTV (SEQ ID NO: 252), PNGIGALKLRXMEHYFSQGLSVQLFNDG (SEQ ID NO: 253), SKGKL NHLGADFVKSHQKPPQGMEIKS (SEQ ID NO: 254), NERCCSFDGDADRIV YYYHDADGHFHLI (SEQ ID NO: 255), DGDKIATLISSFLKELLVEIGESLNIGV (SEQ ID NO: 256), VQTAYANGSSTRYLEEVMKVPVYCTKTG (SEQ ID NO: 257), VKHLHHKAQEFDIGVYFEANGHTALFS (SEQ ID NO: 258), TAVEMK IKQSAEQLEDKKRKAAMLENI (SEQ ID NO: 259), IDLFNQAAGDAISDM LVIEAILALKGLT (SEQ ID NO: 260), VQQWDALYTDLPNRQLKVQVADRR VIST (SEQ ID NO: 261), TXAERQAVTPPGLQEAINDLVKKYKLSR (SEQ ID NO: 262), AFVRPSGTEDVVRVYAEADSQESA (SEQ ID NO: 263), and/or DH LAHEVSLAVFQLAGGIGERPQPGF (SEQ ID NO: 264). Polynucleotides encoding these polypeptides are also provided.

5

10

The gene encoding the disclosed cDNA is believed to reside on chromosome 6. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 6.

This gene is expressed primarily in fetal brain, and, to a lesser extent, in a wide variety of human tissues.

15

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental disorders, particularly of the central nervous system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central and peripheral nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20

25

30

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 127 as residues: Asn-36 to Lys-42, Lys-53 to Gln-60, Ile-64 to Ala-77, Ala-128 to Tyr-135, Lys-184 to Ala-199, Leu-245 to Leu-250. Polynucleotides encoding said polypeptides are also provided.

35

40

45

The tissue distribution of N-acetylglucosamine-phosphate mutase in fetal brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital

30

50

55

5 malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages,
10 schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression,
panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors,
including disorders in feeding, sleep patterns, balance, and perception. In addition,
5 elevated expression of this gene product in regions of the brain indicates it plays a
role in normal neural function.

15 Potentially, this gene product is involved in synapse formation,
neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or
survival. Furthermore, the protein may also be used to determine biological activity,
20 to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to
identify agents that modulate their interactions, in addition to its use as a nutritional
supplement. Protein, as well as, antibodies directed against the protein may show
utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

25 Many polynucleotide sequences, such as EST sequences, are publicly
15 available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO: 14 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
30 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
20 more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 3726 of SEQ ID NO:14, b is an
35 integer of 15 to 3740, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:14, and where b is greater than or equal to a + 14.

40 25 FEATURES OF PROTEIN ENCODED BY GENE NO: 5

This gene is expressed primarily in human stomach and stomach tumor cells.

45 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
30 not limited to, disorders of the gastrointestinal system, particularly cancer or ulcers of
stomach tissue. Similarly, polypeptides and antibodies directed to these polypeptides
50 are useful in providing immunological probes for differential identification of the

5 tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,
10 particularly of the digestive system, expression of this gene at significantly higher or
lower levels is routinely detected in certain tissues or cell types (e.g., gastrointestinal,
or cancerous and wounded tissues) or bodily fluids (e.g., bile, lymph, serum, plasma,
5 urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an
individual having such a disorder, relative to the standard gene expression level, i.e.,
15 the expression level in healthy tissue or bodily fluid from an individual not having the
disorder.

20 The tissue distribution in tumors of the stomach indicates that polynucleotides
and polypeptides corresponding to this gene are useful for diagnosis, treatment and
intervention of these tumors, in addition to other tumors where expression has been
indicated. Additionally, the protein product of this gene may play a role in the normal
25 function of the stomach and/or digestive system. Furthermore, the protein may also be
used to determine biological activity, to raise antibodies, as tissue markers, to isolate
cognate ligands or receptors, to identify agents that modulate their interactions, in
15 addition to its use as a nutritional supplement. Protein, as well as, antibodies directed
against the protein may show utility as a tumor marker and/or immunotherapy targets
30 for the above listed tissues.

35 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO: 15 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
40 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
25 more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 1182 of SEQ ID NO:15, b is an
integer of 15 to 1196, where both a and b correspond to the positions of nucleotide
45 residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14.

30 **FEATURES OF PROTEIN ENCODED BY GENE NO: 6**

50 Preferred polypeptides of the invention comprise the following amino acid
sequences:

5 FEIALPRESNITVLIKLGTPPTLLAKPCYIVISKRHITMLSIKSGERIVFTFSCQSPE
NHFVIEIQKNIDCMMSGPCPFGEVQLQPSTSLPTLNRTFIWDVKAHKSIGLELQ
10 FSIPRLRQIGPGESCPDGVTHSISGRIDATVVRIGTFCSNGTVSRIKM (SEQ ID
NO: 266), and/or GTRAAPGLGAWGRRSPSPFSPRRPGVMAGLNCVSIAL
5 LGVLLGAARLPRGAFAFEIALPRESNITVLIKLGTPPTLLAKPCYIVISKRHITM
LSIKSGERIVFTFSCQSPENHFVIEIQKNIDCMMSGPCPFGEVQLQPSTSLPTLN
15 TFIWDVKAHKSIGLELQFSIPRLRQIGPGESCPDGVTHSISGRIDATVVRIGTF
SNGTVSRIKMQEGVKMALHLPWFHPRNVSGFSIANRSSIKRLCIESVFEGEGS
ATLMSANYPEGFPEDELMTWQFVVP AHLRASVSFLNFNLSNCERKEERVEYY
10 IPGSTTNPEVFKLEDKQPGNMAGNFNLSLQCDQDAQSPGILRLQFQVLVQH
PQNESNKIYVVDLSNERAMSLTIEPRPVKQSRKFVPGCFVCLESRTCSSNLTLT
20 SGSKHKISFLCDDLTRLWMNVEKP (SEQ ID NO: 265). Polynucleotides encoding
these polypeptides are also provided.

25 This gene is expressed primarily in placenta, and to a lesser extent in, prostate
15 and ovary.

Therefore, polynucleotides and polypeptides of the invention are useful as
30 reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, male and female infertility, and associated disorders of the
20 reproductive system. Similarly, polypeptides and antibodies directed to these
polypeptides are useful in providing immunological probes for differential
35 identification of the tissue(s) or cell type(s). For a number of disorders of the above
tissues or cells, particularly of the reproductive system, expression of this gene at
significantly higher or lower levels is routinely detected in certain tissues or cell types
40 25 (e.g., reproductive, or cancerous and wounded tissues) or bodily fluids (e.g., lymph,
amniotic fluid, seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid) or
another tissue or cell sample taken from an individual having such a disorder, relative
to the standard gene expression level, i.e., the expression level in healthy tissue or
45 bodily fluid from an individual not having the disorder.

30 The tissue distribution of this gene in the prostate, placenta and ovary
indicates that polynucleotides and polypeptides corresponding to this gene are useful
50 for treatment, prevention, and/or diagnosis of male or female infertility, endocrine

disorders, fetal deficiencies, ovarian failure, amenorrhea, ovarian cancer, benign prostate hyperplasia and prostate cancer. Similarly, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression within placental tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus, this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:16 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2195 of SEQ ID NO:16, b is an integer of 15 to 2209, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 7

The translation product of this gene shares homology with the human and rat HNK-1 sulfotransferase protein (See, e.g., Genbank Accession Nos. gblAAB88123.11 (AF022729) and gil2921306lgblAAC04707.11 (AF033827); all references available through these accessions are hereby incorporated herein by reference.) Ong E, et al. (J Biol Chem. 273(9):5190-5 (1998)) have characterized the human HNK-1 sulfotransferase, and show that it is involved in the synthesis of the HNK-1

carbohydrate epitope which is expressed on various adhesion molecules in the nervous system and on immune cells (e.g., natural killer cells) and is suggested to play a role in cell-cell and cell-substratum interactions. Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with HNK-1 sulfotransferase proteins. Such activities are known in the art, some of which are described elsewhere herein, or in, for example, Bakker, et al., J Biol Chem. 272:29942-6 (1997), incorporated herein by reference. Based on sequence similarity between sulfotransferases, a consensus sequence for the active site was developed (Ong, et al., supra). The consensus pattern is as follows: xxRPDzzzz, where x represents hydrophobic amino acid residues and z represents any amino acid residue. Therefore,

Preferred polypeptides of the invention comprise the following amino acid sequences: FVRDPFVRL (SEQ ID NO: 267), FLFVRDPFVRLIS (SEQ ID NO: 268), FLFVRDPFVRLISAF (SEQ ID NO: 269), and/or YLHTSFSRPHTGPPLPTPG PDRDRELTADSDVDEFLDKFLSAGVKQSDLPRKETEQPPAPGSMEEENVRGY DWSPRDARRSPDQGRQQAERRSVLRGFCANSSLAFTKERAFDDIPNSELSHL IVDDRHGAIYCYVPKVACTNWKRVMIVLSGSLLHRGAPYRDPLRIPREHVH NASAHLTFNKFWRRYGKLSRHLMKVKLKKYTKFLFVRDPFVRLISAFRSK FELENEEFYRKFAVPMRLRLYANHTSI.PASAREAFRAGLKVSFANFIQYLLDPH TEKLAPFNEHWRQVYRLCHPCQIDYDFVGKLETLEDAAQLQLLQVDRQ LRFPPSYRNRTASSWEEDWFAKIPLAWRQQLYKLYEADFVLFQYKPKPENLL RD (SEQ ID NO: 270). Polynucleotides encoding these polypeptides are also provided.

Further preferred are the sulfotransferase active site polypeptides listed above, and at least 5, 10, 15, 20, 25, 30, 50, or 75 additional contiguous amino acid residues of the sequence referenced in Table I for this gene. The additional contiguous amino acid residues is N-terminal or C-terminal to the sulfotransferase active site polypeptides. Alternatively, the additional contiguous amino acid residues is both N-terminal and C-terminal to the sulfotransferase active site polypeptides, wherein the total N- and C-terminal contiguous amino acid residues equal the specified number. The above preferred polypeptide domains are characteristic of a signature specific to sulfotransferase proteins. The nucleotides sequence of this gene was found to be

homologous to the human hypoxanthine guanine phosphoribosyl transferase 2 cDNA which is known to be involved in the purine salvage pathway resulting in the maintenance of homeostatic levels of uric acid (See Genbank Accession No. T30127).

The gene encoding the disclosed cDNA is believed to reside on chromosome

7. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 7.

This gene is expressed to a very high level in HL-60 myelogenous leukemia cell lines, and to a lesser extent, in most cell types of the immune system.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, myelopoiesis, and metabolic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hematopoietic systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, metabolic, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 130 as residues: Ser-39 to Gly-46, Leu-49 to Ala-62, Lys-79 to Ala-93, Gly-95 to Asp-105, Ser-107 to Val-127, Gly-193 to Leu-200, Lys-218 to Ser-227, Lys-234 to Thr-239, Pro-366 to Asp-379, Pro-406 to Asp-414.

Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in HL-60 myelogenous leukemia cell lines and homology to HNK-1 sulfotransferase proteins indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, prevention and/or treatment of a variety of immune system disorders, including but not limited to, those involving the HNK-1 carbohydrate epitope, (e.g. HNK-1 as an auto-antigen

in peripheral demyelinative neuropathy). Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, expression of this gene product in tonsils indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively, the homology to a conserved purine metabolism protein may suggest that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, prevention, and/or treatment of various metabolic disorders such as Tay-Sach's Disease, phenylketonuria, galactosemia, porphyrias, Hurler's syndrome, and various urogenital disorders related to metabolic conditions, particularly Lesch-Nyhan syndrome. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:17 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-h, where a is any integer between 1 to 1760 of SEQ ID NO:17, b is an integer of 15 to 1774, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 8

When tested against Jurkat T-cell lines, supernatants removed from cells containing this gene activated the gamma activating sequence (GAS) promoter element. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway, a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. Thus, it is likely that this gene activates T-cells through the Jak-STAT signal transduction pathway.

In a specific embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: KLVRLQVPVRNSRVDPRVRSKIGSRRWMLQLI
MQLGSVLLTRCPFWGCFSQLMLYAERAEARRKPDIPVPLYFDMGAAVLCA
SFMSFGVKRRWFALGAALQLAISTYAA YIGGYVHYGDWLKVRMYSRTVAII
GGFLVLASGAGELYRRKPRSRSLQSTGQVFLGIYLCVAYSLQHSKEDRLA
YLNHLPGGELMIQLFFVLYGILALAFLSGYYVTLAAQILAVLLPPVMLLIDG
NVA YWHNTRRVEFWNQMKLLGESVGIFGTAVILATDG (SEQ ID NO: 271).

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MQLGSVLLTRCPFWGCFSQLMLYAERAEARRKPDIPVP
YLYFDMGAAVLCA SFMSFGVKRRWFALGAALQLAISTYAA YIGGYVHYGD

5
10
15
20
25
30
35
40
45
50
55

WLKVRMYSRTVAIGGFLVLASGAGELYRRKPRSRSLQSTGQVFLGIYLCVA
YSLQHSKEDRLAYLNHLPGGELMIQLFFVLYGILAPGLSVRLLRDPRCPDPGC
TAAPCHAAH (SEQ ID NO: 272). Polynucleotides encoding these polypeptides are also provided.

5
10
15
20
25
30
35
40
45
50
55

The gene encoding the disclosed cDNA is believed to reside on chromosome 17. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 17.

This gene is expressed primarily in endometrial tumors, and to a lesser extent, in T-cells, pituitary and to a certain extent in most cell types.

10
15
20
25
30
35
40
45
50
55

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, female reproductive, immune, or endocrine disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive and/or immune systems expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, reproductive, or cancerous and wounded tissues) or bodily fluids (e.g., amniotic fluid, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 131 as residues: Ala-27 to Asp-34, Tyr-116 to Leu-125. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution predominantly in the endometrium indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of a range of immune and/or reproductive disorders including endometriosis, endometritis, and endometrioma. Similarly, the tissue distribution in T-cells and the ability of supernatants expressing this gene to stimulate the GAS promoter element in T-cells indicates polynucleotides and

polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively, the tissue distribution in pituitary indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", and "Binding Activity" sections below, in Example 11, 17, 18, 19, 20 and 27, and elsewhere herein. Briefly, the protein can be used for the detection, treatment, and/or prevention of the Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g., diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-

hypopituitarism), thyroid (e.g., hyper-, hypothyroidism), parathyroid (e.g., hyper-, hypoparathyroidism), hypothalamus, and testes.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:18 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1660 of SEQ ID NO:18, b is an integer of 15 to 1674, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 9

Contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of the myeloid leukemia cell line AML-193 to calcium. Thus, it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of myeloid leukemia cells, in addition to other cell-lines or tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating myeloid leukemia cells.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: SNEILLSFPQNYIQLNGSLIHGLWNLASLFS NLCLFVLMPPFAFFLESEGFAGLKKGIRARILETLVMLLLLALLILGIVWVAS ALIDNDAASMESLYDLWEFYLPYLYSCISLMGCLLLLCTPVGLSRMFTVMG HLLVKPTILEDLDEQIYIITLEEEALQRRNLGLSSSVEYNIMELEQELENVKTL KTKLERRKKASAWERNLVYPAVMVLLLIETISISVLLVACNILCLLVDETAM PKGTRGPGIGNASLSTFGFVGALEIILIFYLMVSSVVGIFYSLRFFGNFTPKKD DTTMTKIIGNCVSILVLSSALPVMSTLGITRFDLLGDFGRFNWLGNFYIVLS YNLLFAIVTTLCLVRKFTSAVREELFKALGLHKLHLPNTSRDSETAKPSVNGH

5 QKAL (SEQ ID NO: 273). Polynucleotides encoding these polypeptides are also provided.

10 This gene is expressed primarily in fetal heart, and to a lesser extent, in colon and the adult pulmonary system.

5 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a
15 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, heart, lung and digestive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological
20 probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular, pulmonary and digestive systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., developmental, cardiovascular,
25 or cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample
15 taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic
20 epitopes shown in SEQ ID NO: 132 as residues: Glu-67 to Asn-74, Glu-88 to Asn-93, Lys-95 to Ala-107, Ala-147 to Arg-153, Phe-197 to Thr-205, Pro-292 to His-308.
35 Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in fetal heart, colon and pulmonary tissues and the biological activity in increasing the permeability of the plasma membrane of the
40 25 myeloid leukemia cell line AML-193 to calcium, likely indicating that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of myeloid leukemia cells, indicates that polynucleotides and polypeptides corresponding to this gene are
45 useful for the treatment, prevention, and/or detection of a range of disorders including
30 a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, myocardial infarction, myocarditis, ischemia, thrombosis, coronary artery disease,
50

arteriosclerosis, and/or atherosclerosis; pulmonary edema and embolism, bronchitis and/or cystic fibrosis; Crohn's Disease and/or colon cancer. Similarly, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:19 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2004 of SEQ ID NO:19, b is an integer of 15 to 2018, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 10

The protein product of this clone shares sequence homology with the human MaxiK channel beta 2 subunit (See, Genbank Accession No. gblAAD23380.11AF099137_1 (AF099137); all references available through this accession are hereby incorporated herein by reference), which is believed to be a modulatory subunit of the voltage and Ca²⁺ activated K⁺ (MaxiK) channel. Additionally, this protein shares homology to the human calcium-activated potassium

channel beta subunit, which, when combined with its corresponding alpha subunit and modulating peptide, are believed to be useful in treating asthma, angina, hypertension, incontinence, migraine, irritable bowel syndrome (IBS). The subsequent heteromultimer that forms upon combining the alpha, beta, and modulator subunits are also thought to be useful in preventing premature labour, preventing and treating cerebral ischemia, inducing pain modulation and decreasing neurogenic inflammation in a patient (See GeneSeq Accession No. R85306).

Preferred polypeptides comprise the soluble domain which consists of the following amino acid sequence: RSYMQSVWTEESQCTLLNASITETFNCSFSCGP.
DCWKLSQYPCLQVYVNLSSGEKLLLYHTEETIKINQKCSYIPKCGKNFEESM
SLVNVVMENFRKYQHFCYSDPEGNQKSVILTKLYSSNVI.FHSLFWPTCMMMA
GGVAIVAMVKLTQYLSLLCERIQRINR (SEQ ID NO: 274). Polynucleotides encoding these polypeptides are also provided. Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with modulatory subunits of voltage and Ca²⁺ activated K⁺ channel proteins. Such activities are known in the art, some of which are described in Wallner, et al., PNAS 96:4137-4142 (1999), incorporated herein by reference.

This gene is expressed primarily in adrenal gland tumor, and to a lesser extent, in Hodgkin's lymphoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endocrine and immune disorders, particularly Hodgkin's Lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and/or endocrine systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, endocrine, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression

level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 133 as residues: Trp-25 to Gln-30, Pro-50 to Gln-57, Pro-93 to Glu-101, Arg-114 to Cys-121, Ser-123 to Gln-129, Ile-177 to Arg-182. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in adrenal gland tumor and its identification as the modulatory subunit of the voltage and Ca^{2+} activated K^{+} (MaxiK) channel indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g., diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g., hyper-, hypothyroidism), parathyroid (e.g., hyper-, hypoparathyroidism), hypothalamus, and testes. Alternatively, expression in proliferative immune tissues combined with its homology to a novel human K channel indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product in Hodgkin's lymphoma indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity

disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:20 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2084 of SEQ ID NO:20, b is an integer of 15 to 2098, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 11

The translation product of this gene shares homology with collagen and collagen like proteins (See, e.g., Genbank Accession Nos. gi2920535|gb|AAC39658.11 (AF018081) and gi2384942|gb|AAB69961.11 (AF022985); all references available through these accession numbers are hereby incorporated by reference herein). Additionally, it has been determined that this gene has homology to the human Kruppel related zinc finger protein (HTF10) which is known to be important as a transcription factor, particularly in development (See Genebank Accession No.L11672).

5
10
15
20
25
30
35
40
45
50
55

In a specific embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: AFAHLQLGPMWKLWRAEEGAAALGGALFLLL
5 FALGVRQLLKQRRPMGFPPGPPGLPFIGNIYSLAASSELPHVYMRKQSQVYG
EVQPRRAPGREGRQAGPGWPGPSWLDLWPPLGRLVGTSPCAGCPLRDTRFPG
LEGRS PRRRAPLQGEPRPCR (SEQ ID NO: 275). Polynucleotides encoding these polypeptides are also provided.

10
20
25
30
35
40
45
50
55

This gene is expressed primarily in human erythroleukemia cell line (HEL), serum induced smooth muscle, and to a lesser extent in human 8 week whole embryo.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, leukemia, musculoskeletal, or developmental disorders. Similarly,
15 polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic system and muscular system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune,
20 musculoskeletal, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25
30
35
40
45
50
55

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 134 as residues: Leu-30 to Gly-38, Arg-67 to Val-72, Val-76 to Ala-89, Pro-118 to Arg-123, Gly-129 to Ala-136, Leu-138 to Arg-146. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in human erythroleukemia cell line (HEL), and serum
30 induced smooth muscle, and the shared homology with collagen and collagen like proteins indicates that polynucleotides and polypeptides corresponding to this gene are useful for disorders of hematopoietic or muscular systems, such as leukemia and

5 muscular dystrophy. Additionally, the shared homology with collagen proteins would
10 suggest that this protein may also be important in the diagnosis or treatment of
various autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma,
dermatomyositis, etc.), dwarfism, spinal deformation, joint abnormalities, and
5 chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial
osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid,
15 etc.).

The secreted protein can also be used to determine biological activity, to raise
antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents
20 that modulate their interactions and as nutritional supplements. It may also have a
very wide range of biological activities although no evidence for any is provided in
the specification. Typical of these are cytokine, cell proliferation/differentiation
modulating activity or induction of other cytokines;
25 immunostimulating/immunosuppressant activities (e.g., for treating human
immunodeficiency virus infection, cancer, autoimmune diseases and allergy);
15 regulation of haematopoiesis (e.g., for treating anaemia or as adjunct to
chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or
nerves (e.g., for treating wounds, stimulation of follicle stimulating hormone (for
30 control of fertility); chemotactic and chemokinetic activities (e.g., for treating
infections, tumours); haemostatic or thrombolytic activity (e.g., for treating
20 haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g., for treating
septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other
hyperproliferative disease; for regulation of metabolism, behaviour, and many others.
35 Also contemplated is the use of the corresponding nucleic acid in gene therapy
procedures. Furthermore, the protein may also be used to determine biological
40 activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors,
to identify agents that modulate their interactions, in addition to its use as a nutritional
supplement. Protein, as well as, antibodies directed against the protein may show
45 utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
50 related to SEQ ID NO:21 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1732 of SEQ ID NO:21, b is an integer of 15 to 1746, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:21, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 12

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MRVRIGLTLLCAVLLSLASASSDEEGSQD
ESLGFQDYFDIR (SEQ ID NO: 276). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 8. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 8.

This gene is expressed primarily in dendritic cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 135 as residues: Ser-22 to Ser-41, Glu-43 to Thr-50,

Ser-63 to Leu-68, Ser-71 to Gly-84, Ser-96 to Gly-114. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in dendritic cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, prevention, and/or treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

The secreted protein can be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities although no evidence for any is provided in the specification. Typical of these are cytokine, cell proliferation/differentiation

modulating activity or induction of other cytokines;
immunostimulating/immunosuppressant activities (e.g., for treating human
immunodeficiency virus infection, cancer, autoimmune diseases and allergy);
regulation of haematopoiesis (e.g., for treating anaemia or as adjunct to
chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or
nerves (e.g., for treating wounds, stimulation of follicle stimulating hormone (for
control of fertility); chemotactic and chemokinetic activities (e.g., for treating
infections, tumours); haemostatic or thrombolytic activity (e.g., for treating
haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g., for treating
septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other
hyperproliferative disease; for regulation of metabolism, behaviour, and many others.
Also contemplated is the use of the corresponding nucleic acid in gene therapy
procedures. Furthermore, the protein may also be used to determine biological
activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to
identify agents that modulate their interactions, in addition to its use as a nutritional
supplement. Protein, as well as, antibodies directed against the protein may show
utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:22 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 2862 of SEQ ID NO:22, b is an
integer of 15 to 2876, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:22, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 13

A preferred polypeptide variant of the invention comprises the following
amino acid sequence: MARGSLRRLRLRLVLGLWLALLRSVAGEQAPGTAPC
SRGSSWSADLDKCMDCSTSCPLPA ALAHPWGRSEPDLRAGAAFWLFGLE

5
10
15
20
25
30
35
40
45
50
55

TMPQE REVHHPHRGDRRRGLPSCGADPVTMCPLPAGARPLIIHSSILEPVSAS
QTRREPSSSNHK GGGGR (SEQ ID NO: 277). Polynucleotides encoding these
polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome
16. Accordingly, polynucleotides related to this invention are useful as a marker in
linkage analysis for chromosome 16.

This gene is expressed primarily in tumor growth factor or lipopolysaccharide
treated bone marrow stroma, epithelioid sarcoma, umbilical vein endothelial cells, and
to a lesser extent, in other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, hematopoiesis or immune disorders. Similarly, polypeptides and
antibodies directed to these polypeptides are useful in providing immunological
probes for differential identification of the tissue(s) or cell type(s). For a number of
disorders of the above tissues or cells, particularly of the hematopoietic,
integumentary, or immune systems expression of this gene at significantly higher or
lower levels is routinely detected in certain tissues or cell types (e.g., hematopoietic,
immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum,
plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken
from an individual having such a disorder, relative to the standard gene expression
level, i.e., the expression level in healthy tissue or bodily fluid from an individual not
having the disorder.

Preferred polypeptides of the present invention comprise immunogenic
epitopes shown in SEQ ID NO: 136 as residues: Pro-35 to Trp-42, Pro-65 to Asp-72,
Thr-86 to Phe-93, Ile-97 to Glu-103. Polynucleotides encoding said polypeptides are
also provided.

The tissue distribution in tumor growth factor or lipopolysaccharide treated
bone marrow stroma, epithelioid sarcoma, and umbilical vein endothelial cells
indicates that polynucleotides and polypeptides corresponding to this gene are useful
for the diagnosis, prevention, and/or treatment of a variety of immune system
disorders. Representative uses are described in the "Immune Activity" and "infectious

disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

The secreted protein can be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities although no evidence for any is provided in the specification. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g., for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of haematopoiesis (e.g., for treating anaemia or as adjunct to chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or nerves (e.g., for treating wounds, stimulation of follicle stimulating hormone (for

5 control of fertility); chemotactic and chemokinetic activities (e.g., for treating
infections, tumours); haemostatic or thrombolytic activity (e.g., for treating
10 haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g., for treating
septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other
5 hyperproliferative disease; for regulation of metabolism, behaviour, and many others.
Also contemplated is the use of the corresponding nucleic acid in gene therapy
15 procedures. Protein, as well as, antibodies directed against the protein may show
utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
20 available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:23 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
25 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
15 more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 1038 of SEQ ID NO:23, b is an
integer of 15 to 1052, where both a and b correspond to the positions of nucleotide
30 residues shown in SEQ ID NO:23, and where b is greater than or equal to a + 14.

20 FEATURES OF PROTEIN ENCODED BY GENE NO: 14

35 The translation product of this gene shares sequence homology with
chromaffin granule amine transporter protein which is thought to be important in
vesicle membrane amine transport, particularly in the neural and endocrine tissue, and
the human vesicular monoamine transporter hVMAT1 which is involved in the
40 25 regulation of amine storage in cardiovascular, endocrine, and central nervous system
function (See, Genbank Accession Nos. gi11314290 and gb1AAC50472.11; all
references available through these accession numbers are hereby incorporated by
reference herein). Based on these sequence similarities, The translation product of
45 this gene is expected to share at least some biological activities with amine transporter
30 proteins. Such activities are known in the art, some of which are described in
Erickson, et al., PNAS 93:5166-5171 (1996), and/or Liu, et al., Cell 70:539-551
50 (1992), which are both incorporated herein by reference.

In a specific embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: GTSFLDPTLSLFLVLEKFNLPGYVGLVFLGMAL
SYAISSPLFGLLSDKRPPLRKWLLVFGNLITAGCYMLLGPVPILHIKSQLWLL
VLILVVSGLSAGMSIIPTFPEILSCAHENGFEGLSTLGLVSGLFSAMWSIGAF
MGPTLGGLYKIGFEWAAAIIQGLWALISGLAMGLFYLLYSRRKRKSKSQNIL
STEEERTTLLPNET (SEQ ID NO: 278). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 6. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 6.

This gene is expressed primarily in colon cancer, osteoclastoma, and T-cell lymphoma, and to a lesser extent in many tumor or proliferative tissues such as endometrial tumor, chondrosarcoma, induced umbilical vein endothelial cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases resulting from disorders in small molecule transport (i.e., signalling molecules) in afflicted tissues and organs, particularly of the endocrine and central nervous systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the musculoskeletal, immune, and/or digestive systems and cancer expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, endocrine, or cancerous and wounded tissues) or bodily fluids (e.g., bile, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5

10

15

20

25

30

35

40

45

50

55

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 137 as residues: Ser-114 to Asn-123, Thr-127 to Thr-132. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in colon cancer, osteoclastoma, and T-cell lymphoma and homology to amine transporter family members indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of disorders or diseases resulted from small molecule transport in afflicted tissues and organs, particularly that of colon, osteoclast or T-cells. The expression in cancer tissues, and shared homology with transporter proteins may also indicate its role in anti-cancer drug resistance. Additionally, the protein can be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities although no evidence for any is provided in the specification. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of haematopoiesis (e.g. for treating anaemia or as adjunct to chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumours); haemostatic or thrombolytic activity (e.g. for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative disease; or for identifying inhibitors or promoters of the transport of toxic molecules to vesicles, for regulation of metabolism, behaviour, and many others. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:24 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1527 of SEQ ID NO:24, b is an integer of 15 to 1541, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:24, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 15

The translation product of this gene shares sequence homology with the human prolyl 4-hydroxylase alpha (II) subunit which is important in catalyzing the formation of 4-hydroxyproline in collagens which is essential for the folding of newly synthesised collagen polypeptide chains into triple-helical molecules (See Genbank Accession No. gblAAB71339.11; all references available through this accession are hereby incorporated herein by reference). Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with Prolyl 4-hydroxylase proteins. Such activities are known in the art, some of which are described in Annunen, et al., J. Biol. Chem. 272:17342-17348 (1997) which is incorporated herein by reference.

When tested against U937 myeloid and Jurkat T-cell cell lines, supernatants removed from cells containing this gene activated the gamma activating sequence (GAS), a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. Thus, it is likely that this gene activates myeloid cells and T-cells through the Jak-STAT signal transduction pathway.

In a specific embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

5 GTREARLRDLTRFYDKVLSLHEDSTTPVANPLLAFTLIKRLQSDWRNVVHSL
EASENIRALKDGYEKVEQDLPAFEDLEGAARALMRLQDVYMLNVKGLAR
10 GVFQRTGSAITDLYSPKRLFSLTGDDCFQVGKVAYDMGDYYHAIPWLEEA
VSLFRGSYGEWKTEDEASLEDALDHLAFAYFRAGNVSCALSLSREFLLYSPD
5 NKRMAENVLKYERLLAESPNNHVVAEAVIQRPNIPHLQTRDTYEGLCQTL
GSQPTLYQIPSLYCSYETNSNAYLLLQPIRKEVIHLEPYIALYHDFVSDSEAQ
15 KIRELAEPWLQRSVVASGEKQLQVEYRISKSAWLKDTVDLKLVTLNHRIAA
LTGLDVRPPYAEYLQVVNYGIGGGHYEPHFDHATSPSSPLYRMKSGNRVATFM
IYLSVEAGGATAFIYANLSVPVVRNAALFWWNLHRSGEGSDTLHAGCP

10 VLVGDKWVANKWIHEYGQEFRPCSSSPED (SEQ ID NO: 282). Additional,

Preferred polypeptides comprise the following amino acid sequence: GTREA
RLRDLTRFYDKVLSLHEDSTTPVANPLLAFTLIKRLQSDWRNVVHSEASENI
RALKDGYEKVEQDLPAFEDLEGAARAL (SEQ ID NO: 279), ALMRLQD (SEQ
25 ID NO: 280), and/or VEAGGAT (SEQ ID NO: 281). Polynucleotides

15 encoding these polypeptides are also provided.

This gene is expressed primarily in lymph node breast cancer, colon
carcinoma, and to a lesser extent in osteoblasts and adipocytes.

30 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
20 biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, disorders of connective and immune tissues, particularly autoimmune
35 disorders. Similarly, polypeptides and antibodies directed to these polypeptides are
useful in providing immunological probes for differential identification of the
tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,
40 particularly of the connective tissues in breast, colon, bone, and fat, expression of this
gene at significantly higher or lower levels is routinely detected in certain tissues or
cell types (e.g., immune, connective, or cancerous and wounded tissues) or bodily
45 fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another
tissue or cell sample taken from an individual having such a disorder, relative to the
30 standard gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an individual not having the disorder.

5

10

15

20

25

30

35

40

45

30

50

55

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 138 as residues: Ser-74 to Ala-84, Gln-156 to Tyr-161, Tyr-184 to Asn-189, Ser-218 to Ile-223, Pro-299 to Ser-308, His-359 to Thr-368, Tyr-390 to Asp-404. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in lymph node breast cancer and colon carcinoma and homology to prollyl 4-hydroxylase alpha (II) subunit indicates that polynucleotides and polypeptides corresponding to this gene are useful for intervention of connective tissue disorders and diseases (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), as well as, in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid. Alternatively, the tissue distribution within various tissue carcinomas and tumor tissues, and biological activity reflected by the binding and activation of the GAS promoter element indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders.

Expression in cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:25 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2065 of SEQ ID NO:25, b is an

integer of 15 to 2079, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:25, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 16

In an additional embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: IQPSHAALLHCRSTFRKTECLDPW WVRRQLLGMAIGIGGLQKMKAPHTGVLHLGSVWVFLGPFLLGVGYTLTFNPL SGCMSTVRWLNSNITANRTLSRSVCHVTPLHRSLSPHDGEYLRQMLLNSSSR AGEAGSWG Y (SEQ ID NO: 283). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 20. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 20.

This gene is expressed primarily in fetal liver, and, to a lesser extent, in a variety of fetal and other tissues and cell types.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, liver disorders and cancers (e.g., hepatoblastoma, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the liver, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., hepatic, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, bile, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 139 as residues: Ser-67 to Tyr-75. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in fetal liver indicates that polynucleotides and polypeptides corresponding to this gene are useful for detection and treatment of liver disorders and cancers (e.g., hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). In addition the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, pre-natal disorders and various wound-healing models and/or tissue trauma. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:26 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1933 of SEQ ID NO:26, b is an integer of 15 to 1947, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:26, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 17

The translation product of this gene shares sequence homology with human laminin B1 which is thought to be an important structural extracellular matrix component involved in cell migration and signalling, particularly in stimulating epithelial cell growth and differentiation (See, Genbank Accession No gill186837).

Preferred polypeptides of the invention comprise the following amino acid sequences: CSSPPGRLPWCWTAPRTLKGHGLISTLRLTAPLHLAWKMMLS
RKALFVLLNTPVLFHALEGRLFSLCHHHTIQRTLTVPKFRSS (SEQ ID NO:
284), RSPTSRVQLLKRQSCPCQRNDLNEEPQHFTHYAIYDFIVKGSCFCNG
HADQCIPVHGFRPVKAPGTFHMHGKCM (SEQ ID NO: 285), and/or HNTAG
SHCQHCAPLYNDRPWEAADGKTGAPNECRTCKCNHADTCHFDVNVWEAS
GNRSGGVCDDCQHNTGQYQQRCKPGFYDLRRPFSA PDACKPCSCHPV
GSAVLPANSVTFC DPSNGDCPKPGVAGRRCDRCMVGYWGF GDY GCRP
CDCAGSCDPITGDCJSSHTDIDWYHEVPDFRPVHNKSEPAWEWEDAQGFSA
LHSGKCECKEQT LGNAKAF CGMKYSYVLKIKILSAHDKGTHVEVNVKIK
KVLKSTKLKIFRGKANIISRIMDGQ RMHLSNPQSWFGIPCSRT (SEQ ID NO:
286). Polynucleotides encoding these polypeptides are also provided.

Included in this invention as preferred domains are Laminin-type EGF-like (LE) domain signatures, which were identified using the ProSite analysis tool (Swiss Institute of Bioinformatics). Laminins are the major noncollagenous components of basement membranes that mediate cell adhesion, growth migration, and differentiation. They are composed of distinct but related alpha, beta and gamma chains. The three chains form a cross-shaped molecule that consist of a long arm and three short globular arms. The long arm consists of a coiled coil structure contributed by all three chains and cross-linked by interchain disulfide bonds. Beside different types of globular domains each subunit contains, in its first half, consecutive repeats of about 60 amino acids in length that include eight conserved cysteines. The tertiary structure of this domain is remotely similar in its N-terminal to that of the EGF-like module. It is known as a 'LE' or 'laminin-type EGF-like' domain. The number of copies of the LE domain in the different forms of laminins is highly variable; from 3 up to 22 copies have been found. A schematic representation of the topology of the four disulfide bonds in the LE domain is shown below.

48



10

```

'C': conserved cysteine involved in a disulfide bond
'a': conserved aromatic residue
'G': conserved glycine (lower case = less conserved)
15 's': region similar to the EGF-like domain
    '**': position of the pattern

```

In mouse laminin gamma-1 chain, the seventh LE domain has been shown to be the only one that binds with a high affinity to nidogen. The binding-sites are located on the surface within the loops C1-C3 and C5-C6. Long consecutive arrays of LE domains in laminins form rod-like elements of limited flexibility, which determine the spacing in the formation of laminin networks of basement membranes. We derived a signature pattern for the LE domain which covers the C-terminal half of the repeat starting with the fourth conserved cysteine. The consensus pattern is as follows: C-x(1,2)-C-x(5)-G-x(2)-C-x(2)-C-x(3,4)-[FYW]-x(3,15)-C [All C's are involved in disulfide bonds]

located on the surface within the loops C1-C3 and C5-C6. Long consecutive arrays of LE domains in laminins form rod-like elements of limited flexibility, which determine the spacing in the formation of laminin networks of basement membranes. We derived a signature pattern for the LE domain which covers the C-terminal half of the repeat starting with the fourth conserved cysteine. The consensus pattern is as follows: C-x(1,2)-C-x(5)-G-x(2)-C-x(2)-C-x(3,4)-[FYW]-x(3,15)-C [All C's are involved in disulfide bonds]

25 follows: C-x(1,2)-C-x(5)-G-x(2)-C-x(2)-C-x(3,4)-[FYW]-x(3,15)-C [All C's are involved in disulfide bonds]

Preferred polypeptides of the invention comprise the following amino acid sequence: CDDCQIINTEGQYQCRCKPGFYRDLRRPFSAPDACKPC (SEQ ID NO: 287) and/or CPCKPGVAGRRCDRCMVGYWGFQDYGCRPCDCAGSC (SEQ ID NO: 288). Polynucleotides encoding these polypeptides are also provided.

Further preferred are polypeptides comprising the laminin-type EGF-like domains listed above, and at least 5, 10, 15, 20, 25, 30, 50, or 75 additional contiguous amino acid residues of the sequence encoded by this gene. The additional contiguous amino acid residues is N-terminal or C- terminal to the laminin-type EGF-

contiguous amino acid residues is N-terminal or C-terminal to the laminin-type EGF-

55

5 like domain. Alternatively, the additional contiguous amino acid residues is both N-
terminal and C-terminal to the laminin-type EGF-like domain, wherein the total N-
10 and C-terminal contiguous amino acid residues equal the specified number. The
above preferred polypeptide domain is characteristic of a signature specific to
5 Laminin proteins. Based on the sequence similarity, the translation product of this
gene is expected to share at least some biological activities with Laminin proteins.
15 Such activities are known in the art, some of which are described elsewhere herein.

This gene is expressed primarily in osteoblastic tissues and cell types,
including osteoblasts, osteoblastomas and osteoclastomas. Expression is also
20 abundant in vascular-pulmonary tissues such as lung, micro-vasculature, pulmonary,
endothelial and smooth muscle cells.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
25 biological sample and for diagnosis of diseases and conditions which include, but are
15 not limited to, cancer and malignancies (particularly of osteoblastic tissues and
rhabdomyosarcoma), as well as cardiovascular and respiratory or pulmonary disorders
such as asthma, pulmonary edema, pneumonia, atherosclerosis, restenosis, stroke,
30 thrombosis hypertension, inflammation and wound healing. Similarly, polypeptides
and antibodies directed to these polypeptides are useful in providing immunological
20 probes for differential identification of the tissue(s) or cell type(s). For a number of
disorders of the above tissues or cells, particularly of the cardio-respiratory system,
and skeletal system expression of this gene at significantly higher or lower levels is
35 routinely detected in certain tissues or cell types (e.g., skeletal, osteoblast, cardio-
respiratory, vascular, or cancerous and wounded tissues) or bodily fluids (e.g., lymph,
40 pulmonary surfactant, serum, plasma, urine, synovial fluid and spinal fluid) or another
tissue or cell sample taken from an individual having such a disorder, relative to the
standard gene expression level, i.e., the expression level in healthy tissue or bodily
45 fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic
30 epitopes shown in SEQ ID NO: 140 as residues: Ser-28 to Cys-34, Thr-51 to Thr-58,
Tyr-64 to Asn-81, Asp-111 to Lys-116, Asp-145 to Phe-160, Pro-203 to Glu-217.
50 Polynucleotides encoding said polypeptides are also provided.

5

10

15

20

25

30

35

40

45

50

55

The tissue distribution in osteoblastic tissues and cell types and homology to laminin indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, prevention and diagnosis of cardiovascular and respiratory or pulmonary disorders such as asthma, pulmonary edema, pneumonia, atherosclerosis, restenosis, stroke, angina, thrombosis hypertension, inflammation and wound healing. As a homolog of laminin, this gene product quite possibly has a role in cell adhesion, migration, proliferation, angiogenesis, chondrogenesis, wound healing and oncogenesis. An EST (Int J Cancer 1996 May 16;66(4):571-577) with an identical sequence to part of this contig was shown to be differentially expressed in human primary myoblasts and embryonal rhabdomyosarcoma and therefore might have an important role in the determination or maintenance of the normal phenotype, and thus its loss is possibly involved in the progression of malignancies, particularly of skeletal muscle. Similarly, the homology to a laminin would suggest a role in the detection and treatment of disorders and conditions afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation) in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:27 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 3365 of SEQ ID NO:27, b is an integer of 15 to 3379, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:27, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 18

The gene encoding the disclosed cDNA is believed to reside on chromosome 10. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 10.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: NISSQYCILKSLEMMISGLKLLVLFLKFAPENY CLSTETLQMPNRHLRLSKATCYLMKCLLPSEYFE (SEQ ID NO: 289).

Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in placenta, brain, and to a lesser extent, in a variety of other tissues and cell types.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive, behavioral, or nervous system disorders, such as: depression, schizophrenia, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, dementia, paranoia, addictive behavior, epilepsy, transmissible spongiform encephalopathy (TSE), Creutzfeldt-Jakob disease (CJD). Other diseases and conditions related to expression in the placenta might include developmental anomalies and fetal deficiencies, ovarian and endometrial cancers, reproductive disfunction and pre-natal disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous and reproductive systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, reproductive, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial

fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 141 as residues: Ala-16 to Leu-22. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions.

Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, expression in placenta would suggest a possible role in the treatment and diagnosis of developmental anomalies and fetal deficiencies, ovarian and endometrial cancers, reproductive dysfunction and pre-natal disorders.

Similarly, expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus, this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may

show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:28 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1992 of SEQ ID NO:28, b is an integer of 15 to 2006, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 19

The translation product of this gene shares sequence homology with the murine transforming protein (See, e.g., Genbank Accession No. gil53529|emb|CAA36859.11; all references available through this accession are hereby incorporated by reference herein).

In a specific embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: PIEGTPAGTGPEFPGRPTRPQRMRSLLISSHPCQHLLLLLLLFLILAILVDVKWYLVLFICISLMTSDVEHLFMCLLAIRISSWRNVY (SEQ ID NO: 290). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in activated and basal T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immunodeficiency, tumor necrosis, infection, lymphomas, auto-immunities, cancer, metastasis, wound healing, inflammation, anemias (leukemia) and other hematopoietic disorders. Similarly, polypeptides and antibodies directed to these

polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in activated T-cells and the homology to a murine transforming protein indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of

various blood lineages, and in the differentiation and/or proliferation of various cell types.

The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities although no evidence for any is provided in the specification. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines;

immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of haematopoiesis (e.g. for treating anaemia or as adjunct to chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumours); haemostatic or thrombolytic activity (e.g. for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative disease; for regulation of metabolism, behaviour, and many others.

Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:29 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3056 of SEQ ID NO:29, b is an

integer of 15 to 3070, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 20

The translation product of this gene was shown to have homology to the Mus musculus ALG-2 protein, which is known to code for a Ca(2+)-binding protein required for T cell receptor-, Fas-, and glucocorticoid-induced cell death. ALG-2 mediate Ca(2+)-regulated signals along the death pathway and may play a role in the onset of Alzheimer's Disease (See e.g., Genbank Accession No.gil1213520; all references available through this accession are hereby incorporated by reference herein).

Preferred polypeptides comprise the following amino acid sequence: NWVPT CLCPSPACSFHLLSRFKCLFSPQRLTDIFRRYDQDQGWIQVSYEQYLSMVFS IV (SEQ ID NO: 291), and/or QRLTDIFRRYDQDQGWIQVSYEQYLSMVFSIV (SEQ ID NO: 292). Polynucleotides encoding these polypeptides are also provided.

When tested against K562 cell lines, supernatants removed from cells containing this gene activated the ISRE (interferon-sensitive responsive element). Thus, it is likely that this gene activates immune or leukemia cells through the Jaks-STAT signal transduction pathway. ISRE is a promoter element found upstream in many genes which are involved in the Jaks-STAT pathway. The Jaks-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MFYKLTILCELSVAGVTQAASQRPLQRLPRHICSQR XPPGRCLLKAXLQTTWXXPKPI PRLSPPLXSDPKR (SEQ ID NO: 293). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 5. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 5.

5 This gene is expressed primarily in placenta, and to a lesser extent, in a variety
of other tissues and cell types.

10 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
5 biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, developmental anomalies, fetal deficiencies ovarian and endometrial
15 cancers, reproductive dysfunction and pre-natal disorders. Similarly, polypeptides and
antibodies directed to these polypeptides are useful in providing immunological
probes for differential identification of the tissue(s) or cell type(s). For a number of
20 disorders of the above tissues or cells, particularly of the reproductive system,
expression of this gene at significantly higher or lower levels is routinely detected in
certain tissues or cell types (e.g., reproductive, developmental, or cancerous and
wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine,
25 synovial fluid and spinal fluid) or another tissue or cell sample taken from an
15 individual having such a disorder, relative to the standard gene expression level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not having the
disorder.

30 Preferred polypeptides of the present invention comprise immunogenic
epitopes shown in SEQ ID NO: 143 as residues: Arg-24 to Arg-31, Ile-33 to Gly-41.
20 Polynucleotides encoding said polypeptides are also provided.

35 The tissue distribution in placenta indicates that polynucleotides and
polypeptides corresponding to this gene are useful for the treatment, prevention
and/or diagnosis of developmental anomalies, fetal deficiencies, ovarian and
endometrial cancers, reproductive dysfunction and pre-natal disorders. Expression
40 25 within embryonic tissue and other cellular sources marked by proliferating cells
combined with the observed ISRE activity, and homology to the apoptosis linked,
ALG-2 indicates that this protein may play a role in the regulation of cellular division,
and may show utility in the diagnosis, treatment, and/or prevention of developmental
45 diseases and disorders, cancer, and other proliferative conditions. Representative uses
30 are described in the "Hyperproliferative Disorders" and "Regeneration" sections
below and elsewhere herein. Briefly, developmental tissues rely on decisions
50 involving cell differentiation and/or apoptosis in pattern formation.

5
10
15
20
25
30
35
40
45
50
55

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:30 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2213 of SEQ ID NO:30, b is an integer of 15 to 2227, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:30, and where b is greater than or equal to a + 14.

5

59

FEATURES OF PROTEIN ENCODED BY GENE NO: 21

10

15

20

25

30

35

40

45

50

55

The translation product of this gene was shown to have homology to the human histo-blood group A transferase (See, e.g., Genbank Accession No. gb|AAD26573.1|AF134413_1 (AF134413); all references available through this accession are hereby incorporated by reference herein) which is known to represent one of the major allogeneic antigens in both erythrocytes and tissues of humans. Its been proposed that the A phenotype is associated with the glycosyltransferase that converts the H substance associated with the O phenotype to A through the addition of alpha1-3-N-acetylgalactosamine or alpha1-3-galactosyl residues to the H antigen Fuc-alpha1-2Gal- beta1-R. Therefore, the primary product of the histo-blood group A is its respective glycosyltransferase. Preferred polypeptides of the invention comprise the following amino acid sequence: TSSPVFSFCSMAVREPDHLQ RVSLPRYNVSASLQWLPCHRIVLQPWHMCAMWELGQVLFHPVAPREGAAPS PVSTLTWPSSCSHSESTMELELQF (SEQ ID NO: 294), LPCHRIV (SEQ ID NO: 296), SLQWLPCHRIVLQPW (SEQ ID NO: 297), and/or MAVREPDHLQRVSLPR (SEQ ID NO: 295). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in 12-week-old human embryo. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental anomalies, fetal deficiencies, pre-natal disorders, hematopoietic disorders, or cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the developing fetus, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., hematopoietic, lymph, developing, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5

10

15

20

25

30

35

40

45

50

55

The tissue distribution in 12 week old embryo indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of developmental anomalies, fetal deficiencies, pre-natal disorders and cancer.

Similarly, expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus, this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Alternatively, the tissue distribution and homology to human blood group A and B glycosyltransferase enzymes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:31 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

5

61

10

15

excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1274 of SEQ ID NO:31, b is an integer of 15 to 1288, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:31, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 22

20

25

30

35

40

45

50

55

The translation product of this gene shares sequence homology with CD97 (EMR1), which is thought to be important in both adhesion and signaling processes early after leukocyte activation (See, e.g., Genbank Accession No. gil784994; all references available through this accession are hereby incorporated by reference herein). EMR1 belongs to a novel family of G-protein receptors that has recently been recognized on the basis of homologous primary amino acid sequences, comprises receptors to hormones of the secretin/vasoactive intestinal peptide/glucagon family, parathyroid hormone and parathyroid hormone-related peptides, growth hormone-releasing factor, corticotropin-releasing factor, and calcitonin. Proteins with seven transmembrane segments (7TM) define a superfamily of receptors (7TMreceptors) sharing the same topology: an extracellular N-terminus, three extramembranous loops on either side of the plasma membrane, and a cytoplasmic C-terminal tail. Upon ligand binding, cytoplasmic portions of the activated receptor interact with heterotrimeric G-coupled proteins to induce various second messengers, which subsequently activate various signal transduction pathways depending upon the specific G-coupled protein associated with the receptor. Preferred polypeptides of the invention comprise the following amino acid sequence: CFKRKPKREHCSCP
ITYQSLGDILNASFFSKRKGMEVKNLSYVVSIGTLKEKISLSEPVFLTFRHN
QPGDKRTKHICVY WEGSEGGRWSTEGCSHVHNSGYTKCKCFHLSSFVAVLV
ALAPKEDPVLTVITQVGLTISLLCLFLAILTFLLCRPIQNTSTSLHLELSLCLFLA
HLLFLTGINRTEPEVLCSSIIAGLLHFLYLACFTWMLLEGLHLFLTVRNLKVAN
YTSTGRFKKRFMY PVGYGIPAVIIAVSAIVGPQNYGTFTHCWLKLDKGFIWSF
MGPVAVIILINLVFYFQVI.WILRSKLSSLNKEVSTIQDTRVMTFKAISQLFILGC
SWGLGFFMVEEVGKTIGSIIAYSFTIINTLQGVLLFVVHCLLNQRQVRMEYKKW

FSGMRKGVETESTEMSRSTTQTKTEEVGKSSEIFIKGGTASSSAESTKQPQPQ
 VHLVSAAWLKMN (SEQ ID NO: 298), and/or FFWKENLRRNGSREDFARRATQ
 LIQSVLSIWNASFASPGKGQISEFDIVYETKRCNETRENAFLEAGNNTMDINC
 ADALKGNLRESTAVALSINLLGIF SEQ ID NO: 299. Polynucleotides

encoding these polypeptides are also provided.

Included in this invention as preferred domains are two EGF-like protein domains, which were identified using the ProSite analysis tool (Swiss Institute of Bioinformatics). First, a sequence of about forty amino-acid residues long found in the sequence of epidermal growth factor (EGF) has been shown to be present in a large number of membrane-bound and extracellular, mostly animal proteins. Many of these proteins require calcium for their biological function and a calcium-binding site has been found to be located at the N-terminus of some EGF-like domains. Calcium-binding is crucial for numerous protein-protein interactions. We have used the N-terminal part of the EGF domain as a consensus pattern. It includes the negative N-terminus and the possible hydroxylation site. The consensus pattern is as follows: [DEQN].[DEQN]{2}C.{3,14}C.{3,7}C.[DN].{4}[FY].C [The four C's are involved in disulfide bonds].

Preferred polypeptides of the invention comprise the following amino acid sequence: DINECEGLAKCKYKAYCRNKVGGYIC (SEQ ID NO: 300).

Polynucleotides encoding these polypeptides are also provided. Secondly, post-translational hydroxylation of aspartic acid or asparagine to form erythro-beta-hydroxyaspartic acid or erythro-beta-hydroxyasparagine has been identified in a number of proteins with domains homologous to (EGF). Based on sequence comparisons of the EGF-homology region that contains hydroxylated Asp or Asn, a consensus sequence located in the N-terminal of EGF-like domains has been identified that seems to be required by the hydroxylase(s). The consensus sequence is as follows: C.[DN].{4}[FY].C.C.

Preferred polypeptides of the invention comprise the following amino acid sequence: CRNKVGGYICSC (SEQ ID NO: 301). Polynucleotides encoding these polypeptides are also provided.

Further preferred are polypeptides comprising the calcium-binding EGF-like domain and aspartic acid and asparagine hydroxylation site listed above, and at least

5 5, 10, 15, 20, 25, 30, 50, or 75 additional contiguous amino acid residues of the
sequence referenced in Table I for this gene and the embodiments listed herein. The
10 additional contiguous amino acid residues is N-terminal or C-terminal to one or both
of the listed domains. Alternatively, the additional contiguous amino acid residues is
5 both N-terminal and C-terminal to one or both of the listed domains, wherein the total
N- and C-terminal contiguous amino acid residues equal the specified number. The
15 above preferred polypeptide domains are characteristic of a signature specific to EGF
like proteins. Based on the sequence similarity and conserved domains, The
translation product of this gene is expected to share at least some biological activities
20 with EGF-like proteins. Such activities are known in the art, some of which are
described elsewhere herein.

This gene is expressed primarily in eosinophils.

Therefore, polynucleotides and polypeptides of the invention are useful as
25 reagents for differential identification of the tissue(s) or cell type(s) present in a
15 biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, hematopoietic disorders or anemias and leukemias,
immunodeficiencies, infection, lymphomas, auto-immunities and cancer. Similarly,
30 polypeptides and antibodies directed to these polypeptides are useful in providing
immunological probes for differential identification of the tissue(s) or cell type(s). For
20 a number of disorders of the above tissues or cells, particularly of the immune and
hematopoietic systems, expression of this gene at significantly higher or lower levels
35 is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, or
cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine,
synovial fluid and spinal fluid) or another tissue or cell sample taken from an
40 25 individual having such a disorder, relative to the standard gene expression level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not having the
disorder.

Preferred polypeptides of the present invention comprise immunogenic
45 epitopes shown in SEQ ID NO: 145 as residues: Ser-22 to Ser-30, Pro-33 to Cys-48,
30 Asp-50 to Lys-67, Pro-117 to Ser-130. Polynucleotides encoding said polypeptides
are also provided.

5 The tissue distribution in eosinophils combined with its homology to a known
human seven transmembrane domain protein indicates that polynucleotides and
10 polypeptides corresponding to this gene are useful for the diagnosis and treatment of
cancer and other proliferative disorders, particularly considering the fact that the
5 majority of 7 transmembrane receptors are tightly associated with signal transduction
pathways which are integral to the modulation of the cell cycle. As such, the protein
15 product of this gene may play a role in the regulation of cellular division, where loss
of regulation may result in proliferating cells and the onset of tumors or cancer.
Additionally, the expression in hematopoietic cells and tissues indicates that this
20 protein may play a role in the proliferation, differentiation, and/or survival of
hematopoietic cell lineages. In such an event, this gene is useful in the treatment of
lymphoproliferative disorders, and in the maintenance and differentiation of various
hematopoietic lineages from early hematopoietic stem and committed progenitor
25 cells. Similarly, embryonic development also involves decisions involving cell
differentiation and/or apoptosis in pattern formation. Thus this protein may also be
involved in apoptosis or tissue differentiation and could again be useful in cancer
therapy. Similarly, the tissue distribution and homology to CD97 indicates that the
30 protein product of this gene might be a marker for differentiation and activation of
eosinophils, and therefore is useful for the diagnosis and treatment of immune
20 disorders including: leukemias, lymphomas, auto-immunities, immunodeficiencies
(e.g., AIDS), immuno-suppressive conditions (transplantation) and hematopoietic
35 disorders. Representative uses are described in the "Immune Activity" and "infectious
disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere
herein. In addition this gene product is applicable in conditions of general microbial
40 25 infection, inflammation or cancer. Furthermore, the protein may also be used to
determine biological activity, to raise antibodies, as tissue markers, to isolate cognate
ligands or receptors, to identify agents that modulate their interactions, in addition to
45 its use as a nutritional supplement. Protein, as well as, antibodies directed against the
protein may show utility as a tumor marker and/or immunotherapy targets for the
30 above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
50 available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:32 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3266 of SEQ ID NO:32, b is an integer of 15 to 3280, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:32, and where b is greater than or equal to a + 14.

10 FEATURES OF PROTEIN ENCODED BY GENE NO: 23

The translation product of this gene has been found to have homology to the rat neural F box protein NFB42, in addition to a conserved Caenorhabditis elegans C14B1.3 protein (See, e.g., Genbank Accession Nos. gil3851648|gb|AAC97505.11 (AF098301) and gil558270; all references available through these accessions are hereby incorporated by reference herein). Preferred polypeptides of the invention comprise the following amino acid sequence: ALCPHPHLILNVTVPAPSCRHVK KVVASPPSTTMIAMDAPHSKAALDSINELPENILLELFTHVPARQLLLNCRL VCSLWRDLIDLMTLWKRKCLREGFITKDWDQPVADWKIFYFLRSLHRNLLR NPCAEEDMFAWQIDFNGGDRWKVESLPGAHGTDFFDPKVKKYFVTSYEMCL KSQLVDLVAEGYWEELDTFRPDIVVKDWFAARADCGCTYQLKVQLASA DYFVLASFEPPTIQQWNNATWTEVSYTFSDYPRGVRYILFQHGGRTQY WAGWYGPRVTNSSIVVSPKMTRNQASSEAQPGQKHGQEEAAQSPYRAVV QIF (SEQ ID NO: 302). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

This gene is expressed primarily in immune cells, especially primary dendritic cells, and T cells, and to a lesser extent in a variety of other tissues including breast, keratinocytes, epididymus (cauda), lung, multiple sclerosis, endometrial stromal cells, IL4 induced umbilical vein endothelial cells, fetal kidney, fetal dura mater, rejected kidney, and osteoblasts.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and other proliferative disorders, particularly of the immune system or endothelial cells. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 146 as residues: Pro-41 to Cys-47, Phe-52 to Gly-59, Pro-62 to His-70. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in immune cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product in T-cells indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,

5 such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and
tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity
10 disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic
lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's
5 Disease, scleroderma and tissues. Moreover, the protein may represent a secreted
factor that influences the differentiation or behavior of other blood cells, or that
15 recruits hematopoietic cells to sites of injury. In addition, this gene product may have
commercial utility in the expansion of stem cells and committed progenitors of
various blood lineages, and in the differentiation and/or proliferation of various cell
10 types.

20 The secreted protein can also be used to determine biological activity, to raise
antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents
that modulate their interactions and as nutritional supplements. It may also have a
25 very wide range of biological activities although no evidence for any is provided in
15 the specification. Typical of these are cytokine, cell proliferation/differentiation
modulating activity or induction of other cytokines;

30 immunostimulating/immunosuppressant activities (e.g., for treating human
immunodeficiency virus infection, cancer, autoimmune diseases and allergy);
regulation of haematopoiesis (e.g., for treating anaemia or as adjunct to
20 chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or
nerves (e.g., for treating wounds, stimulation of follicle stimulating hormone (for
35 control of fertility); chemotactic and chemokinetic activities (e.g. for treating
infections, tumours); haemostatic or thrombolytic activity (e.g., for treating
haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g., for treating
40 septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other
25 hyperproliferative disease; for regulation of metabolism, behaviour, and many others.
Also contemplated is the use of the corresponding nucleic acid in gene therapy
procedures. Protein, as well as, antibodies directed against the protein may show
45 utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
50 related to SEQ ID NO:33 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1283 of SEQ ID NO:33, b is an integer of 15 to 1297, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:33, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 24

The translation product of this gene shares sequence homology with the human, mouse, and bovine dopamine hydroxylase which is thought to be important in the modification of dopamine, a neurotransmitter (See Genbank Accession Nos. gil30474, gil162965, and/or gil2358082; all references available through these accessions are hereby incorporated by reference herein). Preferred polypeptides of the invention comprise the following amino acid sequence: RQRSWNPGT
NCYHPNMPDAFLTCTETVIFAWAIGGEGFSYPPHVGLSLGTPLDPHYVLLEVH
YDNPTYEEGLIDNSGLRFLYTM DIRKYDAGVIEAGLWVSLFHTIPPGMPEF
QSEGHCTLECLEEAEAEKPSGIHVFAVLLIAHLAAGRIRLRHFRKGKEMKL
LAYDDDFDNFQEFQYLKEEQTILPGDNLITECRYNTKDRAEMTWGGLSTR
SEMCLSYLLYYPRINLTRCASIPDIMEQLQFIGVKEIYRPVTTWPFIIKSPKQYK
NLSFMDAMNKFKWTKKEGLSFNKLVLSPVNVRCSTDNAEWSIPRNDST
SRYRCTL (SEQ ID NO: 303). Polynucleotides encoding these polypeptides are also provided.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MCCWPLLLWGLLPGTAAGGSGRTYPHRTLLDSEK
YWLGSQRGSQIAFRLQVRTAGYVGFGFSPTGAMASADIVVGGVAHGR
PYLQDYFTNANRELKKAQQDYHLEYAMENSTHTIIEFTRELHTCDINDKS
ITDSTVRVIWAYHHE DAGEAGPKYHDSNRGTKSLRLNPEKTSVLSTALPYF
DLVNQDVPIPNKDDTYWCQMFKIPVFQEKHHVIKVEPVIQRGHESLVHHILL
YQCSNNFDSVPGIRARIAITPCPMHSSPV KL (SEQ ID NO: 304).
Polynucleotides encoding these polypeptides are also provided.

5 This gene is expressed primarily in brain, the pulmonary system, and to a lesser extent in kidney.

10 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a
5 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological and behavioral disorders. Similarly, polypeptides and
15 antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system, expression
20 of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, endocrine, or cancerous and wounded tissues) or bodily fluids (e.g., sputum, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder,
25 relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 147 as residues: Ser-33 to Trp-38, Gly-40 to Gly-45,
30 Asn-93 to Asp-105, Thr-128 to Thr-137, Glu-150 to Lys-167, Pro-197 to Tyr-203, Cys-242 to Asn-247, Ser-253 to Tyr-258, His-307 to Glu-314, Glu-357 to Gly-362, Trp-373 to Gln-378, Ser-402 to Glu-408. Polynucleotides encoding said polypeptides are also provided.

35 The tissue distribution in brain and homology to a protein involved in the modification of dopamine indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of
40 neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly,
45 the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia,
30 trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive
50

5 compulsive disorder, depression, panic disorder, learning disabilities, ALS,
psychoses, autism, and altered behaviors, including disorders in feeding, sleep
10 patterns, balance, and perception. In addition, the gene or gene product may also play
a role in the treatment and/or detection of developmental disorders associated with the
5 developing embryo, sexually-linked disorders, or disorders of the cardiovascular
system. Alternatively, the homology to dopamine hydroxylase indicates that
15 polynucleotides and polypeptides corresponding to this gene are useful for the
detection, treatment, and/or prevention of various endocrine disorders and cancers,
particularly Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of
20 the pancreas (e.g., diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-,
hypopituitarism), thyroid (e.g., hyper-, hypothyroidism), parathyroid (e.g., hyper-,
hypoparathyroidism), hypothalamus, and testes. Furthermore, the protein may also
be used to determine biological activity, to raise antibodies, as tissue markers, to
25 isolate cognate ligands or receptors, to identify agents that modulate their interactions,
15 in addition to its use as a nutritional supplement. Protein, as well as, antibodies
directed against the protein may show utility as a tumor marker and/or
immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
20 related to SEQ ID NO:34 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
35 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
more polynucleotides comprising a nucleotide sequence described by the general
40 25 formula of a-b, where a is any integer between 1 to 2170 of SEQ ID NO:34, b is an
integer of 15 to 2184, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:34, and where b is greater than or equal to a + 14.

45 FEATURES OF PROTEIN ENCODED BY GENE NO: 25

30 When tested against Jurkat T-cell lines, supernatants removed from cells
containing this gene activated the gamma activating sequence (GAS), a promoter
50 element found upstream of many genes which are involved in the Jak-STAT pathway.

5
10
15
20
25
30
35
40
45
50
55

The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. Thus, it is likely that this gene activates T-cells through the JakStat signal transduction pathway.

This gene is expressed in a variety of human normal and diseased tissues including breast, infant adrenal gland, skin tumor, colon, pituitary, Wilm's tumor, and to a lesser extent in other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, breast cancer and other proliferative disorders, afflicting endocrine or endothelial tissues. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine system or of breast and/or breast lymph nodes, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, endocrine, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in breast, infant adrenal gland, skin tumor, colon, pituitary, and Wilm's tumor, and biological activity in activating the GAS promoter element indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g., diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g., hyper-, hypothyroidism), parathyroid (e.g., hyper-, hypoparathyroidism), hypothalamus, and testes. Alternatively, the tissue distribution and biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the

5 diagnosis and treatment of cancer and other proliferative disorders. Expression within
embryonic tissue and other cellular sources marked by proliferating cells, (i.e., breast,
10 skin and Wilms' tumors) indicates that this protein may play a role in the regulation of
cellular division. Additionally, the expression in hematopoietic cells and tissues
5 indicates that this protein may play a role in the proliferation, differentiation, and/or
survival of hematopoietic cell lineages. Representative uses are described in the
15 "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14,
16, 18, 19, 20, and 27, and elsewhere herein. In such an event, this gene is useful in
the treatment of lymphoproliferative disorders, and in the maintenance and
20 differentiation of various hematopoietic lineages from early hematopoietic stem and
committed progenitor cells. Similarly, embryonic development also involves
decisions involving cell differentiation and/or apoptosis in pattern formation. Thus
25 this protein may also be involved in apoptosis or tissue differentiation and could again
be useful in cancer therapy. Furthermore, the protein may also be used to determine
15 biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or
receptors, to identify agents that modulate their interactions, in addition to its use as a
nutritional supplement. Protein, as well as, antibodies directed against the protein may
30 show utility as a tumor marker and/or immunotherapy targets for the above listed
tissues.

20 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
35 related to SEQ ID NO:35 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
40 25 cumbersome. Accordingly, preferably excluded from the present invention are one or
more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 935 of SEQ ID NO:35, b is an
45 integer of 15 to 949, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:35, and where b is greater than or equal to a + 14.

30

50

55

FEATURES OF PROTEIN ENCODED BY GENE NO: 26

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: TGTFWSPRSQRRGCCGRRAPRPEAMENGA-VYS PTTEEDPGPARGPSGLAAYFFMGRPLLLRRVLKGLQLLSLLAFICEEVVSQ CTLCGGLYFFEFVSCSAFLLSLLILIVYCTPFYERVDTTKVSSDFYITLGTGCV FLLASIIFVSTIIDRTSAEIAAIVFGFIASFMLLDFTMLYEKRQESQLRKPENTT RAEALTEPLNA (SEQ ID NO: 305). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 3. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 3.

This gene is expressed primarily in dendritic cells, and to a lesser extent in melanocytes, fetal liver and spleen and several other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, inflammation, and disorders of the hepatic and immune systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hematopoietic systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., hematopoietic, hepatic, immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 149 as residues: Phe-63 to Ser-75, Thr-97 to Ser-102, Glu-128 to Arg-143. Polynucleotides encoding said polypeptides are also provided.

5

10

15

20

25

30

35

40

45

50

55

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product in dendritic cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively, the tissue distribution in fetal liver indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g., hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). In addition the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, pre-natal disorders and various wound-healing models and/or tissue trauma. Furthermore, the protein may also be used to determine biological activity, raise

antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement.

Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:36 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3324 of SEQ ID NO:36, b is an integer of 15 to 3338, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:36, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 27

In a specific embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: ASAPRVMRGHLAGFPALSGLASVCLWATFSAQLPGPVAAATSWTPAPLGCSAARSGPEKRLGTAAPGSAASLAQAGPGAPCRVLPVDPAPAALNVREPGWLGGFLFDGALLQVLLNFLRKSTDVLMDTREAESLEV E (SEQ ID NO: 306).

In another embodiment polypeptides of the invention comprise the following amino acid sequence: NKLHSFPVFLSQQLLDRQLLHAPQTLPTPHCGGSSSRPGP SHPPWLLIQLPCVHVALWQMLRDFSDSRITPSTLTTQPAQAATAAPAKDQES DIVGGEGLCDIAFLQEDHPLGVGGASAPSSRRELSRRGVHTQTLPEDGTLHG TPSSSFDCGIKYIISWPLAPGCDLPSLELSLVCKGVSSCMGFAAG (SEQ ID NO: 307). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in endothelial cells, lung, and fetal kidney, and to a lesser extent in epididymis, keratinocytes and cerebellum.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cardiovascular diseases involving endothelial cell disturbances such as atherosclerosis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cardiovascular, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 150 as residues: Arg-47 to Leu-54. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in endothelial cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing and treating disorders of endothelial cells such as atherosclerosis, vasculitis, cardiovascular disease, and emphysema. The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. The polypeptide may possess a wide range of undetected biological activities. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g., for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of haematopoiesis (e.g., for treating anaemia or as adjunct to chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or nerves (e.g., for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g., for treating infections, tumours); haemostatic or

5 thrombolytic activity (e.g., for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g., for treating septic shock, Crohn's Disease); as
10 antimicrobials; for treating psoriasis or other hyperproliferative disease; for regulation of metabolism, behaviour, and many others. Also contemplated is the use of the
5 corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or
15 immunotherapy targets for the above listed tissues

Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
20 10 related to SEQ ID NO:37 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
25 more polynucleotides comprising a nucleotide sequence described by the general
15 formula of a-b, where a is any integer between 1 to 1549 of SEQ ID NO:37, b is an
integer of 15 to 1563, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:37, and where b is greater than or equal to a + 14.
30

FEATURES OF PROTEIN ENCODED BY GENE NO: 28

20 In another embodiment, polypeptides comprising the amino acid sequence of
the open reading frame upstream of the predicted signal peptide are contemplated by
35 the present invention. Specifically, polypeptides of the invention comprise the
following amino acid sequence: PGRPTRPTKNKVCVCLGMLFWAYPICVFIDSL
SCQPCLWSTGATSHFNSPTTSPFTLFMPCALAPNPFT QLGKLDDR (SEQ ID
40 25 NO: 308). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in meningioma.

Therefore, polynucleotides and polypeptides of the invention are useful as
45 reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
30 not limited to, tumors or disorders of the central nervous system. Similarly,
polypeptides and antibodies directed to these polypeptides are useful in providing
50 immunological probes for differential identification of the tissue(s) or cell type(s). For

5
10
15
a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20
Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 151 as residues: His-29 to Thr-34. Polynucleotides encoding said polypeptides are also provided.

25
30
35
40
45
50
55
The tissue distribution in meningioma indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception, as well as disorders of the meninges such as meningioma and meningitis. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:38 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1034 of SEQ ID NO:38, b is an integer of 15 to 1048, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:38, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 29

The translation product of this gene has been shown to encode a human brain specific mitochondrial carrier (Genbank Accession No. gi13851540|gbtAAD04346.11 (AF078544); all references available through this accession are hereby incorporated herein by reference) which shares sequence homology with the human body weight disorder associated gene C5 product which is known to be differentially expressed in obese compared to lean mice (See GeneSeq Accession No. R91281). Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with mitochondrial carriers proteins. Such activities are known in the art, some of which are described in Sanchis et al, J. Biol. Chem. 273:34611-34615 (1998), incorporated herein by reference.

Included in this invention as preferred domains are mitochondrial energy transfer protein (METP) domains, which were identified using the ProSite analysis tool (Swiss Institute of Bioinformatics). Structurally, members of the family of mitochondrial energy transfer proteins consist of three tandem repeats of a domain of approximately one hundred residues. Each of these domains contains two transmembrane regions. As a signature pattern, we selected one of the most conserved regions in the repeated domain, located just after the first transmembrane region. To detect this widespread family of proteins, a consensus sequence was developed that contains the most conserved regions in the repeated domain. The consensus pattern is as follows: P.[DE].[LIVAT][RK].[LRH][LIVMFY][QMAIGV].

5 Preferred polypeptides of the invention comprise the following amino acid
sequences: PVDLTKTRLQ (SEQ ID NO: 309) and PTDVLKIRMQ (SEQ ID NO:
10 310). Polynucleotides encoding these polypeptides are also provided.

Further preferred are polypeptides comprising the METP domains of the
5 sequence listed above, and at least 5, 10, 15, 20, 25, 30, 50, or 75 additional
contiguous amino acid residues of the sequence referenced in Table I for this gene.
15 The additional contiguous amino acid residues is N-terminal or C-terminal to the
METP domain. Alternatively, the additional contiguous amino acid residues is both
N-terminal and C-terminal to the METP domain, wherein the total N- and C-terminal
20 contiguous amino acid residues equal the specified number. The above preferred
polypeptide domain is characteristic of a signature specific to mitochondrial energy
transfer proteins.

The gene encoding the disclosed cDNA is believed to reside on chromosome
25 X. Accordingly, polynucleotides related to this invention are useful as a marker in
15 linkage analysis for chromosome X.

This gene is expressed primarily in brain, and to a lesser extent, in T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as
30 reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
20 not limited to, neurological and behavioral disorders and immune disorders and/or
35 obesity. Similarly, polypeptides and antibodies directed to these polypeptides are
useful in providing immunological probes for differential identification of the
tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,
40 particularly of the digestive, immune, and nervous systems, expression of this gene
25 at significantly higher or lower levels is routinely detected in certain tissues or cell
types (e.g., immune, neural, or cancerous and wounded tissues) or bodily fluids (e.g.,
lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell
45 sample taken from an individual having such a disorder, relative to the standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid from an
30 individual not having the disorder.

5 Preferred polypeptides of the present invention comprise immunogenic
epitopes shown in SEQ ID NO: 152 as residues: Gln-189 to Gly-195. Polynucleotides
10 encoding said polypeptides are also provided.

The tissue distribution in brain and homology to mitochondrial carrier proteins
5 indicates polynucleotides and polypeptides corresponding to this gene are useful for
the detection, treatment, and/or prevention of neurodegenerative disease states,
15 behavioral disorders, or inflammatory conditions. Representative uses are described in
the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example
11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to
20 the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's
Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis,
demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital
malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages,
25 schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression,
15 panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors,
including disorders in feeding, sleep patterns, balance, and perception. In addition,
elevated expression of this gene product in regions of the brain indicates it plays a
30 role in normal neural function.

Potentially, this gene product is involved in synapse formation.
20 neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or
survival. Furthermore, the protein may also be used to determine biological activity,
35 to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to
identify agents that modulate their interactions, in addition to its use as a nutritional
supplement. Protein, as well as, antibodies directed against the protein may show
40 25 utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
45 related to SEQ ID NO:39 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
30 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
50 more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 1416 of SEQ ID NO:39, b is an integer of 15 to 1430, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:39, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 30

Preferred polypeptides of the invention comprise the following amino acid sequence: MTFGSTISPTSTHASPGLGFCCSWLLEDLEEQLYCSAFEEAALTR
RICNPTSCWLPLDMELLHRQVLALQTQRVLLGMWLRRAWDTWVSPRRVAP
GSRCLLTASHPCTEKRRKASAXQRNLGYPLAMLCLLVLTGLSVLIVAIHLEL
10 LIDEAAMPGRMQGTSLGQVSFSKLGSGAVIQVVLIFYLMVSSVVGIFYSSPLF
RSLRPRWHDAMTQIIGNCVCLLVLSALPVFSKTLGLTRFDLLGDFGRFNWL
GNFYIVFLYNAAFAGLTTLCLVKTFTA AVRAELIRAFGLDRLPLPVSGFPQAS
RKTQHQ (SEQ ID NO: 311). Polynucleotides encoding such polypeptides are also provided.

15 This gene is expressed primarily in immune system tissues (e.g. resting T-cells, primary dendritic cells, and neutrophils, apoptotic T-cells) and umbilical vein. This gene is expressed to a lesser extent in the gastrointestinal tissue (e.g. small intestine, colon), brain (e.g. cerebellum, frontal cortex), aorta endothelial cells, skin tumor, embryonic tissue, thymus, and cancers (e.g. cheek, breast, synovial).

20 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for
25 differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and gastrointestinal tract expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, gastrointestinal, cancerous and wounded tissues) or bodily fluids (e.g., amniotic, serum, plasma, urine, synovial fluid and
30 spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 153 as residues: Asp-21 to Ser-29. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in immune cells (e.g. T-cells, dendritic cells, neutrophils) indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The tissue distribution in skin tumors and cancerous tissue (e.g. cheek, breast, synovial sarcoma) indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression in cellular sources such as embryonic tissue marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Additionally, the


5 expression in hematopoietic cells and tissues indicates that this protein may play a
10 role in the proliferation, differentiation, and/or survival of hematopoietic cell lineages.
In such an event, this gene is useful in the treatment of lymphoproliferative disorders,
and in the maintenance and differentiation of various hematopoietic lineages from
5 early hematopoietic stem and committed progenitor cells. Similarly, embryonic
development also involves decisions involving cell differentiation and/or apoptosis in
15 pattern formation. Thus this protein may also be involved in apoptosis or tissue
differentiation and could again be useful in cancer therapy. Protein, as well as,
antibodies directed against the protein may show utility as a tumor marker and/or
20 immunotherapy targets for the above listed tissues. The tissue distribution in
cerebellum and frontal cortex indicates polynucleotides and polypeptides
corresponding to this gene are useful for the detection, treatment, and/or prevention of
neurodegenerative disease states, behavioral disorders, or inflammatory conditions.
25 Representative uses are described in the "Regeneration" and "Hyperproliferative
Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly,
the uses include, but are not limited to the detection, treatment, and/or prevention of
30 Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome,
meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia,
trauma, congenital malformations, spinal cord injuries, ischemia and infarction,
20 aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive
compulsive disorder, depression, panic disorder, learning disabilities, ALS,
35 psychoses, autism, and altered behaviors, including disorders in feeding, sleep
patterns, balance, and perception. In addition, elevated expression of this gene product
in regions of the brain indicates it plays a role in normal neural function.
40 25 Potentially, this gene product is involved in synapse formation,
neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or
survival. Furthermore, the protein may also be used to determine biological activity,
45 to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to
identify agents that modulate their interactions, in addition to its use as a nutritional
30 supplement. Protein, as well as, antibodies directed against the protein may show
utility as a tumor marker and/or immunotherapy targets for the above listed tissues.
50
55

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:40 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2089 of SEQ ID NO:40, b is an integer of 15 to 2103, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:40, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 31

The polypeptide of this gene has been determined to have a zinc finger (Zinc finger, C2H2 type) domain at about amino acid position 16-50 of the amino acid sequence referenced in Table 1 for this gene. Therefore,

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: LCVCLVYLCMYGVCLCVIVCVSGVSLCLYVWGVSVCDVCVSVFMCVCLCVIFCVYVGKPRTEHYHSPHLAKQKAFREMCGRHDVSAAGIFQSYV (SEQ ID NO: 312). Polynucleotides encoding these polypeptides are also provided. 'Zinc finger' domains are nucleic acid-binding protein structures first identified in the *Xenopus* transcription factor TFIIIA. These domains have since been found in numerous nucleic acid-binding proteins. A zinc finger domain is composed of 25 to 30 amino-acid residues. There are two cysteine or histidine residues at both extremities of the domain, which are involved in the tetrahedral coordination of a zinc atom. It has been proposed that such a domain interacts with about five nucleotides. A schematic representation of a zinc finger domain is shown below:



Many classes of zinc fingers are characterized according to the number and positions of the histidine and cysteine residues involved in the zinc atom coordination. In the first class to be characterized, called C2H2, the first pair of zinc coordinating residues are cysteines, while the second pair are histidines. A number of experimental reports have demonstrated the zinc-dependent DNA or RNA binding property of some members of this class. Some of the proteins known to include C2H2-type zinc fingers are listed below. We have indicated, between brackets, the number of zinc finger regions found in each of these proteins; a '+' symbol indicates that only partial sequence data is available and that additional finger domains is present.

This gene is expressed primarily in salivary gland.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, salivary gland related diseases, diseases of the mouth, and other digestive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., saliva, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 154 as residues: Gly-46 to His-54. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution indicates that the protein products of this gene are useful for diagnosis and treatment of salivary gland related diseases (mumps, calculi formation in ducts, sarcoidosis, facial palsy, tumors, Sjogrens Syndrome) and other digestive system disorders. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:41 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2335 of SEQ ID NO:41, b is an integer of 15 to 2349, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:41, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 32

This gene is expressed primarily in fetal tissue (e.g. spleen, liver, brain), cancerous tissues (e.g. ovarian, colon, stomach, parathyroid) and to a lesser extent in immune cells and tissue (e.g. B-cells, T-cells, bone marrow), and reproductive organs.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer, particularly of the colon and ovaries, disorders of the developing fetus, neurodegenerative conditions, and immune system disorders.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, reproductive, neural, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 155 as residues: Lys-35 to Lys-47. Polynucleotides encoding said polypeptides are also provided.

The expression of this gene within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in

modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. The tissue distribution in immune cells (such as T-cells and B-cells) and immune tissues (bone marrow) indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The tissue distribution in parathyroid indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", and "Binding Activity" sections below, in Example 11, 17, 18, 19, 20 and 27, and elsewhere herein. Briefly, the protein can be used for

the detection, treatment, and/or prevention of Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. Additionally, the tissue distribution in brain tissue indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:42 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or

more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1545 of SEQ ID NO:42, b is an integer of 15 to 1559, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:42, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 33

When tested against U937 Myeloid cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates myeloid cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in skin tumors.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, skin disorders, particularly skin cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skin, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 156 as residues: Pro-38 to Gly-44, Phe-56 to Thr-64. Polynucleotides encoding said polypeptides are also provided.

5 The tissue distribution in skin indicates that polynucleotides and polypeptides
corresponding to this gene are useful for the treatment, diagnosis, and/or prevention
10 of various skin disorders including congenital disorders (i.e. nevi, moles, freckles,
Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e.
5 keratoses, Bowen's Disease, basal cell carcinoma, squamous cell carcinoma,
malignant melanoma, Paget's Disease, mycosis fungoides, and Kaposi's sarcoma),
15 injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder,
psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity, autoimmune
disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma,
20 pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and
xanthelasma. Moreover, such disorders may predispose increased susceptibility to
viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox,
25 molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea,
athletes foot, and ringworm). Protein, as well as, antibodies directed against the
15 protein may show utility as a tumor marker and immunotherapy targets for the above
listed tumors and tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:43 and may have been publicly available prior to conception of
20 the present invention. Preferably, such related polynucleotides are specifically
35 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
more polynucleotides comprising a nucleotide sequence described by the general
40 formula of a-b, where a is any integer between 1 to 1752 of SEQ ID NO:43, b is an
25 integer of 15 to 1766, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:43, and where b is greater than or equal to a + 14.

45 FEATURES OF PROTEIN ENCODED BY GENE NO: 34

30 The translation product of this gene shares sequence homology with mitogen-
induced prostate carcinoma (mouse) which is thought to be important in the etiology
of cancer. In this respect, this gene is mitogen-induced and/or involved in cell
50 proliferation.

Preferred polypeptides of the invention comprise the following amino acid sequence: GHMPYGWLTEIRAVYPAFDKNNPSNKLVSTSNVTAAHIKKF
TFVCMALSLTLCFVMFWTPNVSEKILIDHGVDFAFELCVVPLRIFSFPPVPT
VRAHLTGWLMTLKKTFVLAPSSVLRIIVLIASLVVLPYLGVBHATLGVGSLLA
GFVGESTMVAIAACYVYRKQKKKMMENESATEGEDSAMTDMPTTEEVTDIVE
MRENE (SEQ ID NO: 313) and/or QVVFVAILLHSHLECREPLLIPILSLYMGA
LVRCTTLCGLGYKNIHDIIPDRSGPELGGDATIRKMLSFWWPLALILATQRI
PIVNLVSRDLGGSSAATEAVAILTATYPV (SEQ ID NO: 314). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 5. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 5.

This gene is expressed primarily in early infant and adult brain, retina, fetal tissue (e.g., liver, spleen, whole embryo) and to a lesser extent in immune cells (e.g., monocytes and T-cells), colon, and parathyroid tumor tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancers, disorders of the immune system and nervous system.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the metabolic system (cancers), expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, neural, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 157 as residues: Arg-122 to Ser-139, Met-144 to Glu-149. Polynucleotides encoding said polypeptides are also provided.

5

10

15

20

25

30

35

40

45

50

55

The tissue distribution and homology to mitogen induced prostate carcinoma (mouse) indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and treatment of cancers, including but not limited to the colon, parathyroid, and adrenal glands. Moreover, the expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. The tissue distribution in immune cells (T-cells, monocytes) indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or

5 activation of hematopoietic cell lineages, including blood stem cells. This gene
product is involved in the regulation of cytokine production, antigen presentation, or
10 other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting
immune responses).

5 Since the gene is expressed in cells of lymphoid origin, the natural gene
product is involved in immune functions. Therefore it is also useful as an agent for
15 immunological disorders including arthritis, asthma, immunodeficiency diseases such
as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory
bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,
20 such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and
tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity
disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic
lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's
25 Disease, and scleroderma. Moreover, the protein may represent a secreted factor that
influences the differentiation or behavior of other blood cells, or that recruits
15 hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in
the expansion of stem cells and committed progenitors of various blood lineages, and
in the differentiation and/or proliferation of various cell types. The tissue distribution
30 in brain indicates polynucleotides and polypeptides corresponding to this gene are
useful for the detection, treatment, and/or prevention of neurodegenerative disease
20 states, behavioral disorders, or inflammatory conditions. Representative uses are
described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in
Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not
40 limited to the detection, treatment, and/or prevention of Alzheimer's Disease,
Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis,
encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma,
congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms,
45 hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive
disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism,
30 and altered behaviors, including disorders in feeding, sleep patterns, balance, and
perception. In addition, elevated expression of this gene product in regions of the
50 brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:44 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2558 of SEQ ID NO:44, b is an integer of 15 to 2572, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 35

This gene is expressed primarily in adult pulmonary tissue, umbilical vein, prostate, and fetal tissue (e.g., heart).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the pulmonary system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the pulmonary system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., pulmonary, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the

5 standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 158 as residues: Arg-45 to Gly-51, Glu-75 to Asn-81.

5 Polynucleotides encoding said polypeptides are also provided.

15 The tissue distribution in pulmonary tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of disorders associated with developing lungs, particularly in premature infants where the lungs are the last tissues to develop. Additionally, the tissue distribution indicates
20 that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and intervention of lung tumors, since the gene is involved in the regulation of cell division, particularly since it is expressed in fetal tissue. Moreover, the expression within fetal tissue and other cellular sources marked by proliferating cells
25 indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases
15 and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections
30 below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

20 Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent
35 of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have
40 25 applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating,
45 detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue
30 differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in
50 modulating the immune response to aberrant polypeptides, as may exist in

proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:45 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-h, where a is any integer between 1 to 512 of SEQ ID NO:45, b is an integer of 15 to 526, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 36

This gene is expressed primarily in adipose tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, fat metabolism. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the metabolic system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,

the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 159 as residues: Pro-96 to Ser-106. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in adipose tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of obesity and other metabolic and endocrine conditions or disorders. Furthermore, the protein product of this gene may show utility in ameliorating conditions which occur secondary to aberrant fatty-acid metabolism (e.g. aberrant myelin sheath development), either directly or indirectly. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:46 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1018 of SEQ ID NO:46, b is an integer of 15 to 1032, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 37

This gene is expressed primarily in adult brain tissue, testes, placenta, kidney, infant and fetal tissue (e.g., liver, spleen, lung) and to a lesser extent in immune cells (e.g., T-cells and neutrophils) and in cancerous tissues (e.g., ovarian tumor, Hodgkins lymphoma, pancreas, T-cell).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

5 not limited to, CNS disorders, disorders of the testicles, cancer, particularly ovarian,
pancreatic, T-cell, and Hodgekin's lymphoma. Similarly, polypeptides and antibodies
10 directed to these polypeptides are useful in providing immunological probes for
differential identification of the tissue(s) or cell type(s). For a number of disorders of
5 the above tissues or cells, particularly of the brain, CNS, and testes expression of this
gene at significantly higher or lower levels is routinely detected in certain tissues or
15 cell types (e.g., neural, urogenital, cancerous and wounded tissues) or bodily fluids
(e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell
sample taken from an individual having such a disorder, relative to the standard gene
20 expression level, i.e., the expression level in healthy tissue or bodily fluid from an
individual not having the disorder.

The tissue distribution in brain indicates polynucleotides and polypeptides
corresponding to this gene are useful for the detection, treatment, and/or prevention of
25 neurodegenerative disease states, behavioral disorders, or inflammatory conditions.
15 Representative uses are described in the "Regeneration" and "Hyperproliferative
Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly,
the uses include, but are not limited to the detection, treatment, and/or prevention of
30 Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome,
meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia,
20 trauma, congenital malformations, spinal cord injuries, ischemia and infarction,
aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive
35 compulsive disorder, depression, panic disorder, learning disabilities, ALS,
psychoses, autism, and altered behaviors, including disorders in feeding, sleep
patterns, balance, and perception. In addition, elevated expression of this gene product
40 25 in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation,
neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or
45 survival. Moreover, the expression within fetal tissue and other cellular sources
marked by proliferating cells indicates this protein may play a role in the regulation of
30 cellular division, and may show utility in the diagnosis, treatment, and/or prevention
of developmental diseases and disorders, including cancer, and other proliferative
50 conditions. Representative uses are described in the "Hyperproliferative Disorders"

and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. The tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,

5 such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and
tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity
10 disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic
lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's
5 Disease, and scleroderma. Moreover, the protein may represent a secreted factor that
influences the differentiation or behavior of other blood cells, or that recruits
15 hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in
the expansion of stem cells and committed progenitors of various blood lineages, and
in the differentiation and/or proliferation of various cell types. Additionally, the
20 tissue distribution in testes indicates that polynucleotides and polypeptides
corresponding to this gene are useful for the treatment and diagnosis of conditions
concerning proper testicular function (e.g. endocrine function, sperm maturation), as
well as cancer. Therefore, this gene product is useful in the treatment of male
25 infertility and/or impotence. This gene product is also useful in assays designed to
15 identify binding agents, as such agents (antagonists) are useful as male contraceptive
agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis
of testicular cancer. The testes are also a site of active gene expression of transcripts
30 that is expressed, particularly at low levels, in other tissues of the body. Therefore,
this gene product is expressed in other specific tissues or organs where it may play
20 related functional roles in other processes, such as hematopoiesis, inflammation, bone
formation, and kidney function, to name a few possible target indications.
35 Furthermore, the protein may also be used to determine biological activity, raise
antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents
that modulate their interactions, in addition to its use as a nutritional supplement.
40 25 Protein, as well as, antibodies directed against the protein may show utility as a tumor
marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
45 available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:47 and may have been publicly available prior to conception of
30 the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
50 cumbersome. Accordingly, preferably excluded from the present invention are one or

more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2666 of SEQ ID NO:47, b is an integer of 15 to 2680, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 38

When tested against fibroblast cell lines, supernatants removed from cells containing this gene activated the EGR1 assay. Thus, it is likely that this gene activates fibroblast cells through a signal transduction pathway. Early growth response 1 (EGR1) is a promoter associated with certain genes that induces various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation.

This gene is expressed primarily in endometrial stromal cells, endometrial tumors, keratinocytes, fetal tissue (e.g. liver, spleen) and to a lesser extent in endothelial cells and immune cells (e.g., T-cells).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endometrial carcinoma and immune cells disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the female reproductive system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in the endometrium indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating female infertility. The protein product is likely involved in preparation of the endometrium of implantation and could be administered either topically or orally. Alternatively, this gene could be

transfected in gene-replacement treatments into the cells of the endometrium and the protein products could be produced. Similarly, these treatments could be performed during artificial insemination for the purpose of increasing the likelihood of implantation and development of a healthy embryo. In both cases this gene or its gene product could be administered at later stages of pregnancy to promote healthy development of the endometrium. Additionally, polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of endometrial carcinoma. The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Additionally, the expression in hematopoietic cells and tissues indicates that this protein may play a role in the proliferation, differentiation, and/or survival of hematopoietic cell lineages. In such an event, this gene is useful in the treatment of lymphoproliferative disorders, and in the maintenance and differentiation of various hematopoietic lineages from early hematopoietic stem and committed progenitor cells. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. The tissue distribution in immune cells such as helper T-cells indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such

5 as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory
bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,
10 such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and
tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity
5 disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic
lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's
15 Disease, and scleroderma. Moreover, the protein may represent a secreted factor that
influences the differentiation or behavior of other blood cells, or that recruits
hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in
20 the expansion of stem cells and committed progenitors of various blood lineages, and
in the differentiation and/or proliferation of various cell types. The tissue distribution
in keratinocytes indicates polynucleotides and polypeptides corresponding to this
gene are useful for the treatment, diagnosis, and/or prevention of various skin
25 disorders. Representative uses are described in the "Biological Activity",
15 "Hyperproliferative Disorders", "infectious disease", and "Regeneration" sections
below, in Example 11, 19, and 20, and elsewhere herein. Briefly, the protein is useful
in detecting, treating, and/or preventing congenital disorders (i.e. nevi, moles,
30 freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary
tumors (i.e. keratoses, Bowen's Disease, basal cell carcinoma, squamous cell
20 carcinoma, malignant melanoma, Paget's Disease, mycosis fungoides, and Kaposi's
sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat
35 disorder, psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity,
autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea,
scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae,
40 purpura, and xanthelasma. In addition, such disorders may predispose increased
25 susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts,
chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas,
impetigo, tinea, athlete's foot, and ringworm). Moreover, the protein product of this
45 gene may also be useful for the treatment or diagnosis of various connective tissue
30 disorders (i.e., arthritis, trauma, tendonitis, chondromalacia and inflammation, etc.),
autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma,
dermatomyositis, etc.), dwarfism, spinal deformation, joint abnormalities, and

5 chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial
10 osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid).
Furthermore, the protein may also be used to determine biological activity, to raise
antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents
5 that modulate their interactions, in addition to its use as a nutritional supplement.
Protein, as well as, antibodies directed against the protein may show utility as a tumor
15 marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databascs. Some of these sequences are
20 related to SEQ ID NO:48 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
25 more polynucleotides comprising a nucleotide sequence described by the general
15 formula of a-b, where a is any integer between 1 to 1716 of SEQ ID NO:48, b is an
integer of 15 to 1730, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14.
30

FEATURES OF PROTEIN ENCODED BY GENE NO: 39

20 This gene is expressed primarily in LNCAP cells (prostate cell line) and retina
35 derived N2b5HR cells.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
40 not limited to, prostate cancer and eye disorders. Similarly, polypeptides and
25 antibodies directed to these polypeptides are useful in providing immunological
probes for differential identification of the tissue(s) or cell type(s). For a number of
disorders of the above tissues or cells, particularly of the male urogenital and
45 reproductive system expression of this gene at significantly higher or lower levels is
30 routinely detected in certain tissues or cell types (e.g., cancerous and wounded
tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or
50 another tissue or cell sample taken from an individual having such a disorder, relative

5 to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 162 as residues: Asn-50 to Ser-57. Polynucleotides
5 encoding said polypeptides are also provided.

15 The expression in prostate may indicate the gene or its products can be used in the disorders of the prostate, including inflammatory disorders, such as chronic prostatitis, granulomatous prostatitis and malacoplakia, prostatic hyperplasia and prostate neoplastic disorders, including adenocarcinoma, transitional cell carcinomas,
20 ductal carcinomas, squamous cell carcinomas, or as hormones or factors with systemic or reproductive functions. The tissue distribution in retina indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or detection of eye disorders including blindness, color blindness,
25 impaired vision, short and long sightedness, retinitis pigmentosa, retinitis proliferans, and retinoblastoma, retinchoroiditis, retinopathy and retinoschisis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as,
30 antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

35 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:49 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically
40 25 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1261 of SEQ ID NO:49, b is an
45 integer of 15 to 1275, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is greater than or equal to a + 14.
30

FEATURES OF PROTEIN ENCODED BY GENE NO: 40

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: RCCCRGCSCRARLCPPARSTAVAPECRGAHPSR AMRPGTALQAVLLAVLLVGLRAATGRLLSGQPVCRRGGTQRPCYKVIYFHD TSRRLNFEEAKEACRRGWRPASQHRVLKMNRN (SEQ ID NO: 315).

Polynucleotides encoding these polypeptides are also provided.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MRPGTALQAVLLAVLLVGLRAATGRLLSGQPVCRRGG TQRPCYKVIYFHDTSRRLNFEEAKEACRRGWRPASQHRVLKMNRN (SEQ ID NO: 316). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in smooth muscle and human thyroid and to a lesser extent in amniotic cells and human endometrial stromal cells-treated with progesterone.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, thyroid disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 163 as residues: Ser-75 to Leu-81. Polynucleotides encoding said polypeptides are also provided.

5 The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis and treatment of endocrine
10 disorders of the thyroid.

Many polynucleotide sequences, such as EST sequences, are publicly
5 available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:50 and may have been publicly available prior to conception of
15 the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
20 10 more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 1748 of SEQ ID NO:50, b is an
integer of 15 to 1762, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:50, and where b is greater than or equal to a + 14.

25 15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 41**

This gene is expressed primarily in human testes tumor and bone marrow.

30 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
20 not limited to, disorders of the testicles including but not limited to testicular
35 cancer and immune system disorders. Similarly, polypeptides and antibodies directed
to these polypeptides are useful in providing immunological probes for differential
identification of the tissue(s) or cell type(s). For a number of disorders of the above
tissues or cells, particularly of the male reproductive system and immune system
40 25 expression of this gene at significantly higher or lower levels is routinely detected in
certain tissues or cell types (e.g., reproductive, immune, cancerous and wounded
tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or
45 another tissue or cell sample taken from an individual having such a disorder, relative
to the standard gene expression level, i.e., the expression level in healthy tissue or
30 bodily fluid from an individual not having the disorder.

50

55

5 Preferred polypeptides of the present invention comprise immunogenic
epitopes shown in SEQ ID NO: 164 as residues: His-31 to Gly-41. Polynucleotides
10 encoding said polypeptides are also provided.

15 The tissue distribution in testes, particularly testicular tumors, indicates that
5 polynucleotides and polypeptides corresponding to this gene are useful for the
treatment and diagnosis of conditions concerning proper testicular function (e.g.
endocrine function, sperm maturation), as well as cancer. Therefore, this gene product
is useful in the treatment of male infertility and/or impotence. This gene product is
also useful in assays designed to identify binding agents, as such agents (antagonists)
20 are useful as male contraceptive agents. Similarly, the protein is believed to be useful
in the treatment and/or diagnosis of testicular cancer. The testes are also a site of
active gene expression of transcripts that is expressed, particularly at low levels, in
other tissues of the body. Therefore, this gene product is expressed in other specific
25 tissues or organs where it may play related functional roles in other processes, such as
15 hematopoiesis, inflammation, bone formation, and kidney function, to name a few
possible target indications. The tissue distribution in bone marrow indicates
polynucleotides and polypeptides corresponding to this gene are useful for the
diagnosis and treatment of a variety of immune system disorders. Representative uses
are described in the "Immune Activity" and "infectious disease" sections below, in
20 Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the
expression of this gene product indicates a role in regulating the proliferation;
35 survival; differentiation; and/or activation of hematopoietic cell lineages, including
blood stem cells. This gene product is involved in the regulation of cytokine
production, antigen presentation, or other processes suggesting a usefulness in the
40 treatment of cancer (e.g. by boosting immune responses).
25

45 Since the gene is expressed in cells of lymphoid origin, the natural gene
product is involved in immune functions. Therefore it is also useful as an agent for
immunological disorders including arthritis, asthma, immunodeficiency diseases such
as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory
30 bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,
such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and
50 tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity

5 disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic
lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's
10 Disease, and scleroderma. Moreover, the protein may represent a secreted factor that
influences the differentiation or behavior of other blood cells, or that recruits
5 hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in
the expansion of stem cells and committed progenitors of various blood lineages, and
15 in the differentiation and/or proliferation of various cell types. Furthermore, the
protein may also be used to determine biological activity, raise antibodies, as tissue
markers, to isolate cognate ligands or receptors, to identify agents that modulate their
20 interactions, in addition to its use as a nutritional supplement. Protein, as well as,
antibodies directed against the protein may show utility as a tumor marker and/or
immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
25 available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:51 and may have been publicly available prior to conception of
15 the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
30 cumbersome. Accordingly, preferably excluded from the present invention are one or
more polynucleotides comprising a nucleotide sequence described by the general
20 formula of a-b, where a is any integer between 1 to 2045 of SEQ ID NO:51, b is an
integer of 15 to 2059, where both a and b correspond to the positions of nucleotide
35 residues shown in SEQ ID NO:51, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 42

40 25 The translation product of this gene shares sequence homology with
protocadherins, which are related to cadherin, and possess cell adhesive ability.
Cadherins are glycosylated integral membrane proteins that are involved in cell-cell
45 adhesion.

This gene is expressed primarily in brain (infant, adult frontal lobe, manic
30 depression tissue) and to a lesser extent in epididymus, healing groin wounds, ovary,
adipocytes, and fetal tissue (e.g., kidney and retina).

5

10

15

20

25

30

35

40

45

50

55

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurodegenerative disorders, impaired male and female fertility, developmental disorders, fibrosis, and manic depression. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system and reproductive system expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, reproductive, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 165 as residues: Val-35 to Lys-41, Ser-68 to Gln-73, Glu-88 to Glu-93, Arg-156 to Gly-163, Ala-199 to Gly-206, Asp-216 to Ser-226, Thr-249 to Asn-254, Asp-339 to Pro-345, Ile-370 to Gly-379, Pro-429 to Glu-434, Arg-461 to Pro-466, Ala-475 to Thr-482, Pro-585 to Gly-593, Glu-631 to Gln-639, Pro-674 to Pro-682, Gln-715 to Gly-720, Ser-736 to Arg-742. Polynucleotides encoding said polypeptides are also provided.

BLAST analysis reveals high homology to protocadherin sequences. These sequences are related to cadherin, and possess cell adhesive ability. Such proteins may have regulatory functions in the cell, as well as the cell-cell adhesive properties. Antibodies produced against these sequences are useful for modulating the binding activity of these protocadherins, and can be used therapeutically. The tissue distribution in brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease,

5
10
15
20
25
30
35
40
45
50
55

Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. The tissue distribution in epididymus indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product is expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Moreover, the expression within fetal tissue (e.g., kidney and retina) and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including blindness, cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent

of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:52 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3268 of SEQ ID NO:52, b is an integer of 15 to 3282, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:52, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 43

Preferred polypeptides of the invention comprise the following amino acid sequence:

5
10
15
20
25
30
35
40
45
50
55

IRHEQQGEEDDEHARPLAESLLLAIAADLLFCPDFTVQSHRRSTVDSAEDVHSL
DSCEYTWEAGVGFAHSPQPNYIHDNMNRMELLKLLTCFSEAMYLPPAPESGS
TNPWVQFFCSTENRHALLFTSLLNTVCA YDPVGYGIPYNHLLFSDYREPLVE
EAAQVLIVTLDHDSASSASPTVDGTTTGTAMDDADPPGPENLFVNYLSRIHRE
5 EDFQFILKGIARLLSNPLLQTYLPNSTKKDPVPPGAASSLLEALRLQQEIPLLRA
EEQRRPRHPCPHLLPQRCPPGRSV (SEQ ID NO: 317). Polynucleotides encoding
such polypeptides are also provided.

This gene is expressed primarily in brain, breast, breast cancer tissue and to a lesser extent in epididymus, amniotic cells, and embryo tissue.

10
15
20
25
30
35
40
45
50
55

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurodegenerative disorders, impaired CNS function, male sterility, and breast cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and reproductive systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, male reproductive, cancerous and wounded tissues) or bodily fluids (e.g., amniotic, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 166 as residues: Pro-22 to Pro-31, Ser-38 to His-43, Asp-74 to Leu-79, Asp-113 to Glu-121, Leu-157 to Val-166, Ala-189 to Arg-196, Gln-206 to Arg-211. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain, particularly in the cerebellum, indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11.

5
10
15
20
25
30
35
40
45
50
55

15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. The tissue distribution in epididymus indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product is expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. The expression in the breast tissue may indicate its uses in the diagnosis and/or treatment of breast neoplasia and breast cancers, such as fibroadenoma, papillary carcinoma, ductal carcinoma, Paget's Disease, medullary carcinoma, mucinous carcinoma, tubular carcinoma, secretory carcinoma and apocrine carcinoma, as well as juvenile hypertrophy and gynecomastia, mastitis and abscess, duct ectasia, fat necrosis and fibrocystic diseases. Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may

show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:53 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 1846 of SEQ ID NO:53, b is an integer of 15 to 1860, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:53, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 44

Contact of cells with supernatant expressing the product of this gene increases the permeability of monocytes to calcium. Thus, it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product of this gene binds a receptor on the surface of the monocyte cell. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating monocyte cells.

This gene is expressed primarily in CD34 positive cells derived from human cord blood.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hematopoietic disorders; immune dysfunction; defects in hematopoietic stem and progenitor cells; susceptibility to chemotherapy and irradiation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 167 as residues: Ala-38 to Leu-59, Ala-63 to Thr-71, Lys-82 to Leu-91, Glu-97 to Ser-107, Gln-143 to Ala-149, Ile-153 to Leu-158, Ser-169 to Arg-182. Polynucleotides encoding said polypeptides are also provided.

5
10
15
20
25
30
35
40
45
50
55

Elevated expression of this gene product in CD34 positive hematopoietic cells indicates that it is expressed by early stem and progenitor cells of the hematopoietic lineages. Therefore, this may represent a soluble factor that is able to control the survival, proliferation, differentiation, or activation of all hematopoietic lineages, including stem and progenitor cells. Thus, it could be quite useful, for example, in ex vivo expansion of stem cell numbers for hematopoietic disorders or for cancer patients. Alternately, it may represent a factor that influences the hematopoietic microenvironment by affecting stromal cells that release other factors required for hematopoietic development. Additionally, the tissue distribution in CD34 positive cells also indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:54 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 756 of SEQ ID NO:54, b is an integer of 15 to 770, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:54, and where b is greater than or equal to a + 14.

5

10

15

20

25

30

35

40

45

50

55

FEATURES OF PROTEIN ENCODED BY GENE NO: 45

This gene is expressed primarily in breast and 12-week old human embryos and to a lesser extent in stomach cancer and liver.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, breast cancer; stomach cancer; embryonic defects; hepatic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive and endocrine systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein products of this gene are useful for the diagnosis and/or treatment of a variety of disorders. Elevated expression of this gene product in stomach cancer indicates it is useful as a marker or therapeutic target for stomach cancer. Alternately, expression in breast tissue is influenced by the presence or absence of breast cancer tissue, and may thus also serve as a diagnostic marker for this cancer as well. Expression in the developing embryo may correlate with the normal development of human embryos, and expression in the liver is involved in the regulation of normal liver function and/or liver regeneration.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:55 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 1079 of SEQ ID NO:55, b is an integer of 15 to 1093, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:55, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 46

This gene is expressed primarily in human hypothalamus derived from a patient with schizophrenia.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, schizophrenia; neurological disorders; impaired nervous system function. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 169 as residues: Glu-34 to Trp-39. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain, particularly in the hypothalamus, indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal

5

10

cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

15

20

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

25

30

35

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:56 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 618 of SEQ ID NO:56, b is an integer of 15 to 632, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:56, and where b is greater than or equal to a + 14.

40

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 47

45

50

The translation product of this gene shares sequence homology with human lecithin-cholesterol acyltransferase (LCAT), which catalyses the transfer of fatty acid from the sn-2 position of lecithin to the free hydroxyl group of cholesterol. Preferred polypeptides of the invention comprise the following amino acid sequence: RLVYN KTSRATQFPDGV DVRVPGFGKTFSLFLDPSKSSVGSYFHTMVESLVGWGYT RGEDVRGAPYDWRAPNENGPYFLALREMIEMYQLYGGPVVLVAHSMGN MYTLYFLQRQPQAWKDKYIRAFVSLGAPWGGVAKTLRVLASGDNNRIPVIG

55

5

10

PLKIREQQRSAVSTSWLLPYNYTWSPEKVFVQTPPTINYTLRDYRKFFQDIGFE
DGWLMRQDTEGLVEATMPPGVQLHCLYGTGVPTPDSFYYESFPDRDPKICFG
DGDGTVNLKSALQCQAWQSRQEHQVLLQELPGSEHIEMLANATTLAYLKRV
LLGP (SEQ ID NO: 318). Polynucleotides encoding such polypeptides are also
5 provided.

15

This gene is expressed primarily in osteoblasts & dendritic cells and to a lesser
extent in muscle and other hematopoietic cell lineages.

20

25

30

35

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
10 biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, hematopoietic disorders; immune dysfunction; osteoporosis;
osteopetrosis; muscle degeneration. Similarly, polypeptides and antibodies directed to
these polypeptides are useful in providing immunological probes for differential
identification of the tissue(s) or cell type(s). For a number of disorders of the above
15 tissues or cells, particularly of the skeletal and immune systems, expression of this
gene at significantly higher or lower levels is routinely detected in certain tissues or
cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma,
urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an
individual having such a disorder, relative to the standard gene expression level, i.e.,
20 the expression level in healthy tissue or bodily fluid from an individual not having the
disorder.

40

45

50

Preferred polypeptides of the present invention comprise immunogenic
epitopes shown in SEQ ID NO: 170 as residues: Cys-65 to Ser-71. Polynucleotides
encoding said polypeptides are also provided.

25

The tissue distribution and homology to lecithin-cholesterol acyltransferase
(LCAT) indicates that polynucleotides and polypeptides corresponding to this gene
are useful for the diagnosis and/or treatment of a variety of disorders. For example,
45 atherosclerosis is a pathological condition of mammals characterised by the
accumulation of cholesterol in the arteries, which leads to heart disease, strokes, heart
30 attacks and peripheral vascular disease. The enzyme could be used in a novel method
of treating atherosclerosis, which involves increasing the level of LCAT activity,
which then causes a decrease in the accumulation of cholesterol. The method and the

55

5 products can be used for the prophylaxis and treatment of atherosclerosis, and
associated heart disease, myocardial infarction, stroke and peripheral vascular disease,
10 as well as individuals suffering from Fish Eye Syndrome (caused by LCAT
deficiency) or Classic LCAT Deficiency Syndrome. Alternately, elevated expression
5 of this gene product in osteoblasts and hematopoietic cell lineages indicates that it
may play additional roles in bone turnover, regulation of immune system function,
15 and muscular function.

Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
20 related to SEQ ID NO:57 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
25 more polynucleotides comprising a nucleotide sequence described by the general
15 formula of a-b, where a is any integer between 1 to 2673 of SEQ ID NO:57, b is an
integer of 15 to 2687, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:57, and where b is greater than or equal to a + 14.

30 FEATURES OF PROTEIN ENCODED BY GENE NO: 48

20 When tested against HELA epithelial cell lines, supernatants removed from
cells containing this gene activated the GAS assay. Thus, it is likely that this gene
35 activates epithelial cells through the Jak-STAT signal transduction pathway. The
gamma activating sequence (GAS) is a promoter element found upstream of many
genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a
40 25 large, signal transduction pathway involved in the differentiation and proliferation of
cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the
GAS element, can be used to indicate proteins involved in the proliferation and
45 differentiation of cells.

This gene is expressed primarily in adult brain, infant brain, fibroblasts,
30 embryonic and fetal tissue (e.g., spleen, liver), placenta and to a lesser extent in
endocrine organs, cancerous colon and breast.

5

10

15

20

25

30

20

35

40

25

45

30

50

55

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, dementia, epilepsy, schizophrenia, and developmental abnormalities.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neural system, endocrine system, and during development, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. In addition, the expression of this gene product in synovium (synovial sarcoma) would suggest a role in the detection and treatment of disorders and

5 conditions afflicting the skeletal system, in particular osteoporosis, bone cancer,
connective tissue disorders (e.g. arthritis, trauma, tendonitis, chondromalacia and
10 inflammation). The protein is also useful in the diagnosis or treatment of various
autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, and
5 dermatomyositis), dwarfism, spinal deformation, joint abnormalities, and
chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial
15 osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid,
etc.). The tissue distribution in endocrine tissues indicates polynucleotides and
polypeptides corresponding to this gene are useful for the detection, treatment, and/or
20 prevention of various endocrine disorders and cancers. Representative uses are
described in the "Biological Activity", "Hyperproliferative Disorders", and "Binding
Activity" sections below, in Example 11, 17, 18, 19, 20 and 27, and elsewhere herein.
Briefly, the protein can be used for the detection, treatment, and/or prevention of
25 Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the
pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-,
15 hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-,
hypoparathyroidism), hypothalamus, and testes. Additionally, the expression within
30 fetal tissue, cancerous colon and breast, and other cellular sources marked by
proliferating cells indicates this protein may play a role in the regulation of cellular
20 division, and may show utility in the diagnosis, treatment, and/or prevention of
developmental diseases and disorders, including cancer, and other proliferative
35 conditions. Representative uses are described in the "Hyperproliferative Disorders"
and "Regeneration" sections below and elsewhere herein. Briefly, developmental
tissues rely on decisions involving cell differentiation and/or apoptosis in pattern
40 25 formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell
death, as occurs in the development of some cancers, or in failure to control the extent
45 of cell death, as is believed to occur in acquired immunodeficiency and certain
neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of
30 potential roles in proliferation and differentiation, this gene product may have
applications in the adult for tissue regeneration and the treatment of cancers. It may
50 also act as a morphogen to control cell and tissue type specification. Therefore, the

polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:58 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 605 of SEQ ID NO:58, b is an integer of 15 to 619, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:58, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 49

Preferred polypeptides of the invention comprise the following amino acid sequence or a subfragment thereof: MNKEDKVWNDCKGVNKLTLNLEEYIILIFQ
NGLDPPANMVFESIINEIGIKNNISNFFAKIPFEEANGRLVACTRITYEESIKGSC
GQKENKIKTVSFESKIQLRSKQEFQFFDEEETGENHTIFIGPVEKLIVPPPPA
KGGISVTNEDLHCLNEGEFLNDVIIDFYLKYL VLEKLKKEDADRIHIFSSFFYK
RLNQRERRNHETTNLISIQQKRHGRVKTWTRHVDIFEKDFIVPLNEAAHWFL
AVVCFPGLEKPKYEPNPHYHENAVIQKCSTVEDSCISSASEMESCSQNSSAK

PVIKKMLNKKHCLVIDSNPGQEESDPRYKRNICSVKYSVKKINHTASENEEF
NKGESTSQKS (SEQ ID NO: 319). Polynucleotides encoding such polypeptides are
also provided.

This gene is expressed primarily in fetal tissue, stomach, brain, endometrial
cells, and bone and to a lesser extent in prostate, retina, adipocytes, smooth muscle,
and tumors of the endometrium, ovaries, and parathyroid.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, disorders of the endocrine system, ulcers, stomach cancer, epilepsy,
schizophrenia, dementia, bone growth, developmental disorders and resorption.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in
providing immunological probes for differential identification of the tissue(s) or cell
type(s). For a number of disorders of the above tissues or cells, particularly of the
digestive system and neural systems expression of this gene at significantly higher or
lower levels is routinely detected in certain tissues or cell types (e.g., neural,
endocrine system, cancerous and wounded tissues) or bodily fluids (e.g., serum,
plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken
from an individual having such a disorder, relative to the standard gene expression
level, i.e., the expression level in healthy tissue or bodily fluid from an individual not
having the disorder.

The tissue distribution in brain indicates polynucleotides and polypeptides
corresponding to this gene are useful for the detection, treatment, and/or prevention of
neurodegenerative disease states, behavioral disorders, or inflammatory conditions.
Representative uses are described in the "Regeneration" and "Hyperproliferative
Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly,
the uses include, but are not limited to the detection, treatment, and/or prevention of
Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome,
meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia,
trauma, congenital malformations, spinal cord injuries, ischemia and infarction,
aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive
compulsive disorder, depression, panic disorder, learning disabilities, ALS.

psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Expression of this gene product in stomach tissue indicates involvement in digestion, processing, and elimination of food, as well as a potential role for this gene as a diagnostic marker or causative agent in the development of stomach cancer, and cancer in general. The expression within embryonic, fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. The tissue distribution in parathyroid tumor indicates polynucleotides and polypeptides corresponding to this

gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", and "Binding Activity" sections below, in Example 11, 17, 18, 19, 20 and 27, and elsewhere herein. Briefly, the protein can be used for the detection, treatment, and/or prevention of Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. The tissue distribution in testes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:59 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1364 of SEQ ID NO:59, b is an integer of 15 to 1378, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:59, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 50

The translation product of this gene shares good protein homology with *Xenopus* NaDC-2 gene and a rabbit renal sodium/dicarboxylate cotransporter. The translation product of this gene also shares good homology with a rat placental protein which is a sodium-coupled high affinity dicarboxylate transporter. Therefore, it is likely that the translated product encoded by this gene shares similar biological activity.

This gene is expressed primarily in the placenta and colon adenocarcinoma. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental abnormalities as well as failure to thrive anomalies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the female reproductive system and colon, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., amniotic, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 173 as residues: Lys-166 to Gly-181. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in human placenta and the shared homology of this translation product to a rat placental protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders of the placenta. Specific expression within the placenta indicates that this gene product may play a role in the proper establishment and maintenance of placental function. Alternately, this gene product is produced by the placenta and then transported to the embryo, where it may play a crucial role in the development and/or

5 survival of the developing embryo or fetus. Expression of this gene product in a
vascular-rich tissue such as the placenta also indicates that this gene product is
10 produced more generally in endothelial cells or within the circulation. In such
instances, it may play more generalized roles in vascular function, such as in
5 angiogenesis. It may also be produced in the vasculature and have effects on other
cells within the circulation, such as hematopoietic cells. It may serve to promote the
15 proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well
as other cells throughout the body. The tissue distribution in colon tissue indicates
that polynucleotides and polypeptides corresponding to this gene are useful for the
20 diagnosis and/or treatment of disorders involving the colon. Expression of this gene
product in colon tissue indicates involvement in digestion, processing, and
elimination of food, as well as a potential role for this gene as a diagnostic marker or
causative agent in the development of colon cancer, and cancer in general.

25 Many polynucleotide sequences, such as EST sequences, are publicly
15 available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:60 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
30 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
20 more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 1112 of SEQ ID NO:60, b is an
35 integer of 15 to 1126, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:60, and where b is greater than or equal to a + 14.

40 25 FEATURES OF PROTEIN ENCODED BY GENE NO: 51

This gene is expressed primarily in the spinal cord.

45 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
30 not limited to, paralysis, neurologic disorders. Similarly, polypeptides and antibodies
directed to these polypeptides are useful in providing immunological probes for
50 differential identification of the tissue(s) or cell type(s). For a number of disorders of

5 the above tissues or cells, particularly of the nervous system, expression of this gene
at significantly higher or lower levels is routinely detected in certain tissues or cell
10 types (e.g., neural, cancerous and wounded tissues) or bodily fluids (e.g., serum,
plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken
5 from an individual having such a disorder, relative to the standard gene expression
level, i.e., the expression level in healthy tissue or bodily fluid from an individual not
15 having the disorder.

The tissue distribution in spinal cord indicates polynucleotides and
polypeptides corresponding to this gene are useful for the detection, treatment, and/or
10 prevention of neurodegenerative disease states, behavioral disorders, or inflammatory
conditions. Representative uses are described in the "Regeneration" and
"Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and
elsewhere herein. Briefly, the uses include, but are not limited to the detection,
25 treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease,
15 Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating
diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal
cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia,
30 mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder,
learning disabilities, ALS, psychoses, autism, and altered behaviors, including
20 disorders in feeding, sleep patterns, balance, and perception. In addition, elevated
expression of this gene product in regions of the brain indicates it plays a role in
35 normal neural function.

Potentially, this gene product is involved in synapse formation,
neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or
40 survival. Furthermore, the protein may also be used to determine biological activity,
25 to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to
identify agents that modulate their interactions, in addition to its use as a nutritional
supplement. Protein, as well as, antibodies directed against the protein may show
45 utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
50 related to SEQ ID NO:61 and may have been publicly available prior to conception of

5 the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
10 cumbersome. Accordingly, preferably excluded from the present invention are one or
more polynucleotides comprising a nucleotide sequence described by the general
5 formula of a-b, where a is any integer between 1 to 2064 of SEQ ID NO:61, b is an
integer of 15 to 2078, where both a and b correspond to the positions of nucleotide
15 residues shown in SEQ ID NO:61, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 52

20 This gene is expressed primarily in keratinocytes, brain, fetal tissues,
pericardium, stomach, and cancerous tissues (e.g., stomach, adrenals, parathyroid,
germ cell, colon, breast).

Therefore, polynucleotides and polypeptides of the invention are useful as
25 reagents for differential identification of the tissue(s) or cell type(s) present in a
15 biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, skin disorders, neurodegenerative and developmental disorders, heart
disease, and cancers. Similarly, polypeptides and antibodies directed to these
30 polypeptides are useful in providing immunological probes for differential
identification of the tissue(s) or cell type(s). For a number of disorders of the above
20 tissues or cells, particularly of the cardiovascular and gastrointestinal systems,
expression of this gene at significantly higher or lower levels is routinely detected in
35 certain tissues or cell types (e.g., neural, immune, cancerous and wounded tissues) or
bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another
tissue or cell sample taken from an individual having such a disorder, relative to the
40 25 standard gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an individual not having the disorder.

The tissue distribution in brain indicates polynucleotides and polypeptides
45 corresponding to this gene are useful for the detection, treatment, and/or prevention of
neurodegenerative disease states, behavioral disorders, or inflammatory conditions.

30 Representative uses are described in the "Regeneration" and "Hyperproliferative
Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly,
50 the uses include, but are not limited to the detection, treatment, and/or prevention of

5 Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome,
meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia,
10 trauma, congenital malformations, spinal cord injuries, ischemia and infarction,
aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive
5 compulsive disorder, depression, panic disorder, learning disabilities, ALS,
psychoses, autism, and altered behaviors, including disorders in feeding, sleep
15 patterns, balance, and perception. In addition, elevated expression of this gene product
in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation,
20 neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or
survival. The tissue distribution in keratinocytes indicates polynucleotides and
polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or
prevention of various skin disorders. Representative uses are described in the
25 "Biological Activity", "Hyperproliferative Disorders", "infectious disease", and
15 "Regeneration" sections below, in Example 11, 19, and 20, and elsewhere herein.
Briefly, the protein is useful in detecting, treating, and/or preventing congenital
disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine
30 syndrome), integumentary tumors (i.e. keratoses, Bowen's Disease, basal cell
carcinoma, squamous cell carcinoma, malignant melanoma, Paget's Disease, mycosis
20 fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds,
35 rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, urticaria, eczema,
photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo,
dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae,
erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may
40 predispose increased susceptibility to viral and bacterial infections of the skin (i.e.
cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis,
erysipelas, impetigo, tinea, athlete's foot, and ringworm). Moreover, the protein
45 product of this gene may also be useful for the treatment or diagnosis of various
connective tissue disorders (i.e., arthritis, trauma, tendonitis, chondromalacia and
30 inflammation, etc.), autoimmune disorders (i.e., rheumatoid arthritis, lupus,
scleroderma, dermatomyositis, etc.), dwarfism, spinal deformation, joint
50 abnormalities, and chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita,

5
10
15
20
25
30
35
40
45
50
55

familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). The expression within fetal tissue (e.g., spleen and liver) and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

10
15
20
25
30
35
40
45
50
55

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Additionally, the tissue distribution in the pericardium of the heart indicates that the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the

5 protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

10 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are
5 related to SEQ ID NO:62 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically
15 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general
20 formula of a-b, where a is any integer between 1 to 748 of SEQ ID NO:62, b is an integer of 15 to 762, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:62, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 53

15 This gene is expressed primarily in the brain and in cartilage and to a lesser extent in the retina, activated T-cells, pineal gland, the lungs, and in synovial sarcoma.

30 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a
20 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological diseases, such as epilepsy and dementia, osteoarthritis,
35 retinopathies, hematopoietic diseases, emphysema, and lung cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For
40 a number of disorders of the above tissues or cells, particularly of the neurologic system, cartilage and musculature, vision, the hematopoietic system, and the
25 pulmonary system expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, immune, cancerous and
45 wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder,
30 relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
50

5 Preferred polypeptides of the present invention comprise immunogenic
epitopes shown in SEQ ID NO: 176 as residues: Arg-34 to Cys-44. Polynucleotides
10 encoding said polypeptides are also provided.

The tissue distribution in brain indicates polynucleotides and polypeptides
5 corresponding to this gene are useful for the detection, treatment, and/or prevention of
neurodegenerative disease states, behavioral disorders, or inflammatory conditions.
15 Representative uses are described in the "Regeneration" and "Hyperproliferative
Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly,
the uses include, but are not limited to the detection, treatment, and/or prevention of
20 Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome,
meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia,
trauma, congenital malformations, spinal cord injuries, ischemia and infarction,
aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive
25 compulsive disorder, depression, panic disorder, learning disabilities, ALS,
15 psychoses, autism, and altered behaviors, including disorders in feeding, sleep
patterns, balance, and perception. In addition, elevated expression of this gene product
in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation,
neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or
20 survival. The tissue distribution in T-cells indicates polynucleotides and polypeptides
corresponding to this gene are useful for the diagnosis and treatment of a variety of
35 immune system disorders. Representative uses are described in the "Immune
Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19,
20, and 27, and elsewhere herein. Briefly, the expression of this gene product
40 25 indicates a role in regulating the proliferation; survival; differentiation; and/or
activation of hematopoietic cell lineages, including blood stem cells. This gene
product is involved in the regulation of cytokine production, antigen presentation, or
45 other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting
immune responses).

30 Since the gene is expressed in cells of lymphoid origin, the natural gene
product is involved in immune functions. Therefore it is also useful as an agent for
50 immunological disorders including arthritis, asthma, immunodeficiency diseases such

as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The expression of this gene product in synovium would suggest a role in the detection and treatment of disorders and conditions afflicting the skeletal system, in particular osteoporosis, bone cancer, connective tissue disorders (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation). The protein is also useful in the diagnosis or treatment of various autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, and dermatomyositis), dwarfism, spinal deformation, joint abnormalities, and chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid, etc.). Additionally, the expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have

5 applications in the adult for tissue regeneration and the treatment of cancers. It may
also act as a morphogen to control cell and tissue type specification. Therefore, the
10 polynucleotides and polypeptides of the present invention are useful in treating,
detecting, and/or preventing said disorders and conditions, in addition to other types
5 of degenerative conditions. Thus this protein may modulate apoptosis or tissue
differentiation and is useful in the detection, treatment, and/or prevention of
15 degenerative or proliferative conditions and diseases. The protein is useful in
modulating the immune response to aberrant polypeptides, as may exist in
proliferating and cancerous cells and tissues. The protein can also be used to gain new
20 insight into the regulation of cellular growth and proliferation. Furthermore, the
protein may also be used to determine biological activity, to raise antibodies, as tissue
markers, to isolate cognate ligands or receptors, to identify agents that modulate their
interactions, in addition to its use as a nutritional supplement. Protein, as well as,
25 antibodies directed against the protein may show utility as a tumor marker and/or
15 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
30 available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:63 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
20 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
35 more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 1080 of SEQ ID NO:63, b is an
integer of 15 to 1094, where both a and b correspond to the positions of nucleotide
40 residues shown in SEQ ID NO:63, and where b is greater than or equal to a + 14.
25

FEATURES OF PROTEIN ENCODED BY GENE NO: 54

45 This gene is expressed primarily in umbilical vein endothelial cells induced by
IL-4.

30 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
50 biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, angiogenesis, inflammatory disorders, hematopoietic disease.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the angiogenic and hematopoietic systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in endothelial cells indicates polynucleotides and polypeptides corresponding to this gene are useful in the detection, treatment, and/or prevention of vascular conditions, which include, but are not limited to, microvascular disease, vascular leak syndrome, aneurysm, stroke, atherosclerosis, arteriosclerosis, or embolism. For example, this gene product may represent a soluble factor produced by smooth muscle that regulates the innervation of organs or regulates the survival of neighboring neurons. Likewise, it is involved in controlling the digestive process, and such actions as peristalsis. Similarly, it is involved in controlling the vasculature in areas where smooth muscle surrounds the endothelium of blood vessels. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological activities. Representative uses are described in the "Chemotaxis" and "Binding Activity" sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere herein. Briefly, the protein may possess the following activities: cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human

5 immunodeficiency virus infection, cancer, autoimmune diseases and allergy);
regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy);
10 stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for
treating wounds, stimulation of follicle stimulating hormone (for control of fertility);
5 chemotactic and chemokinetic activities (e.g. for treating infections, tumors);
hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction
15 etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's Disease); as
antimicrobials; for treating psoriasis or other hyperproliferative diseases; for
regulation of metabolism, and behavior. Also contemplated is the use of the
20 corresponding nucleic acid in gene therapy procedures.

Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:64 and may have been publicly available prior to conception of
25 the present invention. Preferably, such related polynucleotides are specifically
15 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
more polynucleotides comprising a nucleotide sequence described by the general
30 formula of a-b, where a is any integer between 1 to 1347 of SEQ ID NO:64, b is an
integer of 15 to 1361, where both a and b correspond to the positions of nucleotide
20 residues shown in SEQ ID NO:64, and where b is greater than or equal to a + 14.

35 FEATURES OF PROTEIN ENCODED BY GENE NO: 55

This gene is expressed primarily in both normal and cancerous pancreas.

40 Therefore, polynucleotides and polypeptides of the invention are useful as
25 reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, diabetes, gastrointestinal disorders, and pancreatic cancer. Similarly,
45 polypeptides and antibodies directed to these polypeptides are useful in providing
immunological probes for differential identification of the tissue(s) or cell type(s). For
30 a number of disorders of the above tissues or cells, particularly of the digestive and
blood systems, expression of this gene at significantly higher or lower levels is
50 routinely detected in certain tissues or cell types (e.g., cancerous and wounded

tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in pancreas indicates that the protein products of this gene are useful as a therapeutic and/or diagnostic agent for pancreatic disorders and disorders of the endocrine and exocrine system, including but not limited to diabetes, blood disorders, pancreatic cancer, gastrointestinal diseases, hormonal imbalance, autoimmune disorders, cystic fibrosis, pancreatitis, and gallstones. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:65 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 933 of SEQ ID NO:65, b is an integer of 15 to 947, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:65, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 56

The translation product of this gene shares sequence homology with oxidoreductase. Preferred polypeptides of the invention comprise the following amino acid sequence: MSPLSAARAALRVYAVGAAVILAQLLRRCRGGFLEPVXPPRP
DRVAIVTGGTDGIGYSTANIWRDLGMHVIIAGNNSKAKQVVSKEETLND
KVEFLYCDLASMTSIRQFVQFKMKKIPLHVLINNAGVMMVPQRKTRDGFEE
HFGLNYLGHFLLTNLLDCLKESGSPGHSARVVTYSSATHYVAELNMDDLQS

5
10
15
20
25
30
35
40
45
50
55

SACYSPHAAYAQSKLALVLFTYHLQRLAAEGSHVTANVVDPGVVNTDXYK
HVFWATRLAKKLLGWLLFKTPDEGAWTSIYAAVTPELEGVGGRYLYNEKET
KSLHVTYNQKLQQQLWSKSCMTGVLDVTL (SEQ ID NO: 320). The mature
form of this protein begins at residue 32. Thus, polypeptides comprising residues 2-
330 and 32-330 of the sequence shown above are also provided. Polynucleotides
encoding such polypeptides are also provided.

A preferred polypeptide fragment of the invention comprises the following
amino acid sequence: MSPLSAARAALRVYAVGAAVILAQLLRRCRGGFLEP
VXPPRPDRVAIVTGCTDGIG YSTANIWRDLACMLS (SEQ ID NO: 321).

Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in breast cancer cells, osteoclastoma, wilm's
tumor, thymus stromal cells, and T cell helper I.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, cancer, e.g., breast cancer, osteoclastoma, and wilm's tumor. Similarly,
polypeptides and antibodies directed to these polypeptides are useful in providing
immunological probes for differential identification of the tissue(s) or cell type(s). For
a number of disorders of the above tissues or cells, particularly of the immune system,
expression of this gene at significantly higher or lower levels is routinely detected in
certain tissues or cell types (e.g., reproductive, kidney, immune, hematopoietic, and
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, breast milk,
urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an
individual having such a disorder, relative to the standard gene expression level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not having the
disorder.

The tissue distribution in breast cancer tissue, combined with the homology to
oxidoreductase indicates that polynucleotides and polypeptides corresponding to this
gene are useful for diagnosis and treatment of cancer, particularly, breast cancer,
osteoclastoma, and wilm's tumor. This protein may play a role in the regulation of
cellular division, and may show utility in the diagnosis, treatment, and/or prevention
of developmental diseases and disorders, including cancer, and other proliferative

5 conditions. Representative uses are described in the "Hyperproliferative Disorders"
and "Regeneration" sections below and elsewhere herein. Briefly, developmental
10 tissues rely on decisions involving cell differentiation and/or apoptosis in pattern
formation.

5 Dysregulation of apoptosis can result in inappropriate suppression of cell
death, as occurs in the development of some cancers, or in failure to control the extent
15 of cell death, as is believed to occur in acquired immunodeficiency and certain
neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of
potential roles in proliferation and differentiation, this gene product may have
20 applications in the adult for tissue regeneration and the treatment of cancers. It may
also act as a morphogen to control cell and tissue type specification. Therefore, the
polynucleotides and polypeptides of the present invention are useful in treating,
detecting, and/or preventing said disorders and conditions, in addition to other types
25 of degenerative conditions. Thus this protein may modulate apoptosis or tissue
differentiation and is useful in the detection, treatment, and/or prevention of
15 degenerative or proliferative conditions and diseases. The protein is useful in
modulating the immune response to aberrant polypeptides, as may exist in
30 proliferating and cancerous cells and tissues. The protein can also be used to gain new
insight into the regulation of cellular growth and proliferation. Furthermore, the
20 protein may also be used to determine biological activity, to raise antibodies, as tissue
markers, to isolate cognate ligands or receptors, to identify agents that modulate their
35 interactions, in addition to its use as a nutritional supplement. Protein, as well as,
antibodies directed against the protein may show utility as a tumor marker and/or
immunotherapy targets for the above listed tissues.

40 25 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:66 and may have been publicly available prior to conception of
45 the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
30 cumbersome. Accordingly, preferably excluded from the present invention are one or
more polynucleotides comprising a nucleotide sequence described by the general
50 formula of a-b, where a is any integer between 1 to 1362 of SEQ ID NO:66, b is an

integer of 15 to 1376, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:66, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 57

This gene is expressed primarily in monocytes, T cell helper II and B cell lymphoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hematopoietic diseases and/or disorders, particularly B-cell lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 180 as residues: Asp-30 to Val-40. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in monocytes, T cell helper, and B cell lymphoma cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of B cell lymphoma. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or

5 other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

10 Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for
5 immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory
15 bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity
20 disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits
25 hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue
30 markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as,
20 antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

35 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:67 and may have been publicly available prior to conception of
40 25 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or
45 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2420 of SEQ ID NO:67, b is an
30 integer of 15 to 2434, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:67, and where b is greater than or equal to a + 14.

5

10

15

20

25

30

35

40

45

50

55

FEATURES OF PROTEIN ENCODED BY GENE NO: 58

This gene is expressed primarily in human lung cancer.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, pulmonary diseases and/or disorders, particularly cancers of the lung. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., pulmonary, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, pulmonary lavage, pulmonary surfactant, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 181 as residues: Phe-39 to Asp-45. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in lung cancer tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune system disorders such as ARDS, cystic fibrosis, and cancer, particularly lung cancer. This protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of

5 potential roles in proliferation and differentiation, this gene product may have
applications in the adult for tissue regeneration and the treatment of cancers. It may
10 also act as a morphogen to control cell and tissue type specification. Therefore, the
polynucleotides and polypeptides of the present invention are useful in treating,
5 detecting, and/or preventing said disorders and conditions, in addition to other types
of degenerative conditions. Thus this protein may modulate apoptosis or tissue
15 differentiation and is useful in the detection, treatment, and/or prevention of
degenerative or proliferative conditions and diseases. The protein is useful in
modulating the immune response to aberrant polypeptides, as may exist in
20 proliferating and cancerous cells and tissues. The protein can also be used to gain new
insight into the regulation of cellular growth and proliferation. Furthermore, the
protein may also be used to determine biological activity, to raise antibodies, as tissue
25 markers, to isolate cognate ligands or receptors, to identify agents that modulate their
interactions, in addition to its use as a nutritional supplement. Protein, as well as,
15 antibodies directed against the protein may show utility as a tumor marker and/or
immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:68 and may have been publicly available prior to conception of
20 the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
35 cumbersome. Accordingly, preferably excluded from the present invention are one or
more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 1072 of SEQ ID NO:68, b is an
40 25 integer of 15 to 1086, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:68, and where b is greater than or equal to a + 14.

45 FEATURES OF PROTEIN ENCODED BY GENE NO: 59

30 This gene is expressed primarily in larynx carcinoma and early stage human
lung.

50 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a

5 biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, developmental, gastrointestinal, and pulmonary diseases and/or
10 disorders, particularly larynx carcinoma. Similarly, polypeptides and antibodies
directed to these polypeptides are useful in providing immunological probes for
5 differential identification of the tissue(s) or cell type(s). For a number of disorders of
the above tissues or cells, particularly of the immune system, expression of this gene
15 at significantly higher or lower levels is routinely detected in certain tissues or cell
types (e.g., developmental, gastrointestinal, pulmonary, and cancerous and wounded
tissues) or bodily fluids (e.g., serum, plasma, amniotic fluid, pulmonary lavage,
20 sputum, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken
from an individual having such a disorder, relative to the standard gene expression
level, i.e., the expression level in healthy tissue or bodily fluid from an individual not
having the disorder.

25 Preferred polypeptides of the present invention comprise immunogenic
15 epitopes shown in SEQ ID NO: 182 as residues: His-42 to Lys-49. Polynucleotides
encoding said polypeptides are also provided.

30 The tissue distribution in larynx carcinoma and early stage human lung
indicates that polynucleotides and polypeptides corresponding to this gene are useful
for treating immune system disorders such as cancer, particularly larynx carcinoma.
20 This protein may play a role in the regulation of cellular division, and may show
35 utility in the diagnosis, treatment, and/or prevention of developmental diseases and
disorders, including cancer, and other proliferative conditions. Representative uses are
described in the "Hyperproliferative Disorders" and "Regeneration" sections below
and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell
40 25 differentiation and/or apoptosis in pattern formation.

45 Dysregulation of apoptosis can result in inappropriate suppression of cell
death, as occurs in the development of some cancers, or in failure to control the extent
of cell death, as is believed to occur in acquired immunodeficiency and certain
neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of
30 potential roles in proliferation and differentiation, this gene product may have
applications in the adult for tissue regeneration and the treatment of cancers. It may
50 also act as a morphogen to control cell and tissue type specification. Therefore, the

polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:69 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1248 of SEQ ID NO:69, b is an integer of 15 to 1262, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:69, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 60

Preferred polypeptides of the invention comprise the following amino acid sequence: MEVTTEDTSRTDVSEPATSGGAADGVTSIAPTAVASSTTAASITTA
ASSMTVASSAPTTAASSTTVASIAPTTTASSMTAASSTPMTLALPAPTSTXTGR
TPSTTATGHPSLSTALAQVPKSSALPRTATLATLATRAQTVATTANTSSPMST
RPSPSKHMPSDTAASPVPMPXPQAQGPISQVSVDQPVVNTTXKSTXMPSTNT
XEPLTQAVVDKTLVVLLLVLTFTVLVLFALQAYESYKKKDYTQVDYLI

NGMYADSEM (SEQ ID NO: 322). Polynucleotides encoding these polypeptides are also provided.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: ARCPGLPGLRCRPRPRAGPQAPSYCPTRPPG ACCARMRLLEWRVYLR LTCATKDG MARECPTTWLSPPAKPDFAQ RHSV KPTALQGG RWSRLGASP (SEQ ID NO: 323). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in adipocytes, osteoblasts, cerebellum, hypothalamus and Hodgkin's lymphoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, metabolic, skeletal, neural, and immune diseases and/or disorders, particularly Hodgkin's lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., metabolic, skeletal, neural, immune, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 183 as residues: Pro-33 to Gln-40, Gly-51 to Arg-56. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in Hodgkin's lymphoma cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune system disorders such as cancer, particularly Hodgkin's lymphoma. The secreted protein can also be used to determine biological activity, to

5
10
15
20
25
30
35
40
45
50
55

raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological activities. Representative uses are described in the "Chemotaxis" and "Binding Activity" sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere herein. Briefly, the protein may possess the following activities: cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

20
25
30
35
40
45
50
55

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:70 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1628 of SEQ ID NO:70, b is an integer of 15 to 1642, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:70, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 61

The translation product of this gene shares sequence homology with polypeptide in the cystatin family. Cystatin polypeptides are cysteine protease inhibitors. For an analysis of the composition of several members of the cystatin family see Gene (1987) 61(3):329-338, incorporated herein by reference. The cystatin activity of polypeptides encoded by this gene is measured by several assays known in the art including assays described in coowned, copending US Patent Application Serial No. 08/744,138, incorporated herein by reference. Preferred polypeptides of the invention comprise the following amino acid sequence: LPATVEFAVHTFNQQSKD YYAYRLGHILNSWKEQVESKTVFSMELLGRTRCGKFEDDIDNCHFQESTEL NNTFTCFFTISTRPWMTQFSLNKTIC (SEQ ID NO: 324). Fragments of such polypeptides having cystatin activity (cysteine protease inhibitory activity are particularly preferred). Polynucleotides encoding such polypeptides are also provided.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: LLWARGLGRAKSAVPTVST MLGLPWKGGLS WALLLLLLGSQILLIYAWHFHEQRDCDEHNVMARYLPATVEFAVHTFNQQS KDYYAYRLGHILNSWKEQVESKTVFSMELLGRTRCGKFEDDIDNCHFQESTELNNTFTCFFTISTRPWMTQFSLNKTIC (SEQ ID NO: 325).

Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in testes and epididymus. For a review of a cystatin showing testes- specific expression see Mol. Endocrinol. (1992 Oct.) 6(10):1653-1664, incorporated herein by reference.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, They should therefore serve a protective function to regulate the activities of such endogenous proteinases, which otherwise may cause uncontrolled proteolysis and tissue damage. Cysteine proteinase activity can normally not be measured in body fluids, but can be detected extracellularly in conditions like endotoxin-induced sepsis, metastasizing cancer, and at local inflammatory processes

5 in rheumatoid arthritis, purulent bronchiectasis and periodontitis. Similarly,
polypeptides and antibodies directed to these polypeptides are useful in providing
10 immunological probes for differential identification of the tissue(s) or cell type(s). For
a number of disorders of the above tissues or cells, particularly of the immune,
5 expression of this gene at significantly higher or lower levels is routinely detected in
certain tissues or cell types (e.g., reproductive, testicular, and cancerous and wounded
15 tissues) or bodily fluids (e.g., serum, plasma, urine, seminal fluid, synovial fluid and
spinal fluid) or another tissue or cell sample taken from an individual having such a
disorder, relative to the standard gene expression level, i.e., the expression level in
20 healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic
epitopes shown in SEQ ID NO: 184 as residues: Phe-31 to Asp-38, Asn-59 to Tyr-65,
Ser-76 to Glu-82, Thr-96 to Cys-108, Gln-111 to Asn-118. Polynucleotides encoding
25 said polypeptides are also provided.

15 The tissue distribution in testes and epididymus, combined with the
homology to cystatins indicates that polynucleotides and polypeptides corresponding
to this gene are useful for the treatment and diagnosis of conditions concerning proper
30 testicular function (e.g. endocrine function, sperm maturation), as well as cancer.
Therefore, this gene product is useful in the treatment of male infertility and/or
20 impotence. This gene product is also useful in assays designed to identify binding
agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly,
35 the protein is believed to be useful in the treatment and/or diagnosis of testicular
cancer. The testes are also a site of active gene expression of transcripts that is
expressed, particularly at low levels, in other tissues of the body. Therefore, this gene
40 product is expressed in other specific tissues or organs where it may play related
functional roles in other processes, such as hematopoiesis, inflammation, bone
formation, and kidney function, to name a few possible target indications.

45 Representative uses are described in the "Hyperproliferative Disorders" and
"Regeneration" sections below and elsewhere herein. Briefly, developmental tissues
30 rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell
50 death, as occurs in the development of some cancers, or in failure to control the extent

5 of cell death, as is believed to occur in acquired immunodeficiency and certain
neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of
10 potential roles in proliferation and differentiation, this gene product may have
applications in the adult for tissue regeneration and the treatment of cancers. It may
5 also act as a morphogen to control cell and tissue type specification. Therefore, the
polynucleotides and polypeptides of the present invention are useful in treating,
15 detecting, and/or preventing said disorders and conditions, in addition to other types
of degenerative conditions. Thus this protein may modulate apoptosis or tissue
differentiation and is useful in the detection, treatment, and/or prevention of
20 degenerative or proliferative conditions and diseases. The protein is useful in
modulating the immune response to aberrant polypeptides, as may exist in
proliferating and cancerous cells and tissues. The protein can also be used to gain new
insight into the regulation of cellular growth and proliferation. Furthermore, the
25 protein may also be used to determine biological activity, to raise antibodies, as tissue
markers, to isolate cognate ligands or receptors, to identify agents that modulate their
interactions, in addition to its use as a nutritional supplement. Protein, as well as,
30 antibodies directed against the protein may show utility as a tumor marker and/or
immunotherapy targets for the above listed tissues.

Cysteine proteinase inhibitors of the cystatin superfamily are ubiquitous in the
20 body and are generally tight-binding inhibitors of papain-like cysteine proteinases,
such as cathepsins B, H, L, S, and K. They should therefore serve a protective
35 function to regulate the activities of such endogenous proteinases, which otherwise
may cause uncontrolled proteolysis and tissue damage. Cysteine proteinase activity
can normally not be measured in body fluids, but can be detected extracellularly in
40 25 conditions like endotoxin-induced sepsis, metastasizing cancer, and at local
inflammatory processes in rheumatoid arthritis, purulent bronchiectasis and
periodontitis, which indicates that a tight cystatin regulation is a necessity in the
45 normal state. A deficiency state in which the levels of the intracellular cystatin,
cystatin B, are lowered due to mutations has recently been shown to segregate with a
30 form of progressive myoclonus epilepsy, which points to additional specialized
functions of cystatins. Moreover, results showing that chicken cystatin inhibits polio
50 virus replication, human cystatin C inhibits corona- and herpes simplex virus

5 replication, and human cystatin A inhibits rhabdovirus-induced apoptosis in cell
cultures indicates that cystatins play additional roles in the human defense system.
10 The cystatins constitute a superfamily of evolutionarily related proteins, all composed
of at least one 100-120 residue domain with conserved sequence motifs.

5 The previously well characterized single-domain human members of this
superfamily could be grouped in two protein families. The Family 1 members,
15 cystatins (or stefins) A and B, contain approximately 100 amino acid residues, lack
disulfide bridges, and are not synthesized as preproteins with signal peptides. The
Family 2 cystatins (cystatins C, D, S, SN, and SA) are secreted proteins of approx.
20 120 amino acid residues (Mr 13,000-14,000) and have two characteristic intrachain
disulfide bonds. Recently, we identified an additional human cystatin superfamily
member by EST1 sequencing in epithelial cell derived cDNA libraries which we
named cystatin E. The same cystatin was independently discovered by differential
25 display experiments as a mRNA species down-regulated in breast tumor tissue, but
present in the surrounding epithelium and reported under the name cystatin M.
15 Cystatin E/M is an atypical, secreted low-Mr cystatin in that it is a glycoprotein and
just shows 30-35% sequence identity in alignments with the human Family 2
30 cystatins, which shows that additional cystatin families are yet to be identified. The
cystatin E/M gene has been localized to chromosome 2, whereas all human Family 2
20 cystatin genes are clustered on the short arm of chromosome 20, which further
stresses that cystatin E/M is just distantly related to the other secreted human low-Mr
35 cystatins. It is believed therefore, that polypeptides encoded by this gene are useful in
diagnosing and treating disease consistent with the aforementioned conditions in
which cystatins are implicated.

40 25 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:71 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
45 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
30 more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 907 of SEQ ID NO:71, b is an
50

integer of 15 to 921, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:71, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 62

The translation product of this gene shares sequence homology with Neutrophil Gelatinase-Associated Lipocalin which is thought to be important in immune regulation (See Genbank and Geneseq Accession Nos. emb1CAA58127.1, and U55627034, respectively; all references and information available through these accessions are hereby incorporated herein by reference; for example, Biochem. Biophys. Res. Commun. 202 (3), 1468-1475 (1994), and FEBS Lett. 314 (3), 386-388 (1992)).

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: LEQKLELHRGGGRSRTSGSPGLQEFGTREERGE GEQRTGREFSGNGGRAVEAARMRLLCGLWLWLSLLKVLQAQTPTPLPLPP PMQSFQGNQFQGEWFLGLAGNSFRPEHRALLNAFTATFELSDDGRFEVWN AMTRGQHCDTWSYVLIPAAQPGQFTVDHGVGRSWLLPPGTLDQFICLGRAQ GLSDDNIVFPDVTGXAI.DL XSLPWVAAPA (SEQ ID NO: 326). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in epididymus and osteoclastoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive and skeletal diseases and/or disorders, particularly cancers such as osteoclastoma testicular cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, testicular, skeletal, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, seminal fluid, urine, synovial fluid and spinal fluid)

5 or another tissue or cell sample taken from an individual having such a disorder,
relative to the standard gene expression level, i.e., the expression level in healthy
10 tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic
5 epitopes shown in SEQ ID NO: 185 as residues: Met-82 to Thr-90. Polynucleotides
encoding said polypeptides are also provided.

15 The tissue distribution in epididymus and homology to neutrophil gelatinase-
associated lipocalin indicates that polynucleotides and polypeptides corresponding to
this gene are useful for diagnosis and treatment of skin diseases and immune system
20 disorders such as cancer, particularly osteoclastoma. The secreted protein can also be
used to determine biological activity, to raise antibodies, as tissue markers, to isolate
cognate ligands or receptors, to identify agents that modulate their interactions, and as
nutritional supplements. It may also have a very wide range of biological activities.
25 Representative uses are described in the "Chemotaxis" and "Binding Activity"
sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere
15 herein. Briefly, the protein may possess the following activities: cytokine, cell
proliferation/differentiation modulating activity or induction of other cytokines;
30 immunostimulating/immunosuppressant activities (e.g. for treating human
immunodeficiency virus infection, cancer, autoimmune diseases and allergy);
20 regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy);
stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for
35 treating wounds, stimulation of follicle stimulating hormone (for control of fertility);
chemotactic and chemokinetic activities (e.g. for treating infections, tumors);
hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction
40 etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's Disease); as
25 antimicrobials; for treating psoriasis or other hyperproliferative diseases; for
regulation of metabolism, and behavior. Also contemplated is the use of the
corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies
45 directed against the protein may show utility as a tumor marker and/or
30 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
50 available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:72 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 892 of SEQ ID NO:72, b is an integer of 15 to 906, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:72, and where b is greater than or equal to a + 14.

10 FEATURES OF PROTEIN ENCODED BY GENE NO: 63

The translation product of this gene was shown to have homology to colipase which plays an essential role in the intestinal fat digestion by anchoring lipase on lipid/water interfaces in the presence of bile salts (See Genbank Accession No. gb|AAA03513.1; all references and information available through this accession are hereby incorporated by reference herein).

This gene is expressed primarily in epididymus.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive diseases and/or disorders, particularly epididymus-related diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, metabolic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, seminal fluid, bile, chyme, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 186 as residues: Ile-40 to Cys-49, Arg-52 to Cys-57,

Ser-94 to Trp-99, Gly-105 to Gly-111. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in epididymus indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune system diseases and disorders of the epididymus. Polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product is expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:73 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 666 of SEQ ID NO:73, b is an integer of 15 to 680, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:73, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 64

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: MCV CER KRG RE KEGGV TPTMT SNFPFCTLILGI AQAQACPGCPGDWPGLGSGVGEGLHHIRTCRTPIPCSPAPAAAACLGSGH ARLPCVLRLLWPVPANLSSPFRLEALHCSFWSSPLLPAHILAFFGFRDLLTDFL LAACLLTFQKTPLELPMMAVVHLLVATPCYQMLDNLPLPSAAAN WC (SEQ ID NO: 327). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in melanocytes and placenta and to a lesser extent in bone marrow and many cells of the immune system, including B-cells, dendritic cells, and T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, skin cancer and disorders of the reproductive and immune systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive and immune systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues and cell types (e.g., reproductive tissue, hematopoietic tissue, melanocytes and cells and tissue of the immune system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in melanocytes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting the skin, the reproductive system, and the immune system, particularly cancers. Representative uses are described in the "Biological Activity".

5 "Hyperproliferative Disorders", "infectious disease", and "Regeneration" sections
below, in Example 11, 19, and 20, and elsewhere herein. Briefly, the protein is useful
10 in detecting, treating, and/or preventing congenital disorders (i.e. nevi, moles,
freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary
5 tumors (i.e. keratoses, Bowen's Disease, basal cell carcinoma, squamous cell
carcinoma, malignant melanoma, Paget's Disease, mycosis fungoides, and Kaposi's
15 sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat
disorder, psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity,
autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea,
20 scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae,
purpura, and xanthelasma. In addition, such disorders may predispose increased
susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts,
25 chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas,
impetigo, tinea, athlete's foot, and ringworm). Moreover, the protein product of this
15 gene may also be useful for the treatment or diagnosis of various connective tissue
disorders (i.e., arthritis, trauma, tendonitis, chondromalacia and inflammation, etc.),
autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma,
30 dermatomyositis, etc.), dwarfism, spinal deformation, joint abnormalities, and
chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial
20 osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid).
Furthermore, the protein may also be used to determine biological activity, to raise
35 antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents
that modulate their interactions, in addition to its use as a nutritional supplement.
Protein, as well as, antibodies directed against the protein may show utility as a tumor
40 25 marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
45 related to SEQ ID NO:74 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
30 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
50 more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 1619 of SEQ ID NO:74, b is an integer of 15 to 1633, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:74, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 65

Preferred polypeptides of the invention comprise the following amino acid sequence: YLWGRPRLMRAGTSPSPAPWGKREKLGHKLPVALQGYHPWIL
LECTVFWARVVLACFSLYLIRGPNICINRQPEPTYQKACNLDCSDFGQER
APAWELLGPESEQRLREYTAQGLQSLASSHRWRQFKTEGKMRGGASPLPWLI
10 CFW LCSYKGS DNSLKP VVPGPTLCPQSLVSPSVHPSTRSASLGRHRAEAA
(SEQ ID NO: 328). Polynucleotides encoding these polypeptides are also provided.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the
15 following amino acid sequence: MPGILAGIPVKDLCLSLQGFRLLLCVCPGWL
SGWMGGQKGSPRIVDIG (SEQ ID NO: 329). Polynucleotides encoding these polypeptides are also provided. This gene maps to chromosome 15, accordingly, polynucleotides of the invention is used in linkage analysis as a marker for chromosome 15.

20 This gene is expressed primarily in brain and breast and to a lesser extent in the liver, pancreas, and T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are
40 not limited to, disorders affecting the brain and CNS, the reproductive system, or the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,
45 particularly of the central nervous system, the reproductive system, and the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., brain and other tissue of the nervous
50 system, mammary tissue, endocrine tissue, hepatic tissue, reproductive tissue, cells

5 and tissue of the immune system, cancerous and wounded tissues) or bodily fluids
(e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell
10 sample taken from an individual having such a disorder, relative to the standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid from an
5 individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic
15 epitopes shown in SEQ ID NO: 188 as residues: Met-37 to Ser-43. Polynucleotides
encoding said polypeptides are also provided.

The tissue distribution in brain cells indicates that polynucleotides and
20 polypeptides corresponding to this gene are useful for the diagnosis and treatment of
disorders affecting the central nervous system, the reproductive system, and the
immune system, including cancers. Representative uses are described in the
"Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11,
25 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the
15 detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease,
Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating
30 diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal
cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia,
mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder,
20 learning disabilities, ALS, psychoses, autism, and altered behaviors, including
disorders in feeding, sleep patterns, balance, and perception. In addition, elevated
35 expression of this gene product in regions of the brain indicates it plays a role in
normal neural function.

Potentially, this gene product is involved in synapse formation,
40 25 neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or
survival. Furthermore, the protein may also be used to determine biological activity,
to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to
45 identify agents that modulate their interactions, in addition to its use as a nutritional
supplement. Protein, as well as, antibodies directed against the protein may show
30 utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
50 available and accessible through sequence databases. Some of these sequences are

5 related to SEQ ID NO:75 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
10 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
5 more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 1008 of SEQ ID NO:75, b is an
15 integer of 15 to 1022, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:75, and where b is greater than or equal to a + 14.

20 10 FEATURES OF PROTEIN ENCODED BY GENE NO: 66

In another embodiment, polypeptides comprising the amino acid sequence of
the open reading frame upstream of the predicted signal peptide are contemplated by
the present invention. Specifically, polypeptides of the invention comprise the
25 following amino acid sequence: AKGEERKEAFSLKMVQLSSEPISFGLM⁵YL¹⁰YLG¹⁵V
15 FFHLYPGALSITTLGKHSHPF²⁰FTAEQNSTVWMEHTLFHQSPVASHLVCFQSF²⁵
AFSE (SEQ ID NO: 330). Polynucleotides encoding these polypeptides are also
provided.

30 This gene is expressed primarily in the brain and the immune system, in
particular T-cells.

20 Therefore, polynucleotides and polypeptides of the invention are useful as
35 reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, disorders affecting the brain, such as Alzheimer's or disorders affecting
the immune system, such as AIDS. Similarly, polypeptides and antibodies directed to
40 25 these polypeptides are useful in providing immunological probes for differential
identification of the tissue(s) or cell type(s). For a number of disorders of the above
tissues or cells, particularly of the brain and CNS and the immune systems, expression
of this gene at significantly higher or lower levels is routinely detected in certain
45 tissues and cell types (e.g., brain and other tissue of the nervous system, cells and
30 tissue of the immune system, and cancerous and wounded tissues) or bodily fluids
(e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell
50 sample taken from an individual having such a disorder, relative to the standard gene

5 expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 The tissue distribution in brain cells and tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment
5 of disorders affecting the brain and CNS or disorders affecting the immune system. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly,
15 the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia,
20 trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS,
25 psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product
15 in regions of the brain indicates it plays a role in normal neural function.

30 Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity,
20 to raise antibodies, as tissue markers; to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional
35 supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

40 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are
25 related to SEQ ID NO:76 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically
45 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or
30 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1170 of SEQ ID NO:76, b is an

integer of 15 to 1184, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:76, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 67

The translation product of this gene shares sequence homology with pcnacidin-2 which is thought to be a members of a new family of antimicrobial peptides from the hemolymph of shrimps *Penaeus vannamei*. The molecules display antimicrobial activity against fungi and bacteria with a predominant activity against Gram-positive bacteria.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: GPAHPASPPLMTLSLQLAELVHFVCAFAQSQWTGVYPMMPPLKPTPLCFA CVPCR (SEQ ID NO: 331). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hematopoietic diseases and/or disorders, particularly disorders affecting the spleen, including bacterial and fungal infections. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic and immune systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues and cell types (e.g., immune, hematopoietic, and cells and tissue of the immune system, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 The tissue distribution in spleen and homology to the penaeidin family of
antibiotics indicates that polynucleotides and polypeptides corresponding to this gene
10 are useful for the diagnosis and treatment of disorders affecting the spleen, especially
fungal and bacterial infections. Representative uses are described in the "Immune
5 Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19,
20, and 27, and elsewhere herein. Briefly, the expression of this gene product
15 indicates a role in regulating the proliferation; survival; differentiation; and/or
activation of hematopoietic cell lineages, including blood stem cells. This gene
product is involved in the regulation of cytokine production, antigen presentation, or
20 other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting
immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene
product is involved in immune functions. Therefore it is also useful as an agent for
25 immunological disorders including arthritis, asthma, immunodeficiency diseases such
15 as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory
bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,
such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and
30 tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity
disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic
20 lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's
Disease, and scleroderma. Moreover, the protein may represent a secreted factor that
35 influences the differentiation or behavior of other blood cells, or that recruits
hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in
the expansion of stem cells and committed progenitors of various blood lineages, and
40 25 in the differentiation and/or proliferation of various cell types. Furthermore, the
protein may also be used to determine biological activity, raise antibodies, as tissue
markers, to isolate cognate ligands or receptors, to identify agents that modulate their
45 interactions, in addition to its use as a nutritional supplement. Protein, as well as,
antibodies directed against the protein may show utility as a tumor marker and/or
30 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
50 available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:77 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 298 of SEQ ID NO:77, b is an integer of 15 to 312, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:77, and where b is greater than or equal to a + 14.

10 FEATURES OF PROTEIN ENCODED BY GENE NO: 68

Contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of THP-1 cells to calcium. Thus it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of both monocytes, in addition to other cell-lines or tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating immune and hematopoietic cells and tissue cell types. Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium and sodium, as well as alter pH and membrane potential. Alterations in small molecule concentration can be measured to identify supernatants which bind to receptors of a particular cell.

Moreover, when tested in TF-1 cell lines, the protein product of this gene has been shown to alter the steady-state messenger RNA levels of the following genes: c-fos, c-jun, egr-1, b561, bcl-2, CD40, cyclin D2, GADPH, ICER, MAD3, p21, STAT3, ID3, and STAT-1. When tested in U937 cell lines, the protein product of this gene has been shown to alter the steady-state messenger RNA levels of the following genes: egr2, MKP1, ATF3, B562, cyclin D, cyclin D2, GATA3, MAD3, p21, TGF, DHFR, and JAK3. Based upon these results, it is anticipated that polynucleotides and polypeptides corresponding to this gene are useful as agonists or antagonists of the above referenced genes. Such activity is useful in therapeutic and/or diagnostic applications as referenced and more specifically discussed elsewhere herein.

In specific embodiments, polypeptides of the invention comprise the sequence: MLLEVYGD^SISVTVAIPL (SEQ ID NO: 332), MHSPCQSKAADGLGKSETE (SEQ ID NO: 333), and/or MLKSLGLSTN (SEQ ID NO: 334). Polynucleotides encoding these polypeptides are also provided.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: AQR^LAE^ECFYMLLEVYGD^SISVTVAIPLMHSPCQSKAADGLGKSETEMLKSLGLSTNMSPFHLLGLKVFLTWALTLAQICLY FFEVQPLG^LLALNFFCTATAGLKELCMHPPSLAFTPEFHTSLSP^LAI^PSFCGTS VLSNSHTIPLSLYLPF^SKSRMPDTLHLLVHSLPLVHSQVLPVKDVTIEWPLCQRCLGSTCH Q (SEQ ID NO: 335). Polynucleotides encoding these polypeptides are also provided.

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 11 - 27 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 28 to 143 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ia membrane proteins.

This gene is expressed primarily in neutrophils and T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders and/or diseases affecting the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues and cell types (e.g., immune, hematopoietic, cells and tissue of the immune system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene

5 expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 191 as residues: Pro-97 to Asp-104. Polynucleotides
5 encoding said polypeptides are also provided.

15 The tissue distribution in neutrophils and T-cells, combined with the detected calcium flux biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting the immune system. Representative uses are described in the "Immune
20 Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene
25 product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

30 Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such
20 as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic
40 lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in
45 the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue
50 markers, to isolate cognate ligands or receptors, to identify agents that modulate their

interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:78 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1356 of SEQ ID NO:78, b is an integer of 15 to 1370, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:78, and where b is greater than or equal to a + 14.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 69

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: WIPRAAGIRHEVQVSLFQMFCFSSIFCSH
EHTHLPGETFWLFLFLILPPSCPCFLPFSLAIETVRWPCWHHPTSFELCY
PGTSIYYASRGGXPNSSEX (SEQ ID NO: 336). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases and/or disorders affecting the immune system, and neutrophils in particular. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues and cell types (e.g., blood cells,

5
10
15
20
25
30
35
40
45
50
55

and cells and tissue of the immune system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting the immune system and neutrophils in particular. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as,

antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:79 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 354 of SEQ ID NO:79, b is an integer of 15 to 368, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:79, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 70

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: XNXXSPLTIGNKSWSSSTAVAAALELVDPPGCR NSARDSPELVHLGKGRPRKLMTYLFCSSISLLLLKVHSSGHQDIRKAKSKVP RLLIQCPQORE (SEQ ID NO: 337). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in smooth muscle.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders affecting smooth muscle tissue, particularly vascular conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of smooth muscle tissue expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., muscle, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial

fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 193 as residues: Ser-18 to Val-31. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution primarily in smooth muscle indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting smooth muscle tissue. Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:80 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1074 of SEQ ID NO:80, b is an integer of 15 to 1088, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:80, and where b is greater than or equal to a + 14.

30 FEATURES OF PROTEIN ENCODED BY GENE NO: 71

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by

the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: GPEENLSPSTPSQMPTIWVKLCLLQVCHGLFP LLKHWSQPMPLCVTLAPVSYWL (SEQ ID NO: 338). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in fetal heart, smooth muscle, and frontal cortex.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, muscular, vascular, or neural diseases and/or disorders, particularly defects or injury to cardiac muscle. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., muscular, vascular, neural, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in fetal heart indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing and treating defects to the heart either due to injury or congenital defects. Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Alternatively, polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection,

5 treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease,
Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating
10 diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal
cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia,
5 mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder,
learning disabilities, ALS, psychoses, autism, and altered behaviors, including
15 disorders in feeding, sleep patterns, balance, and perception. In addition, elevated
expression of this gene product in regions of the brain indicates it plays a role in
normal neural function. Furthermore, the protein may also be used to determine
20 biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or
receptors, to identify agents that modulate their interactions, in addition to its use as a
nutritional supplement. Protein, as well as, antibodies directed against the protein may
show utility as a tumor marker and/or immunotherapy targets for the above listed
25 tissues.

15 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:81 and may have been publicly available prior to conception of
30 the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
20 cumbersome. Accordingly, preferably excluded from the present invention are one or
35 more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 1848 of SEQ ID NO:81, b is an
integer of 15 to 1862, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:81, and where b is greater than or equal to a + 14.
40

25

FEATURES OF PROTEIN ENCODED BY GENE NO: 72

45 The translation product of this gene shares sequence homology with adipose
complement related protein which is thought to be important in regulating energy
metabolism, insulin levels and fat stores. Moreover, the protein product of this gene
30 has also been shown to have homology to the complement subcomponent C1q A-
chain precursor and HP-25 protein (See Genbank and Geneseq Accession Nos.
50 emblCAA41664.1, dbjIBAA02352.1, and W98013; all references and information

55

5 available through this accession are hereby incorporated by reference herein). Based
10 on the sequence similarity, the translation product of this gene is expected to share at
least some biological activities with complement proteins.

15 In another embodiment, polypeptides comprising the amino acid sequence of
5 the open reading frame upstream of the predicted signal peptide are contemplated by
the present invention. Specifically, polypeptides of the invention comprise the
following amino acid sequence: PRVRKEPEAMQWLRVRESPGEATGHRVTMG
15 TAALGPVWAALLLFLLMCEIPMVELTFDRAVASDCQRCCDSEDPLDPAHVSS
ASSSGRPHALPEIRPYINITLKGDKGDPGPMGLPGYMGREGPQGEPPQGSK
10 GDKGEMGSPGAPCQKRFFAFSVGRKTALHSGEDFQTLLFERVFVNLDGC
20 FDMATGQFAAPLRGIYFFSLNVHSWNYKETVYVHIMHNQKEAVILYAQPS
ERSIMQSQSVMLDLAYGDRVWVRLFKRQRENAIYSNDFDTYITFSGHLIKA
EDD (SEQ ID NO: 339). Polynucleotides encoding these polypeptides are also
25 provided.

15 This gene is expressed primarily in placenta and, fetal kidney, and umbilical
vein and to a lesser extent in fetal heart, fetal liver/spleen, microvascular endothelial
30 cells and cancers of the lung and pharynx.

35 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
20 biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, vascular, renal, and reproductive diseases and/or disorders, particularly
35 cancers of the lung and pharynx. Similarly, polypeptides and antibodies directed to
these polypeptides are useful in providing immunological probes for differential
40 identification of the tissue(s) or cell type(s). For a number of disorders of the above
25 tissues or cells, particularly of the pulmonary and immune systems, expression of this
gene at significantly higher or lower levels is routinely detected in certain tissues or
cell types (e.g., vascular, renal, reproductive, immune, hematopoietic, pulmonary, and
45 cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial
fluid and spinal fluid) or another tissue or cell sample taken from an individual having
30 such a disorder, relative to the standard gene expression level, i.e., the expression
level in healthy tissue or bodily fluid from an individual not having the disorder.
50
55

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 195 as residues: Asp-36 to Asp-48, Ser-57 to His-62, Lys-77 to Gly-84, Met-92 to Gly-114, Gln-203 to Ile-209, Lys-231 to Tyr-239. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in pharynx or lung, combined with the homology to adipose complement related proteins indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing and treating cancers of the pharynx or lung by modifying the metabolic balance in such tissues. Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:82 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1604 of SEQ ID NO:82, b is an integer of 15 to 1618, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:82, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 73

The translation product of this gene shares sequence homology with a hypothetical 54.7 kD protein (F37A4.1) from *Caenorhabditis elegans* (SwissProt locus YPT1_CAEEL, accession P41879). The protein product of this gene also has homology to the human NG26 which is thought to contain a human major histocompatibility complex class III and is involved in T-cell maturation (See Genbank Accession No. gb|AAD18079.11 (AF129756); all references and information available through this accession are hereby incorporated by reference herein; for example, *J. Neurochem.* 69 (6), 2516-2528 (1997)). Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with nitric oxide synthase proteins.

Preferred polypeptides of the invention comprise the following amino acid sequence: MLYPGSVYLLQKALMPVLLQGQARLVEECNGRRRAKLLACDGNE IDTMFVDRRGTAEPQGQKLVICCEGNAGFYEVGCVSTPLEAGYSVLGWNHP GFAGSTGVPPQNEANAMDVVVQFAIHLRGFQPDIIYAWSIGGFTATWAA MSYPDVSAMILDASFDDLVLPLALKVMPDSWRGLVTRTVRQHLNLNNAEQLC RYQGPVLLIRRTKDEIITTTVPEDIMSNRGNDDLLKLLQHRYPRVMAEEGLRV VRQWLEASSQLEEASIYSRWEVEEDWCLSVLRSYQAEHGPDPFWSVGEDMS ADGRRQLALFLARKHLHNFEATHCTPLPAQNFQMPWHL (SEQ ID NO: 340). Polynucleotides encoding such polypeptides are also provided.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: VCPKWCRFLTMLGHCCYFWQVWPASEALAA GPTPSTGSSPSWKQHIGTSLQKTRGSLPTTTLTSGAGQSTSTGKNPAAGR SLEGALPAGVWPCFAQSPCTGGQQTTP SSTGLRSCLVRSPATWWRTTP (SEQ ID NO: 341). Polynucleotides encoding these polypeptides are also provided.

Preferred polypeptides of the invention comprise the following amino acid sequence: WIPRAAGIRHEIYREXDSERAPASVPETPTAVTAPHSSSWDTYYQ PRALEKHADSILALASVFWISISYSSPFAFFYL YRKGYSLSKVVPFSHYAG TLLLLLAGVACXRGIGRWTPNPQYRQFTILEATHRNQSSSENKRQLANYNFD FRSWPVDFHWEPPSSRKESRGGPSRRGVALLRPEPLHRGTADTLLNRVKKL

5 PCQITSYLVAHTLGRRMLYPGSVYLLQKALMPVLLQGQARLVEECNRRRAK
LLACDGNEDTMFVDRRGTAEPQGQKLVICCEGNAGFYEVGCVSTPLEAGYS
10 VLGWNHPGFAGSTGVFPFQNEANAMDVVVQFAIHR LGFQPQDIITYAWSI
GGFTATWAAMSYPDVSAMILDASFDDLVLALKVMPDSWRGLVTRTVRQ
5 HLN LNNAEQLCRYQG P VLLIRRTKDEIITTTVPEDIMSNRGNDLLLKLLQHRY
PRVMAEEGLRVVRQWLEASSQLEEASIYSRWEVEEDWCLSVLRSYQAEHGP
15 DFPWSVGEDMSADGRRQLALFLARKHLHNFEATHCT PLPAQNFQMPWHL
(SEQ ID NO: 342). Polynucleotides encoding these polypeptides are also provided. A
preferred polypeptide variant of the invention comprises the following amino acid
20 sequence: HERAXGPSRGHGELLSCVLGPRLYKIYRERDSERAPASVPETPTA
VTAPHSSSWDTYYQP RALEKHADSILALASVFSISYSSPFAFFYLRYKGY
LSLSKVVPFSHYAGTLLLLLAGV ACSEALAAGPTPSTGSSSPSWKQHIGTSLQ
KTRGSLPTTTLTSGAGQSTSTGKNPAAGRSLEGALPAGVWPCFAQSPCTGG
25 QQTPSSTGL RSCLVRSPATWWRTP (SEQ ID NO: 343). Polynucleotides
15 encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome
6. Accordingly, polynucleotides related to this invention are useful as a marker in
30 linkage analysis for chromosome 6.

This gene is expressed primarily in cerebellum, pituitary, fetal liver, and
20 primary dendritic cells and to a lesser extent in a wide range of tissues and
developmental stages (i.e. fetal and adult tissue, etc.).

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
40 not limited to, neural, developmental, and immune diseases and/or disorders,
25 particularly those involving self recognition and T- and B-cell maturation, and cancer.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in
providing immunological probes for differential identification of the tissue(s) or cell
45 type(s). For a number of disorders of the above tissues or cells, particularly of the
30 neural or hormonal system, expression of this gene at significantly higher or lower
levels is routinely detected in certain tissues or cell types (e.g., neural, developmental,
50 immune, hepatic, and cancerous and wounded tissues) or bodily fluids (e.g., serum,

5
10 plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

15 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 196 as residues: Thr-23 to Lys-34, Leu-41 to Ser-47, Ala-57 to Ala-68, Pro-89 to Gly-101, Pro-110 to Pro-117. Polynucleotides encoding said polypeptides are also provided.

20 The tissue distribution in developmental and immune cells, combined with the homology to the human major histocompatibility complex class III region, indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of cancer and other proliferative disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the
25 expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

30 Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory
35 bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic
40 lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that
45 influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in
50 the expansion of stem cells and committed progenitors of various blood lineages, and

in the differentiation and/or proliferation of various cell types. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:83 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2020 of SEQ ID NO:83, b is an integer of 15 to 2034, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:83, and where b is greater than or equal to a + 14.

20 FEATURES OF PROTEIN ENCODED BY GENE NO: 74

The translation product of this gene shares sequence homology with the br-1 protein from the snail nervous system (EMBL HPBR1 GENE) which codes for nitric oxide synthetase and which is thought to be important in mediating a variety of cellular responses, including vasodilation. Preferred polypeptides of the invention comprise the following amino acid sequence: MFKRHQRLKKDSTQAEEDLSEQ EQNQLNVLKKHGYVVG RVGRVGR TFLYSEEQKDNIPFEFDADSLAFDMENDPVM GTHKSTKQVELTAQDVKDAHWFYDTPGITKENCILNLLTEKEVNIVLPTQSIV PRTFVLKPGMVLFLGAIGRIDFLQGNQSAWFTVVASNILPVHITSLDRADALY QKHAGHTLLQIPMGGKERMAGFPPLVAEDIMLKEGLGASEAVADIKFSSAG WVSVTPNFKDRLHLRGYTPEGTVLTVRPPLLPYIVNIKGQRIKKSVA YKTKKP PSLMYNVRKKKGKINV (SEQ ID NO: 344). Polynucleotides encoding such polypeptides are also provided.

5
10
15
20
25
30
35
40
45
50
55

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MLPARLPFRLLSLFLRGSAPTAARHGLREPLLERRCAA ASSFQHSSSLGREL PYDPVDTGFGEGGDMQERFLFPEYILDPEPQPTREKQL QELQQQEEEEERQRRREERRQQLRARSREHPVVGHPDPALPPSGVNCS GCGAXLHCQDAGVPGYLPREKFLRTAEADGGLARTVCQRCWLLSHHRRALR LQVSREQYLELVSAALRXPGPSLVLYMVDLLDLPDALLPDLPALVGPKQLIV LGNKVDLLPQDAPGYRQLRERLWEDCARAGLLLAPGTKGHSAPSRTSHR TGRIRIRRTGPAQWSGTCG (SEQ ID NO: 345). Polynucleotides encoding these polypeptides are also provided.

10
15
20
25
30
35
40
45
50
55

When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates myeloid cells through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

20
25
30
35
40
45
50
55

This gene is expressed primarily in early stage human brain, smooth muscle, and endometrial tumor and to a lesser extent in a variety of tissues representing many organs and developmental states.

20
25
30
35
40
45
50
55

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cardiovascular, vascular, and neural diseases and/or disorders, particularly congestive heart disease and neurological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the circulatory and neural systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cardiovascular, vascular, neural, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma,

urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 197 as residues: Phe-42 to Leu-48, Pro-53 to Asp-58, Pro-81 to Glu-123, Asp-256 to Trp-269, Gly-282 to Ser-306, Arg-333 to Gly-339, Arg-403 to Gln-425, Ser-446 to Asn-452, His-475 to Gln-480, Gly-592 to Met-597, Pro-635 to His-642, Lys-667 to Lys-672, Lys-678 to Ser-684. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in smooth muscle and vascular tissues, combined with the homology to nitric oxide synthetase indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of congestive heart failure and neurological degenerative disorders. polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to

microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis.

Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement.

Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:84 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2226 of SEQ ID NO:84, b is an integer of 15 to 2240, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:84, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 75

The translation product of this gene shares sequence homology with the human KE04p, in addition to an unidentified *C.elegans* gene.

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 9 - 25 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 1 to 8 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type II membrane proteins.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: PSFRRERVETGGGGPVTHGTEGPFLPLPGGTRM NMTQARVLVAADVGLVAVLLYASIHKIEEGHLAVYYRGGALLTSPSGPGYH

IMLPFITFRSVQTTLQTDEVKNVPCGTSGGVMIYIDRIEVVNMLAPYAVFDIV
RNYTADYDKTLIFNKKIHHELNQFCSAHTLQEVYIELFDQIDENLKQALQKDL
NLMAPGLTIQAVRVTKPKIPEAIRRFELMEAEKTKLLIAAQKQKVVEKEA
ETERKKAVIEAEKIAQVAKIRFQQKVMKEKETEKRISEIEDAAFLAREKAKA
5 DAEYAAHKYATSNKHKLTPEYLELKKYQAIASNSKIYFGSNIPNMFVDSSC
ALKYSD IRTGRESSLPSKEALEPSGENVIQNKESTG (SEQ ID NO: 346).

Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 10. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 10.

This gene is expressed primarily in fetal tissue, including 8 week whole embryo, fetal liver spleen, nine week old early stage human, fetal heart, fetal liver, fetal lung, and placenta and to a lesser extent in a variety of cancers, and other normal tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and diseases of fetal development. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetal tissues, especially the liver, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., developmental, hepatic, immune, hematopoietic, pulmonary, cardiovascular, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 198 as residues: Leu-68 to Lys-74, Tyr-109 to Lys-115, Gln-200 to Val-205, Lys-207 to Lys-214, Glu-237 to Ile-244, Ala-271 to Thr-

279, Ser-317 to Ser-329, Gln-342 to Gly-348. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution of this gene (primarily fetal tissue and cancerous tissue, both of which are undergoing rapid growth) indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of cancer and disorders of fetal development. Moreover, the expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as,

antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:85 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1474 of SEQ ID NO:85, b is an integer of 15 to 1488, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:85, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 76

When tested against U937 and Jurkat cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates myeloid and T-cells, and to a lesser extent in other immune cells and tissue cell types, through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: WSTGNASWEKKDNFILSADFEMMGLGNRR
SMKSPPLVLAALVACIIVLGFNYWIASRSVDLQTRIMELEGRVRRRAAERG
AVELKKNEFQGELEKQREQLDKIQSSHNFQLESVNKLYQDEKAVLVNNITTG
ERLIRVLQDQLKTLQRNYGRLQQDVLQFQKNQTNLERKFSYDLSQCINQMKE
VKEQCEERIEVTKKKGNEAVASRDLENNDQRQQQLQALSEPQRLQAAGL

5
10
15
20
25
30
35
40
45
50
55

PHTEVPQGKGNVLGNSKSTPAPSSEVVLDKRQVEKEETNEIQVVNEE
PQRDRLPQEPGREQVVEDRPVGGRGFGGAGELGQTPQVQAALXVSQENPE
MEGPERDQLVIPDGQEEEQEAAGEGRNQKLRGEDDYNMDENAESETDKQ
AALAGNDRNIDVFNVE DQKRDTINLLDQREKRNTL (SEQ ID NO: 347).

5 Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 9. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 9.

This gene is expressed primarily in human endometrial tumor and other tumors and to a lesser extent in a variety of other healthy adult and fetal tissues

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental diseases and/or disorders, particularly cancer and other proliferative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endometrial tissue, cervix and uterus, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., developmental, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 199 as residues: Asn-6 to Lys-12, Leu-65 to Phe-70, Glu-73 to His-88, Gln-123 to Gln-135, Gln-142 to Leu-156, Arg-173 to Gly-181, Asp-189 to Gln-199, Ser-204 to Arg-209, Glu-219 to Gly-225, Gly-229 to Pro-238, Ser-246 to Asn-256, Glu-263 to Arg-276. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in endometrial tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of

5 endometrial, cervical and uterine cancer. Because of potential roles in proliferation
and differentiation, this gene product may have applications in the adult for tissue
10 regeneration and the treatment of cancers. It may also act as a morphogen to control
cell and tissue type specification. Therefore, the polynucleotides and polypeptides of
5 the present invention are useful in treating, detecting, and/or preventing said disorders
and conditions, in addition to other types of degenerative conditions. Thus this protein
15 may modulate apoptosis or tissue differentiation and is useful in the detection,
treatment, and/or prevention of degenerative or proliferative conditions and diseases.
The protein is useful in modulating the immune response to aberrant polypeptides, as
20 may exist in proliferating and cancerous cells and tissues. The protein can also be
used to gain new insight into the regulation of cellular growth and proliferation.
Furthermore, the protein may also be used to determine biological activity, to raise
antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents
25 that modulate their interactions, in addition to its use as a nutritional supplement.
15 Protein, as well as, antibodies directed against the protein may show

Many polynucleotide sequences, such as EST sequences, are publicly
30 available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:86 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
20 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
35 more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 3160 of SEQ ID NO:86, b is an
integer of 15 to 3174, where both a and b correspond to the positions of nucleotide
40 25 residues shown in SEQ ID NO:86, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 77

45 The translation product of this gene shares sequence homology with protein
disulfide isomerase from *Acanthamoeba castellanii* (See Genbank Locus
30 ACADISPROA accession L28174, genpep locus 456013) which is thought to be
important in converting proteins into their native conformations. The protein product
50 of this gene was also shown to have homology to a phospholipase C homologue

derived from a mast cell cDNA library (See Geneseq Accession No. R99411). All references and information available through these accessions are hereby incorporated by reference herein - for example, Gene 150 (1), 175-179 (1994).

Included in this invention as preferred domains are endoplasmic reticulum targeting sequence domain and the thioredoxin family active site domain, which were identified using the ProSite analysis tool (Swiss Institute of Bioinformatics). Proteins that permanently reside in the lumen of the endoplasmic reticulum (ER) seem to be distinguished from newly synthesized secretory proteins by the presence of the C-terminal sequence Lys-Asp-Glu-Leu (KDEL) [1,2]. While KDEL is the preferred signal in many species, variants of that signal are used by different species. This situation is described in the following table.

Signal	Species-----
KDEL	Vertebrates, <i>Drosophila</i> , <i>Caenorhabditis elegans</i> , plants
HDEL	<i>Saccharomyces cerevisiae</i> , <i>Kluyveromyces lactis</i> , plants
DDEL	<i>Kluyveromyces lactis</i>
ADEL	<i>Schizosaccharomyces pombe</i> (fission yeast)
SDEL	<i>Plasmodium falciparum</i>

The signal is usually very strictly conserved in major ER proteins but some minor ER proteins have divergent sequences (probably because efficient retention of these proteins is not crucial to the cell). Proteins bearing the KDEL-type signal are not simply held in the ER, but are selectively retrieved from a post-ER compartment by a receptor and returned to their normal location. The consensus pattern is as follows: [KRHQA]-[DENQ]-E-L>. Thioredoxins are small proteins of approximately one hundred amino-acid residues which participate in various redox reactions via the reversible oxidation of an active center disulfide bond. They exist in either a reduced form or an oxidized form where the two cysteine residues are linked in an intramolecular disulfide bond. Thioredoxin is present in prokaryotes and eukaryotes and the sequence around the redox-active disulfide bond is well conserved. Bacteriophage T4 also encodes for a thioredoxin but its primary structure is not homologous to bacterial, plant and vertebrate thioredoxins. A number of eukaryotic

5 proteins contain domains evolutionary related to thioredoxin, all of them seem to be
protein disulphide isomerases (PDI). PDI (EC 5.3.4.1) is an endoplasmic reticulum
10 enzyme that catalyzes the rearrangement of disulfide bonds in various proteins. The
various forms of PDI which are currently known are: - PDI major isozyme; a
5 multifunctional protein that also function as the beta subunit of prolyl 4-hydroxylase
(EC 1.14.11.2), as a component of oligosaccharyl transferase (EC 2.4.1.119), as
15 thyroxine deiodinase (EC 3.8. 1.4), as glutathione-insulin transhydrogenase (EC
1.8.4.2) and as a thyroid hormone-binding protein - ERp60 (ER-60; 58 Kd
microsomal protein). ERp60 was originally thought to be a phosphoinositide-specific
20 phospholipase C isozyme and later to be a protease. - ERp72. - P5. All PDI contains
two or three (ERp72) copies of the thioredoxin domain. The consensus pattern is as
follows: [LIVMF]-[LIVMSTA]-x-[LIVMFYC]-[FYWSTHE]-x(2)-[FYWGNTN]-C-
[GATPLVE]-[PHYWSTA]-C-x(6)-[LIVMFYWT]. The two C's form the redox-
25 active bond.

15 Preferred polypeptides of the invention comprise the following amino acid
sequence: SLHRFVLSQAKDEL (SEQ ID NO: 348), FIKFFAPWCGHCKALAPTW
(SEQ ID NO: 349), and/or FIKFYAPWCGHCKTLAPTW (SEQ ID NO: 350).
30 Polynucleotides encoding these polypeptides are also provided.

Further preferred are polypeptides comprising the endoplasmic reticulum
20 targeting sequence domain and thioredoxin family active site domain of the sequence
referenced in Table for this gene, and at least 5, 10, 15, 20, 25, 30, 50, or 75
35 additional contiguous amino acid residues of this referenced sequence. The additional
contiguous amino acid residues is N-terminal or C-terminal to the endoplasmic
reticulum targeting sequence domain and thioredoxin family active site domain.
40 Alternatively, the additional contiguous amino acid residues is both N-terminal and
C-terminal to the endoplasmic reticulum targeting sequence domain and thioredoxin
family active site domain, wherein the total N- and C-terminal contiguous amino acid
45 residues equal the specified number. Based on the sequence similarity, the translation
product of this gene is expected to share at least some biological activities with
30 thioredoxin proteins. Such activities are known in the art, some of which are
described elsewhere herein.

50

55

5 In another embodiment, polypeptides comprising the amino acid sequence of
the open reading frame upstream of the predicted signal peptide are contemplated by
10 the present invention. Specifically, polypeptides of the invention comprise the
following amino acid sequence: RRGRGVPGPRGRRRLWSAACGHCQRLQPTWN
5 DLGDKYNSMEXAKVYVAKVDCTAHSDVCSAQGVRGYPTLKLFPKGQEA
KYQGPRDFQTLNWMQLTLNEEPVTPEPEVEPPSAPELKQGLYELASNFELH
15 VAQGDHFIKFFAPWCGHCKALAPTWEQLALGLEHSETVKIGKVDCTQHY
ELCSGNQVRGYPTLLWFRDGKKVDQYKCKRDLESLREYVESQLQRTETGA
TETVTPSEAPVLAAEPEADKGTVLALTENNFDDTIAEGITFIKFYAPWCGHC
20 KTLAPTWEELSKKEFFGLAGVKIAEVDCTAERNICKYSVRGYPTLLLFRGGK
KVSEHSGGRDLDS LHRFVLSQAKDEL (SEQ ID NO: 351). Polynucleotides
encoding these polypeptides are also provided.

25 This gene is expressed primarily in human chondrosarcoma and endothelial
cells and to a lesser extent in a wide range of normal and diseased adult and fetal
15 tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as
30 reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, chondrosarcoma and other cancers and proliferative disorders.

20 Similarly, polypeptides and antibodies directed to these polypeptides are useful in
35 providing immunological probes for differential identification of the tissue(s) or cell
type(s). For a number of disorders of the above tissues or cells, particularly of the
immune system, expression of this gene at significantly higher or lower levels is
routinely detected in certain tissues or cell types (e.g., vascular, skeletal,
40 25 developmental, and cancerous and wounded tissues) or bodily fluids (e.g., serum,
plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell
sample taken from an individual having such a disorder, relative to the standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid from an
45 individual not having the disorder.

30 The tissue distribution in chondrosarcoma, combined with the homology to
protein disulfide isomerase and phospholipase C indicates that polynucleotides and
50 polypeptides corresponding to this gene are useful for diagnosis and treatment of

5 chondrosarcoma and other cancers and proliferative disorders, and possibly as a
reagent for in vitro production of proteins. Representative uses are described in the
10 "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere
herein. Briefly, developmental tissues rely on decisions involving cell differentiation
5 and/or apoptosis in pattern formation.

15 Dysregulation of apoptosis can result in inappropriate suppression of cell
death, as occurs in the development of some cancers, or in failure to control the extent
of cell death, as is believed to occur in acquired immunodeficiency and certain
neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of
20 potential roles in proliferation and differentiation, this gene product may have
applications in the adult for tissue regeneration and the treatment of cancers. It may
also act as a morphogen to control cell and tissue type specification. Therefore, the
polynucleotides and polypeptides of the present invention are useful in treating,
25 detecting, and/or preventing said disorders and conditions, in addition to other types
of degenerative conditions. Thus this protein may modulate apoptosis or tissue
differentiation and is useful in the detection, treatment, and/or prevention of
degenerative or proliferative conditions and diseases. The protein is useful in
30 modulating the immune response to aberrant polypeptides, as may exist in
proliferating and cancerous cells and tissues. The protein can also be used to gain new
20 insight into the regulation of cellular growth and proliferation. Moreover, the
expression in endothelial cells indicates the protein is useful in the detection,
35 treatment, and/or prevention of a variety of vascular disorders and conditions, which
include, but are not limited to microvascular disease, vascular leak syndrome,
aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis,
40 and/or atherosclerosis. Furthermore, the protein may also be used to determine
biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or
25 receptors, to identify agents that modulate their interactions, in addition to its use as a
nutritional supplement. Protein, as well as, antibodies directed against the protein may
45 show utility as a tumor marker and/or immunotherapy targets for the above listed
30 tissues.

50 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:87 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2766 of SEQ ID NO:87, b is an integer of 15 to 2780, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:87, and where b is greater than or equal to a + 14.

10 FEATURES OF PROTEIN ENCODED BY GENE NO: 78

This gene is expressed primarily in thyroid and thymus

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, thyroid diseases including thyroid cancer and diseases of function including Grave's Disease, hyper- and hypo- thyroidism as well as Diseases of the thymus. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine and immune systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., endocrine, immune, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in thyroid cells and tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of diseases of the thyroid and thymus. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", and "Binding Activity" sections below, in Example 11, 17, 18, 19, 20 and 27, and elsewhere herein. Briefly, the protein can be used for the detection, treatment, and/or prevention of

Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:88 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1047 of SEQ ID NO:88, b is an integer of 15 to 1061, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:88, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 79

The translation product of this gene shares sequence homology with collagen which is thought to be important as a structural material in a variety of human tissues and products including hair, nails, muscle and bone.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MRPQGPAASPQRLRGLLLLLLQLPAPSSASEIPKKGQK AHSGRGRWWTCIMECAYKGQEQECLVETGALGPMAFRVHLGSQVGMDSKEK RGNV (SEQ ID NO: 352). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in smooth muscle and to a lesser extent in 12 week old early stage human. epididymus, healing groin wound, synovial hypoxia,

stromal cells, ulcerative colitis, breast and 8 week old embryo, as well as a variety of other normal and diseased cell types from adult and fetal tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and other proliferative disorders as well as Diseases of smooth muscle. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the muscular system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., vascular, developmental, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 202 as residues: Glu-32 to Glu-46, Pro-63 to Ala-71, Pro-81 to Lys-90, Ser-97 to Trp-111, Lys-130 to Ser-135, Leu-147 to Cys-154, Asp-179 to Asn-186, Ser-219 to Gly-229. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in smooth muscle and homology to collagen indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of diseases of vascular diseases and/or disorders.

Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", "infectious disease", and "Regeneration" sections below, in Example 11, 19, and 20, and elsewhere herein. Briefly, the protein is useful in detecting, treating, and/or preventing congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's Disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's Disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis),

5
10
15
atherosclerosis, urticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, crsipelas, impetigo, tinea, athletes foot, and ringworm).

20
25
30
35
Moreover, the protein product of this gene may also be useful for the treatment or diagnosis of various connective tissue disorders (i.e., arthritis, trauma, tendonitis, chondromalacia and inflammation, etc.), autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, dermatomyositis, etc.), dwarfism, spinal deformation, joint abnormalities, and chondrodysplasias (i.e. spondylocpiphysal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

40
45
50
55
Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:89 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1328 of SEQ ID NO:89, b is an

integer of 15 to 1342, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:89, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 80

This gene is expressed primarily in immune cells and to a lesser extent in a wide variety of human tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, T cell or B cell leukemia and various immunodeficiencies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 203 as residues: Gly-3 to Gln-9. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in immune cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune system diseases such as immunodeficiencies and T cell and/or B cell leukemia. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

5

10

15

20

25

30

35

40

45

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:90 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 756 of SEQ ID NO:90, b is an integer of 15 to 770, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:90, and where b is greater than or equal to a + 14.

30

50

55

FEATURES OF PROTEIN ENCODED BY GENE NO: 81

The translation product of this gene shares sequence homology with IgE receptor. See for example, Isolation and Characterization of cDNAs coding for the Beta Subunit of the High-affinity Receptor for Immunoglobulin E, Proc. Natl. Acad. Sci. U S A. (1988 Sep.) 85(17): 6483-6487. Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with IgE receptor proteins. Such activities are known in the art, some of which are described elsewhere herein. IgE and its receptors are believed to have evolved as a mechanism to protect mammals against parasites. But other and intrinsically innocuous antigens can subvert this system to provoke an allergic response. For human populations in industrialized countries, allergy and asthma now represent a far greater threat than parasitic infection, and the main impetus for current studies of the IgE system is the hope of understanding and intervening in the aetiology of allergic diseases. The high-affinity receptor for immunoglobulin (Ig) E (Fc epsilon RI) on mast cells and basophils plays a key role in IgE-mediated allergies. Fc epsilon RI is composed of one alpha, one beta, and two gamma chains, which are all required for cell surface expression of Fc epsilon RI, but only the alpha chain is involved in the binding to IgE. Fc epsilon RI-IgE interaction is highly species specific, and rodent Fc epsilon RI does not bind human IgE. New homolog can be used to develop anti-allergic agents. FcR deliver signals when they are aggregated at the cell surface. The aggregation of FcR having immunoreceptor tyrosine-based activation motifs (ITAMs) activates sequentially src family tyrosine kinases and syk family tyrosine kinases that connect transduced signals to common activation pathways shared with other receptors. FcR with ITAMs elicit cell activation, endocytosis, and phagocytosis. The nature of responses depends primarily on the cell type. The aggregation of FcR without ITAM does not trigger cell activation. Most of these FcR internalize their ligands, which can be endocytosed, phagocytosed, or transcytosed. The fate of internalized receptor-ligand complexes depends on defined sequences in the intracytoplasmic domain of the receptors. The coaggregation of different FcR results in positive or negative cooperation. Some FcR without ITAM use FcR with ITAM as signal transduction subunits. The coaggregation of antigen receptors or of FcR having ITAMs with FcR having immunoreceptor tyrosine-based inhibition motifs (ITIMs)

negatively regulates cell activation. FcR therefore appear as the subunits of multichain receptors whose constitution is not predetermined and which deliver adaptative messages as a function of the environment.

The polypeptide of this gene has been determined to have four transmembrane domains at about amino acid position 51 - 67, 89 - 105, 119 - 135, and 190 - 206 of the amino acid sequence referenced in Table 1 for this gene. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type IIIa membrane proteins.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: ETRVKTSLELLRTQLEPTGTVGNTIMTSQPVPN ETHVLPSNVINFSQAEKPEPTNQGDLSKKHLHAEIKVIGTIQILCGMMVLSL GILASASFSPNFTQVTSTLLNSAYPFIFGPFFFIISGSLSIATEKRLTKLLVHSSLV GSILSALSALVGFIILSVKQATLNPASLQCELDKNNIPTRSYVSYFYHDSLYTT DCYTAKASLAGXLSLMLICTLLEFCLAVLTAVLRWKQAYSDFPGSVLFLPH SYIGNSGMSSKMTHTDCGYEELLTS (SEQ ID NO: 353). Polynucleotides encoding these polypeptides are also provided.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MMVLSLGILASASFSPNFTQVTSTLLNSAYPFIFGPFFFI ISGSLSIATEKRLTKLLVHSSLVGSILSALSALVGFIILSVKQATLNPASLQCELDKNNIPTRSYVSYFYHDSLYTTDCYTAKASLAGXLSLMLICTLLEFCL AVLTAVLRWKQAYSDFPGSVLFLPHSYIGNSGMSSKMTHTDCGYEELLTS (SEQ ID NO: 354). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

This gene is expressed primarily in immune system tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune system diseases and/or disorders such as cancer. Similarly,

polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 204 as residues: Gln-23 to Lys-39, Glu-150 to Thr-158. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in immune cells and tissues combined with the homology to IgE receptor indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that

influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:91 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1556 of SEQ ID NO:91, b is an integer of 15 to 1570, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:91, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 82

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: GASCEGGGAAARAALGVHRSQKALLVFRRTL
SNLLYMPLLRGLLWLQVLCAGPLHTEAVVLLVPSDDGRAFLRSRLLHPEAH
VPPAADRGASLQCVLHQAPKSRPRSPAAGAALLHXPRRTGDEPCREFHGN
GFPGPTQLTPGECGLPAPSSLLQHASAPVRTGSEGQVVGCPRARGETGEGLSL

AFLSSLMFTSRNGLVGC GASCEGGGAAARAALGVHRSQKALLVFRRTLNL
LYMPLLRGLLWLQVLCAGPLHTEAVVLLVPSDDGRAFLRSRLHPEAHVPP
AADRGASLQCVLHQAAPKSRPRSPAAGAALLHXPRRTGDEPCREFHNGGFP
GPTQLTPGECGLPAPSSLLQHASAPVRTGSEGQVVGCPRARGETGEGLSLA

FLSSLMFTSRNGLVGC (SEQ ID NO: 355). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 7. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 7.

This gene is expressed primarily in activated T cells, and to a lesser extent in a wide variety of human tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hematopoietic diseases and/or disorders, particularly immunodeficiencies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 205 as residues: Pro-67 to Ser-73. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in activated T cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immunodeficiencies. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and

5 elsewhere herein. Briefly, the expression of this gene product indicates a role in
regulating the proliferation; survival; differentiation; and/or activation of
10 hematopoietic cell lineages, including blood stem cells. This gene product is involved
in the regulation of cytokine production, antigen presentation, or other processes
5 suggesting a usefulness in the treatment of cancer (e.g. by boosting immune
responses).

15 Since the gene is expressed in cells of lymphoid origin, the natural gene
product is involved in immune functions. Therefore it is also useful as an agent for
immunological disorders including arthritis, asthma, immunodeficiency diseases such
20 as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory
bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,
such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and
tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity
25 disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic
lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's
15 Disease, and scleroderma. Moreover, the protein may represent a secreted factor that
influences the differentiation or behavior of other blood cells, or that recruits
30 hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in
the expansion of stem cells and committed progenitors of various blood lineages, and
20 in the differentiation and/or proliferation of various cell types. Furthermore, the
protein may also be used to determine biological activity, raise antibodies, as tissue
35 markers, to isolate cognate ligands or receptors, to identify agents that modulate their
interactions, in addition to its use as a nutritional supplement. Protein, as well as,
antibodies directed against the protein may show utility as a tumor marker and/or
40 25 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
45 related to SEQ ID NO:92 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
30 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
50 more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 2936 of SEQ ID NO:92, b is an integer of 15 to 2950, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:92, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 83

The translation product of this gene was shown to have homology to the human transmembrane protein (See Genbank Accession No. gblAAC51364.11 (AF000959); all references and information available through this accession are hereby incorporated by reference herein; for example, Genomics 42 (2), 245-251 (1997)) which is thought to be implicated in velo-cardio-facial syndrome.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MGSAALEILGLVLCLVGWGGILACGLPMWQVTAFLD HNIVTAQTTWKGLWMSCVVQSTGTCSAKCTTRCWL (SEQ ID NO: 356).

Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 22. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 22.

This gene is expressed primarily in dementia brain tissue, and to a lesser extent in a wide variety of human tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural diseases and/or disorders, particularly dementia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 Preferred polypeptides of the present invention comprise immunogenic
epitopes shown in SEQ ID NO: 206 as residues: Ser-201 to Tyr-217. Polynucleotides
10 encoding said polypeptides are also provided.

5 The tissue distribution in dementia brain tissue, combined with the homology
to the transmembrane protein indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis and treatment of dementia, and
15 potentially for velo-cardio-facial syndrome. Representative uses are described in the
"Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11,
15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the
20 10 detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease,
Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating
diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal
cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia,
25 mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder,
15 learning disabilities, ALS, psychoses, autism, and altered behaviors, including
disorders in feeding, sleep patterns, balance, and perception. In addition, elevated
expression of this gene product in regions of the brain indicates it plays a role in
30 normal neural function.

Potentially, this gene product is involved in synapse formation,
20 neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or
survival. Furthermore, the protein may also be used to determine biological activity,
35 to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to
identify agents that modulate their interactions, in addition to its use as a nutritional
supplement. Protein, as well as, antibodies directed against the protein may show
40 25 utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
45 related to SEQ ID NO:93 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
30 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
50 more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 1708 of SEQ ID NO:93, b is an integer of 15 to 1722, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:93, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 84

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: LKRAPPGPALAKGLLQPSSTFQALETNIGDQVR
RHSTAVVIREMTSYILISFVLLIGVGCIEKDQSCPVGGRKRLHLLFVGGQLRQ
VRMLRGELSCACYRPHVQALQLGGCTCF (SEQ ID NO: 357). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in the adult pulmonary system.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cystic fibrosis, bronchitis and any pulmonary disorders in general. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the pulmonary system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., pulmonary, cardiovascular, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, pulmonary surfactant, pulmonary lavage/sputum, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution of this gene only in the pulmonary system indicates that it plays a key role in the functioning of the pulmonary system. This would suggest that misregulation of the expression of this protein product in the adult could lead to lymphoma or sarcoma formation, particularly in the lung and the protein product could be used either in the treatment and/or detection of these disease states. The gene

5 or gene product may also useful in the treatment and/or detection of pulmonary
defects such as pulmonary edema and embolism, bronchitis and cystic fibrosis.
10 Furthermore, the protein may also be used to determine biological activity, to raise
antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents
5 that modulate their interactions, in addition to its use as a nutritional supplement.
Protein, as well as, antibodies directed against the protein may show utility as a tumor
15 marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
20 related to SEQ ID NO:94 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
25 more polynucleotides comprising a nucleotide sequence described by the general
15 formula of a-b, where a is any integer between 1 to 621 of SEQ ID NO:94, b is an
integer of 15 to 635, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:94, and where b is greater than or equal to a + 14.
30

FEATURES OF PROTEIN ENCODED BY GENE NO: 85

20 The translation product of this gene was found to be homologous to CAM
proteins. Based on the sequence similarity, the translation product of this gene is
35 expected to share at least some biological activities with CAM proteins. Such
activities are known in the art, some of which are described elsewhere herein.

A preferred polypeptide variant of the invention comprises the following
40 amino acid sequence: MLCPWRTANLGLLLILTIFLVAEAGAAQPNNSLM
LQTSKENHALASSSLCMDEKQITQNYSKVLAEVNTSWPVKMATNAVLC
CPPIALRNLIITWEIILRGQPSCTKAYKKETNETKETNCTDERITWVSRPDQ
45 NSDLQIRTVAITHDGYRRCIMVTPDGNFHRGYHLQVLVTPEVTLFQNRNRRTA
VCKAVAGKPAAHISWIPEGDCATKQEYWSNGT VTVKSTCHWEVHNVSTV
30 NCHVSHLTGNKSLYIELLPVPGAKKSSKL YIPYIILTHILTVGXIWLLKVNG
CXKYKLNKPESTPVVEEDEMOPYAFYTEKNNPLXXTTNKVKASEALQSEV
50

DTDLHTL (SEQ ID NO:208). Polynucleotides encoding these polypeptides are also provided.

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 271 - 287 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 288 to 348 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ia membrane proteins.

This gene is expressed primarily in dendritic cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immunodeficiency, tumor necrosis, infection, lymphomas, auto-immunities, cancer, metastasis, wound healing, inflammation, anemias (leukemia) and other hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 208 as residues: Asp-53 to Tyr-61, Pro-105 to Ile-128, Arg-133 to Leu-140, Gln-182 to Ala-188, Pro-205 to Asn-218, Gly-259 to Ala-264, Asn-290 to Ser-302, Glu-307 to Tyr-314, Tyr-317 to Lys-332. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in dendritic cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune disorders including: leukemias, lymphomas, auto-immunities,

immunodeficiencies (e.g. AIDS), immuno-suppressive conditions (transplantation) and hematopoietic disorders. In addition this gene product is applicable in conditions of general microbial infection, inflammation or cancer. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:95 and may have been publicly available prior to conception of

5 the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
10 cumbersome. Accordingly, preferably excluded from the present invention are one or
more polynucleotides comprising a nucleotide sequence described by the general
5 formula of a-b, where a is any integer between 1 to 3784 of SEQ ID NO:95, b is an
integer of 15 to 3798, where both a and b correspond to the positions of nucleotide
15 residues shown in SEQ ID NO:95, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 86

20 In another embodiment, polypeptides comprising the amino acid sequence, of
the open reading frame upstream of the predicted signal peptide are contemplated by
the present invention. Specifically, polypeptides of the invention comprise the
following amino acid sequence: VIKLICPAAFPVYFQDMARGCVCSLCASVCIFLS
25 SLFPLPSVHVSVNIISCLLLSKCFEGLELMCEHL YQLSQLHVLHHIFS YLLCTP
(SEQ ID NO: 358). Polynucleotides encoding these polypeptides are also provided.

15 This gene is expressed primarily in embryonic tissue and to a lesser extent in
a variety of other tissues and cell types.

30 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
20 biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, developmental anomalies, fetal deficiencies, cancer and neoplastic
35 states. Similarly, polypeptides and antibodies directed to these polypeptides are useful
in providing immunological probes for differential identification of the tissue(s) or
cell type(s). For a number of disorders of the above tissues or cells, particularly of the
40 developing fetus, expression of this gene at significantly higher or lower levels is
25 routinely detected in certain tissues or cell types (e.g., developmental, differentiating,
and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine,
45 amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken
from an individual having such a disorder, relative to the standard gene expression
30 level, i.e., the expression level in healthy tissue or bodily fluid from an individual not
having the disorder.

5

10

15

20

25

30

35

40

45

50

55

The tissue distribution in embryonic tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of developmental anomalies, fetal deficiencies and pre-natal disorders, as well as abnormal cell proliferation and/or differentiation, neoplastic states and cancer.

Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

5 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
10 related to SEQ ID NO:96 and may have been publicly available prior to conception of
the present invention. Preferably, such related polynucleotides are specifically
5 excluded from the scope of the present invention. To list every related sequence is
cumbersome. Accordingly, preferably excluded from the present invention are one or
15 more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 2669 of SEQ ID NO:96, b is an
integer of 15 to 2683, where both a and b correspond to the positions of nucleotide
20 10 residues shown in SEQ ID NO:96, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 87

25 The translation product of this gene shares sequence homology with inter-
alpha-trypsin inhibitor which is thought to be important in inhibition of trypsin and
15 other serine proteases (See Genbank Accession No. pirlS30350/S30350; all references
and information available through this accession are hereby incorporated herein by
reference; for example, Eur. J. Biochem. 179 (1), 147-154 (1989), J. Biol. Chem. 264
30 (27), 15975-15981 (1989), and J. Biol. Chem. 266 (2), 747-751 (1991)).

35 Contact of cells with supernatant expressing the product of this gene has been
20 shown to increase the permeability of the plasma membrane of THP-1 cells to
calcium. Thus it is likely that the product of this gene is involved in a signal
transduction pathway that is initiated when the product binds a receptor on the surface
of the plasma membrane of both monocytes, in addition to other cell-lines or tissue
40 cell types. Thus, polynucleotides and polypeptides have uses which include, but are
25 not limited to, activating monocytes, and to a lesser extent, other immune and/or
hematopoietic cells. Binding of a ligand to a receptor is known to alter intracellular
levels of small molecules, such as calcium, potassium and sodium, as well as alter pH
45 and membrane potential. Alterations in small molecule concentration can be measured
to identify supernatants which bind to receptors of a particular cell.

50 In another embodiment, polypeptides comprising the amino acid sequence of
the open reading frame upstream of the predicted signal peptide are contemplated by
the present invention. Specifically, polypeptides of the invention comprise the

following amino acid sequence: YXIPGSTHASGRQRGSGRGEDDSGPPSTVINQ
NETFANIIFKPTVVQQARIAQNGILGDFIIRYDVNREQSIGDIQVLNGYFVHYF
APKDLPLPKNVVFVLDSSASMVGTKLRQTKDALFTILHDLRPQDRFSIIGFS
NRIKVWKDHLISVTPDSIRDGKVYIHHMSPTGGTDINGVLQRAIRLLNKYVAH
5 SGIGDRSVSLIVFLTDG KPTVGETHTLKILNNTREAAARGQVCIFTIGINDVD
FRLLEKLSLENCGLTRRVHEEEDAGSQLIGFYDEIRTPLLSDIRIDYPPSSVVQ
15 ATKTLFPNYFNGSEIIIAGKLVDRKLDHLHVEVTASNSKKFILKTDVVPVRPQK
AGKDVGTGSPRPGDGEGDXNHIERLWSYLTTKELLSSWLQSDDEPEKERLRQ
RAQALAVSYRFLTPFTSMKLRGPVPRMDGLEEAHGMSAAMGPEPVVQSVR
20 GAGTQPGPLLKKPYQPRIKISKTSVDGDPHFVVDPLSRLTVCFNIDGQPGDIL
RLVSDHRDSGVTVNDELIGAPAPPNGHKKQRTYLRTITILINKPERSYLEITPS
RVILDGGDRLVLPQNQSVVVGSGWGLEVSVSANANVTVTIQGSIAFVILHLYK
25 KPAPFQRHHLGFYIANSEGLSSNCHGLLGQFLNQDARLTEDPAGPSQNLTHP
LLLQVGEGPEAVLTVKGHQVPVWVKQRKIYN GEEQXDCWFARNMPPN
15 (SEQ ID NO: 359). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in placenta and adipose tissue and to a lesser extent in several other organs and tissues including cancer.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of developing organs and metabolic diseases, in addition to vascular diseases and conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the developing systems and metabolic systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, vascular, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 Preferred polypeptides of the present invention comprise immunogenic
epitopes shown in SEQ ID NO: 210 as residues: Lys-5 to Lys-10, Asn-33 to Lys-39,
10 Asp-48 to Lys-54, Pro-62 to Asp-67, Asn-116 to Arg-123, His-157 to Ala-162, Val-
242 to Lys-249, Val-251 to Asp-264. Polynucleotides encoding said polypeptides are
5 also provided.

15 The tissue distribution in placenta, combined with the homology to inter-
alpha-trypsin inhibitor and the detected calcium flux biological activity indicates that
polynucleotides and polypeptides corresponding to this gene are useful for treatment
and diagnosis of disorders of developing and metabolic systems. This protein may
20 play a role in the regulation of cellular division, and may show utility in the diagnosis,
treatment, and/or prevention of developmental diseases and disorders, including
cancer, and other proliferative conditions. Representative uses are described in the
"Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere
25 herein. Briefly, developmental tissues rely on decisions involving cell differentiation
and/or apoptosis in pattern formation.

30 Dysregulation of apoptosis can result in inappropriate suppression of cell
death, as occurs in the development of some cancers, or in failure to control the extent
of cell death, as is believed to occur in acquired immunodeficiency and certain
neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of
20 potential roles in proliferation and differentiation, this gene product may have
applications in the adult for tissue regeneration and the treatment of cancers. It may
also act as a morphogen to control cell and tissue type specification. Therefore, the
polynucleotides and polypeptides of the present invention are useful in treating,
detecting, and/or preventing said disorders and conditions, in addition to other types
40 of degenerative conditions. Thus this protein may modulate apoptosis or tissue
differentiation and is useful in the detection, treatment, and/or prevention of
degenerative or proliferative conditions and diseases. The protein is useful in
modulating the immune response to aberrant polypeptides, as may exist in
45 proliferating and cancerous cells and tissues. The protein can also be used to gain new
insight into the regulation of cellular growth and proliferation. Moreover, the protein
30 is useful in the detection, treatment, and/or prevention of a variety of vascular
disorders and conditions, which include, but are not limited to microvascular disease,

5
10
15
20
25
30
35
40
45
50
55

vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Polynucleotides and polypeptides of the invention are also useful for the treatment, detection, and/or prevention of inflammation, tumor invasion and metastasis, wound healing, liver disease, disseminated intravascular coagulation, alzheimer's Disease, ophthalmic disease, apoptosis, tissue remodeling, intrauterine growth retardation, preeclampsia, angiogenesis, cell migration, fetal development, trophoblast implantation, ovulation, pemphigus and psoriasis, and antiviral therapy. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:97 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2167 of SEQ ID NO:97, b is an integer of 15 to 2181, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:97, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 88

The translation product of this gene was shown to have homology to the human colon carcinoma antigen NY-CO-7 (See Genbank and Geneseq Accession Nos. gb|AAC18038.11 (AF039689) and WO9904265; all references available through this accession are hereby incorporated herein by reference; for example, Int. J. Cancer 76 (5), 652-658 (1998)).

This gene is expressed primarily in breast and breast cancer and to a lesser extent in several other organs and tissues including cancers.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of reproductive organs and the gastrointestinal system, including cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., gastrointestinal, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, breast milk, chyme, bile, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 211 as residues: Gly-22 to Gly-28, Leu-71 to Phe-77, Asn-101 to Val-108, Pro-122 to Ser-127, Arg-149 to Pro-154, Gly-191 to Phe-196, Pro-199 to Thr-211. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in breast and breast cancer tissue, combined with the homology to a colon cancer antigen indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the reproductive systems and cancers. This protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of

5 potential roles in proliferation and differentiation, this gene product may have
applications in the adult for tissue regeneration and the treatment of cancers. It may
10 also act as a morphogen to control cell and tissue type specification. Therefore, the
polynucleotides and polypeptides of the present invention are useful in treating,
5 detecting, and/or preventing said disorders and conditions, in addition to other types
of degenerative conditions. Thus this protein may modulate apoptosis or tissue
15 differentiation and is useful in the detection, treatment, and/or prevention of
degenerative or proliferative conditions and diseases. The protein is useful in
modulating the immune response to aberrant polypeptides, as may exist in
20 proliferating and cancerous cells and tissues. The protein can also be used to gain new
insight into the regulation of cellular growth and proliferation. Furthermore, the
protein may also be used to determine biological activity, to raise antibodies, as tissue
25 markers, to isolate cognate ligands or receptors, to identify agents that modulate their
interactions, in addition to its use as a nutritional supplement. Protein, as well as,
15 antibodies directed against the protein may show utility as a tumor marker and/or
immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
30 available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:98 and may have been publicly available prior to conception of
20 the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
35 cumbersome. Accordingly, preferably excluded from the present invention are one or
more polynucleotides comprising a nucleotide sequence described by the general
formula of a-b, where a is any integer between 1 to 1943 of SEQ ID NO:98, b is an
40 25 integer of 15 to 1957, where both a and b correspond to the positions of nucleotide
residues shown in SEQ ID NO:98, and where b is greater than or equal to a + 14.

45 FEATURES OF PROTEIN ENCODED BY GENE NO: 89

The translation product of this gene shares sequence homology with the amino
30 acid and protein sequence of a Xenopus transmembrane protein of unknown function.
The very 5'-end of the contig is identical to the mRNA for the human LGN mosaic
50 protein. Based on the sequence similarity, the translation product of this gene is

5 expected to share at least some biological activities with LGN mosaic proteins. Such activities are known in the art, some of which are described elsewhere herein.

10 Preferred polypeptides of the invention comprise the following amino acid sequence:

PRVRPPTKALAVTFTTFFVTEPLKHIGKGTGEFIKALMKEIPALLHLPVLIIMAL

5 AILSFCYGAGKSVHVL RHIGGPEREPPQALRPDRRRQEIDYRPDGGAGDAD

FHYRGQMGPTEQGPYAKTYEGRREILRERDVDLRFQTGNKSPEVLRAFDVPD

15 AEAREHPTVVPSHKSPVLDTKPKETGGILGEGTPKESSTESSQSAKPVSGQDTS

GNTEGSPA AEKAQLKSEAAGSPDQGSTYSPARGVAGPRGQDPVSSPCG (SEQ

ID NO:339). Polynucleotides encoding such polypeptides are also provided.

20 10 The gene encoding the disclosed cDNA is believed to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

25 This gene is expressed primarily in small intestine and adipocytes and to a lesser extent in various other normal and transformed cell types, mostly of endocrine origin.

30 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, conditions of growth and metabolism. Similarly, polypeptides and
20 antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive and endocrine systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., metabolic, gastrointestinal, and
40 cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, bile, chyme, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

45 30 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 212 as residues: Pro-40 to Gly-68, Gly-79 to Arg-93, Phe-106 to Glu-114, Pro-122 to His-129, Thr-143 to Gly-149, Gly-155 to Ala-168,

Val-171 to Gly-182, Ala-195 to Pro-207, Pro-214 to Val-220. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in small intestine indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of disorders of growth and metabolism as well as endocrine abnormalities. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:99 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1098 of SEQ ID NO:99, b is an integer of 15 to 1112, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:99, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 90

The translation product of this gene shares sequence homology with IgE receptor beta chain which is thought to be important in immune function.

This gene is expressed primarily in kidney medulla tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and renal diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and renal systems,

5 expression of this gene at significantly higher or lower levels is routinely detected in
certain tissues or cell types (e.g., immune, renal, urogenital, and cancerous and
10 wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid
and spinal fluid) or another tissue or cell sample taken from an individual having such
5 a disorder, relative to the standard gene expression level, i.e., the expression level in
healthy tissue or bodily fluid from an individual not having the disorder.

15 The tissue distribution in kidney renal medulla tissue, combined with the
homology to the IgE receptor beta chain indicates that polynucleotides and
polypeptides corresponding to this gene are useful for the treatment of immune and
20 10 renal disorders. The protein product of this gene could be used in the treatment and/or
detection of kidney diseases including renal failure, nephritis, renal tubular acidosis,
proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush
syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to
25 Wilm's Tumor Disease, and congenital kidney abnormalities such as horseshoe
15 kidney, polycystic kidney, and Falconi's syndrome. Alternatively, this gene product is
involved in the regulation of cytokine production, antigen presentation, or other
processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune
30 responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene
20 product is involved in immune functions. Therefore it is also useful as an agent for
immunological disorders including arthritis, asthma, immunodeficiency diseases such
35 as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory
bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,
such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and
40 25 tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity
disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic
lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's
45 Disease, and scleroderma. Moreover, the protein may represent a secreted factor that
influences the differentiation or behavior of other blood cells, or that recruits
30 hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in
the expansion of stem cells and committed progenitors of various blood lineages, and
50 in the differentiation and/or proliferation of various cell types. Furthermore, the

protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO: 100 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 873 of SEQ ID NO: 100, b is an integer of 15 to 887, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 100, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 91

The translation product of this gene shares sequence homology with Diff 40 gene product (See Genbank Accession No. gb|AAC51134.1; all references and information available through this reference are hereby incorporated herein).

Preferred polypeptides of the invention comprise the following amino acid sequence: PRVRSIKVTELKGLANHVVVGSVSCETKDLFAALPQVVAVDIN
DLGTIKLSLEVTWSPFDKDDQPSAASSVNKASTVTKRFSTYSQSPDTPS
LREQAFYNMLRRQEELENGTAWLSSESSDDSSSPQLSGTARHSPAPRPLV
QQPEPLPIQVAFRRPETPSSGPLDEEGAVAPVLANGHAPYSRTLHISEASVNA
ALAEASVEAVGPKSLSWGSPPTHAPATHGKHPSPPALDPGHSATSST
LGTGTSVPTSTDPAPSAHLDSVHKSTDSGPSELPGPTHTTTGSTYSAITTTHS
APSPLTHTTTGSTHKPIISTLTITGPTLNIIGPVQTTTSPTHTMPSPSSHNSPQ
YVDFCSSLVDNIFVHYVIGIFFHTLYSSKTL (SEQ ID NO: 360), and/or PRVRS
IKVTELKGLANHVVVGSVSCETKDLFAALPQVVAVDINDLGTIKLSLEVTWSP
FDKDDQPSAASSVNKASTVTKRFSTYSQSPDTPSLREQAFYNMLRRQEELE
NGTAWLSSESSDDSSSPQLSGTARHSPAP RPLVQQPEPLPIQVAFRRPET

PSSGPLDEEGAVAPVLANGHAPYSRTLSHISEASVNAALAEASVEAVGPKSL
SWGSPPTHPAPTHGKHPSVPPALDPGHSATSSTLGTGTVPTSTD (SEQ ID
NO: 361). Polynucleotides encoding these polypeptides are also provided.

Polypeptides of the invention do not consist of the primary amino acid sequence
shown as Geneseq Accession No.W69430, which is hereby incorporated herein by
reference.

This gene is expressed primarily in liver and to a lesser extent in gall bladder
tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include, but are
not limited to, metabolic and endocrine diseases and/or disorders, particularly hepatic
and gall bladder disorders. Similarly, polypeptides and antibodies directed to these
polypeptides are useful in providing immunological probes for differential
identification of the tissue(s) or cell type(s). For a number of disorders of the above
tissues or cells, particularly of the metabolic and endocrine systems, expression of this
gene at significantly higher or lower levels is routinely detected in certain tissues or
cell types (e.g., hepatic, metabolic, gall bladder, gastrointestinal, and cancerous and
wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, bile, synovial
fluid and spinal fluid) or another tissue or cell sample taken from an individual having
such a disorder, relative to the standard gene expression level, i.e., the expression
level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic
epitopes shown in SEQ ID NO: 214 as residues: Val-9 to Cys-14, Pro-42 to Thr-47,
Thr-56 to Ala-64, Asp-88 to His-98, Cys-128 to Ser-136, Arg-153 to Trp-161.
Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in liver and gall bladder, combined with the homology
to the diff 40 gene product indicates that polynucleotides and polypeptides
corresponding to this gene are useful for the study and treatment of endocrine and
metabolic disorders. polynucleotides and polypeptides corresponding to this gene are
useful for the detection and treatment of liver disorders and cancers. Representative
uses are described in the "Hyperproliferative Disorders", "infectious disease", and

"Binding Activity" sections below, in Example 11, and 27, and elsewhere herein. Briefly, the protein can be used for the detection, treatment, and/or prevention of hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:101 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1234 of SEQ ID NO:101, b is an integer of 15 to 1248, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:101, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 92

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 3 - 19 of the amino acid sequence referenced in Table 1 for this gene. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type II membrane proteins.

This gene is expressed primarily in fetal brain and to a lesser extent in pancreas tumor, melanocyte and infant brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural diseases and/or disorders, particularly neurodevelopmental disorders. Similarly, polypeptides and antibodies directed to these polypeptides are

5
10
15
20
25
30
35
40
45
50
55

useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10
15
20
25
30
35
40
45
50
55

The tissue distribution in fetal brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of developmental disorders of the central nervous system. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

10
15
20
25
30
35
40
45
50
55

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

10
15
20
25
30
35
40
45
50
55

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:102 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1827 of SEQ ID NO:102, b is an integer of 15 to 1841, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:102, and where b is greater than or equal to a + 14.

10 FEATURES OF PROTEIN ENCODED BY GENE NO: 93

The translation product of this gene shares sequence homology with a probable membrane protein YGL054c -yeast (*Saccharomyces cerevisiae*). Moreover,

The translation product of this gene also have homology to the human and mouse cornichon protein which is known to be necessary for both anterior-posterior and dorsal-ventral pattern formation in conjunction with the EGF receptor signaling process (See Genbank Accession Nos. gblAAC98388.11 (AF104398), and splP52159; all references and information available through these accessions are hereby incorporated herein by reference; for example, Cell 81 (6), 967-978 (1995)).

The polypeptide of this gene has been determined to have two transmembrane domains at about amino acid position 57 - 73, and 121 - 137 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 1 - 14 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type IIIa membrane proteins.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: YGCEKTTEGGRRRRRRMEAVVFVFSLLDCCALIFLSVYFIFITLSDLECDYINARSCCSKLNKWWIPELIGHTIVTVLLLMSLHWFIFLLNLPVATWNIYR YIMVPSGNMGVFDPTIEHNRGQLKSHMKEAMIKLGFHLLCFFMYLYSMILALIND (SEQ ID NO:362). Polynucleotides encoding these polypeptides are also provided.

5 The gene encoding the disclosed cDNA is believed to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

10 This gene is expressed primarily in activated T-cells and to a lesser extent in endometrial tumor, T cell helper II cells, microvascular endothelial cells, Raji cells treated with cyclohexamide and umbilical vein endothelial cells.

15 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, hematopoietic, and vascular diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, vascular, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 216 as residues: Ser-39 to Asn-45, Asn-103 to Ser-109. Polynucleotides encoding said polypeptides are also provided.

25 The tissue distribution in activated T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune disorders involving activated T-cells. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or

5 other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

10 Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for
5 immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory
15 bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity
20 disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits
25 hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and
15 in the differentiation and/or proliferation of various cell types. Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular
30 disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis; coronary artery
20 disease, arteriosclerosis, and/or atherosclerosis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate
35 cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets
40 25 for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
45 related to SEQ ID NO:103 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically
30 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or
50 more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 671 of SEQ ID NO:103, b is an integer of 15 to 685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:103, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 94

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: ARAPAPSLPPLPSPAPALAPAHSLGLLLGRMS
GSSLPSALALSLLLVSGLLPGPAAQNVRVQSGQDQ (SEQ ID NO: 363).
Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in dendritic cells and to a lesser extent in healing abdomen wound, and pancreas islet cell tumor cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hematopoietic diseases and/or disorders, particularly wound healing disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 217 as residues: Gln-34 to Lys-40. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in dendritic cells and early healing wound indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating

5 wounds to enhance the healing process. Representative uses are described in the
"Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14,
10 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene
product indicates a role in regulating the proliferation; survival; differentiation; and/or
5 activation of hematopoietic cell lineages, including blood stem cells. This gene
product is involved in the regulation of cytokine production, antigen presentation, or
15 other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting
immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene
20 product is involved in immune functions. Therefore it is also useful as an agent for
immunological disorders including arthritis, asthma, immunodeficiency diseases such
as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory
bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,
25 such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and
tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity
15 disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic
lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's
Disease, and scleroderma. Moreover, the protein may represent a secreted factor that
30 influences the differentiation or behavior of other blood cells, or that recruits
hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in
20 the expansion of stem cells and committed progenitors of various blood lineages, and
in the differentiation and/or proliferation of various cell types. Furthermore, the
protein may also be used to determine biological activity, raise antibodies, as tissue
35 markers, to isolate cognate ligands or receptors, to identify agents that modulate their
interactions, in addition to its use as a nutritional supplement. Protein, as well as,
40 antibodies directed against the protein may show utility as a tumor marker and/or
immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
45 available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO: 104 and may have been publicly available prior to conception
30 of the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
50

5
10
15
20
25
30
35
40
45
50
55

cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1154 of SEQ ID NO:104, b is an integer of 15 to 1168, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:104, and where b is greater than or equal to a + 14.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 95

20
25
30
35
40
45
50
55

Contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of aortic smooth muscle cells to calcium. Thus it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of both smooth muscle cells, and in other cell-lines or tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating smooth muscle cells. Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium and sodium, as well as alter pH and membrane potential. Alterations in small molecule concentration can be measured to identify supernatants which bind to receptors of a particular cell.

20
25
30
35
40
45
50
55

This gene is expressed primarily in pancreatic carcinoma, gall bladder and primary dendritic cells.

20
25
30
35
40
45
50
55

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, metabolic and immune diseases and/or disorders, particularly cancers, such as pancreatic carcinoma and gall bladder tumor. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., metabolic, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such

5 a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 218 as residues: Lys-34 to Ile-41. Polynucleotides
5 encoding said polypeptides are also provided.

15 The tissue distribution in pancreatic carcinoma and gall bladder indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing and treating cancer, such as pancreatic carcinoma and gall bladder tumors.

Representative uses are described here and elsewhere herein. Alternatively, the
20 detected calcium flux biological activity indicates the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak
25 syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Furthermore, the protein may also be used to
15 determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to
30 its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the
above listed tissues.

20 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are
35 related to SEQ ID NO: 105 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is
40 25 cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1161 of SEQ ID NO: 105, b is an
45 integer of 15 to 1175, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 105, and where b is greater than or equal to a + 14.

30

50

55

FEATURES OF PROTEIN ENCODED BY GENE NO: 96

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 10 - 26 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 27 to 48 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ib membrane proteins.

This gene is expressed primarily in osteosarcoma, wilm's tumor, ovarian cancer and in T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, inflammatory diseases and cancers, such as osteosarcoma, wilm's tumor and ovarian cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., skeletal, renal, reproductive, immune, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 219 as residues: Ser-30 to Pro-35. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of inflammatory conditions and cancer, such as osteosarcoma, wilm's tumor and ovarian cancer. Moreover, the expression within cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases

5 and disorders, including cancer, and other proliferative conditions. Representative
10 uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections
below and elsewhere herein. Briefly, developmental tissues rely on decisions
involving cell differentiation and/or apoptosis in pattern formation.

5 Dysregulation of apoptosis can result in inappropriate suppression of cell
death, as occurs in the development of some cancers, or in failure to control the extent
15 of cell death, as is believed to occur in acquired immunodeficiency and certain
neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of
potential roles in proliferation and differentiation, this gene product may have
20 applications in the adult for tissue regeneration and the treatment of cancers. It may
also act as a morphogen to control cell and tissue type specification. Therefore, the
polynucleotides and polypeptides of the present invention are useful in treating,
detecting, and/or preventing said disorders and conditions, in addition to other types
25 of degenerative conditions. Thus this protein may modulate apoptosis or tissue
differentiation and is useful in the detection, treatment, and/or prevention of
15 degenerative or proliferative conditions and diseases. The protein is useful in
modulating the immune response to aberrant polypeptides, as may exist in
30 proliferating and cancerous cells and tissues. The protein can also be used to gain new
insight into the regulation of cellular growth and proliferation. Furthermore, the
20 protein may also be used to determine biological activity, to raise antibodies, as tissue
markers, to isolate cognate ligands or receptors, to identify agents that modulate their
35 interactions, in addition to its use as a nutritional supplement. Protein, as well as,
antibodies directed against the protein may show utility as a tumor marker and/or
immunotherapy targets for the above listed tissues.

40 25 Many polynucleotide sequences, such as EST sequences, are publicly
available and accessible through sequence databases. Some of these sequences are
related to SEQ ID NO:106 and may have been publicly available prior to conception
45 of the present invention. Preferably, such related polynucleotides are specifically
excluded from the scope of the present invention. To list every related sequence is
30 cumbersome. Accordingly, preferably excluded from the present invention are one or
more polynucleotides comprising a nucleotide sequence described by the general
50 formula of a-b, where a is any integer between 1 to 1007 of SEQ ID NO: 106, b is an

integer of 15 to 1021, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 106, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 97

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: GTSKDCVLYAFLDPGMAVPLFLYIFTLLPLLPFLLSLCFSPLTVKRSSSESSEKSSL (SEQ ID NO: 364). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in ovarian cancer.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, ovarian cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, ovarian, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial amniotic fluid, fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 220 as residues: Thr-28 to Ser-40. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in ovarian tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating and diagnosing cancer, e.g., ovarian cancer. Moreover, the expression within cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of

developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:107 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 816 of SEQ ID NO:107, b is an integer of 15 to 830, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:107, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 98

This gene is expressed primarily in macrophages and breast cancer tissue and to a lesser extent in osteoblasts and smooth muscle.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune system dysfunction; inflammation; breast cancer; cancer; osteoporosis; osteopetrosis; peristaltic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and skeletal systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 221 as residues: Glu-16 to Ala-40. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of a variety of disorders. Expression in macrophages and other hematopoietic cell types indicates that this gene product is involved in the regulation of hematopoietic cell survival, proliferation, differentiation, or activation. It is involved in the control of such processes as immune surveillance, antigen presentation, T cell activation, cytokine release, and inflammation. Expression in breast cancer tissue may possibly correlate with the diagnosis and differentiation of cancerous tissue from normal breast tissue.

5

10

Expression in osteoblasts and osteoclasts may implicate this gene product in the process of bone turnover, and target it as a likely candidate for the treatment of osteoporosis and/or osteopetrosis. Finally, expressio in smooth muscle may indicate an involvement in the normal function of numerous internal organs and in the function of the digestive system.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:108 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1287 of SEQ ID NO:108, b is an integer of 15 to 1301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:108, and where b is greater than or equal to a + 14.

15

20

25

15

30

35

40

45

50

55

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of S' NT Start Codon	S' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Secreted Pep	First AA of AA of Secreted Portion	Last AA of ORF
1	HDPTK41	209965 06/11/98	pCMVSPORT 3.0	11	1564	1	1564	39	39	124	1	26	27	369
2	HFXGT26	209965 06/11/98	Lambda ZAP II	12	1757	1	1757	13	13	125	1	22	23	85
3	HLTGX30	209965 06/11/98	Uni-ZAP XR	13	1373	1	1373	13	13	126	1	41	42	43
4	HLTHG37	209965 06/11/98	Uni-ZAP XR	14	3740	1908	3740	50	50	127	1	1	2	319
4	HLTHG37	209965 06/11/98	Uni-ZAP XR	109	1932	98	1932	313	313	222	1	35	36	42
5	HNTMZ90	209965 06/11/98	pSPORT	15	1196	1	1196	282	282	128	1	21	22	45

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO:	NT Total Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of AA of Start Codon	Signal NO:	AA SEQ Y	First AA of Sig Pep	Last AA of Secreted Peptide	First AA of AA of Secreted Peptide	Last of ORF
6	HPIBX03	209965 06/11/98	Uni-ZAP XR	16	2209	1	2178	81	81	129	1	29	30	709
7	H6EDY30	209965 06/11/98	Uni-ZAP XR	17	1774	1	1774	321	321	130	1	29	30	414
8	HAMGR28	209965 06/11/98	pCMVSPORT 3.0	18	1674	47	1674	98	98	131	1	18	19	242
8	HAMGR28	209965 06/11/98	pCMVSPORT 3.0	110	1534	1	1534	40	40	223	1	18	19	203
9	HAPNZ94	209965 06/11/98	Uni-ZAP XR	19	2018	255	2018	287	287	132	1	36	37	312
10	HATCP77	209965 06/11/98	Uni-ZAP XR	20	2098	1	2098	37	37	133	1	21	22	182

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of First AA of Signal Rep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Secreted Portion	Last AA of ORF
11	HDABR72	209965 06/11/98	pSport1	21	1746	1	1746	28	134	1	29	146
12	HDPKB18	209965 06/11/98	pCMVSPORT 3.0	22	2876	1	2876	98	135	1	22	122
12	HDPKB18	209965 06/11/98	pCMVSPORT 3.0	111	2871	1	2871	87	224	1	21	42
13	HEQCC55	209965 06/11/98	pCMVSPORT 3.0	23	1052	30	1052	62	136	1	27	112
13	HEQCC55	209965 06/11/98	pCMVSPORT 3.0	112	1037	1	1037	57	225	1	27	155
14	HETIDE26	209965 06/11/98	Uni-ZAP XR	24	1541	1	1541	205	137	1	29	139

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT 3' NT of Clone Seq.	5' NT of Clone Seq.	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
15	HOEDH84	209965 06/11/98	Uni-ZAP XR	25	2079	1	2079	256	138	1	20	21	404
16	HPIBT55	209965 06/11/98	Uni-ZAP XR	26	1947	129	1947	253	139	1	30	31	95
17	HSLCS05	209965 06/11/98	Uni-ZAP XR	27	3379	1	3354	168	140	1	23	24	239
18	HDPDD03	209965 06/11/98	pCMVSPORT 3.0	28	2006	1	2006	233	141	1	21	22	53
19	HDPDI66	209965 06/11/98	pCMVSPORT 3.0	29	3070	1	3070	93	142	1	45	46	66
20	HDTDQ23	209965 06/11/98	pCMVSPORT 2.0	30	2227	1	2206	148	143	1	20	21	108

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT 3' NT of Clone Seq.	5' NT of Clone Seq.	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
20	HDTDQ23	209965 06/11/98	pCMVSPORT 2.0	113	2214	1	2206	148	226	1	20	21	73
21	HE2PY40	209965 06/11/98	Uni-ZAP XR	31	1288	1	1288	147	144	1	22	23	83
22	HEONM66	209965 06/11/98	pSport1	32	3280	1	3280	89	145	1	24	25	166
22	HEONM66	209965 06/11/98	pSport1	114	3300	1	3300	98	227	1	20	21	166
23	HKAEG43	209965 06/11/98	pCMVSPORT 2.0	33	1297	1	1297	32	146	1	29	30	70
23	HKAEG43	209965 06/11/98	pCMVSPORT 2.0	115	1286	1	1286	21	228	1	29	30	70

Genc No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Rep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
24	HLHDP65	209965 06/11/98	Uni-ZAP XR	34	2184	1	2184	19	19	147	1	19	20	412
24	HLHDP65	209965 06/11/98	Uni-ZAP XR	116	2189	1	2189	26	26	229	1	21	22	272
25	HLMD003	209965 06/11/98	Uni-ZAP XR	35	949	1	949	72	72	148	1	45	46	84
26	HIMAGK93	209965 06/11/98	Uni-ZAP XR	36	3338	162	1884	164	164	149	1	30	31	153
27	HMEAL02	209965 06/11/98	Lambda ZAP II	37	1563	1	1563	237	237	150	1	33	34	129
28	IIMKCH52	209965 06/11/98	pSport1	38	1048	1	1048	53	53	151	1	17	18	61

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO:	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of AA of Signal Pep	AA SEQ ID NO:	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
29	HCEFB69	209965 06/11/98	Uni-ZAP XR	39	1430	1	1430	188	152	1	24	25	224
30	HNFFC43	203027 06/26/98	Uni-ZAP XR	40	2103	209	2058	488	153	1	15	16	68
31	HSPMG77	203027 06/26/98	pSport1	41	2349	1	2349	130	154	1	46	47	83
32	HSQAC69	203027 06/26/98	Uni-ZAP XR	42	1559	1	1559	146	155	1	21	22	60
33	HSTB186	203027 06/26/98	Uni-ZAP XR	43	1766	1	1766	120	156	1	24	25	83
34	HLDQR62	203027 06/26/98	pCMVSPORT 3.0	44	2572	427	2572	520	157	1	18	19	161

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO.	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO.	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
35	HUVDJ43	203027 06/26/98	Uni-ZAP XR	45	526	69	526	89	89	158	1	31	32	146
36	HADCP14	203027 06/26/98	pSport1	46	1032	1	1032	35	35	159	1	20	21	142
37	HBXCF95	203027 06/26/98	ZAP Express	47	2680	1	2680	118	118	160	1	22	23	50
38	HFQBU15	203027 06/26/98	pCMVSPORT 3.0	48	1730	1	1730	56	56	161	1	26	27	64
39	HL1BD22	203027 06/26/98	Uni-ZAP XR	49	1275	1	1275	53	53	162	1	39	40	58
40	HOBEU24	203027 06/26/98	Uni-ZAP XR	50	1762	1	1762	113	113	163	1	21	22	374

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT 3' NT of Clone Seq.	5' NT of 5' NT Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
40	HOEEU24	203027 06/26/98	Uni-ZAP XR	117	1763	1	1763	113	230	1	21	22	81
41	HTTBR96	203027 06/26/98	Uni-ZAP XR	51	2059	1	2059	96	164	1	26	27	63
42	HWHQS55	203027 06/26/98	pCMVSPORT 3.0	52	3282	1	3282	169	165	1	26	27	742
43	HCEEK50	203027 06/26/98	Uni-ZAP XR	53	1860	1	1860	233	166	1	17	18	213
44	HCWBU94	203027 06/26/98	ZAP Express	54	770	1	770	109	167	1	26	27	212
45	HE2NR62	203027 06/26/98	Uni-ZAP XR	55	1093	1	1093	145	168	1	38	39	74

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT 3' NT of Clone Seq.	5' NT of Clone Seq.	5' NT of Start Codon	S' NT of First AA of Signal Rep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Portion	First AA of Secreted	Last AA of ORF
46	HHSGH19	203027 06/26/98	Uni-ZAP XR	56	632	1	632	291	291	169	1	15	16	47
47	HDPGT01	203027 06/26/98	pCMVSPORT 3.0	57	2687	138	2687	8	8	170	1	28	29	87
48	HOBFA11	203027 06/26/98	pBluescript	58	619	153	579	166	166	171	1	30	31	41
49	HOHCA35	203027 06/26/98	pCMVSPORT 2.0	59	1378	1	1378	153	153	172	1	15	16	47
50	HPMGP24	203027 06/26/98	Uni-ZAP XR	60	1126	1	1126	215	215	173	1	33	34	232
51	HSDIE16	203027 06/26/98	Uni-ZAP XR	61	2078	1	2078	182	182	174	1	29	30	44

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of S' NT of Start Codon	S' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Secreted Portion	Last AA of ORF
52	HSOBK48	203027 06/26/98	Uni-ZAP XR	62	762	1	762	433	433	175	1	16	84
53	HTADH39	203027 06/26/98	Uni-ZAP XR	63	1094	1	1094	173	173	176	1	24	65
54	HUSGT36	203027 06/26/98	pSport1	64	1361	1	1361	112	112	177	1	16	54
55	HVAABE95	203027 06/26/98	pSport1	65	947	1	947	325	325	178	1	14	82
56	HIIEAH25	203071 07/27/98	pCMVSPORT 3.0	66	1376	1	1376	43	43	179	1	31	330
56	HHEAI125	203071 07/27/98	pCMVSPORT 3.0	118	1375	1	1375	43	43	231	1	31	71

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	NT Total NT Seq.	5' NT 3' NT of Clone Seq.	5' NT of 5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Secreted Portion	Last AA of ORF		
57	HB11Y92	203071 07/27/98	Uni-ZAP XR	67	2434	487	2366	548	548	180	1	29	30	40
58	HCLCW50	203071 07/27/98	Lambda ZAP II	68	1086	1	1086	255	255	181	1	17	18	51
59	HDRMF68	203071 07/27/98	pSport1	69	1262	1	1262	309	309	182	1	22	23	54
60	HOUGG12	203071 07/27/98	Uni-ZAP XR	70	1642	35	1642	116	116	183	1	22	23	61
61	HEEAQ11	203071 07/27/98	Uni-ZAP XR	71	921	1	921	213	213	184	1	28	29	147
62	HEEAZ65	203071 07/27/98	Uni-ZAP XR	72	906	1	906	182	182	185	1	19	20	160

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of 5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Portion	Last AA of Secreted of ORF
63	HEGAN94	203071 07/27/98	Uni-ZAP XR	73	680	1	680	133	133	186	1	23	121
64	HFXML33	203071 07/27/98	Lambda ZAP II	74	1633	1	1633	152	152	187	1	24	162
65	HLIBD68	203071 07/27/98	pCMV Sport I	75	1022	1	1022	186	186	188	1	35	50
66	HLTCO33	203071 07/27/98	Uni-ZAP XR	76	1184	1	1184	80	80	189	1	18	64
67	HLYAC95	203071 07/27/98	pSport!	77	312	1	312	92	92	190	1	16	46
68	HNFGF20	203071 07/27/98	Uni-ZAP XR	78	1370	38	1370	206	206	191	1	45	143

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO:	Total NT Seq	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of AA of Signal	Start Codon	5' NT of AA of Signal	First AA of Sig	First AA of Secreted	Last AA of ORF	
69	HNHKS18	203071 07/27/98	Uni-ZAP XR	79	368	1	368	125	125	192	1	36	37	81
70	HSLJW78	203071 07/27/98	Uni-ZAP XR	80	1088	1	1088	159	159	193	1	20	21	44
71	HHFHD01	203071 07/27/98	Uni-ZAP XR	81	1862	1	1862	177	177	194	1	16	17	41
72	HLWAE11	203071 07/27/98	pCMVSPORT 3.0	82	1618	1	1618	85	85	195	1	27	28	259
73	HCYBN55	203071 07/27/98	pBluescript SK-	83	2034	1	1984	341	341	196	1	19	20	117
73	HCYBN55	203071 07/27/98	pBluescript SK-	119	1022	78	1022			232	1	1	2	225

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal	5' NT of AA of ID	AA of ID	First AA of Sig	Last AA of Sig	First AA of Secreted	Last AA of ORF
74	HEONX38	203071 07/27/98	pSport1	84	2240	5	2240	23	23	197	1	23	24	24	698
74	HEONX38	203071 07/27/98	pSport1	120	2311	1	2311	24	24	233	1	23	24	24	314
75	HLDQU79	203071 07/27/98	pCMVSPORT 3.0	85	1488	1	1488	99	99	198	1	23	24	24	348
76	HSYBK21	203071 07/27/98	pCMVSPORT 3.0	86	3174	1	1466	119	119	199	1	29	30	30	401
77	HELBC12	203071 07/27/98	Uni-ZAP XR	87	2780	2110	2738	120	120	200	1	30	31	31	324
78	HTHDS25	203071 07/27/98	Uni-ZAP XR	88	1061	1	1061	70	70	201	1	15	16	16	90

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig pep	Last AA of Sig pep	First AA of Secreted Portion	Last AA of ORF
79	HFIHO70	203071 07/27/98	pSport1	89	1342	1	1271	141	141	202	1	30	243
79	HFIHO70	203071 07/27/98	pSport1	121	1286	1	1279	131	131	234	1	30	93
80	HPMEI86	203071 07/27/98	Uni-ZAP XR	90	770	40	770	50	50	203	1	30	75
81	HSOBV29	203071 07/27/98	Uni-ZAP XR	91	1570	207	1570	244	244	204	1	24	248
82	HWABY10	203071 07/27/98	pCMVSPORT 3.0	92	2950	78	2914	263	263	205	1	22	168
83	HACCI17	203071 07/27/98	Uni-ZAP XR	93	1722	336	1714	461	461	206	1	24	218

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of S' NT of Start Codon	S' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
83	HACC117	203071 07/27/98	Uni-ZAP XR	122	1380	12	1380	135	135	235	1	24	25	72
84	HAPQT22	203070 07/27/98	Uni-ZAP XR	94	635	1	635	132	132	207	1	17	18	72
85	HDPBO81	203070 07/27/98	pCMVSPORT 3.0	95	3798	1	3798	265	265	208	1	26	27	348
85	HDPBO81	203070 07/27/98	pCMVSPORT 3.0	123	3793	1	3793	255	255	236	1	26	27	348
86	HDPGL49	203070 07/27/98	pCMVSPORT 3.0	96	2683	1	2640	266	266	209	1	29	30	72
87	HDTBV77	203070 07/27/98	pCMVSPORT 2.0	97	2181	1	2181	326	326	210	1	22	23	608

Genc No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT 3' NT of Clone Seq.	5' NT of Clone Seq. Start Codon	5' NT of First AA of Signal	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
88	HFTUE82	203070 07/27/98	pSport1	98	1957	1	1957	24	211	1	23	24	251
89	HHEND31	203070 07/27/98	pCMVSPORT 3.0	99	1112	1	1112	109	212	1	25	26	225
90	HKMND01	203069 07/27/98	pBluescript	100	887	1	887	23	213	1	26	27	50
91	HLDBI84	203069 07/27/98	pCMVSPORT 3.0	101	1248	1	1248	50	214	1	35	36	171
92	HLTEK17	203069 07/27/98	Uni-ZAP XR	102	1841	1	1841	112	215	1	13	14	47
93	HEBEJ18	203069 07/27/98	Uni-ZAP XR	103	685	7	649	51	216	1	15	16	139

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT 3' NT of Clone Seq.	5' NT of Clone Seq.	5' NT of First AA of Signal Rep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
94	HMEAI48	203069 07/27/98	Lambda ZAP II	104	1168	1	1168	95	217	1	29	30	40
95	HNHGN91	203069 07/27/98	Uni-ZAP XR	105	1175	161	1175	184	218	1	24	25	51
96	HODAE92	203069 07/27/98	Uni-ZAP XR	106	1021	1	1021	123	219	1	29	30	48
97	HODDF13	203069 07/27/98	Uni-ZAP XR	107	830	1	830	46	220	1	27	28	41
98	HCDCF30	203027 06/26/98	Uni-ZAP XR	108	1301	102	1301	151	221	1	14	15	40

5 Table 1 summarizes the information corresponding to each "Gene No." described
above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled
10 from partially homologous ("overlapping") sequences obtained from the "cDNA
clone ID" identified in Table 1 and, in some cases, from additional related DNA
5 ciones. The overlapping sequences were assembled into a single contiguous sequence
of high redundancy (usually three to five overlapping sequences at each nucleotide
15 position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding
deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits
10 contain multiple different clones corresponding to the same gene. "Vector" refers to
20 the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig
identified by "Gene No." The deposited clone may contain all or most of these
25 sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq."
15 and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID
NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon."
30 Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence
is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is
20 identified as "AA SEQ ID NO:Y," although other reading frames can also be easily
35 translated using known molecular biology techniques. The polypeptides produced by
these alternative open reading frames are specifically contemplated by the present
invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal
40 peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The
25 predicted first amino acid position of SEQ ID NO:Y of the secreted portion is
identified as "Predicted First AA of Secreted Portion." Finally, the amino acid
45 position of SEQ ID NO:Y of the last amino acid in the open reading frame is
identified as "Last AA of ORF."

30 SEQ ID NO:X and the translated SEQ ID NO:Y are sufficiently accurate and
otherwise suitable for a variety of uses well known in the art and described further
50 below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization

5 probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the
cDNA contained in the deposited clone. These probes will also hybridize to nucleic
10 acid molecules in biological samples, thereby enabling a variety of forensic and
diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID
5 NO:Y may be used to generate antibodies which bind specifically to the secreted
proteins encoded by the cDNA clones identified in Table 1.

15 Nevertheless, DNA sequences generated by sequencing reactions can contain
sequencing errors. The errors exist as misidentified nucleotides, or as insertions or
deletions of nucleotides in the generated DNA sequence. The erroneously inserted or
20 10 deleted nucleotides cause frame shifts in the reading frames of the predicted amino
acid sequence. In these cases, the predicted amino acid sequence diverges from the
actual amino acid sequence, even though the generated DNA sequence may be greater
than 99.9% identical to the actual DNA sequence (for example, one base insertion or
25 deletion in an open reading frame of over 1000 bases).

15 Accordingly, for those applications requiring precision in the nucleotide
sequence or the amino acid sequence, the present invention provides not only the
generated nucleotide sequence identified as SEQ ID NO:X and the predicted
30 translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of
plasmid DNA containing a human cDNA of the invention deposited with the ATCC,
20 as set forth in Table 1. The nucleotide sequence of each deposited clone can readily
be determined by sequencing the deposited clone in accordance with known methods.
35 The predicted amino acid sequence can then be verified from such deposits.
Moreover, the amino acid sequence of the protein encoded by a particular clone can
also be directly determined by peptide sequencing or by expressing the protein in a
40 25 suitable host cell containing the deposited human cDNA, collecting the protein, and
determining its sequence.

The present invention also relates to the genes corresponding to SEQ ID
45 NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be
isolated in accordance with known methods using the sequence information disclosed
30 herein. Such methods include preparing probes or primers from the disclosed
sequence and identifying or amplifying the corresponding gene from appropriate
50 sources of genomic material.

Also provided in the present invention are species homologs. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for the desired homologue.

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural or recombinant sources using antibodies of the invention raised against the secreted protein in methods which are well known in the art.

Signal Sequences

Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, Virus Res. 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, Nucleic Acids Res. 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of

these methods is in the range of 75-80%. (von Heinje, supra.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., Protein Engineering 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Polynucleotide and Polypeptide Variants

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

By a polynucleotide having a nucleotide sequence at least, for example, 95%

5 "identical" to a reference nucleotide sequence of the present invention, it is intended
that the nucleotide sequence of the polynucleotide is identical to the reference
10 sequence except that the polynucleotide sequence may include up to five point
mutations per each 100 nucleotides of the reference nucleotide sequence encoding the
5 polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence
at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides
15 in the reference sequence may be deleted or substituted with another nucleotide, or a
number of nucleotides up to 5% of the total nucleotides in the reference sequence may
be inserted into the reference sequence. The query sequence may be an entire
20 sequence shown in Table 1, the ORF (open reading frame), or any fragment specified
as described herein.

As a practical matter, whether any particular nucleic acid molecule or
polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide
25 sequence of the present invention can be determined conventionally using known
15 computer programs. A preferred method for determining the best overall match
between a query sequence (a sequence of the present invention) and a subject
sequence, also referred to as a global sequence alignment, can be determined using
30 the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App.
Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences
20 are both DNA sequences. An RNA sequence can be compared by converting U's to
T's. The result of said global sequence alignment is in percent identity. Preferred
35 parameters used in a FASTDB alignment of DNA sequences to calculate percent
identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30,
Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty
40 25 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is
shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3'
45 deletions, not because of internal deletions, a manual correction must be made to the
results. This is because the FASTDB program does not account for 5' and 3'
30 truncations of the subject sequence when calculating percent identity. For subject
sequences truncated at the 5' or 3' ends, relative to the query sequence, the
50 percent identity is corrected by calculating the number of bases of the query sequence

5
10
15
20
25
30
35
40
45
50
55

that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

10
15
20
25
30
35
40
45
50
55

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

25
30
35
40
45
50
55

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid.

5 These alterations of the reference sequence may occur at the amino or carboxy
terminal positions of the reference amino acid sequence or anywhere between those
10 terminal positions, interspersed either individually among residues in the reference
sequence or in one or more contiguous groups within the reference sequence.

5 As a practical matter, whether any particular polypeptide is at least 90%, 95%,
96%, 97%, 98% or 99% identical to, for instance, the amino acid sequences shown in
15 Table 1 or to the amino acid sequence encoded by deposited DNA clone can be
determined conventionally using known computer programs. A preferred method for
determining the best overall match between a query sequence (a sequence of the present
20 10 invention) and a subject sequence, also referred to as a global sequence alignment,
can be determined using the FASTDB computer program based on the algorithm of
Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the
query and subject sequences are either both nucleotide sequences or both amino acid
25 sequences. The result of said global sequence alignment is in percent identity.
15 Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0,
k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group
Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size
30 Penalty=2.05, Window Size=500 or the length of the subject amino acid sequence,
whichever is shorter.

20 If the subject sequence is shorter than the query sequence due to N- or C-
35 terminal deletions, not because of internal deletions, a manual correction must be
made to the results. This is because the FASTDB program does not account for N-
and C-terminal truncations of the subject sequence when calculating global percent
identity. For subject sequences truncated at the N- and C-termini, relative to the the
40 25 query sequence, the percent identity is corrected by calculating the number of residues
of the query sequence that are N- and C-terminal of the subject sequence, which are
not matched/aligned with a corresponding subject residue, as a percent of the total
45 bases of the query sequence. Whether a residue is matched/aligned is determined by
results of the FASTDB sequence alignment. This percentage is then subtracted from
30 the percent identity, calculated by the above FASTDB program using the specified
parameters, to arrive at a final percent identity score. This final percent identity score
50 is what is used for the purposes of the present invention. Only residues to the N- and

C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an

organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level.

Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., J. Biol. Chem. 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic

activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as to have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of

the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of the present invention having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a polypeptide to have an amino acid sequence which comprises the amino acid sequence of the present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of the present invention or fragments thereof (e.g., the mature form and/or other fragments described herein), is

1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

Polynucleotide and Polypeptide Fragments

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence contained in the deposited clone or shown in SEQ ID NO:X. The short nucleotide fragments are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in the deposited clone or the nucleotide sequence shown in SEQ ID NO:X. These nucleotide fragments are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments having a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X or the cDNA contained in the deposited clone. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein.

In the present invention, a "polypeptide fragment" refers to a short amino acid sequence contained in SEQ ID NO:Y or encoded by the cDNA contained in the deposited clone. Protein fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the

invention, include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotide fragments encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotide fragments encoding these domains are also contemplated.

Other preferred fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Epitopes & Antibodies

5
10
15
In the present invention, "epitopes" refer to polypeptide fragments having antigenic or immunogenic activity in an animal, especially in a human. A preferred embodiment of the present invention relates to a polypeptide fragment comprising an epitope, as well as the polynucleotide encoding this fragment. A region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope." In contrast, an "immunogenic epitope" is defined as a part of a protein that elicits an antibody response. (See, for instance, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1983).)

20
Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985) further described in U.S. Patent No. 4,631,211.)

25
30
In the present invention, antigenic epitopes preferably contain a sequence of at least seven, more preferably at least nine, and most preferably between about 15 to about 30 amino acids. Antigenic epitopes are useful to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe, J. G. et al., Science 219:660-666 (1983).)

35
40
45
Similarly, immunogenic epitopes can be used to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow, M. et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle, F. J. et al., J. Gen. Virol. 66:2347-2354 (1985).) A preferred immunogenic epitope includes the secreted protein. The immunogenic epitopes may be presented together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse) or, if it is long enough (at least about 25 amino acids), without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting.)

50
55
As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab')₂ fragments) which are capable of specifically binding to protein. Fab and F(ab')₂ fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody. (Wahl et al., J. Nucl. Med. 24:316-325 (1983).) Thus, these

fragments are preferred, as well as the products of a FAB or other immunoglobulin expression library. Moreover, antibodies of the present invention include chimeric, single chain, and humanized antibodies.

5 **Fusion Proteins**

Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the

IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., *J. Biochem.* 270:3958-3964 (1995).)

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., *J. Molecular Recognition* 8:52-58 (1995); K. Johanson et al., *J. Biol. Chem.* 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., *Proc. Natl. Acad. Sci. USA* 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., *Cell* 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

Vectors, Host Cells, and Protein Production

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral

5
10
vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

15
20
The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

25
30
The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

35
40
As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

45
50
Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptkc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1

5 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

10 Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated
5 transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic
15 Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

20 A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity
25 chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for
15 purification.

30 Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical
20 synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant,
35 insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also
40 25 include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency
45 from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some
30 proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

5
10
15
20
25
30
35
40
45
50
55

In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

Uses of the Polynucleotides

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids

5 containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

10 Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per
5 day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping
15 strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.

20 10 Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see
25 Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

30 For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are
20 more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

35 Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation
40 of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .) Assuming 1 megabase mapping resolution and
45 one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

50 30 Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined. First, visible structural alterations in the chromosomes, such as deletions or

translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Both methods rely on binding of the polynucleotide to DNA or RNA. For these techniques, preferred polynucleotides are usually 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

5 The polynucleotides are also useful for identifying individuals from minute
biological samples. The United States military, for example, is considering the use of
10 restriction fragment length polymorphism (RFLP) for identification of its personnel.
In this technique, an individual's genomic DNA is digested with one or more
5 restriction enzymes, and probed on a Southern blot to yield unique bands for
identifying personnel. This method does not suffer from the current limitations of
15 "Dog Tags" which can be lost, switched, or stolen, making positive identification
difficult. The polynucleotides of the present invention can be used as additional DNA
markers for RFLP.

20 The polynucleotides of the present invention can also be used as an alternative
to RFLP, by determining the actual base-by-base DNA sequence of selected portions
of an individual's genome. These sequences can be used to prepare PCR primers for
amplifying and isolating such selected DNA, which can then be sequenced. Using
25 this technique, individuals can be identified because each individual will have a
15 unique set of DNA sequences. Once an unique ID database is established for an
individual, positive identification of that individual, living or dead, can be made from
extremely small tissue samples.

30 Forensic biology also benefits from using DNA-based identification
techniques as disclosed herein. DNA sequences taken from very small biological
20 samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen,
35 etc., can be amplified using PCR. In one prior art technique, gene sequences
amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic
biology to identify individuals. (Erich, H., PCR Technology, Freeman and Co.
40 (1992).) Once these specific polymorphic loci are amplified, they are digested with
25 one or more restriction enzymes, yielding an identifying set of bands on a Southern
blot probed with DNA corresponding to the DQa class II HLA gene. Similarly,
polynucleotides of the present invention can be used as polymorphic markers for
45 forensic purposes.

30 There is also a need for reagents capable of identifying the source of a
particular tissue. Such need arises, for example, in forensics when presented with
tissue of unknown origin. Appropriate reagents can comprise, for example, DNA
50 probes or primers specific to particular tissue prepared from the sequences of the

5 present invention. Panels of such reagents can identify tissue by species and/or by
organ type. In a similar fashion, these reagents can be used to screen tissue cultures
10 for contamination.

In the very least, the polynucleotides of the present invention can be used as
5 molecular weight markers on Southern gels, as diagnostic probes for the presence of a
specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences
15 in the process of discovering novel polynucleotides, for selecting and making
oligomers for attachment to a "gene chip" or other support, to raise anti-DNA
antibodies using DNA immunization techniques, and as an antigen to elicit an
20 immune response.

Uses of the Polypeptides

Each of the polypeptides identified herein can be used in numerous ways. The
25 following description should be considered exemplary and utilizes known techniques.

15 A polypeptide of the present invention can be used to assay protein levels in a
biological sample using antibody-based techniques. For example, protein expression
in tissues can be studied with classical immunohistological methods. (Jalkanen, M.,
30 et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell. Biol. 105:3087-
3096 (1987).) Other antibody-based methods useful for detecting protein gene
20 expression include immunoassays, such as the enzyme linked immunosorbent assay
(ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known
35 in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such
as iodine (125I, 121I), carbon (14C), sulfur (35S), tritium (3H), indium (112In), and
technetium (99mTc), and fluorescent labels, such as fluorescein and rhodamine, and
40 25 biotin.

In addition to assaying secreted protein levels in a biological sample, proteins
can also be detected in vivo by imaging. Antibody labels or markers for in vivo
45 imaging of protein include those detectable by X-radiography, NMR or ESR. For X-
radiography, suitable labels include radioisotopes such as barium or cesium, which
30 emit detectable radiation but are not overtly harmful to the subject. Suitable markers
for NMR and ESR include those with a detectable characteristic spin, such as
50
55

deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example, ^{131}I , ^{112}In , $^{99\text{m}}\text{Tc}$), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of $^{99\text{m}}\text{Tc}$. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder.

Moreover, polypeptides of the present invention can be used to treat disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B), to inhibit the activity of a polypeptide (e.g., an oncogene), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth).

5
10
15
20
25
Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

30
35
40
45
50
55
At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

Biological Activities

15
20
25
30
35
40
45
50
55
The polynucleotides and polypeptides of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides and polypeptides could be used to treat the associated disease.

Immune Activity

15
20
25
30
35
40
45
50
55
A polypeptide or polynucleotide of the present invention may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune deficiencies or disorders may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotide or polypeptide of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

5 A polynucleotide or polypeptide of the present invention may be useful in
treating or detecting deficiencies or disorders of hematopoietic cells. A
10 polypeptide or polynucleotide of the present invention could be used to increase
differentiation and proliferation of hematopoietic cells, including the pluripotent stem
5 cells, in an effort to treat those disorders associated with a decrease in certain (or
many) types hematopoietic cells. Examples of immunologic deficiency syndromes
15 include, but are not limited to: blood protein disorders (e.g. agammaglobulinemia,
dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency,
DiGeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion
20 10 deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe
combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia,
thrombocytopenia, or hemoglobinuria.

25 Moreover, a polypeptide or polynucleotide of the present invention could also
be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity
15 (clot formation). For example, by increasing hemostatic or thrombolytic activity, a
polynucleotide or polypeptide of the present invention could be used to treat blood
30 coagulation disorders (e.g., afibrinogenemia, factor deficiencies), blood platelet
disorders (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other
causes. Alternatively, a polynucleotide or polypeptide of the present invention that
20 can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve
35 clotting. These molecules could be important in the treatment of heart attacks
(infarction), strokes, or scarring.

40 A polynucleotide or polypeptide of the present invention may also be useful in
treating or detecting autoimmune disorders. Many autoimmune disorders result from
25 inappropriate recognition of self as foreign material by immune cells. This
inappropriate recognition results in an immune response leading to the destruction of
the host tissue. Therefore, the administration of a polypeptide or polynucleotide of the
45 present invention that inhibits an immune response, particularly the proliferation,
differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing
30 autoimmune disorders.

50 Examples of autoimmune disorders that can be treated or detected by the
present invention include, but are not limited to: Addison's Disease, hemolytic

anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by a polypeptide or polynucleotide of the present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

A polynucleotide or polypeptide of the present invention may also be used to treat and/or prevent organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polypeptide or polynucleotide of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

Hyperproliferative Disorders

5 A polypeptide or polynucleotide can be used to treat or detect
hyperproliferative disorders, including neoplasms. A polypeptide or polynucleotide
10 of the present invention may inhibit the proliferation of the disorder through direct or
indirect interactions. Alternatively, a polypeptide or polynucleotide of the present
5 invention may proliferate other cells which can inhibit the hyperproliferative disorder.

15 For example, by increasing an immune response, particularly increasing
antigenic qualities of the hyperproliferative disorder or by proliferating,
differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated.
This immune response may be increased by either enhancing an existing immune
20 response, or by initiating a new immune response. Alternatively, decreasing an
immune response may also be a method of treating hyperproliferative disorders, such
as a chemotherapeutic agent.

25 Examples of hyperproliferative disorders that can be treated or detected by a
polynucleotide or polypeptide of the present invention include, but are not limited to
15 neoplasms located in the: abdomen, bone, breast, digestive system, liver, pancreas,
peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus,
thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system,
30 pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by
20 a polynucleotide or polypeptide of the present invention. Examples of such
hyperproliferative disorders include, but are not limited to:
35 hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura,
sarcoidosis, Sezary Syndrome, Waldenström's Macroglobulinemia, Gaucher's
Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia,
40 located in an organ system listed above.

Infectious Disease

45 A polypeptide or polynucleotide of the present invention can be used to treat
or detect infectious agents. For example, by increasing the immune response,
30 particularly increasing the proliferation and differentiation of B and/or T cells,
infectious diseases may be treated. The immune response may be increased by either
50 enhancing an existing immune response, or by initiating a new immune response.

Alternatively, the polypeptide or polynucleotide of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of viruses, include, but are not limited to the following DNA and RNA viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza), Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following Gram-Negative and Gram-positive bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Nocardia), Aspergillosis, Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia, Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, Enterobacteriaceae (Klebsiella, Salmonella, Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales, Neisseriaceae (e.g., Acinetobacter, Gonorrhea, Meningococcal), Pasteurellaceae Infections (e.g., Actinobacillus, Haemophilus, Pasteurella), Pseudomonas, Rickettsiaceae,

Chlamydiaceae, Syphilis, and Staphylococcal. These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea, meningitis, Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Moreover, parasitic agents causing disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following families: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas. These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), Malaria, pregnancy complications, and toxoplasmosis. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Preferably, treatment using a polypeptide or polynucleotide of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

Regeneration

5
10
15
A polynucleotide or polypeptide of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

20
25
Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

30
35
Moreover, a polynucleotide or polypeptide of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or polypeptide of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

40
45
50
55
Similarly, nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide of the present invention to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotide or polypeptide of the present invention.

Chemotaxis

A polynucleotide or polypeptide of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

It is also contemplated that a polynucleotide or polypeptide of the present invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, a polynucleotide or polypeptide of the present invention could be used as an inhibitor of chemotaxis.

Binding Activity

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable

of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

All of these above assays can be used as diagnostic or prognostic markers.

The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues.

Therefore, the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a

5 candidate binding compound with a polypeptide of the invention; and (b) determining
if binding has occurred. Moreover, the invention includes a method of identifying
10 agonists/antagonists comprising the steps of: (a) incubating a candidate compound
with a polypeptide of the invention, (b) assaying a biological activity, and (b)
5 determining if a biological activity of the polypeptide has been altered.

15 Other Activities

A polypeptide or polynucleotide of the present invention may also increase or
decrease the differentiation or proliferation of embryonic stem cells, besides, as
20 discussed above, hematopoietic lineage.

A polypeptide or polynucleotide of the present invention may also be used to
modulate mammalian characteristics, such as body height, weight, hair color, eye
color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic
25 surgery). Similarly, a polypeptide or polynucleotide of the present invention may be
15 used to modulate mammalian metabolism affecting catabolism, anabolism,
processing, utilization, and storage of energy.

A polypeptide or polynucleotide of the present invention may be used to
30 change a mammal's mental state or physical state by influencing biorhythms,
cardiac rhythms, depression (including depressive disorders), tendency for violence,
20 tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like
activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other
35 cognitive qualities.

A polypeptide or polynucleotide of the present invention may also be used as a
40 food additive or preservative, such as to increase or decrease storage capabilities, fat
25 content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional
components.

45 Other Preferred Embodiments

Other preferred embodiments of the claimed invention include an isolated
30 nucleic acid molecule comprising a nucleotide sequence which is at least 95%
identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide
50 sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

5

10

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3'

5 Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

15

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3'

20

10 Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

25

Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

30

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

35

20 Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

40

A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

45

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

50

55

5

10

Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

15

20

Also preferred is a composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

25

30

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

35

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

40

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

45

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said human cDNA clone.

50

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X

55

5 wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by
a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained
10 in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table
1; which method comprises a step of comparing a nucleotide sequence of at least one
5 nucleic acid molecule in said sample with a sequence selected from said group and
determining whether the sequence of said nucleic acid molecule in said sample is at
15 least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences
comprises determining the extent of nucleic acid hybridization between nucleic acid
20 molecules in said sample and a nucleic acid molecule comprising said sequence
selected from said group. Similarly, also preferred is the above method wherein said
step of comparing sequences is performed by comparing the nucleotide sequence
determined from a nucleic acid molecule in said sample with said sequence selected
25 from said group. The nucleic acid molecules can comprise DNA molecules or RNA
15 molecules.

A further preferred embodiment is a method for identifying the species, tissue
or cell type of a biological sample which method comprises a step of detecting nucleic
30 acid molecules in said sample, if any, comprising a nucleotide sequence that is at least
95% identical to a sequence of at least 50 contiguous nucleotides in a sequence
20 selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X
wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by
35 a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained
in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table
1.

40 25 The method for identifying the species, tissue or cell type of a biological
sample can comprise a step of detecting nucleic acid molecules comprising a
nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least
45 one sequence in said panel is at least 95% identical to a sequence of at least 50
contiguous nucleotides in a sequence selected from said group.

30 Also preferred is a method for diagnosing in a subject a pathological condition
associated with abnormal structure or expression of a gene encoding a secreted
50 protein identified in Table 1, which method comprises a step of detecting in a

5 biological sample obtained from said subject nucleic acid molecules, if any,
comprising a nucleotide sequence that is at least 95% identical to a sequence of at
10 least 50 contiguous nucleotides in a sequence selected from the group consisting of: a
nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1;
5 and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA
Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit
15 Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of
detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at
20 10 least two nucleotide sequences, wherein at least one sequence in said panel is at least
95% identical to a sequence of at least 50 contiguous nucleotides in a sequence
selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid
25 molecules wherein the nucleotide sequences of said nucleic acid molecules comprise
15 a panel of at least two nucleotide sequences, wherein at least one sequence in said
panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a
sequence selected from the group consisting of: a nucleotide sequence of SEQ ID
30 NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence
encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1
20 and contained in the deposit with the ATCC Deposit Number shown for said cDNA
clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA
35 molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence
at least 90% identical to a sequence of at least about 10 contiguous amino acids in the
40 25 amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

Also preferred is a polypeptide, wherein said sequence of contiguous amino
acids is included in the amino acid sequence of SEQ ID NO:Y in the range of
45 positions beginning with the residue at about the position of the First Amino Acid of
the Secreted Portion and ending with the residue at about the Last Amino Acid of the
30 Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

5

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

10

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

15

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

20

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

25

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

30

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

35

40

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

45

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1.

50

55

and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

5

10

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

15

20

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

25

30

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

35

40

45

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

30

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

50

55

5

10

15

20

25

30

35

40

45

50

55

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is

defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

Examples

Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector. Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited</u>
<u>Plasmid</u>	
Lambda Zap	pBluescript (pBS)
Uni-Zap XR	pBluescript (pBS)
Zap Express	pBK
lafmid BA	plafmid BA
pSport1	pSport1
pCMVSPORT 2.0	pCMVSPORT 2.0

pCMVSPORT 3.0

pCMVSPORT 3.0

pCR[®]2.1pCR[®]2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128,256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Altling-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Altling-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS-. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the f1 origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the f1 ori generates sense strand DNA and in the other, antisense.

Vectors pSPORT1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR[®]2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional

5
10
15
plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

20
25
10
Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

30
35
40
45
15
20
25
Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with ^{32}P - γ -ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

50
55
30
Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 μl of reaction mixture with 0.5 μg of the above cDNA template. A convenient reaction mixture is 1.5-5 mM MgCl_2 , 0.01% (w/v) gelatin, 20 μM each of dATP, dCTP, dGTP, dTTP, 25

5 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR
(denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1
10 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The
amplified product is analyzed by agarose gel electrophoresis and the DNA band with
5 expected molecular weight is excised and purified. The PCR product is verified to be
the selected sequence by subcloning and sequencing the DNA product.

15 Several methods are available for the identification of the 5' or 3' non-coding
portions of a gene which may not be present in the deposited clone. These methods
include but are not limited to, filter probing, clone enrichment using specific probes,
20 10 and protocols similar or identical to 5' and 3' "RACE" protocols which are well
known in the art. For instance, a method similar to 5' RACE is available for
generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et
al., Nucleic Acids Res. 21(7):1683-1684 (1993).)

25 Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a
15 population of RNA presumably containing full-length gene RNA transcripts. A
primer set containing a primer specific to the ligated RNA oligonucleotide and a
primer specific to a known sequence of the gene of interest is used to PCR amplify
30 the 5' portion of the desired full-length gene. This amplified product may then be
sequenced and used to generate the full length gene.

20 This above method starts with total RNA isolated from the desired source,
although poly-A+ RNA can be used. The RNA preparation can then be treated with
35 phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged
RNA which may interfere with the later RNA ligase step. The phosphatase should
then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order
40 25 to remove the cap structure present at the 5' ends of messenger RNAs. This reaction
leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be
ligated to an RNA oligonucleotide using T4 RNA ligase.

45 This modified RNA preparation is used as a template for first strand cDNA
synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is
30 used as a template for PCR amplification of the desired 5' end using a primer specific
to the ligated RNA oligonucleotide and a primer specific to the known sequence of
50

the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

Example 3: Tissue Distribution of Polypeptide

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P³² using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70°C overnight, and the films developed according to standard procedures.

Example 4: Chromosomal Mapping of the Polynucleotides

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95°C; 1 minute, 56°C; 1 minute, 70°C. This cycle is repeated 32 times followed by one 5 minute cycle at 70°C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing

individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

Example 5: Bacterial Expression of a Polypeptide

A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^r). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1

5 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4°C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4°C or frozen at -80°C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker. 2) an E. coli origin of replication. 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (lacIq). The

origin of replication (oriC) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

Example 6: Purification of a Polypeptide from an Inclusion Body

The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10°C.

Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10°C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction.

5
10
15
20
25
30
35
40
45
50
55

Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4°C without mixing for 12 hours prior to further purification steps.

To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 µm membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A₂₈₀ monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 µg of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

5

Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System

10

In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

15

20

25

15

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

30

20

35

Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

40

25

45

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

50

55

5

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

10

5 The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

15

20

Five µg of a plasmid containing the polynucleotide is co-transfected with 1.0 µg of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One µg of BaculoGold™ virus DNA and 5 µg of the plasmid are mixed in a sterile well of a microtiter plate containing 50 µl of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 µl Lipofectin plus 90 µl Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27° C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27° C for four days.

25

15

30

20

35

40

25 After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then

45

30

50

55

resuspended in a microcentrifuge tube containing 200 μ l of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4° C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 μ Ci of 35 S-methionine and 5 μ Ci 35 S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

Example 8: Expression of a Polypeptide in Mammalian Cells

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV, HIV and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2 χ fr (ATCC 37146), pBC12MI (ATCC 67109),

pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human HeLa, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., *J. Biol. Chem.* 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., *Biochem. et Biophys. Acta*, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., *Biotechnology* 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., *Biochem J.* 227:277-279 (1991); Bebbington et al., *Bio/Technology* 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No. 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., *Molecular and Cellular Biology*, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., *Cell* 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

5 A polynucleotide of the present invention is amplified according to the
protocol outlined in Example 1. If the naturally occurring signal sequence is used to
10 produce the secreted protein, the vector does not need a second signal peptide.
Alternatively, if the naturally occurring signal sequence is not used, the vector can be
5 modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

15 The amplified fragment is isolated from a 1% agarose gel using a
commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment
then is digested with appropriate restriction enzymes and again purified on a 1%
agarose gel.

20 The amplified fragment is then digested with the same restriction enzyme and
purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector
are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then
transformed and bacteria are identified that contain the fragment inserted into plasmid
25 pC6 using, for instance, restriction enzyme analysis.

30 Chinese hamster ovary cells lacking an active DHFR gene is used for
transfection. Five μ g of the expression plasmid pC6 is cotransfected with 0.5 μ g of
the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo
contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme
35 that confers resistance to a group of antibiotics including G418. The cells are seeded
20 in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are
trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha
minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml
40 G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well
25 petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM,
100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of
methotrexate are then transferred to new 6-well plates containing even higher
concentrations of methotrexate (1 μ M, 2 μ M, 5 μ M, 10 mM, 20 mM). The same
45 procedure is repeated until clones are obtained which grow at a concentration of 100 -
200 μ M. Expression of the desired gene product is analyzed, for instance, by SDS-
30 PAGE and Western blot or by reversed phase HPLC analysis.

50 Example 9: Protein Fusions

5
10
15
20
25
The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the half-life time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

15
20
25
30
Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

35
40
45
50
For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

55
If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

5
10
15
20
25
15
GGGATCCGGAGCCCAAATCTTCTGACAAAACACACATGCCACCGTGC
CCAGCACCTGAATTCGAGGGTGACCGTCAGTCTTCTCTTCCCCCAAAA
CCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGT
GGTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
5 ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA
CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCTGCACCAGGACT
GGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCA
ACCCCATCGAGAAAACCATCTCCAAGCCAAAGGGCAGCCCCGAGAAC
CACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAG
10 GTCAGCCTGACCTGGCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGT
GGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCT
CCCGTGTGGACTCCGACGGCTCCTTCTCTCTACAGCAAGCTACCGTG
GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCA
25 TGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGG
15 GTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

30
Example 10: Production of an Antibody from a Polypeptide

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) For example, cells expressing a polypeptide of the present invention is administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of the secreted protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

40
25 In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al., Nature 256:495 (1975); Köhler et al., Eur. J. Immunol. 6:511 (1976); Köhler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in

any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

It will be appreciated that Fab and F(ab')₂ and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced

5 using genetic constructs derived from hybridoma cells producing the monoclonal
antibodies described above. Methods for producing chimeric antibodies are known in
10 the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al.,
BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et
5 al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson
et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature
15 314:268 (1985).)

Example 11: Production Of Secreted Protein For High-Throughput Screening
10 **Assays**

The following protocol produces a supernatant containing a polypeptide to be
tested. This supernatant can then be used in the Screening Assays described in
Examples 13-20.

25 First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution
15 (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for
a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well
plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each
30 well (note: a 12-channel pipetter may be used with tips on every other channel).
Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered
20 Saline). The PBS should remain in the well until just prior to plating the cells and
plates may be poly-lysine coated in advance for up to two weeks.

35 Plate 293T cells (do not carry cells past P+20) at 2×10^5 cells/well in .5ml
DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine
(12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x
40 Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

25 The next day, mix together in a sterile solution basin: 300 ul Lipofectamine
(18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate.
45 With a small volume multi-channel pipetter, aliquot approximately 2ug of an
expression vector containing a polynucleotide insert, produced by the methods
30 described in Examples 8 or 9, into an appropriately labeled 96-well round bottom
plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I
50 mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45

minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimum I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimum I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37°C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl₂ (anhyd); 0.00130 mg/L CuSO₄·5H₂O; 0.050 mg/L of Fe(NO₃)₃·9H₂O; 0.417 mg/L of FeSO₄·7H₂O; 311.80 mg/L of KCl; 28.64 mg/L of MgCl₂; 48.84 mg/L of MgSO₄; 6995.50 mg/L of NaCl; 2400.0 mg/L of NaHCO₃; 62.50 mg/L of NaH₂PO₄·H₂O; 71.02 mg/L of Na₂HPO₄; 4320 mg/L of ZnSO₄·7H₂O; .002 mg/L of Arachidonic Acid; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitic Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine-H₂O; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL-H₂O; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-H₂O; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2H₂O; 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319

5 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and
0.680 mg/L of Vitamin B₁₂; 25 mM of HEPES Buffer; 2.39 mg/L of Na
10 Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL;
55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of
5 Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin
complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed
15 with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal)
with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L
DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for
20 10 endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end
of the incubation period. Person A aspirates off the transfection media, while person
B adds 1.5ml appropriate media to each well. Incubate at 37°C for 45 or 72 hours
25 depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

15 On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml
deep well plate and the remaining supernatant into a 2ml deep well. The supernatants
from each well can then be used in the assays described in Examples 13-20.

30 It is specifically understood that when activity is obtained in any of the assays
described below using a supernatant, the activity originates from either the
20 polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing
expression of other proteins, which are then secreted into the supernatant. Thus, the
35 invention further provides a method of identifying the protein in the supernatant
characterized by an activity in a particular assay.

40 25 Example 12: Construction of GAS Reporter Construct

One signal transduction pathway involved in the differentiation and
proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the
45 Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-
sensitive responsive element ("ISRE"), located in the promoter of many genes. The
30 binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors
50 called Signal Transducers and Activators of Transcription, or "STATs." There are six

5 members of the STATs family. Stat1 and Stat3 are present in many cell types, as is
10 Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in
many cell types though it has been found in T helper class I, cells after treatment with
15 IL-12. Stat5 was originally called mammary growth factor, but has been found at
higher concentrations in other cells including myeloid cells. It can be activated in
tissue culture cells by many cytokines.

15 The STATs are activated to translocate from the cytoplasm to the nucleus
upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks")
family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2,
20 10 Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are
generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table
25 below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-
51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two
15 groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-
12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b)
30 Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved
cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS
motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

20 Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn
35 activate STATs, which then translocate and bind to GAS elements. This entire
process is encompassed in the Jaks-STATs signal transduction pathway.

40 Therefore, activation of the Jaks-STATs pathway, reflected by the binding of
the GAS or the ISRE element, can be used to indicate proteins involved in the
25 proliferation and differentiation of cells. For example, growth factors and cytokines
are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using
GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway
45 can be identified.

5

10

15

20

25

30

35

40

45

30

50

55

<u>Ligand</u>	<u>JAKs</u>				<u>STATs</u>	<u>GAS(elements) or ISRE</u>
	<u>tyk2</u>	<u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>		
<u>IFN family</u>						
IFN-a/B	+	+	-	-	1,2,3	ISRE
IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
IL-10	+	?	?	-	1,3	
<u>gp130 family</u>						
IL-6 (Pleiotrophic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
IL-11(Pleiotrophic)	?	+	?	?	1,3	
OnM(Pleiotrophic)	?	+	+	?	1,3	
LIF(Pleiotrophic)	?	+	+	?	1,3	
CNTF(Pleiotrophic)	-/+	+	+	?	1,3	
G-CSF(Pleiotrophic)	?	+	?	?	1,3	
IL-12(Pleiotrophic)	+	-	+	+	1,3	
<u>g-C family</u>						
IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
IL-7 (lymphocytes)	-	+	-	+	5	GAS
IL-9 (lymphocytes)	-	+	-	+	5	GAS
IL-13 (lymphocyte)	-	+	?	?	6	GAS
IL-15	?	+	?	+	5	GAS
<u>gp140 family</u>						
IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
IL-5 (myeloid)	-	-	+	-	5	GAS
GM-CSF (myeloid)	-	-	+	-	5	GAS
<u>Growth hormone family</u>						
GH	?	-	+	-	5	

5

PRL	?	+/-	+	-	1,3,5
EPO	?	-	+	-	5

GAS(B-CAS>IRF1=IFP>>Ly6)

10

Receptor Tyrosine Kinases

5	EGF	?	+	+	-	1,3
---	-----	---	---	---	---	-----

GAS (IRF1)

PDGF	?	+	+	-	1,3
------	---	---	---	---	-----

15

CSF-1	?	+	+	-	1,3
-------	---	---	---	---	-----

GAS (not IRF1)

20

25

30

35

40

45

50

55

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

5':GCGCCTCGAGATTTCCCGAAATCTAGATTTCCTCGAAATGATTTCCTCGAAATGATTTCCTCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTGTCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

5':CTCGAGATTTCCCGAAATCTAGATTTCCTCGAAATGATTTCCTCGAAATGATTTCCTCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCGCCCCTAACTCCGCCCAGTTCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

5 The above sequence confirmed synthetic GAS-SV40 promoter element is
subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and
10 XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40
promoter element, to create the GAS-SEAP vector. However, this vector does not
5 contain a neomycin resistance gene, and therefore, is not preferred for mammalian
expression systems.

15 Thus, in order to generate mammalian stable cell lines expressing the GAS-
SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using
SalI and NotI, and inserted into a backbone vector containing the neomycin resistance
20 gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning
site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into
mammalian cells, this vector can then be used as a reporter molecule for GAS binding
as described in Examples 13-14.

25 Other constructs can be made using the above description and replacing GAS
15 with a different promoter sequence. For example, construction of reporter molecules
containing NFK-B and EGR promoter sequences are described in Examples 15 and
16. However, many other promoters can be substituted using the protocols described
30 in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be
substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-
20 2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter
construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell),
35 Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

Example 13: High-Throughput Screening Assay for T-cell Activity.

40 25 The following protocol is used to assess T-cell activity by identifying factors,
such as growth factors and cytokines, that may proliferate or differentiate T-cells. T-
cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12.
45 Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-
STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells
30 (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-
1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

5

10

15

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

20

25

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

30

During the incubation period, count cell concentration, spin down the required number of cells (10^7 per transfection), and resuspend in OPTI-MEM to a final concentration of 10^7 cells/ml. Then add 1ml of 1×10^7 cells in OPTI-MEM to T25 flask and incubate at 37°C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

35

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentamicin, and 1% Pen-Strep. These cells are treated with supernatants containing a polypeptide as produced by the protocol described in Example 11.

40

On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

45

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100,000 cells per well).

50

55

After all the plates have been seeded, 50 μ l of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 μ l samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and stored at -20°C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4°C and serve as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

The above protocol may be used in the generation of both transient, as well as, stable transfected cells, which would be apparent to those of skill in the art.

Example 14: High-Throughput Screening Assay Identifying Myeloid Activity

The following protocol is used to assess myeloid activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate myeloid cells. Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest 2×10^7 U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing

10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM Na₂HPO₄·7H₂O, 1 mM MgCl₂, and 675 uM CaCl₂. Incubate at 37°C for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37°C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

These cells are tested by harvesting 1×10^8 cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of 5×10^5 cells/ml. Plate 200 ul cells per well in the 96-well plate (or 1×10^5 cells/well).

Add 50 ul of the supernatant prepared by the protocol described in Example 11. Incubate at 37°C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.

When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor).

5 The EGR1 gene expression is activated during this treatment. Thus, by stably
transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP
10 reporter, activation of PC12 cells can be assessed.

The EGR/SEAP reporter construct can be assembled by the following
5 protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene
6:867-871 (1991)) can be PCR amplified from human genomic DNA using the
15 following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)

5' GCGAAGCTTCGCGACTCCCGGATCCGCCTC-3' (SEQ ID NO:7)

20 Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified
product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector
using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the
EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1
25 promoter.

15 To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30
dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter
sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and
30 allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker)
20 containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-
inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and
35 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is
done every three to four days. Cells are removed from the plates by scraping and
resuspended with pipetting up and down for more than 15 times.

40 Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine
protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by
growing the cells in 300 ug/ml G418. The G418-free medium is used for routine
45 growth but every one to two months, the cells should be re-grown in 300 ug/ml G418
for couple of passages.

30 To assay for neuronal activity, a 10 cm plate with cells around 70 to 80%
confluent is screened by removing the old medium. Wash the cells once with PBS

(Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as 5×10^5 cells/ml.

Add 200 μ l of the cell suspension to each well of 96-well plate (equivalent to 1×10^5 cells/well). Add 50 μ l supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ μ l of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

Example 16: High-Throughput Screening Assay for T-cell Activity

NF- κ B (Nuclear Factor κ B) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF- κ B regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- κ B appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- κ B is retained in the cytoplasm with I- κ B (Inhibitor κ B). However, upon stimulation, I- κ B is phosphorylated and degraded, causing NF- κ B to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- κ B include IL-2, IL-6, GM-CSF, ICAM-1 and class I MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF- κ B promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF- κ B would be useful in treating diseases. For example, inhibitors of NF- κ B could be used to treat those

diseases related to the acute or chronic activation of NF- κ B, such as rheumatoid arthritis.

To construct a vector containing the NF- κ B promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF- κ B binding site (GGGGACTTTCCC) (SEQ ID NO:8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:
5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCCGGGGACTTTCCCGGGGACTTTCCCGGGGACTTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:
5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene)
Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5':CTCGAGGGGACTTTCCCGGGGACTTTCCCGGGGACTTTCCCGGGGACTTTCCATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATCTCCGCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAAGCTT:3' (SEQ ID NO:10)

Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF- κ B/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF- κ B/SV40/SEAP cassette is removed from the above NF- κ B/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly,

the NF- κ B/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

Once NF- κ B/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

Example 17: Assay for SEAP Activity

As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 μ l of 2.5x dilution buffer into Optiplates containing 35 μ l of a supernatant. Seal the plates with a plastic sealer and incubate at 65°C for 30 min. Separate the Optiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 μ l Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 μ l Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

Reaction Buffer Formulation:

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5

5

336

	13	75	3.75
	14	80	4
	15	85	4.25
10	16	90	4.5
	17	95	4.75
	18	100	5
	19	105	5.25
15	20	110	5.5
	21	115	5.75
	22	120	6
	23	125	6.25
20	24	130	6.5
	25	135	6.75
	26	140	7
	27	145	7.25
25	28	150	7.5
	29	155	7.75
	30	160	8
	31	165	8.25
	32	170	8.5
30	33	175	8.75
	34	180	9
	35	185	9.25
	36	190	9.5
35	37	195	9.75
	38	200	10
	39	205	10.25
	40	210	10.5
40	41	215	10.75
	42	220	11
	43	225	11.25
	44	230	11.5
	45	235	11.75
45	46	240	12
	47	245	12.25
	48	250	12.5
	49	255	12.75
50	50	260	13

55

Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO₂ incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37°C in a CO₂ incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2-5x10⁶ cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37°C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1x10⁶ cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular Ca^{++} concentration.

Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4°C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na₃VO₄, 2 mM Na₄P₂O₇ and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4°C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4°C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg₂⁺ (5mM ATP/50mM MgCl₂), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl₂, 5 mM MnCl₂, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30°C for 2 min. Initiate the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37°C for 20 min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37°C for one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity

As a potential alternative and/or complement to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp. (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1

and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4°C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place

of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive

incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky, D., et al., Science 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton, T.A. and Graham, M.W., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenin deoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson, Cg. et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for

precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson, Cv. et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

5 Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl
phosphate (NPP) substrate solution to each well and incubate 1 hour at room
10 temperature. Measure the reaction by a microtiter plate reader. Prepare a standard
curve, using serial dilutions of a control sample, and plot polypeptide concentration
5 on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale).
Interpolate the concentration of the polypeptide in the sample using the standard
15 curve.

Example 23: Formulating a Polypeptide

20 The secreted polypeptide composition will be formulated and dosed in a
fashion consistent with good medical practice, taking into account the clinical
condition of the individual patient (especially the side effects of treatment with the
secreted polypeptide alone), the site of delivery, the method of administration, the
25 scheduling of administration, and other factors known to practitioners. The "effective
15 amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of
secreted polypeptide administered parenterally per dose will be in the range of about 1
30 $\mu\text{g/kg/day}$ to 10 mg/kg/day of patient body weight, although, as noted above, this will
be subject to therapeutic discretion. More preferably, this dose is at least 0.01
20 mg/kg/day , and most preferably for humans between about 0.01 and 1 mg/kg/day for
the hormone. If given continuously, the secreted polypeptide is typically
35 administered at a dose rate of about 1 $\mu\text{g/kg/hour}$ to about 50 $\mu\text{g/kg/hour}$, either by 1-
4 injections per day or by continuous subcutaneous infusions, for example, using a
mini-pump. An intravenous bag solution may also be employed. The length of
40 25 treatment needed to observe changes and the interval following treatment for
responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions containing the secreted protein of the invention
45 are administered orally, rectally, parenterally, intracisternally, intravaginally,
intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal
30 patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier"
refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or
50 formulation auxiliary of any type. The term "parenteral" as used herein refers to

modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., *Biopolymers* 22:547-556 (1983)), poly (2-hydroxyethyl methacrylate) (R. Langer et al., *J. Biomed. Mater. Res.* 15:167-277 (1981), and R. Langer, *Chem. Tech.* 12:98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D-(-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE 3,218,121; Epstein et al., *Proc. Natl. Acad. Sci. USA* 82:3688-3692 (1985); Hwang et al., *Proc. Natl. Acad. Sci. USA* 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

For parenteral administration, in one embodiment, the secreted polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides.

Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's

5 solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl
oleate are also useful herein, as well as liposomes.

10 The carrier suitably contains minor amounts of additives such as substances
that enhance isotonicity and chemical stability. Such materials are non-toxic to
5 recipients at the dosages and concentrations employed, and include buffers such as
phosphate, citrate, succinate, acetic acid, and other organic acids or their salts;
15 antioxidants such as ascorbic acid; low molecular weight (less than about ten
residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum
albumin, gelatin, or immunoglobulins; hydrophilic polymers such as
20 polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or
arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose
or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar
alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic
25 surfactants such as polysorbates, poloxamers, or PEG.

15 The secreted polypeptide is typically formulated in such vehicles at a
concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of
about 3 to 8. It will be understood that the use of certain of the foregoing excipients,
30 carriers, or stabilizers will result in the formation of polypeptide salts.

Any polypeptide to be used for therapeutic administration can be sterile.
20 Sterility is readily accomplished by filtration through sterile filtration membranes
(e.g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are
35 placed into a container having a sterile access port, for example, an intravenous
solution bag or vial having a stopper pierceable by a hypodermic injection needle.

40 Polypeptides ordinarily will be stored in unit or multi-dose containers, for
25 example, sealed ampoules or vials, as an aqueous solution or as a lyophilized
formulation for reconstitution. As an example of a lyophilized formulation, 10-ml
vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous polypeptide solution,
45 and the resulting mixture is lyophilized. The infusion solution is prepared by
reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

30 The invention also provides a pharmaceutical pack or kit comprising one or
more containers filled with one or more of the ingredients of the pharmaceutical
50 compositions of the invention. Associated with such container(s) can be a notice in

the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

Example 24: Method of Treating Decreased Levels of the Polypeptide

It will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

Example 25: Method of Treating Increased Levels of the Polypeptide

Antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

Example 26: Method of Treatment Using Gene Therapy

5
10
15
20
25
30
35
40
45
50
55

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

5
10
15
20
25
30
35
40
45
50
55

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

Example 27: Method of Treatment Using Gene Therapy - In Vivo

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata H. et al. (1997) Cardiovasc. Res. 35(3):470-479, Chao J et al. (1997) Pharmacol. Res. 35(6):517-522, Wolff J.A. (1997) Neuromuscul. Disord. 7(5):314-318, Schwartz B. et al. (1996) Gene Ther. 3(5):405-411, Tsurumi Y. et al. (1996) Circulation 94(12):3281-3290 (incorporated herein by reference).

The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The

polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) Ann. NY Acad. Sci. 772:126-139 and Abdallah B. et al. (1995) Biol. Cell 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely

5 differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In*
10 *vivo* muscle cells are particularly competent in their ability to take up and express
polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or
5 RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg
body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20
15 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as
the artisan of ordinary skill will appreciate, this dosage will vary according to the
tissue site of injection. The appropriate and effective dosage of nucleic acid sequence
20 can readily be determined by those of ordinary skill in the art and may depend on the
condition being treated and the route of administration. The preferred route of
administration is by the parenteral route of injection into the interstitial space of
tissues. However, other parenteral routes may also be used, such as, inhalation of an
25 aerosol formulation particularly for delivery to lungs or bronchial tissues; throat or
15 mucous membranes of the nose. In addition, naked polynucleotide constructs can be
delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is
30 determined as follows. Suitable template DNA for production of mRNA coding for
polypeptide of the present invention is prepared in accordance with a standard
20 recombinant DNA methodology. The template DNA, which may be either circular or
linear, is either used as naked DNA or complexed with liposomes. The quadriceps
35 muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by
intrapitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on
40 25 the anterior thigh, and the quadriceps muscle is directly visualized. The template
DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over
one minute, approximately 0.5 cm from the distal insertion site of the muscle into the
45 knee and about 0.2 cm deep. A suture is placed over the injection site for future
localization, and the skin is closed with stainless steel clips.

30 After an appropriate incubation time (e.g., 7 days) muscle extracts are
prepared by excising the entire quadriceps. Every fifth 15 μ m cross-section of the
50 individual quadriceps muscles is histochemically stained for protein expression. A

time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be used to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

Example 28: Transgenic Animals.

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, *e.g.*, baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (*i.e.*, polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, *e.g.*, Ulmer et al., Science 259:1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse

transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Example 29: Knock-Out Animals.

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (*E.g.*, see Smithies et al., *Nature* 317:230-234 (1985); Thomas & Capecchi, *Cell* 51:503-512 (1987); Thompson et al., *Cell* 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in

the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (e.g., see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e.g., knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e.g., in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and

5

Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

10

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

15

20

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

25

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

30

The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties.

35

40

25

45

50

55

Applicant's or agent's file reference number	PZ031PCT	International application No.	Unassigned
---	----------	-------------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>259</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>July 27, 1998</u>	Accession Number <u>203070</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application Authorized officer <u>Yvette E. Simms</u> PCT International Division	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on: Authorized officer

Applicant's or agent's file reference number	PZ031PCT	International application No.	Unassigned
---	----------	-------------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)


A. The indications made below relate to the microorganism referred to in the description on page <u>260</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit July 27, 1998	Accession Number 203069
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application Authorized officer Yvonne E. Simms PCT International Division	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on: Authorized officer

Applicant's or agent's file reference number	PZ031 PCT	International application No.	Unassigned
--	-----------	-------------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>253</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit July 27, 1998	Accession Number 203071
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application
Authorized officer  Yvette E. Simms PCT International Division

<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on:
Authorized officer

5

Applicant's or agent's file reference number	PZ031PCT	International application No.	Unassigned
--	----------	-------------------------------	------------

10

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

15

A. The indications made below relate to the microorganism referred to in the description on page <u>249</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>June 26, 1998</u>	Accession Number <u>203027</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	


30

35

40

45

50

<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on:
Authorized officer  Yvette E. Starns PCT International Division	Authorized officer

55

Applicant's or agent's file reference number	PZ031PCT	International application No.	Unassigned
--	----------	-------------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>243</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>June 11, 1998</u>	Accession Number <u>209965</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application Authorized officer <u>Yvette E. Simms</u> PCT International Division	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on: Authorized officer

Claims

5

10

15

20

25

30

35

40

45

50

55

5

What Is Claimed Is:

10

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

15

(a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

20

(b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

25

(c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

30

(d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

35

(e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X, having biological activity;

40

(f) a polynucleotide which is a variant of SEQ ID NO:X;

(g) a polynucleotide which is an allelic variant of SEQ ID NO:X;

(h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;

45

(i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

50

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.

55

5

10

15

20

25

30

35

40

45

50

55

3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.

9. A recombinant host cell produced by the method of claim 8.

10. The recombinant host cell of claim 9 comprising vector sequences.

11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

5

(a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

10

(b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;

(c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

15

(d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

20

(f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(g) a variant of SEQ ID NO:Y;

25

(h) an allelic variant of SEQ ID NO:Y; or

(i) a species homologue of the SEQ ID NO:Y.

30

12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

35

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

40

14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

45

15. A method of making an isolated polypeptide comprising:

(a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and

(b) recovering said polypeptide.

50

16. The polypeptide produced by claim 15.

55

5

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.

10

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

15

(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

20

19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

25

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

30

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

35

(a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.

40

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

22. A method of identifying an activity in a biological assay, wherein the method comprises:

45

(a) expressing SEQ ID NO:X in a cell;

(b) isolating the supernatant;

(c) detecting an activity in a biological assay; and

50

(d) identifying the protein in the supernatant having the activity.

55

5

23. The product produced by the method of claim 20.

10

15

20

25

30

35

40

45

50

55

<110> Human Genome Sciences, Inc.
<120> 98 Human Secreted Proteins
<130> PZ031.PCT
<140> Unassigned
<141> 1999-07-28
<150> 60/094,657
<151> 1998-07-30
<150> 60/095,486
<151> 1998-08-05
<150> 60/095,455
<151> 1998-08-06
<150> 60/095,454
<151> 1998-08-06
<150> 60/096,319
<151> 1998-08-12
<160> 364
<170> PatentIn Ver. 2.0

<210> 1
<211> 733
<212> DNA
<213> Homo sapiens.

<400> 1
gggatccgga gccc aaatct tctgacaaaa ctcacacatg cccaccgtgc ccagcacctg 60
aattcgaggg tgcaccgtca gtcttctctt tcccccaaa acccaaggac accctcatga 120
tctcccgga ccttgaggtc acatgcgtgg tggtaggacgt aagccacgaa gaccctgagg 180
tcaagttaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg 240
aggagcagta caacagcacg taccgtgtgg tcagcgtctt caccgtcttg caccaggact 300
ggctgaatgg caaggagtac aagtgcagg tctccaacaa agccctccca acccccatcg 360
agaaaaaccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc 420
catcccgga tgagctgacc aagaaccagg tcagcctgac ctgcctggtc aaaggcttct 480
atccaagcga catgcctgtg gaggggaga gcaatgggca gccggagaac aactacaaga 540
ccaagcctcc cgtgctggac tccgacgct ccttcttctt ctacagcaag ctaccgtgg 600
acaagagcag gtggcagcag gggaaagctt tctcatgctc cgtgatgcat gaggctctgc 660
acaaccacta cagcagaag agcctctccc tgtctccggg taaatgagtg cgacggccgc 720
gactctagag gat 733

<210> 2
<211> 5
<212> PRT
<213> Homo sapiens

<220>
<221> Site
<222> (3)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 2

Trp Ser Xaa Trp Ser
1 5

<210> 3

<211> 86

<212> DNA

<213> Homo sapiens

<400> 3

gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60
cccgaaatat ctgccatctc aattag 86

<210> 4

<211> 27

<212> DNA

<213> Homo sapiens

<400> 4

gcggcaagct ttttgcaaag cctaggc 27

<210> 5

<211> 271

<212> DNA

<213> Homo sapiens

<400> 5

ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60
aaatatctgc catctcaatt agtcagcaac catagtcccc cccctaactc cgcccatccc 120
gccctaact ccgcccagtt ccgcccattc tccgcccatt ggctgactaa ttttttttat 180
ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtaqt qaggaggctt 240
ttttggaggc ctaggctttt gcaaaaagct t 271

<210> 6

<211> 32

<212> DNA

<213> Homo sapiens

<400> 6

gcgctcgagg gatgacagcg atagaacccc gg 32

<210> 7

<211> 31

<212> DNA

<213> Homo sapiens

<400> 7

gcgaagcttc gcgactcccc ggatccgcct c 31

<210> 8

<211> 12

<212> DNA

<213> Homo sapiens

<400> 8

ggggactttc cc

12

<210> 9

<211> 73

<212> DNA

<213> Homo sapiens

<400> 9

gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg
ccatctcaat tag

60

73

<210> 10

<211> 256

<212> DNA

<213> Homo sapiens

<400> 10

ctcgagggga	ctttcccgga	gactttccgg	ggactttccg	ggactttcca	tttgccatct	60
caattagtc	gcaaccatag	tcccgccctt	aactccgccc	atcccgcccc	taactccgcc	120
cagttccgcc	catttcccg	cccatggctg	actaattttt	tttatttatg	cagaggccga	180
ggccgcctcg	gcctctgagc	tattccagaa	gtagtgagga	ggcttttttg	gaggccctagg	240
ctttgcaaa	aagctt					256

<210> 11

<211> 1564

<212> DNA

<213> Homo sapiens

<400> 11

gcggacgggtg	ggctgtgcaa	ccttccctcc	tttcttaaat	gcttggggca	tttgtctggc	60
cttccctttt	actgctggct	gctgctgca	tctgtctctt	aaccttcatt	aactgtgcct	120
atgtcaaatg	gggaaccctg	gtacaagata	ttttcaccta	tgctaaagta	ttggcactga	180
tcgcggtcat	cgttgccaggc	attgttagac	ttggccaggg	agcctctact	cattttgaga	240
attcccttga	gggttccatca	tttgcagtg	gtgacattgc	cctggcactg	tactcagctc	300
tgttctccta	ctcaggctgg	gacaccctca	actatgtcac	tgaagagatc	aagaatccctg	360
agaggaaacct	gccccctctcc	attggcatct	ccatgcccct	tgtaaccatc	atctatatcc	420
tgaccaatgt	ggcctattat	actgtgctag	acatgagaga	catcttgccc	agtgtatgctg	480
ttgctgtgac	ttttgcagat	cagatatttg	gaatatatta	ctggataatt	ccactgtcag	540
ttgcattatc	ctgttttggt	ggcctcaatg	cctccattgt	ggctgtctct	aggtttttct	600
ttgtgggctc	aagagaaggc	catctccctg	atgccatctg	catgatccat	gttgagcggg	660
tcacaccagt	gccttctctg	ctcttcaatg	gtatcatggc	attgatctac	ttgcgcgtgg	720
aagacatctt	ccagctcatt	aactactaca	gcttcagcta	ctgggtctctt	gtggggcttt	780
ctattgtggg	tcagctttat	ctgcgctgga	aggagcctga	tcgacctcgt	ccctcaagc	840
tcagcgtttt	cttcccgatt	gtcttctgcc	tctgcaacct	cttccctggg	gctgttccac	900
tttacagtga	tactatcaac	tccctcatcg	gcattgccat	tgccctctca	ggcctgccct	960
tttacttctt	catcatcaga	gtgccagaac	ataagcgacc	gctttacctc	cgaagatcgt	1020
ggggtctgcc	acaaggtaacc	tccaggtcct	gtgtatgtca	gttgctgcag	aaatggattt	1080
ggaagatgga	ggagagatgc	ccaagcaacg	ggatcccaag	tctaactaaa	caccatctgg	1140
aatcctgatg	tggaaagcag	gggtttctgg	tctactggct	agagctaagg	aagttgaaaa	1200
ggaaagctca	cttcttttga	ggcacctgtc	cagaagccctg	gcctaggccag	cttcaacctt	1260
tgaacttact	ttttgaaatg	aaaagtaatt	tatttgtttt	gctacatact	gttccagact	1320
tttaaaagg	acaatgaagg	tgactgtggg	gaggagcatg	tcagggtttg	gcttgggttg	1380
tttagaagca	cctgggtgtg	cctacctact	cctcttttct	tttaaaagg	cccacaatgc	1440

tccaattttcc tgtctccttt agagagacat gaaactatca cagggtgctgg atgacaataa 1500
aagtttatgt tcttaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaggggcggc 1560
cccg 1564

<210> 12
<211> 1757
<212> DNA
<213> Homo sapiens

<400> 12
ggcacgaggt agatgggttt ttgggtgtgga tgtcctttct gtttgttagt tgtcctttcta 60
acagacagga cctcagctg caggctctgtt ggagtaccct gcaatgtgag gtgtcagtggt 120
gcccctgctg gaggtgtcct ccaggttagg ctgctcgcgg gtcagggggc agggaccacac 180
ttgaggaggc agtctgcccc ttctcagatc tccagctgca tgcctgggaga accactgctc 240
tcttcaaaagc tgtcagacag ggacatttaa gtctgcagag gttactgctg tctttttgtt 300
tgtctgtgcc ctgccccagc aggtggagcc tacagaggca ggcaggcctc cttgagctgt 360
ggtgggtccc acccagttcg agcttccccg ctgctttgtt tacctaagca agcctgggca 420
atggcgggcg cccctcccc agtctcgtg ccgcttgca gtttgatctc agactgctgt 480
gctagcaatc agcgagactc cctggggtag gaccctctga gccagggtgg ggatataatc 540
ttgtgtgtcg ccatttttta agcccgctcg aaaagcgcag tattcaggtg ggagtgaacc 600
gatttttccc attttccagg tgcgctcgt catcccttc ttgtattag aaagggaaact 660
ccctgacccc ttgcgcttcc cgagtggagc aatgccttgc gctgctttgg ctgctgcatg 720
gtgcgtgcac ccactgacct gcgcccactg tctggcactc cctagttaga tgaacccggt 780
acctcagatg gaaatgcaga aatcacccgt cttctgcgtt gctcaggctg ggagctgtag 840
accagagctg ttctatttcc gccattcttg ctctcccc accccccgcc caatccctaag 900
tttatctctt aacaaagtaa atactgcaca cgtatttaca tgttttaaaa tattgtttat 960
ggagcactta ctatgtgttt tacggtccaa gtactttata ttattcactg actctttata 1020
gcaactctat aacatattaa tagattgtct caatttcaat gatgacaaaa ctggcagctt 1080
agtaactaat gagtaacaat accagccctt aaaacctagg gtctttccac tacagcacac 1140
tctgactgac attgccttgg ttccagacaca gcactcttca cctagaaaag gatggagagc 1200
tagaaaagtg ttttcttttt caagttgttc ccattcatca atattctatc aagatattatg 1260
gaagagttat tttctaggtc ttccagaagg gctgcagac acttgggaat tcaaaataat 1320
tactccagag ggaatgtgg gcatagaaac tttttaaaaa ctgaatttcc ccgatctaata 1380
atcggtcttc acatcacagta tattatttct taaaaatcag ccagaaatgc acctgcagtt 1440
ttatctactg gatttttctt tcccagcccc attctctctt aagtagtttt ttttcccat 1500
tttataaaaag aaaagcatac ctcccaccta tagcttccct ccttatggta tattatctca 1560
ggggataatt tgaatatatt cttagacac aattctcatt aagaaataaa ctttcagggt 1620
gggtgcagtg gctcacactt gtaatcccag aactttggga ggccaaggcg ggggaggatc 1680
cctgaaggcc aagagttcaa gaccagcctg gaatatatac caagatcccc tctccacaaa 1740
aaaaaaaaa aaaaaaa 1757

<210> 13
<211> 1373
<212> DNA
<213> Homo sapiens

<400> 13
gtgaaatgaa atatgtatc caaaacacat aaatttaagt tttataattt tctttccttg 60
tggatctgga aaattttctt tctgctgttt ttcattctga tagttgcttt ggtttccct 120
attccctgcc tttccatatt ttgaaatgtt ttgggtcaaat ttttctctgt tgagtgtgca 180
gtatgttttg attgttaatt ttattgacca tcatctcagt ggattattta ttgaaactt 240
ttctgtttcc tgttctggaa tgtttcctgc tctggaagcc atattttaac tgtatactga 300
tccagcttta ttatcttaa gtatttttac aattatttta ctgataatat ataactagg 360
ataatcactc tagtcagtga aatcaaacgt ataacacaaa atgatgctgc tagcaaat 420
agcctgaaaa ggtcagagc aagcatttt tagtctaagt agtcaagatc aataaactta 480
gaatgagagt tttgtattat ttgacctgt gatagaagga aaaagtacag ttattgaatc 540
tgtatattaa tttatgcaaa atacacacat tatctttcca ttaacacagt agtatgacat 600

acagttttat	caccactgga	ttcatgtatg	cttaaaatga	aaatgaaagg	aacacacagg	660
aaagtagctt	cttatcttcc	cagatacagc	ctccaagagt	gcctctgctg	tgtactggag	720
tgagtttgaa	gaagttcagg	taatcctctc	ctaaccagca	gcttaactta	aagtgcatct	780
tcatttttgt	cctaccacta	aaagcttgct	tattgacctc	cttctttcct	gtctcctaaa	840
ttgtgactgg	ctctcagtta	gacttgcatc	tggtgctatt	tgtagcagca	attgcaggat	900
tcatttgctt	ttctctctgc	agtgtatttc	tgaatgtttt	ataactctgg	gtatgcataa	960
tgtacgtata	tgcataacca	tatggtcaag	agttttcaga	attctttgtt	tgaataatga	1020
atgtgtgtat	tcctaccccc	ttgttttgct	ctgtcttaac	atttaagctt	tgcttattaa	1080
aatgtatttg	ttttaatgct	ttctctttag	attgtaagct	cttcatgggc	agtggtcaga	1140
tattctgtat	ttgtaacttc	ccgagaatct	agtattttat	catgtacata	atgaacatag	1200
aattagtattg	attggaagga	cagtgaaagta	caaaatgaga	ttctaaaatg	acattttcat	1260
tagggctcac	aagtgataaa	gaagtatccc	ttctctattt	ttttgtttaa	tactttagaa	1320
gctattacat	taaaaaagct	attctcatta	aaaaaaaaaa	aaaaaaaaaa	aaa	1373

<210> 14
 <211> 3740
 <212> DNA
 <213> Homo sapiens

 <220>
 <221> SITE
 <222> (957)
 <223> n equals a,t,g, or c

<400> 14						
actctctaag	gcttttttgg	actcaccaaa	caggcttctt	gcagtggaga	tgaatacaga	60
tcacttaagg	ttgactgtgc	caaatggcat	aggggccctg	aagctaaggg	aaatggaaaca	120
ctacttctca	cagggcctgt	cagttcagct	gtttaatgat	gggtccaagg	gcaaaactcaa	180
tcatttatgt	ggagctgact	ttgtgaaaag	tcatacagaaa	cctccacagg	gaatggaaat	240
taagccaat	gaaagatgct	gttcttttga	tggagatgca	gacagaattg	tttattacta	300
ccatgatgca	gatggccact	ttcatctcat	agatggagac	aagatagcaa	cgtaacttag	360
cagtttctct	aaagagctcc	tggtggagat	tggagaaaag	ttgaatatgt	gtgttgtaca	420
aactgcatac	gcaaatggaa	gttcaacacg	gtatcttgaa	gaagttatga	aggtacctgt	480
ctattgcact	aagactgggt	taaaacattt	gcaccacaag	gctcaagagt	ttgacattgg	540
agttttattt	gaagcaaatg	ggcatggcac	tgcactgttt	agtacagctg	ttgaaatgaa	600
gataaaacaa	tcagcagaa	aactggaaag	taagaaaaga	aaagctgcta	agatgcttga	660
aaacattatt	gacttggtta	accaggcagc	tggtgatgct	atttctgaca	tgctggtgat	720
tgaagcaatc	ttggctctga	agggcttgac	tgtacaacag	tgggatgctc	tctatacaga	780
tccttccaa	agacaactta	aagttcaggt	tgcagacagg	agagtattta	gcactaccra	840
tgctgaaaga	caagcagtta	cacccccagg	attacaggag	gcaatcaatg	acctgggtga	900
gaagtacaag	ctttctcgag	cttttgtccg	gcctctgggt	acagaagatg	tcgtccngag	960
tatatgcaga	agcagactca	caagaaagtg	cagatcacct	tgacatgaa	gtgagcttgg	1020
cagttattca	gctgggtgga	ggaattggag	aaaggcccca	accagggttc	tgaagataat	1080
tttcatattc	ctgagaaact	ggacttttta	caagtcttta	caaaactgtc	aataataatg	1140
gcagtactaa	gagatttata	atcataatgt	ttacaatgca	gcctactgga	ttgtctctag	1200
atctgttttt	cttaaacact	aacagaataa	ttctttataa	ataggttaagc	cttacacttg	1260
tttaagaaat	ttacctctaa	tttcagcttc	actaatgtaa	aatactggga	cttaagtata	1320
caattcagtc	actaactgta	cagtttttatg	tggggaacaa	ttcatgcagg	ctactggaaa	1380
attaaatctt	attaccaact	ccttgtgata	tctttgccat	caccatcaca	tgagcaagat	1440
gatgttttgc	agcattcccc	attgctgata	caaatggaga	gggcagagaa	gactttatatac	1500
aaccagtttt	tcatttcag	agtcttaaga	aagattatta	gatgacttac	ctatatgact	1560
aatgccatca	ggaactcaga	ggtatgaata	gggggttgtc	catccctctt	ccatactgag	1620
gtggagatgc	tcatgcaata	cttttaagga	tgcattggtcc	agccttcagt	tattcttcac	1680
tgctcttggt	gaaggtatgt	gggagaaaaa	ctaattataa	tacgtttccc	agcctctgat	1740
ggagaaggaa	caccattctg	ataccagaac	atggtttaata	aggaaaagag	aaaaatcccc	1800
aaccaatctt	aattgaacca	agtctgaaac	caatggaaaa	aaaaaatggg	tagtgtatat	1860
tttgcaggtt	taagacaact	caggacaata	aaaacaaagg	actttacatg	tgtatatata	1920
tagctctctt	aggcaccata	atcagtatga	gccaaacata	tttaaaacttg	attcaggcca	1980

cattcagaca	tttgctctta	tatacaata	tttaaattaa	atacaatctg	aaatgtgttc	2040
tgttacatac	aaaaaaggaa	aaactatata	acgcagagca	gtgtgtgtgt	tttaataaat	2100
tacattttaca	tgtaagctaa	atggaaccag	caatgggtgt	caagttttta	tcaccccttc	2160
cagaaaaatct	ttttctacca	tctcttctat	tttttgcttg	gctttgtctg	aacatggttt	2220
gtggttctcc	agtttcatgt	ccttattagg	gaaggcattt	gagtagagga	taggactccc	2280
tgagtgctct	ccacatcggc	ttgtgacttt	gctgttgaag	acttgactga	gcacattgaa	2340
gaacggcagg	agctgctcca	tactgcgcac	ggtgcagatg	gtgagcagca	agtgccttgg	2400
ctcccaaccc	aatgttctcc	ctgagtttgc	ttcctctgga	ttttcttgca	gaaaacaaaa	2460
agtgaactgg	tattaatata	acagacaatg	tggtatgtta	gaaaaattaa	aaatatataa	2520
actttggcaa	ttggtcaaga	aatgaatata	aatgacatta	agtttctaac	tcctgacctg	2580
atcaaaaaccc	ttggtgcttc	tgagaccttt	tactgccatt	tattagtttt	acatggagca	2640
gtctaacatt	gtagttaata	ttcccaacta	gaatgcgcag	ataagcttag	ttacacagaa	2700
tagctttgaa	caggaataga	gtcaaacata	aaagttttat	gttggtgctt	gtattttactc	2760
aaaaagctcc	caggtttctg	aaacctcact	actgtaacca	aggactaggt	cacaaaatta	2820
ctacagaaaa	aaggaaacaaa	gtgctttata	catttcataa	tatatccctc	tttattataa	2880
ttagttaatt	cccctttatc	taaatggcct	aaatttgcca	tgatggtagc	agtgcccaaa	2940
gtgataaatt	actgtcagta	ctgcatcaca	gagaaaggaa	gggatccctc	aggagacact	3000
gctgtctcct	tctgggttgt	gctaacaac	atagggagga	aagctggacc	tggagtcaaa	3060
ggaatttgat	tagtgtgtctg	gctctgccat	acttacggca	cccttgggca	ggatatacaa	3120
aggttctcca	cttataaaaat	gqacagctct	aaaactacct	tttagtagag	aggtcaaatg	3180
agaaggtatg	tgaaaaactct	gtcaactaaa	tataaagact	aataatttgg	gtattaagag	3240
gctagtttga	gaagccacct	gaattacaca	aacacagcta	cagacatcat	tctgtctaga	3300
gaaagataag	agagaacagg	ttggttgaac	ttgggcagaa	tcacagatac	aattccacac	3360
caaagaatga	aaataagcaa	tgaactagac	agaaggagaa	aatcatgaag	acttaggaag	3420
cagaattaca	atctgtcata	ttacaaaatg	gagtttgctt	tctaagatca	gatgttgctc	3480
agaaaacttc	attgtttacc	taataattta	atatcactag	tttcttagtg	ggccaagcag	3540
atgcaaaatc	cagcttattt	tcttctatgt	gctctcaagc	ttattgctta	ttttaaagta	3600
aaatcctgaa	aaaggaaaat	attaggttgg	tgcaaacgta	attggcggtt	ttgcatgttt	3660
gaaatttgcc	gttttatatt	ggagtacatt	cttaataaaa	tgtgggttatg	ttatacaaaa	3720
aaaaaaaaaa	aaaactcgag					3740

<210> 15
 <211> 1196
 <212> DNA
 <213> Homo sapiens

<400> 15						
ccacgcgtcc	ggtgaatctg	gatgatctat	ttatgtcaat	tatctatgtg	tctcttctta	60
tgccagttacc	ccactgtctt	gattattgtg	gctttatggt	gtcttgaaat	taagtattgt	120
taagctttgc	aatcttttcc	aagattgttt	tggtatagg	tcctttcttt	ataaagttta	180
tattaagctt	ctccattttt	ctttaagaaa	aaatctgctg	gaatggcact	gaatttttag	240
gtcgatttgg	gaagaattga	caataatgaa	cctttcaatc	gatggacatg	gtatgtttct	300
gcattttatt	gggcctttta	aaatttatct	cagcaatatt	ttgtagtttt	agtgagaag	360
tcttgatat	atcttttggt	aaatgtattc	ctaaatattt	tgtggaaatg	ttactgtaaa	420
tagtacttta	atttcaattt	taagtttatt	gctggtatcc	agaaatatgt	ttattttttg	480
taatatggac	tttttatatt	tgtaattcta	tttaaatcca	cttagttcag	tagtagttct	540
tatttttatt	ttattgcaag	tgcccttagg	ataccttgtg	tacacaatcc	atgtcatata	600
tgaataacca	acaggtttac	cttttgtttc	ttcttgcctt	gtcgtaatgg	ctaggacctt	660
ccaacctaaa	tgggtqaata	gaagcgggtg	gtgagtttat	tactcttgte	ttattctcaa	720
cagcagagga	tagegtctag	tttttcaact	ttaaaatatg	ttagctatag	gtttttcccg	780
tttcatgctt	ttatcagatt	gaagatccct	tttattctta	ttttgccaa	agtgatcatg	840
atgcattgtg	aatttcacca	agtacttttt	cctgcatctg	tgagagaaat	cttgactttt	900
ctcttttatt	ttgttaattg	agattcttta	atgttaaaat	gatcttgcac	tcttgatata	960
aaccatactt	agtcattgata	tgttatcccc	tttatataat	gctggattcg	gtttgcaaat	1020
attttgtttg	atttttgcac	ctatgctcat	gagacagatt	ggctctgtgat	tttctttctt	1080
tgttaagtctt	gtcagggtgc	agggcttggt	taattttgac	acattttacaa	acatatattt	1140
ttaagataaa	aataaacttc	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaa	1196

<210> 16
<211> 2209
<212> DNA
<213> Homo sapiens

<400> 16
gagctgccc gggcttgggc gctggggccc gccgctcccc accgtcggtt tccccaccga 60
ggccgaggcg tcccggagtc atggccggcc tgaactgcgg ggtctctatc gcaactgctag 120
gggttctgct gctgggtgcg gcgcgcctgc cgcgcggggc agaagctttt gaagtgtctc 180
tgccacgaga aagcaacatt acagttctca taaagctggg gaccccgact ctgctggcaa 240
aacctgttta catcgteatt tctaaaagac atataacatc gttgtccatc aagtctggag 300
aaagaatagt ctttaccctt agctgccaga gtccctgagaa tcaactttgtc atagagatcc 360
agaaaaatat tgactgtatg tcaggcccat gtcccttttg ggaggttcag ctccagccct 420
cgacatcggt gttgcctacc ctcaacagaa ctttcatctg ggatgtcaaa gctcataaga 480
gcatcggttt agagctgcag ttttccatcc ctgcctcagc gcagatcggt ccggg-gaga 540
gctgcccaga cggagtcact cactccatca gccgcggaat cgatgccacc gtggtcagga 600
ttggaacctt ctgcagcaat ggcactgtgt cccggatcaa gatgcawgaa ggagtgaana 660
tggccttaca cctcccatgg ttccacccca gaaatgtctc cggcttcagc attgcaaac 720
gctcatctat aaaacgtctg tgcatactcg aqctctgtgt tgagggtgaa ggtcagcaa 780
ccctgatgtc tgccaactac ccagaaggct tccctgagga tgagctcatg acgtggcagt 840
ttgtcgttcc tgcacacctg cgggccagcg tctccttctt caacttcaac ctctccaact 900
gtraggagaa ggaggagcgg gttgaatact acatcccggg ctccaccacc aaccccgagg 960
tgttcaagct ggaggacaag cagcctggga acatggcggg gaacttcaac ctctctctgc 1020
aaggctgtga ccaagatgcc caaagtcag ggatcctccg gctgcagttc caagttttgg 1080
tccaacatcc acaaaatgaa agcaataaaa tctacgtggt tgacttgagt aatgagcgag 1140
ccatgtcact caccatcgag ccacggcccg tcaaacagag ccgcaagttt gtccctggct 1200
gttctgtgtg tctagaatct cggacctgca gtacgaacct caccctgaca tctggctcca 1260
aacacaaaat ctctctctct tgtgatgatc tgacacgtct gtggatgaat gtggaaaaam 1320
ccataagytg cacagaccac cggactgtcc aaaggaaatc ctactcaety cagggtgcca 1380
gtgacatcc ycamctgcct gtggagctgc atgacttctc ctggaagctg ctggtgcca 1440
aggacaggct cagcctgggt ctgggtgccag cccagaagct gcagcagcat acacacgaga 1500
agccctgcaa caccagcttc agctacctcg tggccagtgc cataccagc caggacctgt 1560
acttcggctc ctctctgccc ggaggctcta tcaagcagat ccaggtgaag cagaacatct 1620
cggtgacctt tcgacacctt gcccccagct tccgacaaqa ggcctccagg cagggtctga 1680
cgggtgctct tataccttat ttcaaaagg aaggcgtttt cagcgtgacc cctgacacaa 1740
aaagcaaggt ctacc:gagg acccccaact gggaccgggg cctgccatcc ctccactctg 1800
tgtcctggaa catcagcgtg cccagagacc aggtggcctg cctgacttct ttaaggagc 1860
ggagcggcgt ggtctgccag acaggggcgg cattcatgat catccaggag cagcggacc 1920
gggctgagga gatcttcagc ctggacgagg atgtgtctcc caagccaagc ttccaccatc 1980
acagcttctg ggtcaacatc tytaaytgma gcccacagag cggcaagcag ctgacctgc 2040
tcttctcggt gacacttacc ccaaggactg tggacttgac tgtcatctcc atcgacgag 2100
tgggaggtgg agtcttactg ctgtctgccc tccgggtcat catttgcgtg gtgaaaaaa 2160
aaaaaarama aacaaggggc cccgctgtgg gtatctacaa tggcaacat 2209

<210> 17
<211> 1774
<212> DNA
<213> Homo sapiens

<400> 17
taggcacccc aggtctttac actttatggt ccggttcgta tgttgtgtga attgtaaccg 60
gataccaatt tcacacaagg aaccagctta tgaccatgat tacgccaagc tcgaaattaa 120
ccctcactaa aggaacaaa agctggagct ccaccgcgtt ggcggccgct ctagaactag 180
tggatccccc gsgctgcagg aattcgccac gagcggctgc gggcgcgagg tgaggggcgc 240
gaggttccca gcaggatgcc ccgctctgac aggaagctga agtgagagc ccggagaggg 300
cccagccgc ccggggcagg atgaccaagg cccgctgtt ccggtgtggt ctggtgtctg 360
ggtcgggtgt catgatctct ctgatcatcg tgtactggga cagcgcagcc gccgcgact 420

tctacttgca	cacgtccttc	tctaggccgc	acacggggcc	gccgtgccc	acgcccgggc	480
cggacagga	cagggagctc	acggccgact	ccgatgtcga	cgagtttctg	gacaaagtctc	540
tcagtgtctg	cgtgaagcag	agtgaccttc	ccagaaagga	gacggagcag	ccgcctgcgc	600
cggggagcat	ggaggagaac	gtgagaggct	acgactggtc	cccgcgcgac	gcccggcgca	660
gcccagacca	gggcccgcag	caggccggagc	ggaggagcgt	gctgcggggc	ttctgcgcca	720
actccagcct	ggccttcccc	accaaggagc	gcgcattcga	cgacatcccc	aactcggagc	780
tgagccacct	gacgtgggac	gaccggcacg	gggccatcta	ctgctacgtg	cccaagggtg	840
cctgcaccaa	ctggaagcgc	gtgatgatcg	tgctgagcgg	aagcctgctg	caccgcggtg	900
cgccctaccg	cgacccgctg	cgcatcccg	gcgagcacgt	gcacaacgcc	agcgcgccac	960
tgaccttcaa	caagtctctg	cgccgctacg	ggaagctctc	ccgccacctc	atgaagggtca	1020
agctcaagaa	gtacaccaag	ttcctcttcg	tgccgcgacc	cttcgtgcgc	ctgatctccg	1080
ccttccgcag	caagtctcag	ctggagaacg	aggagtctta	ccgcaagttc	gccgtgcccc	1140
tgctcgggct	gtacgccaac	cacaccagcc	tgcccgccctc	ggcgcgcgag	gcttctccgcg	1200
ctggcctcaa	ggtgtccttc	gccaaattca	tccagtacct	gctggaccgc	cacacggaga	1260
agctggcgcc	cttcaacgag	cactggcggc	agggtgtacc	cctctgccac	ccgtgccaga	1320
tcgactacga	cttcgtgggg	aagctggaga	ctctggacga	ggacgcccgc	cagctgctgc	1380
agctactcca	ggtggaccgg	cagctccgct	tccccccgag	ctaccggaac	aggaccgcca	1440
gcagctggga	ggaggactgg	ttcgccaaga	tccccctggc	ctggaggcag	cagctgtata	1500
aactctacga	ggccgacttt	gttctcttcg	gctaccccaa	gcccgaatac	ctcctccgag	1560
actgaaagct	ttcgcgttgc	tttttctcgc	gtgcctggaa	cctgacgcac	gcgcactcca	1620
gtttttttat	gacctacgat	tttgcaatct	gggtctcttg	ttcactccac	tgccctctatc	1680
cattgagtac	tgtatcgata	ttgtttttta	agattaatat	atttcaggta	tttaatacga	1740
aaaaaaaaaa	aaaaaacctc	gagggggggc	ccgg			1774

<210> 18

<211> 1674

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (1649)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1663)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1665)

<223> n equals a,t,g, or c

<400> 18

caagttggta	cgccgcagg	taccggctcg	gaattcccg	gtgacccac	gcgtccggtc	60
gaagataggt	tcgagacggt	ggaatgttga	gctgacatg	cagttgggtt	cggtgctgct	120
cacacgctgc	cccttttggg	gctgcttcag	ccagctcatg	ctgtacgctg	agagggtctga	180
ggcacgccc	aagcccagca	tcccagtgcc	ttacctgtat	ttcgacatgg	gggcagccgt	240
gctgtgcgct	agtttcatgt	cctttggcgt	gaagcggcgc	tggttcgcgc	tgggggccgc	300
actccaattg	gccattagca	cctacgcgc	ctacatcggg	ggctacgtcc	actacgggga	360
ctggctgaag	gtccgtatgt	actcgcgcac	agttgccatc	atcgccggct	ttcttgtgtt	420
ggccagcggt	gctggggagc	tgtaccgcgc	gaaacctcgc	agccgctccc	tgacgtccac	480
cgccaggtg	ttcctgggta	tctacctcat	ctgtgtggcc	tactcactgc	agcacagcaa	540
ggaggaccgg	ctggcgatc	tgaacctctc	cccaggagg	gagctgatga	tccagctgtt	600
cttcgtgctg	tatggcatcc	tgccctgggc	ctttctgtca	ggctactacg	tgaccctcgc	660
tgccagatc	ctggctgtac	tgctgcccc	tgctatgctg	ctcattgatg	gcaatgttgc	720
ttactggcac	aacacgcggc	gtgttgagtt	ctggaaccag	atgaagctcc	ttggagagag	780

tgtgggcatt	ttcggaactg	ctgtcatcct	ggccactgat	ggctgagttt	tatggcaaga	840
ggctgagatg	ggcacaggga	gccactgagg	gtcacccctgc	cttccctcctt	gctggcccag	900
ctgctgttta	tttatgcttt	tcggctctgtt	tgcttgatct	tttgcttttt	taaaattgtt	960
ttttgcagtt	aagaggcagc	tcatttctcc	aaatttctgg	gctcagcgct	tgggagggca	1020
ggagccctgg	cactaatgct	gtacaggttt	ttttcctgtt	aggagagctg	aggccagctg	1080
ccactgagt	ctcctgtccc	tgagaaggga	gtatggcagg	gctgggatgc	ggctactgag	1140
agtgggagag	tgggagacag	aggaagggaag	atggagatcg	gaagttagca	aatgtgaaaa	1200
attcctcttt	gaacctggca	gatgcagcta	ggctctgcag	tgctgtttgg	agactgtgag	1260
agggcgtgtg	tgtgttgaca	catgtggatc	aggcccagga	agggcacagg	ggctgagcac	1320
tacagaagtc	acatgggttc	tcagggtatg	ccaggggagc	aaacagtacc	ggctctctgt	1380
cactcacctt	gagagtagag	cagaccctgt	tctgctctgg	gctgtgaagg	ggtggagcag	1440
gcagtggcca	gctttgccct	tcctgctgtc	tctgtttcta	gctccatggt	tggcctggtg	1500
gggggtggagt	tcctcccaa	acaccagacc	acacagtcct	ccaaaaataa	acattttata	1560
tagamaaaaa	aaaaaaaaaa	aaggggcgcc	gctctagagg	atccctcgag	gggcccagc	1620
ttacgcgtgc	atcgacgtc	atagctctnt	ccctatagaa	gtngnaaagg	gttc	1674

<210> 19

<211> 2018

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (2010)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (2012)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (2014)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (2016)

<223> n equals a,t,g, or c

<400> 19

cagcaatgaa	atcctgcttt	cttttccctca	gaactactat	attcagtggc	taaatggctc	60
cctgattcat	ggttttgtga	atctttgcttc	ccttttttcc	aacctttggt	tatttgtatt	120
gatgcccttt	gcctttttct	ttctgggaatc	agaaggcttt	gctggcctga	aaaagggaat	180
ccgagccctg	atttttagaga	ctttgggtcat	gcttcttctt	cttgccgttac	tcattcttgg	240
gatagtgtgg	gtagcttcag	cactcattga	caacyatgcc	gcaagcatgg	aatctttata	300
tgatctctgg	gagttctatc	taccctattt	atattcctgt	atatcattga	tgggatgttt	360
gttactttct	ttgtgtacac	cagttggcct	ttctcgtatg	ttcacagtga	tgggtcactt	420
gctagtgaag	ccaacaattc	ttgaagaacct	ggatgaacaa	atttatatca	ttaccttaga	480
ggaagaagca	ctccagagac	gaactaaatgg	gctgtcttca	tcggtgggaat	acaacataat	540
ggaagtggaa	caagaacttg	aaaatgtaaa	gactcttaag	acaaaattag	agaggcgaaa	600
aaaggcttca	gcattgggaaa	gaaatttgggt	gtatccccgt	gttatgggtc	tccttcttat	660
tgagacatcc	atctcggtcc	tccttggtggc	ttgtaatat	ctttgcctat	tggttgatga	720
aacagcaatg	ccaaaaggaa	caagggggcc	tgggaatagga	aatgcctctc	tttctacgtt	780
tggttttgtg	ggagctgcgc	ttgaaatcat	tttgacttcc	tatcttatgg	tgctctctgt	840
tgctggcttc	tatagccttc	gattttttgg	aaactttact	cccaagaaag	atgacacaa	900
tatgacaaag	atcattggaa	attgtgtgtc	catcttggtt	ttgagctctg	ctctgctctg	960

gatgtcgaga acactgggaa tcactagatt tgatctactt ggcgactttg gaaaggtttaa 1020
ttggctggga aattttctata ttgtattatc ctacaatttg ctttttgcta ttgtgacaac 1080
attgtgtctg gtccgaaaat tcacctctgc agttcgagaa gaacttttca aggccctagg 1140
gcttcataaa cttcacttac caaatacttc aagggattca gaaacagcca agccttctgt 1200
aaatgggcat cagaaagcac tgtgagacgc acagacggcg tcttctgccca ccaagagacc 1260
cgagaactcc agattcacga cattcctgtc ccatgtagaa gcatttccat tcaaccgtgg 1320
ccctcttcca gaacctagac ctatcagtgc catttttttt tcataatcta cgaagaactt 1380
ggctatggct gatctttttt aaatttaact ttctgatgga ccttgtagtt tccagttaag 1440
tgagatttcc ttacagacat atagaacagc gcattcttct gtagacattt gctcatgttg 1500
gtaaatacaa tcaccatata gaaaaaattg ttttcacctg atatgaaaat gttagaaaag 1560
gcaaaactcc ggactttctaa agattttactt aaatcccat atgtacttta ttcagaatgt 1620
agaagctgac ttgaaaggca tccttggtac taagtgaagc ttattcagaa aatgcatttt 1680
tcaaatgcaa tggcaactgc ttgtagatat catttttgca gtgtatgttg gaggctgaat 1740
gggtgcaatt atgtttctta ttcccttaaa agcaaaaagc gtagtctctg atttatgtta 1800
tagaatgata ctgatttagac tttagacca ggggaaaata ctaaatcttt ttaaacctgg 1860
agccttagag agccacagga atatcttctg ttgtacagtc taataagctg tggtaggaag 1920
tatcatgtaa tcacagttaa ttgtacagttt atgtatatat ataattcagt attcctctga 1980
ggggggggccc ggtacccaat tcgccaaggn tnancnag 2018

<210> 20

<211> 2098

<212> DNA

<213> Homo sapiens

<400> 20

ggcagcaggg accgagctat tctcctggga ctggctatga tgggtgtgctc catcatgatg 60
tattttctgc tgggaatcac actcctgcgc tcatacatgc agagcgtgtg gaccgaagag 120
tctcaatgca ccttgctgaa tgcgtccatc acggaaacat ttaattgctc cttcagctgt 180
ggtccagact gctggaaact ttctcagtac ccttgctccc aggtgtacgt taacctgact 240
tcttccgggg aaaagctcct cctctaccac acagaagaga caataaaaat caatcagaag 300
tgctcctata tacctaaaatg tggaaaaaat ttgaagaat ccatgtccct ggtgaatgtt 360
gtcatggaaa acttcaggaa gtatcaaac ttctcctgct attctgacct agaaggaaac 420
cagaagagtg ttatcctaac aaaaactctac agttccaacg tgcgttccca ttcactcttc 480
tggcacaact gtatgatggc tgggggtgtg gcaattgttg ccatgggtga acttacacag 540
tacctctccc tactatgtga gaggatccaa cggatcaata gataaatgca aaaatggata 600
aaataaattt tgttaaagct caaatactgt ttcttttcat tcttcacca agaaccttaa 660
gtttgttaag tgcagctctgt tatgagttcc ctaatatatt cttatatgta gagcaataat 720
gcaaaaagctg ttctatatgc aaacatgatg tctttattat tcaggagaat aaataactgt 780
tttgtgttgg ttggtggttt tcataatctt atttctgtac tggaaactagt actttcttcc 840
ctcattccgc caaaacaggg ctccagttatt catttgccaa gcttcgtgga ggaatgtagg 900
tgacatcaat gtgataaagt ctgtgttctg agttgtcaga tctcttgaag acaatatttt 960
tcatcaacta ttgtttacta aagctacagc caaaaatatt ttttttctt attctaaact 1020
gagccctata gcaagtgaag ggaccagatt tcctaattaa aggaagttag gtacttttct 1080
tgtatttttt accatatcac tgtaaagaag aggggaaacc cagccagcta ctttttttca 1140
tcacttttta ttcataactt cagatttcta aaactaattt ccaaaatata agctgttttc 1200
attagccagt tctataatat cttcctgtga ttatgtaga aaatgaacac accccttttc 1260
catttaagac cctgctactg tgtgaagaga tgatacttac aaggagtgtc attacctgtg 1320
agctgactga atgttggtag gtgtccatt acaatccagg aaagtctgtg ttactgatat 1380
ttgtgtggaa atctttattt cacttcaatt taaccattag atggtaaaat taagatgcta 1440
cttgttggtg aaaaattggtg gactgggtttc aatgggtaaa tgtgttgtgg caaattaatg 1500
tgttggaata ttgctctttg tgaattttgt ctttaagtea tgaatgtgta gtatctctct 1560
ctgacaagca ttccctattg ggattttaaa gctatgagca cagaatatta gtctcttcta 1620
catgttttat ttttctactt ataatccctt tttttgttgt tatattttat acacagaata 1680
gatctttttt ctaacacata ttgtaactga ataacagact taaagaaaagc ctttgttcac 1740
attgtctatt acctttgtgt ttgggggaaa atacgaggga ttgattttta ataaaaaca 1800
ttccatcttt catttaatat caatatcaaa agaagaagac aaacatctat ctttctctac 1860
tatatttaag tacctttttg caatgtagta tcaagttttt ttaggcaatg caaaatttta 1920
caaalcaatt gtggaatgaa tggtaaaact aatctgagga aatggaaaat tatctgcaa 1980

tattgtaatt catagtttga cttttcataa gcaaaataat ccctaggatg taatcaggac 2040
ttcaaatgtg taattcaatt tttttaaaaa aaatctaaaa aaaaaaaaaa aaaaaaaa 2098

<210> 21
<211> 1746
<212> DNA
<213> Homo sapiens

<400> 21
gcgttcgcgc acctccagct cgggccgatg tggaaagcttt ggagagctga agaggcgcg 60
gcggcgctcg gcggcgcgct ctctctgctg ctcttcgcgc taggggtccg ccagctgctg 120
aagcagaggc ggcgatggg cttcccccg gggccgcgg ggctgccatt tatcggaac 180
atctattccc tggcagcttc atccgagctt ccccatgtct acatgagaaa gcagagccag 240
gtgtacggag aggtacagcc ccgacgggcc ccgggcaggg agggccgcca ggctggccc 300
ggctggccag ggccttctcg gttggactta tggccgccc tggccgact agtcgggacc 360
tctccgtgtg ccgctgccc ttgaggggac acccgcttcc cgggtctgga agggagaagt 420
ctcagagccc gtgcgccctt gcagggggag ccccgccctt gccggtgacc cactccgggc 480
cgaggctccg aggcgatcca gtcctgattt tcccgtacc gctcagactc ttgctctgc 540
gcctgcgcgc tttggctcgc cagccgcgc gccacttcag gtccagggtg gacgcattgc 600
ctcagggtgc ggcgtcttgc ggtcggcct cgcagctctg tggaaagctg acgcggttg 660
tcggaaaaatc aaggcgctct gacttctaga tggtaaatag cagggtcttc ggtgtctgca 720
gtcagcaaac gactggtgta ggcgtttgct gtgagaatgg agaatgcagg ggaacgccc 780
tgactgagaa gcgggcccctg ggaacagatt gtgaacgct gaataaatg atgactaaaa 840
tccgtcgcgg ggttcctaca gcgcagatgg taatgccgtt ctgactggct gggaacggca 900
ccttagcaga tacttaaaag gcgccttctg tgtgccactg tcaactgcca ctgtgtgact 960
catttaaaac tcataaccag ccggtgaggt cggtaactcg ctctcctca ttctgaggag 1020
gggaaagcag cacggaaatg cctctgtact ggcagcgga aaggcgacca ccgcttgtgt 1080
gtgggtgtcc cgacgtcccg agggggcagg agtttccacg ggtcctggga cagagctcac 1140
ctgttttgtt ttgaattaca cttatttata tgcaactaca ggcctgacgc tagcggtgaa 1200
gaaggcagat acagcctttt aaggagttgg cagatgagtg ggagagagaa aactaatctc 1260
attatcggcc acaggctgtg gtcagtgttt tgaaggaaaa gtacagggat gtttggcaac 1320
tgtgttattt caggtttgac cttaaatcct tacttaaac agtttttaca aggatttggtc 1380
taggcgcgcg ggcgcggtgc tcacgcctat aatcccagca ctttgggagg ccgaggcggg 1440
cggatcacga aatcaggaga tcgagaccgt cgtggctaac acggtgaaac ccatctctc 1500
ctaaaagaat acaaaaaatt ggcggggcgt ggtggcgggc acctgtggtc ccagctattc 1560
gggaggctgg ggcaggagag tggcgtgaac ccgggaggcg gagctttcag tgagccgaga 1620
tcgcgccant gcactccagc ctgggcaaca gagccagact ccgtctcaaa aaaaaaaaaa 1680
aaaaaggcg ggcgcctctag aggatccaag cttacgtacg cgtgcatgag acgtcaatag 1740
ctcttc 1746

<210> 22
<211> 2876
<212> DNA
<213> Homo sapiens

<400> 22
ccacgcgtcc ggcggcgagg cggcggtggt ggctgagtc gtggtggcag aggcgaaggc 60
gacagctcta ggggttggca ccggcccgga gaggaggatg cgggtccgga tagggctgac 120
gctgctgctg tgtgcggtgc tgcctgagctt ggcctcggcg tectcgatg aagaaggcag 180
ccaggatgaa tccrtagatt ccaagactac tttgacatca gatgagtcag taaaggacca 240
tactactgca ggcagagtag ttgctgggtc aatatttctt gattcagaag aatctgaatt 300
agaatcctct attcaagaag aggaagacag cctcaagagc caagaggggg aaagtgtcac 360
agaagatata agctttctag agtctccaaa tccagaaaac aaggactatg aagagccaaa 420
gaaagtacgg aaaccaggta gtctggacat ttcccttgct ttttgattta tttaggggac 480
aactgaaaat ttttaagtaa tgaataaaga ggcgtgaaga gactggcttc actgattatt 540
acccacaaat aatatatgga gtgtagtttg gagagaattt ctgattttta atataccaaa 600
gttattcact taacagattt gacccaagtt acataagctg aattccatag atgagattgc 660

```

atattatcttt ttattaatat cctgacgttt ctttttggaa tcaagtatgt aaataccttt 720
ctcactgaga aattttaaaaa aataatatgt cagggtagca tacaaaaacag aaactcagga 780
agaactgtct aacatgccac tatgggtatt ttcaggatg tggtaggatt attactacaa 840
taaccttgtc gatcatccta ggtaatttga tttaggtgtt tatccctcag ctgacgcttg 900
tgctgacttc catcctatcc taactttcac aatcttgaaa cctctacttt tcaatttaaa 960
acttgacctt ttccacaata gtcttctaaa tattaatcct tttaaaaatt attaatgtat 1020
gcattctacc atgtcttggt gcccttctgt catttattat ttcaatgatc actgccttat 1080
ctgtttatta ttccattact aaccactctc aggaactgat ccaatttgga acttttttaa 1140
aaaatagaaat ttttttttac tacaaatata ccattctcat gaatagaaaa ctatttttaa 1200
aaaattaaaa gtacatgaat cccatcaact agaaataaca gctgctcaca ccatggagaa 1260
tattctctca ggattttttt aggtgtatca gtagttttaa gaaaagttaa ttgggtcaaa 1320
atgtgtattc tatgttcgag cctgcatttt gcaacttaaca gtttaccatg aatgtttttc 1380
catgtcattt agcttatatt caatttgata gttaatggct ataaaaaatt ttatttgtaa 1440
atatatggta ccataaacca aaacgtttat gttttgctgg gagatcattt tagatgtatc 1500
tttgtgccta tctgtgaaaa ttcccttaga attcttaaag taaatttgct gaattggatg 1560
taaaagttta aaagacaqta gatacacatt gttaaattgt tcttcagaaa agtgattctg 1620
tttacttctc ctgaaaaatac ctctttccct gtacctcacc caagtgtgta ttaccatttt 1680
aaaaattttta ctaaatataa ttttaattca tcttcatttt ttaattaggg attttttttt 1740
ttttttttta gtitttatat ttttagagac atggctctac tctgtcactc aggcctggagt 1800
gcagtggcac gatcatagtt cactgcagcc ttgaactcag gtgatctccc tctttggcct 1860
cccaaagtgc tgggattaca ggcattgagac actacatcaa gccctgggaaa ttttttaaaa 1920
tgcataaaag tagagggtaa aatgacaccc cttaccaacc ctcaactcag tccaataaac 1980
atcaacattc tgcctggctt ttcattctta ctacctaca cacatttgcc ctttttttct 2040
ttcttagaat attttaaggc aaattccgca tgtgctttta catctctgtg tctctctcta 2100
gtaagaatgt tcttttcagc aaaatcacag aattagccat tactctttaa ttacctaata 2160
cccagactgt ttaatttttc tagttgtctc aagtgtctgt ttacaattta ttgtttgaa 2220
ttcatttcta agctactcag gaggctgagt caggagaatt gcttgaacc aagaggcaga 2280
ggttgacagt agctgagatc gtgacctgt actccagcct gggcgacaaa gtgagactcc 2340
atgtcaaaaac aaaaacaaaac aaaacaaaac aaaacaaaac aaacaacaca attgaataat 2400
atccctcagt tattaattag agaagagatg actcaatata aatgtaatat gtgatcattt 2460
ggtcacagaa tgaattcag tcattgtcta ggtaagcctg gtaaaaaaaa aaaaaaacgg 2520
gattccatga ttagtgtgtt gaaaaggggg ttgccaaagt gtaacagaca gagccgggtg 2580
cagtggctca cgcctgtaat cccagaactt tgggagggcca aggcaggcgg atcacgaggt 2640
caagagattg agacaactct ggccaacatg gtgaagccc gtatcaacta aaaaatacaa 2700
aacaattagc tgggcgtgtg gacatgtgcc tgtagtccca gctactcagg aggcagaggc 2760
aggagaattg cttgaacctg ggaggcggag gctgcagtga gctgagattg ctccactgca 2820
ctccagcctg gccacagagt gagatcccat ctcaaaaaaa aaaaaaaa aaaaaa 2876

```

<210> 23

<211> 1052

<212> DNA

<213> Homo sapiens

<400> 23

```

tcgacccacg cgtccgccca cgcgtccgcc cagcgtccg ggcggggcga ggacgtgcac 60
tatggctcgg ggctcgcgc gccggttget gcggctctc gtgctggggc tctggctggc 120
gttgcctcgc tccgtggccg gggagcaagc gccaggcacc gccctctgct cccgcggcag 180
ctcctggagc gcggacctgg acaagtgcac ggactgcagc acctcctgcc ccttccggc 240
tgctttggcc catccttggg ggcgtctga gccagacct cgtgctgggg ctgcttctg 300
gctttttggt ctggagacga tgcgcgagag agagaagttc accaccccca tagaggagac 360
cggcgagag ggctgccag ctgtggcgt gatccagtga caatgtgcc cctgccagcc 420
ggggctcgc cactcatcat tcattcatcc attctagagc cagtctctgc ctccagacg 480
cggcgggagc caagctctc caaccacaag ggggtgggg ggcggtgaa cactctag 540
gcttggggcc agggttcagg ggaaccttc aaggtgtctg gttgccctgc ctctggctcc 600
agaacagaaa gggagcctca cgcctgctca cacaacacag ctgacactga ctaaggaaet 660
gcagcaattg cacaggggag ggggtgccct ccttctaga ggcctgggg gccaggctga 720
cttggggggc agacttgaca ctaggcccca ctcaactaga tgcctgaaa ttccaccag 780
ggggtcacc tgggggtta gggacctatt ttaaacata gggggtggc ccactaggag 840

```

ggctggccct aagatacaga ccccccaac tccccaaagc ggggaggaga tatttatctt	900
ggggagagtt tggaggggag ggtggggggg gggaaaaaaa aataaaaaaa aaaattttta	960
atttttaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa	1020
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa	1052

<210> 24
 <211> 1541
 <212> DNA
 <213> Homo sapiens

<400> 24	
ggcagagct cctcgatcc tactctgtct ccttttgttt tggagaagtt caatttacca	60
gctggatag tgggactagt attcctgggt atggcactgt cctatgccat ctcttcacca	120
ctatttggtc tcctaagtga taaaaggcca cctctaaggga aatggcttct ggtgtttggc	180
aacttaatca cagccgggtg ctacatgctc ttagggcctg tcccaatctt gcatattaaa	240
agtcagctct ggtgctggt gctgatatta gttgtaagt gcctctctgc tggaaatgagt	300
ataattccaa ctttcccgga aattctcagt tgtgcacatg aaaaatgggt tgaagaggga	360
ttaagtacac tgggacttgt atcaggctctt ttagtgcaa tgggtgcaat tgggtgctttt	420
atgggaccaa cgctgggtgg atttctgtat gagaaaattg gttttgaatg ggcagcagct	480
atacaaggtc tatgggtctt gataagtga ttagccatgg gcttgtttta tctactggag	540
tattcaagga gaaaagggtc taaatctcaa aacatcctca gcacagagga ggaacgaact	600
actctcttgc ctaatgaaac ctagtccgat ggtccttggg ttgatacaag gttgagaaat	660
gaatgctcct ggccttaaac atcaccttag gaagggtttt taaaatttta cgcgcaaac	720
tccgtggacc ccgtgccagt gtcttggaag tgtcaactgt tttttggatg atcctgtatt	780
gggctgtact tactgtgata ctgaaaagct gtctgtctga agcagctata tttgaaatat	840
laagtatgaa aggagttaatt aaaaacaagc aaaacaaaac aagacttagt ttttaaatga	900
ccaaacttgt ccttaaatat gttgttatta actcgagtta gttcttattt cctctgttta	960
ttttttattc taagtacact gattctgtga atgtaccttt ttattacac agggaaagaa	1020
atgaattaat ttgatatgct ctaaatacat aaagggtgctt caaaatatgt agaaacatta	1080
ctatgaaatc agtttttaaa agatatactt tctctttctc ctgaggtttt tgggtcttgt	1140
tcaaaaggaa gaattcttgc ctgccatata gaaactctct agcactccct gaccttaagc	1200
ttttctaaaa attctgtttg tgtgaaaagt acaagaataa caatacttac aacttccatt	1260
tttgttaacct acgttcactt atgatctgga tttataaaca ttacttggtg taacgttttt	1320
catttccctt aatgtctctg ttttttggct ctaccatctg ttttgttttt gtttttatct	1380
atatcttggg agatgtattt catccctaga gcaggtcagc ctcttccccc taatgcgaat	1440
gcttgttttg ttagggaagg gcttccctca acttcgtgtg aaattgtgat gttgaagtga	1500
ataaatgtct attgtgtaac aaaaaaaaaa aaaaaaaaaa a	1541

<210> 25
 <211> 2079
 <212> DNA
 <213> Homo sapiens

<400> 25	
ggcagaggg aggcgggct gcgggacctg actagattct acgacaaggt actttctttg	60
catgaggatt caacaacccc tgtggctaac cctctcttg catttactct catcaaacgc	120
ctgcagtcct actggaggaa tgtggatcat agtctggagg ccagtggaaa catccgagct	180
ctgaaggatg gctatgagaa ggtggagcaa gacctccaq cctttgagga ccttgaggga	240
gcagcaaggg cctgatgag gctgcaggac gtgtacatgc tcaatgtgaa aggcctggcc	300
cgagggtgtt ttcagagagt cactggctct gccatcactg acctgtacag ccccaaacgg	360
ctcttttctc tcacagggga tgactgtctc caagtggca aggtggccta tgacatgggg	420
gattattacc atgccattcc atggctggag gaggctgtca gtctcttccg aggatcttac	480
ggagagtggg agacagagga tgaggcaagt ctagaagatg ccttgatca cttggccttt	540
gcttatttcc gggcaggaaa tgtttcgtgt gccctcagcc tctctcggga gttctctctc	600
tacagccagc ataataagag gatggccagg aatgtcttga aatatgaaag gctcttgcca	660
gagagcccca accacgtggt agctgaggct gtcacccaga ggcccaatat accccacctg	720
cagaccagag acacctacga ggggctatgt cagaccctgg gttcccaagg cactctctac	780

cagatcccta	gcctctactg	ttcctatgag	accaattcca	acgcctacct	gctgctccag	840
cccattccgga	aggaggtcat	ccacctggag	ccctacattg	ctctctacca	tgaacttcgtc	900
agtgactcag	aggctcagaa	aattagagaa	cttcgagaac	catggctaca	gaggtcagtg	960
gtggcatcag	gggagaagca	gttacaagtg	gagtaccgca	tcagcaaaag	tgcttggctg	1020
aaggacactg	ttgacctaaa	actggtgacc	ctcaaccacc	gcattgtctg	cctcacaggc	1080
cttgatgtcc	ggcctcccta	tgcagagtat	ctgcaggtgg	tgaactatgg	catcggagga	1140
cactatgagc	ctcactttga	ccatgctacg	tcaccaagca	gccccctcta	cagaatgaag	1200
tcaggaaacc	gagttgcaac	atttatgata	tatctgagct	cggtggaagc	tggaggagcc	1260
acagccttca	tctatgccaa	cctcagcggt	cctgtggtta	ggaatgcagc	actgttttgg	1320
tggaaacctgc	acaggagtgg	tgaaggggac	agtgacacac	ttcatgctgg	ctgtcctgtc	1380
ctgggtgggag	ataagtgggt	ggccaacaag	tggatacatg	agtatggaca	ggaattccgc	1440
agaccctgca	gctccagccc	tgaagactga	actgttggca	gagagaagct	ggtggagtcc	1500
tgtggtcttc	cagagaagcc	aggagccaaa	agctggggta	ggagaggaga	aagcagagca	1560
gcctcctgga	agaaggcctt	gtcagctttg	tctgtgcttc	gcaaatcaga	ggcaaggagag	1620
aggttgttac	caggggacac	tgagaatgta	catttgatct	gccccagcca	cggaagttag	1680
agtaggatgc	acagtacaaa	ggagggggga	gtggaggcct	gagagggaag	tttctggagt	1740
tcagatactc	tctgtttgga	acaggacatc	tcaacagtct	caggttcgat	cagtgggtct	1800
tttggcactt	tgaaccttga	ccacagggac	caagaagtgg	caatgaggac	acctgcagga	1860
ggggctagcc	tgactccccc	aactttaaya	ctttctcccc	actgccttct	gctgcagccc	1920
aagcagggag	tgtccccctc	ccagaagcat	atcccagatg	agtgttacat	tatataagga	1980
ttttttttaa	gttgaaaaaca	actttctttt	ctttttgtat	gatggttttt	taacacagtc	2040
attaaaaatg	ttttataatc	aaaaaaaaaa	aaaaaaaaaa			2079

<210> 26

<211> 1947

<212> DNA

<213> Homo sapiens

<400> 26

tgtaaacaga	ttggagaatc	tagcaataag	attcaaaqct	aatctggagc	ataaaggcac	60
agttcagaga	cagaataaca	gggatcacaa	gcatgaatta	aaaggaattt	atttgcctca	120
agttcctaga	tacaaccttc	ccatgctgca	cttctccact	gtcggagcac	gttccgaaaa	180
acagaaatgcc	ttgatccctg	gtgggtgcga	aggcagttgt	tagggatggc	aggcatttgt	240
gggtctccaaa	agatgaaggc	cccacacaca	ggtgtgctgc	atttgggata	tggtgggtg	300
tttcttggac	cctttctctc	gggagtaggg	tacacactaa	cgtttaatcc	gctgtctggg	360
tgcatgtcca	cagtacgggtg	gctaaactcg	aacatcactg	caaataggac	gctgagcagg	420
tccgtctgtc	atgtcacgcc	actgcacagg	tccttgtccc	cacacgacgg	ggagtacttg	480
cgtcagatgt	tattgaatag	ctcgtctcgg	gcaggggag	cggggagttg	gggatattaa	540
ttgggggttt	taattctatt	atcatgtcag	ctgacattat	gactatataa	tgtagttaga	600
gacaattttt	atcttgcctta	tagtaaaagt	tcagcctgcc	aattgtaaat	cattctaat	660
tggcaggctt	atttttgaca	ttggaaaggg	cagaaagcga	tttggcccag	tagtgtaata	720
ggagtattag	accagaggct	gaaacccaaa	ctatataaaa	aggaattcag	tggagggggc	780
tttgttaatc	ccattaatlt	gtgttgctac	ttccaggatc	acaaaaat-	acatgtaatt	840
ttacatgtta	aacacattga	aacataacct	atgtttataa	agcataacgg	gcttcccttc	900
cagaagctct	cctgcttctc	atgaagtggg	aacaatgaaa	agtcatagca	gatactcagt	960
ttactctctg	gtagaacctta	gtagtgtttg	agctgttatt	cagatttgaa	ttcagactgt	1020
gtgttgtttg	cttatggaca	ctgcctgtcg	ttctgtcact	gttaaattaa	tgagtctata	1080
aggtttttct	tccagagggc	ataggtgaca	tcactaaaa	tgcaagataa	attgtaactc	1140
ttgtctgtgc	tgcaactccc	aacctctccc	ccaccccccg	tggtgtgtcg	ctttctagat	1200
gagcgtgttt	tggagcaggc	ccatctggga	cactctatgc	tttcaccaag	gaagtgcgat	1260
ctgagcagcc	acaatccagc	caaaagagga	tgttagatat	ttgtctgat	caactagatg	1320
aaaatatagc	agaatggatt	tagcccaactg	ctctgtttta	tccaaactgag	tctctgacca	1380
gcaattgggtg	cataattatt	acagcaaaaag	ttaagaaatg	aaactgtagc	aattatgtaa	1440
atgaatgtgt	tggcctctta	atacctgtta	ctagtggact	tcctgtgagg	aagtttagttt	1500
tttgttttga	tgaatgcttt	tctgttttta	aatcttaatt	ctgctgtcca	cactctccca	1560
aagtgtgctt	acttcaattt	tttaatttaa	atgaactttc	ctccttgtat	gtatgaggtg	1620
acttggggg	tgggggtgggt	ggtttttgtt	tttgtgtttt	ttctttctta	gggcactctgc	1680
aggcctcaaa	ggacctttcc	tttaggtcat	attcctcaga	aagctttcaa	tcttcccttg	1740

tttttgtttg	tttgttttcc	ttaaagaata	ttttcaaagc	ttaaatttgt	atattaattt	1800
aggactattt	agaagtatag	gctgtcgttg	gcggcagcag	tatatcttga	aactgtctcat	1860
agatatatat	ttttgaataa	agatgggtgt	gttgaacaaa	aaaaaaaaaa	aaaaaaaaac	1920
tcgagggggg	gcccggtacc	caattcgt				1947

<210> 27

<211> 3379

<212> DNA

<213> Homo sapiens

<400> 27

atgatattca	agtcgaattc	ccctcactaa	agggaaaaaa	gctggagctc	caccgcggtg	60
gcggccgctc	taaacctact	ggatcccccg	ggatgcagga	attcggcacg	aggtctcggc	120
tcctctccgc	accgcgcccg	cccggtcgtc	cccggctcct	cccgcccatg	gggagctgcg	180
cgcggtgctg	gctgcctctg	ggctgcacgg	tggtggccgc	aggactgagt	gaagttagctg	240
gagttagtgc	ccgctgtgaa	aaagcctgca	accctcggaa	gggaaatttg	gctttggggc	300
gaaaactctg	ggcagacacc	acctgcggtc	agaatgttac	cgaactgtac	tgcttctaca	360
gtgagaacac	ggatctgact	tgctggcagc	ccaaatgtga	caaglycaat	gctgcctatc	420
ctcacctggc	tcacctgcca	tctgccatgg	cagactcatic	cttcgggttt	cctcgcacat	480
ggtggcagtc	tgccgaggat	gtgcacagag	aaaagatcca	gttagacctg	gaagctgaat	540
tctactttac	tcaccttaatt	gtgatgttca	agtcctccag	gccggctgcc	atgggtgctgg	600
accgctccca	ggactttggg	aaaacatgga	agccttataa	gtacttttgc	actaactgct	660
ccgcacatt	tgccctggaa	gatgatgttg	tcaagaaagg	cgctatttgc	acttctaaat	720
actccagtc	ttttccatgc	actggaagga	aggttatttt	caaagctttg	tcaccacct	780
acgatacaga	gaacctttac	agtcgcaaa	ttcaggagca	gctgaagatc	accaacctcc	840
cgctgtcagc	tqctgaaacg	acagtcttgt	ccctgtcaga	gaatgacct	gaacgaagag	900
cctcaacatt	ttacacacta	tgccatctat	gatttcattg	tcaagggcag	ctgcttctgc	960
aatggccacg	ctgatcaatg	catacctgtt	catgggttca	gacctgtcaa	ggccccagga	1020
acattccaca	tggtccatgg	gaagtgtatg	tgctagcaca	acacagcagg	cagccactgc	1080
cagcactgtg	ccccgttata	caatgaccgg	ccatgggagg	cagctgatgg	caaaacgggg	1140
gctcccaacg	agtcgagaac	ctgcaagtgt	aatgggcatg	ctgataacct	tcacttcgac	1200
gttaactgtg	gggaggcacc	agggaaatgt	agtggtgggt	tctgtgatga	ctgtcagcac	1260
aacacagaag	gacagtattg	ccagagggtg	aagccaggct	tctatcgtga	cctgcggaga	1320
cccttctcag	ctccagatgc	ttgcaaacgg	tggtccctgc	atccagtagg	atcagctgtc	1380
cttctctgcca	actcagtgac	cttctgcgac	cccagcaatg	gtgactgccc	ttgcaagcct	1440
ggggtggcag	ggcgacgttg	tgacaggtgc	atgggtggat	actgggggct	cggagactat	1500
ggctgtctgac	catgtgactg	tgccagggagc	tgtagcccta	tcaccggaga	ctgcactcagc	1560
agccacacag	acatagactg	gtatcatgaa	gttcctgact	tccgtcccgt	gcacaataag	1620
agcgaaccag	cctggggagt	ggaggatgag	cagggtgttt	ctgcacttct	acactcaggt	1680
aaatgcgaat	gtaaggaaaca	gacatttaga	aatgccaagg	cattctgtgg	aatgaaatat	1740
tcatatgtgc	taaaaataaa	gattttatca	gctcatgata	aaggtactca	tggttaggtc	1800
aatgtgaaga	ttaaaaaggt	cttaaaatct	accaaactga	agattttccg	agggaaagcg	1860
aacattatat	ccagaatcat	ggacggacag	aggatgcact	tgctccatcc	tcaatcctgg	1920
tttggaatac	ctttagtagc	gacatgagga	tataagaaca	ggcaactaa	ttgtgaatat	1980
gaaaagcttt	gtccagcact	ggaaaccttc	tcttgggaaga	aaagtccatg	atatttttaa	2040
aagagagtgc	aagtagcatt	aagatggata	gcacataatg	gcaactggct	atgtccaaaa	2100
cacaaacttt	agagcaagaa	gacctcagac	aggaaactgg	aattttttta	agtgccaaaa	2160
catatagaaa	tgtttgaatg	catgggtctt	tatctaattt	atctctctctg	gacctatggt	2220
taaaatacagt	tttattttcat	gaagagaaat	gaaaacctct	acactgatat	ctgtttttcta	2280
tgggactgat	tctgaaattc	ttaactatta	agaatatatt	aatagcagca	tgacatttag	2340
cagtaatcca	ttaagggcag	tacctctaac	aaggacgcct	tccagcttca	gctatgttac	2400
ttacgtttga	tgctacttaa	agtaaatgaat	gacgttttaa	ggaaatcccta	acctacttat	2460
cagaaaaggt	gtttgtttaa	gagccttctc	ttgtgtgtta	cgcatagaat	ttgtctgtga	2520
gggtgttaaat	ggacctcttc	catgtgtata	tagtatttcc	ttgtataaag	cactttacta	2580
cctaccactt	gtgtgtgtaa	cgcttgggtg	ctgctgttga	aagaaggaaa	aggggtgtgtg	2640
agaaagccta	ctgaagcagc	agcactgcca	ctacatgtgg	acaaaagtga	acataataaa	2700
gaagtgtgtc	tatttaactc	tgaatacttg	gagaaactag	gtgaagatgc	aaccagaaag	2760
gagaatatgt	atgcgtgaag	tctcagcttt	gagctggagg	ctagattcca	agatgacagc	2820

catgatgaaa	ctttttaaaa	aactaaacca	gaagagactt	taaaataaga	gaaagaaatc	2880
ataaatgtag	acatatgctt	ggctaaaggg	gaaatggact	ttaaatttta	aagagctcat	2940
ttgcaatgca	cttgtatata	cttcaaaaat	tattgtagac	acagaatttg	ttatatTTTT	3000
gtgcttagta	tttaaaccctg	aacattgaaa	cagttttcct	ccttgctctt	cttaacagta	3060
atagtcatTA	tatttacctg	ttttttaaca	caatgtatgt	gatagtcaaa	aaatcacagt	3120
ttttcattat	tattcatctt	ctgtaccacc	gcataaccac	tatacatagt	ttcttttgta	3180
cttgaatata	caaaacatga	acacagtgcc	atatgaataa	tttcacatac	agaacctttt	3240
tttctctgaa	gtcctgtgga	cttgcaaaata	tatatataata	ttgctttgtt	aatttgtttt	3300
tatatttcat	atatgtataa	aaggaatatg	atctgaaaaa	aaaaaaaaaa	aaaaactcga	3360
ggggggggccc	gtacccaaaa					3379

<210> 28

<211> 2006

<212> DNA

<213> Homo sapiens

<400> 28

cccacgcgtc	cgcggaacg	tggtatttct	tcttaagaaa	aaaaaaggaa	gacgttttaa	60
tagggaaaaga	aaaacaagaa	gcagtagcag	ctaggtaatt	taaacgtctt	cctttttttt	120
tcttaagaga	aaatggaaca	tttaggttaa	atgtctttta	attttaccac	ttaaacaacac	180
tacatgccca	taaaaatata	ccagtcagta	ctgtatttta	aaatcccttg	aaatgatgat	240
atcaggggta	aaattacttg	tattgtttct	gaagtttgct	cctgaaaact	actgtttgag	300
cactgaaacg	ttacaaatgc	ctaataggca	tttgagactg	agcaaggcta	cttggtatct	360
catgaaatgc	ctgttgccga	gttattttga	atagaaatat	tttaaagtat	caaaagcaga	420
tcttagttta	agggagtttg	gaaaaggaa	tatatctctc	tttttcttga	ttctgtactc	480
aacaagtctt	gatggaatta	aaatactctg	ctttattctg	gtgagcctgc	tagctaatat	540
aagtattgga	caggtaataa	tttgtcatct	ttaataattag	taaaatgaat	taagatatta	600
taggattaaa	cataatttta	tacggttagt	actttatttg	ccgacctaaa	tttatagcgt	660
gtggaatttg	agaaaaatga	agaaacagga	cagatatatg	atgaattaaa	aatatatata	720
ggtcaatttt	ggtctgaaat	ccctgagggt	tttttaacct	gctacactaa	ttgttacct	780
aatttatttc	tttagtctag	aaatagtaaa	ttgtttgcaa	gtcactaata	atcattagat	840
aaattatttt	cttgccata	gccgataatt	ttgtaatcag	tactaagtgc	atcgtatttt	900
ttgccacttt	ttcctcagat	gattaaagta	agtcacacgc	ttattttagg	aaactggaaa	960
agtaaatagg	aaagagattt	cactatttgc	ttcatcagtg	gtaggggggc	ggtgactgca	1020
actgtgttag	cagaaattca	cagagaatgg	ggatttaagg	ttagcagaga	aacttggaaa	1080
gttctgtgtt	aggatcttgc	tggcagaatt	aactttttgc	aaaagtttta	tacacagata	1140
tttgtattaa	atttggaagc	atagtcagaa	gactcagatc	ataattggct	tatttttcta	1200
tttcgcgtac	tattgtaatt	tccacttttg	taataatttt	gatttaaaat	ataaatttat	1260
ttatttattt	tttaatagt	caaaaatctt	tgctgttgta	gtctgcaacc	tctaaaatga	1320
ttgtgttgct	tttaggattg	atcagaagaa	acactccaaa	aattgagatg	aaatgttggt	1380
gcagccagtt	ataagtata	tagttaacaa	gcaaaaaaag	tgctgccacc	ttttatgatg	1440
attttctaaa	tggaagaaac	tttggttgca	tccacataga	cctttatggt	ttgttttcag	1500
ttgaaaactt	gcctcctttg	gcaacattcg	taaaatgaagc	agaatttttt	ttctcttttt	1560
ttccaaatat	gttagttttg	ttcttgtaag	atgtatcatg	ggtattgggt	ctgtgtaatg	1620
aacagcgaa	tttaattagc	atgtggttca	gaatatataa	tgtaggttt	ttaaaaagta	1680
tcttgatggt	tcttttctat	ttataatttc	agactttcat	aaagtgtacc	aagaatttca	1740
taaatttgg	ttcagtgaac	tgctttttgc	tatggtagg	catttaaacac	agcactttact	1800
cttaaaaaatg	aaaatttctg	atcatctagg	atattgacac	atttcaattt	gcagtgtctt	1860
tttgactgga	tatattaacg	ttcctctgaa	tggtcattgat	agatggttca	gaagagaaac	1920
tcaatgaaat	aaagagaata	tttattcaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1980
aaagggcggc	cgctctagag	gatccc				2006

<210> 29

<211> 3070

<212> DNA

<213> Homo sapiens

<400> 29

gttggagcct	tagaccttcg	aagtgcctta	tagaaggtag	gcctgcaggt	accggtccgg	60
aattcccggg	tegacccacg	cgtccgcaac	gtaggaggag	tctgatttct	tcacatcctt	120
gtcaacatct	gttgtgtgtg	ttgttgttgt	tggttttaat	tttagctatc	ctagttagatg	180
-gaagtggta	tctcgtgctt	tttatcttga	ttctctaat	gactagtgat	gttgaaacac	240
ttttcatgtg	cttgttgggc	attcgtatat	cttcttggag	aaatgtctat	taagtccttt	300
gccccatttc	aaattggcct	gcttctttgt	tgagttataa	ccattgaatt	ttaattgctg	360
taaaacactc	catgagtaca	tgtagcatgc	actcaataac	tattagctaa	tactatagtt	420
gtaattatct	ttgccacatg	tggcctgaat	tggaaggaaa	ttgcctagtt	tttccaagta	480
ggagcggaga	tgtaacaaaa	cctgtattta	aggccaataa	agatttgact	ctgtcagttg	540
tgatactttg	cttttaattg	atgctcccaa	atcaagaaat	tagaaacgtg	tatacataag	600
aatcagttta	tcttggcag	aaatcagtat	attatcaatg	tttaattaat	tcctaagaat	660
taatggcaat	agtgcctcta	gttttagctg	agatttagat	catctttctt	cattctgccc	720
tggtatgcga	catttgctat	aaatgccaca	atgagaattt	tttgaacct	gggtcagaga	780
agcctacttt	ttatatttaa	taagtattgt	attgatgtat	tatcattggt	ttatgcttat	840
tgcatcttgg	ttttatgggg	tggtcaaaa	agatagatg	agaatagggt	atccaaagta	900
atttagaatt	ttatcttcca	gttgggactg	aaacctcttg	aactgatgaa	tatatctctac	960
caggtttata	ggtagatatg	cctgttccatt	atatcgggtg	tttggagtga	gacagttagct	1020
ttcaagcaga	acaacagcca	tatgtaaglc	taaatcttgt	tattttcttt	gaataagcaa	1080
tggaacctgt	atgcattcag	gaactggtga	ttcagatata	ttctgaaggc	cctctctccc	1140
ctgtgctccc	acagcttttg	tcctgaactc	tcctgtctcc	ttgcgatgcc	tctgtgccta	1200
tacctatttt	gtgaacctctg	cctgcaatgc	cgtcccaagt	cagttggtga	ctcctcaaac	1260
ctcaactgaag	tctttcgggg	tggattcaaa	tgctgctttt	agccattaaa	atctgt-taca	1320
tctgttacat	actttcacaa	tgcaccttat	cctagtgtag	ttttaaaaat	gcaccttaaaa	1380
atttttaaa	cagtgcctgc	atgcagtaaa	caaaatttga	cagtacagaa	ataaatggtg	1440
aagacagttc	cccagttttc	ttcccccattg	atagcaactt	ctctttttta	tccttccaaa	1500
gatatctttg	gctgatacaa	gaatttttat	accgtatgaa	gtgcttatte	atcttatctt	1560
ttacttcagg	gtaatttatg	agtaattgaaa	aaattcaagc	attacaaaaa	tgtagagtgt	1620
gtgaagcaaa	aggtccccc	tactttgatc	cctaacacta	gccccttcca	ataaacactg	1680
tcttaattaa	cattcctctc	tccagaagta	acctctgtta	taagccttgt	ctgtgccttc	1740
agattgttct	gcttacactt	atatgcctat	ttaaaagtgt	atatttttgt	attttgtttg	1800
tttgtttgtt	tgagacagag	ttctgctctt	gttgcccagg	ctgaagtgca	atggcactat	1860
ctctgtctac	tacaacctgt	gtctcccttg	ttcaagtgtat	tctcctggct	oagcctcctg	1920
agttagctagg	attacagggt	cacgccacca	tgcccggcta	atttttgtat	ttttagtaga	1980
gatggagttt	caccatgttg	gccaggcttg	tcacgaactc	ctgacctcag	gttatccacc	2040
caccttggcc	tttcaaaactg	ctgggattac	aaggcatgag	ccactgtgcc	cggtcaagaa	2100
tttttttate	gataccatag	tgagctctct	gcctcttcgg	aacgatgtcc	actttgtctta	2160
tgatcaaccc	aagcaggact	cttctctccc	tggaacgctc	tcacctgggtc	tggaatcttc	2220
cagtctctgc	agaattggcc	tttcccagat	gctgcaaaat	tccagttgaa	cccccttttc	2280
tggtgtggccc	ctggggctgc	gagaccaaaa	tccatgagtt	ctgtgtaccc	tagacctttg	2340
gaagggtgaga	gcagggccct	gagaaaaggc	aaaacgcctc	ctctccctga	tgataccctt	2400
accccgcccta	ctcctcacca	gaattgtcag	tggtcttcca	ccacagtgtt	ccttctctgc	2460
tgagccctgc	actgtcccag	accacacaga	agtcgtgtca	cctctggggc	cctgggtagg	2520
tcaccgnaaga	gaagcacyct	gtccccgtct	tctctggct	tctgccagaa	aatcgaacaa	2580
gtgcaattaa	cacactgtta	ctgccgaagc	ctgaaactcc	caggacttgt	ccttgatcct	2640
tccagaaacc	accaggtccg	gcacttggag	ccccccggag	agggacctcc	cagccgagcc	2700
ctcaagaac	tccatgaaat	caggaaactgc	ttgatgaaat	gtatctcctt	gtacctggaa	2760
gatgaagccc	aaacacccac	acctctgtct	ccccaggggc	tcgggatgtc	tccagcagcc	2820
cggccacgca	gcttcccagg	tgggctcggg	gaggtgggag	cagggacctt	ctctgtcccc	2880
tccacctca	ctccatccac	ctcggagacc	acctcccccc	agccagatac	ggaataaaac	2940
tacagacgca	gaaaaaaaaa	aaaaaaaaaa	ggggggccgc	tctagaggat	ccctcgaggg	3000
gccccagctt	acgcgtgcat	gcgacgtcat	agctctctcc	ctatagttag	tcgtattata	3060
aggagcaaa						3070

<210> 30

<211> 2227

<212> DNA

<213> Homo sapiens

ttagcctatt	ttcaatttga	tagttaatgg	ctataaaaaa	ttttatttgt	aaatatatgg	1440
taccataaac	caaaacgttt	atgttttgct	gggagatcat	tttagatgta	tctttgtgcc	1500
tatctgtgaa	aatttcctta	gaattcctaa	agtaaatttg	ctgaattgga	tgtaaaagtt	1560
taaaagacag	tagatacaca	ttgttaaatt	gttcttcaga	aaagtgtatc	tgtttacttc	1620
ctctgaaaat	acctctttcc	ctgtacctca	cccaagtgtg	tattaccatt	ttaaaatttt	1680
tactaaatat	aatttaattc	attcttcatt	ttttaattag	ggattttttt	tttttttttt	1740
tagtttttat	atttttagag	acatgggtctc	actctgtcac	tcaggctgga	gtgcagtggc	1800
acgalcatag	ttcactgcag	ccttgaactc	agggtgatctc	cctctttggc	ctcccaaagt	1860
gctgggatta	caggcatgag	acactacatc	aagcctggga	aatttttaaa	cnngcataaa	1920
aagtagaggg	taaaantgcca	ccccttncca	accctcactc	agcttcaata	aacatcaaca	1980
ttctgtctgt	cttttcattc	ttactaccct	acacacattt	gccctttttt	tctttcctag	2040
aattatttaa	ggcaaatcc	gcattgtgctt	ttacatctct	gtgtctctct	ctagttaaga	2100
tgctcttttc	agcaaaatca	cagaattagc	cattactcct	ttattaccta	ataccagac	2160
tgtttaattt	ttctagttgc	ttcaagtgtc	tgtttacaat	ttattgtttt	gaattcattt	2220
ctaagctact	caggaggctg	agtcaggaga	attgcttgaa	ccctagaggc	agagggttga	2280
gtgagctgag	atcgtgccac	tgtaectecag	cctgggtgac	aaagtgtgac	tccatgtcat	2340
aacaaaacaa	aacaaaacaa	aacatgacga	aacaaaacac	acaaatgaat	aatatccctc	2400
agtattattt	tagagaagag	atgactcaat	ataaatgtaa	tatgtgatcc	atttggctac	2460
agaatgaatt	tcagtcattg	cttaggtaag	cctggtaaaa	aaaaaaaaaa	cgggattcca	2520
tgattagtgt	gttgaaaaag	gggtttgtccc	aaagtgtaac	agacagagcc	gggtgcagtg	2580
gctcacgctt	gtaatccca	aactttggga	ggccaaggga	ggcggatcac	gaggtcaaga	2640
gattgagaca	atcctggcca	acatggtgaa	gccctgtatc	aactaaaaat	acaaaaacaa	2700
ttagctgggc	gtggtgacac	gtgcctgtag	tcccagctac	tcaggaggct	gaggcaggag	2760
aattgcttga	acctggggagg	cggagggtgc	agtgagctga	gattgtctca	ctgcactcca	2820
gcctggccac	agagtgaagt	tccatctcaa	aaaaaaaaaa	aaaaaaaaaa	a	2871

<210> 112

<211> 1037

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (936)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (946)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (951)

<223> n equals a,t,g, or c

<400> 112

ccgggtccgga	attccccggg	cgacccacgc	gtccggggcg	gcgcaggacg	tgactatgg	60
ctcggggctc	gctgcgcggg	ttgctgcggc	tcctcgtgct	ggggctctgg	ctggcgttgc	120
tgcgctccgt	ggccggggag	caagcgcag	gcaccgcccc	ctgctccgcg	ggcagctcct	180
ggagcgcgga	cctggacaag	tgcatggact	gcagcacctc	ctgccccctt	ccggctgctt	240
tgccccatcc	ttgggggcgc	tctgagcctg	accttcgtgc	tggggctgct	ttctggcttt	300
ttgggtctga	gacgatccgc	caggagagag	aagttcacca	cccccataga	ggagaccggc	360
ggagagggtc	gcccagctgt	ggcgtgatc	cagtgacaat	gtgccccctg	ccagccgggg	420
ctcgcccact	cateatcca	ccatccattc	tagagccayl	ctctgctccc	cagacgcggc	480
gggagccaag	ctctccaac	cacaaggggg	gtggggggcg	gtgaatcacc	tctgaggcct	540
gggcccaggg	ttcaggggaa	ccttccaagg	tgtctgggtg	ccctgctctt	ggctccagaa	600
cagaaaggga	gcctcacgct	ggctcacaca	aaacagctga	cactgactaa	ggaaactgcag	660

<220>
<221> SITE
<222> (289)
<223> n equals a,t,g, or c

<400> 30
cggacgcgtg ggtcgaccca cgcgtccggg aaaaarggaa aaratgccgt gtaaaatctc 60
gttctgtgtc tgaattgccg taggctcaga tcttcatttg aggttctctg tctgaattgc 120
cgtaggctca gatcttcatt tgaggttatg ttctataagt taacgttgat cttgtgtgag 180
cttccggtag ctggagtaac acaggcggcc tcacagcgac ctctccagcg ccttccaagg 240
cacatctgca gccagcgtaa tcttcctggg agatgcctcc tcaaggccnt gctccagacc 300
acgtggggar ggccctgacar ccaattccca ggtgtccccc acccttgrag agtgacccta 360
aacgctagac agatggggaa tgggaaagaa aagaagctg cagacctcaa gttaaaattc 420
cctcaaaaac gtttlllattt atctgtcttt tctgaaagga taaaggctct tggaaaaata 480
ttttctaaca aataacatga acacttctag aaaccctaga aaaacacaaa gtattcaaaa 540
tagaaagaaa aattacccat tagtctttaa gccagcatta tccattgcgg tgcctttgga 600
tttgggtgag gccgtagcct ctgccaaagtc aaggagcccg gtgggtggctg tggcattcct 660
gcagggttgt tttttttctt ttgagatgga gtctcactct tgtcacccca gctggaatgt 720
ggtggtgtta acagctcact gcagccttga ccctgaggct caagcgatcc ttctgccttg 780
gcctcctgag tagctgggat cccaggcgag agtcaccaca ccctgtccat gtctctgcag 840
gtcttgatat gcgaggacgc tgtgtcttcc ctgccacatt ttctcttctt ttcttgagac 900
agaccttgc tccatcaccc aggccagagt gtggtsgtgc gaacacggct cactgcagcc 960
tcgacctca ggtcaagcg atcctcacgc ctccgacccc caaagtgcgt ggatcacagg 1020
cgagagtcac catgtggcc tgaatcttca ggtatttta cggttgaagt gtcacttact 1080
tarccatsec tgtttcaaga gtgtaggtag tcacctgtc tctgycgctg acctggcctg 1140
gacctcggc tgtgagaggg aggggtggg tgggtggag gaacctraag cctcgtgat 1200
gtcacagcc catctggctg ggcacccct gctgtgtcct gactgcaca tgcccagggt 1260
ggccccaca gcagaggcga gccactgrag ggtgraggc tccacggac ggtcttcagg 1320
ggragaagaa gggcccaggc cccaggaga ctcaggagac cagagcctgg ggtcaggggc 1380
tyagcagggg ctarccagg gctggatgc cggagccagc cccgmagccc tgkgtcttt 1440
gttcttcgca ctcccaccgt ccgtgtgaac agctccagcc ccactgcgc ctccctgtgc 1500
tgggtcccat caggagccc agaagacgtg tgtgtctctg aaattgggtc cctacatgcc 1560
tttgtccag tgcacottgc tcttccatt tactatcgag atttaaatgc ctgtttctc 1620
cccagaggtt gacggatata ttcagacgtt acgacacgga tcaggacggc tggattcagg 1680
tgtctgtacga acagtacctg tccatggctt tcagtatcgt atgacctgg cctctcgtga 1740
agagcagcac aacatggaaa gagccaaaat gtcacagttc ctatctgtga gggaaatggag 1800
cacaggtgca gttagatgct gttcttctt tagattttgt cagctgggga cccagc-gta 1860
catatgtgga taagctgatt aatggttttg caactgtaat agtagc-gta tgcctc-aat 1920
gcagacattg gatttgggta ctgtctcatt gtgccatgag gtaaatgtaa tgtttcaggc 1980
attctgcttg caaaaaaato tatcatgtgc tttcttagat gtctcgggt ctatagtga 2040
aatgctttta ttagccaata ggaattttta aataacatgg aacttacaca aaaggctttt 2100
catgtgcctt acttttttaa aaaggagttt attgtattca ttggaatatg tgacgtaagc 2160
aataaaggga atgttagacg tgtaaaaaaa aaaaaaaa aaaaaaaa aaaaaaaa 2220
aaaaaa 2227

<210> 31
<211> 1288
<212> DNA
<213> Homo sapiens

<400> 31
ccccgggct gcaggaattc ggcacgagcc tgacctcccc agcctcatct ctccctctc 60
tgcctctgcc ctctgtgtc cagccaaagt ggcctgtcac tgcctccact gccatactgt 120
cctgactcca ggcctttgcc tgtgtctatg cctctgttgg gaccactctt gtctctcccc 180
tgctgtgtct gctaattccc actcgtgtca gtgatccatg gctgcagaac acaccactcc 240
atccatggaa aacaatcaca atcattgatt actatctctc cctgggcttc ctggggtgga 300
ctgggctcag ctgggtgtgt cactttgggg cctcagcagt catgggcaga cagtggctgg 360

ggctactgca	aagacttccc	tgcattctctg	gcagttgatg	ctggctgtca	tctgagacac	420
ctaccaggag	cctctcccctg	gggcctgggc	tcctgcttag	cttggttggg	aggctccaag	480
accaacatcc	caagaaagat	gagacagaag	ccagatcacc	tttttggggc	tggtttcaga	540
agtcaccag	catcacttct	gctgcattta	tttcttaaaa	cacaaatc	aaaccccatc	600
ttctgatggg	agggggcctc	atggtttgta	aacatgttct	aaactccact	ctgcccggcc	660
ttggctcaac	gtgtctggta	atgtgtgggc	tgtgaggtc	cccgaacgta	gacctcagac	720
tgcaacgctg	gccgttacag	ggtctggcac	acgggcccac	gtcaggccca	tcgccacagt	780
gatggttgtt	ctgtgactgt	ttctgtggc	ctctgtctca	caactccaggc	tgacgctgtg	840
ccccctccac	tgggaccctc	gggtggcttc	catgcacttg	tgccctaact	cctgctccta	900
gactaaactt	catctcctgt	gttctcattc	tcgagcatgg	ctgttaggga	acctgaccat	960
ctgcagcgcy	lctcgttgcc	aaggtataat	gtcagtgctc	cccttcagtg	gctcccatgt	1020
cacagaattg	tcctgcagcc	ctggcacatg	tgtgccatgt	gggagctggg	gcaggctctc	1080
tttcatctctg	tggtctccgag	ggagggggcc	gctccttccc	cagctctctac	cctgactttg	1140
ccctcgtcct	gcagccactc	agagagcacg	atggagctgg	agcttcagtt	ttgacaaat	1200
gcgtgtcgcc	ggcttttg-g	tgtgtgtgty	lgtgacagag	ccagaccctg	tctttaaaaa	1260
aaaaaaaaaa	aaactcaggg	ggggggccc				1288

<210> 32

<211> 3280

<212> DNA

<213> Homo sapiens

<400> 32

gcgtccggtg	agaggcaagg	acttttctc	tttagggcat	tctgaccacg	tcctgcttca	60
gagagattgt	tcctcgcgctc	tcagtgtctat	ggggagcagg	ttctctcttg	tcctgctctc	120
aggctctact	gtcttacttg	ctctgccagg	atcagaagcc	aagaattctg	gagcttctctg	180
tcctccatgc	cctaaatag	ccagctgcc	caacagcacc	cactgtactt	gtgaagatgg	240
ctttcggggc	aggtctggca	ggacatactt	tcattgattcc	tctgagaagt	gtgaagatat	300
taataaatgt	gaaaccgggc	tggaagagtg	caagtataaa	gcattattgta	ggataaaagt	360
tggaaggttac	atctgtagct	gtttggtaaa	atatacttta	ttcaactttc	tggtgtgtat	420
tatagattat	gatcatccgg	attgttatga	gaacaatagt	caaggagcga	cacagtcaaa	480
cgtggatatt	tggtgtgagt	gggtgaagcc	tggttttggg	aaacagctgg	tacgtataac	540
tatgccattc	tcctacccaa	acattaacat	gtcttctctg	gatttttagg	gtagggtagt	600
tctatccagg	ggtaattttg	tcctctgtcc	caaggtcacc	tgtaaatgac	tggggacact	660
tttggttgtc	ataccttggg	ggtgtatgtg	gtgactggca	tctggtggat	ggagaccagg	720
gatacagctc	aacatcctac	agtgccagg	acagcctccc	acaatcaaga	agtgcctagt	780
gccatagtgc	catagagata	gagaaatata	agtgtagggg	gaaagtgcct	cagctggcac	840
ccaaagacct	acatcaagca	cctagattct	caatgccaca	cgcaccttgt	agcaccctaa	900
taaatatcgt	tgcttctctg	gtctccact	ccaacacttg	tgcatattcc	ctatttctta	960
catttcagta	agagtcaatc	taattagctt	aatttttttg	gaaggaaaat	ctgagaagaa	1020
atggaagcag	agaggacttt	gcaagaagg	ctactcaact	aattcaaaag	gtggagtga	1080
gcattctgaa	tgcgagtgtt	gcttctccag	gaaagggtca	aattttctgaa	tttgatatag	1140
tctatgaaac	caagaggtgc	aatgagacaa	gggagaatgc	ttttctggaa	gctggaaata	1200
acaccatgga	tatcaactgt	gctgatgctt	taaaaggaaa	cctaagagag	agcactgcag	1260
ttgccctatc	acttatcaat	ctcttgggga	tattctgaat	gcattctttt	ttagtataacg	1320
aaaagggatg	caggaagtaa	aactgaactc	ttacgttgtg	agcggcacca	tcggttttga	1380
ggaaaaaatt	tcctctctctg	aacctgtgtt	cctgactttt	cgccataatc	agcctggtga	1440
caagagaaca	aaacatatct	gtgtctactg	ggagggatca	gaggaggcc	gctgggtccac	1500
ggagggctgc	tctcatgtgc	acagcaacgg	ttcttacacc	aaatgcaagt	gcttccatct	1560
gtccagcttt	gccgtcctcg	tggtctcttg	ccccaaaggag	gacctgtgtc	tgaccgtgat	1620
caccaggtg	gggtgacca	tctctctgct	gtgctcttcc	ctggccatcc	tcaccttctc	1680
cctgtgccgg	cccattccaga	acaccagcac	ctccctccat	ctagagctct	ccctctgctc	1740
cttctctggc	caactcctgt	tcctgacggg	catcaacaga	actgagcctg	aggtgctgtg	1800
ctccatcatt	gcagggtgc	tgcaacttct	ctacctggct	tgcttcaact	ggatgctcct	1860
ggaagggtcg	caactcttcc	tcaccgtcag	gaacctcaag	gtgqccaact	acaccagcac	1920
gggcagattc	aagaagaggt	tcattgtacc	tgtaggctac	gggatccag	cgtgtgattat	1980
tgtgtgtgca	gcaatagtgt	gacccagaa	ttatggaaca	tttactcact	gttggtctaa	2040
gcttgataaa	ggattcatct	ggagcttcat	ggggccagta	gcagtcatta	tcttgataaa	2100

```

cctggtgttc tacttccaag ttctgtggat tttgagaagc aaactttcct ccctcaataa 2160
agaagtttcc accattcagg acaccagagt catgacattt aaagccattt ctcagctatt 2220
tatcctggggc tgttcttggg gccttgggtt ttttatgggt gaagaagtag ggaagacgat 2280
tggatcaatc attgcatact cattcaccat catcaacacc cttcagggag tgttgctctc 2340
tgtgttacac tgtctcctta atcgccaggt tcgaatggaa tataaaaagt ggttagtggt 2400
gatgcgaaa ggggtagaaa ctgaaagcac tgagaagtct cgtctacta cccaaacca 2460
aacggaagaa gtggggaagt cctcagaaat ctttcataaa ggaggcactg catcatcatc 2520
tgacagatca accaagcaac cgcagccaca ggttcacatc gtcctgctg cttgcctaaa 2580
gatgaactga cctggcaagt gccatggcaa tgaccggaa gttaccctc ctttccgttt 2640
gtctacagcg cccctgtggt cacacataga ttggacaaat gccactattt ctactcttcc 2700
tgtgaaagt ctagggtcat tcacctattt tggcttttta tgttcataga aagaacaaga 2760
catttgggag aattcttaga tccagagtcc agtagtggtg cagtgcaat gaagtgtcgg 2820
aaggatgcat tttaaagatg gcggggcgga gaagtggatt ttcttcttgc agctactgcc 2880
acctggccag aaactcacta actggcatct ggattcagct catagtctcc tttctggcct 2940
cctgtctgta ttttatgctc ccaaagatct tacattaaca ctccacattc acataattca 3000
acaattttca tatggatcag tattaagag ggtgttgcat tttgcaatc aaaaatgcat 3060
tatcaggtgc tggagagatg gtggagaaat aggaacactt ttacactggt ggtgggactg 3120
taaaactagt caaccattgt ggaagtcagt gtggcgattc ctcagggatc taggactagg 3180
aataccattt gacacagcta tcccattact gggatatata cccaagggtc ataatcatg 3240
ctgctataaa gacacatgca cactgaaaaa aaaaaaaaaa 3280

```

<210> 33
 <211> 1297
 <212> DNA
 <213> Homo sapiens

```

<400> 33
ccacgcgtcc ggactgcttt acggacattg gatgaagccg aagcatttag aatgggtcct 60
ggcacacagt tgggtgcgtga tatggttaag ctttgtgtcc ccaccacat ctcacttga 120
atgtgacggt ttccccgggt cctcctctgc gccatgtgaa gaaggtcggt gcttccccct 180
caccttcac caccatgatt gccatggatg ctcccactc caaagcagcc ctggacagca 240
ttaacagagt gcccgagaac atcctgcttg agctgttcac gcacgtgcc gcccgccagc 300
tgctgctgaa ctgcccgtcg gctgcagcc tctggcgga cctcatcgac ctcatgacc 360
tctggaacg caagtgcctg cgagagggt tcataccaa ggactgggac cagcccggtg 420
cggactgaa aatcttctat ttctacgga gcctgcatag gaacctctg cgcaaccctg 480
gtgctgaaga ggaatgttt gcatggcaaa ttgatttcaa tgggtgggac cgtggaagg 540
tggagagcct ccctggagcc caggggacag attttctga ccccaaagtc aagaagtatt 600
ttgtcacac ctacgaaatg tgctcaagt ccagctggt ggacctgta gccgagggct 660
actgggagga gctactagac acattccggc cggacatcgt ggttaaggac tggtttgctg 720
ccagagccga ctgtggtgc acctaccaac tcaaagtga gctggcctcg gctgactact 780
tcgtgttggc ctcttcagag cccccacctg tgaccatcca acagtggaa aatgccacat 840
ggacagaggt ctctacacc ttctcagact accccgggg tgtccgctac atctcttcc 900
agcatggggg cagggacacc cagtactggg caggctggta tgggccccga gtcaccaaca 960
gcagcattgt cgtcagcccc aagatgacca ggaaccaggc ctctcccgag gctcagcctg 1020
ggcagaagca tggacaggag gaggctgccc aatcgcccta ccgagctgtt gtccagattt 1080
tctgacagct gtccatcctg tgtctgggtc agccagaggt tctccagac aggagctgag 1140
catgggggtg gcagtgaagt ccctgtacca gcgactcctg ccccggttca acctaccag 1200
cttgtgttaa cttactgtca catagctctg acgttttgtt gtaataaatg ttttcaggcc 1260
gggcaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa 1297

```

<210> 34
 <211> 2184
 <212> DNA
 <213> Homo sapiens

```

<400> 34
ggcacgaggg gcccgaggat gtgctgctgg ccgctgctcc tgcgtgggg gctgctcccc 60

```

gggacggcgg	cgggggggctc	gggccgaacc	tatccgcacc	ggaccctcc	ggactcggag	120
ggcaagtact	ggctggggctg	gagccagcgg	ggcagccaga	tcgctctccg	cctccagggtg	180
cgcactgcag	gctacgtggg	cttcgggttc	tcgcccaccg	gggcccattgc	gtccggccgac	240
atcgtcgtgg	gcgggggtggc	ccacggggcg	ccctacctcc	aggattattt	tacaaatgca	300
aatagagagt	tgaaaaaaga	tgctcagcaa	gattaccatc	tagaatatgc	catggaaaaat	360
agcacacaca	caataattga	atttaccaga	gagctgcata	catgtgacat	aaatgacaag	420
agtataacgg	atagcactgt	gagagtgtac	tgggcctacc	accatgaaga	tcaggagaaa	480
gctgggtccca	agtaccatga	ctccaatagg	ggcacciaaga	gtttgcgggt	atgaatcct	540
gagaaaaacta	gtgtgctatc	tacagcctta	ccatactttg	atctgggtaaa	tcaggagcgc	600
cccatcccaa	acaaagatac	aacatattgg	tgccaaatgt	ttaagattcc	tgtgttccaa	660
gaaaagcatc	atgtaataaa	ggttgagcca	gtgatacaga	gaggccatga	gagtcctgtg	720
caccacatcc	tgctctatca	gtgcagcaac	aactttaacg	acagcgttct	ggagtcggcg	780
cacgagtgtc	atcaccccaa	catgcccgat	gcattcctca	cctgtgaaac	tgtgattttt	840
gcctggggcta	ttggtggaga	gggcttttct	tatccacctc	atgttggatt	atcccttggc	900
actccattag	atccgcattla	tggtgtccta	gaagtccatt	atgataatcc	cacttatgag	960
gaaggcttaa	tagataatcc	tggaactgag	ttattttaca	caatggatat	aaggaaatat	1020
gatgctgggg	tgattgaggc	tgccctctgg	gtgagcctct	tccataccat	ccctccaggg	1080
atgctctgagt	tccagctctga	gggtcactgc	actttggagt	gcctgggaaga	gctctggaag	1140
ccgaaaagcc	aagtggaaat	catgtgtttg	ctgttcttct	ccatgctcac	ctggctggca	1200
gagcatcagg	ctgcgtcatt	tccgaaaagg	gaaggaaatg	aaattacttg	cctatgatga	1260
tgattttgac	ttcaatttcc	aggagtttca	gtatctaaag	gaagaacaaa	caatcttacc	1320
aggagataac	ctaattactg	agtgtcgtca	caacacgaaa	gatagagctg	agatgacttg	1380
gggaggacta	agcaccagga	gtgaaatgtg	tctctcatac	cttctttatt	acccaagaat	1440
taattcttact	cgatgtgcaa	gtattccaga	cattatggaa	caacttcagt	tcattggggg	1500
taaggagatc	tacagaccag	tcacgacctg	gcctttcatt	atcaaaagtc	ccaagcaata	1560
taaaaaacctt	tctttcatgg	atgctatgaa	taagtttaaa	tggactaaaa	aggaaggtct	1620
ctccttcaac	aagctgggtcc	tcaqccctgc	agtgaatgtg	agatgttcca	agacagacaa	1680
tgctgagtgg	tcgattccaa	ggaatgacag	cattacctcc	agatatagaa	agaccctata	1740
aagccagaac	cctttgggtg	gtggcagctc	ttcttccctc	tccccctgcc	acagagattt	1800
ctccccatcca	acttgcctgt	ttgccttctg	ctaactcagc	tgacgcgtga	gcaccaagag	1860
cttggtgatca	aaattctgtt	ggacttgaca	atgttttcta	tgatctgaac	ctgtcatttt	1920
aagtacaggt	taaagactgt	gtccactttg	ggcatgaaga	gtgtggagac	tttctctccc	1980
catttttccct	ccctctcttt	tcttttccat	gttacatgag	agacatcaat	caggttctct	2040
tctctttctt	agaaatatct	gatgttatat	atacatgggtc	aataaaaaaa	aactggcctg	2100
acttaagata	accattttta	aaaattgggc	tgctcatgtg	gaataaaaga	attctttctt	2160
ccctaaaaaa	aaaaaaaaaa	aaaa				2184

<210> 35

<211> 949

<212> DNA

<213> Homo sapiens

<400> 35

ggcacgagct	cccattgacc	ttattgctca	gagtgacga	ttagggcaag	gtttcggcac	60
tgctctccctc	catgaatgta	tttctccctc	ctgcccctgg	gacatgggga	gtggcccggt	120
tcttttcccca	tctagtccca	gaaagatgg	gtttgggttt	ctgttgttgg	attttttttt	180
tttttttttt	tttttgacc	aaagtggcaa	ctaggtcagt	gttgggggat	caagctggcc	240
tcgggggtggg	gggcccccc	ctgcctctcc	ctggttccca	cagtgttagc	gtccctgaaa	300
agacaaatatt	ctctctaaag	caataagggg	tgacgggccc	gggggagtg	ttgctgctgc	360
tgggccccag	ctccccctcc	ctgccaggtg	tgggggagac	tcctgttgtg	actgaatgta	420
acccccccac	ccctgccgca	gccaatgcag	gggaaggggg	acactcttcc	tgtctctct	480
ccccagctaa	agagactttg	gacttagggg	gccccatgag	ctggagaggg	cttaaccctg	540
tgagggaagta	taggggggagc	cctctccccc	ccccatcccc	ttctgagagt	ggtcaatgtt	600
tacaagcccc	tgagcccccc	tgcccaggga	ctcagacccc	gttctgtctc	ttccccggcc	660
ccgggtcttcc	tgggccctcg	ctgctctctc	qccctttctg	gggttgggg	gggtgcaggg	720
gtcacccgtgt	tccctgtctg	ccttgtaccc	acagtctccc	cgccccctct	ccaccctgtg	780
tgaacttccct	ctcttttaac	tgtctctgta	aatactccct	tctcccaata	aaacttgggtg	840
tgtgttctcc	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	900

aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa

949

<210> 36
<211> 3338
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (2861)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (3328)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (3330)
<223> n equals a,t,g, or c

<400> 36
taccgggaca ttctggagtc cgagaagtca acggcgcggt tgctgcggcc gccgcgctcc 60
ccggcccgag gcgatggaga acggagcggt gtacagcccc actacggagg aggacccggg 120
ccccgccaga ggcccccgga gcggcctcgc tgcctacttt ttcattggcc ggctccatt 180
gctccggcgc gttctcaagg gcttgcagct gttgctgtct ctgctggcct tcattctgtga 240
agaagtgtga tcacaatgta ctttatgttg aggaactttat ttttttgagt ttgtaagctg 300
cagtgccttt cttctgagtc tccttatact gattgtgtat tgcactccat tttatgagag 360
agttgatacc acaaaagtaa aatcatcgga tttttatatt actttgggaa caggatgtgt 420
gtttttgttg gcatccatca tttttgttcc cacacatgac aggaacttcag ctgagattgc 480
tgcaattgtg ttggatttta tagcaagttt tatgttctta ctgacttta tcactatgct 540
gtatgaaaaa cgacaggagt cccagctgag aaaacctgaa aataccacta gggctgaagc 600
cctcactgag ccacttaatg cctaaagact ctggggagca gatgttacct aaggtagtga 660
cctgcattg tgggtcctga gccctggcag aagctcttgt aaaatttgtt aattgtttaa 720
accacttctt tgggagagca aggggaaggt caagaaggca gttttatcaa tattgtgtca 780
gtcaccacaa agtaggccag ataagttaaa aaaaattttt ttttaataa taattgaaac 840
ttatctcaaa tggagatttt ggtgggagga ggagaaaaca attgttttta aatcacacag 900
ctcaacggtt gataaatgat tctgtcattc tgttacaggt cattctttta ctaggcttag 960
cttccaaatt atgctttata gctgtataaa catcgtgatt atattcatct acttagaaat 1020
tgttttattt ttaaatattt ttgcttagct gttgttttg atgcttagat tatgttctgt 1080
taatgggaat ttaacatatt taagaaacca atatttaaaa tgttggctta ggtttttttc 1140
cttaacatat attaccagyc ttactgtat ttcactcagc cttaaatgtt ataattttt 1200
tggataacgg ttattaatcc tttgagacct tcgtatagcc tataaatgtt atgggagatg 1260
ttggtatttt atgtgtataa aagcaacaat atcagcaact tctgttttat actgcacett 1320
ggttgttgat gtcaagtaaa aaaaagattg ttttgaaca cataaaaaa tggagaaac 1380
tgataccaca cctaaggacc aaagataaga aagacttttt gcccaagaca gtgaaagtaa 1440
ttacaaaaac aagctttgac cacttaccaa gtatcgaag agatgagttc atactatgat 1500
ttagaaagtg g-tcaattcc cctgttgga tatgattatt ttactaaaa ttaatacagc 1560
tctgtgggtc ttctttagtg ttttcttga agccaatctg ttttttttag gacaccagcc 1620
tttgggtttt catctgttcg agatgcctcl tctctgtctc cttatcagat agaaatggag 1680
tcattgtctg ctgcttcac tagcagaggt tggcctcttg ctctgacact tttgtcagc 1740
tgtctttagg tggctcctgaa tcttggggcc ttttgattgt gaatactgt tagcaggatc 1800
ttgagagtc ttgttcttac ataggcattg ctctagtgtt tctttggcaa aaaaaaaaaa 1860
aaaaaaaaag aaatatccag ggaacctgc ccagactaat actgttggtg gcaaaagaga 1920
atcaagccat tctcaagaga taacttcata accagaattg tctgttggtc agcagcgtc 1980
acagataggg agggcacttg ggatatgacc tttctgtcca ggtgattcac agactagacc 2040
tttcttatcc tctctctaga gttttgactt gggactctag tgtaaagatg atgagcccg 2100

gcacacaggtc	cttctgcact	ttgggtggaag	tctcccaggg	taggtttccct	atttgaacaa	2160
gtggaatcat	gtttccagtg	ataaagttaa	atgacctcat	cctttttttt	ttttctcatc	2220
tgccatttgt	gtgtcttaga	tgggttttaa	ttgcatgaat	g:ggctaagt	tggtttctcag	2280
aaattggtea	gtatggcccr	acatagcttc	tgctctgtct	tactgactca	atacctttag	2340
gatttgatc	agagtgttga	tactagtgtt	agtgggtgtg	tcaccactac	ttaattggga	2400
gataatgaaa	ccaatcargg	atgctgtttt	tattgggcat	gtcatctaa	agaggagaaa	2460
tagctgggtt	ttgggtctaa	ttatgaataa	ggactgattc	agaaaacgag	tttatggtag	2520
gtagectaaa	gtttcacatc	agactgtacc	attgtgattt	agacctatct	aaaattcaga	2580
gcataatcat	tgggttacct	cagggtcacc	acccatgtat	tgggtctagt	caggattgac	2640
agatacatc	tcagctggcc	tgcatataa	aacatactgt	cattgagctt	aagctccgct	2700
tggtctgagg	tttcacctcc	atgtgtttca	ttggtgcaaa	agtggatctc	ttagtgggtc	2760
acttaattct	ttctttttca	gaagatagtg	atgttccacty	gtatatattg	tcactcttag	2820
aaccttcctt	cacattgttt	tttatgggac	ccatgaatgg	nttagcctct	cttttctatt	2880
gtagaaggaa	ataaatagga	gtaaaaagac	cattgtagta	aataagttca	aggggaactt	2940
gggaccagaa	accactgtta	tgtacaaaaa	aattggcaaat	tcaataaact	caaattttaa	3000
ataattttta	aattaacagt	tatgataaat	tttatatttt	atcaaatag	attgcttaga	3060
atggttctca	agaattataa	gagaaatgaa	ctcagactac	aaaaatttta	taattactat	3120
acttgtgttt	tggttggggg	ctgggaaatg	tatttttaca	ttgtagccaa	tcattttata	3180
tttgccaatt	taaatcttat	gggtcctttt	ttttttatct	ctcttgatgt	cagattttat	3240
agtcttttta	aataaatcca	tttaattaaa	acgttaaaaa	aaaaaaaaa	aaaaaaaaa	3300
gggcggccgc	tcgcgaatct	agaactangn	cccacgcg			3338

<210> 37

<211> 1563

<212> DNA

<213> Homo sapiens

<400> 37

cgccacgagg	agaaaaaggac	tcagaccttc	cagattggct	ccagaaggca	gctgctgtca	60
gtgattttcc	ttacagacca	ttgcagccac	ctaccttgcc	ccatgggtccc	gagacagcat	120
ggcgtcttcc	cccacacgga	cctgcagggtg	gcctcttagg	agctttctcg	ctgaaggagg	180
tcacccctct	tagtcacatc	tgagcagcac	tcacttaggc	ctcggccccc	agggtcacgc	240
gggggcaact	ggccgggttc	ccggctctgt	ctggctctgc	atctgtctgc	ctttgggcta	300
ccttttcggc	acagctccct	gggcctgtgg	ctgctacaag	ctggactcca	gctccctctg	360
gctgcagtgc	tgctcgcagt	ggccagaaa	agaggctggg	cacagcggct	cctggctcag	420
cagatccct	ggcgcaggct	ggcccaggag	ctccgtgcag	ggtgctgcca	gttgaccagg	480
ccccggctgc	actcaatgtc	cgagaaccgg	gctggctggg	gggcctctt	gacggagctt	540
tactccaagt	cttgctgaat	ttcctgagga	aaagcactga	tggtctcatg	gacacaagg	600
aggcagaatc	tcttgaagta	gaataaactg	cactcctttc	cagtcttctt	ttctcagctt	660
ctcctggacc	gccagctcct	ccatgcgcct	cagacactcc	caacgcgcga	ctgcgggggt	720
tctcccgcc	ctggcccatc	tcacccccct	tggtctgtga	tacagctccc	ctgtgtgcat	780
gtcgcctgt	ggcagatgct	cagggaactc	tcagactcca	ggatcactcc	gagtacactg	840
accacacagc	ctgctgcaca	aactgcagcg	ccagctaagg	accaggaatc	tgacattgtc	900
ggaggtgaa	ggatcccttg	tgacatagct	ttcctccagg	aggaccatcc	actgggtgtc	960
gggggagctt	ctgcccgaag	tagcaggagg	gagctgtcaa	ggcgtggagt	tcacactcaa	1020
acactccagc	aggacggcac	tctgcatggg	acgccatcca	gctccttga	ctgtggaatc	1080
aagtacatta	tcagctggcc	cctggctcct	ggctgtgacc	tccctctcgt	tgaactgagc	1140
cttgtgtgta	agggcgtatc	aagtgtgtatg	ggcttcgccc	ctgggtgacc	ccaaatgcaa	1200
ctccaggaag	catgggttac	caatgactaa	ggttaacgat	cagctgggcg	cgtgtctgac	1260
gcctgtaatc	ccagcacttt	gggaggtcga	ggcgaatgga	tcacgaggtc	aggagtccaa	1320
gaccagcctg	gccaacatgg	tgaaccctcc	atctctacta	aaaatacaaa	aattagccgg	1380
gcgtgggtggc	gggcgcctgt	agtcccagct	actcaagagg	ctgagggcagg	agaatcgcgt	1440
gaactcggga	ggcgcagctt	gcagtgcagt	gagatctcgc	cgcctgcact	ccagcctggg	1500
cggcagagcg	agactccgtc	tcaaaaaaaaa	aaaaaaaaaa	aaaaaaaaa	cagggggggg	1560
ccc						1563

<210> 38

<211> 1048
 <212> DNA
 <213> Homo sapiens

<400> 38
 cccgggtcga cccacgcgtc cgacaaaaa caaggatgt gtgtgccttg ggatgctttt 60
 ctgggcttac cccatctgtg tcttcataga ttctctgtcc tggcagccat gtctttgggc 120
 cacaggagcc acttcccact tcaactctcc cacaacctcc ccactgttta ctctcttcat 180
 gccctgtgct ctgcccacaa atcccttcac ccaattggga aaactggatg atagataagt 240
 agtttcttat ttacatgcat ttctctggaa ataaagtgt ctttccagct agtatttcct 300
 caggtcggaa gcatgtgtaa aataacacat ggaaactatt tccacctggc acataagaaa 360
 aaaagggctc gcctatattg taactgactt ctacactttg catgttttag tctgaccac 420
 aatttttttt ttggatagt tgaagtaaaa aacgtgggta caagatgact aaagtgtggc 480
 ctacaatttc ctgtttggac aacaggaaga attgtgcagt gttttgcaac aggactaatt 540
 ctagattctc actgccctta aagataacta gagggaaagg gtcttctctt tcttttcat 600
 ttattaaaga tacttacagg ttcttcagaa gaagtgtagg gtctttagg taatgaaata 660
 ggtgttgatg gtgttatggg gatgatgta actggtggcg gctgtataaa gtcttcatcc 720
 ttaaacatca gaactgagag ttgggttact gatttaaaag aaaatgtgta ttaattctaca 780
 gtccactacc ttgactacca ggaacttgtc acaactacct catatcctgg cacaggattc 840
 aaaaggcaaa atctggaacc taattacgtg tagccaaata ttaagtttcc tcttagatca 900
 aacagtacaa taaatattcc ttattaagga aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 960
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1020
 aaaaaaaaaa aaaaaaaagg gcggccgc 1048

<210> 39
 <211> 1430
 <212> DNA
 <213> Homo sapiens

<400> 39
 cggcagcagg agcagctgag tcccttccct gtctttcact ctctcggcat cgggtgtttt 60
 actctctcga ttgaacctcg ctctctcgac cccctggga ggccgccttc ttcaggcgcc 120
 tccctctctc ccacgagctc gctctgacag ctgaggaaact ggcaagatcc tgctaccacg 180
 aggggtgaatg ggtatcttct ccggaataat cctaattttt ctaagggtga agtttgcaac 240
 ggccggccgtg attgtaagcg gacaccagaa aagtaccact gtaagtcagt agatgtctgg 300
 tctgaattgg aaaccttttg tatatggcgg ccttgccctc atcgtggctg agtttgggac 360
 ttccctgtg gaccttacca aaacacgact tcaggttcaa ggccaaagca ttgatgcccg 420
 ttccaagag ataaaaataa gagggatgtt ccattgcctg ttctcgatct gtaagaggga 480
 aggtgtattg gctctctatt cagggaattgc tccctgcctg ctaagacaag catcatatgg 540
 caccattaaa attgggattt accaaagctt gaagcgctta ttcgtagaac gtttagaaga 600
 tgaactctt ttaattaata tgatctgtgg ggtagtgtca ggagtgtat ctccactat 660
 agccaatccc accgatgttc taaagattcg aatgcaggct caaggagct tgttccaagg 720
 gagcatgatt ggaagcttta tcgatatata ccaacaagaa ggcaccaggg gtctgtggag 780
 ggtaagtact cttttcctgc tattatccta cactctcagt tctacaatt tgcaagaaat 840
 ttttttttat ataaagacat aaaatcgtga attataatcc aaaaactaag gtaagaaact 900
 cctcatctcc cttgaaaggc ccaaaactta tcattggcct ttattttctg cataatgttt 960
 ggggattata taggtgggga aagttattac attatttgag atggctgttt cgatcatatt 1020
 cacagtgaat gtagttgttc agtgtatttt ttgcaagtt ctgtactaac acgatgatgt 1080
 agtctttgt agtcttatg ttcaaaagct gttaccggct gtgtgctgtg gctcatgcct 1140
 gtagtcccag cactttggga ggccaaacgg ggtggatcac ttgaggtcag aagtccaaga 1200
 ccagcctggc caacctggtg aaacccatc tcaactagaa atacaaaaat tagccaggca 1260
 tgggtggtgca tggctgtggt cacagctact caggaggctg agggcggaga attgtttgag 1320
 ccctggaggt ggagggtgca gtgagccaaq atcatgccac tgcactccag cctgggtgac 1380
 ggggcgagac tctgtctcaa aaaaaaaaaa aaaaaaaaaa aaaactcgag 1430

<210> 40
 <211> 2103

<212> DNA
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (2101)
 <223> n equals a,t,g, or c
 <220>
 <221> SITE
 <222> (2102)
 <223> n equals a,t,g, or c

<400> 40
 ttccctcgtag cgagcctagt ggccgggtgtt tgcattgaaa cgtgagcgcg acccgacctt 60
 aaagagtggg gagcaaaagg aggacagagc cctttaaaac gaggcgggtg gtgcctgccc 120
 ctttaagggc gggggtcccg gacgactgta tctgagcccc agactgcccc gagtttctgt 180
 cgcaggctgc gaggaaggc cccctaggctg ggtctgggtg cttggcgcg gcggcttcct 240
 ccccgctcgt cctccccggg cccagaggca cctcggcttc agtcatgctg agcagagtat 300
 ggaagcacct gactacgaat gctatccctg cgagaacagc tattccacga gaggatccgc 360
 gagtgtatta tatcaacact tctgtttgca acaactgtaca tccctotgcca catcttctcg 420
 acccgcttca agaagcctgc tgaattcacc acagggtgtc ctgggcccgg tctmtgagac 480
 agtgggtgat ttgatgctcc tcactctgct ggctgctagg atgggtgtgg tggcatcagc 540
 cattgtggac aagaacaagg ccaacagaga gtcactctat gacttttggg agtactatct 600
 cccctacctc tactcatgca tctccttctc tgggtttctg ctgctcctgg ctgctggaag 660
 acctggagga gcagctgtac tgctcagcct ttgaggaggc agccctgacc cgcaggatct 720
 qtaatcctac ttctctctgg ctgcctttag acatggagct gctacacaga caggctcctg 780
 ctctgcagac acagagggtc ctgctgggta tgtggcttcg tagggcttgg gataacctgg 840
 ttcccccaag gagagttagc cctgggttcca ggtgcttgcg gacagcctcc catccctgca 900
 cagagaagag gcggaaggct tcagcctgkc aacggaacct gggctacccc ctggctatgc 960
 tgtgcttgcg ggtgctgacg ggccctgtct tgctcattgt ggccatccac atcctggagg 1020
 tgcctatcga tgaggctgcc atgccccgag gcctgcaggg tacctcctta ggccaggctc 1080
 cctctcccaa gctgggctcc tttgtgtccg tcattcaggt tgtactcatc tttaccta 1140
 tgggttcctc agttgtgggc ttctatagct ctccactctt ccggagcctg cgccccagat 1200
 ggcacgacac tgccatgacg cagataattg ggaactgtgt ctgtctcctg gtccctaaag 1260
 cagcacttcc tgtcttctct cgaacctctg ggtcactctg ctttgacctg ctgggtgact 1320
 ttggacgctt caactggctg ggcaatttct acattgtgtt cctcacaac gcagcctttg 1380
 cagggctcac cacactctgt ctgggtgaaga ccttcaactg agctgtgcgg gcagagctga 1440
 tccgggctct tgggctggac agactgcccg tgcctgctc cggtttcccc caggcatcta 1500
 ggaagaccca gcaccagtga cctccagctg ggggtgggaa ggaaaaaact ggacactgcc 1560
 atctgctgcc taggcctgga gggaagccca aggtactctg gacctcagga cctggaatct 1620
 gagagggtgg gtggcagagg ggagcagagc catctgcact attgcataat ctgagccaga 1680
 gtttgggacc aggaacctct gcttttccat acttaactgt ggcctcagca tggggtaggg 1740
 ctgggtgact gggcttagcc cctgatccca aatctgttta cacatcaatc tgcctcactg 1800
 ctgttctggg ccatccccat agccatgttt acatgatatt atgtgcaata ggggtgggta 1860
 ggggcaggga aaggactggg ccagggcagg ctggggagat agattgtctc ccttgcctct 1920
 ggcccagcag agcctaagca ctgtgctatc ctggaggggc tttggaccac ctgaaagacc 1980
 aaggggatag ggaggaggag gcttcagcca tcagcaataa agttgatccc aggggtttgct 2040
 ttgttttttt aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2100
 nna 2103

<210> 41
 <211> 2349
 <212> DNA
 <213> Homo sapiens

<400> 41
 tcgacccacg cgtccgtcta ttctctgtgc tgtatgtatg ggtatgtgtc gattgtgtgt 60

ctgtggtgta tttctgtgtc tgtatgtatg ggggtgtgtg gattgtgtgt gtgtctgtgt 120
tatctctgta tgtatggggt gtgtctgtgt gtgattgtgt gtgtgtctgt tgtatctctg 180
tgtctgtatg tatggggtgt gtctgtgtgt gattgtgtgt ctgtgtctat gtgtgtgtgt 240
ctttgtgtga tttttgtgt atatggcaaa cccagaacag aacattatca ctccacctac 300
ctggcaaaac aaaaagcttt cagagagatg tgtggccgtc atgatgtctc agctgcaggc 360
atctttcaaa gttatgtttg atgcagctgg cactttctct ctccgggaca aatgtgatct 420
ttgatcatg agttgagaat gagtttactc aataatttta aatgcctcg gtgtgagagg 480
atgggtgctt agtaaacatt tgtggcaaat atgcgttgc ttttctctct tcaagtgcct 540
ggggcaggct gcttctctgc acgtccatct ggggtcagt ctgtctctgc acctcccttg 600
cccagggtct tagtgccctg tgtggatcac ggctgcccc gggatgctgg ggaaggattc 660
agcccaacaa atagattcgt tgacgtctc tcaacgaatg tgtgctttta aaaaatgtct 720
taattttgca ctccatttca tacaacaggc gcacatttaa aacatttatt ttaaacagc 780
tctgtctctc cagcactgca gactatttct cgtcacttg acaggcagac gtgggacta 840
tgttcttttc ctgccaagaa tccatcagcc ccccaatgcc tgcacctcga gtccagactc 900
cttagcgttg cgttgggagc taattcccc ttagcatccc cagcccttct tccccctgtg 960
agccagcctg ggttcttttc ttttctctt ctccctgtt tctctcttt cttttttggg 1020
tttgaataa gtaatatata gtgtgtgtgt taagaaatca aaataataa gaagatacgg 1080
cttgaggatt ctgtctctgc actggtcctt ccgccaggac ctggtgcgtc ccccaagagg 1140
gccttgccat gtgcgagctg agacacatgt tcacacttct ctctttttt gtacaaaagg 1200
tagcacatgg taaatagcgt ctgcacgtct ctccctctgc tctgtctctg ggactactcc 1260
acatccatga agaagcagca tcttatttct ctgcacagt gggcagtgcc tacactgtat 1320
tcactcgtct ctgctgatgg gcaactattg agtgggtcaa ttagtacct agtatcatg 1380
cccttcagcg tgtgtactgg tgtatggatc tcacattccc agaggctgag tgaagaataa 1440
aaggcttttt gacagtattc ctccaggtact cacacactcg ctctgtgagc cactgtatca 1500
tgggagcggc tccctgcaga ggtgtctgat gggagaggct gatgtccttg tctgatggtt 1560
gtcccaacct gagaatgggt agtgcctctc ccaatgcaga ctctcatcac ttgcactcct 1620
tgctgtgagt tgaactgctt ctcaatttat tttctatctt tgtttgcca tattttagct 1680
gggttgctaa tcttttaatg ttttctaggc gcttttcata aattaggagg tttagctgta 1740
gtgatgtgg ttgaaagtat ttttcaaat cgtcattgtc ttgacttctc tttttttttt 1800
tcttttgcca cttaaaatat gtagtgaat ctcaagtatt gggggcttct ggattttgag 1860
tcgtagtga aaaggtcttc ctattctgag gttatacagg aattcaccct ttttttctct 1920
aatattttat ttccatttaa actttcgacc cacttgact gattttgtt tatggtgtca 1980
agtatgggtc caagtttgc tttctgacct ggggatccca acatcgttca tcaaaatctc 2040
catgttggcc gggcgtggtg gcccaagcct gtaatccag cactttggga ggctgaggtc 2100
ggtggatcac aaggtcagga gatcgagacc acctggcta acacggtgaa atcctatctc 2160
tactaaaaat acaacaaatt agccgggtgt ggtggcaggg acctgtagtc ccagctactc 2220
aggaggctga ggcaggagaa tgcgttgaac ccgggaagcg gaggttgag tgagctgaga 2280
ttgcgccact gcactccagc ttgggtgaca gagcaagact ctgtctcaca aaaaaaaaaa 2340
aaaaagggc 2349

<210> 42
<211> 1559
<212> DNA
<213> Homo sapiens

<400> 42
attcatgcca aaacataggg tttcagtgcc tattacatat ggctttcagc tctctctact 60
gagggatgta ggagtttatt tctgaggtct gagcctcttt tcttttactt cctttactct 120
ttcctaagcc tctttataaa aaactatgca tgttctattg ttttctttt -gatccctt 180
tcttttatta tcccagtag gagtgacttg taattctcat atgttagaaa ggcaggtctc 240
ctggttgaag aaaagatcca cccaagcaag tcagcagttt aataaatttt tgagggggat 300
ctcaaatgtg ggaaggattg ttatataaga caaccaaatg atgacatgag acaataaatg 360
ctataggaat tatggaggaa taattagcta tttattttct tgggttagga agagataata 420
ttagttgtag aagtaattac taacttctac attttttatt gtggaaatca aaaaatata 480
tatgaaata aaatgttata attgacttca gtgtccata aaccagcttc caacaattac 540
caaattgtga ccaatcttt acacacatgc acaggtgccc ctccagatc tgtgggcat 600
tgggtctagg accacttatg gataccaaca tctatggatg ctcaagtccc tgatataaaa 660
tggtggacta tatgcatata acccgtgtac gtcccgattt aaccaaatcc tccctagatc 720

acttacaaca	cgtaacacaa	tctaaatgcc	acgttaacaa	ccgtcatact	gtattaagcg	780
aataaccccg	ccaaaaatgt	acttctctca	gtccagacgc	cttttttttt	tgtgtgtgga	840
atatcccgagc	ccccaagtcc	ccctcaaccc	cctggcacat	aggaggctga	ctgcgtgtgt	900
gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgcatac	agacacacat	atctctgaaa	960
tgtaaaatct	ctctctttaa	aaaaattatt	atcacagcta	aacaaattac	cagtaattct	1020
cttatctctca	tatacccggt	gttcagattt	tctagattgg	ctcctaattt	ttttacagat	1080
tatttgaatc	tgattcaatt	catgtactgt	aatgtttgat	aacttaagta	ccctttatag	1140
gttcctctta	ccacttcttt	attaaattcc	ttgtaatttg	ttgtactaaa	tggattgtct	1200
ccctagaatt	tcctgtagtc	tgaattatgt	ggtaattggt	cacatgttcc	agtgctctct	1260
tatttctctgt	gagttggtag	ttagatctag	aagcttgatt	aaattcagat	tttctctctt	1320
tagatcatca	acttttagatc	atcaacttgg	atcatttgtt	tcattttgct	tttgatatgt	1380
tgtttttttag	aattacctct	taaaatttgg	atttaatttt	ataatcatgt	aaaatgttca	1440
taaatttcca	aattcagatc	agcaaacac	aataaaatct	attcagagaa	ggcaaaaaaa	1500
aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	1559

<210> 43

<211> 1766

<212> DNA

<213> Homo sapiens

<400> 43

cggcacgagg	agcactgaag	tattcactac	atgaagtata	ttttgcactg	tggacacaaa	60
ctagaaaaat	tgcaagtagt	ggatatattg	aattggcatg	cactatatga	gcagagtcaa	120
tgtgtctcct	tgtagaatat	tctctgatga	tactcactat	tatccccctc	ctgctaagct	180
ttgttctctg	tctgaagggc	ataaagcatg	gaaactacat	ttttcagact	ccattaccag	240
aaggatattg	ttggatttca	gcaatgagtg	ggctttgcat	aaaatttggg	agacgaaaga	300
gaagaaaaac	ctggctgctg	caggttgga	cactggcaac	aatagatagc	gagtttgcaa	360
gaagctgcta	agcttctcca	ggaaaattat	ttgtttcaat	atttctggca	tatgggatca	420
tcaactattg	ttttcagtg	ttctggctga	aaattgggtc	aattcttcta	tctgagaatt	480
gttcatttct	gtgcttcagg	aaactaagac	catcactggc	agtttttgg	gagggatcct	540
tgtgcattca	tttttctcta	aaacagcctt	cctaactttt	actccccag	cttctatggt	600
tgtgtaagtc	tttaattctt	agagttacat	ttctcttacc	cagtatatcc	tagtgcggt	660
tctgttttcc	agaccacaac	ctgactgata	tagtctccat	gtgtttcaga	tgggtgggata	720
gtttggatat	ttgtccctgc	ccaaatttca	tgttgaactc	taatccccag	tgctgtaggt	780
ggggcccaat	gggaggtgtt	cggatcatgg	gggcagatcc	ctcacgggct	ggtgctgtct	840
tcgtgatagt	gagttctctg	aagatctggt	catttttaag	tggttggcac	ttgtaccatt	900
tcactgtgtc	ttgtccctgc	tttcccatg	tgaagtgcct	gtccagcctt	cacttttcc	960
catgattgta	aacttctctga	ggcctcccta	gaagccaagc	agatgccatc	accagggttc	1020
ctgtaaaagca	tgcaaaactg	ttagccaatt	atacctcttt	tctttacaaa	ttaaaaacct	1080
cttttcttta	caaaatggaa	agaataaagg	tatttcttta	tagcaatgca	agaacggcct	1140
aatacagatg	gctctgccat	tagtgagaaa	attgagacgc	tttctctaga	tggcaaaaaa	1200
gttgtaaaaa	taaaaggaaa	ttattaatat	accgtctatt	gtgatcattt	actaagttaa	1260
gcataattatt	aagaagacaa	gcataagttt	aacacaattt	ggcaatgaat	aaaattgaag	1320
gagagagagc	atatgttggc	ttgtctctgt	gaaactcaaa	tgaattggte	acctgttcta	1380
gcagctcatg	aaaaattctg	cattgtttat	tatgtgtcag	gatcaacctt	aaattcagtt	1440
ataaaaagtt	tgatgattac	aaaaaaaagg	gaagcactaa	gtaatatagg	tacagagagg	1500
gaagagtgtc	aaatagaatt	tlcaatctgt	gtataaggat	acttaagcat	tttttaagga	1560
aagcagaaaag	aagcatgaga	aagctctaca	tgacatctat	gtcaatataa	caagctggat	1620
atttagagaa	gaaactcttg	attaaatact	ttttatgata	tgaacacaca	catataatat	1680
gacatgactg	tgttcatgga	acataaagaa	attcctctga	ccaaagagaa	ctggaaaaaa	1740
aaaaaaaaa	actcgagggg	ggggccc				1766

<210> 44

<211> 2572

<212> DNA

<213> Homo sapiens

<220>
<221> SITE
<222> (2527)
<223> n equals a, t, g, or c

<400> 44
aattcggcac gagtctggac ettcttagat tgcttgatat caggtctgtt ttgtagccat 60
tttgcttcac agtcacctgg aatgccggga gccctctctc atcccgatcc tctccttgta 120
catggggcga cttgtgcgct gcaccacct gtgctctggc tactacaaga acattcacga 180
catcatccct gacagaagtg gcccgagct ggggggagat gcaacaataa gaaagatgct 240
gagcttctgg tggcctttgg ctctaattct ggccacacag agaatcagtc ggcctattgt 300
caacctcttt gtttcccggy accttggtgg cagttctgca gccacagagg cagtggcgat 360
tttgacagcc acataccctg tggtcacatg ccatacggct ggttgacgga aatccgtgct 420
gtgtatcctg ctttcgacaa gaataacccc agcaacaaac tggtagacac gagcaacaca 480
gtcacggcag cccacatcaa gaagtccacc ttcgtctgca tggctctgtc actcacgctc 540
tgttctgtga tgttttggac acccaacgtg tctgagaaaa tcttgataga catcatcgga 600
gtggactttg ccttcgcaga actctgtgtt gttcctttgc ggatcttctc cttctccca 660
gttcagtcga cagtgggggc gcattctacc ggttggtgta tgacactgaa gaaaaccttc 720
gtccttgccc ccagctctgt gctgcggatc atcgtctca tgcgcagcct cgtggtctca 780
ccctacctgg gggtagcagg tgcgacctg ggcgtgggct ccctcctggc gggctttgtg 840
ggagaatcca ccattggtcgc catcgctcgc tgcctatgct accggaagca gaaaagaag 900
atggagaatg agtcggccac ggagggggaa gactctgcca tgacagacat gcctccgaca 960
gaggaggtga cagacatcgt ggaaatgaga gaggagaatg aataaggcac gggacgcat 1020
gggcactgca gggacagtca gtcaggatga cacttcggca tcatctcttc cctctcccat 1080
cgtattttgt tccctttttt ttgttttgg ttgtaatga aagaggcctt gatttaagg 1140
tttcgtgca attctctagc aactgggta tgcacact gacgggggga cctagtgaat 1200
ggtcttact gttgctatgt aaaaacaaac gaaacactg acttcatacc cctgcctcac 1260
gaaaaccnaa aagacacagc tgcctcacgg ttgacgttgt gtcctcctcc cctggacaat 1320
ctcctcttgg aaccaaagga ctgcagctgt gccatcgcc ctcggtcacc ctgcacagca 1380
ggccacagac tctcctgtcc cccttcacg ctcttaagaa tcaacaggtt aaaactcggc 1440
ttcctttgat ttgcttccc gtcacatggc cgtacaaaga gatggagccc cgtggcctc 1500
ttaaatttcc ctcccgccac ggagttcgaa accatctact ccacacatgc aggaggcggg 1560
tggcacgctg cagcccgagg tcccgttca cactgaggaa cggagacctg tgaccacagc 1620
aggctgacag atggacagaa tctcccgtag aaagggttgg ttgaaatgc cccgggggca 1680
gaaactgac atggttgaat gatagcatt cactctcgtt tctctagat ctgagcaagc 1740
tgtcagttct cccccacc gtgtatatac atgagctaac ttttttaaat tgcacaaaa 1800
gcgcattctc agattccaga cctgcgcga tgacttttcc tgaaggcttg cttttccctc 1860
gcctttcctg aaggtcgcat tagagcagat cacatggagc atcctaactt tgcattttag 1920
tttttacagt gaactgaagc ttttaagtct atccagcatt ctaatgccag gttgctgtag 1980
ggtaacttt gaagttagata tattacctgg ttctgctatc cttagtata actctgcgg 2040
acaggtaatt gagaatgtac tacggtaact cctcccca ccatacgata aagcaagaca 2100
ttttataacg ataccagagt cactatgtgg tctccctga aataacgcat tggaaatcca 2160
tgcaatgcag tatatttttc taagttttgg aaagcaggtt ttttcttta aaaaaattat 2220
agacacggtt cactaaattg atttagtcag aattcctaga ctgaaagaac ctaaaacaaa 2280
aaatatttta aagatataaa tatatgctgt atatgttatg taattttatt taggctataa 2340
tacatttctt attttcgcat tttaataaa atgtctctaa tacaatcagg tgattgcttg 2400
tgtgctcaac atacctgcag ttgaaacgta ttgtatcaat gaacattgta ctttattggc 2460
agcagtttta taaagtcctt catttgcatt tgaatgtaag gctcagtaaa tgacagaact 2520
atttttncat tatgggtaac tgggggaata aatgggttca ctgggagtag gg 2572

<210> 45
<211> 526
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (66)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (106)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (484)

<223> n equals a,t,g, or c

<400> 45

ctctgacagc	ttctcttttg	gccaaagccct	gcctctgtac	agcctcgagt	ggacagccag	60
aggtcnagac	tggagcccag	agcccaagat	ggagcccag	ctgggncctg	aggctgccgc	120
cctccgccct	ggctggctgg	ccctgctgct	gtgggtctca	gccctgagct	gttctttctc	180
cttgccagct	tcttcccttt	cttctctggt	gccccagtc	agaaccagct	acaatttttg	240
aaggactttc	ctcggctctg	ataaatgcaa	tgccctgcac	gggacatcta	tttgcaagaa	300
gttcttttaa	gaagaaataa	gatctgacaa	ctggctggct	tcccaccttg	ggactgcctc	360
cggattccct	ttgstttctt	atccttgcaa	attactccar	atgattycca	aaactctggg	420
sccttggtga	ratcttttaa	ctggctcaga	awtwtcaaac	gaaatctcca	aacaggaaat	480
cttntgcctc	ctgcateccac	ccccaaagaa	cttgacacatt	gacgtt		526

<210> 46

<211> 1032

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (974)

<223> n equals a,t,g, or c

<400> 46

gtaaaattgt	caaacattta	tttttaaaaa	taaaatgtgg	tgggcggtta	tgggtggagt	60
tattgggtcc	tggctgtcgc	cactgagcat	tgtcgaatgt	tgtcatgact	tgtggacttc	120
tcagagctgc	gagcatgcgg	gtgctctttg	tggagatttg	ctctgtgcct	gtaggaaggt	180
gggtgtgtgg	tgtgcattgc	agcaacattg	gtggaacaga	tgtgtgtgcc	cccatgctgt	240
catcagggtt	cattgcacac	gagcctcata	cacactacag	aaaatatgct	cttctaacc	300
caagttcatg	gggaggcatc	cacacagatg	gcagcagatc	aggaaatgct	ctcagccagt	360
cctcaggggc	agtagggcag	ccttcatctg	ggtgcgcttg	gcagccctga	actttatctc	420
ttcttttcgt	tgtatttctt	taatatctta	ttagcatttt	tagtttcttt	agttggatga	480
gttgttcagt	gtctttgtac	tgtacagttc	tcctgtgctg	ttggaatgga	cgtcatgggc	540
tatgttactc	ttttgaaata	caaatttctc	tttagaagtt	ttggaaaatc	tgttagagga	600
ggagtctctga	gaatatgaga	agaactcttg	ccacatagtt	gtgccctgcc	gatgtatttt	660
tccaaaaaaa	ttgaaggctga	acctgttgga	agctcagttc	tgagtttaat	tgactacttt	720
gcagagacac	aacactctct	ttsttagcatg	tcccttgga	gaaaataggc	tgggtgcttg	780
gtggtgatca	gaactggcag	ttattctagg	cctaaaacag	tttggcaata	aaataagaaa	840
aagggggcac	atgtgggtggc	tcatgcttta	atccccacac	tttagagggc	cgaggcaggg	900
ggattgcgtg	aagccagcct	gggcaacata	aaatttaaaa	attagccaga	catggtggca	960
tgtgcctgtg	ggtnacgcaa	cctgggtggc	taagaccgaa	ggatcacttg	agcccaggaa	1020
gtcaaggctg	ta					1032

<210> 47

<211> 2680

<212> DNA

<213> Homo sapiens

<400> 47

ggcagcagtc	ttacagcaag	tacttaacaa	acttagattt	ccataatcag	atttatctca	60
aaccgcacaaa	aaaagctgat	tttattatgt	taaactgata	ggagattttt	atgagagatg	120
aaagtaagcg	attttaactt	tttaattttt	ttaatttttg	ctctgtttct	cacacttgag	180
gcttttctga	aattcaccac	aagagttttg	gcagttgtgg	ggaatttacc	agaaccccc	240
attattaaaa	caatttggtt	cttatattaa	aatcatcaga	caggttttgt	gtacacagac	300
atttatgtta	agccactgga	tagaactaaa	ctgtgtgtag	gaacctgttt	tctctaagaa	360
aggactcctt	tgagtctctg	aggatatgtg	cttaagggtt	ttctgtgtca	agctatttta	420
tgaataaaaa	ttttacaaac	aatgaagctt	catttcacac	cgttgtattt	gtttaatgca	480
gacttggcct	atacagagtt	ttgaaattaa	gggttttttc	cgtaaaacta	gcttaggagt	540
ttaatgagtc	actgtgtctc	tcacctctgt	aggatgagca	cagagatcac	atttgagaag	600
caggtgtggg	tgttttctgc	tggtcacgtc	tcctctgctt	ctcctctggc	tcagcagtta	660
cttttctcca	gtcatggggg	ctgcattcag	ctgcgatgcc	agcattaggg	ccaagctctc	720
ccgcttctgt	gacgttttat	tacacgtact	ctttatcagt	agtagctgcc	attccctgag	780
tgttctctcc	accgtgcact	gagaagggct	gaggatttcc	gaacatcaac	ctcctctaac	840
cctctgtatg	ggaattagat	ttgtatcacc	ctgactgttg	gggttttcta	gagctcaggc	900
aacttgcccc	tgggggggat	ggagcctgcc	tggggggagt	gtgaatgagg	cttctgttgt	960
ctgtggcttg	gctctctgtg	gttggaaact	tcagaagcag	tagattccag	gtgcaacatt	1020
tgggtgcccg	acaagtgtga	aaacctgacc	ttggggaggg	ccctcactgg	cagccagtgt	1080
ccacccttga	gcccggtgag	cacagacgtt	agagccaggg	ccggcgggct	cagaggttgg	1140
agccggggac	cagtgggctc	agaggtcgga	gccggggacc	agtgggctca	gaggtcggag	1200
ccatgtccct	gccgtgaagc	tctgagggtt	ggtgggtgaca	tcggggcgat	tgtggcatcg	1260
cgatttgtgt	gtcttggtctg	cctttggccg	gcgctggccac	tgccctgggt	tcattgacgta	1320
ggcaccacat	ggtcctgtgt	tgtctcaact	acggctccac	ttctggcttt	tttctacttg	1380
ctcacccttg	agataaacct	ctatttcatt	ttcatttcgg	tttatatgtg	ggttttcttc	1440
caggtctgat	gttaagccta	taatatgtca	atgtgatgtt	ttgaagttaa	ggtgtaatag	1500
agccagtgaa	ccaaggggtc	acaccccggt	gaaatacaaa	tattcagaat	tgagccactg	1560
tgttgccata	ctgattatgt	aatgtgtgat	taacaagtat	aatgtgtcac	tttcaacatc	1620
agtttcatgc	caaagtgtca	ttttattaga	ttatttggga	gttcactttg	ggcccaaagg	1680
ctcgtgtcta	cataataata	acttatgatt	tttctttttg	ttctttgttt	attttttgtt	1740
ttgtgttttt	tgtttcttag	accatgccag	agtaattctca	gcttttctta	gttactggat	1800
cacacatata	cttcctgaga	agagcagtg	ctaaaatgga	atatctcttt	aagaacagct	1860
cctctttaac	aaaaaaactt	aaaagacaaa	tgtgagatgg	gcttagagtt	agttctctgg	1920
gaacttgaaa	gacatttatg	ccatattatt	tattcacgtg	tttgttctgt	gtgggcaaga	1980
tgcctcttga	ggcttcagat	gagaaattgg	ggtaaaatgg	aaatttttca	cttatttgca	2040
attatatata	tcttgaatta	ctacataaaa	cttgattctg	tttctctact	tattgtaaaa	2100
attgaaaatg	gacattctgt	taagttaaat	gtatagtttg	aagctcata	atttttatga	2160
agttttgaat	caccttgat	ctgaaagtct	ctgctttaag	aatgctttct	gggtattaaa	2220
atgttctagt	ttaagttagt	tgaatatagt	tgagtctttt	ttctcttctc	tactttgtga	2280
atcatatcag	gtacctgttt	ttcctgttct	gattttcttt	tctgtgatag	aagcagtcgt	2340
cagttcttgg	tattactaag	tgttaaaagc	atcagtcagg	ccgggtgcgg	ggctcacgc	2400
ctgtaatcct	ggcacttttg	gagacggagg	caggcggtac	acaacgtcag	gagatcgaga	2460
gcctctggc	taacacggtg	aaaccccatc	tctattaaaa	atacaaaaaa	ttagccgggc	2520
gtggtggcgg	gcgcctgtag	tcccagctac	tctggaggct	gaggcaagag	aatggcatga	2580
acctggggag	cagagctttg	agtgaagctga	gatcgcacca	ctgcactgca	gcctgggcga	2640
cagagcgaga	ctccagctca	aaataaaaaa	aaaaaaaaaa			2680

<210> 48

<211> 1730

<212> DNA

<213> Homo sapiens

<400> 48

cccacgcgtc	cgggggcctg	tggcggagtc	caagaggaa	tagggccgct	tcgggatggt	60
gtggagcgct	gctcctgccc	cctgtttcct	cctcgggggc	ctggggctgg	tccaggtgtt	120
ggggggccaa	gccgtgggcc	cctggacggc	tccagcgtgt	ttgggggcag	ctcaggtcta	180
gccctgcagg	ccctgcaagg	agagctctct	gaqgttatcc	tcagcttcag	ctccctcaat	240

gactcactga	atgagctcca	gaccactgtg	gagggccagg	gcgctgatct	ggctgacctg	300
ggggcaacca	aggaccgtat	catttctgag	attaacaggc	tgacgcagga	ggccacagag	360
catgtactag	agagtgaaga	gcgcttccga	ggcctagagg	agggacaagc	acaggccggc	420
cagtgcacca	gcttagaggg	gcgattgggc	cgctctgagg	gtgtctgtga	acggttggac	480
actgtggctg	ggggactgca	gggcctgcgc	gagggccttt	ccagacacgt	ggctgggctc	540
tggtctgggc	tccgggaaac	caacaccacc	agccagatgc	agggagccct	gctggagaaq	600
ctggctcggg	gacagggcgg	cctgggcagg	cggtgggtg	cccttaacag	ctccctgcag	660
ctcctggagg	accgtctgca	ccagctcagc	ctgaaggacc	tcactgggccc	tgaggagag	720
gctgggcccc	cagggcctcc	tggtctgcag	ggacccccag	gccttgcctg	acctccagga	780
tcaccaggca	aggacgggca	agagggcccc	atcgggccac	caggtctcca	aggtgaacag	840
ggagtggagg	gggcaccagc	agccccgtgt	ccccaaagtg	cattttcagc	tgctctgagt	900
ttgccccggt	ctgaaccagg	cacggttccc	ttcgacagag	tcctgctcaa	tgatggaggc	960
tattatgac	cagagacagg	cggtttcaca	gtcgccactg	gctggacgct	acttgctgag	1020
cgcggtgctg	actgggcacc	ggcacagaaa	agtggaggcc	gtgctgtggc	cgctccaacc	1080
agggcggtgg	cggcgtagac	tccgggtygc	tacgagcctg	agggcctgga	gaataagccg	1140
gtggccgaga	gccagcccag	cccgggcacc	ctgggcgtct	tcagcctcat	cctgccgctg	1200
caggccgggg	acacgggtctg	cgctcgacctg	gtcatggggc	agctggcgca	ctcggaggag	1260
cgctccacca	cttcagcggg	ggcctgtctc	tatggggacc	cagagcttga	acacgcgtag	1320
actggggctc	cgcccgacgt	gtctacgtcg	gctgaagaga	cagcgggggc	ggcgggctcc	1380
tggtgctctg	cctgagacgg	ggcaccttagc	cctgggcgag	cgccgcaccc	ggccccgcag	1440
cggcacccgc	cccagagcgg	cctctcccca	cgccccgggc	gcgcgggctc	agggaggctc	1500
ggggccgccc	atgcagactt	ttggcctggc	gcgatccccc	aagaaacccct	ccagggcccg	1560
cctgcggagg	agccgatcct	cgcacccctcc	gctccctcca	ctggccctcc	aggtcgattc	1620
cctgggctcc	aggctccccc	gcgcgggcgc	cgccaccgc	catactaaac	gatcgaggaa	1680
taaagacact	tggtttttct	aaaaaaaaa	aaaaaaaaa	aaggggcccg		1730

<210> 49
<211> 1275
<212> DNA
<213> Homo sapiens

<400> 49						
ggcacgagcc	agctcctctt	ccaagatgtc	ctccttaaac	tttgccagt	aaatggagaa	60
gtaccgtttg	gggaataata	tgctttcaag	gttttgctta	tttttgataa	tgctcctgca	120
catcctctct	tttttggtta	tcttcattca	acgtcacact	gttgtctctc	tctccaagca	180
ccaccccttt	gttccaaact	atggatcaaa	gagttatagc	agcttttaag	gcctgattac	240
tacctgagga	ggacctttgc	ctaggctatt	gctgcaata	agaaagatcc	tttttaaaaa	300
cactgggtgca	attctggaag	gattacaaca	tctatggcag	catcaacaac	cttgggttaag	360
ttgggggtga	agtcaccaag	gagtggttaa	atgctatctg	ggaagagata	ttgaagacat	420
ttgtccatga	cttcaaaaaca	ttgctaagga	tgaggatggt	gcaaaaaaaa	aatatttaca	480
aggcttttagt	tgaatgggca	aacaacttta	agctggatgt	ggaggaggat	gatattgagg	540
aggtcacaga	tgtgttcaact	gaggaattga	ctaagcacga	gttactggaa	ccagaacaga	600
aatgcatagc	aagaggaaag	gaaactacag	gagaaaaaaa	gaaaagcccc	caaggatatt	660
cacagtgtatg	ggttttaggca	gaagcttttg	cagacctcaa	caaaactcctt	aaaacgtttg	720
aaaaatgtga	ctccaacatg	aaatgatttt	cattagtaga	gaggaatggt	catcgtgcat	780
tatctatttta	caagcaaatc	tatgatgaat	aaaagaaaca	aaccaaaaca	accacatga	840
acacattttct	gaaaagagtg	acatctcaag	aagagcctca	ggcaggtcct	tcaggaggta	900
tcccagaaga	agaaggcatt	gttatcacag	gacatgacag	ctccctgggt	gttattgccc	960
ttaaaggcct	tccagtagga	taagggtgtg	agatggaaag	tgccgatttt	tatgatcctg	1020
accctacata	ggtctaggct	aatgggtaac	ggtgtgtttg	tgtcttagtt	tttaaaagaa	1080
aatgtaaaaa	gtaaaaata	aaaataaacat	taatataggt	aaaagttaa	agaataagga	1140
tataaggaga	gaaaaaaatt	atcttctctc	gtatttgtgt	ttcaagctgt	gttactacaa	1200
aagaataaaa	aagttaaag	aaattgtttt	taaagtaaaa	tagttacaat	aatctaaaaa	1260
aaaaaaaaaa	aaaaa					1275

<210> 50
<211> 1762

<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (447)
<223> n equals a.t.g. or c

<400> 50
ggtggcctag agatgctgct gccgcggttg cagttgtcgc gcacgcctct gcccgccagc 60
ccgctccacc gccgtagcgc ccgagtgtcg gggggcgac ccgagtcggg ccatgaggcc 120
gggaaccgag ctacaggcgc tgcgtgctggc cgtgctgctg gtggggctgc gggccgcgac 180
gggtcgccctg ctgagtgggc agccagtcgt ccggggaggg acacagaggc cttgttataa 240
agtcaattac ttccatgata cttctcgaag actgaacttt gaggaagcca aagaagcctg 300
caggagggat ggaggccagc tagtcagcat cgagtcgtga gatgaacaga aactgataga 360
aaaattcatt gaaaacctc tgcctctga tggtagcttc tggattgggc tcaggaggcg 420
tggaggagaaa caaagcaata gcacagmctg ccaggacctt tatgcttggc ctgatggcag 480
catatcacaa tttaggaact ggtatgtgga tgagccgtcc tgcggcagcg aggtctgcgt 540
ggtcactgtac catcagccat cygcaccgcg tggcatcgga gggccctaca tgttccagt 600
gaatgatgac cgggtgcaaa tgaagaacaa ttctatttgc aaatattctg atgagaacc 660
agcagttcct tctagagaag ctgaagggtga ggaacacag ctgacaacac ctgtacttcc 720
agaagaacaa caggaagaag atgccaaaaa aacatttaaa gaaagtagag aagctgcctt 780
gaatctggcc tacatcctaa tccccagca tccccctctc ctccctcttg tggtcaccac 840
agttgtatgt tgggttttgg tctgtagaaa aagaaaacgg gagcagccag acctagcac 900
aaagaagcaa cacacatct gccctctcc tcaccaggga aacagcccg accatagagt 960
ctacaatgtc ataagaaaac aaagcgaagc tgacttagct gagaccggc cagacctgaa 1020
gaatatttca ttccgagtggt gttcgggaga agccactccc gatgacatgt cttgtgacta 1080
tgacaacatg gctgtgaacc catcagaaaag tgggtttgtg actctggtga gcgtggagag 1140
tggattttgt accaatgaca ttatagatt ctccccagac caaatgggga ggagtaagga 1200
gtctggatgg gtggaaaatg aaatatatgg ttattaggac atataaaaaa ctgaaactga 1260
caacaatgga aaagaatga taagcaaaat cctcttattt tctataagga aaatacacag 1320
aagggtctatg aacaagctta gatcaggtcc tgtggatgag catgtggtcc ccacgacctc 1380
ctgttggacc ccacggtttt ggtgtatcc ttatccag ccagtcaccc agctcgacct 1440
tatgagaagg taccttgcgc aggtctggca catagtagag tctcaataaa tgtcacttgg 1500
ttggttctat ctaactttta agggacagag ctttacctgg cagtataaaa gatgggctgt 1560
ggagcttggg aaaccacctc tgtttcctt gctctataca gcagcacata ttatcataca 1620
gacagaaaaa ccagaatctt ttcaaagccc acatatggga gcacaggytg gccgtgtcat 1680
cggaattctc catatctgtt tttttcaag aataaaatca aataaagagc agggaaaaaa 1740
aaaaaaaaa aaaaaactcg ag 1762

<210> 51
<211> 2059
<212> DNA
<213> Homo sapiens

<400> 51
cggcacgagg ttggtctaa gaggtagcag aactgcttg agatgggagc acatttggtt 60
gtgttcaaca cagaagcaga gcagtggag gaggcatgca tccccagctg ataccttcgg 120
ttattgctgt agttttcctc ttacttctcg gtgtctgttt tattgcaagt tgtttggtga 180
ctcatcacaa cttttcacgc tgtaagagag gcacaggagt gcacaagtta gagcacatg 240
caaagctcaa atgcatcaaa gagaatcag aactgaaaag ttgctgaagg gagcacctgg 300
aactgttgc ctattgactg gagaaccttc cagttccaac tgctatttcc ctccctactg 360
acaacaagac gtgggctgag agttgaaagg aactgttcag ggtatggggc ccactctgat 420
accatcagca cggagctga gcagaacttt attattcagt ttctggatag acggctttcc 480
tatttccctg gacttagaga tgagaatgcc aaaggtcagt ggcgttgggt gggaccagac 540
gccatttaac ccacgccaga gtattctggc ataagaatga acccgacaac tytcaggag 600
aaaactgtgt tgttctggtc ttataaccaa gataaatgg cctggaatga tgttccttgt 660
aactttgaag caagtaggat ttgtaaaaa cctggaacaa catgaaacta gaaactcaga 720

aagtggctct	tgtgatggaa	agagaaaaga	aaaaccaatt	agaataaggc	agaatgtacg	780
tgcgtcattg	gaacacagaa	aacatgctgg	ttcatacagc	gttttttagtc	ataatgggtct	840
tttttatttt	gtttgattca	ttcgagacaa	catgtgtgta	tgtgtgtgtg	tgtgtgtgta	900
gataatgtgg	tttttgtatg	gtgtttgatg	gaaggaataa	tctttctttg	ctttcttagt	960
agtatttcaa	ggtgtttact	tttcaattcg	tgtgactga	atgcatgtat	ggaagaatag	1020
cgtgaataat	gcaatctctt	tgtcattttt	tcccttttct	cagactctta	gctcttaaaa	1080
ttcaaaagat	gggatatctt	aactggtagt	ggtgcatcat	ttttaacca	aatattgcaa	1140
gcactttaaa	gatttgaaac	cacattttta	ttgtttgatg	tttcaltttc	agacttttta	1200
atgacagtca	ttacaattac	attgcatgag	gaaaattttt	ccagaacaac	agtgtggaat	1260
agttctgaat	tatgctgttc	tacagatgga	aaaaagtcca	aatgctttta	aaaaattact	1320
tcttactcca	cccaacacgt	ttttgcaaa	caagaagtct	ttgtaagaca	ccttaaacaa	1380
agtccttcaa	ttctacagca	gaggaaataa	aatccccag	aagccaaagg	gctcaccttc	1440
acattgttag	ttcatgacag	acccaggtgt	gcttcattag	agataacata	cattcccttt	1500
gggtatcacag	gaagttactg	gggattactc	gaccctatta	cttagctaac	gactggataa	1560
aatttcttaa	ttgtttgaag	taacattgta	ttcgtgtttg	cattattaat	ttgaatagaa	1620
aataatcaca	ttttcaaccc	atttatacaa	attgttaatg	ttcttttaga	gctgtataac	1680
tatagtttga	actagcaagg	aggttattgt	tttgacaacc	agaaattatg	ctttctcggt	1740
gcattgaaaca	ctaattgcaa	agggcagtc	catccaactt	taataaaata	tggtggctct	1800
tctttaaatt	ttcaatttgc	taatttttcc	tggaaccta	actttcttac	tactactttt	1860
aaaagcagta	ttatttttgt	aaattagcta	ctgatttttt	gggtttgaaa	tactggtgtt	1920
tgattgtgtg	tggtgtgtgg	tggtgatgga	tgctgttagc	tgtgttaaaa	gctgatactt	1980
ttagctgaaa	tggtgtctaaa	taaatttgac	tgtgtttgcc	atattcacta	aaaaaaaaa	2040
aaaaaaacta	gagggggggg					2059

<210> 52
 <211> 3282
 <212> DNA
 <213> Homo sapiens

<400> 52						
cccacgcgtc	cgacttaaaa	gagaagcttt	agctgccaaa	gattgggaaa	gggaaaggac	60
aaaaaagacc	cctgggctac	acggcgttag	tgacgggttt	cctactgctg	ttcttttatg	120
ctgggagctg	tggctgtaac	caactaggaa	ataacgtatg	cagcagctat	ggctgtcaga	180
gagttgtgct	tcccaagaca	aaggcaagtc	ctgtttcttt	ttcttttttg	gggagtgtcc	240
ttggcaggtt	ctgggtttgg	acgttattcg	gtgactgagg	aaacagagaa	aggatccctt	300
gtggtcaatc	tgccaaagga	tctgggacta	gcagaggggg	agctgggtgc	aaggggaacc	360
aggggtggtt	ccgacgataa	caaacaatc	ctgctcctgg	atlcacatac	cgggaaattg	420
ctcacaaatg	agaaactgga	ccgagagaa	ctgtgtggcc	ctaaagagcc	ctgtatgctg	480
tattttccaaa	ttttaatgga	tgatcccttt	cagatttacc	gggtgagct	gagagtcagg	540
gatataaatg	atcacgcgcc	agtatttcag	gacaaagaaa	cagtcttaaa	aatatcagaa	600
aatacagctg	aagggacagc	atttagacta	gaaagagcac	aggatccaga	tgaggagact	660
aacggtatcc	aaaactacac	gatcagcccc	aactcttttt	tccatattaa	tattagtggc	720
gggtgatgaag	gcattgatata	tccagagcta	gtgttgga	aagcactgga	tcgggaggag	780
cagggagagc	tcagcttaac	cctcacagcg	ctggatgggt	ggtctccatc	caggtctggg	840
acctctactg	tacgcactcg	tgtcttgga	gtcaatgaca	atgccccaca	gttgccag	900
gctctgtatg	agacccagcg	tccagaaaac	agccccattg	ggttccctat	tgtaaggta	960
tgggcagaag	atgtagactc	tggaagtcac	gcggaugrat	cctattcatt	tttgatgcc	1020
tcagaaaata	ttcgaacaac	ctttcaaatc	aatccttttt	ctggggaaat	ctttctcaga	1080
gaattgtctg	atttatgagtt	agtaaatctt	tacaaaaaa	atatacagcg	aatggacggt	1140
ggaggccttt	ctgcaagatg	taggggtttt	gtggaagrat	tggaacacaa	tgacaatccc	1200
cctgaactga	tcgtatcacc	attttccaac	tctgtgtgct	agaattctcc	tgagacgccg	1260
ctggctgttt	tttaagattaa	tgacagagac	tctggagaaa	atggaaagat	ggtttgctac	1320
attcaagaga	atctgccatt	cctactaaaa	ccttctgtgg	agaattttta	catcctaatt	1380
acagaaggcg	cgctggacag	agagatcaga	gccgagtaca	acatcactat	caccgtcact	1440
gacttgggga	caccagggct	gaaaaccgag	cacaacataa	ccgtgctggg	ctccgacgct	1500
aataacaacg	cccccgcctt	cacccaaacc	tcctacaccc	tggtctcccg	cgagaacaac	1560
agccccgccc	tgccatcgg	cagctgcagc	gccacagaca	gagactcggg	caccaacgcc	1620
caggtcacct	actcgtgct	gccgccccaa	gacccgcacc	tgccctctgc	ctccctggct	1680

ccatcaacg	cggaacaagg	ccacctgttc	gccctcaggt	cgctggacta	cgaggccctg	1740
caggctttcg	agttcccggt	ggcgccaca	gaccgggct	cccccgct	gaacagcgag	1800
gcgtgggtg	cgctgtgtg	tgctggacgc	caacgacaac	tcgcccttcg	tgctgtaccc	1860
gctgcagaac	ggctcccgcc	cctgcaccga	gctgtgtccc	cgggcgcccg	agccgggcta	1920
cctggtgacc	aaggtgtgtg	cggtggacgg	cgactcgggc	cagaacgcct	ggctgtcgta	1980
ccagctgttc	aaggccacgg	agcccgggct	gttcggtgtg	tgggcgacaca	atggggaggt	2040
gcgcaccgcc	aggctgtcga	gcgagcgcca	cgagcccaag	cacaggctgg	tggtgtttgt	2100
caaggacaat	ggcgagcctc	ctcgctcggc	caccgccacg	ctgcaegtgc	tcctgtgtga	2160
cggtctctcc	cagccctacc	tgctctctcc	ggaggcgcc	ccggcccgag	ccaggccga	2220
cttgcctacc	gtctacctgg	tggtggcggt	ggcctcgggt	tcttcgctct	tcctctctct	2280
gggtcctctg	ttcgtggcgg	tgcggtctgt	caggaggagc	agggcgccct	cggtgggtcg	2340
ctgctcggtg	cccagggttc	ctttccagg	gcctctgtgt	gacgtgaggg	gcgctgagac	2400
cctgtccag	agctaccagt	atgaggtgtg	tctgacggga	ggccccggga	ccagttagtt	2460
caagtctctg	aaaccagtta	tttcggatac	tcaggcacag	ggcctcggga	ggaagggtga	2520
agaaaattcc	accttccgaa	atagctttgg	atttaattatt	cagtaaagtc	tggttttagt	2580
ttcatatact	tttgggtgtg	tacatagcca	tgtttctatt	agtttacttt	taaatctcaa	2640
atttaagtta	ttatgcaact	tcaggcatta	ttttcaagta	gtataccct	gtgggtttac	2700
aatgtttcat	catttttttg	caftaataac	aactgggttt	aatttaatga	gtattttttt	2760
ctaaatgata	gtgttaaggt	tttaattctt	tccaactgcc	caaggaatta	attactatta	2820
tatctcatta	cagaaatctg	aggtttttgat	tcattttcaga	gcttgcatct	catgattcta	2880
atcacttctg	tctatagtgt	acttgcctta	tttaagaagg	catatctaca	tttccaaact	2940
cattctaaaca	ttctatatat	tctgttttga	aaaccatgct	atttatttct	acatcatgta	3000
tttaaaaaga	aattatttct	tactactatg	ctcatgacaa	aatgaaacaa	agcatattgt	3060
gagcaatact	gaacatcaat	aataccctta	gtttatatatac	ttattatttt	atctttaagc	3120
atgctacttt	tacttggcca	atattttctt	atgttaactt	ttgctgatgt	ataaaacaga	3180
ctatgcctta	taattgaaat	aaaattataa	tctgcctgaa	aatgaataaa	aataaaacat	3240
tttgaaattt	gtgaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aa		3282

<210> 53

<211> 1860

<212> DNA

<213> Homo sapiens

<400> 53

aattcggcac	gagcagcagg	gagaagagga	tgatgagcat	gccaggccccc	tgcccgagtc	60
cctgtcctcg	gccattgtcg	acctgtctct	ctgcccgga	ttcacgggtc	agagccaccg	120
gaggagcact	gtggactcgg	cagaggacgt	ccactccctg	gacagctgtg	aatacatctg	180
ggaggctggt	gtgggcttcg	ctcactcccc	ccagcctaac	tacatccacg	atatgaaccg	240
gatggagctg	ctgaaactgc	tgctgacatg	cttctccgag	gccatgtacc	tgccccagc	300
tccggaaaagt	ggcagcacca	acccatgggt	tcagttcttt	tgttccacgg	agaacagaca	360
tgccctgccc	ctcttcaact	ccctctcaca	caccgtgtgt	gcctatgacc	ctg-gggcta	420
cgggatcccc	tacaaccacc	tgctctctct	tgactaccgg	gaacccctgg	tgaggagggc	480
tgcccagggt	ctcattglca	ctttggacca	cgacagtgc	agcagtgcga	gccccactgt	540
ggacggcacc	accactggca	ccgccatgga	tgatgcccgt	cctccaggcc	ctgagaacct	600
gtttgtgaac	tacctgtccc	gcattccatg	tgaggaggac	ttccagtcca	tcctcaaggg	660
tatagcccgg	ctgctgtcca	acccctgtgt	ccagacctac	ctgcctaact	ccaccaagaa	720
agatccagtt	ccaccaggag	ctgctagtct	tcttctggaa	gctctgcyac	ttcaacaaga	780
aattcctctt	cttcgtgtcg	aagagcagcg	acgtccctaga	catcctgtgc	cccatctctt	840
tcttctctca	cgatgcccg	gccgatcagt	gtaagaccag	gggtgggggtg	ggatgctggg	900
ggctttcctg	gcggcgaggt	ggagggtctg	ctatctgccc	tgactccag	gagctcagcc	960
tgccactctg	acctccagg	agggaggcct	ccaaaatggt	cactgcctgg	gccccctctt	1020
ccccctccca	cccgagtga	ccctccacg	ccacctgccc	cagctcgggt	ggcctgatg	1080
cacattgtgt	tcttcatctt	gctgtctctg	agcggggagc	ggaacttcgg	gggtgcggctg	1140
aacaaacct	actcaatccg	cgtgccatg	gacatcccag	tcttccacag	gacccacgcc	1200
gacctgtcca	ttgtgtgtgt	ccacaagtc	atcaccagcg	ggcaccagcg	gttcagccc	1260
ctcttcgact	gcctgtctac	catcgtgtgc	aacggtaggg	gccccgagct	tgactcccc	1320
gcgctcacca	ccagggtgtg	tcagccacag	gccaaacctgc	cacttgcctc	aggtttcaag	1380
ccccccagc	ccacagaaag	aacgcaagct	tgtgtacctt	tcatagtagc	cacattaaaa	1440

aaaaagggg	acaacaattg	aataatatgt	tttatctatc	atcatctcaa	catgtagcca	1500
atatgaaaat	tactaatgag	atatattaata	ttcccttctc	acaetcagtc	ttgtcgccca	1560
ggctggagtg	cagtgggacc	actcagctc	actgcaacct	cgcccccttg	ggttcaagca	1620
attctcatgc	ctcagcctcc	tgagtaggtg	ggattacagg	cgtgtgccac	cacacctggc	1680
taatttttgt	atcttttagta	gagacggggt	tttgccatgt	tgtccaggct	ggctctgaac	1740
tcctgacctc	agatgatatg	cccacctcag	cctcccaaag	tgcgggatt	acaggcatga	1800
gccactgcat	ctggcctttt	taaaaaaaaa	aaaaaaaaaa	actcgagggg	gggcccggta	1860

<210> 54
 <211> 770
 <212> DNA
 <213> Homo sapiens

<400> 54	
aattcggcac	gagccgaggg
gcgaatccat	acatccgtcg
tgtggactcg	ccctgacatc
ccctcaacgc	ttagactcgg
gattcttttc	attgectgat
gccgtttcat	gccttttttg
cgtttctctg	ctctggccct
ctctgtggcc	atccttcccg
cacttcccaa	cgcccatgcc
gcgcggggga	ttggcgccct
gacggcgggc	ggctcccagg
cctcagccaa	ggaagagccc
cagagcaacg	cgcaaccagc
cgccgatgag	cgcaaacac
gactgctcag	ccaggccgag
gaaacccggc	agcgccctgac
cgatctcaag	gccgaactcg
ccggcgccacc	caaggagatc
agcgaggccc	agcgtaacgt
ctccaaactg	gtgagcgagg
acaacagcga	tctgcccag
cgcctctcca	agctttcggt
gccggtaactg	gagcaacgcc
tggcgggccc	cgtggacgag
ctcgccctct	ggcaacaagc
gctcagcgcg	gcccaacagca
tgtctatcag	cgcgacagcc
cgcccccagc	gcccaccagg
cgatatacgc	aagaaccagt
tgcgcacga	cgagatcaac
ggcctgctga	aaagcggtcg
ggagaacaac	aagccgctga
cggacgaacg	tcgcgcgctg
ctcgagagta	cttctagagc
ggccgcgggc	ccatcgattt
tccaccgggg	tggggtaacca
ggttaagtgt	cccaattcgc
cctatagtag	gtcgtattac
aattcactgg	

<210> 55
 <211> 1093
 <212> DNA
 <213> Homo sapiens

<400> 55	
cagattcggc	acgagggttt
ttttaagatt	tattttttta
aaattatttt	tgtggacttg
ggatcaatg	atggcaccta
cttttgggaa	tctgtagctg
tgccttgaga	attgccatcg
gtcatgtgtt	gcaccgttct
ctgtatgttt	acgtcctttg
gactggcttc	tcccaggatt
cttttctgtt	tttgtttttt
tgatttgggc	tttatttttt
tctgtgtact	gtactatatt
gtaaaaggga	ttttagcaga
gacttttagtc	tttggggcaa
gaggagaaca	ggaatgcttg
gctgtttact	ttagggtggag
aacccatctt	cagacctttg
gactattttc	tttcaactgc
agtgtataga	aaaaccaaac
tacgacctca	gagcagagta
ttaatgaaaa	gcacaaaaaa
aggaactaag	ttcagcgagg
gggtggggga	ggggggagat
tttctttttg	aaaaataatg
actcttagga	cattttgttt
tcagtccaag	tgtctctcag
cactgtcttg	tctcccaata
taccaaccca	ctggcacatt
tttctcttgt	tttctctctc
cgatttttgt	ctgtctcttc
agttaagtgt	ttccttctct
tgtgcccccc	gctggcgacc
ctctgtcttc	ctcctctctt
cccttttgga	gtgcaatac
acagtgttat	tttggggaaa
ttaattctagc	aaagcctcgc
cttccatgcc	gagcgtcttc
ttggctctga	gagggaaaag
tctgtccttg	ggatgccttc
tggctctttt	tccccctaag
tctttctctt	tcccatcata
cccttccctg	cccactttgt
tttctgtctc	ctttttatta
ggaattccca	agttaatttt
attaatgttg	gagtggaaaca
gatgctaaaa	gctatccagg
attttggttc	tgtttgtttt
aaatttttgt	gttctctccc
tttctctccc	ctcccatcgc
taagacgttc	tgtgtaacct
ccattaaatt	tggtaaaaaa
ccactcgcca	gagctgtggt
gtcagaaaaa	taaaaatat
tgtttcttam	aaaaaaaaaa
aaaaaaaact	cga

<210> 56
 <211> 632

<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (29)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (46)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (94)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (162)
<223> n equals a,t,g, or c

<400> 56
cgcaattaat gtgagttagc teactcatna ggcaccccag gctttncact ttatgctttc 60
cggctcgtat gttgtgtgga attgtgacgg atancaattt cacacaggaa acagctatgc 120
catgattacg ccaagctcga aattaaccct cactaaaggg ancaaaagct ggagctccac 180
cgcggtggcg gccgctctag aactagtggg tcccccgggc tgcagggaatt cggcagcaga 240
ctatgatat atgtttaata tctgtctttt gaaatgcaga aatagtttaa atgtttcttt 300
gtctattttt cttttttttt aatgctaccc agggaaatat ttctatatca tttttaagt 360
gcccgctca atgtatatat atttctttt aaacaaaaag gttctggaaa ctgtttttct 420
gtagctttaa atgaataggt gagcaaaatc tatatgggat gtaattttt tgttcagctc 480
cttaaaaaat actttgtttt ggtacatttg gttgtgcttg tggggaaaat aaaaacgcag 540
agaaccttat atatttatgt taaagtaata ttttattatc tacataaaac agaaatgcac 600
aataaaaaaa aaaaaaaaaa gctcggggg gg 632

<210> 57
<211> 2687
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1614)
<223> n equals a,t,g, or c

<400> 57
gtacaccatg ggcctccacc tccgccccta ccgtgtgggg ctgctcccg atggcctcct 60
gttctctttg ctgctgctaa tgcgtctcgc ggacccagcg ctcccggcg gacgtcaccc 120
cccagtgtg ctggctccctg gtgatttggg taaccaactg gaagccaagc tggacaagcc 180
gacagtgggt cactacctct gctccaagaa gaccgaaagc tacttcacaa tctggctgaa 240
cctggaactg ctgctgcttg tgcattcattg actgctggat tgacaatatc aggctgggtt 300
acaacaaaac atccagggcc acccagtttc ctgatgggtg ggaatgtacgt gtccctggct 360
ttgggaagac cttctcactg gagttcctgg accccagcaa aagcagcgtg ggttctctatt 420
tcacacccat ggtggagagc cttgtgggct ggggctacac acgggggtgag gatgtccgag 480
gggctcccta tgactggcgc cgagcccacaa atgaaaacgg gccctacttc ctggccctcc 540
gcgagatgat cgaggagatg taaccagctgt atgggggccc cgtgggtgctg gttgccaca 600
gtaaggcaca catgtacacg ctctactttc tgcagcggca gccgcaggcc tggaaargaca 660

```

agtatatccg ggccttcgtg tcaactgggtg cgccctgggg gggcgtggcc aagaccctgc 720
gcgtccctggc ttcaggagac aacaaccgga tcccagtcac cgggcccctg aagatccggg 780
agcagcagcg gtcagctgtc tccaccagct ggctgctgcc ctacaactac acatgggtcac 840
ctgagaaggt gtctgtgcag acaccacaa tcaactacac actgcgggac taccgcaagt 900
tcttccagga catcggcctt gaagatggct ggctcatgcg gcaggacaca gaagggtctg 960
tggaagccac gatgccacct ggcgtgcagc tgcactgctt ctatggtact ggcgtcccca 1020
caccagactc ctctactat gagagcttcc ctgaccgtga cctaaaaatc tgctttgggtg 1080
acggcgatgg tactgtgaac ttgaagagt ggctgcagt ccaggcctgg cagagccgcc 1140
aggagacca agtgttgctg caggagctgc caggcagcga gcacatcgag atgtcggcca 1200
acgccaccac cctggcctat ctgaaacgtg tgcctccttg gccctgactc ctgtgccaca 1260
ggactcctgt ggctcggccg tggacctgct gttggcctct gggcctgtca tggcccacgc 1320
gttttgcaaa gtttgtgact caccattcaa ggcctcagct cttggactgt gaagcatctg 1380
ccatgggaa gtgctgtttg ttatccttct tctgtggcag tgaagaagga agaatgaga 1440
gtctagactc aaggacact ggatggcaag aatgctgctg atggtggaac tgcgtgtracc 1500
ttaggactcg clccacaggg tggactggct gggcctggt cccagtcctt gcctggggcc 1560
atgtgtcccc cctattctcg tggccttttc ataactgctt actgggacct ggcncsgcag 1620
ccttctctat agggatgtta ctgggctgtg gtcctgtacc cagaggtccc agggatcggc 1680
tcttggcccc tcgggtgacc ctcccccac accagccaca gataggcctg cactgggtca 1740
tgggtagcta gagctgctgg ctccctgtgt gcttagctgg tggccagcct ga-tggcttc 1800
ctgggcgagc ctagttagctc ctgcaggcag gggcagtttg ttgcgttctt cgtggttccc 1860
aggcctggg acatctcact ccaactctac ctcccttacc accaggagca ttcaagctct 1920
ggattgggca gcagatgtgc cccagtcctt gcagctgtgt tccaggggcc ctgatttctt 1980
cggatgtgct attggcccca ggaactgaag tgcctccctt caccctggga ctgtggttcc 2040
aaggatgaga gcagggtgtg gagccatggc ctctctggaa cctatggaga aagggaatcc 2100
aaggaagcag ccaaggctgc tcgcagcttc cctgagctgc acctcttctt aaccaccaca 2160
tcacactgcc accctgccct agggctctac tagtaccag tgggtcagca cagggtgag 2220
gatggggctc ctatccaccc tggccagcac ccagcttagt gctgggacta gccacagaaac 2280
ttgaatggga ccttgagaga gccagggtgc cctgaggcc cccctagggg ctctctgtct 2340
gccccagggt gctccatgga tctccctgtg gcagcaggca tggagagtca gggctgcctt 2400
catggcagta ggctctaagt gggtagctgg ccacaggccg agaaaagggt acagcctcta 2460
ggtaggggttc ccaaaagcgc ctccagctg gactgagctg ctctcccaaca ggggttctgt 2520
gcactggat tttctctgtt gcatacatgc ctggcatctg tctccctctg ttcctgagtg 2580
gccccacatg gggctctgag caggctgtat ctggattctg gcaataaag tactctggat 2640
gctgtaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaag ggcggcc 2687

```

<210> 58

<211> 619

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (526)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (619)

<223> n equals a,t,g, or c

<400> 58

```

tcacagctt tcacctgga- catcgtgaca gcctctact gcttctctat catgtggcca 60
gagetatctt ctaaaaatgc attgcatagt tgatcaagtc actctctggc ctaaaacctt 120
ccttggctcc ctgctgccct caggataaag tctggacccc tcagcatggc ttgtgagact 180
catggtgtcc ttgtccctgc tcacctctct ggtctcatca cttgccctct tgcattcttg 240
gtccagcctt cctgtatcca gagatgcagt ggctctecat tggcactctg attcctcctt 300
tcttttggtc acagagaaag ggtactttct ctgtcaaatc tcaacttaga cttgacttcc 360
tccaaggagc ttgggtata ctctctctc ccgaccccca cctggcata ctacacagat 420

```


cactctgggc	tcacttgcct	gcctaattggt	catctcccca	gtagactgta	agctccttga	480
gggcaaggat	tgtgtggaa	ttttgtatt	aacagtgcct	ggcttngtgc	ctggcaccta	540
gaaagcactc	aataaatgtt	tgtttaatga	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	600
aaaaaaaaaa	aaaaaaaaaa					619

<210> 59
<211> 1378
<212> DNA
<213> Homo sapiens

<400> 59						
tcgacttctg	ggatgtagat	tctcctttat	tgaattcttc	atcttcactc	gcagtatgat	60
ttattttttt	cacactgtat	tttacctgc	atatgtttct	cttataacga	gggtcacttt	120
cttcctgccc	aggattggaa	tcaattacag	ctatgcaatg	ttttttgttt	agcatcttct	180
taattacagg	cttggcagaa	gagttttgtg	aacaactctc	catttcactg	gctgaagaag	240
aaatacaact	gtcctctaca	gttgaacatc	tctgtatgac	agcattttca	tggtaatgag	300
gattagggtc	atacttttgt	ttttccaaac	cggggaaaca	aacaacagcc	aaaaaccagt	360
gtgcagcttc	attaaggggt	acaaaaataa	aatccttctc	aaaaatatct	acgtgccggg	420
tccatgtttt	tactctccca	tgccgttttt	gctgtattga	cagattagtt	grrttcatgat	480
ttctcctctc	tctctgatta	aggcgtttat	agaaaaaaga	actgaatata	tgaattcggg	540
cagcgtcttc	cttcttcagt	ttttcaagca	ccaagtattt	caaataaaaag	tctataataa	600
catcatttaa	aaattctcct	tcatttagac	agtgcaggtc	ctcartggta	acagagatgc	660
ctcccttagc	tggagggtgt	ggatatacta	tcaacttttc	tactgggcca	atgaagatgg	720
tgtggttttc	tccagtttct	tcttcttcat	caaaaaactg	aaattcttgt	ttgcttctaa	780
gttgtatttt	agattcaaat	gatacagttt	taattttgtt	ttccttttgc	ccacaacttc	840
ctttgatgct	ctcttcacag	gttcttgtae	aggcaacaag	tctgccatta	gcttcttcaa	900
aggggaattt	cgcaaaaaaa	ttggagatgt	tattctttat	accaatttca	ttaatgatac	960
tttcaaatac	catatttgcc	ggaggatcaa	ggccattttg	aaaaatttaa	attatatatt	1020
gttcttctaa	attgttaaat	ttatttactc	ctttacaatc	attccaaact	ttatcctcct	1080
tattcatttg	cagttggatg	ctcagctttt	gataaaactgc	tgggaattgct	tgaagaaaca	1140
ctacaggtaa	ttttcggaca	ttacaccatt	cacatttagt	tagatcagag	gtatttaata	1200
taatctctac	aggatcatgg	tctggttcgt	ctagctgtat	cttgataaaa	tctaaacaaa	1260
aaattacagg	ctctattaac	agccggaaga	gtgttcctac	tctgcagcgc	ggccgcgaat	1320
tcccgggtcg	acgagctcac	tagtcggcgg	ccgctctaga	ggatccctcg	aggggccc	1378

<210> 60
<211> 1126
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (21)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (35)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (49)
<223> n equals a,t,g, or c

<220>
<221> SITE

<222> (99)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1012)
<223> n equals a,t,g, or c

<400> 60
tccggcttcg taatgtggtg ngaaattgta acggnataac aatttcacnc aggaaccage 60
tatgccatg attacgcaa gttcgaatt aaccctcant aaaggaccaa aagtgaagtt 120
ccaccgcggt gccggccgc tctagaaact agtggatccc ccgggctgca ggaattcggc 180
acgagccggc ccgtaccgcc aggcgatcgc gctgaaggcg gcgctggcag cagcggccaa 240
gaagggtgtg agcgcgcggc ggctgctggt gctgctgttc acgcccctcg cgtcgtgcc 300
gggtgtcttc gccctccgc ccaagggaagg ccgctgcttg tttgtcatcc tgctcatggc 360
gggtgtactg tgacggagg ccctgccgt ctcagtgcg gcgctgctgc ccctcgacac 420
gttccccttc atgggcatct tgcctccaa caagggtctgc cccagttact ccctcgacac 480
caacttcttc ttcctcagt ggctgatcat ggccagcgc attgaggagt ggaacctgca 540
ccggcgaaac gccctcaaga tcctgatgct tgttggagtc cagccggcca ggctcatcct 600
ggggatgatg gtgaccacct cgttcttctc catgtggctg agcaacaccg cctccaactgc 660
catgatgctt ccattgcca atgccatcct gaaaagtctc tttggccaga aggaggttcg 720
aaaggacccc agccaggaga gtgaagagaa cacaggaata gaaccaata ctttctcttc 780
tgaggaaagg ctgaaacttc aagctccct tgtgataaga cttggtcaga taactgagtc 840
tggtcaatgg aatatgagtg gaaatgatgt gtgcaacttc cgggttctgt ccttctgcc 900
gggtggaaatg tgaatatgat ggcacctggg acccaaagac aggagccaca tcttgagaga 960
tagatggcag atctgcccct gtggcttgg atcatttacc tcagtgaaca cnacaagcat 1020
tatccatgaa accataggtt ttgtgtgcta gttctagttt ttaaaatatg aattaaatta 1080
aatacgtatc tgttaaaact taacaaaaaa aaaaaaaa ctcgag 1126

<210> 61
<211> 2078
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (337)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (492)
<223> n equals a,t,g, or c

<400> 61
gattattttc aatagattgt caataaatta tcaaatatg gaaatatcct ttagattcct 60
gtgataatgc tttgtgcatg ttttctatta tttagaaat gaaaacagca gtcatttgac 120
cagccatggt atgacaccag ataataattc gcaaggatct tccaaacagg gagaaactgc 180
aatgggaaca atctttggat atctacattg tgtcaaatgt tatgtgcttt atttcatttt 240
catacttata acagctgtat atcacagttt ttattatcca cattatagag gcaaggcact 300
gatatcagga acttgagtaa ttggcttaca cagcaantgt agttgaaata gaagccagga 360
ctgtctgatt cccaagacag tgttcttgta ctgcaggtaa gcctgggtgt gctgggkttc 420
cctagcactg agtattgcag aaatacggag atttatttac tcaggtgaat gatgaagcag 480
aatctttatt tngcttttta aattatkgat gggkckkgag ttaagctagt tcaccaatga 540
gtctcaaagg gtgaagaact ggccctgtga gttttaaaac aaagcagcag ttttcttcat 600
ttgtagatat tatatttaatt ttaccttga tttccaatag cattaaatat tagaagcgta 660
taagcttttt ctttttatgc ctaggggata tggcttaaca ctgagaacaa cttgagaaac 720
actgccacat tctaaggaaac aaccaataat aagaaaaatt atttcatata aaaggatgca 780

gcttgcatat	aaaatgctga	attcaactga	agttcattat	gctgccttta	tgtgagctca	840
ggggtgacct	tcatgctctg	gactctttaa	ggatccagtg	tgggatacag	ctctgccatt	900
ggagcaatgt	gttcataaac	taggggtgcc	taagtataac	ccctctctcg	ktatctatag	960
ttttctctta	aagggtgtgt	tttcaaaaca	tgaatgttatt	tcatatacmt	atatatatat	1020
atgcacacac	acatatacmt	catgcatgka	tcatatatgt	gtgtgtatgt	atgtatctat	1080
cttcaatctt	tcaggaaagt	ttgtaaaawa	tagccctaag	tagaattatg	gggaaacagt	1140
tgcagaactg	ctgaaattgg	ctcagatgaa	aaggaaagag	caaaaatcta	ggttattcac	1200
aggaagttag	tccagctgtg	ctttgcgagg	catgaaccag	gctgaatcag	agcaagaaca	1260
ggttgcaatc	ttaggtcaca	tggcaattaa	attccagcta	tagaatattg	aagacatgta	1320
agtgcttaat	ttaaggatta	ttcaatgcag	tgaataaatt	tatatcattc	ccaaaagtat	1380
gcacatcaga	taatgagtta	actgcatgta	acttgaaaac	cttaaattatt	taactgaaag	1440
gattttgtgc	atagaagat	gtcttagtca	atgtaaaaat	gccagtgatt	tgtgtagcat	1500
gtcctttgct	aaaagtcatt	atataaactg	aagtcactta	cttttgtttc	caatgtgata	1560
atattccaca	tttaacaggt	gataattatt	gaaaatatta	gtttgcctca	ctaatttgt	1620
gtccgagata	ttctagttta	aaccaagtaa	ctaatactgt	aaaagaagta	ttccttttat	1680
gaagccagca	ttatcctgat	actagaactg	ggaagagaca	cacacaaaaa	gaaaacttca	1740
ggccaatate	gctgatgaac	atcaatgtga	aaatcttcaa	taaaatactg	gcaaaccgaa	1800
tccagcagca	tgaggcgggt	ggatcacaa	gtcaggagat	cgagaccatc	ctggctaaca	1860
tggtgaaacc	ccatctctac	taaaaataca	aaaaattagc	cgggcatggg	gatgggcacc	1920
tgtag:ccca	gctactgggg	aggctgaggc	aggagaatgg	cgtgaacctg	ggaggcggaa	1980
cttacagtga	gccgagattg	caccactgca	ctccagcctg	ggtgacagag	caagactctg	2040
tctcaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aactcgta			2078

<210> 62

<211> 762

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (10)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (12)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (42)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (219)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (747)

<223> n equals a,t,g, or c

<400> 62

cgagtcagtn	anogagaaag	cggagagagc	cccaatcgca	anccgcctct	ccccgcgcgt	60
tgcccgatcc	attaatgcag	ctggcagcac	aggtttcccg	actgaaaagc	ggccagtga	120
cgcaacgcga	ttaatgtgag	ttagctcact	cattaggcac	cccaggcttt	acactttatg	180
cttccggctc	gtatgttgtg	tggaaattgtg	agcggatanc	aatttcacac	aggaaacagc	240

tatgaccatg attacgcca	gctcgaaatt aacccctact	aaagggamca aaagctggag	300
ctccaccggt gtggcgccg	ctctagaact agtggatccc	ccgggctgca ggaattcggc	360
acgagcacia atgectatac	aaaacttttt tccatgtcct	caatactttg tatcagatta	420
tttatatttc tcatggtttg	gtttcttttt ctctgttcca	ttttcttgaa ggtaaaaagg	480
gattttttcc ccccttttct	gatctgtaac ttgttttgta	tttggatgat tacaggcgtg	540
agccaccgcc tccagccaca	aatacttttt agtcgccata	agcataatca agaaatcatt	600
ttgcaaatgg taagcttttc	atgttgtgta ttctttccca	tgattagaga ggtaaaaagt	660
gsccctgggt gcataaagat	gtcgtagacm tmtgcaatct	gccacattat ttctttaaaa	720
aaaaaaaara aaactcgag	gggggggnacg gaacccaggg	cg	762

<210> 63

<211> 1094

<212> DNA

<213> Homo sapiens

<400> 63

tcggcacgag gtcaatcaag	tgaaatatca tgtaaaactgt	ccagcagctt tgaaagtaga	60
gaatgaacaa gggcccttcc	ccaccacccc tgtggaaaagc	ccgtctgggt tgggtctctc	120
ctggacagcg tcttgccggt	cacctttggc catctcccgg	tgcgtgggtc agatgtgggt	180
cctgttttcc tgccccctcc	ctctctgtgt cctgcctgcc	tctgtgtgce cggggcagtg	240
ccttgggtggc cagtggagtg	gacaccagct gcgaactgct	gggaggggct ggcattggcg	300
ctgccactgc agggccttggg	cggttgacat gggacgaggg	ttgcacagct gccagctcct	360
gtctcgctga ctttttttat	acagttttgt ctggggccacc	gccttcagtg ccacggggccc	420
cttgccggttc aggtgtctcc	tcatagatga acaaggccct	gccccgtgct cttacccttt	480
agagctgttt aaattcaaat	gaactgaaac tgaata:gaa	aaatccaggc cctcagccgc	540
ccaggccatg tttcaagtgc	tccatggcca catgtggctg	gtggacagtg cagctctaga	600
acattccatc accacagagg	gttctgtctg acagtggcct	tgggggctgt tttgagggtc	660
cgctgtcag tctcc:ggca	tcaaagtcac tctgccattg	tcaagttaca gttattttcc	720
ttttacctcc aagccactat	gtcgtatgct tgctatgtgt	ctgtatttcc cgctaaactt	780
cctgtcacgg aggggaagggt	gccacagggc cagctcctgg	aggggggttg gatgtctggg	840
tggggggaa ggtgccacag	gcccagctcc cgaggggggt	ttggatgtct ggggtgggggc	900
cagggcgcca cagttccagc	tcccggaggg ggtttggatg	tctgggcggg gctttcttca	960
tgttccatgt atgataacgg	tgactggggg gtttacagag	agaggcatac aaatagtgtt	1020
ggagtgttgt tttcgctaata	ataaatgttt gaataagctaa	aaaaaaaaaa aaaaaactcg	1080
agggggggccc cggt			1094

<210> 64

<211> 1361

<212> DNA

<213> Homo sapiens

<400> 64

cccgggtcga cccacgcgtc	cgaatttctt tagtgtatgt	tatgtacttt tgtattaatt	60
acattgggtg gactgttcca	taaatgtrga atagatccca	ttgtttgggt aatgctattg	120
ttgtgtatcc tgtgattttt	ctgtgtagtt ggtctatcag	ttgttgggag aagagtgttg	180
aagctctaca ctataattgt	gtatttgtct attactcctt	tcagttcttt cagttccatt	240
tcacataatt tccagctcct	gattgggtga cattaatgat	tactatgtct tcttggtgaa	300
tagaccattt tataatttta	tgatgtacct ctctgtcac	tttctttgct ctgaagtcta	360
cctgatatta atatagtcac	tctagctttc ttggagtaa	tgtagtggtg atatatcttt	420
tttcgtccct ttacttttaa	ccctatctat atcattaat	tattttaagt gagttttttg	480
tagatagcac ttacttgtgt	ctgtcatggt tttaaatcca	ctgtacaagt acaaatctgt	540
ctttattttt cttttttatc	cttattttga gacagagctt	cactttgaca ctacgcttag	600
aatgcagtgg tgtgatctcg	gtcactgca acctctgcct	ccgaggggtc agcaatcctt	660
tcacctcagc ctccaagta	gctgggacta caggcatgaa	ccaccatgcc tggctaattt	720
tttttttttt tttttttgta	gagatggggg ttaccatgt	tgctgagggt gggcctgaac	780
cctggggctc aaacgacctg	cccagctcag cctcccagag	aaatatgatt ttaattagca	840
catttagatc atttactttc	aatggaatta ttgatgtatt	acaattcaag tctgtcattt	900

```
tattttattgc ctccatttt tccctccgtt ttccatttct gtgctttttt tctttgcatg 960
taaacaatggt ttaggattct gttttgatgt atttagagta ttttttagtg tatcggttta 1020
tgtagctttt ctagtggatc ctttaagtat tacattatat atacataact aagaagtata 1080
tcagtgtcat cattttacca gttcaagtaa agtacagaaa tctttgtccc ttttacctgt 1140
cctgcttata atgtaaatgt cttaaagatt tccttgacac acatttagaa ccatatcaca 1200
gtgtgttttt tgcttcagtc gtgaaatata atttagaaac tcatgagaat aaaaacccat 1260
tatatttatt tataaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1320
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa agggcgccgc c 1361
```

<210> 65

<211> 947

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (67)

<223> n equals a,t,g, or c

<400> 65

```
ctttctatag ttaaagccgg tacgctgca ggtaccggtc cggaattccc gggtcgaccc 60
acgcgtncgg tttctgggtt ctaggccctg ctcccttgcc cctttgctgc agaagggcag 120
ctgaaggctc accctagaaa ccgggacctg tgggtcttac ccggctcact cctcccttg 180
tccttacaca tacaggaaga caagacctga gtggtgctgt ctttggtgcc gtctgtatg 240
gctctccctg tcttcatttc ttctcactct gtctctaaac ctctctctct ctcccttccc 300
cctcagtact tartaacag acctatgtgc gtgtccctat cctctgtccc ttttctctct 360
tcagctctcc ctgctctca cacacaattt tacatgcccc gaggagccaa gttgggaca 420
tttaccctcc aggcactctgt gtccctctct gaagagaaaa cacacagctt cacacatcca 480
ggcatagggg gcaagctctt ggggcatcag gacctggag caccaggctc ttcctggaat 540
attagatcca cctggagcac caggtctctc taagtctcac ctggggaatt cgggtccacc 600
tgggtcacca gttcccacct agagcactgt gtccctgccc agagcacaaa gacctgctcc 660
tcccagact ctctctgact gcagccaggc atagtacct tgcctgtgtt tgctccctgg 720
tccacagatt tgggtgctgg gcaggtgccc ggacagtgat gaggtcttgc cgccttaact 780
gtccccccca gtcacttctc ccacaggccc agcaggacgc agtcctgagg atcagggatt 840
ctacagctgc attaaaatca atcctatcca aaaaaaaaaa aaaaaggggc gccgctctag 900
aggatccaag cttacgtacg cgtgcatgag acatcaagct ctgaaga 947
```

<210> 66

<211> 1376

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (18)

<223> n equals a,t,g, or c

<400> 66

```
ggcggggcggc gcggaagngg cggckgcycg gccggggcag ccatgtgcc attgtctgag 60
gcgcggggcgg ccctgcgggt ctacgcggtg gccgcgcggg tgatccctggc gcagctgctg 120
cggcgctgcc gcgggggctt cctggagcca gtttcccc cagcactga ccgtgtcgt 180
atagtacgg gagggacaga tggcattggc tattctacag cgaagcatct ggcgagactt 240
ggcatgcatg ttatcatagc tggaaataat gacagcaaa ccaacaagt tgtaagcaaa 300
ataaaagaag aaaccttgaa cgacaaaagt gaatttttat actgtgactt ggcttccatg 360
acttccatcc ggcagtttgt gcagaagttc aagatgaaga agattcctct ccatgtcctg 420
atcaacaatg ctggggtgat gatgggtccc cagaggaaaa ccagagatgg attcgaagaa 480
catttcggcc tgaactacct agggcacttc ctgctgacca accttctctt ggatacgtg 540
```

```

aaagagtctg ggtccccctg ccacagtgcg aggggtggta cgtctctc tgccaccat 600
tacgtcgctg agctgaacat ggatgacctt cagagcagtg cctgctactc accccacgca 660
gcctacgccc agagcaagct ggcccttctc ctgttcacct accacctcca gcggctgctg 720
gcggctgagg gaagccacgt gaccgccaac gtgggtggacc cgggggtggt caacacggac 780
stctacaagc acgtgttctg ggccaccgt ctggcgaaga agcttctcgt ctggttgctt 840
ttcaagaccc ccgatgaagg agcgtggact tccatctacg cagcagtcac ccagagctg 900
gaaggagtgt gtggccgtta cctatacaac gagaaagaga ccaagtcctt ccacgtcacc 960
tacaaccaga aactgcagca gcagctgtgg tctaagagtt gtgagatgac tggggtcctt 1020
gatgtgaccc tgtgatatcc tgtctcagga tagctgctgc cccaagaaac acattgcacc 1080
tgccaatagc ttgtgggtct ggaagactg cgtgttttga gtttctcaca cccacctsc 1140
cacagggtct tgcctctag ttttgagaca gctgctctca cctctgcaga acttcaagaa 1200
gccaaataaa catTTTggag gataatcacc ccaagtggto ttcaaccata aacttttga 1260
ttccaaagtg ccagttgtc acagggtgcca taaataatta catTTTcaa cataaaaaa 1320
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaagggc ggccgc 1376

```

```

<210> 67
<211> 2434
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (10)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (12)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (27)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (73)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (75)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (103)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (130)
<223> n equals a,t,g, or c

```

```

<400> 67
ctgggggtan tncaagaacc ctctgtngga cctagatgtc aagctcttct ctttgggcag 60
cgtgtttcct ttntncgagt agtgtgctgt gtaaaactaaa ttngccggtt cgctttccat 120

```

ttcctgacan	ttgagatgga	atgccttgac	catgggtgct	ctgacagaga	agtcatggag	180
tcattgccat	ttcctgggtg	cccttttggg	atgtgatcct	gttagtagag	gttttctagc	240
ttctactaag	atatttcttt	ccctaaccat	catacacttg	gcatgtttca	ttcccatctc	300
ctttcccttc	accttaaagg	agactacccc	tttgcccat	attgtcaacc	taattttctc	360
tcgtactctc	tctagtgaat	gatgtgctac	caagratatg	ccaggctgtg	agaggattat	420
actgagtagt	agaaagaagc	taatttgaaa	taaaaattat	ttgtataatt	aagaaagcag	480
attagatgca	catggtcaac	aggaagttag	ctgtatgtct	gctagttaga	ttcaaacat	540
cataaagatg	atagcatgtc	aatatattag	cctagccatt	atgttagcct	ttgttaggtg	600
ggcagctttt	ctgctttttc	cccttctctg	tggtgacaac	ggaggaaa-a	tccaacagaa	660
atacgtctaa	cagggaaatt	gggatcatag	tttatatgca	tctgatttga	aaggagtatt	720
gaggaagggt	ttcatatatg	atctatcttt	ggattaaaaa	gaacatttat	gaaatcaagc	780
cttctaacac	tagttataat	tgagaagcaa	caqtaactcc	gtggacagca	atcaagctta	840
aaattgtaaa	taaatatggg	gataattcag	ttgttgcaaa	aaaagggcag	aattcagtag	900
aataaagtc	ttttctctta	caggtattaa	atgaggacag	agaacctcag	gtgttcttat	960
gctagtgcct	gctgagtgca	Lactaagaaa	gcaattccaa	atagatgtat	acatctagag	1020
agagtgggtat	tagagattca	gtgtatgtat	ttatttacct	gagaggaaac	tggaaatata	1080
tcccaataat	tattggaata	taatcccata	aattatcacc	ttttatgact	ggaaaatatt	1140
tgccaatgaa	gaaatgggtc	gtagggtatt	gtcttaagat	tttggctgt	ttataaaaaa	1200
tgtaacttta	acggtttctt	atagttgcct	ttataaagtg	tattgtctaa	aatttttllg	1260
tatcatgtgc	ctttgaaatt	tgacagctga	tttgggtgtt	ggatttctgc	ccagccattt	1320
atcagtatta	tcattttatt	cagtagctgg	caggtgtatt	agacaaacga	gacttaggta	1380
aggaatggaa	cctttcctgt	ggtttgactg	cacatcacac	cagaagactc	cagtatccct	1440
cattccagaa	tgaggaaaaa	gtattctaca	aagaacctaa	tcacctctgt	gaaatctatg	1500
ggatggaaa	agtgtggcct	taggagtcac	atagtctctg	catgggtggg	aggatcatga	1560
tggaatatgt	gaatttctac	ttctagaagt	tgtagaatag	gtcctgcact	ttgcagaat	1620
gtccttcttt	aaacctggct	tattccacag	ctgtagctga	taacatgacc	tggtggcttag	1680
ctgctctage	cctgggttct	tcgagacctc	acactgcctg	gccccggcc	atccacctaa	1740
ggactgcctg	ctttcttggtc	acatgtggac	cttgatacga	ctaagcgggt	acatatgtgg	1800
ttgtgcacaa	gctttctgtt	taatgcatag	tgttaccgat	ttacatcttg	gttttcagtg	1860
gcactatgtc	taggaggcaa	tatcctttta	aacagtgcct	tggttaagat	agatacttgt	1920
gaatcaaaga	tagcacagaa	atgaactaag	tatatccca-	ttggaattat	attttgatac	1980
tatttaaaat	ggtttcacct	gttaaagggc	caacagaact	cttggtttta	cttttgtaat	2040
tactgtacag	aaaatttcaa	gagtgtttga	gtgcttgtea	tcagggtgtt	tccttaataa	2100
gtagggatat	gatcattttac	aggaattata	tatgaaaaaa	gtttttgaaa	tgtatttttg	2160
tgatgtgcta	tggtgagggg	aaaccaaata	tttatgattt	taaaacattc	gtatgaaaaa	2220
attgtacaat	gtaatatgct	caactttctc	aattttttgc	taatttttct	aagatacatt	2280
aaaaatgttt	tatatttttt	tttaagtaaa	atggaccacg	taagaaaaat	aaaaatacca	2340
gaacataaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	2400
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaa			2434

<210> 68

<211> 1086

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (10)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (77)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1056)

<223> n equals a,t,g, or c

<400> 68

ttgaaacacn cttttgagca ttaggtccca gctccaccgc ggtggcgccc gctctagaac	60
tagtggatcc cccgggntgc akkaattcgy cactgagcaac ctgtagttag ttggctgtca	120
ctcagcagct ctggaaaatt acctgtctgc actgaatttc ctcatcagta aaatggaaat	180
gattatagta ctgacctgtt aggtattatc taaaaatcag agaagtccat gcagcttaga	240
acagtgccag gcacatggca aatgctatgg cataactaag catcttcttc tgggtgcct	300
cgatcatcacc atgtgattgt gccttgcttg tccctgttcc accttccaga gggagaaaag	360
tggccaactt taagaatcaa aattctgatg ttacttcggg aaatgcacag agccagagag	420
acacaatttg acctagtatg atccacatca tcccctcagg ctgaatagtg gtggcatgca	480
catctatacc aaaatgtttt accttttttg tagaaggaaa atatttgtat cttctattcc	540
atatcttaga tctttataag agcacttaag ttcaacctcc taagaaactg ccaattttgt	600
tgatcatgat agtctgcaca gattttcgta ctatttagtg ktgggagtg cttagggacc	660
atcaacaaca gggccctcct tttatccatg agactactga ggccttgag gttattttgt	720
catccatggc ggggtgcacrg ctgagggtta tctggttagt agcccaacta agattagaac	780
ccaggaaattt tgatttaac tcgaatgacc tcttttattt ctgcacccgg gaaggagaa	840
aggaagtaa acgggaaatt catgttatct atggaaaagt tatcagtttg atgtttatta	900
aatgatttgt ttcaggagat tgtttacaac ttttatcttc ctgacaata attttctgta	960
agagtaaatg catggtcatt aaggtagtca tattaatgta ttcagtaasc tgtgaagaaa	1020
aatatatac aatgttttcc aataaaatc agtgantacc tgaaaaaaaa aaaaaaaaaa	1080
aaaaaa	1086

<210> 69

<211> 1262

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (568)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (639)

<223> n equals a,t,g, or c

<400> 69

cctyctatag gkmaagctgg tackcctgca ggtaccggtc cggaattccc gggtcgaccc	60
acgcgtccgc ttacaacttc tctyttgttt ctgtgtttct tccacaccat tatggcgat	120
ttactgatct acaaccgggt ttaagttagt tgcctgttta aaattttctc atgaattctc	180
attacatttt caaacaaaat ccaagttttt taccatgacc ttgtggatat ctttctgacc	240
tcatttacta ctgttatctt ccttattcat tccattccac ccacagtggc cttcttgcaa	300
gtcagagaat gcaacaaata tgcctcctgc ttggggcatt tgcactcttg ttcttttggc	360
ctggtcactt cacctccaca ttctccattt ttatgactt tcttctata ttggatctc	420
tgttcaantg tcacccctca aaaaggcctt caaaactacc ctatttataa tagcacctgc	480
cactgccate tccataccca ttttcathtt tccatagcac ttatccctac ttggcattat	540
gttatatatt tgtttatttg kttactgnet gtctcccca ctggactgta agctccatga	600
ctgtaagtac atagatgaat tacaatatga atcaatggng aawtatcctt gmcataatt	660
atttaaatgat tttgctcca ttttaagtaa aaaaaaata ccattttttt cactcttcaa	720
agtgatatag tttaatcttc taaactacat ttttctcatt tcccatttta attaaatcag	780
tgatataaaa aaaagagtga tggggatag tgaagaaga ctaaaataga tgccaggaaa	840
tactaaaact gctgaagttt agtggatat tttttcttta cacacagtat tatttgagtt	900
actaattgtg tcaactgaatt acagaataag caaaatacta ggtaaacaga atcacgcttg	960
ggggctatat tttgtgtaaa atttgtgtta tgcataaata atattaaata ttttaattac	1020
acagttttgt tatttcttcc ttattttagg aaatgatttg cagctgagtg aatcaggaag	1080
tgacagtgat gactgaagaa atatytagct ataaataaaa atttatacag catgtataat	1140


```

ttattttgta ttaacaataa aaattcctaa gactgagggga aatatgtctt aacttttgat 1200
gataaaagaa attaaatttg attcagaaat ttcaaaaaaa aaaaaaaaaa aaggcgggcc 1260
gc 1262

```

```

<210> 70
<211> 1642
<212> DNA
<213> Homo sapiens

```

```

<400> 70
ggcgcgctgc ceggartgc ctgggttgcg ctgccggcca cgtccccgcg ccgggcctca 60
ggctccttcc tactgtccga gggccaccag gccgcggggg gcttgcctgcg cccggatgcg 120
tctgttacta gaggggagag tctacettcg tctcacatgt gccacaaagg atggcatggc 180
ccgggagtg cccaccacgl ggctttcacc ccttgcaaag ccagacttcg cccagcgaca 240
cagtgtcaag cccacagctc tccaaggagg aagatgggtcc aggtctggag catcyctta 300
gcagcagcct ctgatccctt ggccaagcag gagggaacca ttacgagcct gaggagctgg 360
ctggctggga gctcggggga cggccacagc ttgctcccgag ctacccaca agatgtggac 420
agctcttctg ctcatcttga ttttytcctt gtccttatct gaaagccatg cggcatccaa 480
cgatccacgc aactttgtcc ctaacaaat gtggaaggga ttagtcaaga ggaatgcac 540
tgtggaacaa gttgataata aaacgtctga ggatgtaacc atggcagcag ctctcctgt 600
cacattgacc aaagggtatc ggcagcccam ctcaactcta tggaaagtcac aacagaggac 660
acaagcagga cagatgtgag tgaaccagca acttcaggag gtgcagctga tgggtgtgac 720
tccattgtc ccaaggctgt ggctccagct acgactgcgg cctccattac gactgcggcc 780
tccagtatga ctgtggcctc cagtgtctcc acgactgcag cctccagtac aactgtggcc 840
tccattgtc ccaagactac agcctcagct atgactgcgg cctccagcac tcccatgaca 900
cttgcactcc cggcgccac gtccacttgc acagggcgga ccccgctcac taccgcaact 960
gggcatccat ctctcagcac agcctcgcga caagtgccaa agagcagcgc gttgccaaga 1020
acagcaaccc tggccacatt gggccacagt gctcagactg tagcgaccac agcaaacaca 1080
agcagcccca tgagcaactc tccaagtctt tccaagcaca tgccagtgga caccgcgga 1140
agccctgtac cccctatgck tccccagca caaggtccca ttagccagggt gtcagtggac 1200
cagcctgtgg ttaacacaac awataaatcc acamccatgc cctcaaacac aaccmcwgag 1260
cccctcaccc aggcgtggt agacaaaact ctcttcttgg tgggtgtgtt actcggggtg 1320
acccttttca tcacagtctt ggttttgttt gccctgcagg cctatgagag ctacaagaag 1380
aaggactaca cccaggttga ctacttaac aacgggatgt atgcggactc agaaatgtga 1440
ggggggcggg ggcttggcgg gaggcctggc ccttccctcg tcttttctt ttgcctttga 1500
gaccaaacca agtcttcca aattcttttg gtgcaattga ggagatatgc cagatgctta 1560
aacacattta attgtgtca gattaatcc atgatcacta aagagttgct gcttttttca 1620
taaaaaaaaa aaaaaaaaaa gg 1642

```

```

<210> 71
<211> 921
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> SITE
<222> (4)
<223> n equals a,t,g, or c

```

```

<220>
<221> SITE
<222> (9)
<223> n equals a,t,g, or c

```

```

<220>
<221> SITE
<222> (11)

```

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (15)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (20)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (901)

<223> n equals a,t,g, or c

<400> 71

gcgnggggna	naggnaagcn	ccccactatt	gggttcaaaa	gctggagctc	caccgcgggtg	60
gcggccgctc	tagaactagt	ggatcccccg	ggctgcagga	attcggcacg	aggtctgagc	120
agataagatt	aagggtctggg	tctgtgctca	attaactcct	gtgggcacgg	gggctgggaa	180
gagcaaagtc	agcgggtgcct	acagtcagca	ccatgctggg	cctgccgtgg	aaggggagtc	240
tgtcctgggc	gctgctgctg	cttctcttag	getcccagat	cctgctgctc	tatgcctggc	300
atttccacga	gcaaaggagc	tgtgatgaac	acaatgtcat	ggctcgttac	ctccctgcca	360
cagtggagtt	tgtgtccac	acattcaacc	aacagagcaa	ggactactat	gcctacagac	420
tggggcacat	cttgaattcc	tggaaaggagc	aggtggagtc	caagactgta	ttctcaatgg	480
agctactgct	ggggagaact	aggtgtggga	aatttgaaga	cgacattgac	aactgccatt	540
tccaagaaaq	cacagagctg	aacaatactt	tcacctgctt	cttcaccatc	agcaccaggc	600
cctggatgac	tcagttcagc	ctcctgaaca	agacctgctt	ggagggattc	cactgagtga	660
aaccactca	caggcttgcc	catgtgctgc	tcccacattc	cgtggacatc	agcactactc	720
tyctgaggac	tcttcagtg	ctgagcagct	ttggacttgt	ttgttatcct	atcttgcatg	780
tgtttgagat	ctcagatcag	tgttttagaa	aatccacaca	tcttgagcct	aatcatgtag	840
tgtagatcat	taaacatcag	catttttaaga	aaaaaaaaaa	aaaaaaarct	cgaggggggg	900
nccggtacc	agggcggaag	a				921

<210> 72

<211> 906

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (34)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (833)

<223> n equals a,t,g, or c

<400> 72

ggaaattctc	cctcactaat	tggaaacaaa	gctngagctc	caccgcgggtg	gcggccgctc	60
tagaactagt	ggatcccccg	ggctgcagga	attcggcacg	agggaaagaga	gaggggaggg	120
tgagcagagg	acaggccggg	agttttccgg	gaacggagga	agagcagtgg	aggctgccag	180
gatgaggctg	ctgtgtggcc	tgtggctgtg	gctctccttg	ctgaaagtcc	tgcaggccca	240
gaccccaacc	ccccgccac	tcccgcctcc	gatgcagagc	ttccaaggaa	accagtcca	300
gggggaatgg	ttcgtcctgg	gcctggcggg	caacagcttc	aggccggagc	acagggcgct	360
gctgaacgct	ttcaccgcaa	ctttcgagct	aagtgatgat	ggccgctttg	aggtgtggaa	420

```
tgcgatgact cgaggccagc actgtgacac atggtcttat gtgctgatac cggcagccca 480
gcctgggcag ttcactgtgg accacgggtg gggcaggagc tgggtgctgc ctcccgggac 540
gctggaccag ttcactgtgc tgggcagagc tcarggcctc tcggatgaca acattgtctt 600
cccagatgtg actggargtg cectggacct carcagcctg ccttgggtgg cagccccagc 660
ctgaccactc agacagccgc ggcccccaag gcctgactct tcttgtggga gggcgaggct 720
ggtcacccca ggccagcgtc tgttgaagga tgaagcagct cctgtccggc ccagccctgc 780
ctcacagctg tgcgagctct gccctcctca gctctcaaac ctgaataaat gcnccaagcc 840
cagaaaaaaa aaaaaaaaaa aaaaaaaaaa ctcgaggggg ggcccgtac ccaattcggg 900
agattg 906
```

```
<210> 73
<211> 680
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> SITE
<222> (7)
<223> n equals a,t,g, or c
```

```
<220>
<221> SITE
<222> (9)
<223> n equals a,t,g, or c
```

```
<220>
<221> SITE
<222> (15)
<223> n equals a,t,g, or c
```

```
<220>
<221> SITE
<222> (16)
<223> n equals a,t,g, or c
```

```
<220>
<221> SITE
<222> (22)
<223> n equals a,t,g, or c
```

```
<400> 73
cactcantng aacannagct cnagctccac cgcgggtggcg gccgctctag aactagtga 60
tccccggggc tgcaggaatt cggcacgaga tatttcgctg gacccctagaa aagccaccac 120
gaactgtggg ccatgatgct accccaatgg ctgctgctgc tgttcttctt cttcttcttt 180
ctcttctctc tcaccagggg ctcaatttct ocaacaaaat acaacctttt ggagctcaag 240
gagtccttga tccggaacca ggactccgag actggctgct gccaacgtgc tccagacaat 300
tgcgagtcgc actgctcgga gaagggtcc gagggcagtc tgtgtcaaac gcaggtgttc 360
tttgccagat atagagcgtg tccctgcctg cggaaacctga ctgtatata ttcaagaat 420
gagaaatggc ttagcatcgc ctatggccgt tgcagaaaa ttggaaggca gaagtggct 480
aagaaaatgt tcttctagtg ctccctcctt cttgctqset cctcctyety cacctgctct 540
cctccctacc cagagctctg tgtkacacct gttccccaga gcctccacca tgagtggagg 600
gaagtgggga gtgattgaaa taaagagett tttcaatgaa aaaaaaaaaa aaaaaaaaaa 660
aaactcgagg gggggcccg 680
```

```
<210> 74
<211> 1633
<212> DNA
```

<213> Homo sapiens

<400> 74

```

ggcagcagca tcagtaagta ggagctaggg aagagaaagc atgcaaaagg gcaagaatca      60
ggagaattga taaagtagct ggacagaact ctatagtggt gtgtgtgaga gaaagagagg      120
caggggagaag gagggaggag ctaccccac gatgacctcc aacttccctt tctgcacct      180
catcc-gggg atagcacagg ctgaggctcg ccttggttgc cctggcgatt ggcttggcct      240
gggctcaggg gtgggggagg ggctgcacca cattaggacc tgccttactc caatcccatg      300
cagtcctcct gctcctgctg ctgcgtgccct gggctctggt catgccaggc ttccttgtgt      360
cctgcgtctg tggccgggttc ctgccaacct gtctagtcct ttcaggcttg aggccctgca      420
ttgctctttc tggctctctc cctcctctcc cgctcccat ctgacctttt ttgggttccg      480
ggatctgctg acagacttct ttcttctgct ctgcctgctt acatttcaga agacccctct      540
ggaaactgccc atggctgtgg tccacctgct ggtagcaacg ccctgttacc aaatgctaga      600
taatctgcca ctccctctg cagccgccaa ctgggtctga gctgccacct gttgtctgtt      660
tccacacctt tgtacactgc attctgctg tctactctga cagctgcccc gcagctgcag      720
ctgaggccgt cctgccagca cctaccgcag ccccatgggt ggtcctgtcc agttcctggc      780
gtccccagcc tgcctcatct gctgtactta cagagccaca tctgggtgaa tacagagctg      840
gggtagcctg gatgggcccc tggcacactc actccagag aggggggcat cctctctctg      900
gacctctagg gaagggcagg gtctggagcc caataataaa acacagtaat gataatcata      960
gctaattgtt actgagaact taggatgtga taggctcaat gatttaccag aattactcta      1020
tactgcataa ctacctatc aggttaagtac tattaataac ccttttccca catgaagaaa      1080
ctaaggctaa ccaatagaaa tgaacctgtc taatgtccca tgggcataat tcatggagcc      1140
aggattcaga accagggtct ttacttcagg gctgaagctc ataaccacta gaccaaaagc      1200
cctccctcct gacctctggg gaaggccacg caacatctcc tattgcgtcc aatgacttct      1260
ccctggtctg agatccactg actcacaggg gtagggttaa ggttaaggcc agagtctcag      1320
ctaagctttg gatactttct tctggatttg gagaaggctg gaataactga atttctgctc      1380
atcttcagga gcggcctact agagccacac atttccacg tctcctgtg tgtttccag      1440
acccttcttc catcgtgtcc tcaccttag gctcctggaa agttttcaga gagaatcacc      1500
cagtggtaac attgttaaac aaaacaggaa aatgggactt gtgtgtatat atgattaaat      1560
tattaattga tggatctacc ttcttagctc gtgccgaatt cgatatcaag cttatcgata      1620
ccgtcgacct cga

```

<210> 75

<211> 1022

<212> DNA

<213> Homo sapiens

<400> 75

```

ttcccgggtc gacccacgcy tccgcccacg cgtccggctt ggggccagca ccctgtctca      60
aagatggcaa aatgaggcta gttctggatg agctagctgg tgtgggttcc aaccatagga      120
acacactgat gctcaaatcc taagggtcca agctctaggg cctggaggct ggtagaacag      180
gatctatgcc tggaaatcctg gcagggatcc ctgtcaagga cttgtgttta agcctgcttc      240
agggcttcag gctgcttctg ctctgtgtct gccaggctg gctgagcgyy tggatgggtg      300
gacagaaggg ctacccaagg attgtggaca tagggtaggc cctggtacca cgggtttcag      360
gctgttatca ctcccttgt aggaacatag ccagaagcag atgagccagg gttaggggt      420
ggccctcctc ctcatcttcc ctctagcttt aaattgtctc cagcgatggg aagaggccag      480
ggactgtaac ccttgtgtg tgtattctct gacctctgce tcaactctag ggccaagcag      540
ctcccaagcc ggggcccctc ctggccaaa atctgaggag cagtctaggt tacaggcttt      600
ttggtacgta ggttctgggt gcctgttaat gcagttaggg cccctgatta ggtacagtga      660
gaaacaagct agaacaaccc tggcccagaa gactgtgcac tccagcaaga tccagggatg      720
atagccttgc agggccactg ggaatttgtg cccaagcttc tccctcttct cccccaggg      780
ggcactggga ctggctccctg cctcctcctc tagcctgggc ctccccaga ggtat-aaag      840
agaagtatga ttcctctgtc ttcagttcct ttcaggggca tccctcccat agtaccaggt      900
tcccaagggy cccccagtca cgtggtgaag cctagcactc atgcagcctt tagggaacca      960
aaaaccagca ctgaaataaa gctgaatgac tgaactqaaa aaaaaaaaaa aaaggcgggc      1020
cg

```

<210> 76
 <211> 1184
 <212> DNA
 <213> Homo sapiens

<400> 76
 agcaaaagggt gaagagagaa aggaagcttt ttctctaaaa atgggtgcagc tatectctga 60
 accaattttcc ttcgggtttaa tgtacctgta tcttgggggtt tttttccact taattttatcc 120
 tggagctctt tccataacaa cacttggaaa gcactctcat ccttttttca ctgctgaaca 180
 gaattccact gtgtggatgg aacatactct atttcaccag tccctgttag ccagtcactt 240
 ggtttgtttc caatcttttg ctttttcaga gtaataacct tgtatgtcta tcatatttga 300
 tgcatacagg tttatatgta ggaaaaatc ctagagtagg attgctggac caatggataa 360
 aagtatatgg tggacagaca atgccaaatt gcctttcaga gactgtggcc ctgtgcaccc 420
 catcaggcat gtgtgactac caaagctect gtcagctgtt ttattttatc tectttccag 480
 tctcaggctc aatgcagaac tttgaggtaa gcttttctaa aatgtaggct cctaaacgcc 540
 acagccagct ctgccacatg aaggagagct caaatgagac agaaacagcc tctgggcagg 600
 attttctatc tgcacagata tattttccac attctgggaa accgtgaagc ttccagagcc 660
 acaattcccc agaaacacat cccctgtctg gtacagccaa gccccagaac aagctgtgct 720
 tgcttggcac ctcaaagcca agcaccatgg atgccacttg ccatgggtgc ctgcaatttc 780
 aaataatgag aaataagaaa tttcagcttc tcagtccttc tagccaacat tttaggtgca 840
 tgacagcttc aggtggcaag cagctactct gccggacagg gcagaagatg gaacaccca 900
 tccttgggga agatcacgag gtcaggagat caagaccatc ctggctaaca cagtgaacc 960
 ccgtctctac tgaaaataca aaacattagc tgggtgtggt ggcaggcacc tgtagtccca 1020
 gctactcagg aggtgaggc aggagaatgg cgtgaacctg ggaggtggag gttgcagtga 1080
 gccaaagattg cgcactgca ctccagcctg gcaacagagt aagactccat atcaaaaaaa 1140
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 1184

<210> 77
 <211> 312
 <212> DNA
 <213> Homo sapiens

<400> 77
 aatccccggg tcgaccacag cgtccgtgat gagtggattt gtactcttac ccaggtcctg 60
 agggccagcc caccacagcat ccccaccctt gatgacgctg tccctacaac tggctgaact 120
 ggtgcatttt gtgtgtgctt tccagagcca gtggactggt gtgtatccaa tgaatgccacc 180
 tctgaaacct acagaaccac tatgctttgc atgtgtaccc tgcagggtct gagggccagg 240
 ctgtctggtg gctctgctcc tgggtgacag agcaagactc tgtctcaaaa aaaaaaaaaa 300
 agggcgggcg ct 312

<210> 78
 <211> 1370
 <212> DNA
 <213> Homo sapiens

<400> 78
 tgggttaaaga gtacgacatt ttagtcaggg ctgagcacag cgccctggccg agggagtgcctt 60
 ttatatgctc ttggaagtat atggggactc catttctgtc actgtggcga ttccacttat 120
 gcattcacca tgccaatcca aggcagctga tggcttagga aagtcagaga ctgagatggt 180
 aaaatccttg gggctatcta ccaacatgtc tccattccac ctgttagggg taaagggttt 240
 tctaaccctg gccctgacct tagcacagat ctgcctatat ttttttgaag ttcagccacc 300
 tggactatta gccctaaact tttctgtac tgccactgca gggctgaagg agctttgcat 360
 gcattccacca agtctggctt tcacacctga atttcacacc tcgctttcac ccttagctat 420
 tccatctttc tgtggaacat cagtgtcact tagcaatagc catacaatcc cattatcctt 480
 atacctacct ttcccttcaa agtctcggat gcctgataca ttgcacctgc tagtgcattc 540
 actcccatla gtacactccc aagtccttcc agtgaaagat gtaacaattg aatggccact 600
 gtgcaaaagg tgcctgggct ctacctgcca ccagtgatgg ggtcctcaca gccaaaccag 660

```

tggtgtatca tccatttcca aaaccatctc amtgcctggt ttcttggacc actcctggca 720
tcaactgttt caggttagag tgactgaaaa ttgggkktat aagatattta ttagagatca 780
atatctatta aaaatgtgaa aggaagcagg attktgctga ggaagaagat aacaacaaag 840
ataccacaat gtcagcccat caaagccttt ggccaacca gcaaaaaaat ctggagcagg 900
tgtayctttt tcagagtctc cccagttagg tcaaatgtg cgcttttaca cccgcattc 960
cctcaatcac gggcttcagg ctgtcctggg catgacctca gatgaagcgg ctccacacagc 1020
tgaggctaac gttgtcggag ctgacagctg aaagccgttt gctgaccaca ctcccacagc 1080
cgagcagcat gcccttgctt ggaggaggat ttggatgaca cagctctatg tctgccgtat 1140
tttgggggtc acattcctca caccagctc tgcctcaaa- ggcaacattg acaaaaaattc 1200
attccagttg caaaccaatt gtagaatact ataaaaccag agtacaagtc taatagcata 1260
aatctcatcc taagtggaaa agaaaggggtc atttattcac acatttttgg ggaaaaaaa 1320
acaacctttg ctatgtcttt attacaacac ggatactcac aaaaaatagt 1370

```

```

<210> 79
<211> 368
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> SITE
<222> (5)
<223> n equals a,t,g, or c

```

```

<220>
<221> SITE
<222> (13)
<223> n equals a,t,g, or c

```

```

<220>
<221> SITE
<222> (35)
<223> n equals a,t,g, or c

```

```

<220>
<221> SITE
<222> (351)
<223> n equals a,t,g, or c

```

```

<220>
<221> SITE
<222> (367)
<223> n equals a,t,g, or c

```

```

<400> 79
aatgnaactc tcnttactaa ttggaaccaa agctngagct ccaccgcggt ggccggccgct 60
ctagaactag tggatccccc gggctgcagg aattcggcac gaggtccagg tgtctttatt 120
tcagatgttc tgttttttct ctattttctg ctccatgaa catacact tggcaggcac 180
attctggett ttcttatttc tctttctgat ttgcctcct tctgcccct gttttcttcc 240
cttttctctg gctatagaaa ctgtcagggt gccttgctgg catcatccta cctcttttga 300
actgtgttac ccaggaactt ccatttatta tgcctcgagg gggggcccg nacccaattc 360
ggaagant 368

```

```

<210> 80
<211> 1088
<212> DNA
<213> Homo sapiens

```

<220>
 <221> SITE
 <222> (1)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (4)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (5)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (9)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (11)
 <223> n equals a,t,g, or c

<400> 80
 nttnnaacng naaatctccc cttactattg ggaacaaaag ctggagctcc accgcggtgg 60
 cggccgctct agaactagt gatcccccgg gctgcaggaa ttcggcacga gattccccag 120
 aatttggttca tcttgggaaa ggaaggccta ggaagctgat gacctacttg ttttgttcat 180
 ccatttctct actgtctctt aaagtgcact caagcggta ccaggacatc agaaaagcca 240
 aatccaaggt cccaaggctc ttgatcatcc agtgcacaca acagaggagg taagctagac 300
 ggagaagctg aagtgaagga ggaagagag aagggggtgc ctgttccacc cctctcctag 360
 cagctgcttc tgtgggctcc ataatcccca tgcctctctc cccacccac cctccggccg 420
 mccacctctc ctccacccac cccattcctc agtaggaggg cactgtatca gcacagcctt 480
 tcaaggcctg acagttcctt tctgggtgcc cccacatgt aaccacttaa cccccagcac 540
 aaagggccag cctgaatggg cttggagccg gtggctcgtg cgraggggga ggccctcaata 600
 ggatttgggg agctgggtgt ataaaccgct ctgctccagc agccctcaat ggaggagctg 660
 gagttggggc atgtgccgag gggaggagct cggcagctgc atcccgscce tgaacaatga 720
 tttattcatt ctctctggac gcacagagaa gacaggtgg ggaacatgg cccacacaaat 780
 cgccctcage ctccagctgat tcccacggca atcattgcag ttcagagtgc cccctccac 840
 ttgtaatgtt ttgcctcaag cttgcccctc ctcttctgg taaggagta gactacatta 900
 cgggaggcct taagtagcct taaattcagg caagcatcgt tctttgagtt ggttgacccc 960
 aaactcaatc tcaactcttc aaagctttct ggccagggtt tcttcacaca cccatagaaa 1020
 cagatgcaga caaaaaaaaaa aaaaaaaaaa actcgagggg gggcccggaa cccaattcgg 1080
 aagatttg 1088

<210> 81
 <211> 1862
 <212> DNA
 <213> Homo sapiens

<400> 81
 ggcacgagct ctgcaagct cctctctctc cagcacgtcc tgtatttttt caactttgga 60
 tgtttgcaca agctattatc ttttgcaaga atgtectgcc cctctctatc catctgtgga 120
 agtcaacctt tcttttagggc ccaggagaaa acctatcacc ttctacacct tcccagatgc 180
 ccaccatttg ggttaaaactc tgcctctctc aggtttgcca tgggttttct cctctcttaa 240
 agcactggtc ccagccctatg ccatttgtgt tcacctggc tctgtctctc tactggctgt 300
 agatcttttg gargggagga actgggggaa ttctatcctg gggctatggg atagtgtcta 360

ccctaagta	taaaataagc	aagaatcctt	gaattgaaaa	gctccagtga	cttgatagct	420
tccaacagcc	cctaaagatg	gggtagccca	ctgctcccta	tataggaagg	aagaggttca	480
cagtcctcatg	gatttagcag	ccttcgtagc	ctcaggatct	tcccaaatgt	ccccagttct	540
cctgctgggc	cagctgtggt	ctctgagaa	gctcagttcc	ctgggctagg	ctggcctatg	600
gggcccctccc	tcctggacct	gggtccatg	gaccaagtgg	ccagccagcg	agagagccct	660
gggtgatgag	catctggaag	tcagcttgct	tgtctgcct	aatcacagcc	ctgggctcta	720
ccctcaagta	cctactcac	atggtccaag	agggaaaccac	tcttctgtca	ttccctcccc	780
ttctgctccc	catcctaccc	accagctgt	tctgggcaag	atcctgtggg	catgatggaa	840
tctcccttt	tctctacat	ccatccctt	gatcacctaa	tcctrcarct	gccctccaac	900
caaggtgttc	tttctatacc	aaaaaatctg	atcaggccat	cactcctctg	tttaaaacca	960
ttcaacggct	accactgcc	ctcaggataa	aaactaaaat	tcttaacagg	atttacaagt	1020
tcttcacctg	gcccttttga	gataagagga	tttataatct	tttcaaagcc	aacaagcatc	1080
ctgagacaat	cttaattttt	gcagctgtcc	aagctattta	agatttgatga	ggctctgcamt	1140
aagttgttaa	atggtgatta	atttatctgg	cctgaatggc	akgtgaattc	caaggggagc	1200
atttttctct	accttccctg	ctgcacattg	ggacacagca	agggccaggac	acccttytta	1260
ggtgactgsg	taaccagggt	cattaaggca	gtcagcgag	agaagaagca	gaaaatgggg	1320
aggagtgtg	taaatgaaat	tgccgataat	accaaaggaa	ccccaagaga	ggttcagctc	1380
cccaacaatt	gcagctttgc	tgcaacatgg	cagggtggga	cagggttagg	tttggatctg	1440
ggctgctttg	ccmtggaaat	gggggttccag	ggcagggaga	ggcttaccat	cactgagcat	1500
ctttaattga	ctttgtcatt	ttastgagaa	cttacaatt	gagctattct	tcattgagtt	1560
atatttgaa	gcaggttcaa	tacataatac	agtcctccct	ctagaatttc	tgctttatgt	1620
ccactgtgat	cagcttgttc	atttctgaat	tccttttaat	gacaaaaaca	tttggaagga	1680
atgtaagac	tcaaaaagg	gatggcatgt	aaactatagt	tgggaacaata	tgtggccatt	1740
taaaagaagt	gttgtccagg	aggtggaggt	tgacagtgagc	tgagattgca	ccactgcact	1800
ctagcctggg	ccatagaatg	agactccttc	tcaaaaaaaa	aaaagaaaaa	aaaaaactcg	1860
ag						1862

<210> 82

<211> 1618

<212> DNA

<213> Homo sapiens

<400> 82

ccacgcgtcc	gcaaggagcc	agaggccatg	cagtggctca	gggtccgtga	gtcgcctggg	60
gaggccacag	gacacaggt	caccatgggg	acagccgccc	tgggtcccgt	ctgggcagcg	120
ctctctgctct	ttctctctgat	gtgtgagatc	cctatggtgg	agctcacctt	tgacagagct	180
gtggccacagc	actgccaacg	gtgtgtgac	tctgaggacc	ccctggatcc	tgcccatgta	240
tctcagcct	cttctccgg	ccgccccac	gccctgcctg	agatcagacc	ctacattaa	300
atcaccatcc	tgaagggtga	caaaaggagc	ccaggcccaa	tgggcctgcc	agggtacatg	360
ggcaggggagg	gtccccaagg	ggagcctggc	cctcagggca	gcaagggtga	caagggggag	420
atgggcagcc	ccggcgcccc	gtgccagaag	cgtttcttctg	ccttctcagt	gggcccgaag	480
acggccctgc	acagcgcgca	ggacttccag	acgctgctct	tccgaagggt	ctttgtgaac	540
cttgatgggt	gctttgacat	ggcgaccggc	cagtttgcctg	ctcccctgcg	tggcatctac	600
ttcttcagcc	tcaatgtgca	cagctggaat	tacaaggaga	cgtacgtgca	cattatgcat	660
aaccagaaag	aggctgtcat	cctgtacgcg	cagcccagcg	agcgcagcat	catgcagagc	720
cagagtgtga	tgtgtgacct	ggcctacggg	gacgcgtct	gggtgcggct	cttcaagcgc	780
cagcgcgaga	acgccatcta	cagcaacgac	ttcgacacct	acatcacctt	cagcgccac	840
ctcatcaagg	ccgaggacga	ctgagggcct	ctgggccacc	ctcccggctg	gagagctcag	900
ctgatacggc	atcctgcgag	aagacctgcc	ctcctcaetg	ggatcccctt	cctgcctcct	960
cccagggtc	tgccagggcc	ttgctcaqtc	ccttcacca	aagtcactgt	aacttccgtt	1020
tcccagggcc	tccagctgcc	ctcagacact	gatgtctgtc	cccagggtgt	ctctgcccct	1080
catgcccctc	tcacgggccc	agtgcgccga	ctctccaggc	tttatcaagg	tgctaaggcc	1140
cgggtgggca	gctcctcgtc	tcagagccct	cctccggcct	ggtgtgcct	ttacaaacac	1200
ctgcaggaga	agggccacgg	aagccccagg	ctttagagcc	ctcagcaggt	ctggggagct	1260
agagcaaaag	agggacctca	ggccttccgt	ttcttcttcc	aggggtgggt	ggcctggtgt	1320
tcccctagcc	ttccaaaccc	aggtggcctg	cccttctccc	cagagggagg	cggcctccgc	1380
ccattgggtgc	tcatgcagac	tctggggctg	aggtgccccg	gggggtgac	tctggtgctc	1440
acagtcgagg	gagccglggc	tccatggcca	gatgacggaa	acaggggtctg	accaagtgc	1500

aggaagacct gtgctataaa ccaccctgcc tgatcctgcc cctgcctgac cccgccacgc 1560
cctgccgtcc agcatgatta aagaatgctg tctcctcttg gaaaaaaaaa aaaaaaaa 1618

<210> 83

<211> 2034

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (14)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (382)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1999)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (2027)

<223> n equals a,t,g, or c

<400> 83

actcactaag ggancaaaagc tggagctcca ccgcgggtggc ggccgctcta gaactagtgg	60
atccccccggg ctgcaggaat tgggcacgag atctaccggg agakggaytc tgaaggggcc	120
ccggccacgag tccctgagac gccaacggca gtcactgccc ccattccag ctccctgggat	180
acgtactatc agccccgtgc cctggagaaa catgctgaca gcatcctggc actggcttca	240
gtattctggg ccatctctta ttactcctct cccttcgctt tcttctactt gtacaggaaa	300
ggttacttga gtttgtccaa agtgggtgcc ttttctcact atgctgggac attgctgcta	360
cttctggcag gtgtggcctg cntccgaggc attggccgct ggaccaaccc ccagtaccgg	420
cagttcatca ccatcttggg agcaacacat cgggaaccagt cttcagaaaa caagaggcag	480
cttgccaact acaactttga cttccggagc tggccagtcg acttccactg ggaagaaccc	540
agcagccgga aggagtcctg aggggggccc tcccgcggg gtgtggccct gcttcgcccc	600
gagccccctgc accggggggac agcagacacc ctctcaacc gggttaagaa gctgccctgt	660
cagatcacca gctacctggg ggccgacacc ctaggcgccc ggaatgctga tccaggctct	720
gtgtacctgc tgcagaaggc cctcatgcct gtgctgctgc agggccaggc ccgactgggtg	780
gaagagtgtg atggggcgcc ggcaaaactg ctggcctgtg atggcaatga gattgacacc	840
atgtttgtgg accggcgggg gacagctgag ccccagggac agaagctggg gatctgctgt	900
gaggggaatg ctgggtttta tgaggtgggc tqcgtctcca cggccctgga agctggatat	960
tcagtccctg gctggaatca tccaggcttt gctggaagca cgggggtgcc attccccag	1020
aatgaggcta atgccatgga tgggtgggtc cagtttgcca tccaccgctt rggcttcag	1080
ccccaggaca tcatcatcta cgcctggctc atcggcggtt tcactgccac gtgggcagcc	1140
atgtcctacc cagatgttag tgccatgac ctggatgctt cctttgatga cctgggtccc	1200
ttggccttga aggtcatgcc agacagctgg aggggcctgg tgaccaggac cgtgaggcag	1260
catctcaatc taaacaacgc ggagcagctg tgcagatacc agggctcctg actgctgac	1320
cggagaacca aggatgagat catcaccacc acggttcctg aggcacatcat gtccaaccga	1380
ggcaatgacc tccctgctgaa gctcctgcag catcggtatc cccgggtgat ggcagaggag	1440
ggctcttcag tggtaggca gtggttgag gcctcctcac agctggagga agcctcaatt	1500
tatagccgat gggaggtgga agaggactgg tgtctgtctg tctctcgtc ctaccaggca	1560
gaacacgggc ccgacttccc ctggagcgtg ggggaggaca tgagtgcaga tggacggcgg	1620
cagctggctt tgtttctggc tcggaagcat ctgcacaact ttgaggccac tcactgcacc	1680
ccactcccag cccagaactt ccagatgccc tggcacctct agggaccaac tgggactcat	1740

tatggaagaa	tgggggtgaga	ggagacatga	ggaaagaccc	tcttatttgt	gattctctgt	1800
gttcatgttg	ctgtttatag	tttgtgaaa	gtgggggacc	atcccccttc	tcaccactgt	1860
tcctcttgca	cgtttccctt	cattcatgtg	gctgtactta	accttctcca	acatacatcc	1920
tgcattacat	gaatggatta	ttcctaataa	ttataaaaa	ggttattttt	ctacaaaaaa	1980
aaaaaaaaaa	aaactccana	attacttcct	aaaaccggcc	cgcgggnccc	atcc	2034

<210> 84
<211> 2240
<212> DNA
<213> Homo sapiens

<400> 84						
tcgaccacgc	gtccgcttcc	tcattgtgcc	cgctcgcccta	ccgttcaggc	tgctgagcct	60
tttccctcgt	ggatcccgctc	ccacggcagc	gcgcacatggc	ctccgggagc	cgctccctgga	120
gaggaggtgc	gctgccgcctt	cctccttcca	gcactcatcg	agctctgggac	gcgagcttcc	180
ttatgacccc	gtggacacgg	agggctttgg	agaaggtggt	gacatgcagg	agcgttttct	240
gttccccggag	tacatcctgg	atccggagcc	gcaacccacc	cgcgaaaagc	agctgcaggga	300
gctccagcaa	cagcaggagg	aggaggagcg	acagaggcag	caycggcggg	aggagcggcg	360
acagcaaaac	ctacgggcca	ggccccggga	gcacccggtc	gtggggcacc	cggacccggc	420
attgccgccc	agcggcggtga	actgctcggg	ctgcggggca	gagctgcact	gccaggacgc	480
cggagtgccc	ggctacctgc	cccagagaaa	gttccctcgc	acggcgagg	cagacggcgg	540
gctggcacgg	accgtgtgcc	agcgtgtctg	gctgctgtcg	caccacggcg	gcgtctctacg	600
cctgcagggt	agccgcgagc	agtacctgga	gctggtgagc	gccgcgttgc	ggcggccccg	660
ccctccctctg	gtgctctaca	tgggtggacct	gctggacctg	cccagcgcgc	tgctgcccga	720
cttgcccgcg	ctggtggggc	ccaagcagct	gatcgtgtctg	ggaaacaaag	tggacctcct	780
gcccagggat	gctcctggct	accggcagag	gctgcgggag	cgactgtggg	aggactgtgc	840
ccgcgcccgg	ctcctgctgg	cccctggcca	ccaagggcca	cagcgcccgc	tcaaggacga	900
gccacaggac	ggggagaatc	cgaatccgcc	gaactggtcc	cgcacagtgg	tcagggacgt	960
gcggctgctc	agcgccaaga	ccggctatgg	agtggaaag	ttgactctctg	cccttcagcg	1020
ctcctggcgc	taccgtgggg	acgtctactt	agtggcgccc	accaacgcgc	gcaaatccac	1080
ttcttttaac	acgtcctctg	agtcagatta	ctgcactgcc	aagggctccg	acgccatcga	1140
cagagccacc	atctccctct	ggccaggta	tacattaaac	cttctgaaat	ttcctatttg	1200
caacccaact	ccttacagaa	tgtttaaaag	gcacaaaga	ctaaaaaag	attcaactca	1260
agctgaagaa	gatcttagtg	agcaagaaca	aaacagctt	aatgtcctca	aaaagcatgg	1320
ttatgtcgta	ggaagagttg	gaaggacatt	cttgatttca	gaagaacaga	aggataacat	1380
tccttttgag	tttgatgctg	attcacttgc	ctttgacatg	gaaaaatgac	ctgttatggg	1440
tacacacaaa	tccaccaaac	aagtagaatt	gactgcacaa	gatgtgaaag	atgcccactg	1500
gttttatgac	accctctggaa	ttacaaaaga	aaattgtatt	ttaaatcttc	taacagaaaa	1560
agaagtaaat	attgttttgc	caacacagtc	cattgttcca	agaacttttg	tgcttaaaac	1620
aggaatgggt	ctgtttttgg	gtgctatagg	ccgcatagat	tcctgcagg	gaaatcagtc	1680
agcttggttt	acagtctgtg	cttccaacat	cctccctgtg	catatcacct	ccttggacag	1740
ggcagacgct	ctgtatcaga	agcatgcagg	tcatacgtta	ctccagattc	caatgggttg	1800
aaaagaacga	atggcaggat	ttcctctctt	lyttgctgaa	gacattatgt	taaaagaagg	1860
actgggggca	tctgaagcag	tgcccgacat	caagttttcc	cttgcagggt	gggtttcagt	1920
aacacctaata	tttaaggaca	gactgcactt	ccgaggctat	acacctgaag	gaacagtttt	1980
gaccgtccgg	ccccctctct	tgccatatat	tgtaaacatc	aaaggacagc	gcacaaagaa	2040
aagtgtggcc	tataaaacca	agaagcctcc	ttcccttatg	tacaacgtga	ggaagaagaa	2100
aggaaagata	aatgtatgag	accgaccttg	ttcacctccag	atattaactg	tattgaacac	2160
aacaaaatac	attgaatttg	tattaaacat	ataacgcata	aataaagctc	ccattctctac	2220
ccttaaaaaa	aaaaaaaaaa					2240

<210> 85
<211> 1488
<212> DNA
<213> Homo sapiens

<400> 85

cgccaagttt	ccggaggagg	agggtagaaa	ctggaggggg	tggacctgtc	actcacggga	60
ctgagggtcc	ttttctcccg	ctcccaggag	gaacgagaat	gaatatgac	caagcccggg	120
ttctgggtgg	tgcagtggtg	gggttgggtg	ctgtcctgct	ctacgcctcc	atccacaaga	180
ttgaggaggg	ccatctgggt	gtgtactaca	ggggaggagc	ttactaact	agccccagtg	240
gaccaggcta	tcataatcatg	ttgcctttca	ttactacgtt	cagatctgtg	cagacaacac	300
tacaaactga	tgaagttaaa	aatgtgcctt	gtggaacaag	tgggtgggtc	atgatctata	360
ttgaccgaat	agaagtgggt	aatatgttgg	ctccttatgc	agtgtttgat	atcgtgagga	420
actatactgc	agattatgac	aagaccttaa	tcttcaataa	aatccaccat	gagctgaacc	480
agttctgcag	tgcccacaca	cttcagggaag	ttacattga	attgtttgat	caaatagatg	540
aaaaactgaa	gcaagctctg	cagaaaagact	taaacctcat	ggccccaggt	ctcactatac	600
aggctgtgcg	tgttacaaaa	cccaaaatcc	cagaagccat	aagaagaaat	tttgagttaa	660
tggaggctga	gaagacaaaa	ctccttatag	ctgcacagaa	acaaaagggt	gtggaaaaag	720
aagctgagac	agagaggaaa	aaggcagtta	tagaagcaga	gaagattgca	caagtggcaa	780
aaattcggtt	tcagcagaaa	gtgatggaaa	aagaaactga	aaagcgcat	tctgaatctg	840
aagatgctgc	attcctggcc	cyagayaaag	cgaagcaga	tgtggaatat	tatgctgcac	900
acaaatatgc	cacctcaaac	aagcacaaat	tgaccccgga	atatctggag	ctcaaaaagt	960
accaggccat	tgccttcaac	agtaagatct	attttggcag	caacatccct	aacatgttcg	1020
tggactcctc	atgtgctttg	aaatattcag	atattaggac	tggaaagaaa	agctcaactcc	1080
cctctaaagg	ggctcttgaa	ccctctggag	agaacgtcat	ccaaaacaaa	gagagcacag	1140
gttgatgcaa	gaggtggaaa	tgttctccat	atcaagatgt	ggcccaaggg	gttaagtggg	1200
aacaatcatt	atacggactc	ttcagattta	cagagaactt	acacttcatc	tgttccacct	1260
ctcctgcgat	agtctgggt	gtccactga	ttggaggata	gagccagctg	tctgacacac	1320
aaatggtcct	ttcagccaca	gtcttatcaa	gtatcttata	tgtattcctt	tctaaactgc	1380
actcatgaa	tgaggaaaat	ctgatgctaa	gatactgcct	gcactggaat	gttaaacact	1440
aaatatataa	caagctgtgt	tttcctaagc	tgaaaaaaaa	aaaaaaaa		1488

<210> 86

<211> 3174

<212> DNA

<213> Homo sapiens

<400> 86

gcgagcgctg	gxcscaaaaca	ctaaggcctg	agcgggtgaca	atcagggcga	gatgatgggtc	60
aacaggggaat	gcctcgtggg	agaaaaaaga	caattttatt	ctcagcgctg	attttgagat	120
gatgggcttg	ggaaacgggc	gtcgcgcat	gaagtgcgcg	cccctcgtgc	tggccgccct	180
gggtggcctgc	atcatcgctc	tgggcttcaa	ctactggatt	gcgagctccc	ggagcgtgga	240
ctccagaca	cggatcatgg	agctggaagg	cagggtccgc	aggcgggctg	cagagagagg	300
cgccgtggag	ctgaagaaga	acgagttcca	gggagagctg	gagaagcagc	gggagcagct	360
tgacaaaatc	cagtcacgac	acaacttcca	gctggagagc	gtcaacaagc	tgaccagga	420
cgaaaaggcg	gttttgggtg	ataacatcac	cacaggtgag	aggctcatcc	gagtgcctga	480
agaccagtta	aagaccctgc	agaggaatta	cggcaggctg	cagcaggatg	tectccagtt	540
tcagaagaac	cagaccaacc	tggagaggaa	gttctcctac	gacctgagcc	agtgcacaa	600
tcagatgaag	gaggtgaagg	aacagtgtga	ggagcgaata	gaagaggtca	ccaaaagggg	660
gaatgaagct	gtagcttcca	gagacctgag	tgaaaacaac	gaccagagac	agcagctcca	720
agccctcagt	gagcctcagc	ccaggctgca	ggcagcaggg	ctgccacaca	cagaggtgcc	780
acaagggaag	ggaaacgtgc	ttggtaacag	caagtcccag	acaccagccc	ccagttccga	840
agtggttttg	gattcaaaaga	gacaagttag	gaaagaggaa	accaatgaga	tccaggtggg	900
gaatgaggag	cctcagaggg	acaggctgcc	gcaggagcca	ggccggggagc	aggtggtgga	960
agacagacct	gtaggctggaa	gaggcttcgg	gggagccgga	gaactggggc	agaccccaca	1020
gggtgcaggct	gcccctgyag	tgagccagga	aaatccagag	atggaggggc	ctgagcgaga	1080
ccagcttgtc	atccccgacg	gacaggagga	ggagcaggaa	gctgccgggg	aaggagaaaa	1140
ccagcagaaa	ctgagaggag	aagatgacta	caacatggat	gaaaatgaag	cagaatctga	1200
gacagacaag	caagcagccc	cggcagggaa	tgacagaaac	atagatgttt	ttaatgttta	1260
agatcagaaa	agagacacca	taaatattact	tgatcagcgt	gaaaagcggg	atcatacact	1320
ctgaattgaa	ctggaatcac	atatttcaca	acaggqccga	agagatgact	ataaaatggt	1380
catgaggggac	tgaatactga	aaactgtgaa	atgtactaaa	taaaatgtac	atctgaagat	1440
gattattgtg	aaattttagt	atgcactttg	tgtaggaaaa	aatggaatgg	tcttttaaac	1500
agcttttggg	gggtactttg	gaagtgtcta	ataaggtgtc	acaatttttg	gtagtaggta	1560

tttcgtgaga	agttcaacac	caaaactgga	acatagttct	ccttcaagtg	ttggcgacag	1620
cggggcttcc	tgattctgga	atataacttt	gtgtaaat	acagccacct	atagaagagt	1680
ccatctgctg	tgaaggagag	acagagaact	ctggg-tccg	tcgtcctgtc	cacgtgctgt	1740
accaagtgt	gggtgccagcc	tgttacctgt	tctactgaa	aagtctggct	aetgctcttg	1800
tgtagtcact	tctgattctg	acaatcaatc	aatcaatggc	ctagagcact	gactgttaac	1860
acaaacgtca	ctagcaaatg	agcaacagct	ttaagtctaa	atacaaagct	gttctgtgtg	1920
agaatttttt	aaaagggtac	ttgtataata	acccttgtca	tttttaatgt	acaaaacgct	1980
attaagtggc	ttagaatttg	aacatttgtg	gtctttatct	actttgcttc	gtgtgtgggc	2040
aaagcaacat	cttcctctaa	tatatattac	caagaaaagc	aagaagcaga	ttagggtttt	2100
gacaaaacaa	acaggccaaa	agggggctga	cctggagcag	agcatggtga	gaggcaaggc	2160
atgagagggc	aagtctgttg	tggacagatc	tggtcctact	ttattactgg	agtaaaagaa	2220
aacaaagttc	attgatgtcg	aaggatata	acagtgttag	aaatttagac	tggttagaaa	2280
aacagggaata	caatgggtgt	ttttatcata	gtgtacacat	ttagcttgtg	gtaaatagact	2340
cacaaaactg	attttaaat	caagttaatg	tgaattttga	aaattactac	ttaatcctaa	2400
ttcacataaa	caatggcatt	aagggttgac	ttgagttggt	ctcttagtatt	atttatggta	2460
aataggtctt	taccacttgc	aaataactgg	ccacatcatt	aatgactgac	ttcccagtaa	2520
ggctctctaa	ggggtaagta	ggaggatcca	caggatttga	gatgtcaagg	ccccagagat	2580
cgtttgatcc	aacctcttta	ttttcagagg	ggaaaatggg	gcctagaagt	tacagagcat	2640
ctagctgggt	cgctggcacc	cctggcctca	cacagactcc	cgagtacttg	ggactacagc	2700
cacacagtca	ctgaagcagg	ccctgtttgc	aattcacgtt	gccacctcca	acttaaacat	2760
tcttcataatg	tgatgtcctt	agtcactaag	gttaaaactt	cccaccaga	aaaggcaact	2820
tagataaaat	cttagagtac	tttcatactc	ttctaagtcc	tcttccagcc	tcactttgag	2880
tctctcttgg	gggtgatagg	aattttctct	tgctttctca	ataaagtctc	tattcatctc	2940
atgtttaatt	gttacgcata	gaattgtctg	gaaataaaat	gttctgttca	acttaaaaaa	3000
cttgtcacag	ctctgttttt	ttgcttttcc	ccttcactct	ctatttagatc	cttaagaat	3060
ccacctcaaa	actgtggact	aaggatggca	gtttgcctta	aaccttctgt	ggaatgagat	3120
gggctgtcag	gacgtcttca	accacagta	ccccgaaagc	tttgtgtctca	ccac	3174

<210> 87

<211> 2780

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (2760)

<223> n equals a,t,g, or c

<400> 87

ggcgccgagg	gcgggggggtc	ccggggccac	gtggacgccg	acggctcttg	tctgcggcgt	60
gtggacactg	ccagcggctg	cagccgactt	ggaatgacct	gggagacaaa	tacaacagca	120
tggaagakgc	caaagtctat	gtggctaaag	tggactgcac	ggccactccc	gaogtgtgct	180
ccgcccaggg	gggtgcgagga	taccccactt	taaagctttt	caagccaggc	caagaagctg	240
tgaagtacca	gggtcctcgg	gacttccaga	cactggaaaa	ctggatgtctg	cagacactga	300
acgaggagcc	agtgaaccca	gagccggaag	tggaaaccgc	cagtgcctcc	gagctcaagc	360
aagggtctgt	tgagctctca	gcaagcaact	ttgagctgca	cgttgacaaa	ggcgaccact	420
ttatcaagtt	cttcgctccg	tgggtgtggc	actgcaaaag	cctggctcca	acctgggagc	480
agctggctct	gggccttgaa	cattccgaaa	ctgtcaagat	tggcaagggt	gattgtacac	540
agcactatga	actctgtctc	ggaaaccagg	ttcgtggcta	tccactcttt	ctcgggtcc	600
gagatgggaa	aaaggtggat	cagtacaagg	gaaagcggga	tttgaggtca	ctgaggagat	660
acgtggagtc	gcagctgcag	cgcacagaga	ctggagcgac	ggagaccgtc	acgccctcag	720
aggccccggt	gctggcagct	gagcccgagg	ctgacaaggg	cactgtgttg	gactcactg	780
aaaaataactt	cgatgacacc	attgcagaag	gaataacctt	catcaagttt	tatgtccat	840
gggtgtggta	ttgtaagact	ctggctccta	cttgggagga	actctctaaa	aaggaaattcc	900
ctggtctggc	gggggtcaag	atcgccgaag	tagactgcac	tgctgaacgg	aatatctgca	960
gcaagtattc	ggtagcaggg	taccccagct	tattgctttt	ccgaggaggg	aagaaagtca	1020
gtgagcacag	tggaggcaga	gaccttgact	cgttacaccg	ctttgcctg	agccaagcga	1080
aagacgaact	ctaggaacac	agttggaagt	cacctctcct	gccagctcc	cgcacctgac	1140

gtttaggagt	tcagtcaccac	agaggccact	gggttcccag	tgggtgctgt	tcagaaagca	1200
gaacatacta	agcgtgaggt	atcttctcttg	tgtgtgtgtt	ttccaagcca	acacactcta	1260
cagattcttt	attaagttaa	gtttctctaa	gtaaatgtgt	aactcatggt	cactgtgttaa	1320
acattttcag	tggcgatata	tcccccttga	ccttctcttg	atgaaattta	catggtttcc	1380
tttgagacta	aaatagcgtt	gagggaaatg	aaattgctgg	actatttgtg	gctcctgagt	1440
tgaagtattt	tgggtgaaaga	aagcacatcc	aaagcatagt	ttacctgccc	acgagtctctg	1500
gaaagggtgc	cttgtggcag	tattgacgtt	cctctgatct	taaggtcaca	gttgactcaa	1560
tactgtgttg	gtcgttagca	tggagcagat	tgaaatgcaa	aaacccacac	ctctgggaaga	1620
taccttcacg	gcgcgtctg	gagcttctgt	tgtgtggaat	acttctctca	gtctgagagg	1680
ttagccgtga	tgaaagcagc	gttacttctg	accgtgcctg	agtaagagaa	tgctgatgcc	1740
ataactttat	gtgtcgatgc	ttgtcaaatc	agttactgtt	caggggagtc	ttctgtttct	1800
cacgggggtga	aacatgtctt	tagttctctca	tgttaacacg	aagccagagc	ccacatgaac	1860
tgttggtgtg	cttctctaga	aagggtaggg	atggaaaatt	ccacgaggct	cattctcagt	1920
atctcattaa	ctcattgaaa	gattccagtt	gtatttgtca	cctgggggtga	caagaccaga	1980
caggctttcc	cagggctggg	tatccaggga	ggctctgcag	ccctgctgaa	gggcccatac	2040
tagagttcta	gagtttctga	ttctgtttct	cagtagtctt	tttagaggct	tgctatactt	2100
ggtctgcttc	aaggaggctg	acgttctaat	gtatgaagaa	tgggatgcat	ttgatctcaa	2160
gaccaagac	agatgtcagt	gggtctgctt	ggccctgggtg	tgcacggctg	tggcagctgt	2220
tgatgccagt	gtcctctaac	tcatgctgtc	cttgtgatta	aacacctcta	lctcctttgg	2280
gaataagcac	atcacaggctt	aagctctaac	ataggtgttt	gtccttttac	catcgagcta	2340
cttcccataa	taaccacttt	gcattccaaca	ctcttcaccc	acctcccata	cgcaaggggga	2400
tgtggatact	tggcccaaaag	taactgtgtg	taggaatctt	agaaacaaga	ccacttatac	2460
tgtctgtctg	aggcagaaga	taacagcagc	atctcgacca	gcctctgcct	taaaggaaat	2520
ctttatataat	cacgtatggt	tcacagataa	ttcttttttt	aaaaaaaccc	aacctcctag	2580
agaagcacaa	ctgtcaagag	tcttgtacac	acaacttcag	ctttgcatca	cgagtcttgt	2640
attccaagaa	aatcaaatgt	gtacaatttg	tttgtttaca	ctatgatact	ttctaaataa	2700
actctttttt	tttaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaggggg	gggggggggn	2760
ggggcccccc	cccccccaaa					2780

<210> 88
 <211> 1061
 <212> DNA
 <213> Homo sapiens.

<400> 88						
aattcggcac	gagagaagga	aatacatcaa	aatgccaca	ttggttatct	gtagaggata	60
gaatgaaaga	tggctttatt	ctcttgtttg	ctcttattaa	agcaatcaga	tgggtcttct	120
cctgtactca	gagccctggc	tgcttctctg	ctggcctctc	ctgggggcty	ctgtggaacc	180
agaaaagcct	taaacggaaa	tgtgggagag	aagggttgat	tcactttcat	gtcttccag	240
ggttgtgacc	cctcaagtcc	tggttgcctt	tgctgttctc	tattaccttc	aaacagccag	300
ctcgtcttta	ttcttttttt	agttttgtcg	gggttggctt	gatagatgtt	agtccatcat	360
agccagatgt	gtctagcctt	gtcttttgaa	tgcaagattt	aggatgtggg	tacttagctg	420
ttagtggaca	tcagagtcac	tagtcaggat	gaaagagttc	ttggctttaa	ctcccagaaa	480
ttctggtaac	gtcatgtata	gtgacggccg	catgtctaac	aggtggccag	gtaagtcttt	540
tgggtgtgtc	tgtgaatcac	agtttgggag	acatcgactt	ttagggagtc	tqttctgaat	600
tcactagata	atagagatat	aatacagagc	tttgaaagct	ggtgtcttga	tgacagagcc	660
gtggcaatgg	ggaggggttg	ggaggtggct	gttgggctg	ctctcctggg	agagttgaaa	720
gggcctgaac	tcangcagag	gcctcagaac	cgaaggtgg	tggaaggatg	cagcaagagg	780
cgccacacag	gagtactctg	cgccctggca	gggtctgaat	acacgtggga	gtgggtgagag	840
ggagaacttt	aagtcacagt	tttgtgcctc	agtgaactag	tgtggccata	tcattagaaa	900
tgtgttgagg	ccgggcacag	tggctcatgt	ctgtaatccc	agcactttga	gaggctgagg	960
caggaggatg	gcttgaggcc	aggagttaa	aaccagcctg	gacaacacag	tgagagcctg	1020
tctctacaaa	aaaaaaaaaa	aaaactcga	gggggggccc	g		1061

<210> 89
 <211> 1342
 <212> DNA

<213> Homo sapiens

<400> 89

```
ccacgcgtcc gggcgcgccg gtgaaaggcg cattgatgca gcctgcggcg gcctcgagc 60
gcggcgggagc agacgctgac cactgttctc tcctcggtct cctccgcctc cagctccgcg 120
ctgcccggca gccgggagcc atgcgacccc agggcccccgc cgctccccc cagcggtctcc 180
gcggcctcct gctgctcctg ctgctgcagc tgcccgcgcc gtcgagcgcc tctgagatcc 240
ccaaggggaa gcaaaaggcg cagctccggc agaggaggt ggtggacctg tataatggaa 300
tgtgcttaca agggccagca gtagtgctg gtcgagacgg gagccctggg gccaatggca 360
ttccgggtac acctgggac ccaggtcggg atggattcaa aggagaaaag ggggaatgtc 420
tgagggaaag cttlgaggag tcctggacac ccaactacaa gcagtgttca tggagtcat 480
tgaattatgg catagatctt gggaaaattg cggagtgtac attacaaaag atgcgttcaa 540
atagtctct aagagtctt ttcagtggct cacttcggct aaaaagcaga aatgcatgct 600
gtgagcgttg gtatttcaca ttcaatggag ctgaatgttc aggaacctct ccattgaag 660
ctataattta ttgggaccaa ggaagccctg aaatgaaltc aacaattaat attcatcgca 720
cttctctctg ggaaggactt tgtgaaggaa ttggtgctgg attagtggat gttgctatct 780
gggttgccac ttgttcagat taccctaaaag gagatgttc tactggatgg aattcagttt 840
ctcgcacatc tattgaagaa ctacccaaat aaatgcttta attttcattt gctacctctt 900
tttttattat gccttggaaat ggttcaacta aatgacattt aaaaatagtt tatgtatata 960
tctgaatgaa aagcaaaagc aaatatgttt acagacccaa gtgtgatttc acactgtttt 1020
taaatctagc attattcatt ttgttcaat caaaagtggg ttcaatattt tttttagttg 1080
gttagaatac tttctcataa gtcacattct ctcaacctat aatttggaaat attgttgttg 1140
tcttttgttt tttctcttag tatagcattt ttaaaaaaat ataaaagcta ccaatctttg 1200
tacaatttgt aaatgttaag aatttttttt atatctgtta aataaaaaatt atttccaaaa 1260
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1320
aaaaaaaaaa aaaaaaaaaa aa
```

<210> 90

<211> 770

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (690)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (762)

<223> n equals a,t,g, or c

<400> 90

```
ggtagggtcg ggcgcagccg cgcgtccggc tcttctcag gcggcggcca tggcgggaca 60
ggaggatccg gtgcagcggg agattcacca ggactgggct aaccgggagt acattgagat 120
aatcaccagc agcatcaaga aaatcgacga ctttctcaac tcgttcgata tgtcttgtcg 180
ttcaagactt gcaacactaa acgagaaatt gacagccctt gaacggagaa tagagtacat 240
tgaagctcgg gtgacaaaag gtgagacact cacctagaac agtgccgtgc tgcgtctggg 300
aagttgcttt acacaacaca ggccacatgg gaaaggcccc agcagccttc agctccttcc 360
ttctctctta aagagcaaca gggcttattc ttgtttttct tttttcaaaa gtgtggcctt 420
tgggtctctg catctggggt gtggtgtggt atgtgggaag aagttcagag gaaccgttgg 480
aaacgacgtt aggcatttta ccttttcagt aacattttat acatctactt gccaatgtat 540
ttgagacatt cacagccaaa agcctgggac tctttgtgaa ggtctctctc amctctatct 600
ttctttctct ctctctcaaa ctttctctaa agttctcatt gcctttgcac tgcctctgtg 660
aacagttctt gtctctctcc cactttggg ggaagtgcg gggcaatcct ggtcaagaca 720
ctcatgcctt ggcaatgtgg cctgcagaga atgtgttgt anccaccagt 770
```

<210> 91
<211> 1570
<212> DNA
<213> Homo sapiens

<400> 91
gatgggttta ctgaagttgc taaaagttta cagaaaagga agtgcaggaa catttcacaa 60
atctacaatc tgtgagtatc acatcctgta tagctgtmaa cactggaata aggaagggct 120
gatgactttc agaagatgaa ggtaagtaga aacgttgat gggactgaga aaccagagtt 180
aaaacctctt tggagcttct gaggactcag ctggaaccaa cgggcacagt tggcaacacc 240
atcatgacat cacaacctgt tcccaatgag accatcatag tgctcccatc aaatgtcatc 300
aacttctccc aagcagagaa acccgaaccc accaaccagg ggcaggatag cctgaagaaa 360
catctacacg cagaaatcaa agttattggg actatccaga tcttgtgtgg catgatggta 420
ttgagcttgg ggatcatttt ggcactcgtc tccttctctc caaattttac ccaagtgcac 480
tctacactgt tgaactctgc ttaccattc ataggacct ttttttttat catctctggc 540
tctctatcaa tcgccacaga gaaaagggtt accaagcttt tgggtgcatag cagcctgggt 600
ggaagcattc tgagtgtctt gctgtccctg gtgggtttca ttatcctgtc tgtcaaacag 660
gcaaccttaa atcctgcctc actgcagtgt gagttggaca aaaataatat accaacaaga 720
agttatgttt ctacttttta tcatgattca ctttatacca cggactgcta tacagccaaa 780
gccagtctgg ctggawctct ctctctgatg ctgattttga ctctgttggc attctgccta 840
gctgtgtctc ctgtgtgtct gcggtggaaa caggcttact ctgacttccc tgggagtgtg 900
cttttctctc ctacagttta cattggtaat tctggcatgt cctcaaaaat gactcatgac 960
tgtggatag aagaactat gacttcttaa gaaaaaagg agaaatatta atcagaaagt 1020
tgattcttat gataatatg aaaagttaac cattatagaa aagcaaaagt tgagtttctc 1080
aatgtgaagc ttttaaagta atgaacatta aaaaaaacca ttatttctact gtcatttaag 1140
atatgtgttc attggggatc tcttgatttg cctgacattg acttcagcaa aagcagggg 1200
ctgtaaatca ccatttacta gattagccaa atagtctgaa ttccagaaa acaaggcaga 1260
atgatcattc ccagaacat ttcccagaaa atgtttccca gaaactaga cagmatgatc 1320
attcaatgga tcacagtga gcaaaggaca caacttttta ttgtacctc taattgtcaa 1380
caggagttaa ctgatttggg gtgtgtctca gactttttta tacaggtgct agtgttttat 1440
cctatgtatt ttaacctatt agtgcataaa ggcaagcccc atataatgaa gtctcaggg 1500
atatgaaagt agctggcttc aaaataaaat ttttgagtgc aaaaaaaaaa aaaaataaaa 1560
aaaaaaaaa 1570

<210> 92
<211> 2950
<212> DNA
<213> Homo sapiens

<400> 92
cccggctccc gcccgctccc agccggggccc cccagcgggc ggcgggacgg ctcccggctg 60
cagtcctgccc gcccgccccg cgcggggggcc gactcgcgaa gcgcgcctgc gaccggcgct 120
ccgggcgcgc tggagaggac gcgaggagcc atgaggcgc agctgcgaag gtggcgcgcc 180
tgctgtctcg gctgtctctg gactgcacag aagccaaaaa gcattgctgg tatttcgaag 240
gactctatcc aacctattat atatgccgct cctacgagga ctgtgttggc tccaggtgct 300
gtgtgcgggc cctctccata cagaggctgt ggtacttctg gtctcttctg atgatgggcy 360
tgcttttctg ctgcggagcc ggcttcttca tccggaggcg catgtacccc ccgcgcctga 420
tcgaggagcc agcettcaat gtgtcttaca ccaggcagcc cccaaatccc ggcccaggag 480
cccagcagcc ggggcgcgcc tattacacyg acccaggagg accggggatg aacctgtctg 540
ggaattccat ggcaatggct ttccaggtcc caccacaact accccagggg agtggtgcct 600
gcccgcctcc tccagcctac tgcaacacgc ctccgcccc gtacgaacag gtatgaaagg 660
ccaagtagtg ggggtccccc gtgcaagagg agagacagga gagggccttt ccttggcctt 720
tctgtcttct ttgatgttca ctccaggaa cggctctctg ggtgtctaa ggcagttctt 780
ctgataacct cacagcaagc acagctctct ttcaggcttt ccattggagta caatatatga 840
actcacactt tctctctctt gttgtctctg tttctgacgc atctgtgtct tcacatggta 900
gtgtgggtgac agtccccgag ggctgacgtc cttacgggtg cgtgaccaga tctacaggag 960
agagactgag aggaagaagg cagtgtctga ggtgcagggt gcatgtagag gggccaggcc 1020
gagcatccca ggcaagcatt cttctgcctg ggtatttaaa ggaagcccca tgcggggcgg 1080

ctcagccgat	gaagcagcag	cagactgagc	tgagcccagc	aggtcatctg	ctccagcctg	1140
tcctctcgtc	agccttcctc	ttccagaagc	tggtggagag	acattcagga	gagagcaagc	1200
cccttgatcat	gtttctgtct	ctgttcatat	cctaagata	gacttctect	gcaccgccag	1260
gaaagggtag	cacgtgcagc	tctcacgca	gatggggcct	agaatcaggc	ttgcttgagc	1320
gcctgacagt	gatctgacat	ccactaagca	aatttattta	aattcatggg	aaatcacttc	1380
ctgccccaaa	ctgagacatt	gcattttgtg	agctcttggg	ctgatttgga	gaaaggactg	1440
ttacccattt	ttttgggtgt	tttatggaag	tgcatgtaga	gcgtcctgcc	ctttgaaatc	1500
agactgggtg	tggtctctcc	ctggacatca	ctgcctctcc	agggcattct	caggcccggg	1560
gggtctcctc	cctcaggcag	ctccagtggg	gggttctgaa	gggtgctttc	aaaacggggc	1620
acatctggct	gggaagtcac	atggactctt	ccaggagag	agaccagctg	aggcgtctct	1680
ctctgaggtt	gtgttgggtc	taagcgggtg	tggtctgggc	tccaaggagg	aggagcttgc	1740
tgggaaaaga	caggagaagt	actgactcaa	ctgcactgac	catgttgtca	taattagaat	1800
aaagaagaag	tggtcggaaa	tgacatttcc	tggtataggaa	tcacagctca	ccccaggatc	1860
tcacaggtag	tctcctgagt	agttgacggc	tagcggggag	ctagtctccg	cgcatagtta	1920
tagtgttgat	gtgtgaacgc	tgacctglcc	tggtgcttaa	gagctatgca	gcttagctga	1980
ggcgcttaga	ttactagatg	tgctgtatca	cggggaatga	gggtgggggtg	cttatttttt	2040
aatgaactaa	tcagagcctc	gtgagaaatt	gttactcatt	gaactggagc	atcaagacat	2100
ctcatggaaag	tggtatcgga	gtgatttggg	gtccatgctt	ttcactctga	ggacatttaa	2160
tcggagaacc	tcctggggaa	ttttgtggga	gacacttggg	aacaaaacag	acaccctggg	2220
aatgcagtgt	caagcacaga	tgctgccacc	agtgtctctg	accaccctgg	tgtagctgct	2280
gactgccagc	gtggtacctc	ccatgctgca	ggcctccatc	taaatgagac	aacaaagcac	2340
aatgttcaat	gtttacaacc	aagacaactg	cgtgggtcca	aacactcctc	ttcctccagg	2400
tcatttggtt	tgcattttta	atgtctttat	ttttgtaat	gaaaaagcac	actaagctgc	2460
ccctggaatc	gggtgcagct	gaataggcac	ccaaaagtcc	gtgactaaat	ttcgtttgtc	2520
tttttgatag	caaatattat	taagagacag	tgatggctag	ggctcaacaa	ttttgtattc	2580
ccatgtttgt	gtgagacaga	gtttgttttc	ccttgaactt	ggttagaatt	gtgctactgt	2640
gaacgctgat	cctgcataat	gaagtccerc	ttcgttgaca	tttctgggcc	attcttgttt	2700
ccattgtgtg	gatgggtggg	gtgtcccaat	tcctggagtg	agacagctcc	tggtgtgtag	2760
aatccccgga	gcgtccgtgg	ttcagagtaa	acttgaagca	gatctgtgca	tgcttttctc	2820
ctgcaacaat	tggtcctggt	ctcttttttg	ttctcttttg	ataggatcct	gtttcctatg	2880
tggtcaaaat	aaaaataaat	ttgggcaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	2940
aaaaaaaaag						2950

<210> 93

<211> 1722

<212> DNA

<213> Homo sapiens

<400> 93

ggcacgagcc	agagcaggtc	gctaggcctg	ggggcaccac	tgcccctggg	tgctacaccc	60
agtgtgctgg	gtcactggga	acttcttgaa	gtgctgtcac	ctgaactggg	cccccaagga	120
tggggtgcgg	gcagtcacgc	aggaagagga	gcagcccctg	tgaagattga	gagctgccag	180
aggtctctgt	attggctgcg	gcacgatgac	ccgcgcacgg	attggctgct	tcgggcccggg	240
gggcccggcc	cgggggacag	aatccgcccc	cgaaccttca	aagaggggtac	ccccgggcag	300
gagctggcag	accyaggagg	tgcgacagac	ccgcggggca	aacggactgg	ggccaagagc	360
cgggagcgcg	ggcgcaaaag	caccagggcc	cgcccagggc	gccgcgcagc	acggccttgg	420
gggttctgcg	ggccttcggg	tgcgcgcttc	gcctctagcc	atggggctccg	cagcgttgga	480
gatacctgggc	ctgggtgctg	gcctgggtgg	ctgggggggt	ctgatcctgg	cgtgcgggct	540
gccccatgtg	caggtgacgg	ccttctctgga	ccacaacatc	gtgacggcgc	agaccacctg	600
gaaggggctg	tggatgtcgt	gcgtgggtgca	gagcacsggg	cacatgcagt	gcaaatgtta	660
cgactcgggt	ctggctctga	gcaccagggg	gcaggcggcg	cgggcgctca	ccgtgagcgc	720
cgtgctgctg	gcgttcgctg	cgtctctcgt	gaacctggcg	ggcgcgagct	gcaccacctg	780
cgtggcccg	ggccccggca	argcgctgtg	ggccctcacg	ggaggcgtgc	tcacctgtt	840
ttgcgggctg	ctggcgctcg	tgccactctg	ctgggtcgcc	aacattgtcg	tcgcgagatt	900
ttacgaaccg	ctgtgccccg	tgctgcagaa	gtacgaagctg	ggcgagcgcg	tgtacatcgg	960
ctggggcgcc	accgcgctgc	tcattggtagg	cggctgcctc	ttgtgctgcg	gcgcctgggt	1020
ctgcaccggc	cgtcccagac	tcagcttccc	cgtgaagtac	tcagcgccgc	ggcgggccac	1080
ggccaccggc	gactacgaca	agaagaacta	cgtcagagg	cgtcgggcac	ggcgggggcc	1140

ctctctgcag	ccacgcctgc	gaggcgcttg	ataagcctgc	ggagccccgc	atggaccgcg	1200
gcttccgcgc	ggtagcgcgc	cgccgcagct	cctcgggaacg	tccggctctg	cgccccgaag	1260
cggtctcttg	atccgctcct	gctcgcgcgc	gcagctgacc	ttctcctgcc	actagccccg	1320
ccctgccttt	aacagacgga	atgaagtttc	ctttctctgt	cgccgcgcctg	ttcccatagg	1380
cagagcgggt	gtcagactga	ggatttcgct	tccctccaa	gacgctgggg	gtcctggctg	1440
ctgccttact	tcccagaggc	tcctgctgac	ttcggagggg	cggatgcaga	gcccagggcc	1500
cccaccggaa	gatgtgtaca	gctggtcttt	actccatcgg	cagggccccg	gcccagggac	1560
cagtgaactg	gcctggacct	cccggtctca	ctccagcctc	tccccaggca	aggcttgtgg	1620
gcaccggagc	ttgagagagg	gcgggagtg	gaaggctaag	aatctgctta	gtaaatgggt	1680
tgaactctca	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aa		1722

<210> 94
 <211> 635
 <212> DNA
 <213> Homo sapiens

<400> 94						
gcctaaagag	agctccccca	ygaccagccc	tgcccaagg	attgctgcag	ccctcatcca	60
ccttccaagc	actggaaaca	aacattggag	accaagttag	gcgtcactca	acagccgtag	120
taatcaggga	aatgacaagt	tacatactga	tatcctttgt	tttgctgatt	ggagtgtgggt	180
gcattgaaaa	agatcagtcg	tgcccagtg	ttgggggaag	gaagcgtctt	cacctgttgt	240
ttgtgggagg	acagttgagg	caggtgagga	tgctgagagg	tgagctcagc	tgtgcctgtt	300
accgtccaca	tgtagcaagcc	cttcagctcg	gtggtgtgac	ttgtttttga	gatgcagttt	360
cactcttgtc	acccaggctg	gagtgcatgg	catgatcttg	gctcgtgcga	acatccgcct	420
cccggttcca	agcgattctc	ctgtctctac	taaaaataca	aaaattagct	gggtgtgggt	480
gtgcgcgcct	ttaatcccag	ctactcagaa	ggctgaggtg	caagaattgc	ttgaacctgg	540
gaggtggagg	ttgcctgggg	ccgagatcac	gccaccgcac	tccagcctag	gcaacagagc	600
tagactgtct	caaaaaaaaa	aaaatgacct	tcgag			635

<210> 95
 <211> 3798
 <212> DNA
 <213> Homo sapiens

<400> 95						
ccacgcgtcc	ggggcttcat	acaggaaatc	tattgctgtg	tcaagttcca	gagaaaagct	60
tctgttctgc	caagttacta	accaggctaa	accacataga	cgtgaaggaa	ggggctagaa	120
ggaagggagt	gcccactgt	tgatggggta	agaggatcct	gtactgagaa	gttgaccaga	180
gaggggtctca	ccatgcgcac	agttccttct	gtaccagtgt	ggaggaaaag	tactgagtga	240
agggcagaaa	aagagaaaac	agaaatgctc	tgcccttggg	gaactgctaa	cctagggcta	300
ctgttgattt	tgactatctt	cttagtgccc	gaagcggagg	gtgctgctca	accaaacaac	360
tcattaatgc	tgcaaaactag	caaggagaat	catgctttag	cttcaagcag	tttatgtatg	420
gatgaaaaac	agattacaca	gaactactcg	aaagtactcg	cagaagttaa	cacttcatgg	480
cctgtaaaaga	tggtacaaa	tgctgtgctt	tgttgccctc	ctatcgcat	aagaaatttg	540
atcataataa	catgggaaat	aatcctgaga	ggccagcctt	cctgcacaaa	agcctacaag	600
aaagaaacaa	atgagaccan	ggaacccaac	tgtaactgat	agagaataac	ctggytctcc	660
agacctgac	agaattcgga	ccttcagatt	cgtaccgtgg	ccatcactca	tgacgggtat	720
tacagatgca	taattggtaac	acctgatggg	aatttccatc	gtggatatca	cctccaaqtg	780
ttagttaac	ctgaagtgc	cctgtttcaa	aacagggaata	gaactgcagt	atgcaaggca	840
gttgccaggga	agccagctgc	gcatactctc	tggatcccag	aggcgcat	tgccactaag	900
caagaatact	ggagcaatgg	cacagtgc	gttaagagta	catgccactg	ggaggtccac	960
aattgtgtcta	ccgtgaactg	ccacgtctcc	catttgactg	gcaacaagag	tctgtacata	1020
gagctacttc	ctgttccagg	tgccaaaaaa	tcagcaaaat	tatatattcc	atatatcctc	1080
cttactatta	ttattttgac	catcgtggga	ttcattttgt	tgtgaaaagt	caatggctgc	1140
agaaaaata	aattgaataa	aacagaatct	actccagtgg	tgaggagga	tgaatgcag	1200
ccctatgcca	gctacacaga	gaagaacaat	cctctctaag	atactacaaa	caagctgaag	1260
gcatctgagg	cattacaaag	tgaagttgac	acagacctcc	atactttata	agttgttggg	1320

ctctagtacc	aagaacaac	aacaaacgag	atacattata	attactgtct	gattttctta	1380
cagttctaga	atgaagactt	atattgaaat	taggttttcc	aaggttctta	gaagacattt	1440
taatggattc	tcattccatac	ccttgataaa	ttggaatttt	tgattcttag	ctgtaccag	1500
ctagttctct	gaagaactga	tgttattaca	aagaaaatac	atgcccatga	ccaaatatcc	1560
aaattgtgca	ggacagtaaa	taatgaaaac	caaatttcct	caagaaataa	ctgaagaagg	1620
agcaagtgtg	aacagtttct	tgtgtatcct	ttcagaatat	tttaatgtac	atatgacatg	1680
tgtatatgcc	tatggtatat	gtgtcaattt	atgtgtcccc	ttacatatac	atgcacatat	1740
ctttgtcaag	gcaccagtgg	gaacaataca	ctgcattact	gttctataca	tatgaaaacc	1800
taataatata	agtcttagag	atcattttat	atcatgacaa	gtagagctac	ctcaattctt	1860
ttaatggtta	tataaaattc	cattgtatag	ttatatcatt	atttaattaa	aaaccaacct	1920
aatgatggat	atttagattc	ttttaagttt	tgtttatctt	ttttaagttt	tgtttggtgt	1980
ataaacaata	ccacatagaa	tgttcttgtt	gcataatctt	ctttgttttt	gagtatatct	2040
gtaggataac	tttcttgagt	ggaattgtca	gggtcaagggt	tttgtgcatt	ttactattga	2100
tatatatgtt	aaattgtgtc	aaalatata	gtcaaatccc	ctccaacatt	gtttaaatgt	2160
gcctttccct	aaatttctat	tttaataact	gtactattcc	tgctcttaca	gttgccacct	2220
tctcttttta	atcaaccaga	ttaaatatga	tgtgagatta	taataagaat	tatactattt	2280
ataaaaaatg	gattttatatt	tttggtcatg	tttctaagag	agtgaatgca	cgtgtgagaa	2340
cattagcttc	ttctgaactc	atttatcttc	cacagagggt	ttgatacttg	atgacctaca	2400
g-tttgcaga	tgtgctacat	tggaattgtg	tatttttatg	gtgtacattc	tattgtgata	2460
tattttattga	ataaattaatg	tctattgacc	atataagtgg	cgaaaaatgc	accatagagg	2520
acatggggtta	tttattttaca	aactatgagc	tacataataa	gcaagtggcc	atgggagtggc	2580
a-gaccctcc	cctccatatt	tttgtggagc	aaaatatggg	caatgtttat	gtaaatcatt	2640
gttaatatca	tgaattattt	tttaattaaa	aacataagtc	tatttgctcc	atagcagaaa	2700
aaacatgaga	agtttttttca	tcattgataga	aattgaaaca	aaatatattc	attcttcaat	2760
cataccatct	gagattttta	agacagctat	tttgtcttat	aagtatatatt	ttctccctct	2820
agacatttca	gttacctatgg	attttgtcct	caaagggacc	tttagtctat	tttggtatga	2880
aagctaattc	aatgacactt	ggcacatgat	attttgatca	agccattttg	acttgaccac	2940
aaagcagtgt	ccattaggtt	tctgcataata	aatattacca	agcaatgttc	acaatagaca	3000
tcattacact	gtccttgaaa	tttatttaatt	cttcatccaa	ccctgggtga	gctgaggctc	3060
atagttaggt	tcaagactat	ctgttttaaat	attactgaaa	aacaaagtaa	gacagtacta	3120
tgcttacctc	tttaacttgat	aatgtcaaaa	caggcatggt	aatgacatc	atagaaaaga	3180
cttcaagata	attttatagaa	gttaaatatt	attgtacaga	aaataattgt	atgaaaatct	3240
ctactatggg	gctggaacat	ggttgaacat	tagaatgata	taaaaaatta	tatatattct	3300
ccaaatccac	gctagacctg	tcaaattaga	gaatctagag	attagacctg	gcgtgcagc	3360
aaggtcatcc	aggaagcaga	ggctgagacg	gagttagggt	tgattactta	catagtcgat	3420
tacattttac	aaataacatt	ttatatgtct	catttactgt	gctttctccc	catcccattt	3480
tgtatccttt	cctttgtctt	gctagatttg	tcaattttct	ctctctttct	gtctctctct	3540
ctttcaatat	ctctaataat	ttgaaagtaa	ttcatcataa	ctaaataact	attggggtta	3600
tgcttcactt	acaaacttct	gaaaacggct	ttactgagat	ataattgata	tatttaagtg	3660
tacagtttgt	taaaattttgc	acataattta	aatgtggact	ttggtaaatg	ttgacatagt	3720
tttacatctg	tgaaccatc	agcataatca	agataataaa	cttgtccatc	acccccaaaa	3780
aaaaaaaaa	aaaaaaaaa					3798

<210> 96
 <211> 2683
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (2640)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (2676)
 <223> n equals a,t,g, or c

```

<400> 96
acaasgtmac gcctgacagg ttraccggatc cgggaattcc cgggtcgacc cacggcggtcc      60
gcattttgcaa taacagaaaa ggaattgcat gtatgaagtt ttcaatcgtg ggctttttctt      120
tggttggggg aggggggtcgg gggatagttt gatttccatt ttctgaaaaac gacagacttg      180
gattctgttt gtgtgtgcat attttatcca gccttaagtt ataaagctca tctgtcccgc      240
tgatttccct gtgtattttc aggacatggc tctgtgggtg gtgtgttcat tgtgtcgctc      300
tgtatgtatt tttctgtcat cactgttccc tctctcccag agtgtgcatt cagttaatat      360
aatcagttgc ttgtcttctt caaagtgtct tgaaggtctt gaactcatgt gtgagcatct      420
ttatcaacta cccaattgc atgttctcca tcacatatcc tcttatttgc tctgtacccc      480
ctgagaatat gttttagaga tattggaata aagctgtctg ggtaaggagt aggttagcc      540
gacctatgaa taatacactt tagtttagtt ctttattcta aatctggatt gccagttatt      600
tgtattttaa ccaagtctgt gaatacctgc ttttttggc cacagagtaa caagttttca      660
cgtaagatct tcataccaaa gttaggaagta aaaaatagctt agaaagctct gtcaggtgtt      720
ttgtgcagct gacagargta atgtttacat accataaaaa gaaagataca cggtcagttt      780
tcctaaaaat aaattgtttg gaaagtacaa tgcaccacat tttttagaaa gtcactatt      840
tgataaacag ttgaaattca agatgtgttt gaccttagt cttttttact ctttggctct      900
gagtatacct attttcttag cgtatctgct ttgtttatct ttttcttacc cttttaacaa      960
gtatgacata ggaaggtcat tttttttag aattcatgga tcaagtctgat ctactcttat      1020
tcataatgga acatgtaaat atactgaaaa ctgtttttca ggagagaaa atgagttgga      1080
gggaaggaaa agtggctcta ctaagtctcc aaaaatctca tcagagaaag tatgatgttc      1140
tcaggtgtgg aaaaattttt ttagtgtgatt gagaatgcag gtttaacaga agagataagg      1200
ggcataatga ctgtcggttt tccagactgg attttctac cgcaactatt aatgttctca      1260
gagttgatga ggaccacctt tgtgtatata ctgttagttt taaaccttgc attggttaaca      1320
aaatgatcaa ctttaatcca ggtagaatcc aagatggctg tacttcagtt gtatgataaa      1380
aatatgggtt ctcatgacct gtgtggcatc taaaaataat gtttttatag catctctctg      1440
ccactaaatt gttgacttga attttgggaa aaaaaaaagt tgggtgttgat atgtatatgt      1500
gtgtgtgtat atatgtattt ataaacaagt gtgtttgagt aacaagttag tttcatagtc      1560
ttcccctacg catgtgtatt ccacacacaa atggctgagt tatagtcata aaacaatttg      1620
caataaaaaa aaaacaaaaa cagattgtca gtttaaccag aaacagttaa tgttttttaa      1680
tgaactctggc attatagtga gcaaatgtcg tattaattta ggctaatttc taatactacc      1740
ataattttgt tctaaatttc tgttggggta gaaattacta aaattgtggg gatttttttc      1800
tgatttttac attgcttttag tatgtgtcat tgttagtggc ctcagaattc tgaacagtaa      1860
tagttttctt cctgtttttt tacaaccctt ttgaatgctc cagtggaaaa cgtatccctc      1920
ctttgtgtat gatgctgaat tacaaccctt tccctcagtg tccacatta taccaacctc      1980
tactttcttc agttgtagaa aagggtcaatt tccctcagtg tccacatta taccaacctc      2040
agagaagaac aggtaatagg gagaataaaa catcaggtgg tttcagtggt tttgggtcatg      2100
tgtccacagg agaaactaac catcagttg tcttaatttt agttcgttct accctgtgag      2160
gagtttgggt ccatcagttg ttgactttcc aaaatgttgc attaagtaat agttgtcact      2220
ctgttgggtc catggtcaat atcaatcaga ctttcagat ctctactaat tatttagtaga      2280
gtcctgtact atgtctgtaa ctactaagtt taaagaaaag cacatagtca cttcatctct      2340
ttttttctta gcctacgctc actccccaac ccacccaac attgacatgc tatctgtgga      2400
caaatagcag ttctcagaat ctagtcaagt tgccatcctc ccccttgctt ggccgttca      2460
tagtaggtat gcatatgttt gtttctgtac agtactgtgt gtgtgtgtgt atatatatat      2520
acatctgtat gcacacatct ttgataaaat agctatttga cttagcaggtt taaagtggct      2580
tttaattact tctgtgagtg tattggatcc atcttaaaaa aaaaaaatct ggaccacagan      2640
ccatgccata cttggttggg ctattttggg gcattnaaaa ttg
2683

```

<210> 97

<211> 2181

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (5)

<223> n equals a,t,g, or c

<400> 97

gtacnngatt cccgggtcga cccacgctc cggcaggcag aggggcagtg ggcgcgggga 60
 agatgattct gggcctcccc catctactgt cattaacca aatgaaacat ttgccaaacat 120
 aatttttaaa cctactgtag tacaacaagc caggattgcc cagaatggaa ttttgggaga 180
 ctttatcatt agatattgacg tcaatagaga acagagcatt ggggacatcc aggttctaaa 240
 tggctatttt gtgcactact ttgctcctaa agaccttct cctttaccca agaattgtgt 300
 attcgtgctt gacagcagtg cttctatggt gggaaacaaa ctccggcaga ccaaggatgc 360
 cctcttcaca attctccatg acctccgacc ccaggaccgt ttcagtatca ttggattttc 420
 caaccggatc aaagtatgga aggaccactt gatatacgtc actccagaca gcatacaggga 480
 tgggaaagtg tacattcacc atatgtcacc cactggaggc acagacatca acggggtcct 540
 gcagaggggc atcaggctcc tcaacaagta cgtggcccac agtggcattg gagaccggag 600
 cgtgtccctc ategttcttc tgacggatgg gaagcccacg gtcggggaga cgcacacctc 660
 caagatcctc aacaacaccc gagaggccgc ccgagggcaa gtctgcatct tcaccattgg 720
 catcggcaac gacgtggact tcaggctgct ggagaaactg tcgctggaga actgcccct 780
 cacacgggc gtgcacgagg agggaggcgc aggtctcgag ctcatcggtt tctacgtga 840
 aatcaggacc ccgtctctct ctgacatccg catcgattat ccccccagct cagtgggtga 900
 gggccaccaag accctgttcc ccaactactt caacggctcg gagatcatca ttgcggggaa 960
 gctggtggac aggaagctgg atcacctgca cgtggaggtc accgccagca acagtaagaa 1020
 attcatcatc ctgaagacag atgtgcctgt gcggcctcag aaggcaggga aagatgtcac 1080
 aggaagcccc aggcctggag gcatgggaga gggggacmcu aaccacatcg agcgtctctg 1140
 gagctacctc accacaaagg agctgctgag ctctggctg caaagtacg atgaaccgga 1200
 gaaggagcgg ctgcccagc gggcccaggc cctggctgtg agctaccgct tctcactcc 1260
 ctccacctc atgaagctga gggggccggt cccacgcatg gacggcctgg agggggcca 1320
 cggcatgtcg gctgccatgg gaccgaacc ggtgtgtag agcgtgtag gagctggcac 1380
 gcagccaggga cctttgtcga agaagccata ccagccaaga attaaaatct ctaaaacatc 1440
 agtgatgggt gatccccact ttgtttgga ttccccctg agcagactca ccgtgtgctt 1500
 caacattgat gggcagcccg gggacatcct caggctggtc tctgatcaca gggactctgg 1560
 tgcacacgtg aacggagagt taattggggc acccgccct ccaaatggcc acaagaaaca 1620
 ggcacttac ttgcgacta tcaccatcct catcaacaag ccagagagat cttatctcga 1680
 gatcacaccg agcagagtea tcttgatgg tggggacaga ctggtgtctc cctgcaacca 1740
 gagtgtggtg gtggggagct ggggkctgga ggtgtccgtg tctgccaacg ccaatgtcac 1800
 cgtcaaccatc cagggtccca tagcctttgt catctcctc cactctcaca aaaagccggc 1860
 gcccttccag cgacaccacc tgggtttcta cattgccaac agcaggggcc ttccagcaa 1920
 ctgcccaggga ctgctgggic agttcctgaa ccaggatgcc agactcacag aagaccctgc 1980
 agggcccagc cagaacctca ctaccctct gctccttcag gtgggagagg ggcctgaggc 2040
 cgtcctaaca gtgaaaggcc accaagtccc agtggctgg aagcaaggga agatttaca 2100
 cggggaagag cagwtngayt gytggtttgc caggaaacat ccgccaacct gattgacggg 2160
 gagtacagga ttacctggga t 2181

<210> 98
 <211> 1957
 <212> DNA
 <213> Homo sapiens

<400> 98
 acgcgtccgg agggggcagg ctcatggcgc cggcgtcgg gttgctcgg ctctggcgc 60
 tggcggctgt ggctctaccc ggctccgggg cggaggggga cggcgggtgg cgcccgggcg 120
 ggccggggggc cgtgqcgag gaggagcgt gcacgglgga ggtcggggcc gacctcacct 180
 acgaggagtt cgtgcagcag tacgcttctg tcaggcccgat catcctgcag ggactcacgg 240
 acaactcgag gttccgggcc ctgtgctccc gcgacaggtt gctggcttctg ttgggggaca 300
 gagtgggtccg gctgagcacc gccaacacct actcctacca caaagtggac ttgcccttcc 360
 aggtatgtat ggagcagctg ctgcacccc agggacccac ctccctgggc aatgacaccc 420
 tgtacttctt cggggacaac aacttcaccg agtgggctc tctcttctgg cactactccc 480
 caccctcatt tggcctgctg ggaaccgctc cagcttacag ctttgaatc gcaggagctg 540
 gctcgggggt gcccttccac tggcaaggac ccgggtactc agaagtgate tacggctcga 600
 agcgtcgggt cctttaccca cctgaagaaga ccgagagtt ccaccccaac aagaccacgc 660
 tggcctgggt ccgggacaca taaccagcct gcacgctcg cacggccctg gagtgtacca 720
 tccgggcttg taggtgctg acttcccgac cgtggtggc atgctacgt caaccttgac 780
 accagcgtct tcactcacc ttcccgggt agccaaaaca gctggcagga ctgcccgtca 840

cacaccagca	cgccccacct	cggtctcag	gattttatta	cacagatagt	ggcggcaatg	900
gcctcagccc	agcccaccct	cacctgcttt	tccagccccc	aaagggggac	gatcacggcc	960
cagcaaaagc	gatgctgaga	ggggaaacag	tccagagtcc	aacagcagaa	cttgggggaa	1020
gcggtcgggg	tgcccaggaa	cataaactat	gtataggggc	cgggggcttc	tgcccagggc	1080
tccctcggac	caggacgcca	ggtagggcag	ggaacctcag	tagtctctca	cccagccatt	1140
ctcagagatg	aatgcgtcaa	taacctcctt	catagcccaag	ttggggatga	gctgttcttg	1200
ggtcaggggg	ctccgggtca	cggggtcaaa	atgacccaca	cgctgcagtg	acaagaaggg	1260
cagagggcag	tcatggggcc	caggaccatg	ccactggccc	tgctccccc	gccgcaggcc	1320
tcacctgcag	gtgctcctcg	atgtccttgc	ggtcgttaggt	gatgccactg	ggcgtgatgc	1380
acggctcccc	catcagctca	aagctgatct	tgccacacag	gtagtggggg	atgtctcgct	1440
tctgtggcac	aggggcacac	ggtcagaggc	tgaaaagggg	cactgcacga	gcacctgcc	1500
gccatcgcca	gcaagcgaca	cacactcacc	ttcctcttct	catccacctg	agaaaaaagc	1560
tcgtccatgt	ccgccatgta	cttgtctctg	gaagagttag	gtgctgtgct	tgggggagac	1620
accccacctc	cctcctccat	ggggcacaga	cccaacacaa	ggcggggatg	ctcccacgcc	1680
acgtgcacac	acacagacc	acatgtgggt	ggggggcacc	ctcacgtgct	tggcctcaat	1740
gcaggcctgc	tgggcccgga	cggtgctgtc	gtcctcatca	ccctcgtggt	ttcgtggcca	1800
ctcttcacgc	tccttggggg	ttgaccagga	gccggtcaga	gatggacctg	gccagatgtc	1860
tgaccacacc	ccaatctcag	agctaacatc	cacacttccc	cacatttctt	gcttgccagt	1920
aaagcctctg	ataaacaaaa	aaaaaaaaaa	aaaaaaa			1957

<210> 99
<211> 1112
<212> DNA
<213> Homo sapiens

<400> 99						
ccacgcgtcc	gcccccaac	aaaggcactt	gcagttacat	tcaccacatt	tgtaacggag	60
ccattgaagc	atattgaaaa	aggaactggg	gaattttatta	aagcactcat	gaaggaaatt	120
ccagcgctgc	ttcatcttcc	agtgtctgata	attatggcat	tagccatcct	gagtttctgc	180
tatgggtgctg	gaaaatcagt	tcatgtgctg	agacatatag	gcggctctga	gagagaacct	240
ccccaggcac	ttcgccacg	ggatagaaga	cggcaggagg	aaattgatta	tagacctgat	300
ggtaggagcag	gtgatgccga	tttcatttat	aggggccaaa	tgggccccc	tgagcaaggc	360
ccttatgcc	aaacgtatga	gggtagaaga	gagattttga	gagagagaga	tgttgacttg	420
agatttcaga	ctggcaacaa	gagccctgaa	gtgctccggg	catttgatgt	accagacgca	480
gaggcacgag	agcatccccc	ggtagtacc	agtcataaat	cacctgtttt	ggatcacaaag	540
ccaagggaga	caggtggaat	cctgggggaa	ggcacaccga	aagaaaagcag	tactgaaagc	600
agccagtcgg	ccaagcctgt	ctctggccaa	gacacatcag	ggaatacaga	aggttacccc	660
gcagcggaaa	aggcccagct	caagtctgaa	gccgcaggca	gccagaccca	aggcagcaca	720
tacagccccg	caagaggtgt	ggctggacca	cgtggacagg	atccggtcag	cagccctgtg	780
ggctagagga	acaccagcac	aaacgacagc	ctcaagtctc	cttcgagctt	tgtaaaagtaa	840
tctcacagc	tgccaaagaa	cacatcccaa	gcagtaataca	cagatgatga	agcaccttac	900
aggacccctc	cacctcaca	cgcgcattgc	cagagaagta	ttaatgcctt	aatagactac	960
tgaaggttaa	ctatttacat	cattctaaaa	atatttttaag	ctgtattaca	gtgctataaa	1020
ttctcctttt	aaggaaaaaa	gtaatagatt	gtttccttac	cgtgtttgaa	aggaaaaaaa	1080
ataaatccat	agtaactaaa	aaaaaaaaaa	aa			1112

<210> 100
<211> 887
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (303)
<223> n equals a,t,g, or c

<400> 100

```

ggcagcagag aattataggt gcatgatggg gcttttggag actggcaatg tctgttttgg 60
ggctctgggta gtgggtactt gtgtgtattc actttatget aactcattga actgtacaga 120
tatggactgt gcccctttct atagtgtgtt aatgcttcaa caaagtggtc aatagtgtatg 180
catgcacatg ttaaaatttc aaactatatt aaagagtgtg caattaaaag gaagttatcc 240
tctcactcta aagtcctatt tctctcttct agtctatcat tactactagt tcttagtata 300
tonttttagaa atgkgctgta aaagaacaa- gatgtgtatg tctctacagg tatatattta 360
tcttttttgt aaltacaaaa atataaaact actacatatg ttattctacc acatgctttt 420
tttcatgtaa cagtatgtct tagacatctt ttcctattat tgcgtggaag ctatcaacct 480
tattctttgt aatgactcca taaattatct tactgtgaaa acacaccatg tttaaccagt 540
tctctgttag tgaacattta ggatttttcc agttttttaa tattacagtg acatattaaa 600
cattaaacat atctttttgac acatgtcctt gcacacatgt ataggtatga tggactttaa 660
caccccttgg ctaga-tctt tagcacataa cgtaaatato ccatagatgc aaaaccacc 720
ttaaacttc ctcaggaggc tgggtgtggt ggctcacgcc cgtaatocca gcactttagg 780
aggccgaggt gggcggtatc cgaggtcagg agatcgagac catctggcc aacatggtga 840
aaccctgtct ctactaaaaa taaaaaaa aaaaaaaa actcgta 887

```

<210> 101
 <211> 1248
 <212> DNA
 <213> Homo sapiens

```

<400> 101
ccacgcgtcc ggtctattaa ggtgacagaa ctgaagggcc tggccaacca tgtggttgtg 60
ggcagtgctc cctgtgagac caaggacctg ttgcccgc tggcccagggt tgtggtgtg 120
gatataatg accttggtac catcaagctc agcctggaag tcacatggag ccccttcgac 180
aaggatgacc agccctcagc tgettcttct gtcaacaagg cctccacagt caccagcgc 240
ttctccacct atagccagag cccaccggac acacccctac ttgggaaca ggc-ttctat 300
aacatgctgc gacggcagga ggagctggag aatgggacag catggtccct gtcactgtaa 360
tcttcagacg actcatccag cccacagctc tcaggcactg cccgccactc accagccct 420
aggccctgg tgcagcagcc cgagccctt cccatccaa ttgcttctcg caggcctgag 480
accccagct ctgggcccct ggatgaggag ggggccgtgg cccagtcctt ggcattggg 540
catgaccct acagtggac tctgagccac atcagtgagg ctagtgtaaa tgcgtcctt 600
gctgaggtct cagtggaggc cgttgggcca aaaagcctat cctggggacc tagccacct 660
acacaccag ctcccacca tggaaagcac cccagtcctg ttctctctgc cctggacct 720
ggccactctg ccacaagctc taccctcgtt acaacaggct ctgtccccac atctacagac 780
cctgccccat ctgcacacct agactcagtt cataagtcac cagactctgg ccttcagaa 840
ctgccaggcc ccactcacac cactacaggc tctacctata gtgccattac cactaccac 900
agtgtccaa gccccctcac tcaactact acagggtcca cccacaagcc cataatctct 960
acccttacta ctacaggccc taccctcaat atcataggcc cagtccagac taccacaagc 1020
cccaccaca ctatgccaaag cctttcttcc cacagcaata gtccccata cgtagatttt 1080
tgctcttctg tatgtgacaa catttttcta cattatgtta ttggaatttt ctttcataca 1140
ttatatctct ttaaaactct caaaaaaaa aaaaaaaa aaaaaaaa aaaaaaaa 1200
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa 1248

```

<210> 102
 <211> 1841
 <212> DNA
 <213> Homo sapiens

```

<400> 102
ggcagcagct ggtgcaggag ctggagcagt accagttgtt gccgaagaga ttggactggg 60
agggcaacga gcacaacagg agctacagg agttggtctt gtccaataag catgtggctc 120
ctgatcatct ttgcaaatc tgccagcgca tcggtcctat gttggataaa gaaattccac 180
ccagtatttc aagagtcact tctttacttg gtgcaggaa gcagtctttg ctacgtacag 240
caaaaggtag cttaatttga agaagtgttc tgctttgtat taatagccta ataattatta 300
taattgtgaa gtaatgtaag catgtggaag aaaggtgata atgtaactat aaatcatgct 360
gtggactata aaatttctct catttagcat agaacattga attttattac ataagtgttt 420

```

aattgggtcc	tctgcattaa	aaaagttgat	aaagatatag	atgttaagct	aaaaagcttg	480
aatttattct	gagatgttgt	ttgaggtttt	atcaatgtga	gttcttaatt	ttccattttg	540
tagctcactc	ataacttcat	tgaatgtaat	tgtatgtgtc	taataaactc	tttaaagtct	600
agaggatatt	catttgatat	ttagcttctg	aaagcccttt	gttataaagg	gaagtgattt	660
ctaaattttg	gtagcagctt	gaaaacaagc	accacaaatg	taaaattgca	tggttctttt	720
tttactaatt	taattttttt	gccaagttat	gtgctagcaa	aatgtttgaa	attgctattc	780
tttttctgtt	agcttgggtat	atatgactta	gactaagtat	atgtatgtga	tataatatat	840
gtgtacatgt	ggctaaaactg	ctaattgggca	aagattgttg	gttcttctga	tgctgagtat	900
acatcaagtt	catcccatga	ttatttttta	ttacgagcta	ttgctgatgt	gatgctactc	960
ttagctgcac	caccagtata	aagcttaact	gagaaagaac	acccctccct	cttagttccg	1020
tgccagactg	gtttgttagc	tttagttgtt	tcttagtgct	ctagccatgt	caccctgtgg	1080
cactaatcag	gacactgttt	atattcttcc	tcttctgtgt	ccctattcac	tttgaatta	1140
ttctatttta	gctgggtata	tggtagttaa	ttggtagcct	gttttctttt	gttttcttta	1200
cttgtgtcaa	gctccatgtc	gttlylltlyl	gatgagcagt	gatttagaac	tgccagacc	1260
tragaagagt	cttcagcaag	ctgccctagg	gtaggggcat	attctctgtt	tgttttgtac	1320
tggtacccca	ggaggatgcc	ttgtaactgc	tctttgttca	tgatagtggg	aatgaatcca	1380
ttcatgtaaa	atgcaatatg	tctgttagtt	tggggcaccc	gaggctcagt	agagggttag	1440
tatgatgect	tccttttctt	ctttgagttt	tgaagaaact	aatttctggc	acagtgtgac	1500
tgcttcaaac	ctatgttctg	ctgcctatct	ctatagagga	gggcagactt	tttttcttta	1560
gtgcatttgc	tggtaggcca	aggagggatg	gactttgaat	tagtgctcag	agtcacagat	1620
cctacgtatg	tgctcttcag	tagaggattt	tctgtgatcc	tacaatgaag	ggaaagctat	1680
ataatttatt	ggtacttctt	aaagatagag	actaaagtca	tggtagtatt	ggccaaatta	1740
attttaaaac	tgaaacaagtc	atgaattttc	atataaatca	aagaactttt	tccttataaa	1800
agcttccatt	tttgaagaat	tgaaaaaaaa	aaaaaaaaaa	a		1841

<210> 103

<211> 685

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (678)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (679)

<223> n equals a,t,g, or c

<400> 103

actacggctg	cgagaagacg	acagaagggg	ggcggcgacg	gaggaggagg	atggaggcgg	60
tggtgttcgt	cttctctctc	ctcgattgtt	gcgcgctcat	cttctctctg	gtctacttca	120
taattacatt	gtctgattta	gaatgtgatt	acattaatgc	tagatcatgt	tgctcaaaat	180
taaacaaagt	gstaattcca	gaattgattg	gccataccat	tgtcactgta	ttactgtctca	240
tgtcatttga	ctggttcctc	ttcttcttca	acttacctgt	tgccacttgg	aatatataatc	300
gatacattat	ggtgccgagt	ggtaacatgg	gagtgtttga	tccaacagaa	atacacaatc	360
gaggggcagct	gaagtcacac	atgaaagaag	ccatgatcaa	gcttgggttc	cacttgctct	420
gcttcttctat	gtatctttat	agtatgatct	tagctttgat	aaatgactga	agctggagaa	480
gccgtgggtg	aagtcagcct	acactacagt	gcacagtcca	ggagccagag	acttcttaaa	540
tcattccttag	aaccgtgacc	atagcagtat	atattttcct	cttggaaaca	aaaactattt	600
ttgctgtatt	tttaccatat	aaagtattta	aaaaacatga	aaaaaaaaaa	aaaaaaaaaa	660
aaaaaaaaaa	aaaaaaaaaa	aaaaaa				685

<210> 104

<211> 1168

<212> DNA

<213> Homo sapiens

<400> 104

ggcagagcc	ccgcgccct	cctccctcc	cctccctcc	ccggcccg	ctctggccc	60
ggccattcg	ctgttgggtc	ttctgctagg	gaggatgtcg	ggctcgtcgc	tgcccagcgc	120
cctggccctc	tcgctgttgc	tggtctctgg	ctccctcctc	ccagggccag	gcgccgtca	180
gaacgtgaga	gtacaatctg	gacaggatca	gaagtagaga	atgaagtgtg	aagagaaagg	240
gaaagacaga	agaaagcctg	cagtagtaca	aggagaaaag	caggatgcaa	gaatgaggaa	300
tgaatcttgg	tttggaggagc	atccggaaaa	atataagctg	tcagaaagag	taaataagacc	360
agggacctct	aaagttaaatt	cacacatcaa	agttaaaata	atgttggaga	atccctccct	420
gtgaaaaatt	ggcttagctt	tcagtatgcc	tctttaaaca	aaacattatc	attttataca	480
aatttttaaa	atgttgttca	taatatggag	tttaatttta	agcaccttag	ataatgcatt	540
tgttagcttg	tttgtgaaat	ttttatggat	tttttttttc	aaaattccta	attttagttg	600
gtaaggatta	acttcgggaa	gacaggaaac	ccctccagta	aaatttaattg	gttataaatg	660
gttacctatt	ttaggcttat	atacataaca	aaatttctaa	ctgaattttaa	aagtgatctt	720
gtgtaaaaac	attatcttag	tgatattgat	gtctaaattt	aaaagagtga	atacacaagt	780
aaaatatatc	tgttttttaa	ggatctattc	agtttaggaa	ggagagtcac	aatttgtatt	840
taattttcaat	ttatttatatt	gtctgaaact	gaaagtaggc	ctaacttttg	tttgtttttg	900
tgtatgtaca	aaggcaaaac	tttatcaatc	actcttatt	aatttgagat	tatttlgacc	960
tgattgtcga	gaacttttgt	ctatctgtat	agaaatgggg	ttttctaaat	atttaaagaa	1020
tttccctacgt	atgtaaattt	acttgacac	agtaagttag	gggagacatt	taattattcct	1080
caatatacctg	ctgttttctt	gttgtgtttc	tgttttttca	aataaataaa	ctgagtgtta	1140
tctgttcatt	aaaatagaat	gtagtacg				1168

<210> 105

<211> 1175

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (24)

<223> n equals a,t,g, or c

<400> 105

gcatggaaat	atatcctata	catnaagtgc	tgtcctgagc	tgtacatwta	gccatattta	60
gratttttatt	argcaggatt	caaggcctcc	taaaaatgga	tattcagata	tttaaaaaata	120
cactatttaag	gaatgcaatg	taaaatcaca	ctaacatttg	catagcactt	tatagtttac	180
aaaatgcctt	cacatatacg	agctcattta	tttctccttc	tcttcttctt	attcatctat	240
caagggaatat	cttctataag	ccaggcatca	ggcttgacac	tgaagacaca	aaatgaaaaa	300
gatatacaag	tctctattct	taaagagttc	gtagtttaat	gaagtgaccc	aaaaagtaaa	360
cagttgcaat	ataacatgca	aaggagtgtg	atgaaatata	cctagagtac	tatgaaaatg	420
gcatagaggg	accaagcctg	taatgaagtc	agagaaagta	aaagaggtga	agcckgagct	480
aagtttttaa	ggatgaacaa	aaattgacca	gacaaaaggag	ttggagaagt	gggatggtac	540
aggataaaaag	actttctaat	ttgggggaagt	gtgagtcgtc	gatatttagat	gatattatta	600
atagattgtg	cacagagtgc	acatggtaga	gaggtgagag	atgaggttagc	actgttaggg	660
cagataggly	aattctcaca	gtaaccctgt	gwtgtacmtt	atcatcctcc	tctccattac	720
gtagggggaga	acaccaaagc	ccaaagagat	taagtaactt	tccagaattt	tgattttcaa	780
tcttaagcgt	ttgttagctg	tgtttccctg	catatagtct	gcctcaaaaag	aaaattttaa	840
gttgtatttt	gtattaaatt	taaaacaaata	raggcgggtg	gcagtggctc	acgcctgtag	900
tcccagcact	ttggtagggc	aaggtggggc	gatcacctga	ggtcaggatt	tcgagaccag	960
cctggccaat	atggtgaaac	cccattctcta	ctaacatata	aaaattagct	gggcatgggtg	1020
gcacatgcct	gtaatcctgt	ctacttggga	agctgaggca	ggagaatctc	ttgaaccag	1080
gaggcgagg	ttgcagttag	ccgagattgt	gccactgcac	tacaacctgg	acaacagagc	1140
aagattccgt	ctcaaaaaaa	aaaaaaaaaa	ctcga			1175

<210> 106

<211> 1021
<212> DNA
<213> Homo sapiens

<400> 106
ggcagcagaa taaaatagat ttaggggtatt cgacacattt aatacataat gaatag-gaa 60
tttcttgaat aatataatgc cteaatgtga ctgatatgca aaatatattaa atcccttaca 120
gcatgtgcat ttaccaatca gaacagatgt tggctttact gcttgtattta gttttctgta 180
ttagtttgc tgtattagtt tgctggggca gccataacaa agtaccacag aaattttat 240
tctcacaatt ctgggggcta gaagactgag ataaagatgt ctgcagggtt ggtttcttct 300
aaggactctc ttgttggctt gtagatgggt gttgtctccc tgtgtcttca cctgcacttc 360
cctctgtacc tgcccgatc ttaacctctt cttataagga cagagtcata ttggattagg 420
gcctcaccct aatgacctcc ttttaactta attacctctt tagagactct gtcttcaa 480
acaggcacat tctgaggtag ttttaaggtta gaacttcaac atatgcattt ggaactgggg 540
cataactgag tccatgacac tattggagag ggttctggag ccataacaga tggatgaat 600
gggcttgggt tggattctaa ttttaataaa ccaactatag aaaaacatgt tttaggcaat 660
cagatttttt gttatgggct aaattatttag aagatgttaa gaaatgttta ttaatttc 720
taggttaaat aatgttgggt tggttatgta gagtatgact tacgtgcaca gaacagaatg 780
ataaggtgtc caggatttgc ttttaaatat tctagatctt tttaaaaggt gagaggaaat 840
gacacatgta tatctaaatt ttgatgggtt ttgaagctgg ctggtaggta cctagtattt 900
cattacactt tttcttctgt gtgtttggaa atttttataa taagcaggaa aataaaaagt 960
aagaatatal gtattataga taatttgaaa tatgtagaat catgaaaaaa aaaaaaaaaa 1020
a 1021

<210> 107
<211> 830
<212> DNA
<213> Homo sapiens

<400> 107
ggcagcagta aggactgtgt tctttatgca tttcttgatc caggcatggc agttcctctt 60
ttcctgtaca ta-tcacact cctgccactt ctacccttcc tcttatecct ctgcttttca 120
cctctgactg taaaaagaag tagcagttcc gaaagcaaga gttccctatg aacacggaag 180
aagacattgg caacttttga gtacaacaac tataattaat agagtaattt aagaacatca 240
gccagtgaat tttatacaag atagtgaag agaaaaggaa gattaattag gggtagttta 300
ggatgccatt aaatagccta gaattagggg agtagtcgtt gaatagaag gaggccacaa 360
atttgaggga tataagctaa gaattggtaa gccaaagaaga aggaaaaggt ttgggcagta 420
aggataa-ga ggaacaaaat agagaactca gaagcaatat ctgactgtta tcattggaag 480
aattttttgg cttgcttgag gctggatat tgaagtggatc aggatacttg agtgactatc 540
tgatgggctt ttggaactag ctctcaagag gtgaaaatta gctttttttt cttttctttt 600
cttttttttt ttttttgagg caaggtctca ctgttgttga ggctgaacct cctgggctca 660
agcagttgtc ccattgcagc ctectcagat actctgtaag ccaaggcagg gggaaatatt 720
tgtgctcagt agtttgaggc tgtggtgagc taagatcaca ctgctgtgct cacttcagcc 780
tgggcaacac agtgaaaccc cgtctccatc tgtttaaaaa aaaaaaaaaa 830

<210> 108
<211> 1301
<212> DNA
<213> Homo sapiens

<400> 108
aagaggggtg ctgcnagatt cttgtttgtc ctgtgctctg agagtgggtga gttatggaga 60
cccaggtccc agcccccccc acctcagcca ggcttgaca ctgacctctg ccttgcacct 120
cngtgcctcg attcatcaag tacacaggct atgggaatgc tgcctggcctt ctggctgcca 180
ggggcctcat ggcaggaggc cggcccgagg gccagtacc agaggatgag gacacagaca 240
cagatgagta caaggaaagc aaagccagca taaacctgt gaccgggagg gtggaggaga 300
agccgcttaa ccttatggag ggcagtagag aggagcagaa ggagcacag gccatgaagc 360

tggtgaccat	gtttgacaag	ctctccagga	acagagtcac	ccagccaatg	gggatgagtc	420
ccccgggtca	tcttacgtcc	ctgcaggatg	ccatgtgcga	gactatggag	cagcagctct	480
cctcggaccc	tgactcggac	cccgactgag	gatggcagct	ctctgctccc	cccatcagga	540
ctgggtgctgc	ttccagagac	ttccttgggg	ttgcaacctg	gggaagccac	atcccactgg	600
atccacaccc	gccccacttt	ctccatctta	gaaacccctt	ctcttgactc	ccgttctgtt	660
catgattttg	ctctgggtcca	gtttctcctc	tctggactgc	aacggtcttc	ttgtgctaga	720
actcagggtc	agcctcgaat	tccacagacg	aagtactttc	ttttgtctgc	gccaagagga	780
atgtgttcag	aagctgtctg	ctgagggcag	ggcctacctg	ggcacacaga	agagcatatg	840
ggagggcgagg	ggtttgggtg	tgggtgcaca	caaagcaagc	accatctggg	attggcacac	900
tggcagagcc	agtgtgttgg	gggtatgtgt	gcacttccca	gggagaaaac	ctgtcagaa	960
tttccatacg	agtatatcag	aacacaccct	tccaaggtat	gtatgctctg	ttgttcttgt	1020
cctgtcttca	ctgagcgcag	ggctggaggc	ctcttagaca	ttctccttgg	tcccgttca	1080
gctgcccact	gtagtatcca	cagtgcctga	gttctcgtctg	gttttggcaa	ttaaacctcc	1140
ttcctactgg	tttagactac	acttacaaca	aggaaaatgc	ccctcgtgtg	accatagatt	1200
gagatttata	ccacatacca	cacatagcca	cagaaacatc	atcttgaaat	aaagaagagt	1260
tttggacaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaactcg	a		1301

<210> 109

<211> 1932

<212> DNA

<213> Homo sapiens

<400> 109

aatttttttt	tttttttttt	tttttttgaa	aaaaaaaaatg	ggtagtgtat	attttgcagg	60
tttaagacaa	ctcaggacaa	taaaaaacaat	ggacttttaca	tgtgtatata	tatagctctc	120
ttaggcacca	taatcagtat	gagccaacaa	tatttaaaact	tgatttcaggc	cacattcaga	180
catttgctct	tatatacaaa	tattttaaatt	aaatacaatc	tgaatgtgt	tctgttacct	240
acaaaaaagg	aaaaactata	caacgcagag	cagtgtgtgt	gttttaata	attacattta	300
catgtaagct	aaatggaacc	agcaatgggtg	ctcaagtttt	tatcctccct	tccagaaaat	360
ctttttctac	catctcttct	attttttggc	tggcttttgc	ggaacatgg	ttgtggttct	420
ccagtttcat	gtccttatta	gggaaggcat	ttgagttagag	gataggactc	cctgagtgtc	480
ctccacatcg	gcttgtgact	ttgctgttga	agacttgact	gagcacattg	aagaacggca	540
ggagctgtctc	catactgggc	acggtgcaga	tggtagcag	caagtgcct	ggctcccaac	600
ccaatgttct	ccctgagttg	tcctcctctg	gatttttctg	cagaaaaaaa	aaagtgaact	660
ggtatttaata	caacagacaa	tgttggtatgt	tagaaaaatt	aaaaatatat	aaactttggc	720
aatttggtcaa	gaaaagaata	caaatgacat	taagttttct	actcctgacc	tgatcaaaac	780
ccttggtgct	tctgagacct	tttactgcc	tttattagtt	ttacatggag	cagcttaaca	840
ttgtagtaat	agttcccaac	tagaatgcgc	agataagctt	agtttaacaga	aatagctttg	900
aacaggaata	gagtcaaaaca	taaaagtgtt	atgttgtgct	ttgtatttac	tcaaaaagct	960
cccagggttc	tgaacocctca	ctactgtaac	caaggactag	gtcacaaaat	tactacagaa	1020
aaaaggaaaca	aagtgtctta	tacatttcat	aatatatccc	cttttattat	aattagttaa	1080
ttccctttta	tctaaatggc	ctaaaattgc	catgatggta	gcagtgtcca	aagtgaataa	1140
ttactgtcag	tactgcatca	cagagaaaagg	aagggtatccc	tcaggagaca	ctgctgtctc	1200
cttctgggtt	gtgctaaaca	acatagggag	gaaagctgga	cctggagtca	aaggaaattga	1260
gttagtgtgc	tggctctgcc	atacttacgg	cacccttggg	caggatatac	aaaggtccct	1320
cacttaataa	atgggacagt	ctaaaactac	cttttagtag	agaagtcaaa	tgagaaggta	1380
tgtgaaaact	ctgtcaacta	aatataaaga	ctaataattt	gggtattaaq	aggctagttt	1440
gagaagccac	ctgaattaca	caaacacagc	tacagacatc	attctgtcta	gagaaagata	1500
agagagaaca	ggttgggttga	acttgggcag	aatcacagat	acaattccac	actaaagaat	1560
gaaaataaagc	aatgaactag	acagaaggaa	gaaatcatga	agacttagga	agcagaatta	1620
caatctgtca	tattaaacaa	tggagtttgc	cttctaagat	cagatgtttg	tcagaaactt	1680
tcattgttta	cctaataatt	taatatcact	agtttcttag	tgggtcaagc	agatgcaaaa	1740
tccagcttat	ttcttcttat	gtgcctccaa	gcttattgct	tattttaaag	taaaatcctg	1800
aaaaaggaaa	atattaggtt	ggtgcaaaacg	taattgcggt	ttttgcattg	ttgaaatttg	1860
ccgtttttata	ttggagtaaca	ttcttaataa	aatgtgggta	tgttatataca	aaaaaaaaaa	1920
aaaaaactcg	ag					1932

<210> 110
 <211> 1534
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (1212)
 <223> n equals a,t,g, or c

<400> 110
 tcgaagatag gtccgagacg gtggatgttg cagctgatca tgcagttggg ttccgg-gctg 60
 ctcacacgct gccctttttg gggctgcttc agccagctca tgctgtacgc tgagagggct 120
 gaggcacgcc ggaagcccga catcccagtg ccttacctgt atttcgacat gggggcagcc 180
 gtgctgtgcg ctagtttcat gtcctttggc gtgaagcggc gctggttcgc gctggggggc 240
 gcactccaat tggccattag cacctaegcc gcctacatcg ggggctacgt ccactacggg 300
 gactggctga aggtccgtat gtaactcgcgc acagtgtcca tcactggcgg ctttcttgtg 360
 ttggccagcg gtgctgggga gctgtaccgc cggaaacctc gcagccgctc cctgcagtcc 420
 accggccagg tgttcctggg tatctacctc atctgtgtgg cctactcact gcagcacagc 480
 aaggaggacc ggctggcgta tctgaacctc ctcacaggag gggagctgat gatccagctg 540
 ttcttcgtgc tgtatggcat cctggccctt ggctttctg tcaggctact acgtgacct 600
 cgctgcccag atcctggctg tactgctgcc ccctgtcatg ctgctcattg atggcaatgt 660
 tgcttactgg cacaacacgc ggcgtgttga gttctgggaa cagatgaagc tccttgagga 720
 gagtgtgggc atcttcggaa ctgctgtcat cctggccact gatggctgag ttttatggca 780
 agaggctgag atgggcacag ggaagccactg agggtcaccc tgccttcctc cttgtgggcc 840
 cagctgctgt ttattttatgc ttttgggtct gtttggttga tcttttgctt ttttaaaatt 900
 gttttttgca gtttaagggc agctcatttg tccaaatttc tgggcttcay cgttggggag 960
 ggcaggaacc ctggcactaa tgctgtacaa ggtttttttc ctgttaggaa gaacttgagg 1020
 ccagctgccc actgagtcct ctgtccctga agaaaggag tattgggcag ggcttgggat 1080
 ccggctactg aagatgggag agtgggagac agaggaagga agatggagat tggagtgag 1140
 caaatgtgaa aaattcctct ttgaacctgg cagatgcagc taaactctgc agtagtgctt 1200
 ggagactgtg anagggagtg tgtgtgttga cacatgtgga tcaggcccgag gaagggcaca 1260
 ggggctgagc actacagaag tcacatgggt tctcagggtg tgccaggggc agaaacagta 1320
 ccggctctct gtcactcacc ttgagagtag agcagacccc gttctgctct gggctgtgaa 1380
 ggggtggagc aggcagtgcc cagctttgcc ctccctgctg tctctgtttc tagctccatg 1440
 gttggcctgg tgggggtgga gttccctccc aaacaccaga ccacacagtc ctccaaaaat 1500
 aaacatttta tatagacaaa aaaaaaaaaa aaaa 1534

<210> 111
 <211> 2871
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (1234)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1259)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1283)
 <223> n equals a,t,g, or c

```

<220>
<221> SITE
<222> (1284)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1287)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1378)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1912)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1913)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1935)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1947)
<223> n equals a,t,g, or c

<400> 1:1
gcggcgaggc ggcgggtggtg gctgagtcg tgggtggcaga ggcgaaggcg acagctctag 60
gggttggcac cggccccgag aggaggatgc ggggtccggat agggctgacg ctgctgctgt 120
gtgcgggtgct gctgagcttg gcttcggcgt cctcggatga agaaggcagc caggatgaat 180
ccttaggatt ccaagactac tttgacatca gatgagtcag taaaggacca tactactgca 240
ggcagagtag ttgctgggtca aatatttctt gattcegaag aatctgaatt agaatectct 300
attcaagaag aggaagacag cctcaagagc caagaggggg aaagtgtcac agaagatata 360
agcttttctag agtctccaaa tccagaaaac aaggactatg aagagccaaa gaaagtacgg 420
aaaccaggta gtctggacat ttctcttgct ttttgattta tttaggggac aactgaaaat 480
tttaagctaa tgaataaaga agctgaagaa gactggcttc actgattatt acccacaat 540
aataatgga gtgtagtttg gagagaattt ctgatttta atataccaaa gttattcact 600
taacagattt gacccaagtt acataagctg aattccatag atgagattgc atttatcttt 660
ttattaatat cctgacgttt ctttttggaa tcaagtatgt aaatacttt ctactgaga 720
aatttaaaaa aataatattt cagggtagca tacaaaacag aaactcagga agaactgtct 780
aacatgccac tatggttatt ttcaggattg tggtaggatt attactacaa taaccttgtc 840
gatcatccta ggtaatttga tttaggtgtt tatccctcca gcttgacgct tgtgtgtact 900
tccatcctat tctaactttc acaatcttga aacctctact ttcaattta aaacttgacc 960
ttttccacaa tagtcttcta aatatcaatc cttttaaaaa ttattaatgt atctgtttat 1020
ccatgtcttg ttgcccttct gtcatttatt attccaatga tcaactgcctt atctgtttat 1080
tattccatta ctaaccactc tcaggaactg atccaaattg gaacttttta aaaaaataga 1140
atttttttt octacaaata taccattctc atgaatacaa aactattttt aaaaaattaa 1200
aagtacttga atcccatcaa ctagaataaa agntgtctca catcatggag aatattctnt 1260
caggattttt ttaggtgtat carnagnttt aaqaaaagta aattgggtca aaatgtgtat 1320
tctatgttgc agcctgcatt ttgcacttaa cagttttacca tgaatgtttt tccatgtnat 1380

```

catttgacaca	ggggaagggg	gtgccctcct	tcctagaggc	cctggggg-c	aggctgactt	720
ggggggcaga	cttgacacta	ggccccactc	accagatgt	cctgaaatc	caccacgggg	780
gtcaccctgg	gggggttagg	acctattttt	aacactagg	ggctggccca	ctaggagggc	840
tggccctaag	atacagaccc	ccccaaactc	ccaaagcggg	ggggggatat	ttattttggg	900
gagagtttgg	aggggagggg	gatttttttt	ttaaangatt	ttttantttt	naaaaaaaaa	960
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1020
aaaaaaaaaa	aaaaaaa					1037

<210> 113

<211> 2214

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (289)

<223> n equals a,t,g, or c

<400> 113

cggacgcgtg	ggctcgaccca	cgcgtccggg	aaaaarggaa	aatatgccgt	gtaaaatctc	60
gttctgtgtc	tgaattgccg	taggttcaga	tcttcatttg	aggttctgtg	tctgaattgc	120
cgttaggctca	gatcttctat	tgaggttatg	ttctataagt	taacgttgat	cttgtgtgag	180
ctttcggtag	ctggagtaac	acagggcgcc	tcacagcgac	ctctccagcg	ccttccaagg	240
caacatctga	gccagcgtam	tcctcctggg	agatgcctcc	tcaaggcent	gctccagacc	300
acgtgggrar	ggcctgacaa	gccaattccc	aggtgtgccc	cacccttgra	gagtgacct	360
aaacgctaga	cagatgggga	atgggaaaga	aaagaaagct	cgagacctca	agttaaaatt	420
ccctcaaaaa	cgtttttatt	tatctgcttt	ttctgaaagg	ataaaggctt	tttgaatt	480
attttctaac	aaataacatg	aacacttcta	gaaaccctag	aaaaacacaa	agtattcaaa	540
atagaagaa	aaattaccca	ttactcttta	agccagcatt	atccattgog	gtgcttttgg	600
agtgtgggtg	ggcggtagcc	tctgccaaag	caaggagccc	ggtgtgtgct	gtggcattcc	660
tgcagggttg	tttttttttc	tttgagatgg	agtctcactc	ttgtcaccce	agctggaatg	720
tgtgtgtgta	aacagctcac	tgcagccttg	accctgaggg	tcaagcgatc	cttctgcctt	780
ggcc-cctga	gtagctggga	tcccagccga	gagtcaccac	accctgtcca	tgttctctga	840
ggtcttgata	tgcgaggagc	ctgtgtcttc	cctgccacat	tttctctctc	tttcttgaga	900
cagacccttg	ctccatcacc	caggccagag	tgtggtsgtg	cgaacacggc	tcactgcagc	960
ctcgaccctc	aggctcaagc	gatccctcac	cctcggaccc	ccaaagtgtc	gggatcacag	1020
gcgagagtca	ccatgtctgc	ctgaatcttc	agggattttr	cgggtgargt	gycaattact	1080
tarccatccc	tgtttcaaga	gtgtaggtgg	tcaccctgtc	tctgccgtcg	acctggcctg	1140
gaccctcggc	tgtgagaggg	aggggtgggc	tgggctggag	gaacctraag	ccctcgtgat	1200
gtcacaagcc	catctggctg	ggcatccctt	gctgtgtcct	gagctgcaca	tgcccagggt	1260
ggccccccca	gcagaggcga	gccactgrag	ggtgragggc	ttccacggac	ggtcttcagg	1320
ggragaagaa	ggggccaggc	ccccaggaga	ctcaggagac	cagagcctgg	ggtcaggggc	1380
tmagcagggg	ctyareccagg	gctggatgtc	cggagccagc	cccgmagccc	tgkgktcttt	1440
gttcttctga	ctcccaccgt	ccgtgtgaac	agctccagcc	ccacctgcgc	ctccctgtgc	1500
tgggtcccat	cagggagccc	agaagacgtg	tgtgtctctg	aaattgggtc	ctacatgcc	1560
tttgtccag	tgcaccttgc	tccttccatt	tactatcgag	atttaaatgc	ctgttttctc	1620
cccagaggtt	gacggatata	ttcagacgtt	acgacacgga	tcaggacggc	tggattcagg	1680
tgtctgtacg	acagtacctg	tccatggctc	tcagtatcgt	atgaccttgg	cctctcgtga	1740
agagcagcac	aacatggaaa	gagccaaaat	gtcacagtcc	ctatctgtga	gggaatggag	1800
cacaggtgca	gttagatgct	gttcttctct	tagattttgt	cacgtgggga	cccagctgta	1860
catatgagg	taagctgatt	aatggttttg	caactgtaat	agtagctgta	tcgttctaat	1920
gcagacattg	gatttgggtga	ctgtctcat	gtgccatgaq	qtaaatgtaa	tgtttcaggg	1980
attctgcttg	caaaaaaatc	tatcatgtgc	ttttctagat	gtctctgggt	ctatagtcca	2040
aatgctttta	ttagccaata	ggaattttaa	aataacatgg	aacttacaca	aaaggctttt	2100
catgtgcctt	acttttttaa	aaaggagttt	attgtattca	ttggaatatg	tgacgtaagg	2160
aataaaggga	atgttcagacg	tgtaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaag	2214

<210> 114
 <211> 3300
 <212> DNA
 <213> Homo sapiens

<400> 114
 tcgaccacg cgtccggtga gaggcaagga cttttcatct ttagggcatt ctgaccacgt 60
 cctgcttcag agagattggt cccggcgctc cagtgcctatg gggagcaggt tctctctggt 120
 cctgctctca ggtctcactg tcttactggc tctgccagga tcagaagcca agaattctgg 180
 agcttctctgt cctccatgcc ctaaataatgc cagctgccac aacagcacc actgtacttg 240
 tgaagatggc tttcggggcca ggtctggcag gacatacttt catgattcct ctgagaagtg 300
 tgaagatatt aatgaatgtg aaaccgggct ggcaaatgc aagtataaag catattgtag 360
 gaataaagt ggaggttaca tctgtagctg tttggtaaaa tatacttta tcaactttct 420
 ggctgggtatt atagattatg atcatccgga ttgttatgag aacaatagtc aagggacgac 480
 acagtcaaac gtggatattt ggtgagtggt ggtgaagcct ggatttggga aacagctggt 540
 acgtataact atgccatttt cctaccctaaa cattaacatg tcttctctgt atttttaggg 600
 tagggtagtt ctatccagggt gtatttttgc cctctgtccc aagggtcact gtcaatgact 660
 ggggacactt ttggtgtgca taccttgggg gtgatgtgtg tgaactggcat ctggtggatg 720
 gagaccaggg atacagctca acatcctaca gtgccagga cagcctccca caatcaagaa 780
 gtgcctagtg ccatatgtcc atagagatag agaaatacaa gtgtaggggg aaagtgcctc 840
 agctggcatt caaagaccta catcaagcac ctgattcttc aatgccacac gcacctgtga 900
 gcaccttaat aatatcgtt gcctctctgg cctccctc caacacttgt gcaattccc 960
 tatttcttac atttctagta gactcaatct aattagctta atttttttgg aaggaaaatc 1020
 tgagaagaaa tggagcaga gaggacttgc caagaagggc tactcaacta attcaaacgg 1080
 tggagttag catctggaat gcgagttttg cttctccagg aaagggtcaa atttctgaat 1140
 ttgatatagt ctatgaaacc aagaggtgca atgagacaag ggagaatgct tttctgggaug 1200
 ctggaaataa cccatggat atcaactgtg ctgatgcttt aaaaggaaac ctaagagaga 1260
 gcactgcagt tgcctatca cttatcaatc tcttggggat attctgaatg catccttttt 1320
 tagtaaacga aaagggatgc aggaagtaaa actgaactct tacttctgga gcggcaccat 1380
 cggtttgaag gaaaaaattt cctctctctga acctgtgttc ctgacttttc gccataatca 1440
 gcctgtgac aagagaacaa aacatctctg tgtctactgg gagggatcag agggaggccg 1500
 ctgttccacg gagggtgct ctcactgtga cagcaacggt tcttacacca aatgcaagt 1560
 cttccatctg tccagctttg ccgtctctgt ggctcttggc cccaaggagg acctgtgct 1620
 gaccgtgac acccaggtgg ggtgacctat ctctctctgt tgcctcttcc tggccatcct 1680
 caccctctc ctgtgccggc ccatccagaa caccagcacc tccctccalc tagagctctc 1740
 cctctgcctc ttcctggccc acctctgtt cctgacgggc atcaacagaa ctgagcctga 1800
 ggtgtctgtg tccatcattg cagggtgct gcacttctc tacctggctt gcttcacctg 1860
 gatgtctctg gaagggctgc acctcttct caccgtcagg aacctcaagg tggccaacta 1920
 caccagcagc ggcagattca agaagaggtt catgtacct gtaggctacg ggtccacg 1980
 tgtgattatt gctgtgtcag caatagttgg accccagaat tatggaacat ttactcactg 2040
 ttggctcaag cttgataaag gattcatctg gagcttcatg gggccagtag cagtcattat 2100
 cttgataaac ctggtgttct acctccaagt tctgtggatt ttgagaagca aactttcttc 2160
 cctcaataaa gaagtttcca ccattcagga caccagagtc atgacattta aagccatttc 2220
 tcagctattt atcctgggct gttcttgggg cettgtgttt tttatggttg aagaagttag 2280
 gaagacgatt ggtatcaatc ttgcatactc attcaccatc atcaacaccc ttcaggaggt 2340
 gttgtctctt gtggtacact gtcctctaa tegccaggt cgaatggaat ataaaaagt 2400
 gtttagtggg atgcggaaa ggttagaaac tgaagcact gagatgtct gctctactac 2460
 ccaaaccaaa acggaagaag tggggaagtc ctcaagaaatc tttcataaag gaggcactgc 2520
 atcatcatct gcagagtcaa ccaagcaacc gcagccacag gttcatctcg tctctgctgc 2580
 ttggctaaag atgaactgac ctggcaagtg ccatggcaat gaccgggaag ttacccctcc 2640
 tttccgtttg tctacagcgc cctgtgtgct acacatagat tggacaaatg ccactatttc 2700
 tagctttct gtgaaaagtc taggctcatt caccattttt ggtcttttat gttcatagaa 2760
 agaacaagac atttgggaga attcttagat ccagagtcca gtagtgggc acgtgcaatg 2820
 aagtgtcgga aggatgcat ttaagatgg cggcgaggag aagtggattt tcttcttga 2880
 gctactgcca ccttgcaga aactcactaa ctggcatctg gattcagctc atagtccct 2940
 tcttggccto tctgtgtat tttatgtccc caaagatctt acattaacac tccacatca 3000
 cataattcaa caattttcat atggatcagt attaaagagg gtgttgcat ttgcaatata 3060
 aaaatgcatt atcaggtgct ggagaggatg tggagaaata ggaacacttt tacactgttg 3120
 gtgggactgt aaactagttc aaccatcgtg gaagtcagtg tggcgattcc tcagggatct 3180

agaactagaa ataccatttg acacagctat cccattactg ggtatatacc ccaagggcta 3240
 taaatcatgc tgctataaag acacatgcac acgtaaaaaa aaaaaaaaag ggcggccgct 3300

<210> 115
 <211> 1286
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (1149)
 <223> n equals a,t,g, or c

<400> 115
 gactgcttta cggacattgg atgaagccga agcattttaga atgggtgcctg gcacacagtt 60
 ggtgcgtgat atggttaagc ttgtgtgcc caccacatc tcattctttaa tgtgacggtt 120
 tccccggctc cctcctgccg ccatgtgaag aaggtcgttg cttcccttc accctccacc 180
 accatgattg ccatggatgc tccccactcc aaagcagccc tggacagcat taacgagctg 240
 cccgagaaca tctgctgga gctgttcacg cactgcccg cccgccagct gctgctgaac 300
 tgcgcctgg tctgcagcct ctggcgggga cctcatcgac ctcatgaccc tctggaaacg 360
 caatgcctgc gagagggtt catcaccaag gactgggacc agccccgtggc cgactggaaa 420
 atcttctatt tctacggag cctgcatagg aactcctgcg caaccctgtg gctgaagagg 480
 atatgtttgc atggcaaat gatttcaatg gtggggaccg ctggaagggtg gagagcctcc 540
 ctggagccca cgggacagat ttctctgacc ccaagtcaa gaagtatttt gtcacatcct 600
 acgaaatgtg cctcaagtc cagctgggtg accctgtagc cgagggttac tgggaggagc 660
 tactagacac attccggccg gacatcgtgg ttaaggactg gtttgcctgc agagccgact 720
 gtggctgcac ctaccaactc aaagtgcagc tggcctcggc tgactacttc gtgttgccct 780
 ccttcgagcc cccacctgtg accatccaac agtggaaaca tgccacatgg acagaggtct 840
 cctacacett ctacagctac cccccgggtg tccgctacat cctcttccag catgggggca 900
 gggacaccca gtactgggca ggctgggtatg ggcccgagt caccacacgc agcattgtcg 960
 tcagcccaaa gatgaccagg aaccaggcct cctccgagcc tcagcctggg cagaagcatg 1020
 gacaggagga ggctgcccaa tgcacctacc gagctgttgt ccagatttcc tgacagctgt 1080
 ccatcctgtg tctgggtcag ccagaggttc ctccaggcag gagctgagca tgggggtggg 1140
 aagtgggnc cctgtacca ggcacttctg ccccggttca accctacca gcttggggga 1200
 acttactgca catagctctg acgttttgtt gtaataaatg ttttcaggcc gggcaaaaaa 1260
 aaaaaaaaaa aaaaaaaaaa aaaaaa 1286

<210> 116
 <211> 2189
 <212> DNA
 <213> Homo sapiens

<400> 116
 ggaattcggc acgaggcgcc cgaggatgtg ctgctggccg ctgctcctgc tgtgggggct 60
 gctccccggg acggcggcgg ggggctcggg ccgaacctat ccgcaccgga ccctcctgga 120
 ctccggagggc aagtactggc tgggctggag ccagcggggc agccagatcg ccttccgcct 180
 ccaggcgcc actgcaggct acgtgggctc cggtttctcg cccaccgggg ccatggcgctc 240
 cgccgacatc glcgtgggag gggtggccca cgggaggccc tacctccagg attattttac 300
 aaatgcaaat agagagttga aaaaagatgc tcagcaagat taccatctag aatatgccat 360
 ggaaaatagc acacacacaa taattgaatt taccagagag ctgcatacat gtgacataaa 420
 tgacaagagt ataacggata gcaactgtgag agtgatctgg gcttaccacc atgaagatgc 480
 aggagaagct ggtcccaagt accatgactc caataggggc accaagagtt tgcggttatt 540
 gaatccttag aaaactagtg tgcctatctac agccttacca tactttgatc tggtaaatca 600
 ggacgtcccc atcccaaaaca aagatacaac atattgggtg caaatgttta agattcctgt 660
 gttcccaagaa aagcatcatg taataaagggt tgagccagtg atacagagag gccatgagag 720
 tctgggtgcac cacatcctgc tctatcagtg cagcaacaac tttacgaca gcgttccctg 780
 aatccgggca cgaattgcta tcacccaac atgcccgaat cattctcac ctgtgaaact 840

gtgatttttg	cctgggctat	tggtggagag	ggcttttctt	atccacctca	tggtggatta	900
tcccttgcca	ctccattaga	tccgcattat	gtgctcctag	aagtccatta	tgataatccc	960
acttatgagg	aaggcttaat	agataattct	ggactgaggt	tattttacac	aatggatata	1020
aggaatatg	atgclggggl	gailgaggct	ggcctctggy	tyagcctcll	ccataccatc	1080
cctccaggga	tgcttgagtt	ccagtctgag	ggcactgca	ctttggagtg	cctggaagag	1140
gtctcggag	ccqaaaagcc	aagtggaatt	catgtgtttg	ctgttcttct	ccatgctcac	1200
ctggctgcca	gaggcatcag	gctgcgtcat	tttcgaaaag	ggaaggaaat	gaaattactt	1260
gcctatgatg	atgattttga	cttcaatttc	caggagtttc	agtatctaaa	ggaagaacaa	1320
acaa:cttac	caggagataa	cctaattact	gagtgtcgct	acaacacgaa	agatagagct	1380
gagatgactt	ggggaggact	aagcaccagg	agtgaatgt	gtctctcata	ccttctttat	1440
tacccaagaa	ttaatcttac	tcgatgtgca	agtattccag	acattatgga	acaacttcag	1500
ttcatgggg	ttaaggagat	ctacagacca	gtcacgacct	ggcctttcat	tatcaaaagt	1560
cccaagcaat	ataaaaacct	ttcttccatg	gatgctatga	ataagtttaa	atggactaaa	1620
aaggaggctc	tctccttcaa	caagctggtc	ctcagcctgc	cagtgaatgt	gagatgttcc	1680
aagcagaca	atgctgagtg	gtcgattcca	aggaatgaca	gcattacctc	cagatataga	1740
aagaccctat	aaagcagaac	cctttggtgt	gtggcagtc	ttcttctctt	tccttgcaaa	1800
gagattttct	ccatcaactt	gcttggttgc	cttctgctac	tcagctgcac	gctgagacc	1860
aaggcttgt	gatcaaaat	ctgttgagct	tgacaatgtt	ttctatgato	tgaaactgtc	1920
atllgaagla	caggtttaaag	actgtgtcca	ctttgggcat	gaagagtgtg	gagacttttc	1980
ttccccattt	tccttccttc	ctttttccct	tcctatgtac	atgagagaca	tcaatcaggt	2040
tctcttctct	ttcttagaaa	tatctgatgt	tatatataca	tggtcaataa	ataaaactg	2100
gcctgactta	agataaccat	tttaaaaaat	tggtgtgtca	tgtgggaata	aaagaattcl	2160
ttctttccta	aaaaaaaaaa	aaaaaaaaaa				2289

<210> 117

<211> 1763

<212> DNA

<213> Homo sapiens

<400> 117

ggtggcctag	agatgctgct	gccgcggttg	cagttgtcgc	gcacgcctct	gcccgccagc	60
ccgctccacc	gccgtagcgc	ccgagtgctg	gggggcgcac	ccgagtcggy	ccatgaggcc	120
gggaaccgcy	ctacaggccg	tgctgctggc	cgtgctgctg	gtgggctgct	gggcgcgcac	180
gggtcgccctg	ctgagtgggc	agccagtcctg	ccggggaggy	acacagaggy	cttgtataaa	240
agtcatttac	ttccatgata	cttctcgaag	actgaacttt	gaggaagcca	aagaagcctg	300
caggagggga	tggaggccag	ctagtacgca	tcgagttctg	aagatgaaca	gaaactgata	360
gaaaaktcca	ttgaaaacct	cttgccatct	gatggtgayt	tctggawtgg	gctcaggagg	420
cgtgaggaga	aacaaagcaa	tagcacagct	gccaggacct	ttatgcttgg	actgatggca	480
gcata:caca	atttaggaac	tggatatgtg	atgagccgtc	c:gcggcagc	gagg:ctgcy	540
tggctcatgta	ccatcagcca	tcggcaccgg	ctggcatcgg	aggcccttac	agt:ccagt	600
ggaatgatga	ccggtgcaac	atgaagaaca	atttcatttg	caaatattct	gatgagaaac	660
cagcaqttcc	ttctagagaa	gctgaaggtg	aggaacagca	gctgacaaca	cctq:acttc	720
cagaagaaac	acaggaagaa	gatgccaaaa	aaacatttaa	agaaagtaga	gaagctgect	780
tgaatctggc	ctacatccta	atcccccagca	ttcccttctt	cctcctcctt	gkgttcacca	840
cagttgtatg	ttgggttttg	atctgtagaa	aaagaaaacg	ggagcagcca	gacccatgca	900
caaagaagca	acacaccatc	tggtccctctc	ctcaccaggy	aaacagcccg	gacctagagg	960
tctacaatgt	catwagaaaa	caaagcgaaq	ctgacttagc	tgagaccggg	ccagacctga	1020
agaatatttc	attccgagtg	tggtcgggag	aagccactcc	cgatgacatg	tcttgtgact	1080
atgacaacat	ggctgtgaac	ccatcagaaa	gtgggtttgt	gactctggty	agcgtggaga	1140
gtggattttg	gaccaatgac	atcttatgagt	tctccccaga	ccaaatgggg	aggagtaagg	1200
agtcctggatg	ggtggaaaaat	gaaatatatg	gttattagga	cataaaaaaa	actgaaactg	1260
acaacaatgg	aaaagaaatg	ataagcaaaa	tcctcttatt	ttctataagg	aaaatacaca	1320
gaaggtctat	gaacaagcct	agatcagggtc	ctgtggatga	gcattgtggtc	cccacgacct	1380
cctgttggac	ccccacgttt	tggtctgtatc	ctttatccca	gccagtcac	cagctcgacc	1440
ttatgagaag	gtaccttgcc	caggtctggc	acatagtaga	gtctcaataa	atgtcacttg	1500
gttggttgta	tctaactttt	aaggagcaga	gctttacctg	gcagtgataa	agatgggctg	1560
tggagcttgg	aaaaccacct	ctgttttccct	tgtctctatac	agcagcacat	attatcatac	1620
agacagaaaa	tccagaatct	tttcaaagcc	cacatatggt	agcacagggt	ggcctgtgca	1680

tcggcaattc tcatatctgt ttttttcaaa gaataaaatc aaataaagag caggaaaaaa 1740
 aaaaaaaa aaaaaaactc gag 1763

<210> 118
 <211> 1175
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (18)
 <223> n equals a,t,g, or c

<400> 118
 ggcggggcggc gcggaagngg gggckgcgcg gccggggcag ccatgtcgcc attgtctgcg 60
 gcgcggggcgg ccctgcgggt ctacgcggta ggcggcggcg tgatcctggc gcagctgctg 120
 cggcgctgcc gsgggggcctt cctggagcca gtttccccc cagcacctga ccgtg-cgct 180
 atagtgcagg gaggggacaga tggcattggc tattctacag cgaacatctg gcgagacttg 240
 gcatgcatgt tatcatagct ggaataaatg acagcaaagc caaacaagtt gtaagcaaaa 300
 taaaagaaga aaccttgaac gacaaagtgg aatttttata ctgtgacttg gcttccatga 360
 ctcccatcgg gcagtttctg cagaagtcca agatgaagaa gatctctctc catgtcctga 420
 tcaacaatgc tggggtgatg atgggtccctc agaggaaaac cagagatgga ttcgaagaac 480
 atttcggcct gaactaccta gggcacttcc tgcctgaccaa ccttctcttg gatacgtctga 540
 aagagtctgg gtcccttggc cacagtgcga ggggtggcac cgtctcctct gccacccatt 600
 acgtcgtctga gctgaacatg gatgaccttc agagcagtcg ctgctactca cccacgcgag 660
 cctacgccca gagcaagctg gcccttctgc tggttcaccta ccacctccag cggctgctgg 720
 cggctgaggg aagccacgtg accgccaacg tgggtggacc cgggggtggc aacacggacs 780
 tctacaagca cgtgttctgg gccacccgtc tggcgaagaa gcttctcggc tgggtgcttt 840
 tcaagacccc cgatgaagga gcgtggactt ccactctacg agcagtcacc ccagagctgg 900
 aaggagttgg tggccgttac ctatacaacg agaaagagac caagtccctc cactcacct 960
 acaaccagaa actgcagcag cagctgtggt ctaagagttg tgagatgact ggggtccttg 1020
 atgtgacctt gtgatctcct gtctcaggat agctgctgcc ccaagaaaca cattgcacct 1080
 gccaatagct tgtgggtctg tgaagactgc ggtgtttgag tttctcacac ccacctgccc 1140
 acagggtctt gtctctctagt tttagacag ctgcctcaac ctctgcagaa cttcaagaag 1200
 ccaataaac atttggagg ataatcacc caagtgtgtc tcaaccataa actttgtgat 1260
 tccaaagtgc ccagttgtca caggtgccat aaataattac attttccaac ataaaaaaa 1320
 aaaaaaaa aaaaaaaa aaaaaaaa aaaaaaaa aaaaaggcgc gccgc 1375

<210> 119
 <211> 1022
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (937)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (990)
 <223> n equals a,t,g, or c

<400> 119
 ggcacgagag agccrgcggc ccgagccggg gccatggcga actgctgagc tgcgtcttag 60
 gcccccggt ctacaaaatc taccgggaga gggactctga aaaggccccg gccacgtcc 120
 ctgagatgcc aacggcagtc actgcccccc attccagctc ctgggatacg tactatcage 180

```

cccgtgcctt ggagaaacat gctgacagca tcctggcact ggttcagta ttctggtcca 240
tctcttatta ctctctctcc ttctgcttct tctacttgta caggaaagggt tacttgagtt 300
tgtccaaagt ggtgcccgtt tctcactatg ctgggacatt gctgctacct ctggcagggtg 360
tggcctgctc cgaggcattg gccgctggac caacccccag taccggcagt tcatcaccat 420
cttggaaagca acacatcgga accagtcttc agaaaaacaag aggcagcttg ccaactacaa 480
ctttgacttc cggagctggc cagtcgactt ccactgggaa gaaccagca gccggaagga 540
gtctcgaggg ggcccttccc gccggggtgt ggccctgctt cgccagagc cctgcaccg 600
ggggacagca gacacctcc tcaaccgggt taagaagctg ccttgtcaga tcaccagcta 660
cctggtggcg cacaccttag ggcgcgggat gctgtatcca ggctctgtgt acctgctgca 720
gaaggccctc atgctgtgc tgctgcaggg ccaggcccga ctggtggaag agtghtaatgg 780
gcgcggggca aagctgctgg cctgtgatgg caatgagatt gacacctgt ttgtggaccg 840
gcgggggaca gctgagcccc aggcacagaag ctgggatct gctgtgargy gaatgctggg 900
ttttatgarg tgggctgcgt ctccamgccc ctggaanctg gatattcatc ckgggtggaa 960
tcaccagct ttgctggaac acagggggtt ccattcccgc aaaatgaagg ctaatgccat 1020
gg 1022

```

<210> 120

<211> 2311

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (654)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (2293)

<223> n equals a,t,g, or c

<400> 120

```

tgcaccacg cgtccgcttc ctcatgctgc ccgctcgcct accgttcagg ctgctgaqcc 60
tttctcttcg tggatccgct cccacggcag cgcgcctatgg cctccgggag ccgctcctgg 120
agaggagggtg cgtgcccgc tctctcttcc agcactcacc gagctcggga cgcgagcttc 180
cttatgaccc cgtggacacg gagggtcttg gagaagggtg tgacatgcag gagcgttttc 240
tgttcccgga gtacatcctg gatccggagc cgcaaccac cgcgaaaaag cagctgcagg 300
agctccagca acagcaggag gaggaggagc gacagaggca gcagcggcgg gaggagcggc 360
gacagcaaaa cctacgggccc aggtcccggg agcaccgggt cgtggggcac ccggaccggg 420
cattgccgcc cagcggcgtg aactgctcgg gctgcccggc asactgtcac tgccaggacg 480
ccggagtgcc cggctacctg ccccagagaa agttcctccg cagcggcggg gcagacggcg 540
ggctggcagc gaccgtgtgc cagcgtgtgt ggctgtgtgc gcaccaccgg cgcgtcttac 600
gctgagaggt gagccgcgag cagtacctgg agctgggtgag cgcgcggttg cggngggccc 660
gccccctcct ggtgtctctc atgtgtggac tgctggacct gcccagcgc ctgctgcccg 720
acttgcccgc gctggtgggc cccaagcagc tgatcgtgct gggaaacaaa gtggaccttc 780
tgccccagga tgctcctggc taccggcaga ggctgcccga gcgactgtgg gaggactgtg 840
ccgcgcggcg gctcctgctg gcccttgcca ccaaggggca cagcgcggcg tcaaggacga 900
gccacaggac ggggaqaaac cgaatccgcc gaactgggtcc cgcacagtgg tcaggagcgt 960
gcggctgata agccccaaga ccggctatgg agtgggaagag ttgatctctg ccttcagcg 1020
ctcctggcgc taccgtgggg acgtctactt agtgggcgcc accaacggcg gcaaatccac 1080
tctctttaac acgctcctgg agtccgatta ctgcaactgc aagggtccg aggccatcga 1140
cagagccacc atctcccctt ggccaggtag tacattaaac cttctgaagt ttctatttg 1200
caaccacact ccttacagaa tgtttaaaag gcatcaaaag cttaaaaaag attcaactca 1260
agctgaagaa gatcttagtg agcaagaaca aaatcagctt aatgtcctca aaaagcatgg 1320
ttatgtcgta ggaagagttg gaaggacatt ctltgattca gaagaacaga aggataacat 1380
tccctttgag tttgatgctg attcacttgc ctttgacatg gaaaatgacc ctg-tatggg 1440
tacacacaaa tccaccaaac aagtagaatt gactgcacaa gatgtgaaag atgcccactg 1500
gtttta-gac acccctggaa ttacaaaaga aaattgtatt ttaaatcttc taacagaaaa 1560

```

```

agaagtaaat attgttttgc caacacagtc cattgttcca agaacttttg tgcttaaaacc 1620
aggaatgggt ctgttttttg gtgtatagg ccgcatagat ttccctgcagg gaaatcagtc 1680
agcttgggtt acagtcgttg cttccaacat cctccctgtg catatcacct ccttggacag 1740
ggcagacgct ctgtatcaga agcatgcagg tcatacgtta ctccagattc caatgggttg 1800
aaaagaacga atggcrggat ttccctctct tgttgcgtga gacattatgt taaaagaagg 1860
actgggggca tctgaagcag tggccgacat caagttttcc tctgcagggt gggtttcagt 1920
aacacctaatt ttaaggaca gactgcattc ccgaggctat acacctgaag gaacagtttt 1980
gaccgtccgg cccctctctc tgccatatat tgtaacatc aaaggacagc gcatcaagaa 2040
aagtgtggcc tataaaacca agaagcctcc ttcccttatg taczacgtga ggaagaagaa 2100
aggaagata aatgtatgag accgaccttg ttactccag atattaactg tattgaacac 2160
aacaaaatac attgaatttg tattaacat ataacgcata aataaagctc ccattcttac 2220
ccttaaaaaa aaaaaaaag ggcggccgct ctagaggatc caagcttacg tacgcgtgca 2280
tgcgacgtca tancctcgtc ataggaactg g 2311

```

```

<210> 121
<211> 1286
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1284)
<223> n equals a,t,g, or c

```

```

<400> 121
gggcgcgcgg gtgaaaggcg cattgatgca gcctgcggcg gcctcggagc gcggcggagc 60
agacgctgac cacgttcttc tctcgggtct cctccgcctc cagctccgcg ctgcccggca 120
gccgggagcc atgcgacccc agggcccgcg cgcctcccg cagcggctcc gcggcctcct 180
gtgctcctg ctgctgcagc tgccgcgcgc gtcgagcgcc tctgagatcc ccaaggggaa 240
gcaaaaggcg cactccggca gaggaggtg gtggacctgt ataaggaat gtgcttacaa 300
gggccagcag gagtgccttg tcgagacggg agccctgggg ccaatggcat tccgggtaca 360
cctgggatcc caggtcggga tggattcaaa ggagaaaagg ggaatgtct gagggaaagc 420
tttgaggagt cctggacacc caactacaag cagtgttcat ggagtgcatt gaattatggc 480
atagatcttg ggaataattg ggaagtaca ttacaaaaga tgcgttcaaa tagtgcctca 540
agagttttgt tcagtggctc acttcggcta aaatgcagaa atgcatgctg tcagcgttgg 600
tatttcacat tcaatggagc tgaatgttca ggacctcttc ccattgaagc tataatttat 660
ttggaccaag gaagccctga aatgaattca acaattaata ttcacgcac tctctctgtg 720
gaaggacttt gtgaaggaa tgggtgctga ttagtggatg ttgctatctg ggttggcact 780
tggtcagatt acccaaaag agatgcttct actggatgga attcagtttc tcgcatcatt 840
attgaagaac taccaaaata aatgctttaa ttttcatttg ctacctcttt ttttattatg 900
ccttggaaatg gttcacttaa atgacatttt aaataagttt atgtatacat ctgaatgaaa 960
agcaaaagcta aatatgttta cagaccaaag tgtgatttca cactgttttt aaatctagca 1020
ttattcattt tgcctcaatc aaaagtgggt tcaatatatt ttttagttgg ttagaatact 1080
ttcttcatag tcacattctc tcaacctata atttggaaata ttgttgggtt cttttgtttt 1140
ttctcttagt atagcatttt taaaaaata taaaagctac caatcttctg acaatttcta 1200
aatgttaaga atttttttta tatctgttaa ataaaaatca ttcccaaca aaaaaaaa 1260
aaaaaaaaa aaaaaaaaaa aaaaaa 1286

```

```

<210> 122
<211> 1380
<212> DNA
<213> Homo sapiens

```

```

<400> 122
cagacccgcg gggcaaacgg actggggcca agagccggga gcgcgggcgc aaaggcacca 60
gggcccgcgc agggcgccgc gcacacggcc ttgggggttc tgcgggcctt cgggtgcgcg 120
tctcgcctct agccatgggg tccgcacgct tggagatcct gggcctgggt ctgtgcctgg 180

```

tggtgctggg	gggtctgac	ctggcgtg	ggctgccc	gtggcagg	accgccttc	240
tgaccacaa	categtgac	gcgcagaca	cctggaagg	gctgtggat	tcgtgctgg	300
tgagagcac	gggcacatg	agtgcacaa	gtacgactc	gtgctggct	tgagcacga	360
ggtgcagg	gcgcggg	tcaccgtg	cgccgtgt	ctggcgttc	ttgcgtctt	420
cgtgacctg	gcggggcgc	agtgcacc	ctgcgtgg	ccggggccc	ccaaggcgc	480
tggtgacct	acgggagg	tgctctacc	gttttcgg	ctgctggc	tcgtgcact	540
ctgctggtc	gccaacatt	tcgtccgca	gttttacgc	ccgtctgt	ccgtgtcga	600
gaagtacga	ctgggcgc	gctgtacac	ggctggg	ccaccgc	gctcatgta	660
ggcggtgcc	ttttgtgt	cgccgctg	gtctgcacc	gccgtccc	cctcagctt	720
ccgtgaagt	actcagcgc	gcggcgccc	acggccacc	gcgactac	caagaaga	780
tacgtctga	ggcgctgg	acggcggg	ccctcctg	agccacgc	gcgaggcgt	840
ggataagcc	ggggagccc	gcattggac	cggtctcc	cggtagcgc	ggcgcgagg	900
ctcctcgaa	cgcccggtc	tcgcgccga	cgcggtcct	ggatccgct	ctgcctg	960
ccgcagctga	ccttctcct	ccactagcc	ggccctg	ttacagac	gaatgaagt	1020
tcctttctg	tgccggcgc	tgtttcata	ggcagagcg	gtgtcagac	gaggatttc	1080
cttccctcc	aagacgctg	gggtcttgc	tgctgcctt	cttcccag	gctcctgct	1140
acttcggag	ggcgatgca	gagccagg	ccccaccg	aagatgtgt	cacctggct	1200
ttactccat	ggcagggcc	gagccagg	accagtga	tgccctgg	ctcccgtct	1260
cactccagca	ctccccagg	caaggcttg	gggcaccga	gcttgagag	ggcgggagt	1320
gggaaggcta	agaatctgt	tagtaaatg	tttgaactc	caaaaaaaaa	aaaaaaaaa	1380

<210> 123
 <211> 3793
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (1102)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1132)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1199)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1228)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1229)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1231)
 <223> n equals a,t,g, or c

<220>
 <221> SITE

<222> (3176)

<223> n equals a,t,g, or c

<400> 123

ggggcttcat	acaggaaatc	tattgctgtg	tcaagttcca	gagaaaagct	tctgttcgtc	60
caagttacta	accaggctaa	accacataga	cgtgaaggaa	ggggctagaa	ggaagggagt	120
gccccactgt	tgatggggta	agaggatcct	gtactgagaa	gttgaccaga	gaggggtctca	180
ccatgcgcac	agttctctct	gtaccagtgt	ggaggaaaag	tactgagtga	agggcagaaa	240
aagagaaaac	agaaatgctc	tgcccttgga	gaactgctaa	cctagggcta	ctgttgattt	300
tgactatctt	cttagtgccc	gaagcggagg	gtgctgctca	accaaacaac	tcattaatgc	360
tgcaaaactag	caaggagaat	catgcttttag	cttcaagcag	tttatgtatg	gatgaaaaac	420
agattacaca	gaactactcg	aaagtactcg	cagaagttaa	caettcatgg	cctgtaaaga	480
tggtacaaaa	tgctgtgctt	tggtgcccct	ctatcgcat	aagaaatttg	atcataataa	540
catgggaaat	aatcctgaga	ggccagcctc	cctgcacaaa	agcctacaag	aaagaaacaa	600
atgagaccac	ggaaaccaac	tgtaactgat	agagaataac	ctgggtctcc	agacctgatc	660
agaattcggg	ccttcagatt	cgtaccgtgg	ccatcactca	tgacgggtat	tacagatgca	720
taatggtaac	acctgatggg	atcttccatc	gtggatatca	cctccaagtg	ttagtacac	780
ctgaagtgc	cctgtttcaa	aacaggaata	gaactgcagt	atgcaaggca	gttgacggga	840
agccagctgc	gcatatctcc	tggtatccag	agggcgattg	tgccactaag	caagaataact	900
ggagcaatgg	cacagtgcct	gttaagagta	catgccactg	ggaggtccac	aatgtgtcta	960
ccgtgaaactg	ccacgtctcc	catcttgactg	gcaacaagag	tctgtacata	gagctacttc	1020
ctgttccagg	tgccaaaaaa	tcatacaaat	tatatattcc	atatatcatc	cttactatta	1080
ttattttgac	catcgtggga	tcnatttggg	tggtgaaagt	caatggctgc	anaaaatata	1140
aattgaataa	accagaatct	actccagttg	ttgaggagga	tgaaatgcag	ccctatgcnt	1200
tttacacaga	gaagaacaat	cctctctnng	ntactacaaa	caaggtgaag	gcattctgag	1260
cattacaaag	tgaaagttgac	acagacctcc	atactttata	agttgttgga	ctctagtacc	1320
aagaaacaac	aacaacacag	atacattata	attactgtct	gattttctta	cagttctaga	1380
atgaagactt	atattgaaat	taggttttcc	aaggttctta	gaagacattt	taattggattc	1440
tcattcatcac	ccttgataaa	ttggaatttt	tgattcttag	ctgctaccag	ctagttctct	1500
gaagaactga	tggtattaca	aagaaaatac	atgcccatga	ccaaatattc	aaatttgtca	1560
ggacagttaa	taatgaaaa	caaatcttct	caagaataaa	ctgaagaagg	agcaagtgtg	1620
aacagtttct	tggttatcct	ttcagaatat	tttaagtac	atatgacatg	tgatatatgcc	1680
tatggtatat	gtgtcaattt	atgtgtcccc	ttacatatac	catgcacctc	atcttctgca	1740
aggcaaccag	gggaaccaata	cactgcatta	ctgttctata	catatgaaaa	cctaataata	1800
taagctcttag	agatcatttt	atatcatgac	aagtagagct	acctcattct	ttttaatggt	1860
tataaaaaat	tcattgttat	agttatatac	ttatttaatt	aaaaacaacc	ctaattgatg	1920
atattttagat	tcttttaagt	tttgtttatt	tcttttaagt	ttgtttgtg	gtataaaca	1980
taccacatag	aatgtttctt	gtgcataat	ctctttgttt	ttgagtatat	ctgtaggata	2040
acttctctga	gtggaattgt	caggtcaaat	ggttttgtga	ttttactatt	gatataatag	2100
ttaaaattgtg	tcaaatatat	atgtcaaat	ccctccaaca	tggtttaaat	gtgcttttcc	2160
ctaaatttct	attttaataa	ctgtactatt	cctgcttcta	cagttgccc	tttctctttt	2220
taatcaacca	gattaaatat	gatgtgagat	tataataaga	attatactat	tttaataaaa	2280
tggatttata	tttttggtca	tggttgtaag	agagtgaatg	cacgtgtgag	aacattagct	2340
tcttctgaac	tcatttatat	tccacagagg	tggtgatact	tgatgcctaa	cagttttgca	2400
gatgtgctac	attggaattg	tgatatttta	tggtgtacat	tctatttgta	tataattttt	2460
gaataaattaa	tgctctattga	ccatataagt	ggcgaaaaat	gcaccataga	ggacatgggg	2520
tattttattta	caaaactatga	gctacataat	aagcaagtgg	ccatgggatg	gcattgacct	2580
ccctccata	tttttggtga	gcaaaatatt	ggcaatgttt	atgtaaatca	ttgttaatat	2640
catgaaatta	tttttaatta	aaaacataag	tctatttgct	ccatagcaga	aaaaacatga	2700
gaagtttttt	catcatgata	gaaattgaaa	caaaatata	tcattcttca	atcataccat	2760
ctgagatttt	taagacagct	attttgtctt	ataagtatat	ttttctccct	ctagacattt	2820
cagttactat	ggattttgtc	ctcaaggga	cytttagtct	aattttggga	tgtaaaagcta	2880
atcttaatga	cacttgccac	atgatatatt	gatcaagcca	ttttgacttg	acaaaaaagc	2940
agtgctccat	aggtttctgc	atataaatat	taccaagcaa	tggtcacaa	agacatcatt	3000
acactgtcct	tgaaatttat	taattcttca	tccaacctg	gttgagctga	ggctcatagt	3060
taggttcaag	actatctggt	taaatattac	tgaanaacaa	agtaagncag	tactatgctt	3120
acctcttaac	ttgataatgt	caaaccaggc	atgttaaatg	acatcataga	aaaganttca	3180
agataattta	tagaagttaa	attatattgt	acagaaaaata	attgtatgaa	aatctctact	3240
atggggctgg	aacatggttg	aacattagaa	tgatataaaa	aattatatat	attctccaaa	3300

```

tccacgctag accgtgcaaa ttagagaatc tagagattag acctggcgtg tcagcaaggt 3360
catccaggaa gcagaggctg agacggagtt aggtgtgatt acctacatag tcgattacat 3420
tttacaata acattttata tgtctcattt actgtgcttt ctccccatcc cattttgtat 3480
cttttctttt gctttgctag atttgtcaat ttctctcttc tttctgtctc tctctcttc 3540
aatactctta ataatttgaa agtaattcat cataactaaa tatctattgg ggttatgctt 3600
cacttacaaa cttctgaaaa cggctttact gagatataat tgatatattt aagtgtacag 3660
tttgtaaat tttgcacata tttaaaatgt ggactttggt aaatgttgac atagtittac 3720
atctgtgaaa ccatcagcat aatcaagata ataaacttgt ccatcacccc ccaaaaaaaa 3780
aaaaaaaaaaa aaa 3793

```

<210> 124

<211> 370

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (370)

<223> Xaa equals stop translation

<430> 124

```

Met Leu Gly Ala Phe Val Trp Pro Ser Leu Leu Leu Ala Ala Ala
 1           5           10          15
Cys Ile Cys Leu Leu Thr Phe Ile Asn Cys Ala Tyr Val Lys Trp Gly
          20           25           30
Thr Leu Val Gln Asp Ile Phe Thr Tyr Ala Lys Val Leu Ala Leu Ile
          35           40           45
Ala Val Ile Val Ala Gly Ile Val Arg Leu Gly Gln Gly Ala Ser Thr
          50           55           60
His Phe Glu Asn Ser Phe Glu Gly Ser Ser Phe Ala Val Gly Asp Ile
          65           70           75           80
Ala Leu Ala Leu Tyr Ser Ala Leu Phe Ser Tyr Ser Gly Trp Asp Thr
          85           90           95
Leu Asn Tyr Val Thr Glu Glu Ile Lys Asn Pro Glu Arg Asn Leu Pro
          100          105          110
Leu Ser Ile Gly Ile Ser Met Pro Ile Val Thr Ile Ile Tyr Ile Leu
          115          120          125
Thr Asn Val Ala Tyr Tyr Thr Val Leu Asp Met Arg Asp Ile Leu Ala
          130          135          140
Ser Asp Ala Val Ala Val Thr Phe Ala Asp Gln Ile Phe Gly Ile Phe
          145          150          155          160
Asn Trp Ile Ile Pro Leu Ser Val Ala Leu Ser Cys Phe Gly Gly Leu
          165          170          175
Asn Ala Ser Ile Val Ala Ala Ser Arg Leu Phe Phe Val Gly Ser Arg
          180          185          190
Glu Gly His Leu Pro Asp Ala Ile Cys Met Ile His Val Glu Arg Phe

```

```

      195              200              205
Thr Pro Val Pro Ser Leu Leu Phe Asn Gly Ile Met Ala Leu Ile Tyr
 210              215              220
Leu Cys Val Glu Asp Ile Phe Gln Leu Ile Asn Tyr Tyr Ser Phe Ser
 225              230              235              240
Tyr Trp Phe Phe Val Gly Leu Ser Ile Val Gly Gln Leu Tyr Leu Arg
      245              250              255
Trp Lys Glu Pro Asp Arg Pro Arg Pro Leu Lys Leu Ser Val Phe Phe
      260              265              270
Pro Ile Val Phe Cys Leu Cys Thr Ile Phe Leu Val Ala Val Pro Leu
      275              280              285
Tyr Ser Asp Thr Ile Asn Ser Leu Ile Gly Ile Ala Ile Ala Leu Ser
      290              295              300
Gly Leu Pro Phe Tyr Phe Leu Ile Ile Arg Val Pro Glu His Lys Arg
      305              310              315              320
Pro Leu Tyr Leu Arg Arg Ser Trp Gly Leu Pro Gln Gly Thr Ser Arg
      325              330              335
Ser Cys Val Cys Gln Leu Leu Gln Lys Trp Ile Trp Lys Met Glu Glu
      340              345              350
Arg Cys Pro Ser Asn Gly Ile Pro Ser Leu Thr Lys His His Leu Glu
      355              360              365
Ser Xaa
      370

```

```

<210> 125
<211> 86
<212> PRT
<213> Homo sapiens

```

```

<220>
<221> SITE
<222> (86)
<223> Xaa equals stop translation

```

```

<400> 125
Met Gly Phe Trp Cys Gly Cys Pro Phe Cys Leu Leu Val Val Leu Leu
  1              5              10              15
Thr Asp Arg Thr Leu Ser Cys Arg Ser Val Gly Val Pro Cys Asn Val
      20              25              30
Arg Cys Gln Cys Ala Pro Ala Gly Gly Cys Leu Pro Val Arg Leu Leu
      35              40              45
Ala Gly Gln Gly Ser Gly Thr His Leu Arg Arg Gln Ser Ala Arg Ser
      50              55              60

```

Gln Ile Ser Ser Cys Met Leu Gly Glu Pro Leu Leu Ser Ser Lys Leu
 65 70 75 80

Ser Asp Arg Asp Ile Xaa
 85

<210> 126
 <211> 44
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (44)
 <223> Xaa equals stop translation

<400> 126
 Met Tyr Thr Lys Thr His Lys Phe Lys Phe Tyr Asn Phe Leu Ser Leu
 1 5 10 15

Trp Ile Trp Lys Ile Phe Phe Leu Leu Phe Phe Ile Leu Ile Val Ala
 20 25 30

Leu Ala Phe Pro Ile Pro Cys Leu Ser Ile Phe Xaa
 35 40

<210> 127
 <211> 319
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (264)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (303)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 127
 Met Asn Thr Asp His Leu Arg Leu Thr Val Pro Asn Gly Ile Gly Ala
 1 5 10 15

Leu Lys Leu Arg Glu Met Glu His Tyr Phe Ser Gln Gly Leu Ser Val
 20 25 30

Gln Leu Phe Asn Asp Gly Ser Lys Gly Lys Leu Asn His Leu Cys Gly
 35 40 45

Ala Asp Phe Val Lys Ser His Gln Lys Pro Pro Gln Gly Met Glu Ile
 50 55 60

Lys Ser Asn Glu Arg Cys Cys Ser Phe Asp Gly Asp Ala Asp Arg Ile
 65 70 75 80

Val Tyr Tyr Tyr His Asp Ala Asp Gly His Phe His Leu Ile Asp Gly
 85 90 95
 Asp Lys Ile Ala Thr Leu Ile Ser Ser Phe Leu Lys Glu Leu Leu Val
 100 105 110
 Glu Ile Gly Glu Ser Leu Asn Ile Gly Val Val Gln Thr Ala Tyr Ala
 115 120 125
 Asn Gly Ser Ser Thr Arg Tyr Leu Glu Glu Val Met Lys Val Pro Val
 130 135 140
 Tyr Cys Thr Lys Thr Gly Val Lys His Leu His His Lys Ala Gln Glu
 145 150 155 160
 Phe Asp Ile Gly Val Tyr Phe Glu Ala Asn Gly His Gly Thr Ala Leu
 165 170 175
 Phe Ser Thr Ala Val Glu Met Lys Ile Lys Gln Ser Ala Glu Gln Leu
 180 185 190
 Glu Asp Lys Lys Arg Lys Ala Ala Lys Met Leu Glu Asn Ile Ile Asp
 195 200 205
 Leu Phe Asn Gln Ala Ala Gly Asp Ala Ile Ser Asp Met Leu Val Ile
 210 215 220
 Glu Ala Ile Leu Ala Leu Lys Gly Leu Thr Val Gln Gln Trp Asp Ala
 225 230 235 240
 Leu Tyr Thr Asp Leu Pro Asn Arg Gln Leu Lys Val Gln Val Ala Asp
 245 250 255
 Arg Arg Val Ile Ser Thr Thr Xaa Ala Glu Arg Gln Ala Val Thr Pro
 260 265 270
 Pro Gly Leu Gln Glu Ala Ile Asn Asp Leu Val Lys Lys Tyr Lys Leu
 275 280 285
 Ser Arg Ala Phe Val Arg Pro Ser Gly Thr Glu Asp Val Val Xaa Ser
 290 295 300
 Ile Cys Arg Ser Arg Leu Thr Arg Lys Cys Arg Ser Pro Cys Thr
 305 310 315

<210> 128

<211> 46

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (46)

<223> Xaa equals stop translation

<430> 128

Met Asp Met Val Cys Phe Cys Ile Tyr Leu Gly Leu Leu Lys Phe Ile
 1 5 10 15

Ser Ala Ile Phe Cys Ser Phe Ser Glu Glu Val Leu Tyr Ile Ser Phe
 20 25 30
 Val Lys Cys Ile Pro Lys Tyr Phe Val Glu Met Leu Leu Xaa
 35 40 45

<210> 129
 <211> 709
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (189)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (275)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (414)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (438)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (641)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (643)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (696)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (697)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 129
 Met Ala Gly Leu Asn Cys Gly Val Ser Ile Ala Leu Leu Gly Val Leu
 1 5 10 15
 Leu Leu Gly Ala Ala Arg Leu Pro Arg Gly Ala Glu Ala Phe Glu Ile
 20 25 30

Ala Leu Pro Arg Glu Ser Asn Ile Thr Val Leu Ile Lys Leu Gly Thr
 35 40 45
 Pro Thr Leu Leu Ala Lys Pro Cys Tyr Ile Val Ile Ser Lys Arg His
 50 55 60
 Ile Thr Met Leu Ser Ile Lys Ser Gly Glu Arg Ile Val Phe Thr Phe
 65 70 75 80
 Ser Cys Gln Ser Pro Glu Asn His Phe Val Ile Glu Ile Gln Lys Asn
 85 90 95
 Ile Asp Cys Met Ser Gly Pro Cys Pro Phe Gly Glu Val Gln Leu Gln
 100 105 110
 Pro Ser Thr Ser Leu Leu Pro Thr Leu Asn Arg Thr Phe Ile Trp Asp
 115 120 125
 Val Lys Ala His Lys Ser Ile Gly Leu Glu Leu Gln Phe Ser Ile Pro
 130 135 140
 Arg Leu Arg Gln Ile Gly Pro Gly Glu Ser Cys Pro Asp Gly Val Thr
 145 150 155 160
 His Ser Ile Ser Gly Arg Ile Asp Ala Thr Val Val Arg Ile Gly Thr
 165 170 175
 Phe Cys Ser Asn Gly Thr Val Ser Arg Ile Lys Met Xaa Glu Gly Val
 180 185 190
 Lys Met Ala Leu His Leu Pro Trp Phe His Pro Arg Asn Val Ser Gly
 195 200 205
 Phe Ser Ile Ala Asn Arg Ser Ser Ile Lys Arg Leu Cys Ile Ile Glu
 210 215 220
 Ser Val Phe Glu Gly Glu Gly Ser Ala Thr Leu Met Ser Ala Asn Tyr
 225 230 235 240
 Pro Glu Gly Phe Pro Glu Asp Glu Leu Met Thr Trp Gln Phe Val Val
 245 250 255
 Pro Ala His Leu Arg Ala Ser Val Ser Phe Leu Asn Phe Asn Leu Ser
 260 265 270
 Asn Cys Xaa Arg Lys Glu Glu Arg Val Glu Tyr Tyr Ile Pro Gly Ser
 275 280 285
 Thr Thr Asn Pro Glu Val Phe Lys Leu Glu Asp Lys Gln Pro Gly Asn
 290 295 300
 Met Ala Gly Asn Phe Asn Leu Ser Leu Gln Gly Cys Asp Gln Asp Ala
 305 310 315 320
 Gln Ser Pro Gly Ile Leu Arg Leu Gln Phe Gln Val Leu Val Gln His
 325 330 335
 Pro Gln Asn Glu Ser Asn Lys Ile Tyr Val Val Asp Leu Ser Asn Glu

340	345	350
Arg Ala Met Ser Leu Thr Ile Glu Pro Arg Pro Val Lys Gln Ser Arg		
355	360	365
Lys Phe Val Pro Gly Cys Phe Val Cys Leu Glu Ser Arg Thr Cys Ser		
370	375	380
Ser Asn Leu Thr Leu Thr Ser Gly Ser Lys His Lys Ile Ser Phe Leu		
385	390	395
Cys Asp Asp Leu Thr Arg Leu Trp Met Asn Val Glu Lys Xaa Ile Ser		
405	410	415
Cys Thr Asp His Arg Tyr Cys Gln Arg Lys Ser Tyr Ser Leu Gln Val		
420	425	430
Pro Ser Asp Ile Leu Xaa Leu Pro Val Glu Leu His Asp Phe Ser Trp		
435	440	445
Lys Leu Leu Val Pro Lys Asp Arg Leu Ser Leu Val Leu Val Pro Ala		
450	455	460
Gln Lys Leu Gln Gln His Thr His Glu Lys Pro Cys Asn Thr Ser Phe		
465	470	475
Ser Tyr Leu Val Ala Ser Ala Ile Pro Ser Gln Asp Leu Tyr Phe Gly		
485	490	495
Ser Phe Cys Pro Gly Gly Ser Ile Lys Gln Ile Gln Val Lys Gln Asn		
500	505	510
Ile Ser Val Thr Leu Arg Thr Phe Ala Pro Ser Phe Arg Gln Glu Ala		
515	520	525
Ser Arg Gln Gly Leu Thr Val Ser Phe Ile Pro Tyr Phe Lys Glu Glu		
530	535	540
Gly Val Phe Thr Val Thr Pro Asp Thr Lys Ser Lys Val Tyr Leu Arg		
545	550	555
Thr Pro Asn Trp Asp Arg Gly Leu Pro Ser Leu Thr Ser Val Ser Trp		
565	570	575
Asn Ile Ser Val Pro Arg Asp Gln Val Ala Cys Leu Thr Phe Phe Lys		
580	585	590
Glu Arg Ser Gly Val Val Cys Gln Thr Gly Arg Ala Phe Met Ile Ile		
595	600	605
Gln Glu Gln Arg Thr Arg Ala Glu Glu Ile Phe Ser Leu Asp Glu Asp		
610	615	620
Val Leu Pro Lys Pro Ser Phe His His His Ser Phe Trp Val Asn Ile		
625	630	635
Xaa Asn Xaa Ser Pro Thr Ser Gly Lys Gln Leu Asp Leu Leu Phe Ser		
645	650	655

Val Thr Leu Thr Pro Arg Thr Val Asp Leu Thr Val Ile Leu Ile Ala
660 665 670

Ala Val Gly Gly Gly Val Leu Leu Ser Ala Leu Gly Leu Ile Ile
675 680 685

Cys Cys Val Lys Lys Lys Lys Xaa Xaa Thr Arg Gly Pro Ala Val Gly
690 695 700

Ile Tyr Asn Gly Asn
705

<210> 130

<211> 415

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (415)

<223> Xaa equals stop translation

<400> 130

Met Thr Lys Ala Arg Leu Phe Arg Leu Trp Leu Val Leu Gly Ser Val
1 5 10 15

Phe Met Ile Leu Leu Ile Ile Val Tyr Trp Asp Ser Ala Gly Ala Ala
20 25 30

His Phe Tyr Leu His Thr Ser Phe Ser Arg Pro His Thr Gly Pro Pro
35 40 45

Leu Pro Thr Pro Gly Pro Asp Arg Asp Arg Glu Leu Thr Ala Asp Ser
50 55 60

Asp Val Asp Glu Phe Leu Asp Lys Phe Leu Ser Ala Gly Val Lys Gln
65 70 75 80

Ser Asp Leu Pro Arg Lys Glu Thr Glu Gln Pro Pro Ala Pro Gly Ser
85 90 95

Met Glu Glu Asn Val Arg Gly Tyr Asp Trp Ser Pro Arg Asp Ala Arg
100 105 110

Arg Ser Pro Asp Gln Gly Arg Gln Gln Ala Glu Arg Arg Ser Val Leu
115 120 125

Arg Gly Phe Cys Ala Asn Ser Ser Leu Ala Phe Pro Thr Lys Glu Arg
130 135 140

Ala Phe Asp Asp Ile Pro Asn Ser Glu Leu Ser His Leu Ile Val Asp
145 150 155 160

Asp Arg His Gly Ala Ile Tyr Cys Tyr Val Pro Lys Val Ala Cys Thr
165 170 175

Asn Trp Lys Arg Val Met Ile Val Leu Ser Gly Ser Leu Leu His Arg
180 185 190

Gly Ala Pro Tyr Arg Asp Pro Leu Arg Ile Pro Arg Glu His Val His
 195 200 205
 Asn Ala Ser Ala His Leu Thr Phe Asn Lys Phe Trp Arg Arg Tyr Gly
 210 215 220
 Lys Leu Ser Arg His Leu Met Lys Val Lys Leu Lys Lys Tyr Thr Lys
 225 230 235 240
 Phe Leu Phe Val Arg Asp Pro Phe Val Arg Leu Ile Ser Ala Phe Arg
 245 250 255
 Ser Lys Phe Glu Leu Glu Asn Glu Glu Phe Tyr Arg Lys Phe Ala Val
 260 265 270
 Pro Met Leu Arg Leu Tyr Ala Asn His Thr Ser Leu Pro Ala Ser Ala
 275 280 285
 Arg Glu Ala Phe Arg Ala Gly Leu Lys Val Ser Phe Ala Asn Phe Ile
 290 295 300
 Gln Tyr Leu Leu Asp Pro His Thr Glu Lys Leu Ala Pro Phe Asn Glu
 305 310 315 320
 His Trp Arg Gln Val Tyr Arg Leu Cys His Pro Cys Gln Ile Asp Tyr
 325 330 335
 Asp Phe Val Gly Lys Leu Glu Thr Leu Asp Glu Asp Ala Ala Gln Leu
 340 345 350
 Leu Gln Leu Leu Gln Val Asp Arg Gln Leu Arg Phe Pro Pro Ser Tyr
 355 360 365
 Arg Asn Arg Thr Ala Ser Ser Trp Glu Glu Asp Trp Phe Ala Lys Ile
 370 375 380
 Pro Leu Ala Trp Arg Gln Gln Leu Tyr Lys Leu Tyr Glu Ala Asp Phe
 385 390 395 400
 Val Leu Phe Gly Tyr Pro Lys Pro Glu Asn Leu Leu Arg Asp Xaa
 405 410 415

<210> 131

<211> 242

<212> PRT

<213> Homo sapiens

<400> 131

Met Gln Leu Gly Ser Val Leu Leu Thr Arg Cys Pro Phe Trp Gly Cys
 1 5 10 15
 Phe Ser Gln Leu Met Leu Tyr Ala Glu Arg Ala Glu Ala Arg Arg Lys
 20 25 30
 Pro Asp Ile Pro Val Pro Tyr Leu Tyr Phe Asp Met Gly Ala Ala Val
 35 40 45

Leu Cys Ala Ser Phe Met Ser Phe Gly Val Lys Arg Arg Trp Phe Ala
 50 55 60
 Leu Gly Ala Ala Leu Gln Leu Ala Ile Ser Thr Tyr Ala Ala Tyr Ile
 65 70 75 80
 Gly Gly Tyr Val His Tyr Gly Asp Trp Leu Lys Val Arg Met Tyr Ser
 85 90 95
 Arg Thr Val Ala Ile Ile Gly Gly Phe Leu Val Leu Ala Ser Gly Ala
 100 105 110
 Gly Glu Leu Tyr Arg Arg Lys Pro Arg Ser Arg Ser Leu Gln Ser Thr
 115 120 125
 Gly Gln Val Phe Leu Gly Ile Tyr Leu Ile Cys Val Ala Tyr Ser Leu
 130 135 140
 Gln His Ser Lys Glu Asp Arg Leu Ala Tyr Leu Asn His Leu Pro Gly
 145 150 155 160
 Gly Glu Leu Met Ile Gln Leu Phe Phe Val Leu Tyr Gly Ile Leu Ala
 165 170 175
 Leu Ala Phe Leu Ser Gly Tyr Tyr Val Thr Leu Ala Ala Gln Ile Leu
 180 185 190
 Ala Val Leu Leu Pro Pro Val Met Leu Leu Ile Asp Gly Asn Val Ala
 195 200 205
 Tyr Trp His Asn Thr Arg Arg Val Glu Phe Trp Asn Gln Met Lys Leu
 210 215 220
 Leu Gly Glu Ser Val Gly Ile Phe Gly Thr Ala Val Ile Leu Ala Thr
 225 230 235 240
 Asp Gly

<210> 132
 <211> 313
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (313)
 <223> Xaa equals stop translation

<400> 132
 Met Glu Ser Leu Tyr Asp Leu Trp Glu Phe Tyr Leu Pro Tyr Leu Tyr
 1 5 10 15
 Ser Cys Ile Ser Leu Met Gly Cys Leu Leu Leu Leu Cys Thr Pro
 20 25 30
 Val Gly Leu Ser Arg Met Phe Thr Val Met Gly His Leu Leu Val Lys
 35 40 45

Pro Thr Ile Leu Glu Asp Leu Asp Glu Gln Ile Tyr Ile Ile Thr Leu
 50 55 60
 Glu Glu Glu Ala Leu Gln Arg Arg Leu Asn Gly Leu Ser Ser Ser Val
 65 70 75 80
 Glu Tyr Asn Ile Met Glu Leu Glu Gln Glu Leu Glu Asn Val Lys Thr
 85 90 95
 Leu Lys Thr Lys Leu Glu Arg Arg Lys Lys Ala Ser Ala Trp Glu Arg
 100 105 110
 Asn Leu Val Tyr Pro Ala Val Met Val Leu Leu Leu Ile Glu Thr Ser
 115 120 125
 Ile Ser Val Leu Leu Val Ala Cys Asn Ile Leu Cys Leu Leu Val Asp
 130 135 140
 Glu Thr Ala Met Pro Lys Gly Thr Arg Gly Pro Gly Ile Gly Asn Ala
 145 150 155 160
 Ser Leu Ser Thr Phe Gly Phe Val Gly Ala Ala Leu Glu Ile Ile Leu
 165 170 175
 Ile Phe Tyr Leu Met Val Ser Ser Val Val Gly Phe Tyr Ser Leu Arg
 180 185 190
 Phe Phe Gly Asn Phe Thr Pro Lys Lys Asp Asp Thr Thr Met Thr Lys
 195 200 205
 Ile Ile Gly Asn Cys Val Ser Ile Leu Val Leu Ser Ser Ala Leu Pro
 210 215 220
 Val Met Ser Arg Thr Leu Gly Ile Thr Arg Phe Asp Leu Leu Gly Asp
 225 230 235 240
 Phe Gly Arg Phe Asn Trp Leu Gly Asn Phe Tyr Ile Val Leu Ser Tyr
 245 250 255
 Asn Leu Leu Phe Ala Ile Val Thr Thr Leu Cys Leu Val Arg Lys Phe
 260 265 270
 Thr Ser Ala Val Arg Glu Glu Leu Phe Lys Ala Leu Gly Leu His Lys
 275 280 285
 Leu His Leu Pro Asn Thr Ser Arg Asp Ser Glu Thr Ala Lys Pro Ser
 290 295 300
 Val Asn Gly His Gln Lys Ala Leu Xaa
 305 310

<210> 133
 <211> 183
 <212> PRT
 <213> Homo sapiens

<220>

<221> SITE

<222> (183)

<223> Xaa equals stop translation

<400> 133

Met Met Val Cys Ser Ile Met Met Tyr Phe Leu Leu Gly Ile Thr Leu
 1 5 10 15

Leu Arg Ser Tyr Met Gln Ser Val Trp Thr Glu Glu Ser Gln Cys Thr
 20 25 30

Leu Leu Asn Ala Ser Ile Thr Glu Thr Phe Asn Cys Ser Phe Ser Cys
 35 40 45

Gly Pro Asp Cys Trp Lys Leu Ser Gln Tyr Pro Cys Leu Gln Val Tyr
 50 55 60

Val Asn Leu Thr Ser Ser Gly Glu Lys Leu Leu Leu Tyr His Thr Glu
 65 70 75 80

Glu Thr Ile Lys Ile Asn Gln Lys Cys Ser Tyr Ile Pro Lys Cys Gly
 85 90 95

Lys Asn Phe Glu Glu Ser Met Ser Leu Val Asn Val Val Met Glu Asn
 100 105 110

Phe Arg Lys Tyr Gln His Phe Ser Cys Tyr Ser Asp Pro Glu Gly Asn
 115 120 125

Gln Lys Ser Val Ile Leu Thr Lys Leu Tyr Ser Ser Asn Val Leu Phe
 130 135 140

His Ser Leu Phe Trp Pro Thr Cys Met Met Ala Gly Gly Val Ala Ile
 145 150 155 160

Val Ala Met Val Lys Leu Thr Gln Tyr Leu Ser Leu Leu Cys Glu Arg
 165 170 175

Ile Gln Arg Ile Asn Arg Xaa
 180

<210> 134

<211> 147

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (147)

<223> Xaa equals stop translation

<400> 134

Met Trp Lys Leu Trp Arg Ala Glu Glu Gly Ala Ala Ala Leu Gly Gly
 1 5 10 15

Ala Leu Phe Leu Leu Leu Phe Ala Leu Gly Val Arg Gln Leu Leu Lys
 20 25 30

Gln Arg Arg Pro Met Gly Phe Pro Pro Gly Pro Pro Gly Leu Pro Phe
 35 40 45
 Ile Gly Asn Ile Tyr Ser Leu Ala Ala Ser Ser Glu Leu Pro His Val
 50 55 60
 Tyr Met Arg Lys Gln Ser Gln Val Tyr Gly Glu Val Gln Pro Arg Arg
 65 70 75 80
 Ala Pro Gly Arg Glu Gly Arg Gln Ala Gly Pro Gly Trp Pro Gly Pro
 85 90 95
 Ser Trp Leu Asp Leu Trp Pro Pro Leu Gly Arg Leu Val Gly Thr Ser
 100 105 110
 Pro Cys Ala Gly Cys Pro Leu Arg Asp Thr Arg Phe Pro Gly Leu Glu
 115 120 125
 Gly Arg Ser Pro Arg Arg Arg Ala Pro Leu Gln Gly Glu Pro Arg Pro
 130 135 140
 Cys Arg Xaa
 145

<210> 135
 <211> 122
 <212> PRT
 <213> Homo sapiens

<400> 135
 Met Arg Val Arg Ile Gly Leu Thr Leu Leu Leu Cys Ala Val Leu Leu
 1 5 10 15
 Ser Leu Ala Ser Ala Ser Ser Asp Glu Glu Gly Ser Gln Asp Glu Ser
 20 25 30
 Leu Asp Ser Lys Thr Thr Leu Thr Ser Asp Glu Ser Val Lys Asp His
 35 40 45
 Thr Thr Ala Gly Arg Val Val Ala Gly Gln Ile Phe Leu Asp Ser Glu
 50 55 60
 Glu Ser Glu Leu Glu Ser Ser Ile Gln Glu Glu Glu Asp Ser Leu Lys
 65 70 75 80
 Ser Gln Glu Gly Glu Ser Val Thr Glu Asp Ile Ser Phe Leu Glu Ser
 85 90 95
 Pro Asn Pro Glu Asn Lys Asp Tyr Glu Glu Pro Lys Lys Val Arg Lys
 100 105 110
 Pro Gly Ser Leu Asp Ile Phe Leu Ala Phe
 115 120

<210> 136
 <211> 112
 <212> PRT

<213> Homo sapiens

<400> 136

Met Ala Arg Gly Ser Leu Arg Arg Leu Leu Arg Leu Leu Val Leu Gly
1 5 10 15
Leu Trp Leu Ala Leu Leu Arg Ser Val Ala Gly Glu Gln Ala Pro Gly
20 25 30
Thr Ala Pro Cys Ser Arg Gly Ser Ser Trp Ser Ala Asp Leu Asp Lys
35 40 45
Cys Met Asp Cys Ser Thr Ser Cys Pro Leu Pro Ala Ala Leu Ala His
50 55 60
Pro Trp Gly Arg Ser Glu Pro Asp Leu Arg Ala Gly Ala Ala Phe Trp
65 70 75 80
Leu Phe Gly Leu Glu Thr Met Pro Gln Arg Glu Lys Phe Thr Thr Pro
85 90 95
Ile Glu Glu Thr Gly Gly Glu Gly Cys Pro Ala Val Ala Leu Ile Gln
100 105 110

<210> 137

<211> 140

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (140)

<223> Xaa equals stop translation

<400> 137

Met Leu Leu Gly Pro Val Pro Ile Leu His Ile Lys Ser Gln Leu Trp
1 5 10 15
Leu Leu Val Leu Ile Leu Val Val Ser Gly Leu Ser Ala Gly Met Ser
20 25 30
Ile Ile Pro Thr Phe Pro Glu Ile Leu Ser Cys Ala His Glu Asn Gly
35 40 45
Phe Glu Glu Gly Leu Ser Thr Leu Gly Leu Val Ser Gly Leu Phe Ser
50 55 60
Ala Met Trp Ser Ile Gly Ala Phe Met Gly Pro Thr Leu Gly Gly Phe
65 70 75 80
Leu Tyr Glu Lys Ile Gly Phe Glu Trp Ala Ala Ala Ile Gln Gly Leu
85 90 95
Trp Ala Leu Ile Ser Gly Leu Ala Met Gly Leu Phe Tyr Leu Leu Glu
100 105 110

Tyr Ser Arg Arg Lys Arg Ser Lys Ser Gln Asn Ile Leu Ser Thr Glu
 115 120 125

Glu Glu Arg Thr Thr Leu Leu Pro Asn Glu Thr Xaa
 130 135 140

<210> 138
 <211> 404
 <212> PRT
 <213> Homo sapiens

<400> 138
 Met Arg Leu Gln Asp Val Tyr Met Leu Asn Val Lys Gly Leu Ala Arg
 1 5 10 15

Gly Val Phe Gln Arg Val Thr Gly Ser Ala Ile Thr Asp Leu Tyr Ser
 20 25 30

Pro Lys Arg Leu Phe Ser Leu Thr Gly Asp Asp Cys Phe Gln Val Gly
 35 40 45

Lys Val Ala Tyr Asp Met Gly Asp Tyr Tyr His Ala Ile Pro Trp Leu
 50 55 60

Glu Glu Ala Val Ser Leu Phe Arg Gly Ser Tyr Gly Glu Trp Lys Thr
 65 70 75 80

Glu Asp Glu Ala Ser Leu Glu Asp Ala Leu Asp His Leu Ala Phe Ala
 85 90 95

Tyr Phe Arg Ala Gly Asn Val Ser Cys Ala Leu Ser Leu Ser Arg Glu
 100 105 110

Phe Leu Leu Tyr Ser Pro Asp Asn Lys Arg Met Ala Arg Asn Val Leu
 115 120 125

Lys Tyr Glu Arg Leu Leu Ala Glu Ser Pro Asn His Val Val Ala Glu
 130 135 140

Ala Val Ile Gln Arg Pro Asn Ile Pro His Leu Gln Thr Arg Asp Thr
 145 150 155 160

Tyr Glu Gly Leu Cys Gln Thr Leu Gly Ser Gln Pro Thr Leu Tyr Gln
 165 170 175

Ile Pro Ser Leu Tyr Cys Ser Tyr Glu Thr Asn Ser Asn Ala Tyr Leu
 180 185 190

Leu Leu Gln Pro Ile Arg Lys Glu Val Ile His Leu Glu Pro Tyr Ile
 195 200 205

Ala Leu Tyr His Asp Phe Val Ser Asp Ser Glu Ala Gln Lys Ile Arg
 210 215 220

Glu Leu Ala Glu Pro Trp Leu Gln Arg Ser Val Val Ala Ser Gly Glu
 225 230 235 240

Lys Gln Leu Gln Val Glu Tyr Arg Ile Ser Lys Ser Ala Trp Leu Lys
 245 250 255
 Asp Thr Val Asp Leu Lys Leu Val Thr Leu Asn His Arg Ile Ala Ala
 260 265 270
 Leu Thr Gly Leu Asp Val Arg Pro Pro Tyr Ala Glu Tyr Leu Gln Val
 275 280 285
 Val Asn Tyr Gly Ile Gly Gly His Tyr Glu Pro His Phe Asp His Ala
 290 295 300
 Thr Ser Pro Ser Ser Pro Leu Tyr Arg Met Lys Ser Gly Asn Arg Val
 305 310 315 320
 Ala Thr Phe Met Ile Tyr Leu Ser Ser Val Glu Ala Gly Gly Ala Thr
 325 330 335
 Ala Phe Ile Tyr Ala Asn Leu Ser Val Pro Val Val Arg Asn Ala Ala
 340 345 350
 Leu Phe Trp Trp Asn Leu His Arg Ser Gly Glu Gly Asp Ser Asp Thr
 355 360 365
 Leu His Ala Gly Cys Pro Val Leu Val Gly Asp Lys Trp Val Ala Asn
 370 375 380
 Lys Trp Ile His Glu Tyr Gly Gln Glu Phe Arg Arg Pro Cys Ser Ser
 385 390 395 400
 Ser Pro Glu Asp

<210> 139

<211> 96

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (96)

<223> Xaa equals stop translation

<400> 139

Met	Lys	Ala	Pro	His	Thr	Gly	Val	Leu	His	Leu	Gly	Ser	Val	Trp	Val
1				5					10					15	
Phe	Leu	Gly	Pro	Phe	Leu	Leu	Gly	Val	Gly	Tyr	Thr	Leu	Thr	Phe	Asn
			20					25					30		
Pro	Leu	Ser	Gly	Cys	Met	Ser	Thr	Val	Arg	Trp	Leu	Asn	Ser	Asn	Ile
		35					40					45			
Thr	Ala	Asn	Arg	Thr	Leu	Ser	Arg	Ser	Val	Cys	His	Val	Thr	Pro	Leu
	50					55					60				
His	Arg	Ser	Leu	Ser	Pro	His	Asp	Gly	Glu	Tyr	Leu	Arg	Gln	Met	Leu
65					70					75					80

Leu Asn Ser Ser Ser Arg Ala Gly Glu Ala Gly Ser Trp Gly Tyr Xaa
 85 90 95

<210> 140
 <211> 240
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (240)
 <223> Xaa equals stop translation

<400> 140
 Met Gly Ser Cys Ala Arg Leu Leu Leu Trp Gly Cys Thr Val Val
 1 5 10 15
 Ala Ala Gly Leu Ser Gly Val Ala Gly Val Ser Ser Arg Cys Glu Lys
 20 25 30
 Ala Cys Asn Pro Arg Met Gly Asn Leu Ala Leu Gly Arg Lys Leu Trp
 35 40 45
 Ala Asp Thr Thr Cys Gly Gln Asn Ala Thr Glu Leu Tyr Cys Phe Tyr
 50 55 60
 Ser Glu Asn Thr Asp Leu Thr Cys Arg Gln Pro Lys Cys Asp Lys Cys
 65 70 75 80
 Asn Ala Ala Tyr Pro His Leu Ala His Leu Pro Ser Ala Met Ala Asp
 85 90 95
 Ser Ser Phe Arg Phe Pro Arg Thr Trp Trp Gln Ser Ala Glu Asp Val
 100 105 110
 His Arg Glu Lys Ile Gln Leu Asp Leu Glu Ala Glu Phe Tyr Phe Thr
 115 120 125
 His Leu Ile Val Met Phe Lys Ser Pro Arg Pro Ala Ala Met Val Leu
 130 135 140
 Asp Arg Ser Gln Asp Phe Gly Lys Thr Trp Lys Pro Tyr Lys Tyr Phe
 145 150 155 160
 Ala Thr Asn Cys Ser Ala Thr Phe Gly Leu Glu Asp Asp Val Val Lys
 165 170 175
 Lys Gly Ala Ile Cys Thr Ser Lys Tyr Ser Ser Pro Phe Pro Cys Thr
 180 185 190
 Gly Arg Lys Val Ile Phe Lys Ala Leu Ser Pro Pro Tyr Asp Thr Glu
 195 200 205
 Asn Pro Tyr Ser Ala Lys Val Gln Glu Gln Leu Lys Ile Thr Asn Leu

210 215 220
Pro Arg Ala Ala Ala Glu Thr Thr Val Leu Ser Leu Ser Glu Lys Xaa
225 230 235 240

<210> 141
<211> 54
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (54)
<223> Xaa equals stop translation

<400> 141
Met Met Ile Ser Gly Leu Lys Leu Leu Val Leu Phe Leu Lys Phe Ala
1 5 10 15
Pro Glu Asn Tyr Cys Leu Ser Thr Glu Thr Leu Gln Met Pro Asn Arg
20 25 30
His Leu Arg Leu Ser Lys Ala Thr Cys Tyr Leu Met Lys Cys Leu Leu
35 40 45
Pro Ser Tyr Phe Glu Xaa
50

<210> 142
<211> 67
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (67)
<223> Xaa equals stop translation

<400> 142
Met Arg Ser Leu Ile Ser Ser His Pro Cys Gln His Leu Leu Leu Leu
1 5 10 15
Leu Leu Leu Leu Phe Leu Ile Leu Ala Ile Leu Val Asp Val Lys Trp
20 25 30
Tyr Leu Val Leu Phe Ile Cys Ile Ser Leu Met Thr Ser Asp Val Glu
35 40 45
His Leu Phe Met Cys Leu Leu Ala Ile Arg Ile Ser Ser Trp Arg Asn
50 55 60
Val Tyr Xaa
65

<210> 143
<211> 108
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (48)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (58)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (67)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 143
Met Phe Tyr Lys Leu Thr Leu Ile Leu Cys Glu Leu Ser Val Ala Gly
1 5 10 15
Val Thr Gln Ala Ala Ser Gln Arg Pro Leu Gln Arg Leu Pro Arg His
20 25 30
Ile Cys Ser Gln Arg Asn Pro Pro Gly Arg Cys Leu Leu Lys Ala Xaa
35 40 45
Leu Gln Thr Thr Trp Gly Xaa Pro Asp Xaa Gln Phe Pro Gly Cys Pro
50 55 60
His Pro Xaa Arg Val Thr Leu Asn Ala Arg Gln Met Gly Asn Gly Lys
65 70 75 80
Glu Lys Lys Ala Ala Asp Leu Lys Leu Lys Phe Pro Gln Lys Arg Phe
85 90 95
Tyr Leu Ser Ala Phe Ser Glu Arg Ile Lys Ala Phe
100 105

<210> 144
<211> 84
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (84)
<223> Xaa equals stop translation

<400> 144

Met Ala Ser Val Gly Thr Thr Leu Val Ser Pro Leu Leu Cys Leu Leu
 1 5 10 15
 Ile Pro Thr Arg Val Ser Asp Pro Trp Leu Gln Asn Thr Pro Leu His
 20 25 30
 Pro Trp Lys Thr Ile Thr Ile Ile Asp Tyr Tyr Leu Ser Leu Gly Phe
 35 40 45
 Leu Gly Trp Thr Gly Leu Ser Trp Val Val His Phe Gly Ala Ser Ala
 50 55 60
 Val Met Gly Arg Gln Trp Leu Gly Ser Leu Gln Arg Leu Pro Cys Ile
 65 70 75 80
 Ser Gly Ser Xaa

<210> 145

<211> 166

<212> PRT

<213> Homo sapiens

<400> 145

Met Gly Ser Arg Phe Leu Leu Val Leu Leu Ser Gly Leu Thr Val Leu
 1 5 10 15
 Leu Ala Leu Pro Gly Ser Glu Ala Lys Asn Ser Gly Ala Ser Cys Pro
 20 25 30
 Pro Cys Pro Lys Tyr Ala Ser Cys His Asn Ser Thr His Cys Thr Cys
 35 40 45
 Glu Asp Gly Phe Arg Ala Arg Ser Gly Arg Thr Tyr Phe His Asp Ser
 50 55 60
 Ser Glu Lys Cys Glu Asp Ile Asn Glu Cys Glu Thr Gly Leu Ala Lys
 65 70 75 80
 Cys Lys Tyr Lys Ala Tyr Cys Arg Asn Lys Val Gly Gly Tyr Ile Cys
 85 90 95
 Ser Cys Leu Val Lys Tyr Thr Leu Phe Asn Phe Leu Ala Gly Ile Ile
 100 105 110
 Asp Tyr Asp His Pro Asp Cys Tyr Glu Asn Asn Ser Gln Gly Thr Thr
 115 120 125
 Gln Ser Asn Val Asp Ile Trp Val Ser Gly Val Lys Pro Gly Phe Gly
 130 135 140
 Lys Gln Leu Val Arg Ile Thr Met Pro Phe Ser Tyr Pro Asn Ile Asn
 145 150 155 160
 Met Ser Ser Cys Asp Phe
 165

<210> 146
 <211> 70
 <212> PRT
 <213> Homo sapiens

<400> 146
 Met Lys Pro Lys His Leu Glu Trp Cys Leu Ala His Ser Trp Cys Val
 1 5 10 15
 Ile Trp Leu Ser Phe Val Ser Pro Pro Thr Ser His Leu Glu Cys Asp
 20 25 30
 Gly Phe Pro Gly Ser Leu Leu Pro Pro Cys Glu Glu Gly Arg Cys Phe
 35 40 45
 Pro Phe Thr Phe His His His Asp Cys His Gly Cys Ser Pro Leu Gln
 50 55 60
 Ser Ser Pro Gly Gln His
 65 70

<210> 147
 <211> 412
 <212> PRT
 <213> Homo sapiens

<400> 147
 Met Cys Cys Trp Pro Leu Leu Leu Leu Trp Gly Leu Leu Pro Gly Thr
 1 5 10 15
 Ala Ala Gly Gly Ser Gly Arg Thr Tyr Pro His Arg Thr Leu Leu Asp
 20 25 30
 Ser Glu Gly Lys Tyr Trp Leu Gly Trp Ser Gln Arg Gly Ser Gln Ile
 35 40 45
 Ala Phe Arg Leu Gln Val Arg Thr Ala Gly Tyr Val Gly Phe Gly Phe
 50 55 60
 Ser Pro Thr Gly Ala Met Ala Ser Ala Asp Ile Val Val Gly Gly Val
 65 70 75 80
 Ala His Gly Arg Pro Tyr Leu Gln Asp Tyr Phe Thr Asn Ala Asn Arg
 85 90 95
 Glu Leu Lys Lys Asp Ala Gln Gln Asp Tyr His Leu Glu Tyr Ala Met
 100 105 110
 Glu Asn Ser Thr His Thr Ile Ile Glu Phe Thr Arg Glu Leu His Thr
 115 120 125
 Cys Asp Ile Asn Asp Lys Ser Ile Thr Asp Ser Thr Val Arg Val Ile
 130 135 140
 Trp Ala Tyr His His Glu Asp Ala Gly Glu Ala Gly Pro Lys Tyr His
 145 150 155 160

Asp Ser Asn Arg Gly Thr Lys Ser Leu Arg Leu Leu Asn Pro Glu Lys
 165 170 175
 Thr Ser Val Leu Ser Thr Ala Leu Pro Tyr Phe Asp Leu Val Asn Gln
 180 185 190
 Asp Val Pro Ile Pro Asn Lys Asp Thr Thr Tyr Trp Cys Gln Met Phe
 195 200 205
 Lys Ile Pro Val Phe Gln Glu Lys His His Val Ile Lys Val Glu Pro
 210 215 220
 Val Ile Gln Arg Gly His Glu Ser Leu Val His His Ile Leu Leu Tyr
 225 230 235 240
 Gln Cys Ser Asn Asn Phe Asn Asp Ser Val Leu Glu Ser Gly His Glu
 245 250 255
 Cys Tyr His Pro Asn Met Pro Asp Ala Phe Leu Thr Cys Glu Thr Val
 260 265 270
 Ile Phe Ala Trp Ala Ile Gly Gly Glu Gly Phe Ser Tyr Pro Pro His
 275 280 285
 Val Gly Leu Ser Leu Gly Thr Pro Leu Asp Pro His Tyr Val Leu Leu
 290 295 300
 Glu Val His Tyr Asp Asn Pro Thr Tyr Glu Glu Gly Leu Ile Asp Asn
 305 310 315 320
 Ser Gly Leu Arg Leu Phe Tyr Thr Met Asp Ile Arg Lys Tyr Asp Ala
 325 330 335
 Gly Val Ile Glu Ala Gly Leu Trp Val Ser Leu Phe His Thr Ile Pro
 340 345 350
 Pro Gly Met Pro Glu Phe Gln Ser Glu Gly His Cys Thr Leu Glu Cys
 355 360 365
 Leu Glu Glu Leu Trp Lys Pro Lys Ser Gln Val Glu Phe Met Cys Leu
 370 375 380
 Leu Phe Phe Ser Met Leu Thr Trp Leu Ala Glu His Gln Ala Ala Ser
 385 390 395 400
 Phe Ser Lys Arg Glu Gly Asn Glu Ile Thr Cys Leu
 405 410

<210> 148

<211> 85

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (85)

<223> Xaa equals stop translation

<400> 148

```

Met Asn Val Phe Leu Pro Pro Ala Leu Gly Thr Trp Gly Val Ala Arg
  1           5           10           15
Phe Phe Pro His Leu Val Pro Glu Arg Trp Cys Leu Val Phe Cys Cys
      20           25           30
Trp Ile Phe Phe Phe Phe Phe Phe Cys Thr Lys Val Ala Thr Arg
      35           40           45
Ser Val Leu Gly Asp Gln Ala Gly Leu Gly Val Gly Gly Pro His Leu
      50           55           60
Pro Leu Pro Gly Ser His Ser Val Ser Val Pro Glu Lys Thr Ile Phe
      65           70           75           80
Ser Leu Lys Gln Xaa
      85

```

<210> 149

<211> 154

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (154)

<223> Xaa equals stop translation

<400> 149

```

Met Gly Arg Leu Pro Leu Leu Arg Arg Val Leu Lys Gly Leu Gln Leu
  1           5           10           15
Leu Leu Ser Leu Leu Ala Phe Ile Cys Glu Glu Val Val Ser Gln Cys
      20           25           30
Thr Leu Cys Gly Gly Leu Tyr Phe Phe Glu Phe Val Ser Cys Ser Ala
      35           40           45
Phe Leu Leu Ser Leu Leu Ile Leu Ile Val Tyr Cys Thr Pro Phe Tyr
      50           55           60
Glu Arg Val Asp Thr Thr Lys Val Lys Ser Ser Asp Phe Tyr Ile Thr
      65           70           75           80
Leu Gly Thr Gly Cys Val Phe Leu Leu Ala Ser Ile Ile Phe Val Ser
      85           90           95
Thr His Asp Arg Thr Ser Ala Glu Ile Ala Ala Ile Val Phe Gly Phe
      100          105          110
Ile Ala Ser Phe Met Phe Leu Leu Asp Phe Ile Thr Met Leu Tyr Glu
      115          120          125
Lys Arg Gln Glu Ser Gln Leu Arg Lys Pro Glu Asn Thr Thr Arg Ala
      130          135          140
Glu Ala Leu Thr Glu Pro Leu Asn Ala Xaa

```

145

150

<210> 150
 <211> 130
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (130)
 <223> Xaa equals stop translation

<400> 150

Met Arg Gly His Leu Ala Gly Phe Pro Ala Leu Ser Gly Leu Ala Ser
 1 5 10 15
 Val Cys Leu Trp Ala Thr Phe Ser Ala Gln Leu Pro Gly Pro Val Ala
 20 25 30
 Ala Thr Ser Trp Thr Pro Ala Pro Leu Gly Cys Ser Ala Ala Arg Ser
 35 40 45
 Gly Pro Glu Lys Arg Leu Gly Thr Ala Ala Pro Gly Ser Ala Ala Ser
 50 55 60
 Leu Ala Gln Ala Gly Pro Gly Ala Pro Cys Arg Val Leu Pro Val Asp
 65 70 75 80
 Pro Ala Pro Ala Ala Leu Asn Val Arg Glu Pro Gly Trp Leu Gly Gly
 85 90 95
 Leu Phe Asp Gly Ala Leu Leu Gln Val Leu Leu Asn Phe Leu Arg Lys
 100 105 110
 Ser Thr Asp Val Leu Met Asp Thr Arg Glu Ala Glu Ser Leu Glu Val
 115 120 125
 Glu Xaa
 130

<210> 151
 <211> 62
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (62)
 <223> Xaa equals stop translation

<400> 151

Met Leu Phe Trp Ala Tyr Pro Ile Cys Val Phe Ile Asp Ser Leu Ser
 1 5 10 15
 Cys Gln Pro Cys Leu Trp Ser Thr Gly Ala Thr Ser His Phe Asn Ser
 20 25 30

Pro Thr Thr Ser Pro Leu Phe Thr Leu Phe Met Pro Cys Ala Leu Ala
 35 40 45
 Pro Asn Pro Phe Thr Gln Leu Gly Lys Leu Asp Asp Arg Xaa
 50 55 60

<210> 152
 <211> 225
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (225)
 <223> Xaa equals stop translation

<400> 152
 Met Gly Ile Phe Pro Gly Ile Ile Leu Ile Phe Leu Arg Val Lys Phe
 1 5 10 15
 Ala Thr Ala Ala Val Ile Val Ser Gly His Gln Lys Ser Thr Thr Val
 20 25 30
 Ser His Glu Met Ser Gly Leu Asn Trp Lys Pro Phe Val Tyr Gly Gly
 35 40 45
 Leu Ala Ser Ile Val Ala Glu Phe Gly Thr Phe Pro Val Asp Leu Thr
 50 55 60
 Lys Thr Arg Leu Gln Val Gln Gly Gln Ser Ile Asp Ala Arg Phe Lys
 65 70 75 80
 Glu Ile Lys Tyr Arg Gly Met Phe His Ala Leu Phe Arg Ile Cys Lys
 85 90 95
 Glu Glu Gly Val Leu Ala Leu Tyr Ser Gly Ile Ala Pro Ala Leu Leu
 100 105 110
 Arg Gln Ala Ser Tyr Gly Thr Ile Lys Ile Gly Ile Tyr Gln Ser Leu
 115 120 125
 Lys Arg Leu Phe Val Glu Arg Leu Glu Asp Glu Thr Leu Leu Ile Asn
 130 135 140
 Met Ile Cys Gly Val Val Ser Gly Val Ile Ser Ser Thr Ile Ala Asn
 145 150 155 160
 Pro Thr Asp Val Leu Lys Ile Arg Met Gln Ala Gln Gly Ser Leu Phe
 165 170 175
 Gln Gly Ser Met Ile Gly Ser Phe Ile Asp Ile Tyr Gln Gln Glu Gly
 180 185 190
 Thr Arg Gly Leu Trp Arg Val Ser Thr Leu Phe Leu Leu Leu Ser Tyr
 195 200 205
 Thr Leu Ser Ser Tyr Asn Leu Gln Arg Ile Phe Phe Tyr Ile Lys Thr
 210 215 220

Xaa
225

<210> 153
<211> 69
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (69)
<223> Xaa equals stop translation

<400> 153
Met Leu Met Leu Leu Thr Leu Leu Val Leu Gly Met Val Trp Val Ala
1 5 10 15
Ser Ala Ile Val Asp Lys Asn Lys Ala Asn Arg Glu Ser Leu Tyr Asp
20 25 30
Phe Trp Glu Tyr Tyr Leu Pro Tyr Leu Tyr Ser Cys Ile Ser Phe Leu
35 40 45
Gly Val Leu Leu Leu Leu Ala Ala Gly Arg Pro Gly Gly Ala Ala Val
50 55 60
Leu Leu Ser Leu Xaa
65

<210> 154
<211> 84
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (84)
<223> Xaa equals stop translation

<400> 154
Met Tyr Gly Val Cys Leu Cys Val Ile Val Cys Val Ser Gly Val Ser
1 5 10 15
Leu Cys Leu Tyr Val Trp Gly Val Ser Val Cys Asp Cys Val Ser Val
20 25 30
Phe Met Cys Val Cys Leu Cys Val Ile Phe Cys Val Tyr Gly Lys Pro
35 40 45
Arg Thr Glu His Tyr His Ser Pro His Leu Ala Lys Gln Lys Ala Phe
50 55 60
Arg Glu Met Cys Gly Arg His Asp Val Ser Ala Ala Gly Ile Phe Gln
65 70 75 80
Ser Tyr Val Xaa

<210> 155
<211> 61
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (61)
<223> Xaa equals stop translation

<400> 155
Met His Val Leu Leu Phe Ser Phe Leu Ile Pro Phe Leu Leu Leu Ser
1 5 10 15
Pro Val Gly Val Thr Cys Asn Ser His Met Leu Glu Arg Gln Val Ser
20 25 30
Trp Leu Lys Lys Arg Ser Thr Gln Ala Ser Gln Gln Phe Asn Lys Phe
35 40 45
Leu Arg Gly Ile Ser Asn Val Gly Arg Ile Val Ile Xaa
50 55 60

<210> 156
<211> 84
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (84)
<223> Xaa equals stop translation

<400> 156
Met Cys Leu Leu Val Glu Tyr Ser Leu Met Ile Leu Thr Ile Ile Pro
1 5 10 15
Ser Leu Leu Ser Phe Val Leu Cys Leu Lys Gly Ile Lys His Gly Asn
20 25 30
Tyr Ile Phe Gln Thr Pro Leu Pro Glu Gly Tyr Gly Trp Ile Ser Ala
35 40 45
Met Ser Gly Leu Cys Ile Lys Phe Gly Arg Arg Lys Arg Arg Lys Thr
50 55 60
Trp Leu Leu Gln Val Gly Thr Leu Ala Thr Ile Asp Thr Glu Phe Ala
65 70 75 80
Arg Ser Cys Xaa

<210> 157
<211> 162

<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (162)
<223> Xaa equals stop translation

<400> 157
Met Ala Leu Ser Leu Thr Leu Cys Phe Val Met Phe Trp Thr Pro Asn
1 5 10 15
Val Ser Glu Lys Ile Leu Ile Asp Ile Ile Gly Val Asp Phe Ala Phe
20 25 30
Ala Glu Leu Cys Val Val Pro Leu Arg Ile Phe Ser Phe Phe Pro Val
35 40 45
Pro Val Thr Val Arg Ala His Leu Thr Gly Trp Leu Met Thr Leu Lys
50 55 60
Lys Thr Phe Val Leu Ala Pro Ser Ser Val Leu Arg Ile Ile Val Leu
65 70 75 80
Ile Ala Ser Leu Val Val Leu Pro Tyr Leu Gly Val His Gly Ala Thr
85 90 95
Leu Gly Val Gly Ser Leu Leu Ala Gly Phe Val Gly Glu Ser Thr Met
100 105 110
Val Ala Ile Ala Ala Cys Tyr Val Tyr Arg Lys Gln Lys Lys Met
115 120 125
Glu Asn Glu Ser Ala Thr Glu Gly Glu Asp Ser Ala Met Thr Asp Met
130 135 140
Pro Pro Thr Glu Glu Val Thr Asp Ile Val Glu Met Arg Glu Glu Asn
145 150 155 160
Glu Xaa

<210> 158
<211> 146
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (96)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (107)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE
 <222> (111)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (115)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (122)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (132)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 158
 Met Glu Pro Gln Leu Gly Pro Glu Ala Ala Ala Leu Arg Pro Gly Trp
 1 5 10 15
 Leu Ala Leu Leu Leu Trp Val Ser Ala Leu Ser Cys Ser Phe Ser Leu
 20 25 30
 Pro Ala Ser Ser Leu Ser Ser Leu Val Pro Gln Val Arg Thr Ser Tyr
 35 40 45
 Asn Phe Gly Arg Thr Phe Leu Gly Leu Asp Lys Cys Asn Ala Cys Ile
 50 55 60
 Gly Thr Ser Ile Cys Lys Lys Phe Phe Lys Glu Glu Ile Arg Ser Asp
 65 70 75 80
 Asn Trp Leu Ala Ser His Leu Gly Thr Ala Ser Arg Phe Pro Leu Xaa
 85 90 95
 Ser Tyr Pro Cys Lys Leu Leu Gln Met Ile Xaa Lys Ile Trp Xaa Pro
 100 105 110
 Cys Gly Xaa Leu Leu Thr Gly Gln Gln Xaa Ser Asn Glu Ile Ser Lys
 115 120 125
 Gln Glu Ile Xaa Cys Leu Leu His Pro Pro Pro Lys Asn Leu His Ile
 130 135 140
 Asp Val
 145

<210> 159
 <211> 143
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (143)

<223> Xaa equals stop translation

<400> 159

```

Met Trp Trp Ala Val Met Gly Gly Val Ile Gly Ser Trp Leu Ser Pro
 1           5           10           15

Leu Ser Ile Ala Glu Cys Cys His Asp Leu Trp Thr Ser Gln Ser Cys
      20           25           30

Glu His Ala Gly Ala Leu Cys Gly Asp Leu Leu Cys Ala Cys Arg Lys
      35           40           45

Val Gly Val Trp Cys Ala Leu Gln Gln His Trp Trp Asn Arg Cys Val
      50           55           60

Cys Pro His Ala Val Ile Arg Val His Cys Thr Gly Ala Ser Tyr Thr
      65           70           75           80

Leu Gln Lys Ile Cys Ser Cys Asn Pro Lys Phe Met Gly Arg His Pro
      85           90           95

His Arg Trp Gln Gln Ile Arg Lys Cys Ser Gln Pro Val Leu Arg Gly
      100          105          110

Ser Arg Ala Ala Phe Ile Trp Val Arg Leu Ala Ala Leu Asn Phe Ile
      115          120          125

Ser Ser Phe Arg Cys Ile Ser Leu Ile Ser Tyr Ser Ala Phe Xaa
      130          135          140

```

<210> 160

<211> 51

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (51)

<223> Xaa equals stop translation

<400> 160

```

Met Lys Val Ser Asp Phe Asn Phe Leu Ile Phe Leu Ile Phe Ala Leu
 1           5           10           15

Phe Leu Thr Leu Glu Ala Phe Leu Lys Phe Thr Lys Arg Val Leu Ala
      20           25           30

Val Val Gly Asn Leu Pro Glu Pro Pro Ile Ile Lys Thr Ile Gly Phe
      35           40           45

Leu Tyr Xaa
      50

```

<210> 161

<211> 65

<212> PRT

<213> Homo sapiens

<220>
 <221> SITE
 <222> (65)
 <223> Xaa equals stop translation

 <400> 161
 Met Val Trp Ser Ala Ala Pro Ala Pro Cys Cys Leu Leu Gly Val Leu
 1 5 10 15
 Gly Leu Val Gln Val Leu Gly Ala Gln Ala Val Gly Pro Trp Thr Ala
 20 25 30
 Ser Ala Cys Leu Gly Ala Ala Gln Ala Gln Pro Cys Arg Pro Cys Lys
 35 40 45
 Glu Ser Ser Leu Arg Leu Phe Ser Ala Ser Ala Pro Ser Met Thr His
 50 55 60
 Xaa
 65

<210> 162
 <211> 59
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (59)
 <223> Xaa equals stop translation

 <400> 162
 Met Glu Lys Tyr Cys Leu Gly Asn Asn Met Leu Ser Arg Phe Cys Leu
 1 5 10 15
 Phe Leu Ile Met Leu Leu His Ile Leu Leu Phe Leu Val Ile Phe Ile
 20 25 30
 Gln Arg His Thr Val Val Ser Leu Ser Lys His His Pro Phe Val Pro
 35 40 45
 Thr Asn Gly Ser Lys Ser Tyr Ser Ser Phe Xaa
 50 55

<210> 163
 <211> 374
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (84)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE

<222> (112)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 163

Met Arg Pro Gly Thr Ala Leu Gln Ala Val Leu Leu Ala Val Leu Leu
 1 5 10 15

Val Gly Leu Arg Ala Ala Thr Gly Arg Leu Leu Ser Gly Gln Pro Val
 20 25 30

Cys Arg Gly Gly Thr Gln Arg Pro Cys Tyr Lys Val Ile Tyr Phe His
 35 40 45

Asp Thr Ser Arg Arg Leu Asn Phe Glu Glu Ala Lys Glu Ala Cys Arg
 50 55 60

Arg Asp Gly Gly Gln Leu Val Ser Ile Glu Ser Glu Asp Glu Gln Lys
 65 70 75 80

Leu Ile Glu Xaa Phe Ile Glu Asn Leu Leu Pro Ser Asp Gly Asp Phe
 85 90 95

Trp Ile Gly Leu Arg Arg Arg Glu Glu Lys Gln Ser Asn Ser Thr Xaa
 100 105 110

Cys Gln Asp Leu Tyr Ala Trp Thr Asp Gly Ser Ile Ser Gln Phe Arg
 115 120 125

Asn Trp Tyr Val Asp Glu Pro Ser Cys Gly Ser Glu Val Cys Val Val
 130 135 140

Met Tyr His Gln Pro Ser Ala Pro Ala Gly Ile Gly Gly Pro Tyr Met
 145 150 155 160

Phe Gln Trp Asn Asp Asp Arg Cys Asn Met Lys Asn Asn Phe Ile Cys
 165 170 175

Lys Tyr Ser Asp Glu Lys Pro Ala Val Pro Ser Arg Glu Ala Glu Gly
 180 185 190

Glu Glu Thr Glu Leu Thr Thr Pro Val Leu Pro Glu Glu Thr Gln Glu
 195 200 205

Glu Asp Ala Lys Lys Thr Phe Lys Glu Ser Arg Glu Ala Ala Leu Asn
 210 215 220

Leu Ala Tyr Ile Leu Ile Pro Ser Ile Pro Leu Leu Leu Leu Val
 225 230 235 240

Val Thr Thr Val Val Cys Trp Val Trp Ile Cys Arg Lys Arg Lys Arg
 245 250 255

Glu Gln Pro Asp Pro Ser Thr Lys Lys Gln His Thr Ile Trp Pro Ser
 260 265 270

Pro His Gln Gly Asn Ser Pro Asp Leu Glu Val Tyr Asn Val Ile Arg
 275 280 285

Lys Gln Ser Glu Ala Asp Leu Ala Glu Thr Arg Pro Asp Leu Lys Asn

```

290          295          300
Ile Ser Phe Arg Val Cys Ser Gly Glu Ala Thr Pro Asp Asp Met Ser
305          310          315          320
Cys Asp Tyr Asp Asn Met Ala Val Asn Pro Ser Glu Ser Gly Phe Val
325          330          335
Thr Leu Val Ser Val Glu Ser Gly Phe Val Thr Asn Asp Ile Tyr Glu
340          345          350
Phe Ser Pro Asp Gln Met Gly Arg Ser Lys Glu Ser Gly Trp Val Glu
355          360          365
Asn Glu Ile Tyr Gly Tyr
370

```

```

<210> 164
<211> 64
<212> PRT
<213> Homo sapiens

```

```

<220>
<221> SITE
<222> (64)
<223> Xaa equals stop translation

```

```

<400> 164
Met His Pro Gln Leu Ile Pro Ser Val Ile Ala Val Val Phe Ile Leu
1          5          10          15
Leu Leu Gly Val Cys Phe Ile Ala Ser Cys Leu Val Thr His His Asn
20          25          30
Phe Ser Arg Cys Lys Arg Gly Thr Gly Val His Lys Leu Glu His His
35          40          45
Ala Lys Leu Lys Cys Ile Lys Glu Lys Ser Glu Leu Lys Ser Cys Xaa
50          55          60

```

```

<210> 165
<211> 743
<212> PRT
<213> Homo sapiens

```

```

<220>
<221> SITE
<222> (743)
<223> Xaa equals stop translation

```

```

<400> 165
Met Ala Val Arg Glu Leu Cys Phe Pro Arg Gln Arg Gln Val Leu Phe
1          5          10          15

```

Leu Phe Leu Phe Trp Gly Val Ser Leu Ala Gly Ser Gly Phe Gly Arg
 20 25 30
 Tyr Ser Val Thr Glu Glu Thr Glu Lys Gly Ser Phe Val Val Asn Leu
 35 40 45
 Ala Lys Asp Leu Gly Leu Ala Glu Gly Glu Leu Ala Ala Arg Gly Thr
 50 55 60
 Arg Val Val Ser Asp Asp Asn Lys Gln Tyr Leu Leu Leu Asp Ser His
 65 70 75 80
 Thr Gly Asn Leu Leu Thr Asn Glu Lys Leu Asp Arg Glu Lys Leu Cys
 85 90 95
 Gly Pro Lys Glu Pro Cys Met Leu Tyr Phe Gln Ile Leu Met Asp Asp
 100 105 110
 Pro Phe Gln Ile Tyr Arg Ala Glu Leu Arg Val Arg Asp Ile Asn Asp
 115 120 125
 His Ala Pro Val Phe Gln Asp Lys Glu Thr Val Leu Lys Ile Ser Glu
 130 135 140
 Asn Thr Ala Glu Gly Thr Ala Phe Arg Leu Glu Arg Ala Gln Asp Pro
 145 150 155 160
 Asp Gly Gly Leu Asn Gly Ile Gln Asn Tyr Thr Ile Ser Pro Asn Ser
 165 170 175
 Phe Phe His Ile Asn Ile Ser Gly Gly Asp Glu Gly Met Ile Tyr Pro
 180 185 190
 Glu Leu Val Leu Asp Lys Ala Leu Asp Arg Glu Glu Gln Gly Glu Leu
 195 200 205
 Ser Leu Thr Leu Thr Ala Leu Asp Gly Gly Ser Pro Ser Arg Ser Gly
 210 215 220
 Thr Ser Thr Val Arg Ile Val Val Leu Asp Val Asn Asp Asn Ala Pro
 225 230 235 240
 Gln Phe Ala Gln Ala Leu Tyr Glu Thr Gln Ala Pro Glu Asn Ser Pro
 245 250 255
 Ile Gly Phe Leu Ile Val Lys Val Trp Ala Glu Asp Val Asp Ser Gly
 260 265 270
 Val Asn Ala Glu Val Ser Tyr Ser Phe Phe Asp Ala Ser Glu Asn Ile
 275 280 285
 Arg Thr Thr Phe Gln Ile Asn Pro Phe Ser Gly Glu Ile Phe Leu Arg
 290 295 300
 Glu Leu Leu Asp Tyr Glu Leu Val Asn Ser Tyr Lys Ile Asn Ile Gln
 305 310 315 320
 Ala Met Asp Gly Gly Gly Leu Ser Ala Arg Cys Arg Val Leu Val Glu
 325 330 335

Val Leu Asp Thr Asn Asp Asn Pro Pro Glu Leu Ile Val Ser Ser Phe
 340 345 350
 Ser Asn Ser Val Ala Glu Asn Ser Pro Glu Thr Pro Leu Ala Val Phe
 355 360 365
 Lys Ile Asn Asp Arg Asp Ser Gly Glu Asn Gly Lys Met Val Cys Tyr
 370 375 380
 Ile Gln Glu Asn Leu Pro Phe Leu Leu Lys Pro Ser Val Glu Asn Phe
 385 390 395 400
 Tyr Ile Leu Ile Thr Glu Gly Ala Leu Asp Arg Glu Ile Arg Ala Glu
 405 410 415
 Tyr Asn Ile Thr Ile Thr Val Thr Asp Leu Gly Thr Pro Arg Leu Lys
 420 425 430
 Thr Glu His Asn Ile Thr Val Leu Val Ser Asp Val Asn Asn Ala
 435 440 445
 Pro Ala Phe Thr Gln Thr Ser Tyr Thr Leu Phe Val Arg Glu Asn Asn
 450 455 460
 Ser Pro Ala Leu His Ile Gly Ser Val Ser Ala Thr Asp Arg Asp Ser
 465 470 475 480
 Gly Thr Asn Ala Gln Val Thr Tyr Ser Leu Leu Pro Pro Gln Asp Pro
 485 490 495
 His Leu Pro Leu Ala Ser Leu Val Ser Ile Asn Ala Asp Asn Gly His
 500 505 510
 Leu Phe Ala Leu Arg Ser Leu Asp Tyr Glu Ala Leu Gln Ala Phe Glu
 515 520 525
 Phe Arg Val Gly Ala Thr Asp Arg Gly Ser Pro Ala Leu Asn Ser Glu
 530 535 540
 Ala Leu Gly Ala Arg Ala Gly Ala Gly Arg Gln Arg Gln Leu Ala Leu
 545 550 555 560
 Arg Ala Val Pro Ala Ala Glu Arg Leu Arg Ala Leu His Arg Ala Gly
 565 570 575
 Ala Pro Gly Gly Arg Ala Gly Leu Pro Gly Asp Gln Gly Gly Gly Gly
 580 585 590
 Gly Arg Arg Leu Gly Pro Glu Arg Leu Ala Val Val Pro Ala Ala Gln
 595 600 605
 Gly His Gly Ala Arg Ala Val Arg Cys Val Gly Ala Gln Trp Gly Gly
 610 615 620
 Ala His Arg Gln Ala Ala Glu Arg Ala Arg Arg Ser Gln Ala Gln Ala
 625 630 635 640
 Gly Gly Ala Cys Gln Gly Gln Trp Arg Ala Ser Ser Leu Gly His Arg

645 650 655
 His Ala Ala Arg Ala Pro Gly Gly Arg Leu Leu Pro Ala Leu Pro Ala
 660 665 670
 Ser Pro Gly Gly Gly Pro Gly Pro Gly Pro Gly Arg Leu Ala His Arg
 675 680 685
 Leu Pro Gly Gly Gly Val Gly Leu Gly Val Phe Ala Leu Pro Pro Leu
 690 695 700
 Gly Ala Pro Val Arg Gly Gly Ala Ala Val Gln Glu Glu Gln Gly Gly
 705 710 715 720
 Leu Gly Gly Ser Leu Leu Gly Ala Arg Gly Ser Phe Ser Arg Ala Ser
 725 730 735
 Gly Gly Arg Glu Gly Arg Xaa
 740

 <210> 166
 <211> 214
 <212> PRT
 <213> Homo sapiens

 <220>
 <221> SITE
 <222> (214)
 <223> Xaa equals stop translation

 <400> 166
 Met Asn Arg Met Glu Leu Leu Lys Leu Leu Leu Thr Cys Phe Ser Glu
 1 5 10 15
 Ala Met Tyr Leu Pro Pro Ala Pro Glu Ser Gly Ser Thr Asn Pro Trp
 20 25 30
 Val Gln Phe Phe Cys Ser Thr Glu Asn Arg His Ala Leu Pro Leu Phe
 35 40 45
 Thr Ser Leu Leu Asn Thr Val Cys Ala Tyr Asp Pro Val Gly Tyr Gly
 50 55 60
 Ile Pro Tyr Asn His Leu Leu Phe Ser Asp Tyr Arg Glu Pro Leu Val
 65 70 75 80
 Glu/Glu Ala Ala Gln Val Leu Ile Val Thr Leu Asp His Asp Ser Ala
 85 90 95
 Ser Ser Ala Ser Pro Thr Val Asp Gly Thr Thr Thr Gly Thr Ala Met
 100 105 110
 Asp Asp Ala Asp Pro Pro Gly Pro Glu Asn Leu Phe Val Asn Tyr Leu
 115 120 125
 Ser Arg Ile His Arg Glu Glu Asp Phe Gln Phe Ile Leu Lys Gly Ile
 130 135 140

Ala Arg Leu Leu Ser Asn Pro Leu Leu Gln Thr Tyr Leu Pro Asn Ser
 145 150 155 160
 Thr Lys Lys Asp Pro Val Pro Pro Gly Ala Ala Ser Ser Leu Leu Glu
 165 170 175
 Ala Leu Arg Leu Gln Gln Glu Ile Pro Leu Leu Arg Ala Glu Glu Gln
 180 185 190
 Arg Arg Pro Arg His Pro Cys Pro His Pro Leu Leu Pro Gln Arg Cys
 195 200 205
 Pro Gly Arg Ser Val Xaa
 210
 <210> 167
 <211> 213
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (213)
 <223> Xaa equals stop translation
 <400> 167
 Met Pro Ser Leu Arg Phe Leu Ala Leu Ala Leu Leu Leu Ala Ile Leu
 1 5 10 15
 Pro Ala Leu Pro Asn Ala His Ala Ala Pro Gly Ile Gly Gly Leu Ile
 20 25 30
 Gly Gly Gly Ser Gln Ala Ser Ala Lys Glu Glu Pro Gln Ser Asn Ala
 35 40 45
 Gln Pro Ser Ala Asp Glu Arg Lys Gln Arg Leu Leu Ser Gln Ala Glu
 50 55 60
 Glu Thr Arg Gln Arg Leu Thr Asp Leu Lys Ala Glu Leu Ala Gly Ala
 65 70 75 80
 Pro Lys Glu Ile Ser Glu Ala Gln Arg Thr Leu Ser Lys Leu Val Ser
 85 90 95
 Glu Asp Asn Ser Asp Leu Pro Glu Arg Leu Ser Lys Leu Ser Val Pro
 100 105 110
 Val Leu Glu Gln Arg Leu Ala Ala Arg Val Asp Glu Leu Ala Leu Trp
 115 120 125
 Gln Gln Ala Leu Ser Ala Ala Asn Ser Met Leu Ile Ser Ala Gln Thr
 130 135 140
 Arg Pro Glu Arg Ala Gln Ala Asp Ile Ser Lys Asn Gln Leu Arg Ile
 145 150 155 160
 Asp Glu Ile Asn Gly Leu Leu Lys Ser Gly Arg Glu Asn Asn Lys Pro
 165 170 175

Leu Thr Asp Glu Arg Arg Ala Leu Leu Glu Ser Thr Ser Arg Ala Ala
 180 185 190

Ala Gly Pro Ser Ile Phe His Pro Gly Gly Val Pro Gly Lys Cys Thr
 195 200 205

Gln Phe Ala Leu Xaa
 210

<210> 168

<211> 75

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (75)

<223> Xaa equals stop translation

<400> 168

Met Phe Thr Ser Phe Gly Leu Ala Ser Pro Arg Ile Leu Phe Cys Phe
 1 5 10 15

Cys Phe Phe Asp Leu Gly Phe Ile Phe Phe Cys Val Leu Tyr Tyr Ile
 20 25 30

Val Lys Gly Ile Leu Ala Glu Thr Leu Val Phe Gly Ala Arg Gly Glu
 35 40 45

Gln Glu Cys Trp Ala Val Tyr Phe Arg Trp Arg Thr His Leu Gln Thr
 50 55 60

Phe Gly Leu Phe Ser Phe Asn Cys Ser Val Xaa
 65 70 75

<210> 169

<211> 48

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (48)

<223> Xaa equals stop translation

<400> 169

Met Phe Leu Cys Leu Phe Phe Phe Phe Asn Ala Thr Gln Gly Asn
 1 5 10 15

Ile Phe Ile Ser Phe Leu Ser Gly Leu Pro Gln Cys Ile Phe Ile Ser
 20 25 30

Phe Glu Thr Lys Arg Phe Trp Lys Leu Phe Phe Cys Ser Phe Lys Xaa
 35 40 45

<210> 170
<211> 88
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (88)
<223> Xaa equals stop translation

<400> 170
Met Gly Leu His Leu Arg Pro Tyr Arg Val Gly Leu Leu Pro Asp Gly
1 5 10 15
Leu Leu Phe Leu Leu Leu Leu Met Leu Leu Ala Asp Pro Ala Leu
20 25 30
Pro Ala Gly Arg His Pro Pro Val Val Leu Val Pro Gly Asp Leu Gly
35 40 45
Asn Gln Leu Glu Ala Lys Leu Asp Lys Pro Thr Val Val His Tyr Leu
50 55 60
Cys Ser Lys Lys Thr Glu Ser Tyr Phe Thr Ile Trp Leu Asn Leu Glu
65 70 75 80
Leu Leu Leu Pro Val His His Xaa
85

<210> 171
<211> 42
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (42)
<223> Xaa equals stop translation

<400> 171
Met Ala Cys Glu Thr His Gly Val Leu Val Pro Ala His Leu Ser Gly
1 5 10 15
Leu Ile Thr Cys Leu Leu Ala Phe Trp Val Pro Ala Ser Cys Ile Gln
20 25 30
Arg Cys Ser Gly Ser Pro Leu Pro Leu Xaa
35 40

<210> 172
<211> 48
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (48)
<223> Xaa equals stop translation

<400> 172
Met Gln Cys Phe Leu Phe Ser Ile Phe Leu Ile Thr Gly Leu Ala Glu
1 5 10 15
Glu Phe Cys Glu Gln Leu Ser Ile Ser Leu Ala Glu Glu Glu Ile Gln
20 25 30
Leu Ser Ser Thr Val Glu His Phe Cys Met Thr Ala Phe Ser Trp Xaa
35 40 45

<210> 173
<211> 233
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (233)
<223> Xaa equals stop translation

<400> 173
Met Ala Ala Leu Ala Ala Ala Lys Lys Val Trp Ser Ala Arg Arg
1 5 10 15
Leu Leu Val Leu Leu Phe Thr Pro Leu Ala Leu Leu Pro Val Val Phe
20 25 30
Ala Leu Pro Pro Lys Glu Gly Arg Cys Leu Phe Val Ile Leu Leu Met
35 40 45
Ala Val Tyr Trp Cys Thr Glu Ala Leu Pro Leu Ser Val Thr Ala Leu
50 55 60
Leu Pro Ile Val Leu Phe Pro Phe Met Gly Ile Leu Pro Ser Asn Lys
65 70 75 80
Val Cys Pro Gln Tyr Phe Leu Asp Thr Asn Phe Leu Phe Leu Ser Gly
85 90 95
Leu Ile Met Ala Ser Ala Ile Glu Glu Trp Asn Leu His Arg Arg Ile
100 105 110
Ala Leu Lys Ile Leu Met Leu Val Gly Val Gln Pro Ala Arg Leu Ile
115 120 125
Leu Gly Met Met Val Thr Thr Ser Phe Leu Ser Met Trp Leu Ser Asn
130 135 140
Thr Ala Ser Thr Ala Met Met Leu Pro Ile Ala Asn Ala Ile Leu Lys
145 150 155 160

Ser Leu Phe Gly Gln Lys Glu Val Arg Lys Asp Pro Ser Gln Glu Ser
 165 170 175
 Glu Glu Asn Thr Gly Ile Glu Pro Asn Thr Phe Leu Ser Glu Glu Arg
 180 185 190
 Leu Lys Leu Gln Ala Pro Leu Val Ile Arg Leu Gly Gln Ile Thr Glu
 195 200 205
 Ser Gly Gln Trp Asn Met Ser Gly Asn Asp Val Cys Asn Phe Arg Val
 210 215 220
 Leu Ser Phe Leu Pro Gly Gly Met Xaa
 225 230

<210> 174
 <211> 45
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (45)
 <223> Xaa equals stop translation

<400> 174
 Met Gly Thr Ile Phe Gly Tyr Leu His Cys Val Lys Cys Tyr Val Leu
 1 5 10 15
 Tyr Phe Ile Phe Ile Leu Ile Thr Ala Val Tyr His Ser Phe Tyr Tyr
 20 25 30
 Pro His Tyr Arg Gly Lys Ala Leu Ile Ser Gly Thr Xaa
 35 40 45

<210> 175
 <211> 85
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (77)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (85)
 <223> Xaa equals stop translation

<400> 175
 Met Val Trp Phe Leu Phe Leu Val Phe Ile Phe Leu Lys Val Lys Gly
 1 5 10 15
 Asp Phe Phe Pro Pro Phe Leu Ile Cys Asn Leu Phe Cys Ile Trp Met
 20 25 30

Ile Thr Gly Val Ser His Arg Leu Gln Pro Gln Ile Leu Phe Ser Arg
 35 40 45
 His Lys His Asn Gln Glu Ile Ile Leu Gln Met Val Ser Phe Ser Cys
 50 55 60
 Cys Val Phe Phe Pro Met Ile Arg Glu Val Lys Ser Xaa Leu Gly Cys
 65 70 75 80
 Ile Lys Met Ser Xaa
 85

<210> 176
 <211> 66
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (66)
 <223> Xaa equals stop translation

<400> 176
 Met Trp Val Leu Leu Ser Cys Pro Leu Pro Pro Leu Cys Leu Pro Ala
 1 5 10 15
 Ser Ala Val Pro Gly Gln Cys Leu Gly Gly Gln Trp Ser Gly His Gln
 20 25 30
 Leu Arg Leu Arg Gly Arg Gly Trp His Cys Arg Cys His Cys Arg Ala
 35 40 45
 Trp Ala Ala Asp Met Gly Arg Gly Leu His Ser Cys Gln Leu Leu Ser
 50 55 60
 Arg Xaa
 65

<210> 177
 <211> 55
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (55)
 <223> Xaa equals stop translation

<400> 177
 Met Leu Leu Leu Cys Ile Leu Leu Ile Phe Cys Val Val Gly Leu Ser
 1 5 10 15
 Val Val Gly Arg Arg Val Leu Lys Ser Thr Thr Ile Ile Val Tyr Leu
 20 25 30
 Ser Ile Thr Pro Phe Ser Ser Phe Ser Ser Ile Ser His Ile Phe Gln

35 40 45

Leu Leu Ile Gly Ala His Xaa
50 55

<210> 178
<211> 83
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (4)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (83)
<223> Xaa equals stop translation

<400> 178
Met Cys Val Xaa Leu Ser Phe Cys Pro Phe Leu Ser Ser Ala Leu Pro
1 5 10 15
Ala Ser His Thr Gln Phe Tyr Met Pro Arg Gly Ala Lys Phe Gly Thr
20 25 30
Phe Thr Leu Gln Ala Ser Val Ser Pro Leu Glu Glu Lys Thr His Ser
35 40 45
Phe Thr His Pro Gly Ile Gly Gly Lys Leu Leu Gly His Gln Asp Pro
50 55 60
Gly Ala Pro Gly Pro Ser Trp Asn Ile Arg Ser Thr Trp Ser Thr Arg
65 70 75 80
Ser Leu Xaa

<210> 179
<211> 330
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (247)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 179
Met Ser Pro Leu Ser Ala Ala Arg Ala Ala Leu Arg Val Tyr Ala Val
1 5 10 15

Gly Ala Ala Val Ile Leu Ala Gln Leu Leu Arg Arg Cys Arg Gly Gly
 20 25 30
 Phe Leu Glu Pro Val Xaa Pro Pro Arg Pro Asp Arg Val Ala Ile Val
 35 40 45
 Thr Gly Gly Thr Asp Gly Ile Gly Tyr Ser Thr Ala Lys His Leu Ala
 50 55 60
 Arg Leu Gly Met His Val Ile Ile Ala Gly Asn Asn Asp Ser Lys Ala
 65 70 75 80
 Lys Gln Val Val Ser Lys Ile Lys Glu Glu Thr Leu Asn Asp Lys Val
 85 90 95
 Glu Phe Leu Tyr Cys Asp Leu Ala Ser Met Thr Ser Ile Arg Gln Phe
 100 105 110
 Val Gln Lys Phe Lys Met Lys Lys Ile Pro Leu His Val Leu Ile Asn
 115 120 125
 Asn Ala Gly Val Met Met Val Pro Gln Arg Lys Thr Arg Asp Gly Phe
 130 135 140
 Glu Glu His Phe Gly Leu Asn Tyr Leu Gly His Phe Leu Leu Thr Asn
 145 150 155 160
 Leu Leu Leu Asp Thr Leu Lys Glu Ser Gly Ser Pro Gly His Ser Ala
 165 170 175
 Arg Val Val Thr Val Ser Ser Ala Thr His Tyr Val Ala Glu Leu Asn
 180 185 190
 Met Asp Asp Leu Gln Ser Ser Ala Cys Tyr Ser Pro His Ala Ala Tyr
 195 200 205
 Ala Gln Ser Lys Leu Ala Leu Val Leu Phe Thr Tyr His Leu Gln Arg
 210 215 220
 Leu Leu Ala Ala Glu Gly Ser His Val Thr Ala Asn Val Val Asp Pro
 225 230 235 240
 Gly Val Val Asn Thr Asp Xaa Tyr Lys His Val Phe Trp Ala Thr Arg
 245 250 255
 Leu Ala Lys Lys Leu Leu Gly Trp Leu Leu Phe Lys Thr Pro Asp Glu
 260 265 270
 Gly Ala Trp Thr Ser Ile Tyr Ala Ala Val Thr Pro Glu Leu Glu Gly
 275 280 285
 Val Gly Gly Arg Tyr Leu Tyr Asn Glu Lys Glu Thr Lys Ser Leu His
 290 295 300
 Val Thr Tyr Asn Gln Lys Leu Cln Cln Gln Leu Trp Ser Lys Ser Cys
 305 310 315 320
 Glu Met Thr Gly Val Leu Asp Val Thr Leu

325

330

<210> 180
<211> 41
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (41)
<223> Xaa equals stop translation

<400> 180
Met Ile Ala Cys Gln Tyr Ile Ser Leu Ala Ile Met Leu Ala Phe Val
1 5 10 15
Arg Trp Ala Ala Phe Leu Leu Phe Pro Phe Leu Cys Gly Asp Asn Gly
20 25 30
Gly Asn Ile Gln Gln Lys Tyr Val Xaa
35 40

<210> 181
<211> 52
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (52)
<223> Xaa equals stop translation

<400> 181
Met Ala Asn Ala Met Ala Tyr Leu Ser Ile Phe Leu Cys Gly Ala Ser
1 5 10 15
Ser Ser Pro Cys Asp Cys Ala Leu Leu Val Pro Val Ser Leu Phe Arg
20 25 30
Gly Arg Lys Val Ala Asn Phe Lys Asn Gln Asn Ser Asp Val Thr Ser
35 40 45
Gly Asn Ala Xaa
50

<210> 182
<211> 55
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (55)
<223> Xaa equals stop translation

<400> 182

Met Gln Gln Ile Cys Ser Cys Leu Gly Ala Phe Ala Leu Leu Phe Phe
1 5 10 15
Trp Pro Gly His Phe Thr Ser Thr Phe Ser Ile Phe Tyr Asp Phe Leu
20 25 30
Pro Ile Phe Gly Ser Leu Phe Lys Cys His Pro Ser Lys Arg Pro Ser
35 40 45
Lys Leu Pro Tyr Leu Lys Xaa
50 55

<210> 183
<211> 62
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (62)
<223> Xaa equals stop translation

<400> 183
Met Arg Leu Leu Leu Glu Trp Arg Val Tyr Leu Arg Leu Thr Cys Ala
1 5 10 15
Thr Lys Asp Gly Met Ala Arg Glu Cys Pro Thr Thr Trp Leu Ser Pro
20 25 30
Pro Ala Lys Pro Asp Phe Ala Gln Arg His Ser Val Lys Pro Thr Ala
35 40 45
Leu Gln Gly Gly Arg Trp Ser Arg Leu Gly Ala Ser Pro Xaa
50 55 60

<210> 184
<211> 148
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (148)
<223> Xaa equals stop translation

<400> 184
Met Leu Gly Leu Pro Trp Lys Gly Gly Leu Ser Trp Ala Leu Leu Leu
1 5 10 15
Leu Leu Leu Gly Ser Gln Ile Leu Leu Ile Tyr Ala Trp His Phe His
20 25 30
Glu Gln Arg Asp Cys Asp Glu His Asn Val Met Ala Arg Tyr Leu Pro
35 40 45
Ala Thr Val Glu Phe Ala Val His Thr Phe Asn Gln Gln Ser Lys Asp
50 55 60

Tyr Tyr Ala Tyr Arg Leu Gly His Ile Leu Asn Ser Trp Lys Glu Gln
 65 70 75 80
 Val Glu Ser Lys Thr Val Phe Ser Met Glu Leu Leu Leu Gly Arg Thr
 85 90 95
 Arg Cys Gly Lys Phe Glu Asp Asp Ile Asp Asn Cys His Phe Gln Glu
 100 105 110
 Ser Thr Glu Leu Asn Asn Thr Phe Thr Cys Phe Phe Thr Ile Ser Thr
 115 120 125
 Arg Pro Trp Met Thr Gln Phe Ser Leu Leu Asn Lys Thr Cys Leu Glu
 130 135 140
 Gly Phe His Xaa
 145

<210> 185
 <211> 161
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (146)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (151)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (161)
 <223> Xaa equals stop translation

<400> 185
 Met Arg Leu Leu Cys Gly Leu Trp Leu Trp Leu Ser Leu Leu Lys Val
 1 5 10 15
 Leu Gln Ala Gln Thr Pro Thr Pro Leu Pro Leu Pro Pro Pro Met Gln
 20 25 30
 Ser Phe Gln Gly Asn Gln Phe Gln Gly Glu Trp Phe Val Leu Gly Leu
 35 40 45
 Ala Gly Asn Ser Phe Arg Pro Glu His Arg Ala Leu Leu Asn Ala Phe
 50 55 60
 Thr Ala Thr Phe Glu Leu Ser Asp Asp Gly Arg Phe Glu Val Trp Asn
 65 70 75 80
 Ala Met Thr Arg Gly Gln His Cys Asp Thr Trp Ser Tyr Val Leu Ile
 85 90 95

Pro Ala Ala Gln Pro Gly Gln Phe Thr Val Asp His Gly Val Gly Arg
 100 105 110
 Ser Trp Leu Leu Pro Pro Gly Thr Leu Asp Gln Phe Ile Cys Leu Gly
 115 120 125
 Arg Ala Gln Gly Leu Ser Asp Asp Asn Ile Val Phe Pro Asp Val Thr
 130 135 140
 Gly Xaa Ala Leu Asp Leu Xaa Ser Leu Pro Trp Val Ala Ala Pro Ala
 145 150 155 160
 Xaa

<210> 186
 <211> 122
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (122)
 <223> Xaa equals stop translation

<400> 186
 Met Met Leu Pro Gln Trp Leu Leu Leu Leu Phe Leu Leu Phe Phe Phe
 1 5 10 15
 Leu Phe Leu Leu Thr Arg Gly Ser Leu Ser Pro Thr Lys Tyr Asn Leu
 20 25 30
 Leu Glu Leu Lys Glu Ser Cys Ile Arg Asn Gln Asp Cys Glu Thr Gly
 35 40 45
 Cys Cys Gln Arg Ala Pro Asp Asn Cys Glu Ser His Cys Ala Glu Lys
 50 55 60
 Gly Ser Glu Gly Ser Leu Cys Gln Thr Gln Val Phe Phe Gly Gln Tyr
 65 70 75 80
 Arg Ala Cys Pro Cys Leu Arg Asn Leu Thr Cys Ile Tyr Ser Lys Asn
 85 90 95
 Glu Lys Trp Leu Ser Ile Ala Tyr Gly Arg Cys Gln Lys Ile Gly Arg
 100 105 110
 Gln Lys Leu Ala Lys Lys Met Phe Phe Xaa
 115 120

<210> 187
 <211> 163
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE

<222> (163)

<223> Xaa equals stop translation

<400> 187

Met Thr Ser Asn Phe Pro Phe Cys Thr Leu Ile Leu Gly Ile Ala Gln
 1 5 10 15
 Ala Gln Ala Cys Pro Gly Cys Pro Gly Asp Trp Pro Gly Leu Gly Ser
 20 25 30
 Gly Val Gly Glu Gly Leu His His Ile Arg Thr Cys Arg Thr Pro Ile
 35 40 45
 Pro Cys Ser Pro Pro Ala Pro Ala Ala Ala Cys Leu Gly Ser Gly His
 50 55 60
 Ala Arg Leu Pro Cys Val Leu Arg Leu Trp Pro Val Pro Ala Asn Leu
 65 70 75 80
 Ser Ser Pro Phe Arg Leu Glu Ala Leu His Cys Ser Phe Trp Ser Ser
 85 90 95
 Pro Leu Leu Pro Ala Pro His Leu Ala Phe Phe Gly Phe Arg Asp Leu
 100 105 110
 Leu Thr Asp Phe Leu Leu Ala Ala Cys Leu Leu Thr Phe Gln Lys Thr
 115 120 125
 Pro Leu Glu Leu Pro Met Ala Val Val His Leu Leu Val Ala Thr Pro
 130 135 140
 Cys Tyr Gln Met Leu Asp Asn Leu Pro Leu Pro Ser Ala Ala Ala Asn
 145 150 155 160
 Trp Cys Xaa

<210> 188

<211> 51

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (51)

<223> Xaa equals stop translation

<400> 188

Met Pro Gly Ile Leu Ala Gly Ile Pro Val Lys Asp Leu Cys Leu Ser
 1 5 10 15
 Leu Leu Gln Gly Phe Arg Leu Leu Leu Leu Cys Val Cys Pro Gly Trp
 20 25 30
 Leu Ser Gly Trp Met Gly Gly Gln Lys Gly Ser Pro Arg Ile Val Asp
 35 40 45
 Ile Gly Xaa

50

<210> 189
<211> 65
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (65)
<223> Xaa equals stop translation

<400> 189
Met Tyr Leu Tyr Leu Gly Val Phe Phe His Leu Ile Tyr Pro Gly Ala
1 5 10 15
Leu Ser Ile Thr Thr Leu Gly Lys His Ser His Pro Phe Phe Thr Ala
20 25 30
Glu Gln Asn Ser Thr Val Trp Met Glu His Thr Leu Phe His Gln Ser
35 40 45
Pro Val Ala Ser His Leu Val Cys Phe Gln Ser Phe Ala Phe Ser Glu
50 55 60

Xaa
65

<210> 190
<211> 47
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (47)
<223> Xaa equals stop translation

<400> 190
Met Thr Leu Ser Leu Gln Leu Ala Glu Leu Val His Phe Val Cys Ala
1 5 10 15
Phe Gln Ser Gln Trp Thr Gly Val Tyr Pro Met Met Pro Pro Leu Lys
20 25 30
Pro Thr Glu Pro Leu Cys Phe Ala Cys Val Pro Cys Arg Val Xaa
35 40 45

<210> 191
<211> 144
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (144)

<221> Xaa equals stop translation

<400> 191

```

Met Ser Pro Phe His Leu Leu Gly Leu Lys Val Phe Leu Thr Trp Ala
 1           5           10           15
Leu Thr Leu Ala Gln Ile Cys Leu Tyr Phe Phe Glu Val Gln Pro Leu
          20           25           30
Gly Leu Leu Ala Leu Asn Phe Phe Cys Thr Ala Thr Ala Gly Leu Lys
          35           40           45
Glu Leu Cys Met His Pro Pro Ser Leu Ala Phe Thr Pro Glu Phe His
          50           55           60
Thr Ser Leu Ser Pro Leu Ala Ile Pro Ser Phe Cys Gly Thr Ser Val
          65           70           75           80
Ser Leu Ser Asn Ser His Thr Ile Pro Leu Ser Leu Tyr Leu Pro Phe
          85           90           95
Pro Ser Lys Ser Arg Met Pro Asp Thr Leu His Leu Leu Val His Ser
          100          105          110
Leu Pro Leu Val His Ser Gln Val Leu Pro Val Lys Asp Val Thr Ile
          115          120          125
Glu Trp Pro Leu Cys Gln Arg Cys Leu Gly Ser Thr Cys His Gln Xaa
          130          135          140

```

<210> 192

<211> 81

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (76)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (81)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 192

```

Met Phe Cys Phe Ser Ser Ile Phe Cys Ser His Glu His Thr His Leu
 1           5           10           15
Pro Gly Thr Phe Trp Leu Phe Leu Phe Leu Ile Leu Pro Pro
          20           25           30
Ser Cys Pro Cys Phe Leu Pro Phe Ser Leu Ala Ile Glu Thr Val Arg
          35           40           45

```


Trp Pro Cys Trp His His Pro Thr Ser Phe Glu Leu Cys Tyr Pro Gly
50 55 60
Thr Ser Ile Tyr Tyr Ala Ser Arg Gly Gly Pro Xaa Pro Asn Ser Glu
65 70 75 80
Xaa

<210> 193
<211> 45
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (45)
<223> Xaa equals stop translation

<400> 193
Met Thr Tyr Leu Phe Cys Ser Ser Ile Ser Leu Leu Leu Lys Val
1 5 10 15
His Ser Ser Gly His Gln Asp Ile Arg Lys Ala Lys Ser Lys Val Pro
20 25 30
Arg Leu Leu Ile Ile Gln Cys Pro Gln Gln Arg Glu Xaa
35 40 45

<210> 194
<211> 42
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (42)
<223> Xaa equals stop translation

<400> 194
Met Pro Thr Ile Trp Val Lys Leu Cys Leu Leu Gln Val Cys His Gly
1 5 10 15
Leu Phe Pro Leu Leu Lys His Trp Ser Gln Pro Met Pro Leu Cys Val
20 25 30
Thr Leu Ala Pro Val Ser Tyr Trp Leu Xaa
35 40

<210> 195
<211> 260
<212> PRT
<213> Homo sapiens

<220>
<221> SITE

<222> (260)

<223> Xaa equals stop translation

<400> 195

Met Gly Thr Ala Ala Leu Gly Pro Val Trp Ala Ala Leu Leu Leu Phe
 1 5 10 15

Leu Leu Met Cys Glu Ile Pro Met Val Glu Leu Thr Phe Asp Arg Ala
 20 25 30

Val Ala Ser Asp Cys Gln Arg Cys Cys Asp Ser Glu Asp Pro Leu Asp
 35 40 45

Pro Ala His Val Ser Ser Ala Ser Ser Ser Gly Arg Pro His Ala Leu
 50 55 60

Pro Glu Ile Arg Pro Tyr Ile Asn Ile Thr Ile Leu Lys Gly Asp Lys
 65 70 75 80

Gly Asp Pro Gly Pro Met Gly Leu Pro Gly Tyr Met Gly Arg Glu Gly
 85 90 95

Pro Gln Gly Glu Pro Gly Pro Gln Gly Ser Lys Gly Asp Lys Gly Glu
 100 105 110

Met Gly Ser Pro Gly Ala Pro Cys Gln Lys Arg Phe Phe Ala Phe Ser
 115 120 125

Val Gly Arg Lys Thr Ala Leu His Ser Gly Glu Asp Phe Gln Thr Leu
 130 135 140

Leu Phe Glu Arg Val Phe Val Asn Leu Asp Gly Cys Phe Asp Met Ala
 145 150 155 160

Thr Gly Gln Phe Ala Ala Pro Leu Arg Gly Ile Tyr Phe Phe Ser Leu
 165 170 175

Asn Val His Ser Trp Asn Tyr Lys Glu Thr Tyr Val His Ile Met His
 180 185 190

Asn Gln Lys Glu Ala Val Ile Leu Tyr Ala Gln Pro Ser Glu Arg Ser
 195 200 205

Ile Met Gln Ser Gln Ser Val Met Leu Asp Leu Ala Tyr Gly Asp Arg
 210 215 220

Val Trp Val Arg Leu Phe Lys Arg Gln Arg Glu Asn Ala Ile Tyr Ser
 225 230 235 240

Asn Asp Phe Asp Thr Tyr Ile Thr Phe Ser Gly His Leu Ile Lys Ala
 245 250 255

Glu Asp Asp Xaa
 260

<210> 196

<211> 117

<212> PRT

<213> Homo sapiens

<400> 196

Met Leu Gly His Cys Cys Tyr Phe Trp Gln Val Trp Pro Ala Ser Glu
 1 5 10 15
 Ala Leu Ala Ala Gly Pro Thr Pro Ser Thr Gly Ser Ser Ser Pro Ser
 20 25 30
 Trp Lys Gln His Ile Gly Thr Ser Leu Gln Lys Thr Arg Gly Ser Leu
 35 40 45
 Pro Thr Thr Thr Leu Thr Ser Gly Ala Gly Gln Ser Thr Ser Thr Gly
 50 55 60
 Lys Asn Pro Ala Ala Gly Arg Ser Leu Glu Gly Ala Leu Pro Ala Gly
 65 70 75 80
 Val Trp Pro Cys Phe Ala Gln Ser Pro Cys Thr Gly Gly Gln Gln Thr
 85 90 95
 Pro Ser Ser Thr Gly Leu Arg Ser Cys Leu Val Arg Ser Pro Ala Thr
 100 105 110
 Trp Trp Arg Thr Pro
 115

<210> 197

<211> 698

<212> PRT

<213> Homo sapiens

<400> 197

Met Leu Pro Ala Arg Leu Pro Phe Arg Leu Leu Ser Leu Phe Leu Arg
 1 5 10 15
 Gly Ser Ala Pro Thr Ala Ala Arg His Gly Leu Arg Glu Pro Leu Leu
 20 25 30
 Glu Arg Arg Cys Ala Ala Ala Ser Ser Phe Gln His Ser Ser Ser Leu
 35 40 45
 Gly Arg Glu Leu Pro Tyr Asp Pro Val Asp Thr Glu Gly Phe Gly Glu
 50 55 60
 Gly Gly Asp Met Gln Glu Arg Phe Leu Phe Pro Glu Tyr Ile Leu Asp
 65 70 75 80
 Pro Glu Pro Gln Pro Thr Arg Glu Lys Gln Leu Gln Glu Leu Gln Gln
 85 90 95
 Gln Gln Glu Glu Glu Glu Arg Gln Arg Gln Gln Arg Arg Glu Glu Arg
 100 105 110
 Arg Gln Gln Asn Leu Arg Ala Arg Ser Arg Glu His Pro Val Val Gly
 115 120 125
 His Pro Asp Pro Ala Leu Pro Pro Ser Gly Val Asn Cys Ser Gly Cys

130	135	140
Gly Ala Glu Leu His Cys Gln Asp Ala Gly Val Pro Gly Tyr Leu Pro 145 150 155 160		
Arg Glu Lys Phe Leu Arg Thr Ala Glu Ala Asp Gly Gly Leu Ala Arg 165 170 175		
Thr Val Cys Gln Arg Cys Trp Leu Leu Ser His His Arg Arg Ala Leu 180 185 190		
Arg Leu Gln Val Ser Arg Glu Gln Tyr Leu Glu Leu Val Ser Ala Ala 195 200 205		
Leu Arg Arg Pro Gly Pro Ser Leu Val Leu Tyr Met Val Asp Leu Leu 210 215 220		
Asp Leu Pro Asp Ala Leu Leu Pro Asp Leu Pro Ala Leu Val Gly Pro 225 230 235 240		
Lys Gln Leu Ile Val Leu Gly Asn Lys Val Asp Leu Leu Pro Gln Asp 245 250 255		
Ala Pro Gly Tyr Arg Gln Arg Leu Arg Glu Arg Leu Trp Glu Asp Cys 260 265 270		
Ala Arg Ala Gly Leu Leu Leu Ala Pro Gly His Gln Gly Pro Gln Arg 275 280 285		
Pro Val Lys Asp Glu Pro Gln Asp Gly Glu Asn Pro Asn Pro Pro Asn 290 295 300		
Trp Ser Arg Thr Val Val Arg Asp Val Arg Leu Ile Ser Ala Lys Thr 305 310 315 320		
Gly Tyr Gly Val Glu Glu Leu Ile Ser Ala Leu Gln Arg Ser Trp Arg 325 330 335		
Tyr Arg Gly Asp Val Tyr Leu Val Gly Ala Thr Asn Ala Gly Lys Ser 340 345 350		
Thr Leu Phe Asn Thr Leu Leu Glu Ser Asp Tyr Cys Thr Ala Lys Gly 355 360 365		
Ser Asp Ala Ile Asp Arg Ala Thr Ile Ser Pro Trp Pro Gly Thr Thr 370 375 380		
Leu Asn Leu Leu Lys Phe Pro Ile Cys Asn Pro Thr Pro Tyr Arg Met 385 390 395 400		
Phe Lys Arg His Gln Arg Leu Lys Lys Asp Ser Thr Gln Ala Glu Glu 405 410 415		
Asp Leu Ser Glu Gln Glu Gln Asn Gln Leu Asn Val Leu Lys Lys His 420 425 430		
Gly Tyr Val Val Gly Arg Val Gly Arg Thr Phe Leu Tyr Ser Glu Glu 435 440 445		

Gln Lys Asp Asn Ile Pro Phe Glu Phe Asp Ala Asp Ser Leu Ala Phe
 450 455 460
 Asp Met Glu Asn Asp Pro Val Met Gly Thr His Lys Ser Thr Lys Gln
 465 470 475 480
 Val Glu Leu Thr Ala Gln Asp Val Lys Asp Ala His Trp Phe Tyr Asp
 485 490 495
 Thr Pro Gly Ile Thr Lys Glu Asn Cys Ile Leu Asn Leu Leu Thr Glu
 500 505 510
 Lys Glu Val Asn Ile Val Leu Pro Thr Gln Ser Ile Val Pro Arg Thr
 515 520 525
 Phe Val Leu Lys Pro Gly Met Val Leu Phe Leu Gly Ala Ile Gly Arg
 530 535 540
 Ile Asp Phe Leu Gln Gly Asn Gln Ser Ala Trp Phe Thr Val Val Ala
 545 550 555 560
 Ser Asn Ile Leu Pro Val His Ile Thr Ser Leu Asp Arg Ala Asp Ala
 565 570 575
 Leu Tyr Gln Lys His Ala Gly His Thr Leu Leu Gln Ile Pro Met Gly
 580 585 590
 Gly Lys Glu Arg Met Ala Gly Phe Pro Pro Leu Val Ala Glu Asp Ile
 595 600 605
 Met Leu Lys Glu Gly Leu Gly Ala Ser Glu Ala Val Ala Asp Ile Lys
 610 615 620
 Phe Ser Ser Ala Gly Trp Val Ser Val Thr Pro Asn Phe Lys Asp Arg
 625 630 635 640
 Leu His Leu Arg Gly Tyr Thr Pro Glu Gly Thr Val Leu Thr Val Arg
 645 650 655
 Pro Pro Leu Leu Pro Tyr Ile Val Asn Ile Lys Gly Gln Arg Ile Lys
 660 665 670
 Lys Ser Val Ala Tyr Lys Thr Lys Lys Pro Pro Ser Leu Met Tyr Asn
 675 680 685
 Val Arg Lys Lys Lys Gly Lys Ile Asn Val
 690 695

<210> 198

<211> 348

<212> PRT

<213> Homo sapiens

<400> 198

Met Asn Met Thr Gln Ala Arg Val Leu Val Ala Ala Val Val Gly Leu
 1 5 10 15

Val Ala Val Leu Leu Tyr Ala Ser Ile His Lys Ile Glu Glu Gly His

20 25 30
 Leu Ala Val Tyr Tyr Arg Gly Gly Ala Leu Leu Thr Ser Pro Ser Gly
 35 40 45
 Pro Gly Tyr His Ile Met Leu Pro Phe Ile Thr Thr Phe Arg Ser Val
 50 55 60
 Gln Thr Thr Leu Gln Thr Asp Glu Val Lys Asn Val Pro Cys Gly Thr
 65 70 75 80
 Ser Gly Gly Val Met Ile Tyr Ile Asp Arg Ile Glu Val Val Asn Met
 85 90 95
 Leu Ala Pro Tyr Ala Val Phe Asp Ile Val Arg Asn Tyr Thr Ala Asp
 100 105 110
 Tyr Asp Lys Thr Leu Ile Phe Asn Lys Ile His His Glu Leu Asn Gln
 115 120 125
 Phe Cys Ser Ala His Thr Leu Gln Glu Val Tyr Ile Glu Leu Phe Asp
 130 135 140
 Gln Ile Asp Glu Asn Leu Lys Gln Ala Leu Gln Lys Asp Leu Asn Leu
 145 150 155 160
 Met Ala Pro Gly Leu Thr Ile Gln Ala Val Arg Val Thr Lys Pro Lys
 165 170 175
 Ile Pro Glu Ala Ile Arg Arg Asn Phe Glu Leu Met Glu Ala Glu Lys
 180 185 190
 Thr Lys Leu Leu Ile Ala Ala Gln Lys Gln Lys Val Val Glu Lys Glu
 195 200 205
 Ala Glu Thr Glu Arg Lys Lys Ala Val Ile Glu Ala Glu Lys Ile Ala
 210 215 220
 Gln Val Ala Lys Ile Arg Phe Gln Gln Lys Val Met Glu Lys Glu Thr
 225 230 235 240
 Glu Lys Arg Ile Ser Glu Ile Glu Asp Ala Ala Phe Leu Ala Arg Glu
 245 250 255
 Lys Ala Lys Ala Asp Ala Glu Tyr Tyr Ala Ala His Lys Tyr Ala Thr
 260 265 270
 Ser Asn Lys His Lys Leu Thr Pro Glu Tyr Leu Glu Leu Lys Lys Tyr
 275 280 285
 Gln Ala Ile Ala Ser Asn Ser Lys Ile Tyr Phe Gly Ser Asn Ile Pro
 290 295 300
 Asn Met Phe Val Asp Ser Ser Cys Ala Leu Lys Tyr Ser Asp Ile Arg
 305 310 315 320
 Thr Gly Arg Glu Ser Ser Leu Pro Ser Lys Glu Ala Leu Glu Pro Ser
 325 330 335

Gly Glu Asn Val Ile Gln Asn Lys Glu Ser Thr Gly
 340 345

<210> 199

<211> 401

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (307)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 199

Met Met Gly Leu Gly Asn Gly Arg Arg Ser Met Lys Ser Pro Pro Leu
 1 5 10 15
 Val Leu Ala Ala Leu Val Ala Cys Ile Ile Val Leu Gly Phe Asn Tyr
 20 25 30
 Trp Ile Ala Ser Ser Arg Ser Val Asp Leu Gln Thr Arg Ile Met Glu
 35 40 45
 Leu Glu Gly Arg Val Arg Arg Ala Ala Glu Arg Gly Ala Val Glu
 50 55 60
 Leu Lys Lys Asn Glu Phe Gln Gly Glu Leu Glu Lys Gln Arg Glu Gln
 65 70 75 80
 Leu Asp Lys Ile Gln Ser Ser His Asn Phe Gln Leu Glu Ser Val Asn
 85 90 95
 Lys Leu Tyr Gln Asp Glu Lys Ala Val Leu Val Asn Asn Ile Thr Thr
 100 105 110
 Gly Glu Arg Leu Ile Arg Val Leu Gln Asp Gln Leu Lys Thr Leu Gln
 115 120 125
 Arg Asn Tyr Gly Arg Leu Gln Gln Asp Val Leu Gln Phe Gln Lys Asn
 130 135 140
 Gln Thr Asn Leu Glu Arg Lys Phe Ser Tyr Asp Leu Ser Gln Cys Ile
 145 150 155 160
 Asn Gln Met Lys Glu Val Lys Glu Gln Cys Glu Glu Arg Ile Glu Glu
 165 170 175
 Val Thr Lys Lys Gly Asn Glu Ala Val Ala Ser Arg Asp Leu Ser Glu
 180 185 190
 Asn Asn Asp Gln Arg Gln Gln Leu Gln Ala Leu Ser Glu Pro Gln Pro
 195 200 205
 Arg Leu Gln Ala Ala Gly Leu Pro His Thr Glu Val Pro Gln Gly Lys
 210 215 220
 Gly Asn Val Leu Gly Asn Ser Lys Ser Gln Thr Pro Ala Pro Ser Ser
 225 230 235 240

Glu Val Val Leu Asp Ser Lys Arg Gln Val Glu Lys Glu Glu Thr Asn
 245 250 255
 Glu Ile Gln Val Val Asn Glu Glu Pro Gln Arg Asp Arg Leu Pro Gln
 260 265 270
 Glu Pro Gly Arg Glu Gln Val Val Glu Asp Arg Pro Val Gly Gly Arg
 275 280 285
 Gly Phe Gly Gly Ala Gly Glu Leu Gly Gln Thr Pro Gln Val Gln Ala
 290 295 300
 Ala Leu Xaa Val Ser Gln Glu Asn Pro Glu Met Glu Gly Pro Glu Arg
 305 310 315 320
 Asp Gln Leu Val Ile Pro Asp Gly Gln Glu Glu Gln Glu Ala Ala
 325 330 335
 Gly Glu Gly Arg Asn Gln Gln Lys Leu Arg Gly Glu Asp Asp Tyr Asn
 340 345 350
 Met Asp Glu Asn Glu Ala Glu Ser Glu Thr Asp Lys Gln Ala Ala Leu
 355 360 365
 Ala Gly Asn Asp Arg Asn Ile Asp Val Phe Asn Val Glu Asp Gln Lys
 370 375 380
 Arg Asp Thr Ile Asn Leu Leu Asp Gln Arg Glu Lys Arg Asn His Thr
 385 390 395 400
 Leu

<210> 200

<211> 324

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (3)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 200

Met Glu Xaa Ala Lys Val Tyr Val Ala Lys Val Asp Cys Thr Ala His
 1 5 10 15
 Ser Asp Val Cys Ser Ala Gln Gly Val Arg Gly Tyr Pro Thr Leu Lys
 20 25 30
 Leu Phe Lys Pro Gly Gln Glu Ala Val Lys Tyr Gln Gly Pro Arg Asp
 35 40 45
 Phe Gln Thr Leu Glu Asn Trp Met Leu Gln Thr Leu Asn Glu Glu Pro
 50 55 60
 Val Thr Pro Glu Pro Glu Val Glu Pro Pro Ser Ala Pro Glu Leu Lys


```
<210> 201
<211> 90
<212> PRT
<213> Homo sapiens
```

<400> 201
Met Ala Leu Phe Ser Cys Leu Leu Leu Leu Lys Gln Ser Asp Gly Ala
1 5 10 15

Ser Pro Val Leu Arg Ala Leu Ala Ala Ser Cys Leu Ala Ser Pro Ala
 20 25 30
 Gly Cys Cys Gly Thr Arg Lys Ala Leu Asn Gly Asn Val Gly Glu Lys
 35 40 45
 Val Gly Phe Thr Phe Met Ser Phe Gln Gly Cys Asp Pro Ser Ser Pro
 50 55 60
 Gly Cys Leu Cys Cys Ser Leu Leu Pro Ser Asn Ser Gln Leu Val Phe
 65 70 75 80
 Ile Ser Phe Leu Val Leu Ser Gly Leu Ala
 85 90

<210> 202
 <211> 243
 <212> PRT
 <213> Homo sapiens

<400> 202
 Met Arg Pro Gln Gly Pro Ala Ala Ser Pro Gln Arg Leu Arg Gly Leu
 1 5 10 15
 Leu Leu Leu Leu Leu Leu Gln Leu Pro Ala Pro Ser Ser Ala Ser Glu
 20 25 30
 Ile Pro Lys Gly Lys Gln Lys Ala Gln Leu Arg Gln Arg Glu Val Val
 35 40 45
 Asp Leu Tyr Asn Gly Met Cys Leu Gln Gly Pro Ala Gly Val Pro Gly
 50 55 60
 Arg Asp Gly Ser Pro Gly Ala Asn Gly Ile Pro Gly Thr Pro Gly Ile
 65 70 75 80
 Pro Gly Arg Asp Gly Phe Lys Gly Glu Lys Gly Glu Cys Leu Arg Glu
 85 90 95
 Ser Phe Glu Glu Ser Trp Thr Pro Asn Tyr Lys Gln Cys Ser Trp Ser
 100 105 110
 Ser Leu Asn Tyr Gly Ile Asp Leu Gly Lys Ile Ala Glu Cys Thr Phe
 115 120 125
 Thr Lys Met Arg Ser Asn Ser Ala Leu Arg Val Leu Phe Ser Gly Ser
 130 135 140
 Leu Arg Leu Lys Cys Arg Asn Ala Cys Cys Glu Arg Trp Tyr Phe Thr
 145 150 155 160
 Phe Asn Gly Ala Glu Cys Ser Gly Pro Leu Pro Ile Glu Ala Ile Ile
 165 170 175
 Tyr Leu Asp Gln Gly Ser Pro Glu Met Asn Ser Thr Ile Asn Ile His
 180 185 190

Arg Thr Ser Ser Val Glu Gly Leu Cys Glu Gly Ile Gly Ala Gly Leu
195 200 205

Val Asp Val Ala Ile Trp Val Gly Thr Cys Ser Asp Tyr Pro Lys Gly
210 215 220

Asp Ala Ser Thr Gly Trp Asn Ser Val Ser Arg Ile Ile Ile Glu Glu
225 230 235 240

Leu Pro Lys

<210> 203

<211> 75

<212> PRT

<213> Homo sapiens

<400> 203

Met Ala Gly Gln Glu Asp Pro Val Gln Arg Glu Ile His Gln Asp Trp
1 5 10 15

Ala Asn Arg Glu Tyr Ile Glu Ile Ile Thr Ser Ser Ile Lys Lys Ile
20 25 30

Ala Asp Phe Leu Asn Ser Phe Asp Met Ser Cys Arg Ser Arg Leu Ala
35 40 45

Thr Leu Asn Glu Lys Leu Thr Ala Leu Glu Arg Arg Ile Glu Tyr Ile
50 55 60

Glu Ala Arg Val Thr Lys Gly Glu Thr Leu Thr
65 70 75

<210> 204

<211> 248

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (185)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 204

Met Thr Ser Gln Pro Val Pro Asn Glu Thr Ile Ile Val Leu Pro Ser
1 5 10 15

Asn Val Ile Asn Phe Ser Gln Ala Glu Lys Pro Glu Pro Thr Asn Gln
20 25 30

Gly Gln Asp Ser Leu Lys Lys His Leu His Ala Glu Ile Lys Val Ile
35 40 45

Gly Thr Ile Gln Ile Leu Cys Gly Met Met Val Leu Ser Leu Gly Ile
50 55 60

Ile Leu Ala Ser Ala Ser Phe Ser Pro Asn Phe Thr Gln Val Thr Ser

```

65              70              75              80
Thr Leu Leu Asn Ser Ala Tyr Pro Phe Ile Gly Pro Phe Phe Phe Ile
      85              90              95
Ile Ser Gly Ser Leu Ser Ile Ala Thr Glu Lys Arg Leu Thr Lys Leu
      100             105             110
Leu Val His Ser Ser Leu Val Gly Ser Ile Leu Ser Ala Leu Ser Ala
      115             120             125
Leu Val Gly Phe Ile Ile Leu Ser Val Lys Gln Ala Thr Leu Asn Pro
      130             135             140
Ala Ser Leu Gln Cys Glu Leu Asp Lys Asn Asn Ile Pro Thr Arg Ser
      145             150             155             160
Tyr Val Ser Tyr Phe Tyr His Asp Ser Leu Tyr Thr Thr Asp Cys Tyr
      165             170             175
Thr Ala Lys Ala Ser Leu Ala Gly Xaa Leu Ser Leu Met Leu Ile Cys
      180             185             190
Thr Leu Leu Glu Phe Cys Leu Ala Val Leu Thr Ala Val Leu Arg Trp
      195             200             205
Lys Gln Ala Tyr Ser Asp Phe Pro Gly Ser Val Leu Phe Leu Pro His
      210             215             220
Ser Tyr Ile Gly Asn Ser Gly Met Ser Ser Lys Met Thr His Asp Cys
      225             230             235             240
Gly Tyr Glu Glu Leu Leu Thr Ser
      245

```

<210> 205

<211> 168

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (83)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 205

```

Met Pro Leu Leu Arg Gly Leu Leu Trp Leu Gln Val Leu Cys Ala Gly
  1              5              10             15
Pro Leu His Thr Glu Ala Val Val Leu Leu Val Pro Ser Asp Asp Gly
      20              25              30
Arg Ala Phe Leu Leu Arg Ser Arg Leu Leu His Pro Glu Ala His Val
      35              40              45
Pro Pro Ala Ala Asp Arg Gly Ala Ser Leu Gln Cys Val Leu His Gln
      50              55              60

```

Ala Ala Pro Lys Ser Arg Pro Arg Ser Pro Ala Ala Gly Ala Ala Leu
 65 70 75 80
 Leu His Xaa Pro Arg Arg Thr Gly Asp Glu Pro Cys Arg Glu Phe His
 85 90 95
 Gly Asn Gly Phe Pro Gly Pro Thr Gln Leu Thr Pro Gly Glu Cys Gly
 100 105 110
 Leu Pro Ala Pro Ser Ser Leu Leu Gln His Ala Ser Ala Pro Val Arg
 115 120 125
 Thr Gly Ser Glu Gly Gln Val Val Gly Cys Pro Arg Ala Arg Gly Glu
 130 135 140
 Thr Gly Glu Gly Leu Ser Leu Ala Phe Leu Ser Ser Leu Met Phe Thr
 145 150 155 160
 Ser Arg Asn Gly Leu Val Gly Cys
 165

<210> 206
 <211> 218
 <212> PRT
 <213> Homo sapiens

<400> 206
 Met Gly Ser Ala Ala Leu Glu Ile Leu Gly Leu Val Leu Cys Leu Val
 1 5 10 15
 Gly Trp Gly Gly Leu Ile Leu Ala Cys Gly Leu Pro Met Trp Gln Val
 20 25 30
 Thr Ala Phe Leu Asp His Asn Ile Val Thr Ala Gln Thr Thr Trp Lys
 35 40 45
 Gly Leu Trp Met Ser Cys Val Val Gln Ser Thr Gly His Met Gln Cys
 50 55 60
 Lys Val Tyr Asp Ser Val Leu Ala Leu Ser Thr Glu Val Gln Ala Ala
 65 70 75 80
 Arg Ala Leu Thr Val Ser Ala Val Leu Leu Ala Phe Val Ala Leu Phe
 85 90 95
 Val Thr Leu Ala Gly Ala Gln Cys Thr Thr Cys Val Ala Pro Gly Pro
 100 105 110
 Ala Lys Ala Arg Val Ala Leu Thr Gly Gly Val Leu Tyr Leu Phe Cys
 115 120 125
 Gly Leu Leu Ala Leu Val Pro Leu Cys Trp Phe Ala Asn Ile Val Val
 130 135 140
 Arg Glu Phe Tyr Asp Pro Ser Val Pro Val Ser Gln Lys Tyr Glu Leu
 145 150 155 160
 Gly Ala Ala Leu Tyr Ile Gly Trp Ala Ala Thr Ala Leu Leu Met Val

165 170 175
 Gly Gly Cys Leu Leu Cys Cys Gly Ala Trp Val Cys Thr Gly Arg Pro
 180 185 190
 Asp Leu Ser Phe Pro Val Lys Tyr Ser Ala Pro Arg Arg Pro Thr Ala
 195 200 205
 Thr Gly Asp Tyr Asp Lys Lys Asn Tyr Val
 210 215

<210> 207
 <211> 73
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (73)
 <223> Xaa equals stop translation

<400> 207
 Met Thr Ser Tyr Ile Leu Ile Ser Phe Val Leu Leu Ile Gly Val Gly
 1 5 10 15
 Cys Ile Glu Lys Asp Gln Ser Cys Pro Val Phe Gly Gly Arg Lys Arg
 20 25 30
 Leu His Leu Leu Phe Val Gly Gly Gln Leu Arg Gln Val Arg Met Leu
 35 40 45
 Arg Gly Glu Leu Ser Cys Ala Cys Tyr Arg Pro His Val Gln Ala Leu
 50 55 60
 Gln Leu Gly Gly Cys Thr Cys Phe Xaa
 65 70

<210> 208
 <211> 348
 <212> PRT
 <213> Homo sapiens

<400> 208
 Met Leu Cys Pro Trp Arg Thr Ala Asn Leu Gly Leu Leu Ile Leu
 1 5 10 15
 Thr Ile Phe Leu Val Ala Glu Ala Glu Gly Ala Ala Gln Pro Asn Asn
 20 25 30
 Ser Leu Met Leu Gln Thr Ser Lys Glu Asn His Ala Leu Ala Ser Ser
 35 40 45
 Ser Leu Cys Met Asp Glu Lys Gln Ile Thr Gln Asn Tyr Ser Lys Val
 50 55 60
 Leu Ala Glu Val Asn Thr Ser Trp Pro Val Lys Met Ala Thr Asn Ala
 65 70 75 80

Val Leu Cys Cys Pro Pro Ile Ala Leu Arg Asn Leu Ile Ile Ile Thr
 85 90 95
 Trp Glu Ile Ile Leu Arg Gly Gln Pro Ser Cys Thr Lys Ala Tyr Lys
 100 105 110
 Lys Glu Thr Asn Glu Thr Lys Glu Thr Asn Cys Thr Asp Glu Arg Ile
 115 120 125
 Thr Trp Val Ser Arg Pro Asp Gln Asn Ser Asp Leu Gln Ile Arg Thr
 130 135 140
 Val Ala Ile Thr His Asp Gly Tyr Tyr Arg Cys Ile Met Val Thr Pro
 145 150 155 160
 Asp Gly Asn Phe His Arg Gly Tyr His Leu Gln Val Leu Val Thr Pro
 165 170 175
 Glu Val Thr Leu Phe Gln Asn Arg Asn Arg Thr Ala Val Cys Lys Ala
 180 185 190
 Val Ala Gly Lys Pro Ala Ala His Ile Ser Trp Ile Pro Glu Gly Asp
 195 200 205
 Cys Ala Thr Lys Gln Glu Tyr Trp Ser Asn Gly Thr Val Thr Val Lys
 210 215 220
 Ser Thr Cys His Trp Glu Val His Asn Val Ser Thr Val Asn Cys His
 225 230 235 240
 Val Ser His Leu Thr Gly Asn Lys Ser Leu Tyr Ile Glu Leu Leu Pro
 245 250 255
 Val Pro Gly Ala Lys Lys Ser Ala Lys Leu Tyr Ile Pro Tyr Ile Ile
 260 265 270
 Leu Thr Ile Ile Ile Leu Thr Ile Val Gly Phe Ile Trp Leu Leu Lys
 275 280 285
 Val Asn Gly Cys Arg Lys Tyr Lys Leu Asn Lys Thr Glu Ser Thr Pro
 290 295 300
 Val Val Glu Glu Asp Glu Met Gln Pro Tyr Ala Ser Tyr Thr Glu Lys
 305 310 315 320
 Asn Asn Pro Leu Tyr Asp Thr Thr Asn Lys Val Lys Ala Ser Glu Ala
 325 330 335
 Leu Gln Ser Glu Val Asp Thr Asp Leu His Thr Leu
 340 345

<210> 209

<211> 73

<212> PRT

<213> Homo sapiens

<220>

<221> SITE
 <222> (73)
 <223> Xaa equals stop translation

 <400> 209
 Met Ala Arg Gly Cys Val Cys Ser Leu Cys Ala Ser Val Cys Ile Phe
 1 5 10 15
 Leu Ser Ser Leu Phe Pro Leu Leu Pro Ser Val His Ser Val Asn Ile
 20 25 30
 Ile Ser Cys Leu Leu Leu Ser Lys Cys Phe Glu Gly Leu Glu Leu Met
 35 40 45
 Cys Glu His Leu Tyr Gln Leu Ser Gln Leu His Val Leu His His Ile
 50 55 60
 Phe Ser Tyr Leu Leu Cys Thr Pro Xaa
 65 70

<210> 210
 <211> 608
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (265)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (597)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 210
 Met Val Gly Thr Lys Leu Arg Gln Thr Lys Asp Ala Leu Phe Thr Ile
 1 5 10 15
 Leu His Asp Leu Arg Pro Gln Asp Arg Phe Ser Ile Ile Gly Phe Ser
 20 25 30
 Asn Arg Ile Lys Val Trp Lys Asp His Leu Ile Ser Val Thr Pro Asp
 35 40 45
 Ser Ile Arg Asp Gly Lys Val Tyr Ile His His Met Ser Pro Thr Gly
 50 55 60
 Gly Thr Asp Ile Asn Gly Val Leu Gln Arg Ala Ile Arg Leu Leu Asn
 65 70 75 80
 Lys Tyr Val Ala His Ser Gly Ile Gly Asp Arg Ser Val Ser Leu Ile
 85 90 95
 Val Phe Leu Thr Asp Gly Lys Pro Thr Val Gly Glu Thr His Thr Leu
 100 105 110
 Lys Ile Leu Asn Asn Thr Arg Glu Ala Ala Arg Gly Gln Val Cys Ile

115	120	125
Phe Thr Ile Gly Ile Gly Asn Asp Val Asp Phe Arg Leu Leu Glu Lys		
130	135	140
Leu Ser Leu Glu Asn Cys Gly Leu Thr Arg Arg Val His Glu Glu Glu		
145	150	155
Asp Ala Gly Ser Gln Leu Ile Gly Phe Tyr Asp Glu Ile Arg Thr Pro		
	165	170
		175
Leu Leu Ser Asp Ile Arg Ile Asp Tyr Pro Pro Ser Ser Val Val Gln		
	180	185
		190
Ala Thr Lys Thr Leu Phe Pro Asn Tyr Phe Asn Gly Ser Glu Ile Ile		
	195	200
		205
Ile Ala Gly Lys Leu Val Asp Arg Lys Leu Asp His Leu His Val Glu		
	210	215
		220
Val Thr Ala Ser Asn Ser Lys Lys Phe Ile Ile Leu Lys Thr Asp Val		
	225	230
		235
Pro Val Arg Pro Gln Lys Ala Gly Lys Asp Val Thr Gly Ser Pro Arg		
	245	250
		255
Pro Gly Gly Asp Gly Glu Gly Asp Xaa Asn His Ile Glu Arg Leu Trp		
	260	265
		270
Ser Tyr Leu Thr Thr Lys Glu Leu Leu Ser Ser Trp Leu Gln Ser Asp		
	275	280
		285
Asp Glu Pro Glu Lys Glu Arg Leu Arg Gln Arg Ala Gln Ala Leu Ala		
	290	295
		300
Val Ser Tyr Arg Phe Leu Thr Pro Phe Thr Ser Met Lys Leu Arg Gly		
	305	310
		315
Pro Val Pro Arg Met Asp Gly Leu Glu Glu Ala His Gly Met Ser Ala		
	325	330
		335
Ala Met Gly Pro Glu Pro Val Val Gln Ser Val Arg Gly Ala Gly Thr		
	340	345
		350
Gln Pro Gly Pro Leu Leu Lys Lys Pro Tyr Gln Pro Arg Ile Lys Ile		
	355	360
		365
Ser Lys Thr Ser Val Asp Gly Asp Pro His Phe Val Val Asp Phe Pro		
	370	375
		380
Leu Ser Arg Leu Thr Val Cys Phe Asn Ile Asp Gly Gln Pro Gly Asp		
	385	390
		395
		400
Ile Leu Arg Leu Val Ser Asp His Arg Asp Ser Gly Val Thr Val Asn		
	405	410
		415
Gly Glu Leu Ile Gly Ala Pro Ala Pro Pro Asn Gly His Lys Lys Gln		
	420	425
		430

Arg Thr Tyr Leu Arg Thr Ile Thr Ile Leu Ile Asn Lys Pro Glu Arg
 435 440 445
 Ser Tyr Leu Glu Ile Thr Pro Ser Arg Val Ile Leu Asp Gly Gly Asp
 450 455 460
 Arg Leu Val Leu Pro Cys Asn Gln Ser Val Val Val Gly Ser Trp Gly
 465 470 475 480
 Leu Glu Val Ser Val Ser Ala Asn Ala Asn Val Thr Val Thr Ile Gln
 485 490 495
 Gly Ser Ile Ala Phe Val Ile Leu Ile His Leu Tyr Lys Lys Pro Ala
 500 505 510
 Pro Phe Gln Arg His His Leu Gly Phe Tyr Ile Ala Asn Ser Glu Gly
 515 520 525
 Leu Ser Ser Asn Cys His Gly Leu Leu Gly Gln Phe Leu Asn Gln Asp
 530 535 540
 Ala Arg Leu Thr Glu Asp Pro Ala Gly Pro Ser Gln Asn Leu Thr His
 545 550 555 560
 Pro Leu Leu Leu Gln Val Gly Glu Gly Pro Glu Ala Val Leu Thr Val
 565 570 575
 Lys Gly His Gln Val Pro Val Val Trp Lys Gln Arg Lys Ile Tyr Asn
 580 585 590
 Gly Glu Glu Gln Xaa Asp Cys Trp Phe Ala Arg Asn Met Pro Pro Asn
 595 600 605

<210> 211
 <211> 252
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (252)
 <223> Xaa equals stop translation

<400> 211
 Met Ala Pro Ala Ser Arg Leu Leu Ala Leu Trp Ala Leu Ala Ala Val
 1 5 10 15
 Ala Leu Pro Gly Ser Gly Ala Glu Gly Asp Gly Gly Trp Arg Pro Gly
 20 25 30
 Gly Pro Gly Ala Val Ala Glu Glu Glu Arg Cys Thr Val Glu Arg Arg
 35 40 45
 Ala Asp Leu Thr Tyr Ala Glu Phe Val Gln Gln Tyr Ala Phe Val Arg
 50 55 60

Pro Val Ile Leu Gln Gly Leu Thr Asp Asn Ser Arg Phe Arg Ala Leu
 65 70 75 80
 Cys Ser Arg Asp Arg Leu Leu Ala Ser Phe Gly Asp Arg Val Val Arg
 85 90 95
 Leu Ser Thr Ala Asn Thr Tyr Ser Tyr His Lys Val Asp Leu Pro Phe
 100 105 110
 Gln Glu Tyr Val Glu Gln Leu Leu His Pro Gln Asp Pro Thr Ser Leu
 115 120 125
 Gly Asn Asp Thr Leu Tyr Phe Phe Gly Asp Asn Asn Phe Thr Glu Trp
 130 135 140
 Ala Ser Leu Phe Arg His Tyr Ser Pro Pro Phe Gly Leu Leu Gly
 145 150 155 160
 Thr Ala Pro Ala Tyr Ser Phe Gly Ile Ala Gly Ala Gly Ser Gly Val
 165 170 175
 Pro Phe His Trp His Gly Pro Gly Tyr Ser Glu Val Ile Tyr Gly Arg
 180 185 190
 Lys Arg Trp Phe Leu Tyr Pro Pro Glu Lys Thr Pro Glu Phe His Pro
 195 200 205
 Asn Lys Thr Thr Leu Ala Trp Leu Arg Asp Thr Tyr Pro Ala Cys Thr
 210 215 220
 Val Cys Thr Ala Leu Glu Cys Thr Ile Arg Ala Gly Glu Val Leu Thr
 225 230 235 240
 Ser Arg Pro Leu Val Ala Cys Tyr Ala Gln Pro Xaa
 245 250

<210> 212
 <211> 226
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (226)
 <223> Xaa equals stop translation

<400> 212
 Met Lys Glu Ile Pro Ala Leu Leu His Leu Pro Val Leu Ile Ile Met
 1 5 10 15
 Ala Leu Ala Ile Leu Ser Phe Cys Tyr Gly Ala Gly Lys Ser Val His
 20 25 30
 Val Leu Arg His Ile Gly Gly Pro Glu Arg Glu Pro Pro Gln Ala Leu
 35 40 45
 Arg Pro Arg Asp Arg Arg Arg Gln Glu Glu Ile Asp Tyr Arg Pro Asp

<210> 214
 <211> 172
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (172)
 <223> Xaa equals stop translation

<400> 214
 Met Trp Leu Trp Ala Val Ser Pro Val Arg Pro Arg Thr Cys Leu Pro
 1 5 10 15
 Pro Cys Pro Arg Leu Trp Leu Trp Ile Ser Met Thr Leu Val Pro Ser
 20 25 30
 Ser Ser Ala Trp Lys Ser His Gly Ala Pro Ser Thr Arg Met Thr Ser
 35 40 45
 Pro Gln Leu Leu Leu Leu Ser Thr Arg Pro Pro Gln Ser Pro Ser Ala
 50 55 60
 Ser Pro Pro Ile Ala Arg Ala His Arg Thr His Pro His Phe Gly Asn
 65 70 75 80
 Arg Leu Ser Ile Thr Cys Cys Asp Gly Arg Arg Ser Trp Arg Met Gly
 85 90 95
 Gln His Gly Pro Cys His Leu Asn Leu Gln Thr Thr His Pro Ala His
 100 105 110
 Ser Ser Gln Ala Leu Pro Ala Thr His Gln Pro Leu Gly Pro Trp Cys
 115 120 125
 Ser Ser Pro Ser Pro Phe Pro Ser Lys Leu Pro Ser Ala Gly Lou Arg
 130 135 140
 Pro Pro Ala Leu Gly Pro Trp Met Arg Arg Gly Pro Trp Pro Gln Ser
 145 150 155 160
 Trp Gln Met Gly Met His Pro Thr Val Gly Leu Xaa
 165 170

<210> 215
 <211> 48
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (48)
 <223> Xaa equals stop translation

<400> 215
 Met Trp Leu Leu Ile Ile Phe Cys Lys Ser Ala Ser Ala Ser Val Leu
 1 5 10 15

Cys Trp Ile Lys Lys Phe His Pro Val Phe Gln Glu Ser Leu Leu Tyr
 20 25 30
 Leu Val Gln Glu Gly Ser Leu Cys Tyr Val Gln Gln Lys Val Pro Xaa
 35 40 45

<210> 216
 <211> 139
 <212> PRT
 <213> Homo sapiens

<400> 216
 Met Glu Ala Val Val Phe Val Phe Ser Leu Leu Asp Cys Cys Ala Leu
 1 5 10 15
 Ile Phe Leu Ser Val Tyr Phe Ile Ile Thr Leu Ser Asp Leu Glu Cys
 20 25 30
 Asp Tyr Ile Asn Ala Arg Ser Cys Cys Ser Lys Leu Asn Lys Trp Val
 35 40 45
 Ile Pro Glu Leu Ile Gly His Thr Ile Val Thr Val Leu Leu Leu Met
 50 55 60
 Ser Leu His Trp Phe Ile Phe Leu Leu Asn Leu Pro Val Ala Thr Trp
 65 70 75 80
 Asn Ile Tyr Arg Tyr Ile Met Val Pro Ser Gly Asn Met Gly Val Phe
 85 90 95
 Asp Pro Thr Glu Ile His Asn Arg Gly Gln Leu Lys Ser His Met Lys
 100 105 110
 Glu Ala Met Ile Lys Leu Gly Phe His Leu Leu Cys Phe Phe Met Tyr
 115 120 125
 Leu Tyr Ser Met Ile Leu Ala Leu Ile Asn Asp
 130 135

<210> 217
 <211> 41
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (41)
 <223> Xaa equals stop translation

<400> 217
 Met Ser Gly Ser Ser Leu Pro Ser Ala Leu Ala Leu Ser Leu Leu Leu
 1 5 10 15

Val Ser Gly Ser Leu Leu Pro Gly Pro Gly Ala Ala Gln Asn Val Arg
20 25 30

Val Gln Ser Gly Gln Asp Gln Lys Xaa
35 40

<210> 218
<211> 52
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (52)
<223> Xaa equals stop translation

<400> 218
Met Pro Ser His Ile Arg Ala His Leu Phe Leu Leu Leu Phe Phe Leu
1 5 10 15
Phe Ile Tyr Gln Gly Ile Ser Ser Ile Ser Gln Ala Ser Gly Leu Thr
20 25 30
Leu Lys Thr Gln Asn Glu Lys Asp Ile Gln Val Ser Ile Leu Lys Glu
35 40 45

Phe Val Val Xaa
50

<210> 219
<211> 49
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (49)
<223> Xaa equals stop translation

<400> 219
Met Cys Ile Tyr Gln Ser Glu Gln Met Leu Ala Leu Leu Leu Val Leu
1 5 10 15
Val Phe Cys Ile Ser Leu Leu Val Leu Val Cys Trp Gly Ser His Asn
20 25 30
Lys Val Pro Gln Lys Phe Ile Phe Ser Gln Phe Trp Gly Leu Glu Asp
35 40 45

Xaa

<210> 220
<211> 42
<212> PRT
<213> Homo sapiens

<220>
 <221> SITE
 <222> (42)
 <223> Xaa equals stop translation

<400> 220
 Met Ala Val Pro Leu Phe Leu Tyr Ile Phe Thr Leu Leu Pro Leu Leu
 1 5 10 15
 Pro Phe Leu Leu Ser Leu Cys Phe Ser Pro Leu Thr Val Lys Arg Ser
 20 25 30
 Ser Ser Ser Glu Ser Lys Ser Ser Leu Xaa
 35 40

<210> 221
 <211> 41
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (41)
 <223> Xaa equals stop translation

<400> 221
 Met Gly Met Leu Leu Ala Phe Trp Leu Pro Gly Ala Ser Trp Gln Glu
 1 5 10 15
 Ala Gly Pro Arg Ala Ser Thr Gln Arg Met Arg Thr Gln Thr Gln Met
 20 25 30
 Ser Thr Arg Lys Pro Lys Pro Ala Xaa
 35 40

<210> 222
 <211> 43
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (43)
 <223> Xaa equals stop translation

<400> 222
 Met Glu Pro Ala Met Val Leu Lys Phe Leu Ser Ser Leu Pro Glu Asn
 1 5 10 15
 Leu Phe Leu Pro Ser Leu Leu Phe Phe Ala Trp Leu Cys Trp Asn Met
 20 25 30
 Val Cys Gly Ser Pro Val Ser Cys Pro Tyr Xaa
 35 40

<210> 223
 <211> 204
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (204)
 <223> Xaa equals stop translation

<400> 223
 Met Gln Leu Gly Ser Val Leu Leu Thr Arg Cys Pro Phe Trp Gly Cys
 1 5 10 15
 Phe Ser Gln Leu Met Leu Tyr Ala Glu Arg Ala Glu Ala Arg Arg Lys
 20 25 30
 Pro Asp Ile Pro Val Pro Tyr Leu Tyr Phe Asp Met Gly Ala Ala Val
 35 40 45
 Leu Cys Ala Ser Phe Met Ser Phe Gly Val Lys Arg Arg Trp Phe Ala
 50 55 60
 Leu Gly Ala Ala Leu Gln Leu Ala Ile Ser Thr Tyr Ala Ala Tyr Ile
 65 70 75 80
 Gly Gly Tyr Val His Tyr Gly Asp Trp Leu Lys Val Arg Met Tyr Ser
 85 90 95
 Arg Thr Val Ala Ile Ile Gly Gly Phe Leu Val Leu Ala Ser Gly Ala
 100 105 110
 Gly Glu Leu Tyr Arg Arg Lys Pro Arg Ser Arg Ser Leu Gln Ser Thr
 115 120 125
 Gly Gln Val Phe Leu Gly Ile Tyr Leu Ile Cys Val Ala Tyr Ser Leu
 130 135 140
 Gln His Ser Lys Glu Asp Arg Leu Ala Tyr Leu Asn His Leu Pro Gly
 145 150 155 160
 Gly Glu Leu Met Ile Gln Leu Phe Phe Val Leu Tyr Gly Ile Leu Ala
 165 170 175
 Pro Gly Leu Ser Val Arg Leu Leu Arg Asp Pro Arg Cys Pro Asp Pro
 180 185 190
 Gly Cys Thr Ala Ala Pro Cys His Ala Ala His Xaa
 195 200

<210> 224
 <211> 43
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (43)

<223> Xaa equals stop translation

<400> 224

Met Arg Val Arg Ile Gly Leu Thr Leu Leu Leu Cys Ala Val Leu Leu
1 5 10 15

Ser Leu Ala Ser Ala Ser Ser Asp Glu Glu Gly Ser Gln Asp Glu Ser
20 25 30

Leu Gly Phe Gln Asp Tyr Phe Asp Ile Arg Xaa
35 40

<210> 225

<211> 156

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (156)

<223> Xaa equals stop translation

<400> 225

Met Ala Arg Gly Ser Leu Arg Arg Leu Leu Arg Leu Leu Val Leu Gly
1 5 10 15

Leu Trp Leu Ala Leu Leu Arg Ser Val Ala Gly Glu Gln Ala Pro Gly
20 25 30

Thr Ala Pro Cys Ser Arg Gly Ser Ser Trp Ser Ala Asp Leu Asp Lys
35 40 45

Cys Met Asp Cys Ser Thr Ser Cys Pro Leu Pro Ala Ala Leu Ala His
50 55 60

Pro Trp Gly Arg Ser Glu Pro Asp Leu Arg Ala Gly Ala Ala Phe Trp
65 70 75 80

Leu Phe Gly Leu Glu Thr Met Pro Gln Glu Arg Glu Val His His Pro
85 90 95

His Arg Gly Asp Arg Arg Arg Gly Leu Pro Ser Cys Gly Ala Asp Pro
100 105 110

Val Thr Met Cys Pro Leu Pro Ala Gly Ala Arg Pro Leu Ile Ile His
115 120 125

Ser Ser Ile Leu Glu Pro Val Ser Ala Ser Gln Thr Arg Arg Glu Pro
130 135 140

Ser Ser Ser Asn His Lys Gly Gly Gly Gly Arg Xaa
145 150 155

<210> 226

<211> 74

<212> PRT

<213> Homo sapiens

<220>
 <221> SITE
 <222> (38)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (48)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (54)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (55)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (68)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (74)
 <223> Xaa equals stop translation

 <400> 226
 Met Phe Tyr Lys Leu Thr Leu Ile Leu Cys Glu Leu Ser Val Ala Gly
 1 5 10 15
 Val Thr Gln Ala Ala Ser Gln Arg Pro Leu Gln Arg Leu Pro Arg His
 20 25 30
 Ile Cys Ser Gln Arg Xaa Pro Pro Gly Arg Cys Leu Leu Lys Ala Xaa
 35 40 45
 Leu Gln Thr Thr Trp Xaa Xaa Pro Asp Lys Pro Ile Pro Arg Leu Ser
 50 55 60
 Pro Pro Leu Xaa Ser Asp Pro Lys Arg Xaa
 65 70

<210> 227
 <211> 167
 <212> PRT
 <213> Homo sapiens

 <220>
 <221> SITE
 <222> (167)
 <223> Xaa equals stop translation

 <400> 227

Met Gly Ser Arg Phe Leu Leu Val Leu Leu Ser Gly Leu Thr Val Leu
 1 5 10 15
 Leu Ala Leu Pro Gly Ser Glu Ala Lys Asn Ser Gly Ala Ser Cys Pro
 20 25 30
 Pro Cys Pro Lys Tyr Ala Ser Cys His Asn Ser Thr His Cys Thr Cys
 35 40 45
 Glu Asp Gly Phe Arg Ala Arg Ser Gly Arg Thr Tyr Phe His Asp Ser
 50 55 60
 Ser Glu Lys Cys Glu Asp Ile Asn Glu Cys Glu Thr Gly Leu Ala Lys
 65 70 75 80
 Cys Lys Tyr Lys Ala Tyr Cys Arg Asn Lys Val Gly Gly Tyr Ile Cys
 85 90 95
 Ser Cys Leu Val Lys Tyr Thr Leu Phe Asn Phe Leu Ala Gly Ile Ile
 100 105 110
 Asp Tyr Asp His Pro Asp Cys Tyr Glu Asn Asn Ser Gln Gly Thr Thr
 115 120 125
 Gln Ser Asn Val Asp Ile Trp Val Ser Gly Val Lys Pro Gly Phe Gly
 130 135 140
 Lys Gln Leu Val Arg Ile Thr Met Pro Phe Ser Tyr Pro Asn Ile Asn
 145 150 155 160
 Met Ser Ser Cys Asp Phe Xaa
 165

<210> 228

<211> 71

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (71)

<223> Xaa equals stop translation

<400> 228

Met Lys Pro Lys His Leu Glu Trp Cys Leu Ala His Ser Trp Cys Val
 1 5 10 15
 Ile Trp Leu Ser Phe Val Ser Pro Pro Thr Ser His Leu Glu Cys Asp
 20 25 30
 Gly Phe Pro Gly Ser Leu Leu Pro Pro Cys Glu Glu Gly Arg Cys Phe
 35 40 45
 Pro Phe Thr Phe His His His Asp Cys His Gly Cys Ser Pro Leu Gln
 50 55 60
 Ser Ser Pro Gly Gln His Xaa
 65 70

<210> 229
 <211> 273
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (273)
 <223> Xaa equals stop translation

<400> 229
 Met Cys Cys Trp Pro Leu Leu Leu Leu Trp Gly Leu Leu Pro Gly Thr
 1 5 10 15
 Ala Ala Gly Gly Ser Gly Arg Thr Tyr Pro His Arg Thr Leu Leu Asp
 20 25 30
 Ser Glu Gly Lys Tyr Trp Leu Gly Trp Ser Gln Arg Gly Ser Gln Ile
 35 40 45
 Ala Phe Arg Leu Gln Val Arg Thr Ala Gly Tyr Val Gly Phe Gly Phe
 50 55 60
 Ser Pro Thr Gly Ala Met Ala Ser Ala Asp Ile Val Val Gly Gly Val
 65 70 75 80
 Ala His Gly Arg Pro Tyr Leu Gln Asp Tyr Phe Thr Asn Ala Asn Arg
 85 90 95
 Glu Leu Lys Lys Asp Ala Gln Gln Asp Tyr His Leu Glu Tyr Ala Met
 100 105 110
 Glu Asn Ser Thr His Thr Ile Ile Glu Phe Thr Arg Glu Leu His Thr
 115 120 125
 Cys Asp Ile Asn Asp Lys Ser Ile Thr Asp Ser Thr Val Arg Val Ile
 130 135 140
 Trp Ala Tyr His His Glu Asp Ala Gly Glu Ala Gly Pro Lys Tyr His
 145 150 155 160
 Asp Ser Asn Arg Gly Thr Lys Ser Leu Arg Leu Leu Asn Pro Glu Lys
 165 170 175
 Thr Ser Val Leu Ser Thr Ala Leu Pro Tyr Phe Asp Leu Val Asn Gln
 180 185 190
 Asp Val Pro Ile Pro Asn Lys Asp Thr Thr Tyr Trp Cys Gln Met Phe
 195 200 205
 Lys Ile Pro Val Phe Gln Glu Lys His His Val Ile Lys Val Glu Pro
 210 215 220
 Val Ile Gln Arg Gly His Glu Ser Leu Val His His Ile Leu Leu Tyr
 225 230 235 240
 Gln Cys Ser Asn Asn Phe Asn Asp Ser Val Pro Gly Ile Arg Ala Arg

245 250 255
 Ile Ala Ile Thr Pro Thr Cys Pro Met His Ser Ser Pro Val Lys Leu
 260 265 270

Xaa

<210> 230
 <211> 82
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (82)
 <223> Xaa equals stop translation

<400> 230
 Met Arg Pro Gly Thr Ala Leu Gln Ala Val Leu Leu Ala Val Leu Leu
 1 5 10 15
 Val Gly Leu Arg Ala Ala Thr Gly Arg Leu Leu Ser Gly Gln Pro Val
 20 25 30
 Cys Arg Gly Gly Thr Gln Arg Pro Cys Tyr Lys Val Ile Tyr Phe His
 35 40 45
 Asp Thr Ser Arg Arg Leu Asn Phe Glu Glu Ala Lys Glu Ala Cys Arg
 50 55 60
 Arg Gly Trp Arg Pro Ala Ser Gln His Arg Val Leu Lys Met Asn Arg
 65 70 75 80

Asn Xaa

<210> 231
 <211> 71
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (38)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 231
 Met Ser Pro Leu Ser Ala Ala Arg Ala Ala Leu Arg Val Tyr Ala Val
 1 5 10 15
 Gly Ala Ala Val Ile Leu Ala Gln Leu Leu Arg Arg Cys Arg Gly Gly
 20 25 30
 Phe Leu Glu Pro Val Xaa Pro Pro Arg Pro Asp Arg Val Ala Ile Val
 35 40 45

Thr Gly Gly Thr Asp Gly Ile Gly Tyr Ser Thr Ala Asn Ile Trp Arg
 50 55 60

Asp Leu Ala Cys Met Leu Ser
 65 70

<210> 232
 <211> 225
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (5)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 232
 His Glu Arg Ala Xaa Gly Pro Ser Arg Gly His Gly Glu Leu Leu Ser
 1 5 10 15
 Cys Val Leu Gly Pro Arg Leu Tyr Lys Ile Tyr Arg Glu Arg Asp Ser
 20 25 30
 Glu Arg Ala Pro Ala Ser Val Pro Glu Thr Pro Thr Ala Val Thr Ala
 35 40 45
 Pro His Ser Ser Ser Trp Asp Thr Tyr Tyr Gln Pro Arg Ala Leu Glu
 50 55 60
 Lys His Ala Asp Ser Ile Leu Ala Leu Ala Ser Val Phe Trp Ser Ile
 65 70 75 80
 Ser Tyr Tyr Ser Ser Pro Phe Ala Phe Phe Tyr Leu Tyr Arg Lys Gly
 85 90 95
 Tyr Leu Ser Leu Ser Lys Val Val Pro Phe Ser His Tyr Ala Gly Thr
 100 105 110
 Leu Leu Leu Leu Leu Ala Gly Val Ala Cys Ser Glu Ala Leu Ala Ala
 115 120 125
 Gly Pro Thr Pro Ser Thr Gly Ser Ser Ser Pro Ser Trp Lys Gln His
 130 135 140
 Ile Gly Thr Ser Leu Gln Lys Thr Arg Gly Ser Leu Pro Thr Thr Thr
 145 150 155 160
 Leu Thr Ser Gly Ala Gly Gln Ser Thr Ser Thr Gly Lys Asn Pro Ala
 165 170 175
 Ala Gly Arg Ser Leu Glu Gly Ala Leu Pro Ala Gly Val Trp Pro Cys
 180 185 190
 Phe Ala Gln Ser Pro Cys Thr Gly Gly Gln Gln Thr Pro Ser Ser Thr
 195 200 205
 Gly Leu Arg Ser Cys Leu Val Arg Ser Pro Ala Thr Trp Trp Arg Thr
 210 215 220

Pro
225

<210> 233
<211> 314
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (147)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (211)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 233
Met Leu Pro Ala Arg Leu Pro Phe Arg Leu Leu Ser Leu Phe Leu Arg
1 5 10 15
Gly Ser Ala Pro Thr Ala Ala Arg His Gly Leu Arg Glu Pro Leu Leu
20 25 30
Glu Arg Arg Cys Ala Ala Ala Ser Ser Phe Gln His Ser Ser Ser Leu
35 40 45
Gly Arg Glu Leu Pro Tyr Asp Pro Val Asp Thr Glu Gly Phe Gly Glu
50 55 60
Gly Gly Asp Met Gln Glu Arg Phe Leu Phe Pro Glu Tyr Ile Leu Asp
65 70 75 80
Pro Glu Pro Gln Pro Thr Arg Glu Lys Gln Leu Gln Glu Leu Gln Gln
85 90 95
Gln Gln Glu Glu Glu Glu Arg Gln Arg Gln Gln Arg Arg Glu Glu Arg
100 105 110
Arg Gln Gln Asn Leu Arg Ala Arg Ser Arg Glu His Pro Val Val Gly
115 120 125
His Pro Asp Pro Ala Leu Pro Pro Ser Gly Val Asn Cys Ser Gly Cys
130 135 140
Gly Ala Xaa Leu His Cys Gln Asp Ala Gly Val Pro Gly Tyr Leu Pro
145 150 155 160
Arg Glu Lys Phe Leu Arg Thr Ala Glu Ala Asp Gly Gly Leu Ala Arg
165 170 175
Thr Val Cys Gln Arg Cys Trp Leu Leu Ser His His Arg Arg Ala Leu
180 185 190
Arg Leu Gln Val Ser Arg Glu Gln Tyr Leu Glu Leu Val Ser Ala Ala
195 200 205

Leu Arg Xaa Pro Gly Pro Ser Leu Val Leu Tyr Met Val Asp Leu Leu
 210 215 220
 Asp Leu Pro Asp Ala Leu Leu Pro Asp Leu Pro Ala Leu Val Gly Pro
 225 230 235 240
 Lys Gln Leu Ile Val Leu Gly Asn Lys Val Asp Leu Leu Pro Gln Asp
 245 250 255
 Ala Pro Gly Tyr Arg Gln Arg Leu Arg Glu Arg Leu Trp Glu Asp Cys
 260 265 270
 Ala Arg Ala Gly Leu Leu Leu Ala Pro Gly Thr Lys Gly His Ser Ala
 275 280 285
 Pro Ser Arg Thr Ser His Arg Thr Gly Arg Ile Arg Ile Arg Arg Thr
 290 295 300
 Gly Pro Ala Gln Trp Ser Gly Thr Cys Gly
 305 310

<210> 234
 <211> 93
 <212> PRT
 <213> Homo sapiens

<400> 234
 Met Arg Pro Gln Gly Pro Ala Ala Ser Pro Gln Arg Leu Arg Gly Leu
 1 5 10 15
 Leu Leu Leu Leu Leu Leu Gln Leu Pro Ala Pro Ser Ser Ala Ser Glu
 20 25 30
 Ile Pro Lys Gly Lys Gln Lys Ala His Ser Gly Arg Gly Arg Trp Trp
 35 40 45
 Thr Cys Ile Met Glu Cys Ala Tyr Lys Gly Gln Gln Glu Cys Leu Val
 50 55 60
 Glu Thr Gly Ala Leu Gly Pro Met Ala Phe Arg Val His Leu Gly Ser
 65 70 75 80
 Gln Val Gly Met Asp Ser Lys Glu Lys Arg Gly Asn Val
 85 90

<210> 235
 <211> 73
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (73)
 <223> Xaa equals stop translation
 <400> 235

Met Gly Ser Ala Ala Leu Glu Ile Leu Gly Leu Val Leu Cys Leu Val
 1 5 10 15
 Gly Trp Gly Gly Leu Ile Leu Ala Cys Gly Leu Pro Met Trp Gln Val
 20 25 30
 Thr Ala Phe Leu Asp His Asn Ile Val Thr Ala Gln Thr Thr Trp Lys
 35 40 45
 Gly Leu Trp Met Ser Cys Val Val Gln Ser Thr Gly Thr Cys Ser Ala
 50 55 60
 Lys Cys Thr Thr Arg Cys Trp Leu Xaa
 65 70

<210> 236
 <211> 349
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (283)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (293)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (325)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (326)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (349)
 <223> Xaa equals stop translation

<400> 236
 Met Leu Cys Pro Trp Arg Thr Ala Asn Leu Gly Leu Leu Ile Leu
 1 5 10 15
 Thr Ile Phe Leu Val Ala Glu Ala Glu Gly Ala Ala Gln Pro Asn Asn
 20 25 30
 Ser Leu Met Leu Gln Thr Ser Lys Glu Asn His Ala Leu Ala Ser Ser
 35 40 45
 Ser Leu Cys Met Asp Glu Lys Gln Ile Thr Gln Asn Tyr Ser Lys Val
 50 55 60

Leu Ala Glu Val Asn Thr Ser Trp Pro Val Lys Met Ala Thr Asn Ala
 65 70 75 80
 Val Leu Cys Cys Pro Pro Ile Ala Leu Arg Asn Leu Ile Ile Ile Thr
 85 90 95
 Trp Glu Ile Ile Leu Arg Gly Gln Pro Ser Cys Thr Lys Ala Tyr Lys
 100 105 110
 Lys Glu Thr Asn Glu Thr Lys Glu Thr Asn Cys Thr Asp Glu Arg Ile
 115 120 125
 Thr Trp Val Ser Arg Pro Asp Gln Asn Ser Asp Leu Gln Ile Arg Thr
 130 135 140
 Val Ala Ile Thr His Asp Gly Tyr Tyr Arg Cys Ile Met Val Thr Pro
 145 150 155 160
 Asp Gly Asn Phe His Arg Gly Tyr His Leu Gln Val Leu Val Thr Pro
 165 170 175
 Glu Val Thr Leu Phe Gln Asn Arg Asn Arg Thr Ala Val Cys Lys Ala
 180 185 190
 Val Ala Gly Lys Pro Ala Ala His Ile Ser Trp Ile Pro Glu Gly Asp
 195 200 205
 Cys Ala Thr Lys Gln Glu Tyr Trp Ser Asn Gly Thr Val Thr Val Lys
 210 215 220
 Ser Thr Cys His Trp Glu Val His Asn Val Ser Thr Val Asn Cys His
 225 230 235 240
 Val Ser His Leu Thr Gly Asn Lys Ser Leu Tyr Ile Glu Leu Leu Pro
 245 250 255
 Val Pro Gly Ala Lys Lys Ser Ser Lys Leu Tyr Ile Pro Tyr Ile Ile
 260 265 270
 Leu Thr Ile Ile Ile Leu Thr Ile Val Gly Xaa Ile Trp Leu Leu Lys
 275 280 285
 Val Asn Gly Cys Xaa Lys Tyr Lys Leu Asn Lys Pro Glu Ser Thr Pro
 290 295 300
 Val Val Glu Glu Asp Glu Met Gln Pro Tyr Ala Phe Tyr Thr Glu Lys
 305 310 315 320
 Asn Asn Pro Leu Xaa Xaa Thr Thr Asn Lys Val Lys Ala Ser Glu Ala
 325 330 335
 Leu Gln Ser Glu Val Asp Thr Asp Leu His Thr Leu Xaa
 340 345

<210> 237

<211> 17

<212> PRT

<213> Homo sapiens

<400> 237

Leu Ala Leu Tyr Ser Ala Leu Phe Ser Tyr Ser Gly Trp Asp Thr Leu
1 5 10 15

Asn

<210> 238

<211> 14

<212> PRT

<213> Homo sapiens

<400> 238

Val Thr Glu Glu Ile Lys Asn Pro Glu Arg Asn Leu Pro Leu
1 5 10

<210> 239

<211> 9

<212> PRT

<213> Homo sapiens

<400> 239

Ile Gly Ile Ser Met Pro Ile Val Thr
1 5

<210> 240

<211> 13

<212> PRT

<213> Homo sapiens

<400> 240

Ile Tyr Ile Leu Thr Asn Val Ala Tyr Tyr Thr Val Leu
1 5 10

<210> 241

<211> 11

<212> PRT

<213> Homo sapiens

<400> 241

Ser Asp Ala Val Ala Val Thr Phe Ala Asp Gln
1 5 10

<210> 242

<211> 13

<212> PRT

<213> Homo sapiens

<400> 242

Val Ala Leu Ser Cys Phe Gly Gly Leu Asn Ala Ser Ile
1 5 10

<210> 243
<211> 15
<212> PRT
<213> Homo sapiens

<400> 243
Ser Arg Leu Phe Phe Val Gly Ser Arg Glu Gly His Leu Pro Asp
1 5 10 15

<210> 244
<211> 11
<212> PRT
<213> Homo sapiens

<400> 244
Ser Phe Ser Tyr Trp Phe Phe Val Gly Leu Ser
1 5 10

<210> 245
<211> 11
<212> PRT
<213> Homo sapiens

<400> 245
Val Gly Gln Leu Tyr Leu Arg Trp Lys Glu Pro
1 5 10

<210> 246
<211> 16
<212> PRT
<213> Homo sapiens

<400> 246
Arg Pro Arg Pro Leu Lys Leu Ser Val Phe Phe Pro Ile Val Phe Cys
1 5 10 15

<210> 247
<211> 9
<212> PRT
<213> Homo sapiens

<400> 247
Asp Thr Ile Asn Ser Leu Ile Gly Ile
1 5

<210> 248
<211> 44
<212> PRT
<213> Homo sapiens

<400> 248

Ala Thr Ala Leu Pro Pro Lys Ile Val Gly Ser Ala Thr Arg Tyr Leu
 1 5 10 15
 Gln Val Leu Cys Met Ser Val Ala Ala Glu Met Asp Leu Glu Asp Gly
 20 25 30
 Gly Glu Met Pro Lys Gln Arg Asp Pro Lys Ser Asn
 35 40

<210> 249
 <211> 352
 <212> PRT
 <213> Homo sapiens

<400> 249
 Leu Leu Ala Ala Ala Cys Ile Cys Leu Leu Thr Phe Ile Asn Cys Ala
 1 5 10 15
 Tyr Val Lys Trp Gly Thr Leu Val Gln Asp Ile Phe Thr Tyr Ala Lys
 20 25 30
 Val Leu Ala Leu Ile Ala Val Ile Val Ala Gly Ile Val Arg Leu Gly
 35 40 45
 Gln Gly Ala Ser Thr His Phe Glu Asn Ser Phe Glu Gly Ser Ser Phe
 50 55 60
 Ala Val Gly Asp Ile Ala Leu Ala Leu Tyr Ser Ala Leu Phe Ser Tyr
 65 70 75 80
 Ser Gly Trp Asp Thr Leu Asn Tyr Val Thr Glu Glu Ile Lys Asn Pro
 85 90 95
 Glu Arg Asn Leu Pro Leu Ser Ile Gly Ile Ser Met Pro Ile Val Thr
 100 105 110
 Ile Ile Tyr Ile Leu Thr Asn Val Ala Tyr Tyr Thr Val Leu Asp Met
 115 120 125
 Arg Asp Ile Leu Ala Ser Asp Ala Val Ala Val Thr Phe Ala Asp Gln
 130 135 140
 Ile Phe Gly Ile Phe Asn Trp Ile Ile Pro Leu Ser Val Ala Leu Ser
 145 150 155 160
 Cys Phe Gly Gly Leu Asn Ala Ser Ile Val Ala Ala Ser Arg Leu Phe
 165 170 175
 Phe Val Gly Ser Arg Glu Gly His Leu Pro Asp Ala Ile Cys Met Ile
 180 185 190
 His Val Glu Arg Phe Thr Pro Val Pro Ser Leu Leu Phe Asn Gly Ile
 195 200 205
 Met Ala Leu Ile Tyr Leu Cys Val Glu Asp Ile Phe Gln Leu Ile Asn
 210 215 220
 Tyr Tyr Ser Phe Ser Tyr Trp Phe Phe Val Gly Leu Ser Ile Val Gly

```
<210> 250
<211> 119
<212> PRT
<213> Homo sapiens
```

<210> 251

<211> 356
 <212> PRT
 <213> Homo sapiens

 <220>
 <221> SITE
 <222> (37)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (280)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <400> 251
 Leu Ser Lys Ala Phe Leu Asp Ser Pro Asn Arg Leu Leu Ala Val Glu
 1 5 10 15
 Met Asn Thr Asp His Leu Arg Leu Thr Val Pro Asn Gly Ile Gly Ala
 20 25 30
 Leu Lys Leu Arg Xaa Met Glu His Tyr Phe Ser Gln Gly Leu Ser Val
 35 40 45
 Gln Leu Phe Asn Asp Gly Ser Lys Gly Lys Leu Asn His Leu Cys Gly
 50 55 60
 Ala Asp Phe Val Lys Ser His Gln Lys Pro Pro Gln Gly Met Glu Ile
 65 70 75 80
 Lys Ser Asn Glu Arg Cys Cys Ser Phe Asp Gly Asp Ala Asp Arg Ile
 85 90 95
 Val Tyr Tyr Tyr His Asp Ala Asp Gly His Phe His Leu Ile Asp Gly
 100 105 110
 Asp Lys Ile Ala Thr Leu Ile Ser Ser Phe Leu Lys Glu Leu Leu Val
 115 120 125
 Glu Ile Gly Glu Ser Leu Asn Ile Gly Val Val Gln Thr Ala Tyr Ala
 130 135 140
 Asn Gly Ser Ser Thr Arg Tyr Leu Glu Glu Val Met Lys Val Pro Val
 145 150 155 160
 Tyr Cys Thr Lys Thr Gly Val Lys His Leu His His Lys Ala Gln Glu
 165 170 175
 Phe Asp Ile Gly Val Tyr Phe Glu Ala Asn Gly His Gly Thr Ala Leu
 180 185 190
 Phe Ser Thr Ala Val Glu Met Lys Ile Lys Gln Ser Ala Glu Gln Leu
 195 200 205
 Glu Asp Lys Lys Arg Lys Ala Ala Lys Met Leu Glu Asn Ile Ile Asp
 210 215 220
 Leu Phe Asn Gln Ala Ala Gly Asp Ala Ile Ser Asp Met Leu Val Ile
 225 230 235 240

Glu Ala Ile Leu Ala Leu Lys Gly Leu Thr Val Gln Gln Trp Asp Ala
 245 250 255
 Leu Tyr Thr Asp Leu Pro Asn Arg Gln Leu Lys Val Gln Val Ala Asp
 260 265 270
 Arg Arg Val Ile Ser Thr Thr Xaa Ala Glu Arg Gln Ala Val Thr Pro
 275 280 285
 Pro Gly Leu Gln Glu Ala Ile Asn Asp Leu Val Lys Lys Tyr Lys Leu
 290 295 300
 Ser Arg Ala Phe Val Arg Pro Ser Gly Thr Glu Asp Val Val Arg Val
 305 310 315 320
 Tyr Ala Glu Ala Asp Ser Gln Glu Ser Ala Asp His Leu Ala His Glu
 325 330 335
 Val Ser Leu Ala Val Phe Gln Leu Ala Gly Gly Ile Gly Glu Arg Pro
 340 345 350
 Gln Pro Gly Phe
 355

<210> 252
 <211> 26
 <212> PRT
 <213> Homo sapiens

<400> 252
 Leu Ser Lys Ala Phe Leu Asp Ser Pro Asn Arg Leu Leu Ala Val Glu
 1 5 10 15

Met Asn Thr Asp His Leu Arg Leu Thr Val
 20 25

<210> 253
 <211> 28
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (11)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 253
 Pro Asn Gly Ile Gly Ala Leu Lys Leu Arg Xaa Met Glu His Tyr Phe
 1 5 10 15

Ser Gln Gly Leu Ser Val Gln Leu Phe Asn Asp Gly
 20 25

<210> 254
 <211> 28

<212> PRT

<213> Homo sapiens

<400> 254

Ser Lys Gly Lys Leu Asn His Leu Cys Gly Ala Asp Phe Val Lys Ser
1 5 10 15

His Gln Lys Pro Pro Gln Gly Met Glu Ile Lys Ser
20 25

<210> 255

<211> 28

<212> PRT

<213> Homo sapiens

<400> 255

Asn Glu Arg Cys Cys Ser Phe Asp Gly Asp Ala Asp Arg Ile Val Tyr
1 5 10 15

Tyr Tyr His Asp Ala Asp Gly His Phe His Leu Ile
20 25

<210> 256

<211> 28

<212> PRT

<213> Homo sapiens

<400> 256

Asp Gly Asp Lys Ile Ala Thr Leu Ile Ser Ser Phe Leu Lys Glu Leu
1 5 10 15

Leu Val Glu Ile Gly Glu Ser Leu Asn Ile Gly Val
20 25

<210> 257

<211> 28

<212> PRT

<213> Homo sapiens

<400> 257

Val Gln Thr Ala Tyr Ala Asn Gly Ser Ser Thr Arg Tyr Leu Glu Glu
1 5 10 15

Val Met Lys Val Pro Val Tyr Cys Thr Lys Thr Gly
20 25

<210> 258

<211> 28

<212> PRT

<213> Homo sapiens

<400> 258

Val Lys His Leu His His Lys Ala Gln Glu Phe Asp Ile Gly Val Tyr
1 5 10 15

Phe Glu Ala Asn Gly His Gly Thr Ala Leu Phe Ser
20 25

<210> 259
<211> 28
<212> PRT
<213> Homo sapiens

<400> 259
Thr Ala Val Glu Met Lys Ile Lys Gln Ser Ala Glu Gln Leu Glu Asp
1 5 10 15
Lys Lys Arg Lys Ala Ala Lys Met Leu Glu Asn Ile
20 25

<210> 260
<211> 28
<212> PRT
<213> Homo sapiens

<400> 260
Ile Asp Leu Phe Asn Gln Ala Ala Gly Asp Ala Ile Ser Asp Met Leu
1 5 10 15
Val Ile Glu Ala Ile Leu Ala Leu Lys Gly Leu Thr
20 25

<210> 261
<211> 28
<212> PRT
<213> Homo sapiens

<400> 261
Val Gln Gln Trp Asp Ala Leu Tyr Thr Asp Leu Pro Asn Arg Gln Leu
1 5 10 15
Lys Val Gln Val Ala Asp Arg Arg Val Ile Ser Thr
20 25

<210> 262
<211> 28
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 262
Thr Xaa Ala Glu Arg Gln Ala Val Thr Pro Pro Gly Leu Gln Glu Ala
1 5 10 15
Ile Asn Asp Leu Val Lys Lys Tyr Lys Leu Ser Arg
20 25

<210> 263
<211> 24
<212> PRT
<213> Homo sapiens

<400> 263
Ala Phe Val Arg Pro Ser Gly Thr Glu Asp Val Val Arg Val Tyr Ala
1 5 10 15
Glu Ala Asp Ser Gln Glu Ser Ala
20

<210> 264
<211> 26
<212> PRT
<213> Homo sapiens

<400> 264
Asp His Leu Ala His Glu Val Ser Leu Ala Val Phe Gln Leu Ala Gly
1 5 10 15
Gly Ile Gly Glu Arg Pro Gln Pro Gly Phe
20 25

<210> 265
<211> 443
<212> PRT
<213> Homo sapiens

<400> 265
Gly Thr Arg Ala Ala Pro Gly Leu Gly Ala Trp Gly Arg Arg Ser Pro
1 5 10 15
Pro Ser Phe Ser Pro Pro Arg Pro Arg Arg Pro Gly Val Met Ala Gly
20 25 30
Leu Asn Cys Gly Val Ser Ile Ala Leu Leu Gly Val Leu Leu Leu Gly
35 40 45
Ala Ala Arg Leu Pro Arg Gly Ala Glu Ala Phe Glu Ile Ala Leu Pro
50 55 60
Arg Glu Ser Asn Ile Thr Val Leu Ile Lys Leu Gly Thr Pro Thr Leu
65 70 75 80
Leu Ala Lys Pro Cys Tyr Ile Val Ile Ser Lys Arg His Ile Thr Met
85 90 95
Leu Ser Ile Lys Ser Gly Glu Arg Ile Val Phe Thr Phe Ser Cys Gln
100 105 110
Ser Pro Glu Asn His Phe Val Ile Glu Ile Gln Lys Asn Ile Asp Cys
115 120 125
Met Ser Gly Pro Cys Pro Phe Gly Glu Val Gln Leu Gln Pro Ser Thr

130 135 140
 Ser Leu Leu Pro Thr Leu Asn Arg Thr Phe Ile Trp Asp Val Lys Ala
 145 150 155 160
 His Lys Ser Ile Gly Leu Glu Leu Gln Phe Ser Ile Pro Arg Leu Arg
 165 170 175
 Gln Ile Gly Pro Gly Glu Ser Cys Pro Asp Gly Val Thr His Ser Ile
 180 185 190
 Ser Gly Arg Ile Asp Ala Thr Val Val Arg Ile Gly Thr Phe Cys Ser
 195 200 205
 Asn Gly Thr Val Ser Arg Ile Lys Met Gln Glu Gly Val Lys Met Ala
 210 215 220
 Leu His Leu Pro Trp Phe His Pro Arg Asn Val Ser Gly Phe Ser Ile
 225 230 235 240
 Ala Asn Arg Ser Ser Ile Lys Arg Leu Cys Ile Ile Glu Ser Val Phe
 245 250 255
 Glu Gly Glu Gly Ser Ala Thr Leu Met Ser Ala Asn Tyr Pro Glu Gly
 260 265 270
 Phe Pro Glu Asp Glu Leu Met Thr Trp Gln Phe Val Val Pro Ala His
 275 280 285
 Leu Arg Ala Ser Val Ser Phe Leu Asn Phe Asn Leu Ser Asn Cys Glu
 290 295 300
 Arg Lys Glu Glu Arg Val Glu Tyr Tyr Ile Pro Gly Ser Thr Thr Asn
 305 310 315 320
 Pro Glu Val Phe Lys Leu Glu Asp Lys Gln Pro Gly Asn Met Ala Gly
 325 330 335
 Asn Phe Asn Leu Ser Leu Gln Gly Cys Asp Gln Asp Ala Gln Ser Pro
 340 345 350
 Gly Ile Leu Arg Leu Gln Phe Gln Val Leu Val Gln His Pro Gln Asn
 355 360 365
 Glu Ser Asn Lys Ile Tyr Val Val Asp Leu Ser Asn Glu Arg Ala Met
 370 375 380
 Ser Leu Thr Ile Glu Pro Arg Pro Val Lys Gln Ser Arg Lys Phe Val
 385 390 395 400
 Pro Gly Cys Phe Val Cys Leu Glu Ser Arg Thr Cys Ser Ser Asn Leu
 405 410 415
 Thr Leu Thr Ser Gly Ser Lys His Lys Ile Ser Phe Leu Cys Asp Asp
 420 425 430
 Leu Thr Arg Leu Trp Met Asn Val Glu Lys Pro
 435 440

<210> 266
 <211> 159
 <212> PRT
 <213> Homo sapiens

<400> 266
 Phe Glu Ile Ala Leu Pro Arg Glu Ser Asn Ile Thr Val Leu Ile Lys
 1 5 10 15
 Leu Gly Thr Pro Thr Leu Leu Ala Lys Pro Cys Tyr Ile Val Ile Ser
 20 25 30
 Lys Arg His Ile Thr Met Leu Ser Ile Lys Ser Gly Glu Arg Ile Val
 35 40 45
 Phe Thr Phe Ser Cys Gln Ser Pro Glu Asn His Phe Val Ile Glu Ile
 50 55 60
 Gln Lys Asn Ile Asp Cys Met Ser Gly Pro Cys Pro Phe Gly Glu Val
 65 70 75 80
 Gln Leu Gln Pro Ser Thr Ser Leu Leu Pro Thr Leu Asn Arg Thr Phe
 85 90 95
 Ile Trp Asp Val Lys Ala His Lys Ser Ile Gly Leu Glu Leu Gln Phe
 100 105 110
 Ser Ile Pro Arg Leu Arg Gln Ile Gly Pro Gly Glu Ser Cys Pro Asp
 115 120 125
 Gly Val Thr His Ser Ile Ser Gly Arg Ile Asp Ala Thr Val Val Arg
 130 135 140
 Ile Gly Thr Phe Cys Ser Asn Gly Thr Val Ser Arg Ile Lys Met
 145 150 155

<210> 267
 <211> 9
 <212> PRT
 <213> Homo sapiens

<400> 267
 Phe Val Arg Asp Pro Phe Val Arg Leu
 1 5

<210> 268
 <211> 13
 <212> PRT
 <213> Homo sapiens

<400> 268
 Phe Leu Phe Val Arg Asp Pro Phe Val Arg Leu Ile Ser
 1 5 10

<210> 269

<211> 15
 <212> PRT
 <213> Homo sapiens

<400> 269
 Phe Leu Phe Val Arg Asp Pro Phe Val Arg Leu Ile Ser Ala Phe
 1 5 10 15

<210> 270
 <211> 380
 <212> PRT
 <213> Homo sapiens

<400> 270
 Tyr Leu His Thr Ser Phe Ser Arg Pro His Thr Gly Pro Pro Leu Pro
 1 5 10 15
 Thr Pro Gly Pro Asp Arg Asp Arg Glu Leu Thr Ala Asp Ser Asp Val
 20 25 30
 Asp Glu Phe Leu Asp Lys Phe Leu Ser Ala Gly Val Lys Gln Ser Asp
 35 40 45
 Leu Pro Arg Lys Glu Thr Glu Gln Pro Pro Ala Pro Gly Ser Met Glu
 50 55 60
 Glu Asn Val Arg Gly Tyr Asp Trp Ser Pro Arg Asp Ala Arg Arg Ser
 65 70 75 80
 Pro Asp Gln Gly Arg Gln Gln Ala Glu Arg Arg Ser Val Leu Arg Gly
 85 90 95
 Phe Cys Ala Asn Ser Ser Leu Ala Phe Pro Thr Lys Glu Arg Ala Phe
 100 105 110
 Asp Asp Ile Pro Asn Ser Glu Leu Ser His Leu Ile Val Asp Asp Arg
 115 120 125
 His Gly Ala Ile Tyr Cys Tyr Val Pro Lys Val Ala Cys Thr Asn Trp
 130 135 140
 Lys Arg Val Met Ile Val Leu Ser Gly Ser Leu Leu His Arg Gly Ala
 145 150 155 160
 Pro Tyr Arg Asp Pro Leu Arg Ile Pro Arg Glu His Val His Asn Ala
 165 170 175
 Ser Ala His Leu Thr Phe Asn Lys Phe Trp Arg Arg Tyr Gly Lys Leu
 180 185 190
 Ser Arg His Leu Met Lys Val Lys Leu Lys Lys Tyr Thr Lys Phe Leu
 195 200 205
 Phe Val Arg Asp Pro Phe Val Arg Leu Ile Ser Ala Phe Arg Ser Lys
 210 215 220
 Phe Glu Leu Glu Asn Glu Glu Phe Tyr Arg Lys Phe Ala Val Pro Met
 225 230 235 240

```

Leu Arg Leu Tyr Ala Asn His Thr Ser Leu Pro Ala Ser Ala Arg Glu
      245                                250                                255
Ala Phe Arg Ala Gly Leu Lys Val Ser Phe Ala Asn Phe Ile Gln Tyr
      260                                265                                270
Leu Leu Asp Pro His Thr Glu Lys Leu Ala Pro Phe Asn Glu His Trp
      275                                280                                285
Arg Gln Val Tyr Arg Leu Cys His Pro Cys Gln Ile Asp Tyr Asp Phe
      290                                295                                300
Val Gly Lys Leu Glu Thr Leu Asp Glu Asp Ala Ala Gln Leu Leu Gln
      305                                310                                315
Leu Leu Gln Val Asp Arg Gln Leu Arg Phe Pro Pro Ser Tyr Arg Asn
      325                                330                                335
Arg Thr Ala Ser Ser Trp Glu Glu Asp Trp Phe Ala Lys Ile Pro Leu
      340                                345                                350
Ala Trp Arg Gln Gln Leu Tyr Lys Leu Tyr Glu Ala Asp Phe Val Leu
      355                                360                                365
Phe Gly Tyr Pro Lys Pro Glu Asn Leu Leu Arg Asp
      370                                375                                380

<210> 271
<211> 274
<212> PRT
<213> Homo sapiens

<400> 271
Lys Leu Val Arg Leu Gln Val Pro Val Arg Asn Ser Arg Val Asp Pro
  1          5          10          15
Arg Val Arg Ser Lys Ile Gly Ser Arg Arg Trp Met Leu Gln Leu Ile
      20          25          30
Met Gln Leu Gly Ser Val Leu Leu Thr Arg Cys Pro Phe Trp Gly Cys
      35          40          45
Phe Ser Gln Leu Met Leu Tyr Ala Glu Arg Ala Glu Ala Arg Arg Lys
      50          55          60
Pro Asp Ile Pro Val Pro Tyr Leu Tyr Phe Asp Met Gly Ala Ala Val
      65          70          75          80
Leu Cys Ala Ser Phe Met Ser Phe Gly Val Lys Arg Arg Trp Phe Ala
      85          90          95
Leu Gly Ala Ala Leu Gln Leu Ala Ile Ser Thr Tyr Ala Ala Tyr Ile
      100          105          110
Gly Gly Tyr Val His Tyr Gly Asp Trp Leu Lys Val Arg Met Tyr Ser
      115          120          125

```


Arg Thr Val Ala Ile Ile Gly Gly Phe Leu Val Leu Ala Ser Gly Ala
 130 135 140
 Gly Glu Leu Tyr Arg Arg Lys Pro Arg Ser Arg Ser Leu Gln Ser Thr
 145 150 155 160
 Gly Gln Val Phe Leu Gly Ile Tyr Leu Ile Cys Val Ala Tyr Ser Leu
 165 170 175
 Gln His Ser Lys Glu Asp Arg Leu Ala Tyr Leu Asn His Leu Pro Gly
 180 185 190
 Gly Glu Leu Met Ile Gln Leu Phe Phe Val Leu Tyr Gly Ile Leu Ala
 195 200 205
 Leu Ala Phe Leu Ser Gly Tyr Tyr Val Thr Leu Ala Ala Gln Ile Leu
 210 215 220
 Ala Val Leu Leu Pro Pro Val Met Leu Leu Ile Asp Gly Asn Val Ala
 225 230 235 240
 Tyr Trp His Asn Thr Arg Arg Val Glu Phe Trp Asn Gln Met Lys Leu
 245 250 255
 Leu Gly Glu Ser Val Gly Ile Phe Gly Thr Ala Val Ile Leu Ala Thr
 260 265 270

Asp Gly

<210> 272
 <211> 203
 <212> PRT
 <213> Homo sapiens

<400> 272
 Met Gln Leu Gly Ser Val Leu Leu Thr Arg Cys Pro Phe Trp Gly Cys
 1 5 10 15
 Phe Ser Gln Leu Met Leu Tyr Ala Glu Arg Ala Glu Ala Arg Arg Lys
 20 25 30
 Pro Asp Ile Pro Val Pro Tyr Leu Tyr Phe Asp Met Gly Ala Ala Val
 35 40 45
 Leu Cys Ala Ser Phe Met Ser Phe Gly Val Lys Arg Arg Trp Phe Ala
 50 55 60
 Leu Gly Ala Ala Leu Gln Leu Ala Ile Ser Thr Tyr Ala Ala Tyr Ile
 65 70 75 80
 Gly Gly Tyr Val His Tyr Gly Asp Trp Leu Lys Val Arg Met Tyr Ser
 85 90 95
 Arg Thr Val Ala Ile Ile Gly Gly Phe Leu Val Leu Ala Ser Gly Ala
 100 105 110
 Gly Glu Leu Tyr Arg Arg Lys Pro Arg Ser Arg Ser Leu Gln Ser Thr

115 120 125
 Gly Gln Val Phe Leu Gly Ile Tyr Leu Ile Cys Val Ala Tyr Ser Leu
 130 135 140
 Gln His Ser Lys Glu Asp Arg Leu Ala Tyr Leu Asn His Leu Pro Gly
 145 150 155 160
 Gly Glu Leu Met Ile Gln Leu Phe Phe Val Leu Tyr Gly Ile Leu Ala
 165 170 175
 Pro Gly Leu Ser Val Arg Leu Leu Arg Asp Pro Arg Cys Pro Asp Pro
 180 185 190
 Gly Cys Thr Ala Ala Pro Cys His Ala Ala His
 195 200

 <210> 273
 <211> 407
 <212> PRT
 <213> Homo sapiens

 <400> 273
 Ser Asn Glu Ile Leu Leu Ser Phe Pro Gln Asn Tyr Tyr Ile Gln Trp
 1 5 10 15
 Leu Asn Gly Ser Leu Ile His Gly Leu Trp Asn Leu Ala Ser Leu Phe
 20 25 30
 Ser Asn Leu Cys Leu Phe Val Leu Met Pro Phe Ala Phe Phe Phe Leu
 35 40 45
 Glu Ser Glu Gly Phe Ala Gly Leu Lys Lys Gly Ile Arg Ala Arg Ile
 50 55 60
 Leu Glu Thr Leu Val Met Leu Leu Leu Leu Ala Leu Leu Ile Leu Gly
 65 70 75 80
 Ile Val Trp Val Ala Ser Ala Leu Ile Asp Asn Asp Ala Ala Ser Met
 85 90 95
 Glu Ser Leu Tyr Asp Leu Trp Glu Phe Tyr Leu Pro Tyr Leu Tyr Ser
 100 105 110
 Cys Ile Ser Leu Met Gly Cys Leu Leu Leu Leu Cys Thr Pro Val
 115 120 125
 Gly Leu Ser Arg Met Phe Thr Val Met Gly His Leu Leu Val Lys Pro
 130 135 140
 Thr Ile Leu Glu Asp Leu Asp Glu Gln Ile Tyr Ile Ile Thr Leu Glu
 145 150 155 160
 Glu Glu Ala Leu Gln Arg Arg Leu Asn Gly Leu Ser Ser Ser Val Glu
 165 170 175
 Tyr Asn Ile Met Glu Leu Glu Gln Glu Leu Glu Asn Val Lys Thr Leu
 180 185 190

Lys Thr Lys Leu Glu Arg Arg Lys Lys Ala Ser Ala Trp Glu Arg Asn
 195 200 205
 Leu Val Tyr Pro Ala Val Met Val Leu Leu Leu Ile Glu Thr Ser Ile
 210 215 220
 Ser Val Leu Leu Val Ala Cys Asn Ile Leu Cys Leu Leu Val Asp Glu
 225 230 235 240
 Thr Ala Met Pro Lys Gly Thr Arg Gly Pro Gly Ile Gly Asn Ala Ser
 245 250 255
 Leu Ser Thr Phe Gly Phe Val Gly Ala Ala Leu Glu Ile Ile Leu Ile
 260 265 270
 Phe Tyr Leu Met Val Ser Ser Val Val Gly Phe Tyr Ser Leu Arg Phe
 275 280 285
 Phe Gly Asn Phe Thr Pro Lys Lys Asp Asp Thr Thr Met Thr Lys Ile
 290 295 300
 Ile Gly Asn Cys Val Ser Ile Leu Val Leu Ser Ser Ala Leu Pro Val
 305 310 315 320
 Met Ser Arg Thr Leu Gly Ile Thr Arg Phe Asp Leu Leu Gly Asp Phe
 325 330 335
 Gly Arg Phe Asn Trp Leu Gly Asn Phe Tyr Ile Val Leu Ser Tyr Asn
 340 345 350
 Leu Leu Phe Ala Ile Val Thr Thr Leu Cys Leu Val Arg Lys Phe Thr
 355 360 365
 Ser Ala Val Arg Glu Glu Leu Phe Lys Ala Leu Gly Leu His Lys Leu
 370 375 380
 His Leu Pro Asn Thr Ser Arg Asp Ser Glu Thr Ala Lys Pro Ser Val
 385 390 395 400
 Asn Gly His Gln Lys Ala Leu
 405

<210> 274
 <211> 165
 <212> PRT
 <213> Homo sapiens

<400> 274
 Arg Ser Tyr Met Gln Ser Val Trp Thr Glu Glu Ser Gln Cys Thr Leu
 1 5 10 15
 Leu Asn Ala Ser Ile Thr Glu Thr Phe Asn Cys Ser Phe Ser Cys Gly
 20 25 30
 Pro Asp Cys Trp Lys Leu Ser Gln Tyr Pro Cys Leu Gln Val Tyr Val
 35 40 45

Asn Leu Thr Ser Ser Gly Glu Lys Leu Leu Leu Tyr His Thr Glu Glu
 50 55 60
 Thr Ile Lys Ile Asn Gln Lys Cys Ser Tyr Ile Pro Lys Cys Gly Lys
 65 70 75 80
 Asn Phe Glu Glu Ser Met Ser Leu Val Asn Val Val Met Glu Asn Phe
 85 90 95
 Arg Lys Tyr Gln His Phe Ser Cys Tyr Ser Asp Pro Glu Gly Asn Gln
 100 105 110
 Lys Ser Val Ile Leu Thr Lys Leu Tyr Ser Ser Asn Val Leu Phe His
 115 120 125
 Ser Leu Phe Trp Pro Thr Cys Met Met Ala Gly Gly Val Ala Ile Val
 130 135 140
 Ala Met Val Lys Leu Thr Gln Tyr Leu Ser Leu Leu Cys Glu Arg Ile
 145 150 155 160
 Gln Arg Ile Asn Arg
 165

<210> 275
 <211> 155
 <212> PRT
 <213> Homo sapiens

<400> 275
 Ala Phe Ala His Leu Gln Leu Gly Pro Met Trp Lys Leu Trp Arg Ala
 1 5 10 15
 Glu Glu Gly Ala Ala Ala Leu Gly Gly Ala Leu Phe Leu Leu Phe
 20 25 30
 Ala Leu Gly Val Arg Gln Leu Leu Lys Gln Arg Arg Pro Met Gly Phe
 35 40 45
 Pro Pro Gly Pro Pro Gly Leu Pro Phe Ile Gly Asn Ile Tyr Ser Leu
 50 55 60
 Ala Ala Ser Ser Glu Leu Pro His Val Tyr Met Arg Lys Gln Ser Gln
 65 70 75 80
 Val Tyr Gly Glu Val Gln Pro Arg Arg Ala Pro Gly Arg Glu Gly Arg
 85 90 95
 Gln Ala Gly Pro Gly Trp Pro Gly Pro Ser Trp Leu Asp Leu Trp Pro
 100 105 110
 Pro Leu Gly Arg Leu Val Gly Thr Ser Pro Cys Ala Gly Cys Pro Leu
 115 120 125
 Arg Asp Thr Arg Phe Pro Gly Leu Glu Gly Arg Ser Pro Arg Arg Arg
 130 135 140
 Ala Pro Leu Gln Gly Glu Pro Arg Pro Cys Arg

145

150

155

<210> 276

<211> 42

<212> PRT

<213> Homo sapiens

<400> 276

Met Arg Val Arg Ile Gly Leu Thr Leu Leu Cys Ala Val Leu Leu
1 5 10 15

Ser Leu Ala Ser Ala Ser Ser Asp Glu Glu Gly Ser Gln Asp Glu Ser
20 25 30

Leu Gly Phe Gln Asp Tyr Phe Asp Ile Arg
35 40

<210> 277

<211> 155

<212> PRT

<213> Homo sapiens

<400> 277

Met Ala Arg Gly Ser Leu Arg Arg Leu Leu Arg Leu Leu Val Leu Gly
1 5 10 15

Leu Trp Leu Ala Leu Leu Arg Ser Val Ala Gly Glu Gln Ala Pro Gly
20 25 30

Thr Ala Pro Cys Ser Arg Gly Ser Ser Trp Ser Ala Asp Leu Asp Lys
35 40 45

Cys Met Asp Cys Ser Thr Ser Cys Pro Leu Pro Ala Ala Leu Ala His
50 55 60

Pro Trp Gly Arg Ser Glu Pro Asp Leu Arg Ala Gly Ala Ala Phe Trp
65 70 75 80

Leu Phe Gly Leu Glu Thr Met Pro Gln Glu Arg Glu Val His His Pro
85 90 95

His Arg Gly Asp Arg Arg Arg Gly Leu Pro Ser Cys Gly Ala Asp Pro
100 105 110

Val Thr Met Cys Pro Leu Pro Ala Gly Ala Arg Pro Leu Ile Ile His
115 120 125

Ser Ser Ile Leu Glu Pro Val Ser Ala Ser Gln Thr Arg Arg Glu Pro
130 135 140

Ser Ser Ser Asn His Lys Gly Gly Gly Gly Arg
145 150 155

<210> 278

<211> 207

<212> PRT

<213> Homo sapiens

<400> 278

Gly Thr Ser Phe Leu Asp Pro Thr Leu Ser Leu Phe Val Leu Glu Lys
 1 5 10 15
 Phe Asn Leu Pro Ala Gly Tyr Val Gly Leu Val Phe Leu Gly Met Ala
 20 25 30
 Leu Ser Tyr Ala Ile Ser Ser Pro Leu Phe Gly Leu Leu Ser Asp Lys
 35 40 45
 Arg Pro Pro Leu Arg Lys Trp Leu Leu Val Phe Gly Asn Leu Ile Thr
 50 55 60
 Ala Gly Cys Tyr Met Leu Leu Gly Pro Val Pro Ile Leu His Ile Lys
 65 70 75 80
 Ser Gln Leu Trp Leu Leu Val Leu Ile Leu Val Val Ser Gly Leu Ser
 85 90 95
 Ala Gly Met Ser Ile Ile Pro Thr Phe Pro Glu Ile Leu Ser Cys Ala
 100 105 110
 His Glu Asn Gly Phe Glu Glu Gly Leu Ser Thr Leu Gly Leu Val Ser
 115 120 125
 Gly Leu Phe Ser Ala Met Trp Ser Ile Gly Ala Phe Met Gly Pro Thr
 130 135 140
 Leu Gly Gly Phe Leu Tyr Glu Lys Ile Gly Phe Glu Trp Ala Ala Ala
 145 150 155 160
 Ile Gln Gly Leu Trp Ala Leu Ile Ser Gly Leu Ala Met Gly Leu Phe
 165 170 175
 Tyr Leu Leu Glu Tyr Ser Arg Arg Lys Arg Ser Lys Ser Gln Asn Ile
 180 185 190
 Leu Ser Thr Glu Glu Glu Arg Thr Thr Leu Leu Pro Asn Glu Thr
 195 200 205

<210> 279

<211> 85

<212> PRT

<213> Homo sapiens

<400> 279

Gly Thr Arg Glu Ala Arg Leu Arg Asp Leu Thr Arg Phe Tyr Asp Lys
 1 5 10 15
 Val Leu Ser Leu His Glu Asp Ser Thr Thr Pro Val Ala Asn Pro Leu
 20 25 30
 Leu Ala Phe Thr Leu Ile Lys Arg Leu Gln Ser Asp Trp Arg Asn Val
 35 40 45
 Val His Ser Leu Glu Ala Ser Glu Asn Ile Arg Ala Leu Lys Asp Gly

50 55 60
 Tyr Glu Lys Val Glu Gln Asp Leu Pro Ala Phe Glu Asp Leu Glu Gly
 65 70 75 80
 Ala Ala Arg Ala Leu
 85

 <210> 280
 <211> 7
 <212> PRT
 <213> Homo sapiens

 <400> 280
 Ala Leu Met Arg Leu Gln Asp
 1 5

 <210> 281
 <211> 7
 <212> PRT
 <213> Homo sapiens

 <400> 281
 Val Glu Ala Gly Gly Ala Thr
 1 5

 <210> 282
 <211> 489
 <212> PRT
 <213> Homo sapiens

 <400> 282
 Gly Thr Arg Glu Ala Arg Leu Arg Asp Leu Thr Arg Phe Tyr Asp Lys
 1 5 10 15
 Val Leu Ser Leu His Glu Asp Ser Thr Thr Pro Val Ala Asn Pro Leu
 20 25 30
 Leu Ala Phe Thr Leu Ile Lys Arg Leu Gln Ser Asp Trp Arg Asn Val
 35 40 45
 Val His Ser Leu Glu Ala Ser Glu Asn Ile Arg Ala Leu Lys Asp Gly
 50 55 60
 Tyr Glu Lys Val Glu Gln Asp Leu Pro Ala Phe Glu Asp Leu Glu Gly
 65 70 75 80
 Ala Ala Arg Ala Leu Met Arg Leu Gln Asp Val Tyr Met Leu Asn Val
 85 90 95
 Lys Gly Leu Ala Arg Gly Val Phe Gln Arg Val Thr Gly Ser Ala Ile
 100 105 110
 Thr Asp Leu Tyr Ser Pro Lys Arg Leu Phe Ser Leu Thr Gly Asp Asp
 115 120 125

Cys Phe Gln Val Gly Lys Val Ala Tyr Asp Met Gly Asp Tyr Tyr His
 130 135 140
 Ala Ile Pro Trp Leu Glu Glu Ala Val Ser Leu Phe Arg Gly Ser Tyr
 145 150 155 160
 Gly Glu Trp Lys Thr Glu Asp Glu Ala Ser Leu Glu Asp Ala Leu Asp
 165 170 175
 His Leu Ala Phe Ala Tyr Phe Arg Ala Gly Asn Val Ser Cys Ala Leu
 180 185 190
 Ser Leu Ser Arg Glu Phe Leu Leu Tyr Ser Pro Asp Asn Lys Arg Met
 195 200 205
 Ala Arg Asn Val Leu Lys Tyr Glu Arg Leu Leu Ala Glu Ser Pro Asn
 210 215 220
 His Val Val Ala Glu Ala Val Ile Gln Arg Pro Asn Ile Pro His Leu
 225 230 235 240
 Gln Thr Arg Asp Thr Tyr Glu Gly Leu Cys Gln Thr Leu Gly Ser Gln
 245 250 255
 Pro Thr Leu Tyr Gln Ile Pro Ser Leu Tyr Cys Ser Tyr Glu Thr Asn
 260 265 270
 Ser Asn Ala Tyr Leu Leu Leu Gln Pro Ile Arg Lys Glu Val Ile His
 275 280 285
 Leu Glu Pro Tyr Ile Ala Leu Tyr His Asp Phe Val Ser Asp Ser Glu
 290 295 300
 Ala Gln Lys Ile Arg Glu Leu Ala Glu Pro Trp Leu Gln Arg Ser Val
 305 310 315 320
 Val Ala Ser Gly Glu Lys Gln Leu Gln Val Glu Tyr Arg Ile Ser Lys
 325 330 335
 Ser Ala Trp Leu Lys Asp Thr Val Asp Leu Lys Leu Val Thr Leu Asn
 340 345 350
 His Arg Ile Ala Ala Leu Thr Gly Leu Asp Val Arg Pro Pro Tyr Ala
 355 360 365
 Glu Tyr Leu Gln Val Val Asn Tyr Gly Ile Gly Gly His Tyr Glu Pro
 370 375 380
 His Phe Asp His Ala Thr Ser Pro Ser Ser Pro Leu Tyr Arg Met Lys
 385 390 395 400
 Ser Gly Asn Arg Val Ala Thr Phe Met Ile Tyr Leu Ser Ser Val Glu
 405 410 415
 Ala Gly Gly Ala Thr Ala Phe Ile Tyr Ala Asn Leu Ser Val Pro Val
 420 425 430
 Val Arg Asn Ala Ala Leu Phe Trp Trp Asn Leu His Arg Ser Gly Glu
 435 440 445

Gly Asp Ser Asp Thr Leu His Ala Gly Cys Pro Val Leu Val Gly Asp
 450 455 460
 Lys Trp Val Ala Asn Lys Trp Ile His Glu Tyr Gly Gln Glu Phe Arg
 465 470 475 480
 Arg Pro Cys Ser Ser Ser Pro Glu Asp
 485

<210> 283
 <211> 136
 <212> PRT
 <213> Homo sapiens

<400> 283
 Ile Gln Pro Ser His Ala Ala Leu Leu His Cys Arg Ser Thr Phe Arg
 1 5 10 15
 Lys Thr Glu Cys Leu Asp Pro Trp Trp Val Arg Arg Gln Leu Leu Gly
 20 25 30
 Met Ala Gly Ile Gly Gly Leu Gln Lys Met Lys Ala Pro His Thr Gly
 35 40 45
 Val Leu His Leu Gly Ser Val Trp Val Phe Leu Gly Pro Phe Leu Leu
 50 55 60
 Gly Val Gly Tyr Thr Leu Thr Phe Asn Pro Leu Ser Gly Cys Met Ser
 65 70 75 80
 Thr Val Arg Trp Leu Asn Ser Asn Ile Thr Ala Asn Arg Thr Leu Ser
 85 90 95
 Arg Ser Val Cys His Val Thr Pro Leu His Arg Ser Leu Ser Pro His
 100 105 110
 Asp Gly Glu Tyr Leu Arg Gln Met Leu Leu Asn Ser Ser Ser Arg Ala
 115 120 125
 Gly Glu Ala Gly Ser Trp Gly Tyr
 130 135

<210> 284
 <211> 86
 <212> PRT
 <213> Homo sapiens

<400> 284
 Cys Ser Ser Pro Pro Gly Arg Leu Pro Trp Cys Trp Thr Ala Pro Arg
 1 5 10 15
 Thr Leu Gly Lys His Gly Ser Leu Ile Ser Thr Leu Arg Leu Thr Ala
 20 25 30
 Pro Leu His Leu Ala Trp Lys Met Met Leu Ser Arg Lys Ala Leu Phe
 35 40 45

Val Leu Leu Asn Thr Pro Val Leu Phe His Ala Leu Glu Gly Arg Leu
 50 55 60
 Phe Ser Lys Leu Cys His His Thr Ile Gln Arg Thr Leu Thr Val
 65 70 75 80
 Pro Lys Phe Arg Ser Ser
 85

<210> 285
 <211> 75
 <212> PRT
 <213> Homo sapiens

<400> 285
 Arg Ser Pro Thr Ser Arg Val Gln Leu Leu Lys Arg Gln Ser Cys Pro
 1 5 10 15
 Cys Gln Arg Asn Asp Leu Asn Glu Glu Pro Gln His Phe Thr His Tyr
 20 25 30
 Ala Ile Tyr Asp Phe Ile Val Lys Gly Ser Cys Phe Cys Asn Gly His
 35 40 45
 Ala Asp Gln Cys Ile Pro Val His Gly Phe Arg Pro Val Lys Ala Pro
 50 55 60
 Gly Thr Phe His Met Val His Gly Lys Cys Met
 65 70 75

<210> 286
 <211> 296
 <212> PRT
 <213> Homo sapiens

<400> 286
 His Asn Thr Ala Gly Ser His Cys Gln His Cys Ala Pro Leu Tyr Asn
 1 5 10 15
 Asp Arg Pro Trp Glu Ala Ala Asp Gly Lys Thr Gly Ala Pro Asn Glu
 20 25 30
 Cys Arg Thr Cys Lys Cys Asn Gly His Ala Asp Thr Cys His Phe Asp
 35 40 45
 Val Asn Val Trp Glu Ala Ser Gly Asn Arg Ser Gly Gly Val Cys Asp
 50 55 60
 Asp Cys Gln His Asn Thr Glu Gly Gln Tyr Cys Gln Arg Cys Lys Pro
 65 70 75 80
 Gly Phe Tyr Arg Asp Leu Arg Arg Pro Phe Ser Ala Pro Asp Ala Cys
 85 90 95
 Lys Pro Cys Ser Cys His Pro Val Gly Ser Ala Val Leu Pro Ala Asn
 100 105 110

Ser Val Thr Phe Cys Asp Pro Ser Asn Gly Asp Cys Pro Cys Lys Pro
 115 120 125
 Gly Val Ala Gly Arg Arg Cys Asp Arg Cys Met Val Gly Tyr Trp Gly
 130 135 140
 Phe Gly Asp Tyr Gly Cys Arg Pro Cys Asp Cys Ala Gly Ser Cys Asp
 145 150 155 160
 Pro Ile Thr Gly Asp Cys Ile Ser Ser His Thr Asp Ile Asp Trp Tyr
 165 170 175
 His Glu Val Pro Asp Phe Arg Pro Val His Asn Lys Ser Glu Pro Ala
 180 185 190
 Trp Glu Trp Glu Asp Ala Gln Gly Phe Ser Ala Leu Leu His Ser Gly
 195 200 205
 Lys Cys Glu Cys Lys Glu Gln Thr Leu Gly Asn Ala Lys Ala Phe Cys
 210 215 220
 Gly Met Lys Tyr Ser Tyr Val Leu Lys Ile Lys Ile Leu Ser Ala His
 225 230 235 240
 Asp Lys Gly Thr His Val Glu Val Asn Val Lys Ile Lys Lys Val Leu
 245 250 255
 Lys Ser Thr Lys Leu Lys Ile Phe Arg Gly Lys Ala Asn Ile Ile Ser
 260 265 270
 Arg Ile Met Asp Gly Gln Arg Met His Leu Ser Asn Pro Gln Ser Trp
 275 280 285
 Phe Gly Ile Pro Cys Ser Arg Thr
 290 295

<210> 287
 <211> 37
 <212> PRT
 <213> Homo sapiens

<400> 287
 Cys Asp Asp Cys Gln His Asn Thr Glu Gly Gln Tyr Cys Gln Arg Cys
 1 5 10 15
 Lys Pro Gly Phe Tyr Arg Asp Leu Arg Arg Pro Phe Ser Ala Pro Asp
 20 25 30
 Ala Cys Lys Pro Cys
 35

<210> 288
 <211> 36
 <212> PRT
 <213> Homo sapiens

<400> 288

Cys Pro Cys Lys Pro Gly Val Ala Gly Arg Arg Cys Asp Arg Cys Met
 1 5 10 15

Val Gly Tyr Trp Gly Phe Gly Asp Tyr Gly Cys Arg Pro Cys Asp Cys
 20 25 30

Ala Gly Ser Cys
 35

<210> 289

<211> 66

<212> PRT

<213> Homo sapiens

<400> 289

Asn Ile Ser Ser Gln Tyr Cys Ile Leu Lys Ser Leu Glu Met Met Ile
 1 5 10 15

Ser Gly Leu Lys Leu Leu Val Leu Phe Leu Lys Phe Ala Pro Glu Asn
 20 25 30

Tyr Cys Leu Ser Thr Glu Thr Leu Gln Met Pro Asn Arg His Leu Arg
 35 40 45

Leu Ser Lys Ala Thr Cys Tyr Leu Met Lys Cys Leu Leu Pro Ser Tyr
 50 55 60

Phe Glu
 65

<210> 290

<211> 88

<212> PRT

<213> Homo sapiens

<400> 290

Pro Ile Glu Gly Thr Pro Ala Gly Thr Gly Pro Glu Phe Pro Gly Arg
 1 5 10 15

Pro Thr Arg Pro Gln Arg Met Arg Ser Leu Ile Ser Ser His Pro Cys
 20 25 30

Gln His Leu Leu Leu Leu Leu Leu Leu Phe Leu Ile Leu Ala Ile
 35 40 45

Leu Val Asp Val Lys Trp Tyr Leu Val Leu Phe Ile Cys Ile Ser Leu
 50 55 60

Met Thr Ser Asp Val Glu His Leu Phe Met Cys Leu Leu Ala Ile Arg
 65 70 75 80

Ile Ser Ser Trp Arg Asn Val Tyr
 85

<210> 291

<211> 60
<212> PRT
<213> Homo sapiens

<400> 291
Asn Trp Val Pro Thr Cys Leu Cys Pro Ser Ala Pro Cys Ser Phe His
1 5 10 15
Leu Leu Ser Arg Phe Lys Cys Leu Phe Ser Pro Gln Arg Leu Thr Asp
20 25 30
Ile Phe Arg Arg Tyr Asp Thr Asp Gln Asp Gly Trp Ile Gln Val Ser
35 40 45
Tyr Glu Gln Tyr Leu Ser Met Val Phe Ser Ile Val
50 55 60

<210> 292
<211> 33
<212> PRT
<213> Homo sapiens

<400> 292
Gln Arg Leu Thr Asp Ile Phe Arg Arg Tyr Asp Thr Asp Gln Asp Gly
1 5 10 15
Trp Ile Gln Val Ser Tyr Glu Gln Tyr Leu Ser Met Val Phe Ser Ile
20 25 30
Val

<210> 293
<211> 73
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (48)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (68)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 293
Met Phe Tyr Lys Leu Thr Leu Ile Leu Cys Glu Leu Ser Val Ala Gly
1 5 10 15
Val Thr Gln Ala Ala Ser Gln Arg Pro Leu Gln Arg Leu Pro Arg His
20 25 30
Ile Cys Ser Gln Arg Xaa Pro Pro Gly Arg Cys Leu Leu Lys Ala Xaa
35 40 45
Leu Gln Thr Thr Trp Xaa Xaa Pro Asp Lys Pro Ile Pro Arg Leu Ser
50 55 60
Pro Pro Leu Xaa Ser Asp Pro Lys Arg
65 70

<210> 294
<211> 95
<212> PRT
<213> Homo sapiens

<400> 294
Thr Ser Ser Pro Val Phe Ser Phe Cys Ser Met Ala Val Arg Glu Pro
1 5 10 15
Asp His Leu Gln Arg Val Ser Leu Pro Arg Tyr Asn Val Ser Ala Ser
20 25 30
Leu Gln Trp Leu Pro Cys His Arg Ile Val Leu Gln Pro Trp His Met
35 40 45
Cys Ala Met Trp Glu Leu Gly Gln Val Leu Phe His Pro Val Ala Pro
50 55 60
Arg Glu Gly Ala Ala Pro Ser Pro Val Ser Thr Leu Thr Trp Pro Ser
65 70 75 80
Ser Cys Ser His Ser Glu Ser Thr Met Glu Leu Glu Leu Gln Phe
85 90 95

<210> 295
<211> 16
<212> PRT
<213> Homo sapiens

<400> 295
Met Ala Val Arg Glu Pro Asp His Leu Gln Arg Val Ser Leu Pro Arg
1 5 10 15

<210> 296
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 296
 Leu Pro Cys His Arg Ile Val
 1 5

<210> 297
 <211> 15
 <212> PRT
 <213> Homo sapiens

<400> 297
 Ser Leu Gln Trp Leu Pro Cys His Arg Ile Val Leu Gln Pro Trp
 1 5 10 15

<210> 298
 <211> 454
 <212> PRT
 <213> Homo sapiens

<400> 298
 Cys Phe Lys Arg Lys Pro Lys Arg Glu His Cys Ser Cys Pro Ile Thr
 1 5 10 15
 Tyr Gln Ser Leu Gly Asp Ile Leu Asn Ala Ser Phe Phe Ser Lys Arg
 20 25 30
 Lys Gly Met Gln Glu Val Lys Leu Asn Ser Tyr Val Val Ser Gly Thr
 35 40 45
 Ile Gly Leu Lys Glu Lys Ile Ser Leu Ser Glu Pro Val Phe Leu Thr
 50 55 60
 Phe Arg His Asn Gln Pro Gly Asp Lys Arg Thr Lys His Ile Cys Val
 65 70 75 80
 Tyr Trp Glu Gly Ser Glu Gly Gly Arg Trp Ser Thr Glu Gly Cys Ser
 85 90 95
 His Val His Ser Asn Gly Ser Tyr Thr Lys Cys Lys Cys Phe His Leu
 100 105 110
 Ser Ser Phe Ala Val Leu Val Ala Leu Ala Pro Lys Glu Asp Pro Val
 115 120 125
 Leu Thr Val Ile Thr Gln Val Gly Leu Thr Ile Ser Leu Leu Cys Leu
 130 135 140
 Phe Leu Ala Ile Leu Thr Phe Leu Leu Cys Arg Pro Ile Gln Asn Thr
 145 150 155 160
 Ser Thr Ser Leu His Leu Glu Leu Ser Leu Cys Leu Phe Leu Ala His
 165 170 175

Leu Leu Phe Leu Thr Gly Ile Asn Arg Thr Glu Pro Glu Val Leu Cys
 180 185 190
 Ser Ile Ile Ala Gly Leu Leu His Phe Leu Tyr Leu Ala Cys Phe Thr
 195 200 205
 Trp Met Leu Leu Glu Gly Leu His Leu Phe Leu Thr Val Arg Asn Leu
 210 215 220
 Lys Val Ala Asn Tyr Thr Ser Thr Gly Arg Phe Lys Lys Arg Phe Met
 225 230 235 240
 Tyr Pro Val Gly Tyr Gly Ile Pro Ala Val Ile Ile Ala Val Ser Ala
 245 250 255
 Ile Val Gly Pro Gln Asn Tyr Gly Thr Phe Thr His Cys Trp Leu Lys
 260 265 270
 Leu Asp Lys Gly Phe Ile Trp Ser Phe Met Gly Pro Val Ala Val Ile
 275 280 285
 Ile Leu Ile Asn Leu Val Phe Tyr Phe Gln Val Leu Trp Ile Leu Arg
 290 295 300
 Ser Lys Leu Ser Ser Leu Asn Lys Glu Val Ser Thr Ile Gln Asp Thr
 305 310 315 320
 Arg Val Met Thr Phe Lys Ala Ile Ser Gln Leu Phe Ile Leu Gly Cys
 325 330 335
 Ser Trp Gly Leu Gly Phe Phe Met Val Glu Glu Val Gly Lys Thr Ile
 340 345 350
 Gly Ser Ile Ile Ala Tyr Ser Phe Thr Ile Ile Asn Thr Leu Gln Gly
 355 360 365
 Val Leu Leu Phe Val Val His Cys Leu Leu Asn Arg Gln Val Arg Met
 370 375 380
 Glu Tyr Lys Lys Trp Phe Ser Gly Met Arg Lys Gly Val Glu Thr Glu
 385 390 395 400
 Ser Thr Glu Met Ser Arg Ser Thr Thr Gln Thr Lys Thr Glu Glu Val
 405 410 415
 Gly Lys Ser Ser Glu Ile Phe His Lys Gly Gly Thr Ala Ser Ser Ser
 420 425 430
 Ala Glu Ser Thr Lys Gln Pro Gln Pro Gln Val His Leu Val Ser Ala
 435 440 445
 Ala Trp Leu Lys Met Asn
 450

<210> 299

<211> 101

<212> PRT

<213> Homo sapiens

<400> 299

Phe Phe Trp Lys Glu Asn Leu Arg Arg Asn Gly Ser Arg Glu Asp Phe
 1 5 10 15
 Ala Arg Arg Ala Thr Gln Leu Ile Gln Ser Val Glu Leu Ser Ile Trp
 20 25 30
 Asn Ala Ser Phe Ala Ser Pro Gly Lys Gly Gln Ile Ser Glu Phe Asp
 35 40 45
 Ile Val Tyr Glu Thr Lys Arg Cys Asn Glu Thr Arg Glu Asn Ala Phe
 50 55 60
 Leu Glu Ala Gly Asn Asn Thr Met Asp Ile Asn Cys Ala Asp Ala Leu
 65 70 75 80
 Lys Gly Asn Leu Arg Glu Ser Thr Ala Val Ala Leu Ser Leu Ile Asn
 85 90 95
 Leu Leu Gly Ile Phe
 100

<210> 300

<211> 27

<212> PRT

<213> Homo sapiens

<400> 300

Asp Ile Asn Glu Cys Glu Thr Gly Leu Ala Lys Cys Lys Tyr Lys Ala
 1 5 10 15
 Tyr Cys Arg Asn Lys Val Gly Gly Tyr Ile Cys
 20 25

<210> 301

<211> 12

<212> PRT

<213> Homo sapiens

<400> 301

Cys Arg Asn Lys Val Gly Gly Tyr Ile Cys Ser Cys
 1 5 10

<210> 302

<211> 331

<212> PRT

<213> Homo sapiens

<400> 302

Ala Leu Cys Pro His Pro His Leu Ile Leu Asn Val Thr Val Ser Pro
 1 5 10 15
 Ala Pro Ser Cys Arg His Val Lys Lys Val Val Ala Ser Pro Ser Pro
 20 25 30

Ser Thr Thr Met Ile Ala Met Asp Ala Pro His Ser Lys Ala Ala Leu
 35 40 45
 Asp Ser Ile Asn Glu Leu Pro Glu Asn Ile Leu Leu Glu Leu Phe Thr
 50 55 60
 His Val Pro Ala Arg Gln Leu Leu Leu Asn Cys Arg Leu Val Cys Ser
 65 70 75 80
 Leu Trp Arg Asp Leu Ile Asp Leu Met Thr Leu Trp Lys Arg Lys Cys
 85 90 95
 Leu Arg Glu Gly Phe Ile Thr Lys Asp Trp Asp Gln Pro Val Ala Asp
 100 105 110
 Trp Lys Ile Phe Tyr Phe Leu Arg Ser Leu His Arg Asn Leu Leu Arg
 115 120 125
 Asn Pro Cys Ala Glu Glu Asp Met Phe Ala Trp Gln Ile Asp Phe Asn
 130 135 140
 Gly Gly Asp Arg Trp Lys Val Glu Ser Leu Pro Gly Ala His Gly Thr
 145 150 155 160
 Asp Phe Pro Asp Pro Lys Val Lys Lys Tyr Phe Val Thr Ser Tyr Glu
 165 170 175
 Met Cys Leu Lys Ser Gln Leu Val Asp Leu Val Ala Glu Gly Tyr Trp
 180 185 190
 Glu Glu Leu Leu Asp Thr Phe Arg Pro Asp Ile Val Val Lys Asp Trp
 195 200 205
 Phe Ala Ala Arg Ala Asp Cys Gly Cys Thr Tyr Gln Leu Lys Val Gln
 210 215 220
 Leu Ala Ser Ala Asp Tyr Phe Val Leu Ala Ser Phe Glu Pro Pro Pro
 225 230 235 240
 Val Thr Ile Gln Gln Trp Asn Asn Ala Thr Trp Thr Glu Val Ser Tyr
 245 250 255
 Thr Phe Ser Asp Tyr Pro Arg Gly Val Arg Tyr Ile Leu Phe Gln His
 260 265 270
 Gly Gly Arg Asp Thr Gln Tyr Trp Ala Gly Trp Tyr Gly Pro Arg Val
 275 280 285
 Thr Asn Ser Ser Ile Val Val Ser Pro Lys Met Thr Arg Asn Gln Ala
 290 295 300
 Ser Ser Glu Ala Gln Pro Gly Gln Lys His Gly Gln Glu Glu Ala Ala
 305 310 315 320
 Gln Ser Pro Tyr Arg Ala Val Val Gln Ile Phe
 325 330

<210> 303
 <211> 328
 <212> PRT
 <213> Homo sapiens

<400> 303

Arg Gln Arg Ser Trp Asn Pro Gly Thr Asn Cys Tyr His Pro Asn Met
 1 5 10 15
 Pro Asp Ala Phe Leu Thr Cys Glu Thr Val Ile Phe Ala Trp Ala Ile
 20 25 30
 Gly Gly Glu Gly Phe Ser Tyr Pro Pro His Val Gly Leu Ser Leu Gly
 35 40 45
 Thr Pro Leu Asp Pro His Tyr Val Leu Leu Glu Val His Tyr Asp Asn
 50 55 60
 Pro Thr Tyr Glu Glu Gly Leu Ile Asp Asn Ser Gly Leu Arg Leu Phe
 65 70 75 80
 Tyr Thr Met Asp Ile Arg Lys Tyr Asp Ala Gly Val Ile Glu Ala Gly
 85 90 95
 Leu Trp Val Ser Leu Phe His Thr Ile Pro Pro Gly Met Pro Glu Phe
 100 105 110
 Gln Ser Glu Gly His Cys Thr Leu Glu Cys Leu Glu Glu Ala Leu Glu
 115 120 125
 Ala Glu Lys Pro Ser Gly Ile His Val Phe Ala Val Leu Leu His Ala
 130 135 140
 His Leu Ala Gly Arg Gly Ile Arg Leu Arg His Phe Arg Lys Gly Lys
 145 150 155 160
 Glu Met Lys Leu Leu Ala Tyr Asp Asp Asp Phe Asp Phe Asn Phe Gln
 165 170 175
 Glu Phe Gln Tyr Leu Lys Glu Glu Gln Thr Ile Leu Pro Gly Asp Asn
 180 185 190
 Leu Ile Thr Glu Cys Arg Tyr Asn Thr Lys Asp Arg Ala Glu Met Thr
 195 200 205
 Trp Gly Gly Leu Ser Thr Arg Ser Glu Met Cys Leu Ser Tyr Leu Leu
 210 215 220
 Tyr Tyr Pro Arg Ile Asn Leu Thr Arg Cys Ala Ser Ile Pro Asp Ile
 225 230 235 240
 Met Glu Gln Leu Gln Phe Ile Gly Val Lys Glu Ile Tyr Arg Pro Val
 245 250 255
 Thr Thr Trp Pro Phe Ile Ile Lys Ser Pro Lys Gln Tyr Lys Asn Leu
 260 265 270
 Ser Phe Met Asp Ala Met Asn Lys Phe Lys Trp Thr Lys Lys Glu Gly
 275 280 285

Leu Ser Phe Asn Lys Leu Val Leu Ser Leu Pro Val Asn Val Arg Cys
 290 295 300

Ser Lys Thr Asp Asn Ala Glu Trp Ser Ile Pro Arg Asn Asp Ser Ile
 305 310 315 320

Thr Ser Arg Tyr Arg Lys Thr Leu
 325

<210> 304

<211> 272

<212> PRT

<213> Homo sapiens

<400> 304

Met Cys Cys Trp Pro Leu Leu Leu Trp Gly Leu Leu Pro Gly Thr
 1 5 10 15

Ala Ala Gly Gly Ser Gly Arg Thr Tyr Pro His Arg Thr Leu Leu Asp
 20 25 30

Ser Glu Gly Lys Tyr Trp Leu Gly Trp Ser Gln Arg Gly Ser Gln Ile
 35 40 45

Ala Phe Arg Leu Gln Val Arg Thr Ala Gly Tyr Val Gly Phe Gly Phe
 50 55 60

Ser Pro Thr Gly Ala Met Ala Ser Ala Asp Ile Val Val Gly Gly Val
 65 70 75 80

Ala His Gly Arg Pro Tyr Leu Gln Asp Tyr Phe Thr Asn Ala Asn Arg
 85 90 95

Glu Leu Lys Lys Asp Ala Gln Gln Asp Tyr His Leu Glu Tyr Ala Met
 100 105 110

Glu Asn Ser Thr His Thr Ile Ile Glu Phe Thr Arg Glu Leu His Thr
 115 120 125

Cys Asp Ile Asn Asp Lys Ser Ile Thr Asp Ser Thr Val Arg Val Ile
 130 135 140

Trp Ala Tyr His His Glu Asp Ala Gly Glu Ala Gly Pro Lys Tyr His
 145 150 155 160

Asp Ser Asn Arg Gly Thr Lys Ser Leu Arg Leu Leu Asn Pro Glu Lys
 165 170 175

Thr Ser Val Leu Ser Thr Ala Leu Pro Tyr Phe Asp Leu Val Asn Gln
 180 185 190

Asp Val Pro Ile Pro Asn Lys Asp Thr Thr Tyr Trp Cys Gln Met Phe
 195 200 205

Lys Ile Pro Val Phe Gln Glu Lys His His Val Ile Lys Val Glu Pro
 210 215 220

Val Ile Gln Arg Gly His Glu Ser Leu Val His His Ile Leu Leu Tyr
 225 230 235 240
 Gln Cys Ser Asn Asn Phe Asn Asp Ser Val Pro Gly Ile Arg Ala Arg
 245 250 255
 Ile Ala Ile Thr Pro Thr Cys Pro Met His Ser Ser Pro Val Lys Leu
 260 265 270

<210> 305

<211> 207

<212> PRT

<213> Homo sapiens

<400> 305

Thr Gly Thr Phe Trp Ser Pro Arg Ser Gln Arg Arg Gly Cys Cys Gly
 1 5 10 15
 Arg Arg Ala Pro Arg Pro Glu Ala Met Glu Asn Gly Ala Val Tyr Ser
 20 25 30
 Pro Thr Thr Glu Glu Asp Pro Gly Pro Ala Arg Gly Pro Arg Ser Gly
 35 40 45
 Leu Ala Ala Tyr Phe Phe Met Gly Arg Leu Pro Leu Leu Arg Arg Val
 50 55 60
 Leu Lys Gly Leu Gln Leu Leu Leu Ser Leu Leu Ala Phe Ile Cys Glu
 65 70 75 80
 Glu Val Val Ser Gln Cys Thr Leu Cys Gly Gly Leu Tyr Phe Phe Glu
 85 90 95
 Phe Val Ser Cys Ser Ala Phe Leu Leu Ser Leu Leu Ile Leu Ile Val
 100 105 110
 Tyr Cys Thr Pro Phe Tyr Glu Arg Val Asp Thr Thr Lys Val Lys Ser
 115 120 125
 Ser Asp Phe Tyr Ile Thr Leu Gly Thr Gly Cys Val Phe Leu Leu Ala
 130 135 140
 Ser Ile Ile Phe Val Ser Thr His Asp Arg Thr Ser Ala Glu Ile Ala
 145 150 155 160
 Ala Ile Val Phe Gly Phe Ile Ala Ser Phe Met Phe Leu Leu Asp Phe
 165 170 175
 Ile Thr Met Leu Tyr Glu Lys Arg Gln Glu Ser Gln Leu Arg Lys Pro
 180 185 190
 Glu Asn Thr Thr Arg Ala Glu Ala Leu Thr Glu Pro Leu Asn Ala
 195 200 205

<210> 306
 <211> 135
 <212> PRT
 <213> Homo sapiens

<400> 306
 Ala Ser Ala Pro Arg Val Met Arg Gly His Leu Ala Gly Phe Pro Ala
 1 5 10 15
 Leu Ser Gly Leu Ala Ser Val Cys Leu Trp Ala Thr Phe Ser Ala Gln
 20 25 30
 Leu Pro Gly Pro Val Ala Ala Thr Ser Trp Thr Pro Ala Pro Leu Gly
 35 40 45
 Cys Ser Ala Ala Arg Ser Gly Pro Glu Lys Arg Leu Gly Thr Ala Ala
 50 55 60
 Pro Gly Ser Ala Ala Ser Leu Ala Gln Ala Gly Pro Gly Ala Pro Cys
 65 70 75 80
 Arg Val Leu Pro Val Asp Pro Ala Pro Ala Leu Asn Val Arg Glu
 85 90 95
 Pro Gly Trp Leu Gly Gly Leu Phe Asp Gly Ala Leu Leu Gln Val Leu
 100 105 110
 Leu Asn Phe Leu Arg Lys Ser Thr Asp Val Leu Met Asp Thr Arg Glu
 115 120 125
 Ala Glu Ser Leu Glu Val Glu
 130 135

<210> 307
 <211> 188
 <212> PRT
 <213> Homo sapiens

<400> 307
 Asn Lys Leu His Ser Phe Pro Val Phe Leu Ser Gln Leu Leu Leu Asp
 1 5 10 15
 Arg Gln Leu Leu His Ala Pro Gln Thr Leu Pro Thr Pro His Cys Gly
 20 25 30
 Gly Ser Ser Arg Pro Gly Pro Ser His Pro Pro Trp Leu Leu Ile Gln
 35 40 45
 Leu Pro Cys Val His Val Ala Leu Trp Gln Met Leu Arg Asp Phe Ser
 50 55 60
 Asp Ser Arg Ile Thr Pro Ser Thr Leu Thr Thr Gln Pro Ala Ala Gln
 65 70 75 80
 Thr Ala Ala Pro Ala Lys Asp Gln Glu Ser Asp Ile Val Gly Gly Glu
 85 90 95
 Gly Ile Leu Cys Asp Ile Ala Phe Leu Gln Glu Asp His Pro Leu Gly

100 105 110
 Val Gly Gly Ala Ser Ala Pro Ser Ser Arg Arg Glu Leu Ser Arg Arg
 115 120 125
 Gly Val His Thr Gln Thr Leu Pro Glu Asp Gly Thr Leu His Gly Thr
 130 135 140
 Pro Ser Ser Ser Phe Asp Cys Gly Ile Lys Tyr Ile Ile Ser Trp Pro
 145 150 155 160
 Leu Ala Pro Gly Cys Asp Leu Pro Ser Leu Glu Leu Ser Leu Val Cys
 165 170 175
 Lys Gly Val Ser Ser Cys Met Gly Phe Ala Ala Gly
 180 185

<210> 308
 <211> 78
 <212> PRT
 <213> Homo sapiens

<400> 308
 Pro Gly Arg Pro Thr Arg Pro Thr Lys Asn Lys Val Cys Val Cys Leu
 1 5 10 15
 Gly Met Leu Phe Trp Ala Tyr Pro Ile Cys Val Phe Ile Asp Ser Leu
 20 25 30
 Ser Cys Gln Pro Cys Leu Trp Ser Thr Gly Ala Thr Ser His Phe Asn
 35 40 45
 Ser Pro Thr Thr Ser Pro Leu Phe Thr Leu Phe Met Pro Cys Ala Leu
 50 55 60
 Ala Pro Asn Pro Phe Thr Gln Leu Gly Lys Leu Asp Asp Arg
 65 70 75

<210> 309
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 309
 Pro Val Asp Leu Thr Lys Thr Arg Leu Gln
 1 5 10

<210> 310
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 310
 Pro Thr Asp Val Leu Lys Ile Arg Met Gln
 1 5 10

<210> 311
 <211> 313
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (117)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 311
 Met Thr Phe Gly Ser Thr Ile Ser Pro Thr Ser Thr His Ala Ser Pro
 1 5 10 15
 Ser Leu Gly Phe Cys Cys Ser Trp Leu Leu Glu Asp Leu Glu Glu Gln
 20 25 30
 Leu Tyr Cys Ser Ala Phe Glu Glu Ala Ala Leu Thr Arg Arg Ile Cys
 35 40 45
 Asn Pro Thr Ser Cys Trp Leu Pro Leu Asp Met Glu Leu Leu His Arg
 50 55 60
 Gln Val Leu Ala Leu Gln Thr Gln Arg Val Leu Leu Gly Met Trp Leu
 65 70 75 80
 Arg Arg Ala Trp Asp Thr Trp Val Ser Pro Arg Arg Val Ala Pro Gly
 85 90 95
 Ser Arg Cys Leu Leu Thr Ala Ser His Pro Cys Thr Glu Lys Arg Arg
 100 105 110
 Lys Ala Ser Ala Xaa Gln Arg Asn Leu Gly Tyr Pro Leu Ala Met Leu
 115 120 125
 Cys Leu Leu Val Leu Thr Gly Leu Ser Val Leu Ile Val Ala Ile His
 130 135 140
 Ile Leu Glu Leu Leu Ile Asp Glu Ala Ala Met Pro Arg Gly Met Gln
 145 150 155 160
 Gly Thr Ser Leu Gly Gln Val Ser Phe Ser Lys Leu Gly Ser Phe Gly
 165 170 175
 Ala Val Ile Gln Val Val Leu Ile Phe Tyr Leu Met Val Ser Ser Val
 180 185 190
 Val Gly Phe Tyr Ser Ser Pro Leu Phe Arg Ser Leu Arg Pro Arg Trp
 195 200 205
 His Asp Thr Ala Met Thr Gln Ile Ile Gly Asn Cys Val Cys Leu Leu
 210 215 220
 Val Leu Ser Ser Ala Leu Pro Val Phe Ser Arg Thr Leu Gly Leu Thr
 225 230 235 240
 Arg Phe Asp Leu Leu Gly Asp Phe Gly Arg Phe Asn Trp Leu Gly Asn
 245 250 255

Phe Tyr Ile Val Phe Leu Tyr Asn Ala Ala Phe Ala Gly Leu Thr Thr
 260 265 270
 Leu Cys Leu Val Lys Thr Phe Thr Ala Ala Val Arg Ala Glu Leu Ile
 275 280 285
 Arg Ala Phe Gly Leu Asp Arg Leu Pro Leu Pro Val Ser Gly Phe Pro
 290 295 300
 Gln Ala Ser Arg Lys Thr Gln His Gln
 305 310

<210> 312
 <211> 92
 <212> PRT
 <213> Homo sapiens

<400> 312
 Leu Cys Val Cys Leu Val Tyr Leu Cys Met Tyr Gly Val Cys Leu Cys
 1 5 10 15
 Val Ile Val Cys Val Ser Gly Val Ser Leu Cys Leu Tyr Val Trp Gly
 20 25 30
 Val Ser Val Cys Asp Cys Val Ser Val Phe Met Cys Val Cys Leu Cys
 35 40 45
 Val Ile Phe Cys Val Tyr Gly Lys Pro Arg Thr Glu His Tyr His Ser
 50 55 60
 Pro His Leu Ala Lys Gln Lys Ala Phe Arg Glu Met Cys Gly Arg His
 65 70 75 80
 Asp Val Ser Ala Ala Gly Ile Phe Gln Ser Tyr Val
 85 90

<210> 313
 <211> 207
 <212> PRT
 <213> Homo sapiens

<400> 313
 Gly His Met Pro Tyr Gly Trp Leu Thr Glu Ile Arg Ala Val Tyr Pro
 1 5 10 15
 Ala Phe Asp Lys Asn Asn Pro Ser Asn Lys Leu Val Ser Thr Ser Asn
 20 25 30
 Thr Val Thr Ala Ala His Ile Lys Lys Phe Thr Phe Val Cys Met Ala
 35 40 45
 Leu Ser Leu Thr Leu Cys Phe Val Met Phe Trp Thr Pro Asn Val Ser
 50 55 60
 Glu Lys Ile Leu Ile Asp Ile Ile Gly Val Asp Phe Ala Phe Ala Glu
 65 70 75 80

Leu Cys Val Val Pro Leu Arg Ile Phe Ser Phe Phe Pro Val Pro Val
 85 90 95
 Thr Val Arg Ala His Leu Thr Gly Trp Leu Met Thr Leu Lys Lys Thr
 100 105 110
 Phe Val Leu Ala Pro Ser Ser Val Leu Arg Ile Ile Val Leu Ile Ala
 115 120 125
 Ser Leu Val Val Leu Pro Tyr Leu Gly Val His Gly Ala Thr Leu Gly
 130 135 140
 Val Gly Ser Leu Leu Ala Gly Phe Val Gly Glu Ser Thr Met Val Ala
 145 150 155 160
 Ile Ala Ala Cys Tyr Val Tyr Arg Lys Gln Lys Lys Lys Met Glu Asn
 165 170 175
 Glu Ser Ala Thr Glu Gly Glu Asp Ser Ala Met Thr Asp Met Pro Pro
 180 185 190
 Thr Glu Glu Val Thr Asp Ile Val Glu Met Arg Glu Glu Asn Glu
 195 200 205

<210> 314
 <211> 114
 <212> PRT
 <213> Homo sapiens

<400> 314
 Gln Val Val Phe Val Ala Ile Leu Leu His Ser His Leu Glu Cys Arg
 1 5 10 15
 Glu Pro Leu Leu Ile Pro Ile Leu Ser Leu Tyr Met Gly Ala Leu Val
 20 25 30
 Arg Cys Thr Thr Leu Cys Leu Gly Tyr Tyr Lys Asn Ile His Asp Ile
 35 40 45
 Ile Pro Asp Arg Ser Gly Pro Glu Leu Gly Gly Asp Ala Thr Ile Arg
 50 55 60
 Lys Met Leu Ser Phe Trp Trp Pro Leu Ala Leu Ile Leu Ala Thr Gln
 65 70 75 80
 Arg Ile Ser Arg Pro Ile Val Asn Leu Phe Val Ser Arg Asp Leu Gly
 85 90 95
 Gly Ser Ser Ala Ala Thr Glu Ala Val Ala Ile Leu Thr Ala Thr Tyr
 100 105 110
 Pro Val

<210> 315
 <211> 115

<212> PRT

<213> Homo sapiens

<400> 315

Arg Cys Cys Cys Arg Gly Cys Ser Cys Arg Ala Arg Leu Cys Pro Pro
 1 5 10 15
 Ala Arg Ser Thr Ala Val Ala Pro Glu Cys Arg Gly Ala His Pro Ser
 20 25 30
 Arg Ala Met Arg Pro Gly Thr Ala Leu Gln Ala Val Leu Leu Ala Val
 35 40 45
 Leu Leu Val Gly Leu Arg Ala Ala Thr Gly Arg Leu Leu Ser Gly Gln
 50 55 60
 Pro Val Cys Arg Gly Gly Thr Gln Arg Pro Cys Tyr Lys Val Ile Tyr
 65 70 75 80
 Phe His Asp Thr Ser Arg Arg Leu Asn Phe Glu Glu Ala Lys Glu Ala
 85 90 95
 Cys Arg Arg Gly Trp Arg Pro Ala Ser Gln His Arg Val Leu Lys Met
 100 105 110
 Asn Arg Asn
 115

<210> 316

<211> 81

<212> PRT

<213> Homo sapiens

<400> 316

Met Arg Pro Gly Thr Ala Leu Gln Ala Val Leu Leu Ala Val Leu Leu
 1 5 10 15
 Val Gly Leu Arg Ala Ala Thr Gly Arg Leu Leu Ser Gly Gln Pro Val
 20 25 30
 Cys Arg Gly Gly Thr Gln Arg Pro Cys Tyr Lys Val Ile Tyr Phe His
 35 40 45
 Asp Thr Ser Arg Arg Leu Asn Phe Glu Glu Ala Lys Glu Ala Cys Arg
 50 55 60
 Arg Gly Trp Arg Pro Ala Ser Gln His Arg Val Leu Lys Met Asn Arg
 65 70 75 80
 Asn

<210> 317

<211> 290

<212> PRT

<213> Homo sapiens

<400> 317
 Ile Arg His Glu Gln Gln Gly Glu Glu Asp Asp Glu His Ala Arg Pro
 1 5 10 15
 Leu Ala Glu Ser Leu Leu Leu Ala Ile Ala Asp Leu Leu Phe Cys Pro
 20 25 30
 Asp Phe Thr Val Gln Ser His Arg Arg Ser Thr Val Asp Ser Ala Glu
 35 40 45
 Asp Val His Ser Leu Asp Ser Cys Glu Tyr Ile Trp Glu Ala Gly Val
 50 55 60
 Gly Phe Ala His Ser Pro Gln Pro Asn Tyr Ile His Asp Met Asn Arg
 65 70 75 80
 Met Glu Leu Leu Lys Leu Leu Leu Thr Cys Phe Ser Glu Ala Met Tyr
 85 90 95
 Leu Pro Pro Ala Pro Glu Ser Gly Ser Thr Asn Pro Trp Val Gln Phe
 100 105 110
 Phe Cys Ser Thr Glu Asn Arg His Ala Leu Pro Leu Phe Thr Ser Leu
 115 120 125
 Leu Asn Thr Val Cys Ala Tyr Asp Pro Val Gly Tyr Gly Ile Pro Tyr
 130 135 140
 Asn His Leu Leu Phe Ser Asp Tyr Arg Glu Pro Leu Val Glu Glu Ala
 145 150 155 160
 Ala Gln Val Leu Ile Val Thr Leu Asp His Asp Ser Ala Ser Ser Ala
 165 170 175
 Ser Pro Thr Val Asp Gly Thr Thr Thr Gly Thr Ala Met Asp Asp Ala
 180 185 190
 Asp Pro Pro Gly Pro Glu Asn Leu Phe Val Asn Tyr Leu Ser Arg Ile
 195 200 205
 His Arg Glu Glu Asp Phe Gln Phe Ile Leu Lys Gly Ile Ala Arg Leu
 210 215 220
 Leu Ser Asn Pro Leu Leu Gln Thr Tyr Leu Pro Asn Ser Thr Lys Lys
 225 230 235 240
 Asp Pro Val Pro Pro Gly Ala Ala Ser Ser Leu Leu Glu Ala Leu Arg
 245 250 255
 Leu Gln Gln Glu Ile Pro Leu Leu Arg Ala Glu Glu Gln Arg Arg Pro
 260 265 270
 Arg His Pro Cys Pro His Pro Leu Leu Pro Gln Arg Cys Pro Gly Arg
 275 280 285
 Ser Val
 290

<210> 318
 <211> 318
 <212> PRT
 <213> Homo sapiens

<400> 318

Arg Leu Val Tyr Asn Lys Thr Ser Arg Ala Thr Gln Phe Pro Asp Gly
 1 5 10 15
 Val Asp Val Arg Val Pro Gly Phe Gly Lys Thr Phe Ser Leu Glu Phe
 20 25 30
 Leu Asp Pro Ser Lys Ser Ser Val Gly Ser Tyr Phe His Thr Met Val
 35 40 45
 Glu Ser Leu Val Gly Trp Gly Tyr Thr Arg Gly Glu Asp Val Arg Gly
 50 55 60
 Ala Pro Tyr Asp Trp Arg Arg Ala Pro Asn Glu Asn Gly Pro Tyr Phe
 65 70 75 80
 Leu Ala Leu Arg Glu Met Ile Glu Glu Met Tyr Gln Leu Tyr Gly Gly
 85 90 95
 Pro Val Val Leu Val Ala His Ser Met Gly Asn Met Tyr Thr Leu Tyr
 100 105 110
 Phe Leu Gln Arg Gln Pro Gln Ala Trp Lys Asp Lys Tyr Ile Arg Ala
 115 120 125
 Phe Val Ser Leu Gly Ala Pro Trp Gly Gly Val Ala Lys Thr Leu Arg
 130 135 140
 Val Leu Ala Ser Gly Asp Asn Asn Arg Ile Pro Val Ile Gly Pro Leu
 145 150 155 160
 Lys Ile Arg Glu Gln Gln Arg Ser Ala Val Ser Thr Ser Trp Leu Leu
 165 170 175
 Pro Tyr Asn Tyr Thr Trp Ser Pro Glu Lys Val Phe Val Gln Thr Pro
 180 185 190
 Thr Ile Asn Tyr Thr Leu Arg Asp Tyr Arg Lys Phe Phe Gln Asp Ile
 195 200 205
 Gly Phe Glu Asp Gly Trp Leu Met Arg Gln Asp Thr Glu Gly Leu Val
 210 215 220
 Glu Ala Thr Met Pro Pro Gly Val Gln Leu His Cys Leu Tyr Gly Thr
 225 230 235 240
 Gly Val Pro Thr Pro Asp Ser Phe Tyr Tyr Glu Ser Phe Pro Asp Arg
 245 250 255
 Asp Pro Lys Ile Cys Phe Gly Asp Gly Asp Gly Thr Val Asn Leu Lys
 260 265 270
 Ser Ala Leu Gln Cys Gln Ala Trp Gln Ser Arg Gln Glu His Gln Val
 275 280 285

Leu Leu Gln Glu Leu Pro Gly Ser Glu His Ile Glu Met Leu Ala Asn
 290 295 300

Ala Thr Thr Leu Ala Tyr Leu Lys Arg Val Leu Leu Gly Pro
 305 310 315

<210> 319

<211> 362

<212> PRT

<213> Homo sapiens

<400> 319

Met Asn Lys Glu Asp Lys Val Trp Asn Asp Cys Lys Gly Val Asn Lys
 1 5 10 15

Leu Thr Asn Leu Glu Glu Gln Tyr Ile Ile Leu Ile Phe Gln Asn Gly
 20 25 30

Leu Asp Pro Pro Ala Asn Met Val Phe Glu Ser Ile Ile Asn Glu Ile
 35 40 45

Gly Ile Lys Asn Asn Ile Ser Asn Phe Phe Ala Lys Ile Pro Phe Glu
 50 55 60

Glu Ala Asn Gly Arg Leu Val Ala Cys Thr Arg Thr Tyr Glu Glu Ser
 65 70 75 80

Ile Lys Gly Ser Cys Gly Gln Lys Glu Asn Lys Ile Lys Thr Val Ser
 85 90 95

Phe Glu Ser Lys Ile Gln Leu Arg Ser Lys Gln Glu Phe Gln Phe Phe
 100 105 110

Asp Glu Glu Glu Thr Gly Glu Asn His Thr Ile Phe Ile Gly Pro
 115 120 125

Val Glu Lys Leu Ile Val Tyr Pro Pro Pro Pro Ala Lys Gly Gly Ile
 130 135 140

Ser Val Thr Asn Glu Asp Leu His Cys Leu Asn Glu Gly Glu Phe Leu
 145 150 155 160

Asn Asp Val Ile Ile Asp Phe Tyr Leu Lys Tyr Leu Val Leu Glu Lys
 165 170 175

Leu Lys Lys Glu Asp Ala Asp Arg Ile His Ile Phe Ser Ser Phe Phe
 180 185 190

Tyr Lys Arg Leu Asn Gln Arg Glu Arg Arg Asn His Glu Thr Thr Asn
 195 200 205

Leu Ser Ile Gln Gln Lys Arg His Gly Arg Val Lys Thr Trp Thr Arg
 210 215 220

His Val Asp Ile Phe Glu Lys Asp Phe Ile Phe Val Pro Leu Asn Glu
 225 230 235 240

Ala Ala His Trp Phe Leu Ala Val Val Cys Phe Pro Gly Leu Glu Lys
 245 250 255
 Pro Lys Tyr Glu Pro Asn Pro His Tyr His Glu Asn Ala Val Ile Gln
 260 265 270
 Lys Cys Ser Thr Val Glu Asp Ser Cys Ile Ser Ser Ser Ala Ser Glu
 275 280 285
 Met Glu Ser Cys Ser Gln Asn Ser Ser Ala Lys Pro Val Ile Lys Lys
 290 295 300
 Met Leu Asn Lys Lys His Cys Ile Ala Val Ile Asp Ser Asn Pro Gly
 305 310 315 320
 Gln Glu Glu Ser Asp Pro Arg Tyr Lys Arg Asn Ile Cys Ser Val Lys
 325 330 335
 Tyr Ser Val Lys Lys Ile Asn His Thr Ala Ser Glu Asn Glu Glu Phe
 340 345 350
 Asn Lys Gly Glu Ser Thr Ser Gln Lys Ser
 355 360

<210> 320

<211> 330

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (38)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (247)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 320

Met Ser Pro Leu Ser Ala Ala Arg Ala Ala Leu Arg Val Tyr Ala Val
 1 5 10 15
 Gly Ala Ala Val Ile Leu Ala Gln Leu Leu Arg Arg Cys Arg Gly Gly
 20 25 30
 Phe Leu Glu Pro Val Xaa Pro Pro Arg Pro Asp Arg Val Ala Ile Val
 35 40 45
 Thr Gly Gly Thr Asp Gly Ile Gly Tyr Ser Thr Ala Asn Ile Trp Arg
 50 55 60
 Asp Leu Gly Met His Val Ile Ile Ala Gly Asn Asn Asp Ser Lys Ala
 65 70 75 80
 Lys Gln Val Val Ser Lys Ile Lys Glu Glu Thr Leu Asn Asp Lys Val
 85 90 95

Glu Phe Leu Tyr Cys Asp Leu Ala Ser Met Thr Ser Ile Arg Gln Phe
 100 105 110
 Val Gln Lys Phe Lys Met Lys Lys Ile Pro Leu His Val Leu Ile Asn
 115 120 125
 Asn Ala Gly Val Met Met Val Pro Gln Arg Lys Thr Arg Asp Gly Phe
 130 135 140
 Glu Glu His Phe Gly Leu Asn Tyr Leu Gly His Phe Leu Leu Thr Asn
 145 150 155 160
 Leu Leu Leu Asp Thr Leu Lys Glu Ser Gly Ser Pro Gly His Ser Ala
 165 170 175
 Arg Val Val Thr Val Ser Ser Ala Thr His Tyr Val Ala Glu Leu Asn
 180 185 190
 Met Asp Asp Leu Gln Ser Ser Ala Cys Tyr Ser Pro His Ala Ala Tyr
 195 200 205
 Ala Gln Ser Lys Leu Ala Leu Val Leu Phe Thr Tyr His Leu Gln Arg
 210 215 220
 Leu Leu Ala Ala Glu Gly Ser His Val Thr Ala Asn Val Val Asp Pro
 225 230 235 240
 Gly Val Val Asn Thr Asp Xaa Tyr Lys His Val Phe Trp Ala Thr Arg
 245 250 255
 Leu Ala Lys Lys Leu Leu Gly Trp Leu Leu Phe Lys Thr Pro Asp Glu
 260 265 270
 Gly Ala Trp Thr Ser Ile Tyr Ala Ala Val Thr Pro Glu Leu Glu Gly
 275 280 285
 Val Gly Gly Arg Tyr Leu Tyr Asn Glu Lys Glu Thr Lys Ser Leu His
 290 295 300
 Val Thr Tyr Asn Gln Lys Leu Gln Gln Gln Leu Trp Ser Lys Ser Cys
 305 310 315 320
 Glu Met Thr Gly Val Leu Asp Val Thr Leu
 325 330

<210> 321

<211> 71

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (38)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 321

Met Ser Pro Leu Ser Ala Ala Arg Ala Ala Leu Arg Val Tyr Ala Val
 1 5 10 15

Gly Ala Ala Val Ile Leu Ala Gln Leu Leu Arg Arg Cys Arg Gly Gly
 20 25 30
 Phe Leu Glu Pro Val Xaa Pro Pro Arg Pro Asp Arg Val Ala Ile Val
 35 40 45
 Thr Gly Gly Thr Asp Gly Ile Gly Tyr Ser Thr Ala Asn Ile Trp Arg
 50 55 60
 Asp Leu Ala Cys Met Leu Ser
 65 70

<210> 322
 <211> 266
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (97)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (174)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (195)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (199)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (206)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 322
 Met Glu Val Thr Thr Glu Asp Thr Ser Arg Thr Asp Val Ser Glu Pro
 1 5 10 15
 Ala Thr Ser Gly Gly Ala Ala Asp Gly Val Thr Ser Ile Ala Pro Thr
 20 25 30
 Ala Val Ala Ser Ser Thr Thr Ala Ala Ser Ile Thr Thr Ala Ala Ser
 35 40 45
 Ser Met Thr Val Ala Ser Ser Ala Pro Thr Thr Ala Ala Ser Ser Thr
 50 55 60
 Thr Val Ala Ser Ile Ala Pro Thr Thr Thr Ala Ser Ser Met Thr Ala
 65 70 75 80

Ala Ser Ser Thr Pro Met Thr Leu Ala Leu Pro Ala Pro Thr Ser Thr
85 90 95

Xaa Thr Gly Arg Thr Pro Ser Thr Thr Ala Thr Gly His Pro Ser Leu
100 105 110

Ser Thr Ala Leu Ala Gln Val Pro Lys Ser Ser Ala Leu Pro Arg Thr
115 120 125

Ala Thr Leu Ala Thr Leu Ala Thr Arg Ala Gln Thr Val Ala Thr Thr
130 135 140

Ala Asn Thr Ser Ser Pro Met Ser Thr Arg Pro Ser Pro Ser Lys His
145 150 155 160

Met Pro Ser Asp Thr Ala Ala Ser Pro Val Pro Pro Met Xaa Pro Gln
165 170 175

Ala Gln Gly Pro Ile Ser Gln Val Ser Val Asp Gln Pro Val Val Asn
180 185 190

Thr Thr Xaa Lys Ser Thr Xaa Met Pro Ser Asn Thr Thr Xaa Glu Pro
195 200 205

Leu Thr Gln Ala Val Val Asp Lys Thr Leu Leu Leu Val Val Leu Leu
210 215 220

Leu Gly Val Thr Leu Phe Ile Thr Val Leu Val Leu Phe Ala Leu Gln
225 230 235 240

Ala Tyr Glu Ser Tyr Lys Lys Lys Asp Tyr Thr Gln Val Asp Tyr Leu
245 250 255

Ile Asn Gly Met Tyr Ala Asp Ser Glu Met
260 265

<210> 323

<211> 99

<212> PRT

<213> Homo sapiens

<400> 323

Ala Arg Cys Pro Glu Leu Pro Gly Leu Arg Cys Arg Pro Arg Pro Arg
1 5 10 15

Ala Gly Pro Gln Ala Pro Ser Tyr Cys Pro Arg Ala Thr Arg Pro Pro
20 25 30

Gly Ala Cys Cys Ala Arg Met Arg Leu Leu Leu Glu Trp Arg Val Tyr
35 40 45

Leu Arg Leu Thr Cys Ala Thr Lys Asp Gly Met Ala Arg Glu Cys Pro
50 55 60

Thr Thr Trp Leu Ser Pro Pro Ala Lys Pro Asp Phe Ala Gln Arg His
65 70 75 80

Ser Val Lys Pro Thr Ala Leu Gln Gly Gly Arg Trp Ser Arg Leu Gly
 85 90 95

Ala Ser Pro

<210> 324

<211> 96

<212> PRT

<213> Homo sapiens

<400> 324

Leu Pro Ala Thr Val Glu Phe Ala Val His Thr Phe Asn Gln Gln Ser
 1 5 10 15
 Lys Asp Tyr Tyr Ala Tyr Arg Leu Gly His Ile Leu Asn Ser Trp Lys
 20 25 30
 Glu Gln Val Glu Ser Lys Thr Val Phe Ser Met Glu Leu Leu Leu Gly
 35 40 45
 Arg Thr Arg Cys Gly Lys Phe Glu Asp Asp Ile Asp Asn Cys His Phe
 50 55 60
 Gln Glu Ser Thr Glu Leu Asn Asn Thr Phe Thr Cys Phe Phe Thr Ile
 65 70 75 80
 Ser Thr Arg Pro Trp Met Thr Gln Phe Ser Leu Leu Asn Lys Thr Cys
 85 90 95

<210> 325

<211> 166

<212> PRT

<213> Homo sapiens

<400> 325

Leu Leu Trp Ala Arg Gly Leu Gly Arg Ala Lys Ser Ala Val Pro Thr
 1 5 10 15
 Val Ser Thr Met Leu Gly Leu Pro Trp Lys Gly Gly Leu Ser Trp Ala
 20 25 30
 Leu Leu Leu Leu Leu Leu Gly Ser Gln Ile Leu Leu Ile Tyr Ala Trp
 35 40 45
 His Phe His Glu Gln Arg Asp Cys Asp Glu His Asn Val Met Ala Arg
 50 55 60
 Tyr Leu Pro Ala Thr Val Glu Phe Ala Val His Thr Phe Asn Gln Gln
 65 70 75 80
 Ser Lys Asp Tyr Tyr Ala Tyr Arg Leu Gly His Ile Leu Asn Ser Trp
 85 90 95

Lys Glu Gln Val Glu Ser Lys Thr Val Phe Ser Met Glu Leu Leu Leu
 100 105 110
 Gly Arg Thr Arg Cys Gly Lys Phe Glu Asp Asp Ile Asp Asn Cys His
 115 120 125
 Phe Gln Glu Ser Thr Glu Leu Asn Asn Thr Phe Thr Cys Phe Phe Thr
 130 135 140
 Ile Ser Thr Arg Pro Trp Met Thr Gln Phe Ser Leu Leu Asn Lys Thr
 145 150 155 160
 Cys Leu Glu Gly Phe His
 165

<210> 326

<211> 214

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (200)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (205)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 326

Leu Glu Gln Lys Leu Glu Leu His Arg Gly Gly Gly Arg Ser Arg Thr
 1 5 10 15
 Ser Gly Ser Pro Gly Leu Gln Glu Phe Gly Thr Arg Glu Glu Arg Gly
 20 25 30
 Glu Gly Glu Gln Arg Thr Gly Arg Glu Phe Ser Gly Asn Gly Gly Arg
 35 40 45
 Ala Val Glu Ala Ala Arg Met Arg Leu Leu Cys Gly Leu Trp Leu Trp
 50 55 60
 Leu Ser Leu Leu Lys Val Leu Gln Ala Gln Thr Pro Thr Pro Leu Pro
 65 70 75 80
 Leu Pro Pro Pro Met Gln Ser Phe Gln Gly Asn Gln Phe Gln Gly Glu
 85 90 95
 Trp Phe Val Leu Gly Leu Ala Gly Asn Ser Phe Arg Pro Glu His Arg
 100 105 110
 Ala Leu Leu Asn Ala Phe Thr Ala Thr Phe Glu Leu Ser Asp Asp Gly
 115 120 125
 Arg Phe Glu Val Trp Asn Ala Met Thr Arg Gly Gln His Cys Asp Thr
 130 135 140

Trp Ser Tyr Val Leu Ile Pro Ala Ala Gln Pro Gly Gln Phe Thr Val
 145 150 155 160
 Asp His Gly Val Gly Arg Ser Trp Leu Leu Pro Pro Gly Thr Leu Asp
 165 170 175
 Gln Phe Ile Cys Leu Gly Arg Ala Gln Gly Leu Ser Asp Asp Asn Ile
 180 185 190
 Val Phe Pro Asp Val Thr Gly Xaa Ala Leu Asp Leu Xaa Ser Leu Pro
 195 200 205
 Trp Val Ala Ala Pro Ala
 210
 <210> 327
 <211> 181
 <212> PRT
 <213> Homo sapiens
 <400> 327
 Met Cys Val Cys Glu Arg Lys Arg Gly Arg Glu Lys Glu Gly Gly Val
 1 5 10 15
 Thr Pro Thr Met Thr Ser Asn Phe Pro Phe Cys Thr Leu Ile Leu Gly
 20 25 30
 Ile Ala Gln Ala Gln Ala Cys Pro Gly Cys Pro Gly Asp Trp Pro Gly
 35 40 45
 Leu Gly Ser Gly Val Gly Glu Gly Leu His His Ile Arg Thr Cys Arg
 50 55 60
 Thr Pro Ile Pro Cys Ser Pro Pro Ala Pro Ala Ala Cys Leu Gly
 65 70 75 80
 Ser Gly His Ala Arg Leu Pro Cys Val Leu Arg Leu Trp Pro Val Pro
 85 90 95
 Ala Asn Leu Ser Ser Pro Phe Arg Leu Glu Ala Leu His Cys Ser Phe
 100 105 110
 Trp Ser Ser Pro Leu Leu Pro Ala Pro His Leu Ala Phe Phe Gly Phe
 115 120 125
 Arg Asp Leu Leu Thr Asp Phe Leu Leu Ala Ala Cys Leu Leu Thr Phe
 130 135 140
 Gln Lys Thr Pro Leu Glu Leu Pro Met Ala Val Val His Leu Leu Val
 145 150 155 160
 Ala Thr Pro Cys Tyr Gln Met Leu Asp Asn Leu Pro Leu Pro Ser Ala
 165 170 175
 Ala Ala Asn Trp Cys
 180

<210> 328
 <211> 195
 <212> PRT
 <213> Homo sapiens

<400> 328
 Tyr Leu Trp Gly Arg Pro Arg Leu Arg Met Arg Ala Gly Thr Ser Pro
 1 5 10 15
 Ser Ala Pro Trp Gly Glu Lys Arg Glu Lys Leu Gly His Lys Leu Pro
 20 25 30
 Val Ala Leu Gln Gly Tyr His Pro Trp Ile Leu Leu Glu Cys Thr Val
 35 40 45
 Phe Trp Ala Arg Val Val Leu Ala Cys Phe Ser Leu Tyr Leu Ile Arg
 50 55 60
 Gly Pro Asn Cys Ile Asn Arg Gln Pro Glu Pro Thr Tyr Gln Lys Ala
 65 70 75 80
 Cys Asn Leu Asp Cys Scr Ser Asp Phe Gly Gln Glu Arg Ala Pro Ala
 85 90 95
 Trp Glu Leu Leu Gly Pro Glu Ser Glu Gln Arg Leu Arg Glu Tyr Thr
 100 105 110
 Ala Gln Gly Leu Gln Ser Leu Ala Ser Ser His Arg Trp Arg Gln Phe
 115 120 125
 Lys Thr Glu Gly Lys Met Arg Gly Gly Ala Ser Pro Leu Pro Trp Leu
 130 135 140
 Ile Cys Phe Trp Leu Cys Ser Tyr Lys Gly Ser Asp Asn Ser Leu Lys
 145 150 155 160
 Pro Val Val Pro Gly Pro Thr Leu Cys Pro Gln Ser Leu Val Ser Pro
 165 170 175
 Ser Val His Pro Ser Thr Arg Ser Ala Ser Leu Gly Arg His Arg Ala
 180 185 190
 Glu Ala Ala
 195

<210> 329
 <211> 50
 <212> PRT
 <213> Homo sapiens

<400> 329
 Met Pro Gly Ile Leu Ala Gly Ile Pro Val Lys Asp Leu Cys Leu Ser
 1 5 10 15
 Leu Leu Gln Gly Phe Arg Leu Leu Leu Leu Cys Val Cys Pro Gly Trp
 20 25 30
 Leu Ser Gly Trp Met Gly Gly Gln Lys Gly Ser Pro Arg Ile Val Asp

35 40 45

Ile Gly
50

<210> 330
<211> 90
<212> PRT
<213> Homo sapiens

<400> 330
Ala Lys Gly Glu Glu Arg Lys Glu Ala Phe Ser Leu Lys Met Val Gln
1 5 10 15
Leu Ser Ser Glu Pro Ile Ser Phe Gly Leu Met Tyr Leu Tyr Leu Gly
20 25 30
Val Phe Phe His Leu Ile Tyr Pro Gly Ala Leu Ser Ile Thr Thr Leu
35 40 45
Gly Lys His Ser His Pro Phe Phe Thr Ala Glu Gln Asn Ser Thr Val
50 55 60
Trp Met Glu His Thr Leu Phe His Gln Ser Pro Val Ala Ser His Leu
65 70 75 80
Val Cys Phe Gln Ser Phe Ala Phe Ser Glu
85 90

<210> 331
<211> 56
<212> PRT
<213> Homo sapiens

<400> 331
Gly Pro Ala His Pro Ala Ser Pro Pro Leu Met Thr Leu Ser Leu Gln
1 5 10 15
Leu Ala Glu Leu Val His Phe Val Cys Ala Phe Gln Ser Gln Trp Thr
20 25 30
Gly Val Tyr Pro Met Met Pro Pro Leu Lys Pro Thr Glu Pro Leu Cys
35 40 45
Phe Ala Cys Val Pro Cys Arg Val
50 55

<210> 332
<211> 18
<212> PRT
<213> Homo sapiens

<400> 332
Met Leu Leu Glu Val Tyr Gly Asp Ser Ile Ser Val Thr Val Ala Ile
1 5 10 15

Pro Leu

<210> 333
<211> 19
<212> PRT
<213> Homo sapiens

<400> 333
Met His Ser Pro Cys Gln Ser Lys Ala Ala Asp Gly Leu Gly Lys Ser
1 5 10 15

Glu Thr Glu

<210> 334
<211> 10
<212> PRT
<213> Homo sapiens

<400> 334
Met Leu Lys Ser Leu Gly Leu Ser Thr Asn
1 5 10

<210> 335
<211> 200
<212> PRT
<213> Homo sapiens

<400> 335
Ala Gln Arg Leu Ala Glu Glu Cys Phe Tyr Met Leu Leu Glu Val Tyr
1 5 10 15

Gly Asp Ser Ile Ser Val Thr Val Ala Ile Pro Leu Met His Ser Pro
20 25 30

Cys Gln Ser Lys Ala Ala Asp Gly Leu Gly Lys Ser Glu Thr Glu Met
35 40 45

Leu Lys Ser Leu Gly Leu Ser Thr Asn Met Ser Pro Phe His Leu Leu
50 55 60

Gly Leu Lys Val Phe Leu Thr Trp Ala Leu Thr Leu Ala Gln Ile Cys
65 70 75 80

Leu Tyr Phe Phe Glu Val Gln Pro Leu Gly Leu Leu Ala Leu Asn Phe
85 90 95

Phe Cys Thr Ala Thr Ala Gly Leu Lys Glu Leu Cys Met His Pro Pro
100 105 110

Ser Leu Ala Phe Thr Pro Glu Phe His Thr Ser Leu Ser Pro Leu Ala
115 120 125

Ile Pro Ser Phe Cys Gly Thr Ser Val Ser Leu Ser Asn Ser His Thr
130 135 140

Ile Pro Leu Ser Leu Tyr Leu Pro Phe Pro Ser Lys Ser Arg Met Pro
 145 150 155 160
 Asp Thr Leu His Leu Leu Val His Ser Leu Pro Leu Val His Ser Gln
 165 170 175
 Val Leu Pro Val Lys Asp Val Thr Ile Glu Trp Pro Leu Cys Gln Arg
 180 185 190
 Cys Leu Gly Ser Thr Cys His Gln
 195 200

<210> 336
 <211> 99
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (94)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (99)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 336
 Trp Ile Pro Arg Ala Ala Gly Ile Arg His Glu Val Gln Val Ser Leu
 1 5 10 15
 Phe Gln Met Phe Cys Phe Ser Ser Ile Phe Cys Ser His Glu His Thr
 20 25 30
 His Leu Pro Gly Thr Phe Trp Leu Phe Leu Phe Leu Ile Leu
 35 40 45
 Pro Pro Ser Cys Pro Cys Phe Leu Pro Phe Ser Leu Ala Ile Glu Thr
 50 55 60
 Val Arg Trp Pro Cys Trp His His Pro Thr Ser Phe Glu Leu Cys Tyr
 65 70 75 80
 Pro Gly Thr Ser Ile Tyr Tyr Ala Ser Arg Gly Gly Pro Xaa Pro Asn
 85 90 95
 Ser Glu Xaa

<210> 337
 <211> 96
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE

<222> (1)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (3)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 337

Xaa Asn Xaa Lys Ser Pro Leu Thr Ile Gly Asn Lys Ser Trp Ser Ser
 1 5 10 15
 Thr Ala Val Ala Ala Ala Leu Glu Leu Val Asp Pro Pro Gly Cys Arg
 20 25 30
 Asn Ser Ala Arg Asp Ser Pro Glu Leu Val His Leu Gly Lys Gly Arg
 35 40 45
 Pro Arg Lys Leu Met Thr Tyr Leu Phe Cys Ser Ser Ile Ser Leu Leu
 50 55 60
 Leu Leu Lys Val His Ser Ser Gly His Gln Asp Ile Arg Lys Ala Lys
 65 70 75 80
 Ser Lys Val Pro Arg Leu Leu Ile Ile Gln Cys Pro Gln Gln Arg Glu
 85 90 95

<210> 338

<211> 54

<212> PRT

<213> Homo sapiens

<400> 338

Gly Pro Glu Glu Asn Leu Ser Pro Ser Thr Pro Ser Gln Met Pro Thr
 1 5 10 15
 Ile Trp Val Lys Leu Cys Leu Leu Gln Val Cys His Gly Leu Phe Pro
 20 25 30
 Leu Leu Lys His Trp Ser Gln Pro Met Pro Leu Cys Val Thr Leu Ala
 35 40 45
 Pro Val Ser Tyr Trp Leu
 50

<210> 339

<211> 287

<212> PRT

<213> Homo sapiens

<400> 339

Pro Arg Val Arg Lys Glu Pro Glu Ala Met Gln Trp Leu Arg Val Arg
 5 10 15

Glu Ser Pro Gly Glu Ala Thr Gly His Arg Val Thr Met Gly Thr Ala
 20 25 30
 Ala Leu Gly Pro Val Trp Ala Ala Leu Leu Leu Phe Leu Leu Met Cys
 35 40 45
 Glu Ile Pro Met Val Glu Leu Thr Phe Asp Arg Ala Val Ala Ser Asp
 50 55 60
 Cys Gln Arg Cys Cys Asp Ser Glu Asp Pro Leu Asp Pro Ala His Val
 65 70 75 80
 Ser Ser Ala Ser Ser Ser Gly Arg Pro His Ala Leu Pro Glu Ile Arg
 85 90 95
 Pro Tyr Ile Asn Ile Thr Ile Leu Lys Gly Asp Lys Gly Asp Pro Gly
 100 105 110
 Pro Met Gly Leu Pro Gly Tyr Met Gly Arg Glu Gly Pro Gln Gly Glu
 115 120 125
 Pro Gly Pro Gln Gly Ser Lys Gly Asp Lys Gly Glu Met Gly Ser Pro
 130 135 140
 Gly Ala Pro Cys Gln Lys Arg Phe Phe Ala Phe Ser Val Gly Arg Lys
 145 150 155 160
 Thr Ala Leu His Ser Gly Glu Asp Phe Gln Thr Leu Leu Phe Glu Arg
 165 170 175
 Val Phe Val Asn Leu Asp Gly Cys Phe Asp Met Ala Thr Gly Gln Phe
 180 185 190
 Ala Ala Pro Leu Arg Gly Ile Tyr Phe Phe Ser Leu Asn Val His Ser
 195 200 205
 Trp Asn Tyr Lys Glu Thr Tyr Val His Ile Met His Asn Gln Lys Glu
 210 215 220
 Ala Val Ile Leu Tyr Ala Gln Pro Ser Glu Arg Ser Ile Met Gln Ser
 225 230 235 240
 Gln Ser Val Met Leu Asp Leu Ala Tyr Gly Asp Arg Val Trp Val Arg
 245 250 255
 Leu Phe Lys Arg Gln Arg Glu Asn Ala Ile Tyr Ser Asn Asp Phe Asp
 260 265 270
 Thr Tyr Ile Thr Phe Ser Gly His Leu Ile Lys Ala Glu Asp Asp
 275 280 285

<210> 340

<211> 339

<212> PRT

<213> Homo sapiens

<400> 340

Met Leu Tyr Pro Gly Ser Val Tyr Leu Leu Gln Lys Ala Leu Met Pro

1	5	10	15
Val Leu Leu Gln Gly Gln Ala Arg Leu Val Glu Glu Cys Asn Gly Arg	20	25	30
Arg Ala Lys Leu Leu Ala Cys Asp Gly Asn Glu Ile Asp Thr Met Phe	35	40	45
Val Asp Arg Arg Gly Thr Ala Glu Pro Gln Gly Gln Lys Leu Val Ile	50	55	60
Cys Cys Glu Gly Asn Ala Gly Phe Tyr Glu Val Gly Cys Val Ser Thr	65	70	75
Pro Leu Glu Ala Gly Tyr Ser Val Leu Gly Trp Asn His Pro Gly Phe	85	90	95
Ala Gly Ser Thr Gly Val Pro Phe Pro Gln Asn Glu Ala Asn Ala Met	100	105	110
Asp Val Val Val Gln Phe Ala Ile His Arg Leu Gly Phe Gln Pro Gln	115	120	125
Asp Ile Ile Ile Tyr Ala Trp Ser Ile Gly Gly Phe Thr Ala Thr Trp	130	135	140
Ala Ala Met Ser Tyr Pro Asp Val Ser Ala Met Ile Leu Asp Ala Ser	145	150	155
Phe Asp Asp Leu Val Pro Leu Ala Leu Lys Val Met Pro Asp Ser Trp	165	170	175
Arg Gly Leu Val Thr Arg Thr Val Arg Gln His Leu Asn Leu Asn Asn	180	185	190
Ala Glu Gln Leu Cys Arg Tyr Gln Gly Pro Val Leu Leu Ile Arg Arg	195	200	205
Thr Lys Asp Glu Ile Ile Thr Thr Thr Val Pro Glu Asp Ile Met Ser	210	215	220
Asn Arg Gly Asn Asp Leu Leu Leu Lys Leu Leu Gln His Arg Tyr Pro	225	230	235
Arg Val Met Ala Glu Glu Gly Leu Arg Val Val Arg Gln Trp Leu Glu	245	250	255
Ala Ser Ser Gln Leu Glu Glu Ala Ser Ile Tyr Ser Arg Trp Glu Val	260	265	270
Glu Glu Asp Trp Cys Leu Ser Val Leu Arg Ser Tyr Gln Ala Glu His	275	280	285
Gly Pro Asp Phe Pro Trp Ser Val Gly Glu Asp Met Ser Ala Asp Gly	290	295	300
Arg Arg Gln Leu Ala Leu Phe Leu Ala Arg Lys His Leu His Asn Phe	305	310	315
			320

Glu Ala Thr His Cys Thr Pro Leu Pro Ala Gln Asn Phe Gln Met Pro
 325 330 335

Trp His Leu

<210> 341
 <211> 127
 <212> PRT
 <213> Homo sapiens

<400> 341
 Val Cys Pro Lys Trp Cys Arg Phe Leu Thr Met Leu Gly His Cys Cys
 1 5 10 15
 Tyr Phe Trp Gln Val Trp Pro Ala Ser Glu Ala Leu Ala Ala Gly Pro
 20 25 30
 Thr Pro Ser Thr Gly Ser Ser Ser Pro Ser Trp Lys Gln His Ile Gly
 35 40 45
 Thr Ser Leu Gln Lys Thr Arg Gly Ser Leu Pro Thr Thr Thr Leu Thr
 50 55 60
 Ser Gly Ala Gly Gln Ser Thr Ser Thr Gly Lys Asn Pro Ala Ala Gly
 65 70 75 80
 Arg Ser Leu Glu Gly Ala Leu Pro Ala Gly Val Trp Pro Cys Phe Ala
 85 90 95
 Gln Ser Pro Cys Thr Gly Gly Gln Gln Thr Pro Ser Ser Thr Gly Leu
 100 105 110
 Arg Ser Cys Leu Val Arg Ser Pro Ala Thr Trp Trp Arg Thr Pro
 115 120 125

<210> 342
 <211> 554
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (16)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (109)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 342
 Trp Ile Pro Arg Ala Ala Gly Ile Arg His Glu Ile Tyr Arg Glu Xaa
 1 5 10 15
 Asp Ser Glu Arg Ala Pro Ala Ser Val Pro Glu Thr Pro Thr Ala Val
 20 25 30

Thr Ala Pro His Ser Ser Ser Trp Asp Thr Tyr Tyr Gln Pro Arg Ala
 35 40 45
 Leu Glu Lys His Ala Asp Ser Ile Leu Ala Leu Ala Ser Val Phe Trp
 50 55 60
 Ser Ile Ser Tyr Tyr Ser Ser Pro Phe Ala Phe Phe Tyr Leu Tyr Arg
 65 70 75 80
 Lys Gly Tyr Leu Ser Leu Ser Lys Val Val Pro Phe Ser His Tyr Ala
 85 90 95
 Gly Thr Leu Leu Leu Leu Ala Gly Val Ala Cys Xaa Arg Gly Ile
 100 105 110
 Gly Arg Trp Thr Asn Pro Gln Tyr Arg Gln Phe Ile Thr Ile Leu Glu
 115 120 125
 Ala Thr His Arg Asn Gln Ser Ser Glu Asn Lys Arg Gln Leu Ala Asn
 130 135 140
 Tyr Asn Phe Asp Phe Arg Ser Trp Pro Val Asp Phe His Trp Glu Glu
 145 150 155 160
 Pro Ser Ser Arg Lys Glu Ser Arg Gly Gly Pro Ser Arg Arg Gly Val
 165 170 175
 Ala Leu Leu Arg Pro Glu Pro Leu His Arg Gly Thr Ala Asp Thr Leu
 180 185 190
 Leu Asn Arg Val Lys Lys Leu Pro Cys Gln Ile Thr Ser Tyr Leu Val
 195 200 205
 Ala His Thr Leu Gly Arg Arg Met Leu Tyr Pro Gly Ser Val Tyr Leu
 210 215 220
 Leu Gln Lys Ala Leu Met Pro Val Leu Leu Gln Gly Gln Ala Arg Leu
 225 230 235 240
 Val Glu Glu Cys Asn Gly Arg Arg Ala Lys Leu Leu Ala Cys Asp Gly
 245 250 255
 Asn Glu Ile Asp Thr Met Phe Val Asp Arg Arg Gly Thr Ala Glu Pro
 260 265 270
 Gln Gly Gln Lys Leu Val Ile Cys Cys Glu Gly Asn Ala Gly Phe Tyr
 275 280 285
 Glu Val Gly Cys Val Ser Thr Pro Leu Glu Ala Gly Tyr Ser Val Leu
 290 295 300
 Gly Trp Asn His Pro Gly Phe Ala Gly Ser Thr Gly Val Pro Phe Pro
 305 310 315 320
 Gln Asn Glu Ala Asn Ala Met Asp Val Val Val Gln Phe Ala Ile His
 325 330 335
 Arg Leu Gly Phe Gln Pro Gln Asp Ile Ile Ile Tyr Ala Trp Ser Ile

340 345 350
 Gly Gly Phe Thr Ala Thr Trp Ala Ala Met Ser Tyr Pro Asp Val Ser
 355 360 365
 Ala Met Ile Leu Asp Ala Ser Phe Asp Asp Leu Val Pro Leu Ala Leu
 370 375 380
 Lys Val Met Pro Asp Ser Trp Arg Gly Leu Val Thr Arg Thr Val Arg
 385 390 395 400
 Gln His Leu Asn Leu Asn Asn Ala Glu Gln Leu Cys Arg Tyr Gln Gly
 405 410 415
 Pro Val Leu Leu Ile Arg Arg Thr Lys Asp Glu Ile Ile Thr Thr Thr
 420 425 430
 Val Pro Glu Asp Ile Met Ser Asn Arg Gly Asn Asp Leu Leu Leu Lys
 435 440 445
 Leu Leu Gln His Arg Tyr Pro Arg Val Met Ala Glu Glu Gly Leu Arg
 450 455 460
 Val Val Arg Gln Trp Leu Glu Ala Ser Ser Gln Leu Glu Glu Ala Ser
 465 470 475 480
 Ile Tyr Ser Arg Trp Glu Val Clu Clu Asp Trp Cys Leu Ser Val Leu
 485 490 495
 Arg Ser Tyr Gln Ala Glu His Gly Pro Asp Phe Pro Trp Ser Val Gly
 500 505 510
 Glu Asp Met Ser Ala Asp Gly Arg Arg Gln Leu Ala Leu Phe Leu Ala
 515 520 525
 Arg Lys His Leu His Asn Phe Glu Ala Thr His Cys Thr Pro Leu Pro
 530 535 540
 Ala Gln Asn Phe Gln Met Pro Trp His Leu
 545 550

 <210> 343
 <211> 225
 <212> PRT
 <213> Homo sapiens

 <220>
 <221> SITE
 <222> (5)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <400> 343
 His Glu Arg Ala Xaa Gly Pro Ser Arg Gly His Gly Glu Leu Leu Ser
 1 5 10 15
 Cys Val Leu Gly Pro Arg Leu Tyr Lys Ile Tyr Arg Glu Arg Asp Ser
 20 25 30

Glu Arg Ala Pro Ala Ser Val Pro Glu Thr Pro Thr Ala Val Thr Ala
 35 40 45
 Pro His Ser Ser Ser Trp Asp Thr Tyr Tyr Gln Pro Arg Ala Leu Glu
 50 55 60
 Lys His Ala Asp Ser Ile Leu Ala Leu Ala Ser Val Phe Trp Ser Ile
 65 70 75 80
 Ser Tyr Tyr Ser Ser Pro Phe Ala Phe Phe Tyr Leu Tyr Arg Lys Gly
 85 90 95
 Tyr Leu Ser Leu Ser Lys Val Val Pro Phe Ser His Tyr Ala Gly Thr
 100 105 110
 Leu Leu Leu Leu Leu Ala Gly Val Ala Cys Ser Glu Ala Leu Ala Ala
 115 120 125
 Gly Pro Thr Pro Ser Thr Gly Ser Ser Ser Pro Ser Trp Lys Gln His
 130 135 140
 Ile Gly Thr Ser Leu Gln Lys Thr Arg Gly Ser Leu Pro Thr Thr Thr
 145 150 155 160
 Leu Thr Ser Gly Ala Gly Gln Ser Thr Ser Thr Gly Lys Asn Pro Ala
 165 170 175
 Ala Gly Arg Ser Leu Glu Gly Ala Leu Pro Ala Gly Val Trp Pro Cys
 180 185 190
 Phe Ala Gln Ser Pro Cys Thr Gly Gly Gln Gln Thr Pro Ser Ser Thr
 195 200 205
 Gly Leu Arg Ser Cys Leu Val Arg Ser Pro Ala Thr Trp Trp Arg Thr
 210 215 220
 Pro
 225

<210> 344
 <211> 299
 <212> PRT
 <213> Homo sapiens

<400> 344
 Met Phe Lys Arg His Gln Arg Leu Lys Lys Asp Ser Thr Gln Ala Glu
 1 5 10 15
 Glu Asp Leu Ser Glu Gln Glu Gln Asn Gln Leu Asn Val Leu Lys Lys
 20 25 30
 His Gly Tyr Val Val Gly Arg Val Gly Arg Thr Phe Leu Tyr Ser Glu
 35 40 45
 Glu Gln Lys Asp Asn Ile Pro Phe Glu Phe Asp Ala Asp Ser Leu Ala
 50 55 60
 Phe Asp Met Glu Asn Asp Pro Val Met Gly Thr His Lys Ser Thr Lys


```

65              70              75              80
Gln Val Glu Leu Thr Ala Gln Asp Val Lys Asp Ala His Trp Phe Tyr
      85              90              95
Asp Thr Pro Gly Ile Thr Lys Glu Asn Cys Ile Leu Asn Leu Leu Thr
      100             105             110
Glu Lys Glu Val Asn Ile Val Leu Pro Thr Gln Ser Ile Val Pro Arg
      115             120             125
Thr Phe Val Leu Lys Pro Gly Met Val Leu Phe Leu Gly Ala Ile Gly
      130             135             140
Arg Ile Asp Phe Leu Gln Gly Asn Gln Ser Ala Trp Phe Thr Val Val
      145             150             155             160
Ala Ser Asn Ile Leu Pro Val His Ile Thr Ser Leu Asp Arg Ala Asp
      165             170             175
Ala Leu Tyr Gln Lys His Ala Gly His Thr Leu Leu Gln Ile Pro Met
      180             185             190
Gly Gly Lys Glu Arg Met Ala Gly Phe Pro Pro Leu Val Ala Glu Asp
      195             200             205
Ile Met Leu Lys Glu Gly Leu Gly Ala Ser Glu Ala Val Ala Asp Ile
      210             215             220
Lys Phe Ser Ser Ala Gly Trp Val Ser Val Thr Pro Asn Phe Lys Asp
      225             230             235             240
Arg Leu His Leu Arg Gly Tyr Thr Pro Glu Gly Thr Val Leu Thr Val
      245             250             255
Arg Pro Pro Leu Leu Pro Tyr Ile Val Asn Ile Lys Gly Gln Arg Ile
      260             265             270
Lys Lys Ser Val Ala Tyr Lys Thr Lys Lys Pro Pro Ser Leu Met Tyr
      275             280             285
Asn Val Arg Lys Lys Lys Gly Lys Ile Asn Val
      290             295

```

<210> 345

<211> 314

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (147)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (211)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 345

Met Leu Pro Ala Arg Leu Pro Phe Arg Leu Leu Ser Leu Phe Leu Arg
 1 5 10 15
 Gly Ser Ala Pro Thr Ala Ala Arg His Gly Leu Arg Glu Pro Leu Leu
 20 25 30
 Glu Arg Arg Cys Ala Ala Ala Ser Ser Phe Gln His Ser Ser Ser Leu
 35 40 45
 Gly Arg Glu Leu Pro Tyr Asp Pro Val Asp Thr Glu Gly Phe Gly Glu
 50 55 60
 Gly Gly Asp Met Gln Glu Arg Phe Leu Phe Pro Glu Tyr Ile Leu Asp
 65 70 75 80
 Pro Glu Pro Gln Pro Thr Arg Glu Lys Gln Leu Gln Glu Leu Gln Gln
 85 90 95
 Gln Gln Glu Glu Glu Glu Arg Gln Arg Gln Gln Arg Arg Glu Glu Arg
 100 105 110
 Arg Gln Gln Asn Leu Arg Ala Arg Ser Arg Glu His Pro Val Val Gly
 115 120 125
 His Pro Asp Pro Ala Leu Pro Pro Ser Gly Val Asn Cys Ser Gly Cys
 130 135 140
 Gly Ala Xaa Leu His Cys Gln Asp Ala Gly Val Pro Gly Tyr Leu Pro
 145 150 155 160
 Arg Glu Lys Phe Leu Arg Thr Ala Glu Ala Asp Gly Gly Leu Ala Arg
 165 170 175
 Thr Val Cys Gln Arg Cys Trp Leu Leu Ser His His Arg Arg Ala Leu
 180 185 190
 Arg Leu Gln Val Ser Arg Glu Gln Tyr Leu Glu Leu Val Ser Ala Ala
 195 200 205
 Leu Arg Xaa Pro Gly Pro Ser Leu Val Leu Tyr Met Val Asp Leu Leu
 210 215 220
 Asp Leu Pro Asp Ala Leu Leu Pro Asp Leu Pro Ala Leu Val Gly Pro
 225 230 235 240
 Lys Gln Leu Ile Val Leu Gly Asn Lys Val Asp Leu Leu Pro Gln Asp
 245 250 255
 Ala Pro Gly Tyr Arg Gln Arg Leu Arg Glu Arg Leu Trp Glu Asp Cys
 260 265 270
 Ala Arg Ala Gly Leu Leu Leu Ala Pro Gly Thr Lys Gly His Ser Ala
 275 280 285
 Pro Ser Arg Thr Ser His Arg Thr Gly Arg Ile Arg Ile Arg Arg Thr
 290 295 300

Gly Pro Ala Gln Trp Ser Gly Thr Cys Gly
305 310

<210> 346
<211> 380
<212> PRT
<213> Homo sapiens

<400> 346

Pro Ser Phe Arg Arg Glu Arg Val Glu Thr Gly Gly Gly Gly Pro Val
1 5 10 15
Thr His Gly Thr Glu Gly Pro Phe Leu Pro Leu Pro Gly Gly Thr Arg
20 25 30
Met Asn Met Thr Gln Ala Arg Val Leu Val Ala Ala Val Val Gly Leu
35 40 45
Val Ala Val Leu Leu Tyr Ala Ser Ile His Lys Ile Glu Glu Gly His
50 55 60
Leu Ala Val Tyr Tyr Arg Gly Gly Ala Leu Leu Thr Ser Pro Ser Gly
65 70 75 80
Pro Gly Tyr His Ile Met Leu Pro Phe Ile Thr Thr Phe Arg Ser Val
85 90 95
Gln Thr Thr Leu Gln Thr Asp Glu Val Lys Asn Val Pro Cys Gly Thr
100 105 110
Ser Gly Gly Val Met Ile Tyr Ile Asp Arg Ile Glu Val Val Asn Met
115 120 125
Leu Ala Pro Tyr Ala Val Phe Asp Ile Val Arg Asn Tyr Thr Ala Asp
130 135 140
Tyr Asp Lys Thr Leu Ile Phe Asn Lys Ile His His Glu Leu Asn Gln
145 150 155 160
Phe Cys Ser Ala His Thr Leu Gln Glu Val Tyr Ile Glu Leu Phe Asp
165 170 175
Gln Ile Asp Glu Asn Leu Lys Gln Ala Leu Gln Lys Asp Leu Asn Leu
180 185 190
Met Ala Pro Gly Leu Thr Ile Gln Ala Val Arg Val Thr Lys Pro Lys
195 200 205
Ile Pro Glu Ala Ile Arg Arg Asn Phe Glu Leu Met Glu Ala Glu Lys
210 215 220
Thr Lys Leu Leu Ile Ala Ala Gln Lys Gln Lys Val Val Glu Lys Glu
225 230 235 240
Ala Glu Thr Glu Arg Lys Lys Ala Val Ile Glu Ala Glu Lys Ile Ala
245 250 255
Gln Val Ala Lys Ile Arg Phe Gln Gln Lys Val Met Glu Lys Glu Thr

```
<220>
<221> SITE
<222> (328)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```

<400> 347
Trp Ser Thr Gly Asn Ala Ser Trp Glu Lys Lys Asp Asn Phe Ile Leu
  1          5          10          15
Ser Ala Asp Phe Glu Met Met Gly Leu Gly Asn Gly Arg Arg Ser Met
          20          25          30
Lys Ser Pro Pro Leu Val Leu Ala Ala Leu Val Ala Cys Ile Ile Val
          35          40          45
Leu Gly Phe Asn Tyr Trp Ile Ala Ser Ser Arg Ser Val Asp Leu Gln
  50          55          60
Thr Arg Ile Met Glu Leu Glu Gly Arg Val Arg Arg Arg Ala Ala Glu
  65          70          75          80
Arg Gly Ala Val Glu Leu Lys Lys Asn Glu Phe Cln Gly Glu Leu Glu
          85          90          95
Lys Gln Arg Glu Gln Leu Asp Lys Ile Gln Ser Ser His Asn Phe Gln
          100          105          110
Leu Glu Ser Val Asn Lys Leu Tyr Gln Asp Glu Lys Ala Val Leu Val
          115          120          125

```

Asn Asn Ile Thr Thr Gly Glu Arg Leu Ile Arg Val Leu Gln Asp Gln
 130 135 140
 Leu Lys Thr Leu Gln Arg Asn Tyr Gly Arg Leu Gln Gln Asp Val Leu
 145 150 155 160
 Gln Phe Gln Lys Asn Gln Thr Asn Leu Glu Arg Lys Phe Ser Tyr Asp
 165 170 175
 Leu Ser Gln Cys Ile Asn Gln Met Lys Glu Val Lys Glu Gln Cys Glu
 180 185 190
 Glu Arg Ile Glu Glu Val Thr Lys Lys Gly Asn Glu Ala Val Ala Ser
 195 200 205
 Arg Asp Leu Ser Glu Asn Asn Asp Gln Arg Gln Gln Leu Gln Ala Leu
 210 215 220
 Ser Glu Pro Gln Pro Arg Leu Gln Ala Ala Gly Leu Pro His Thr Glu
 225 230 235 240
 Val Pro Gln Gly Lys Gly Asn Val Leu Gly Asn Ser Lys Ser Gln Thr
 245 250 255
 Pro Ala Pro Ser Ser Glu Val Val Leu Asp Ser Lys Arg Gln Val Glu
 260 265 270
 Lys Glu Glu Thr Asn Glu Ile Gln Val Val Asn Glu Glu Pro Gln Arg
 275 280 285
 Asp Arg Leu Pro Gln Glu Pro Gly Arg Glu Gln Val Val Glu Asp Arg
 290 295 300
 Pro Val Gly Gly Arg Gly Phe Gly Gly Ala Gly Glu Leu Gly Gln Thr
 305 310 315 320
 Pro Gln Val Gln Ala Ala Leu Xaa Val Ser Gln Glu Asn Pro Glu Met
 325 330 335
 Glu Gly Pro Glu Arg Asp Gln Leu Val Ile Pro Asp Gly Gln Glu Glu
 340 345 350
 Glu Gln Glu Ala Ala Gly Glu Gly Arg Asn Gln Gln Lys Leu Arg Gly
 355 360 365
 Glu Asp Asp Tyr Asn Met Asp Glu Asn Glu Ala Glu Ser Glu Thr Asp
 370 375 380
 Lys Gln Ala Ala Leu Ala Gly Asn Asp Arg Asn Ile Asp Val Phe Asn
 385 390 395 400
 Val Glu Asp Gln Lys Arg Asp Thr Ile Asn Leu Leu Asp Gln Arg Glu
 405 410 415
 Lys Arg Asn His Thr Leu
 420

<211> 14
 <212> PRT
 <213> Homo sapiens

<400> 348
 Ser Leu His Arg Phe Val Leu Ser Gln Ala Lys Asp Glu Leu
 1 5 10

<210> 349
 <211> 19
 <212> PRT
 <213> Homo sapiens

<400> 349
 Phe Ile Lys Phe Phe Ala Pro Trp Cys Gly His Cys Lys Ala Leu Ala
 1 5 10 15

Pro Thr Trp

<210> 350
 <211> 19
 <212> PRT
 <213> Homo sapiens

<400> 350
 Phe Ile Lys Phe Tyr Ala Pro Trp Cys Gly His Cys Lys Thr Leu Ala
 1 5 10 15

Pro Thr Trp

<210> 351
 <211> 363
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (42)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 351
 Arg Arg Gly Arg Gly Val Pro Gly Pro Arg Gly Arg Arg Arg Leu Trp
 1 5 10 15

Ser Ala Ala Cys Gly His Cys Gln Arg Leu Gln Pro Thr Trp Asn Asp
 20 25 30

Leu Gly Asp Lys Tyr Asn Ser Met Glu Xaa Ala Lys Val Tyr Val Ala
 35 40 45

Lys Val Asp Cys Thr Ala His Ser Asp Val Cys Ser Ala Gln Gly Val
 50 55 60

Arg Gly Tyr Pro Thr Leu Lys Leu Phe Lys Pro Gly Gln Glu Ala Val

65	70	75	80
Lys Tyr Gln Gly Pro Arg Asp Phe Gln Thr Leu Glu Asn Trp Met Leu	85	90	95
Gln Thr Leu Asn Glu Glu Pro Val Thr Pro Glu Pro Glu Val Glu Pro	100	105	110
Pro Ser Ala Pro Glu Leu Lys Gln Gly Leu Tyr Glu Leu Ser Ala Ser	115	120	125
Asn Phe Glu Leu His Val Ala Gln Gly Asp His Phe Ile Lys Phe Phe	130	135	140
Ala Pro Trp Cys Gly His Cys Lys Ala Leu Ala Pro Thr Trp Glu Gln	145	150	155
Leu Ala Leu Gly Leu Glu His Ser Glu Thr Val Lys Ile Gly Lys Val	165	170	175
Asp Cys Thr Gln His Tyr Glu Leu Cys Ser Gly Asn Gln Val Arg Gly	180	185	190
Tyr Pro Thr Leu Leu Trp Phe Arg Asp Gly Lys Lys Val Asp Gln Tyr	195	200	205
Lys Gly Lys Arg Asp Leu Glu Ser Leu Arg Glu Tyr Val Glu Ser Gln	210	215	220
Leu Gln Arg Thr Glu Thr Gly Ala Thr Glu Thr Val Thr Pro Ser Glu	225	230	235
Ala Pro Val Leu Ala Ala Glu Pro Glu Ala Asp Lys Gly Thr Val Leu	245	250	255
Ala Leu Thr Glu Asn Asn Phe Asp Asp Thr Ile Ala Glu Gly Ile Thr	260	265	270
Phe Ile Lys Phe Tyr Ala Pro Trp Cys Gly His Cys Lys Thr Leu Ala	275	280	285
Pro Thr Trp Glu Glu Leu Ser Lys Lys Glu Phe Pro Gly Leu Ala Gly	290	295	300
Val Lys Ile Ala Glu Val Asp Cys Thr Ala Glu Arg Asn Ile Cys Ser	305	310	315
Lys Tyr Ser Val Arg Gly Tyr Pro Thr Leu Leu Leu Phe Arg Gly Gly	325	330	335
Lys Lys Val Ser Glu His Ser Gly Gly Arg Asp Leu Asp Ser Leu His	340	345	350
Arg Phe Val Leu Ser Gln Ala Lys Asp Glu Leu	355	360	

<210> 352

<211> 93

<212> PRT

<213> Homo sapiens

<400> 352

Met Arg Pro Gln Gly Pro Ala Ala Ser Pro Gln Arg Leu Arg Gly Leu
 1 5 10 15
 Leu Leu Leu Leu Leu Leu Gln Leu Pro Ala Pro Ser Ser Ala Ser Glu
 20 25 30
 Ile Pro Lys Gly Lys Gln Lys Ala His Ser Gly Arg Gly Arg Trp Trp
 35 40 45
 Thr Cys Ile Met Glu Cys Ala Tyr Lys Gly Gln Gln Glu Cys Leu Val
 50 55 60
 Glu Thr Gly Ala Leu Gly Pro Met Ala Phe Arg Val His Leu Gly Ser
 65 70 75 80
 Gln Val Gly Met Asp Ser Lys Glu Lys Arg Gly Asn Val
 85 90

<210> 353

<211> 273

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (210)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 353

Glu Thr Arg Val Lys Thr Ser Leu Glu Leu Leu Arg Thr Gln Leu Glu
 1 5 10 15
 Pro Thr Gly Thr Val Gly Asn Thr Ile Met Thr Ser Gln Pro Val Pro
 20 25 30
 Asn Glu Thr Ile Ile Val Leu Pro Ser Asn Val Ile Asn Phe Ser Gln
 35 40 45
 Ala Glu Lys Pro Glu Pro Thr Asn Gln Gly Gln Asp Ser Leu Lys Lys
 50 55 60
 His Leu His Ala Glu Ile Lys Val Ile Gly Thr Ile Gln Ile Leu Cys
 65 70 75 80
 Gly Met Met Val Leu Ser Leu Gly Ile Ile Leu Ala Ser Ala Ser Phe
 85 90 95
 Ser Pro Asn Phe Thr Gln Val Thr Ser Thr Leu Leu Asn Ser Ala Tyr
 100 105 110
 Pro Phe Ile Gly Pro Phe Phe Phe Ile Ile Ser Gly Ser Leu Ser Ile
 115 120 125
 Ala Thr Glu Lys Arg Leu Thr Lys Leu Leu Val His Ser Ser Leu Val

130 135 140
 Gly Ser Ile Leu Ser Ala Leu Ser Ala Leu Val Gly Phe Ile Ile Leu
 145 150 155 160
 Ser Val Lys Gln Ala Thr Leu Asn Pro Ala Ser Leu Gln Cys Glu Leu
 165 170 175
 Asp Lys Asn Asn Ile Pro Thr Arg Ser Tyr Val Ser Tyr Phe Tyr His
 180 185 190
 Asp Ser Leu Tyr Thr Thr Asp Cys Tyr Thr Ala Lys Ala Ser Leu Ala
 195 200 205
 Gly Xaa Leu Ser Leu Met Leu Ile Cys Thr Leu Leu Glu Phe Cys Leu
 210 215 220
 Ala Val Leu Thr Ala Val Leu Arg Trp Lys Gln Ala Tyr Ser Asp Phe
 225 230 235 240
 Pro Gly Ser Val Leu Phe Leu Pro His Ser Tyr Ile Gly Asn Ser Gly
 245 250 255
 Met Ser Ser Lys Met Thr His Asp Cys Gly Tyr Glu Glu Leu Leu Thr
 260 265 270
 Ser

<210> 354
 <211> 192
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (129)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 354
 Met Met Val Leu Ser Leu Gly Ile Ile Leu Ala Ser Ala Ser Phe Ser
 1 5 10 15
 Pro Asn Phe Thr Gln Val Thr Ser Thr Leu Leu Asn Ser Ala Tyr Pro
 20 25 30
 Phe Ile Gly Pro Phe Phe Phe Ile Ile Ser Gly Ser Leu Ser Ile Ala
 35 40 45
 Thr Glu Lys Arg Leu Thr Lys Leu Leu Val His Ser Ser Leu Val Gly
 50 55 60
 Ser Ile Leu Ser Ala Leu Ser Ala Leu Val Gly Phe Ile Ile Leu Ser
 65 70 75 80
 Val Lys Gln Ala Thr Leu Asn Pro Ala Ser Leu Gln Cys Glu Leu Asp
 85 90 95

Lys Asn Asn Ile Pro Thr Arg Ser Tyr Val Ser Tyr Phe Tyr His Asp
 100 105 110
 Ser Leu Tyr Thr Thr Asp Cys Tyr Thr Ala Lys Ala Ser Leu Ala Gly
 115 120 125
 Xaa Leu Ser Leu Met Leu Ile Cys Thr Leu Leu Glu Phe Cys Leu Ala
 130 135 140
 Val Leu Thr Ala Val Leu Arg Trp Lys Gln Ala Tyr Ser Asp Phe Pro
 145 150 155 160
 Gly Ser Val Leu Phe Leu Pro His Ser Tyr Ile Gly Asn Ser Gly Met
 165 170 175
 Ser Ser Lys Met Thr His Asp Cys Gly Tyr Glu Glu Leu Leu Thr Ser
 180 185 190

<210> 355

<211> 204

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (119)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 355

Gly Ala Ser Cys Glu Gly Gly Gly Ala Ala Ala Arg Ala Ala Leu Gly
 1 5 10 15
 Val His Arg Ser Gln Lys Ala Leu Leu Val Phe Arg Arg Thr Leu Ser
 20 25 30
 Asn Leu Leu Tyr Met Pro Leu Leu Arg Gly Leu Leu Trp Leu Gln Val
 35 40 45
 Leu Cys Ala Gly Pro Leu His Thr Glu Ala Val Val Leu Leu Val Pro
 50 55 60
 Ser Asp Asp Gly Arg Ala Phe Leu Leu Arg Ser Arg Leu Leu His Pro
 65 70 75 80
 Glu Ala His Val Pro Pro Ala Ala Asp Arg Gly Ala Ser Leu Gln Cys
 85 90 95
 Val Leu His Gln Ala Ala Pro Lys Ser Arg Pro Arg Ser Pro Ala Ala
 100 105 110
 Gly Ala Ala Leu Leu His Xaa Pro Arg Arg Thr Gly Asp Glu Pro Cys
 115 120 125
 Arg Glu Phe His Gly Asn Gly Phe Pro Gly Pro Thr Gln Leu Thr Pro
 130 135 140

Gly Glu Cys Gly Leu Pro Ala Pro Ser Ser Leu Leu Gln His Ala Ser
 145 150 155 160
 Ala Pro Val Arg Thr Gly Ser Glu Gly Gln Val Val Gly Cys Pro Arg
 165 170 175
 Ala Arg Gly Glu Thr Gly Glu Gly Leu Ser Leu Ala Phe Leu Ser Ser
 180 185 190
 Leu Met Phe Thr Ser Arg Asn Gly Leu Val Gly Cys
 195 200

<210> 356
 <211> 72
 <212> PRT
 <213> Homo sapiens

<400> 356
 Met Gly Ser Ala Ala Leu Glu Ile Leu Gly Leu Val Leu Cys Leu Val
 1 5 10 15
 Gly Trp Gly Gly Leu Ile Leu Ala Cys Gly Leu Pro Met Trp Gln Val
 20 25 30
 Thr Ala Phe Leu Asp His Asn Ile Val Thr Ala Gln Thr Thr Trp Lys
 35 40 45
 Gly Leu Trp Met Ser Cys Val Val Gln Ser Thr Gly Thr Cys Ser Ala
 50 55 60
 Lys Cys Thr Thr Arg Cys Trp Leu
 65 70

<210> 357
 <211> 115
 <212> PRT
 <213> Homo sapiens

<400> 357
 Leu Lys Arg Ala Pro Pro Gly Pro Ala Leu Ala Lys Gly Leu Leu Gln
 1 5 10 15
 Pro Ser Ser Thr Phe Gln Ala Leu Glu Thr Asn Ile Gly Asp Gln Val
 20 25 30
 Arg Arg His Ser Thr Ala Val Val Ile Arg Glu Met Thr Ser Tyr Ile
 35 40 45
 Leu Ile Ser Phe Val Leu Leu Ile Gly Val Gly Cys Ile Glu Lys Asp
 50 55 60
 Gln Ser Cys Pro Val Phe Gly Gly Arg Lys Arg Leu His Leu Leu Phe
 65 70 75 80
 Val Gly Gly Gln Leu Arg Gln Val Arg Met Leu Arg Gly Glu Leu Ser
 85 90 95

Cys Ala Cys Tyr Arg Pro His Val Gln Ala Leu Gln Leu Gly Gly Cys
100 105 110

Thr Cys Phe
115

<210> 358
<211> 88
<212> PRT
<213> Homo sapiens

<400> 358
Val Ile Lys Leu Ile Cys Pro Ala Ala Phe Pro Val Tyr Phe Gln Asp
1 5 10 15

Met Ala Arg Gly Cys Val Cys Ser Leu Cys Ala Ser Val Cys Ile Phe
20 25 30

Leu Ser Ser Leu Phe Pro Leu Leu Pro Ser Val His Ser Val Asn Ile
35 40 45

Ile Ser Cys Leu Leu Leu Ser Lys Cys Phe Glu Gly Leu Glu Leu Met
50 55 60

Cys Glu His Leu Tyr Gln Leu Ser Gln Leu His Val Leu His His Ile
65 70 75 80

Phe Ser Tyr Leu Leu Cys Thr Pro
85

<210> 359
<211> 716
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (373)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (705)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 359
Tyr Xaa Ile Pro Gly Ser Thr His Ala Ser Gly Arg Gln Arg Gly Ser
1 5 10 15

Gly Arg Gly Glu Asp Asp Ser Gly Pro Pro Pro Ser Thr Val Ile Asn
20 25 30

Gln Asn Glu Thr Phe Ala Asn Ile Ile Phe Lys Pro Thr Val Val Gln
35 40 45
Gln Ala Arg Ile Ala Gln Asn Gly Ile Leu Gly Asp Phe Ile Ile Arg
50 55 60
Tyr Asp Val Asn Arg Glu Gln Ser Ile Gly Asp Ile Gln Val Leu Asn
65 70 75 80
Gly Tyr Phe Val His Tyr Phe Ala Pro Lys Asp Leu Pro Pro Leu Pro
85 90 95
Lys Asn Val Val Phe Val Leu Asp Ser Ser Ala Ser Met Val Gly Thr
100 105 110
Lys Leu Arg Gln Thr Lys Asp Ala Leu Phe Thr Ile Leu His Asp Leu
115 120 125
Arg Pro Gln Asp Arg Phe Ser Ile Ile Gly Phe Ser Asn Arg Ile Lys
130 135 140
Val Trp Lys Asp His Leu Ile Ser Val Thr Pro Asp Ser Ile Arg Asp
145 150 155 160
Gly Lys Val Tyr Ile His His Met Ser Pro Thr Gly Gly Thr Asp Ile
165 170 175
Asn Gly Val Leu Gln Arg Ala Ile Arg Leu Leu Asn Lys Tyr Val Ala
180 185 190
His Ser Gly Ile Gly Asp Arg Ser Val Ser Leu Ile Val Phe Leu Thr
195 200 205
Asp Gly Lys Pro Thr Val Gly Glu Thr His Thr Leu Lys Ile Leu Asn
210 215 220
Asn Thr Arg Glu Ala Ala Arg Gly Gln Val Cys Ile Phe Thr Ile Gly
225 230 235 240
Ile Gly Asn Asp Val Asp Phe Arg Leu Leu Glu Lys Leu Ser Leu Glu
245 250 255
Asn Cys Gly Leu Thr Arg Arg Val His Glu Glu Glu Asp Ala Gly Ser
260 265 270
Gln Leu Ile Gly Phe Tyr Asp Glu Ile Arg Thr Pro Leu Leu Ser Asp
275 280 285
Ile Arg Ile Asp Tyr Pro Pro Ser Ser Val Val Gln Ala Thr Lys Thr
290 295 300
Leu Phe Pro Asn Tyr Phe Asn Gly Ser Glu Ile Ile Ile Ala Gly Lys
305 310 315 320
Leu Val Asp Arg Lys Leu Asp His Leu His Val Glu Val Thr Ala Ser
325 330 335
Asn Ser Lys Lys Phe Ile Ile Leu Lys Thr Asp Val Pro Val Arg Pro

340	345	350
Gln Lys Ala Gly Lys Asp Val Thr Gly Ser Pro Arg Pro Gly Gly Asp 355 360 365		
Gly Glu Gly Asp Xaa Asn His Ile Glu Arg Leu Trp Ser Tyr Leu Thr 370 375 380		
Thr Lys Glu Leu Leu Ser Ser Trp Leu Gln Ser Asp Asp Glu Pro Glu 385 390 395 400		
Lys Glu Arg Leu Arg Gln Arg Ala Gln Ala Leu Ala Val Ser Tyr Arg 405 410 415		
Phe Leu Thr Pro Phe Thr Ser Met Lys Leu Arg Gly Pro Val Pro Arg 420 425 430		
Met Asp Gly Leu Glu Glu Ala His Gly Met Ser Ala Ala Met Gly Pro 435 440 445		
Glu Pro Val Val Gln Ser Val Arg Gly Ala Gly Thr Gln Pro Gly Pro 450 455 460		
Leu Leu Lys Lys Pro Tyr Gln Pro Arg Ile Lys Ile Ser Lys Thr Ser 465 470 475 480		
Val Asp Gly Asp Pro His Phe Val Val Asp Phe Pro Leu Ser Arg Leu 485 490 495		
Thr Val Cys Phe Asn Ile Asp Gly Gln Pro Gly Asp Ile Leu Arg Leu 500 505 510		
Val Ser Asp His Arg Asp Ser Gly Val Thr Val Asn Gly Glu Leu Ile 515 520 525		
Gly Ala Pro Ala Pro Pro Asn Gly His Lys Lys Gln Arg Thr Tyr Leu 530 535 540		
Arg Thr Ile Thr Ile Leu Ile Asn Lys Pro Glu Arg Ser Tyr Leu Glu 545 550 555 560		
Ile Thr Pro Ser Arg Val Ile Leu Asp Gly Gly Asp Arg Leu Val Leu 565 570 575		
Pro Cys Asn Gln Ser Val Val Val Gly Ser Trp Gly Leu Glu Val Ser 580 585 590		
Val Ser Ala Asn Ala Asn Val Thr Val Thr Ile Gln Gly Ser Ile Ala 595 600 605		
Phe Val Ile Leu Ile His Leu Tyr Lys Lys Pro Ala Pro Phe Gln Arg 610 615 620		
His His Leu Gly Phe Tyr Ile Ala Asn Ser Glu Gly Leu Ser Ser Asn 625 630 635 640		
Cys His Gly Leu Leu Gly Gln Phe Leu Asn Gln Asp Ala Arg Leu Thr 645 650 655		

Glu Asp Pro Ala Gly Pro Ser Gln Asn Leu Thr His Pro Leu Leu Leu
660 665 670
Gln Val Gly Glu Gly Pro Glu Ala Val Leu Thr Val Lys Gly His Gln
675 680 685
Val Pro Val Val Trp Lys Gln Arg Lys Ile Tyr Asn Gly Glu Glu Gln
690 695 700
Xaa Asp Cys Trp Phe Ala Arg Asn Met Pro Pro Asn
705 710 715

<210> 360
<211> 387
<212> PRT
<213> Homo sapiens

<400> 360
Pro Arg Val Arg Ser Ile Lys Val Thr Glu Leu Lys Gly Leu Ala Asn
1 5 10 15
His Val Val Val Gly Ser Val Ser Cys Glu Thr Lys Asp Leu Phe Ala
20 25 30
Ala Leu Pro Gln Val Val Ala Val Asp Ile Asn Asp Leu Gly Thr Ile
35 40 45
Lys Leu Ser Leu Glu Val Thr Trp Ser Pro Phe Asp Lys Asp Asp Gln
50 55 60
Pro Ser Ala Ala Ser Ser Val Asn Lys Ala Ser Thr Val Thr Lys Arg
65 70 75 80
Phe Ser Thr Tyr Ser Gln Ser Pro Pro Asp Thr Pro Ser Leu Arg Glu
85 90 95
Gln Ala Phe Tyr Asn Met Leu Arg Arg Gln Glu Glu Leu Glu Asn Gly
100 105 110
Thr Ala Trp Ser Leu Ser Ser Glu Ser Ser Asp Asp Ser Ser Ser Pro
115 120 125
Gln Leu Ser Gly Thr Ala Arg His Ser Pro Ala Pro Arg Pro Leu Val
130 135 140
Gln Gln Pro Glu Pro Leu Pro Ile Gln Val Ala Phe Arg Arg Pro Glu
145 150 155 160
Thr Pro Ser Ser Gly Pro Leu Asp Glu Glu Gly Ala Val Ala Pro Val
165 170 175
Leu Ala Asn Gly His Ala Pro Tyr Ser Arg Thr Leu Ser His Ile Ser
180 185 190
Glu Ala Ser Val Asn Ala Ala Leu Ala Glu Ala Ser Val Glu Ala Val
195 200 205
Gly Pro Lys Ser Leu Ser Trp Gly Pro Ser Pro Pro Thr His Pro Ala

210 215 220
 Pro Thr His Gly Lys His Pro Ser Pro Val Pro Pro Ala Leu Asp Pro
 225 230 235 240
 Gly His Ser Ala Thr Ser Ser Thr Leu Gly Thr Thr Gly Ser Val Pro
 245 250 255
 Thr Ser Thr Asp Pro Ala Pro Ser Ala His Leu Asp Ser Val His Lys
 260 265 270
 Ser Thr Asp Ser Gly Pro Ser Glu Leu Pro Gly Pro Thr His Thr Thr
 275 280 285
 Thr Gly Ser Thr Tyr Ser Ala Ile Thr Thr Thr His Ser Ala Pro Ser
 290 295 300
 Pro Leu Thr His Thr Thr Thr Gly Ser Thr His Lys Pro Ile Ile Ser
 305 310 315 320
 Thr Leu Thr Thr Thr Gly Pro Thr Leu Asn Ile Ile Gly Pro Val Gln
 325 330 335
 Thr Thr Thr Ser Pro Thr His Thr Met Pro Ser Pro Ser Ser His Ser
 340 345 350
 Asn Ser Pro Gln Tyr Val Asp Phe Cys Ser Ser Val Cys Asp Asn Ile
 355 360 365
 Phe Val His Tyr Val Ile Gly Ile Phe Phe His Thr Leu Tyr Ser Ser
 370 375 380
 Lys Thr Leu
 385

 <210> 361
 <211> 260
 <212> PRT
 <213> Homo sapiens

 <400> 361
 Pro Arg Val Arg Ser Ile Lys Val Thr Glu Leu Lys Gly Leu Ala Asn
 1 5 10 15
 His Val Val Val Gly Ser Val Ser Cys Glu Thr Lys Asp Leu Phe Ala
 20 25 30
 Ala Leu Pro Gln Val Val Ala Val Asp Ile Asn Asp Leu Gly Thr Ile
 35 40 45
 Lys Leu Ser Leu Glu Val Thr Trp Ser Pro Phe Asp Lys Asp Asp Gln
 50 55 60
 Pro Ser Ala Ala Ser Ser Val Asn Lys Ala Ser Thr Val Thr Lys Arg
 65 70 75 80
 Phe Ser Thr Tyr Ser Gln Ser Pro Pro Asp Thr Pro Ser Leu Arg Glu
 85 90 95

Gln Ala Phe Tyr Asn Met Leu Arg Arg Gln Glu Glu Leu Glu Asn Gly
 100 105 110
 Thr Ala Trp Ser Leu Ser Ser Glu Ser Ser Asp Asp Ser Ser Ser Pro
 115 120 125
 Gln Leu Ser Gly Thr Ala Arg His Ser Pro Ala Pro Arg Pro Leu Val
 130 135 140
 Gln Gln Pro Glu Pro Leu Pro Ile Gln Val Ala Phe Arg Arg Pro Glu
 145 150 155 160
 Thr Pro Ser Ser Gly Pro Leu Asp Glu Glu Gly Ala Val Ala Pro Val
 165 170 175
 Leu Ala Asn Gly His Ala Pro Tyr Ser Arg Thr Leu Ser His Ile Ser
 180 185 190
 Glu Ala Ser Val Asn Ala Ala Leu Ala Glu Ala Ser Val Glu Ala Val
 195 200 205
 Gly Pro Lys Ser Leu Ser Trp Gly Pro Ser Pro Pro Thr His Pro Ala
 210 215 220
 Pro Thr His Gly Lys His Pro Ser Pro Val Pro Pro Ala Leu Asp Pro
 225 230 235 240
 Gly His Ser Ala Thr Ser Ser Thr Leu Gly Thr Thr Gly Ser Val Pro
 245 250 255
 Thr Ser Thr Asp
 260

<210> 362

<211> 155

<212> PRT

<213> Homo sapiens

<400> 362

Tyr Gly Cys Glu Lys Thr Thr Glu Gly Gly Arg Arg Arg Arg Arg Arg
 1 5 10 15
 Met Glu Ala Val Val Phe Val Phe Ser Leu Leu Asp Cys Cys Ala Leu
 20 25 30
 Ile Phe Leu Ser Val Tyr Phe Ile Ile Thr Leu Ser Asp Leu Glu Cys
 35 40 45
 Asp Tyr Ile Asn Ala Arg Ser Cys Cys Ser Lys Leu Asn Lys Trp Val
 50 55 60
 Ile Pro Glu Leu Ile Gly His Thr Ile Val Thr Val Leu Leu Leu Met
 65 70 75 80
 Ser Leu His Trp Phe Ile Phe Leu Leu Asn Leu Pro Val Ala Thr Trp
 85 90 95

Asn Ile Tyr Arg Tyr Ile Met Val Pro Ser Gly Asn Met Gly Val Phe
 100 105 110
 Asp Pro Thr Glu Ile His Asn Arg Gly Gln Leu Lys Ser His Met Lys
 115 120 125
 Glu Ala Met Ile Lys Leu Gly Phe His Leu Leu Cys Phe Phe Met Tyr
 130 135 140
 Leu Tyr Ser Met Ile Leu Ala Leu Ile Asn Asp
 145 150 155

<210> 363
 <211> 70
 <212> PRT
 <213> Homo sapiens

<400> 363
 Ala Arg Ala Pro Ala Pro Ser Leu Pro Pro Leu Pro Ser Pro Ala Pro
 1 5 10 15
 Ala Leu Ala Pro Ala His Ser Leu Leu Gly Leu Leu Leu Gly Arg Met
 20 25 30
 Ser Gly Ser Ser Leu Pro Ser Ala Leu Ala Leu Ser Leu Leu Val
 35 40 45
 Ser Gly Ser Leu Leu Pro Gly Pro Gly Ala Ala Gln Asn Val Arg Val
 50 55 60
 Gln Ser Gly Gln Asp Gln
 65 70

<210> 364
 <211> 56
 <212> PRT
 <213> Homo sapiens

<400> 364
 Gly Thr Ser Lys Asp Cys Val Leu Tyr Ala Phe Leu Asp Pro Gly Met
 1 5 10 15
 Ala Val Pro Leu Phe Leu Tyr Ile Phe Thr Leu Leu Pro Leu Leu Pro
 20 25 30
 Phe Leu Leu Ser Leu Cys Phe Ser Pro Leu Thr Val Lys Arg Ser Ser
 35 40 45
 Ser Ser Glu Ser Lys Ser Ser Leu
 50 55

PCT/US99/17130

Applicant's or agent's file reference number	P2031PCT	International application	Unassigned
--	----------	---------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>280</u> line <u>N/A</u>		REC'D 18 AUG 1999 WIPO PCT
B. IDENTIFICATION OF DEPOSIT		Further deposits are identified on an additional sheet <input type="checkbox"/>
Name of depositary institution <u>American Type Culture Collection</u>		
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>		
Date of deposit <u>July 27, 1998</u>	Accession Number <u>203069</u>	
C. ADDITIONAL INDICATIONS (leave blank if not applicable)		This information is continued on an additional sheet <input type="checkbox"/>
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)		
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).		
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)		
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")		

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input checked="" type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <u>Yves E. Simme</u> PCT International Division	<u>18 AUGUST 1999</u> Authorized officer <u>P. G. G. G.</u>

Form PCT/RO/134 (July 1992)

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

PCT/US99/17130

Applicant's or agent's file reference number	PZ031PCT	International application:	Unassigned
--	----------	----------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>243</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit June 11, 1998	Accession Number 209965
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application Authorized officer Yvette Z. Smith PCT Administrative Division	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on: Authorized officer

Form PCT/RQ/134 (July 1992)

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PZ031PCT	International application	Unassigned
--	----------	---------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>249</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit June 25, 1998	Accession Number 203027
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
<div>For receiving Office use only</div> <div><input checked="" type="checkbox"/> This sheet was received with the international application</div> <div>Authorized officer Yusef E. Sidani PCT International Division</div>	<div>For International Bureau use only</div> <div><input type="checkbox"/> This sheet was received by the International Bureau on:</div> <div>Authorized officer</div>

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PZ031PCT	International applicant	Unassigned
--	----------	-------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>253</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>July 27, 1998</u>	Accession Number <u>203071</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
<div style="border: 1px solid black; padding: 5px;"> <div style="display: flex; justify-content: space-between;"> For receiving Office use only For International Bureau use only </div> <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer <u>Yvette E. Simms</u> <u>PCT International Division</u> </div> <div style="width: 45%;"> <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer _____ </div> </div> </div>	

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PZ031PCT	International application
--	----------	---------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>259</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit July 27, 1988	Accession Number 203070
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer <i>[Signature]</i> Yvonne E. Simms PCT International Division	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/17130

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1, 23.5; 435/69.1, 320.1, 252.3, 325, 6, 7.1; 530/350, 300, 387.1; 514/2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG - Biotech Files

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JACOBS, K. A. et al. A Genetic Selection For Isolating cDNAs Encoding Secreted Proteins. Gene. 1997, Vol. 198, pages 289-296, see entire document.	1-23

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

05 OCTOBER 1999

Date of mailing of the international search report

21 OCT 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ELIZABETH C. KEMMERER

Telephone No. (703) 308-6196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/17130

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-23
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Please See Extra Sheet.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/17130

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (6):

C12N 1/21, 5/10, 15/11, 15/12, 15/63; A61K 38/16, 38/17; C07K 14/00, 14/435, 16/00; G01N 33/50

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

536/23.1, 23.5; 435/69.1, 320.1, 252.3, 325, 6, 7.1; 530/350, 300, 387.1; 514/2

BOX I. OBSERVATIONS WHERE CLAIMS WERE FOUND UNSEARCHABLE

2. Where no meaningful search could be carried out, specifically:

All of the claims were unsearchable to the extent that they require reference to sequences from the sequence listing or an ATCC deposit. However, the specific sequence and deposit numbers were replaced in the claims with generic designators X, Y and Z. Therefore, no meaningful search of the sequences or deposits per se can be carried out by this Authority. The subject matter of the claims has been searched only to the extent possible with reference to the balance of the description.